PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Arico, S; Pattingre, S; Bauvy, C; Gane, P; Barbat, A; Codogno, P; Ogier-Denis, E				Arico, S; Pattingre, S; Bauvy, C; Gane, P; Barbat, A; Codogno, P; Ogier-Denis, E			Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; NF-KAPPA-B; CYCLOOXYGENASE-2 INHIBITOR; COLORECTAL-CANCER; INTESTINAL POLYPOSIS; SIGNALING PATHWAYS; SULINDAC SULFIDE; BCL-2 EXPRESSION; ASPIRIN USE	Nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase (COX) activity, are powerful antineoplastic agents that exert their antiproliferative and proapoptotic effects on cancer cells by COX-dependent and/or COX-independent pathways. Celecoxib, a COX-2-specific inhibitor, has been shown to reduce the number of adenomatous colorectal polyps in patients with familial adenomatous polyposis. Here, we show that celecoxib induces apoptosis in the colon cancer cell line HT-29 by inhibiting the 3-phosphoinositide-dependent kinase 1 (PDK1) activity. This effect was correlated with inhibition of the phosphorylation of the PDK1 downstream substrate Akt/protein kinase B (PKB) on two regulatory sites, Thr(308) and Ser(473). However, expression of a constitutive active form of Akt/PKB (myristoylated PKB) has a low protective effect toward celecoxib-induced cell death. In contrast, overexpression of constitutive active mutant of PDK1 (PDK1(A280V)) was as potent as the pan-caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, to impair celecoxib-induced apoptosis. By contrast, cells expressing a kinase-defective mutant of PDK1 (PDK1(K114G)) remained sensitive to celecoxib. Furthermore, in vitro measurement reveals that celecoxib was a potential inhibitor of PDK1 activity with an IC50 = 3.5 muM. These data indicate that inhibition of PDK1 signaling is involved in the proapoptotic effect of celecoxib in HT-29 cells.	INSERM, U504, F-94807 Villejuif, France; Inst Natl Transfus Sanguine, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Ogier-Denis, E (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Codogno, Patrice/G-1384-2013; Ogier-Denis, Eric/E-5030-2016	Codogno, Patrice/0000-0002-5492-3180; Pattingre, Sophie/0000-0001-6284-6050; Ogier-Denis, Eric/0000-0002-0057-7593				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1999, APOPTOSIS, V4, P365, DOI 10.1023/A:1009696505108; Everts B, 2000, CLIN RHEUMATOL, V19, P331, DOI 10.1007/s100670070024; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Grubbs CJ, 2000, CANCER RES, V60, P5599; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Jacoby RF, 2000, CANCER RES, V60, P5040; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Johnson AJ, 2001, ADV ENZYME REGUL, V41, P221, DOI 10.1016/S0065-2571(00)00015-7; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Liu XH, 1998, CANCER RES, V58, P4245; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ozes ON, 1999, NATURE, V401, P82; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Rice PL, 2001, CANCER RES, V61, P1541; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; Sheng HM, 1998, CANCER RES, V58, P362; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Shureiqi I, 2000, CANCER RES, V60, P6846; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; THUN MJ, 1993, CANCER RES, V53, P1322; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Weaver SA, 2001, TRENDS MOL MED, V7, P455, DOI 10.1016/S1471-4914(01)02107-4; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Yamada T, 2001, J BIOL CHEM, V276, P5339, DOI 10.1074/jbc.M005685200	58	269	287	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27613	27621		10.1074/jbc.M201119200	http://dx.doi.org/10.1074/jbc.M201119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12000750	hybrid			2022-12-27	WOS:000177189800007
J	McCabe, D; Cukierman, T; Gabay, JE				McCabe, D; Cukierman, T; Gabay, JE			Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HUMAN HBP/CAP37/AZUROCIDIN; SERINE PROTEASES; PROTEIN CAP37; LACTOFERRIN; LIPOPOLYSACCHARIDE; NEUTROPHILS; IDENTIFICATION; MONOCYTE; CELLS	Azurocidin/CAP37/HBP is an antimicrobial and chemotactic protein that is part of the innate defenses of human neutrophils. In addition, azurocidin is an inactive serine protease homolog with binding sites for diverse ligands including heparin and the bovine pancreatic trypsin inhibitor (BPTI). The structure of the protein reveals a highly cationic domain concentrated on one side of the molecule and responsible for its strong polarity. To investigate the role of this highly basic region, we produced three recombinant azurocidin mutant proteins that were altered in either one or both of two clusters of 4 basic residues located symmetrically on each side of a central cleft in the cationic domain. Two of the mutant proteins (Loop 3: R5Q, K6Q, R8Q, and R10Q; Loop 4: R61Q, R62Q, R63Q, and R65Q) exhibited little or no change in heparin and BPTI binding or in antimicrobial function. In contrast, the Loop 3/Loop 4 mutant (R5Q, K6Q, R8Q, R10Q, R61Q, R62Q R63Q, and R65Q) in which all 8 basic residues were replaced showed greatly decreased ability to bind heparin and to kill Escherichia coli and Candida albicans. Thus, we report that the 8 basic residues that were altered in the Loop 3/Loop 4 mutant contribute to the ability of the wild-type azurocidin molecule to bind heparin and to kill E. coli and C. albicans. Because BPTI binding was comparable in wild-type and Loop 3/Loop 4 mutant protein, we conclude that the same 8 basic residues are not involved in the binding of BPTI to azurocidin, supporting the notion that the binding site for BPTI is distinct from the site involved in heparin binding and antimicrobial activity. Finally, we show that removal of all 4 positively charged amino acids in the 20-44 azurocidin sequence (DMC1: R23Q,H24S,H32S,R34Q), a region previously thought to contain an antimicrobial domain, does not affect the activity of the protein against E. coli, Streptococcus faecalis, and C. albicans.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Gabay, JE (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023807] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23807] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMEIDA RP, 1991, BIOCHEM BIOPH RES CO, V177, P688, DOI 10.1016/0006-291X(91)91843-2; Almeida RP, 1996, PROTEIN EXPRES PURIF, V7, P355, DOI 10.1006/prep.1996.0053; Baveye S, 1999, CLIN CHEM LAB MED, V37, P281, DOI 10.1515/CCLM.1999.049; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brackett DJ, 1997, INFECT IMMUN, V65, P2803, DOI 10.1128/IAI.65.7.2803-2811.1997; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Chertov O, 1997, J EXP MED, V186, P739, DOI 10.1084/jem.186.5.739; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOHERTY DE, 1999, CHEST S1, V116, P34; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GABAY JE, 1994, CIBA F SYMP, V186, P237; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Heinzelmann M, 1998, INFECT IMMUN, V66, P5842, DOI 10.1128/IAI.66.12.5842-5847.1998; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iversen LF, 1997, NAT STRUCT BIOL, V4, P265, DOI 10.1038/nsb0497-265; Karlsen S, 1998, ACTA CRYSTALLOGR D, V54, P598, DOI 10.1107/S0907444997016193; Kastrup JS, 2001, PROTEINS, V42, P442, DOI 10.1002/1097-0134(20010301)42:4<442::AID-PROT30>3.0.CO;2-S; Kwan CP, 2001, J BIOL CHEM, V276, P23421, DOI 10.1074/jbc.M010786200; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Levy O, 2000, BLOOD, V96, P2664; Linde V, 2000, BIOTECHNIQUES, V28, P218, DOI 10.2144/00282bm06; MANN DM, 1994, J BIOL CHEM, V269, P23661; MORGAN JG, 1991, J IMMUNOL, V147, P3210; Nakamura I, 2001, PROTEIN EXPRES PURIF, V21, P424, DOI 10.1006/prep.2001.1396; PELLEGRINI A, 1992, J APPL BACTERIOL, V72, P180, DOI 10.1111/j.1365-2672.1992.tb01821.x; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; PETERSEN LC, 1993, EUR J BIOCHEM, V214, P271, DOI 10.1111/j.1432-1033.1993.tb17921.x; Rasmussen PB, 1996, FEBS LETT, V390, P109, DOI 10.1016/0014-5793(96)00639-4; SHAFER WM, 1984, INFECT IMMUN, V45, P29, DOI 10.1128/IAI.45.1.29-35.1984; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	34	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27477	27488		10.1074/jbc.M201586200	http://dx.doi.org/10.1074/jbc.M201586200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994286	hybrid			2022-12-27	WOS:000177055900097
J	Ruehl, M; Somasundaram, R; Schoenfelder, I; Farndale, RW; Knight, CG; Schmid, M; Ackermann, R; Riecken, EO; Zeitz, M; Schuppan, D				Ruehl, M; Somasundaram, R; Schoenfelder, I; Farndale, RW; Knight, CG; Schmid, M; Ackermann, R; Riecken, EO; Zeitz, M; Schuppan, D			The epithelial mitogen keratinocyte growth factor binds to collagens via the consensus sequence glycine-proline-hydroxyproline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; EXTRACELLULAR-MATRIX; FACTOR RECEPTORS; HEPARIN; INJURY; CELLS; RATS; PROLIFERATION; SIMILARITIES; TRANSCRIPTS	The binding of certain growth factors and cytokines to components of the extracellular matrix can regulate their local availability and modulate their biological activities. We show that mesenchymal cell-derived keratinocyte growth factor (KGF), a key stimulator of epithelial cell proliferation during wound healing, preferentially binds to collagens I, III, and VI. Binding is inhibited in a dose-dependent manner by denatured single collagen chains and collagen cyanogen bromide peptides. This interaction is saturable with dissociation constants of similar to10(-8) to 10(-9) m and estimated molar ratios of up to three molecules of KGF bound to one molecule of triple helical collagen. Furthermore, collagen-bound KGF stimulated the proliferation of transformed keratinocyte or HaCaT cells. Ligand blotting of collagen-derived peptides points to a limited set of collagenous consensus sequences that bind KGF. By using synthetic collagen peptides, we defined the consensus sequence (Gly-Pro-Hyp), as the collagen binding motif. We conclude that the preferential binding of KGF to the abundant collagens leads to a spatial pattern of bioavailable KGF that is dictated by the local organization of the collagenous extracellular matrix. The defined collagenous consensus peptide or its analogue may be useful in wound healing by increasing KGF bioactivity and thus modulating local epithelial remodeling and regeneration.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Med 1, D-12200 Berlin, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; University of Erlangen Nuremberg	Schuppan, D (corresponding author), Univ Erlangen Nurnberg, Med Klin 1, Krankenhousstr 12, D-91054 Erlangen, Germany.	detlef.schuppan@med1.imed.uni-erlangen.de		Somasundaram, Rajan/0000-0003-3461-3326				BajajElliott M, 1997, AM J PATHOL, V151, P1469; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Deterding RR, 1997, P ASSOC AM PHYSICIAN, V109, P254; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Farrell CL, 1998, CANCER RES, V58, P933; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; Finch PW, 1999, GUT, V45, P848, DOI 10.1136/gut.45.6.848; Gillis P, 1999, J CELL SCI, V112, P2049; Han DS, 2000, AM J PHYSIOL-GASTR L, V279, pG1011, DOI 10.1152/ajpgi.2000.279.5.G1011; Haseltine WA, 2001, J AM ACAD DERMATOL, V45, P473, DOI 10.1067/mjd.2001.117383; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; Jang JH, 2001, CANCER RES, V61, P3541; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; Jimenez PA, 1999, J SURG RES, V81, P238, DOI 10.1006/jsre.1998.5501; Khan WB, 1997, RADIAT RES, V148, P248, DOI 10.2307/3579609; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; La Rosa S, 2001, APPL IMMUNOHISTO M M, V9, P319, DOI 10.1097/00022744-200112000-00006; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MATTHES H, 1992, GASTROENTEROLOGY, V102, P431, DOI 10.1016/0016-5085(92)90087-F; Playford RJ, 1998, J PATHOL, V184, P316, DOI 10.1002/(SICI)1096-9896(199803)184:3<316::AID-PATH3>3.0.CO;2-#; Potten CS, 2001, CELL GROWTH DIFFER, V12, P265; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Schuppan D, 2001, SEMIN LIVER DIS, V21, P351, DOI 10.1055/s-2001-17556; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Somasundaram R, 2000, J BIOL CHEM, V275, P38170, DOI 10.1074/jbc.M006616200; Somasundaram R, 2002, J BIOL CHEM, V277, P3242, DOI 10.1074/jbc.M110011200; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tanahashi T, 1996, J BIOL CHEM, V271, P8221, DOI 10.1074/jbc.271.14.8221; Ueda T, 1999, CANCER RES, V59, P6080; Ulich TR, 1997, CANCER RES, V57, P472; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; Zeeh JM, 1996, GASTROENTEROLOGY, V110, P1077, DOI 10.1053/gast.1996.v110.pm8612996	45	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26872	26878		10.1074/jbc.M202335200	http://dx.doi.org/10.1074/jbc.M202335200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11973338	hybrid			2022-12-27	WOS:000177055900024
J	Chipuk, JE; Stewart, LV; Ranieri, A; Song, K; Danielpour, D				Chipuk, JE; Stewart, LV; Ranieri, A; Song, K; Danielpour, D			Identification and characterization of a novel rat ov-serpin family member, trespin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; GRANZYME-B INHIBITOR; CRYSTAL-STRUCTURE; TGF-BETA; ALPHA-1-PROTEINASE INHIBITOR; PROTEASE INHIBITOR; MOLECULAR-CLONING; OVALBUMIN FAMILY	Serpins are responsible for regulating a variety of proteolytic processes through a unique irreversible suicide substrate mechanism. To discover novel genes regulated by transforming growth factor-beta1 (TGF-beta1), we performed differential display reverse transcriptase-PCR analysis of NRP-152 rat prostatic epithelial cells and cloned a novel rat serpin that is transcriptionally down-regulated by TGF-beta and hence named trespin (TGF-beta-repressible serine proteinase inhibitor (trespin). Trespin is a 397-amino acid member of the ov-serpin clade with a calculated molecular mass of 45.2 kDa and 72% amino acid sequence homology to human bomapin; however, trespin exhibits different tissue expression, cellular localization, and proteinase specificity compared with bomapin. Trespin mRNA is expressed in many tissues, including brain, heart, kidney, liver, lung, prostate, skin, spleen, and stomach. FILAG-trespin expressed in HEK293 cells is localized predominantly in the cytoplasm and is not constitutively secreted. The presence of an arginine at the P1 position of trespin's reactive site loop suggests that trespin inhibits trypsin-like proteinases. Accordingly, in vitro transcribed and translated trespin forms detergent-stable and thermostable complexes with plasmin and elastase but not subtilisin A, trypsin, chymotrypsin, thrombin, or papain. Trespin interacts with plasmin at a near 1:1 stoichiometry, and immunopurified mammal-expressed trespin inhibits plasmin in a dose-dependent manner. These data suggest that trespin is a novel and functional member of the rat ov-serpin family.	Ireland Canc Ctr, Res Labs, Cleveland, OH 44106 USA; Case Western Reserve Univ Hosp, Dept Pharmacol, Cleveland, OH 44106 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Danielpour, D (corresponding author), Ireland Canc Ctr, Res Labs, Samuel Gerber Bldg,Suite 200,Lab 3,11001 Cedar Rd, Cleveland, OH 44106 USA.	dxd49@po.cwru.edu		Chipuk, Jerry Edward/0000-0002-1337-842X; Stewart, LaMonica/0000-0002-8056-6359	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, 1R01 CA3069-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Askew YS, 2001, J BIOL CHEM, V276, P49320, DOI 10.1074/jbc.M108879200; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bonham MJ, 1996, BIOTECHNIQUES, V21, P57; Buzza MS, 2001, CELL IMMUNOL, V210, P21, DOI 10.1006/cimm.2001.1806; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Chen YQ, 2001, THROMB HAEMOSTASIS, V86, P1563, DOI 10.1055/s-0037-1616763; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chuang TL, 1999, J BIOL CHEM, V274, P11194, DOI 10.1074/jbc.274.16.11194; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; CROWTHER D C, 1992, Current Opinion in Biotechnology, V3, P399, DOI 10.1016/0958-1669(92)90169-J; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1999, J CELL SCI, V112, P169; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Falk P, 2000, SCAND J CLIN LAB INV, V60, P439, DOI 10.1080/003655100448419; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Hayashida-Hibino S, 2001, INVEST OPHTH VIS SCI, V42, P1691; Hopkins PCR, 2000, J MOL EVOL, V51, P507, DOI 10.1007/s002390010114; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Hsing AY, 1996, CANCER RES, V56, P5146; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Maass N, 2000, ACTA ONCOL, V39, P931; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Riewald M, 1996, J BIOL CHEM, V271, P14526, DOI 10.1074/jbc.271.24.14526; Riewald M, 1998, BLOOD, V91, P1256, DOI 10.1182/blood.V91.4.1256; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Schleef RR, 2000, J BIOL CHEM, V275, P26385, DOI 10.1074/jbc.C000389200; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tang BW, 1999, CANCER RES, V59, P4834; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Wimalasena K, 1996, ANAL BIOCHEM, V234, P175, DOI 10.1006/abio.1996.0069; YE RD, 1989, J BIOL CHEM, V264, P5495; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZHAO S, 1995, BIOTECHNIQUES, V18, P842; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	69	6	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26412	26421		10.1074/jbc.M201244200	http://dx.doi.org/10.1074/jbc.M201244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986314	hybrid			2022-12-27	WOS:000176908700078
J	De Wulf, P; McGuire, AM; Liu, XQ; Lin, ECC				De Wulf, P; McGuire, AM; Liu, XQ; Lin, ECC			Genome-wide profiling of promoter recognition by the two-component response regulator CpxR-P in Escherichia coli.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ENVELOPE STRESS; SEQUENCE LOGOS; PROTEINS; MUTATIONS; BINDING; SYSTEM; INVOLVEMENT; SUPPRESSES; ACTIVATION	In Escherichia coli, the two-component Cpx system comprising the CpxA sensor kinase and the CpxR response regulator modulates gene expression in response to a variety of stresses including membrane-protein damage, starvation, and high osmolarity. To date, the few known CpxR-P target operons were mostly identified by genetic screens. To facilitate the discovery of all target operons, we derived a 15-bp weighted matrix for CpxR-P recognition that takes into account the relative base frequency at each nucleotide position. This matrix essentially consists of two tandem 5'-GTAAA-3' motifs separated by a 5-bp linker. All of the 15-bp stretches on both strands of the E. coli MG1655 genome were then scored for their degree of matching with the matrix and classified in statistical deviation groups. The effectiveness of this screening is indicated by the identification of eight new target operons (ung, ompC,psd, mviA, aroK, rpoErseABC, secA, and aer) among eleven candidates tested. Moreover, the matrix score correlates with the likelihood that a site is a true target and with the relative site affinity for CpxR-P in vitro. Our data indicate that some 100 operons are under direct CpxR-P control and that the signal transduction pathway interacts with several other control circuits in manners hitherto unanticipated.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	elin@hms.harvard.edu	Manson, Abigail/B-7132-2016	Manson, Abigail/0000-0002-3800-0714; LIU, XUEQIAO/0000-0001-7652-241X; De Wulf, Peter/0000-0001-9772-5881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; COSMA CL, 1995, MOL MICROBIOL, V18, P491, DOI 10.1111/j.1365-2958.1995.mmi_18030491.x; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Danese PN, 1998, J BACTERIOL, V180, P5875, DOI 10.1128/JB.180.22.5875-5884.1998; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; De Wulf P, 2000, MICROBIOL-UK, V146, P247, DOI 10.1099/00221287-146-2-247; De Wulf P, 2000, J BACTERIOL, V182, P1423, DOI 10.1128/JB.182.5.1423-1426.2000; Dorel C, 1999, FEMS MICROBIOL LETT, V178, P169, DOI 10.1016/S0378-1097(99)00347-X; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GROSS CA, 1996, ESCHERICHIA COLI SAL, V2, P1382; Harrison-McMonagle P, 1999, J MOL BIOL, V285, P555, DOI 10.1006/jmbi.1998.2375; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; MCEWEN J, 1980, P NATL ACAD SCI-BIOL, V77, P513, DOI 10.1073/pnas.77.1.513; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; Missiakas Dominique, 1996, P481; NAKAYAMA S, 1995, J BACTERIOL, V177, P5062, DOI 10.1128/jb.177.17.5062-5069.1995; Pogliano J, 1998, J BACTERIOL, V180, P3486, DOI 10.1128/JB.180.13.3486-3490.1998; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; RAINWATER S, 1990, J BACTERIOL, V172, P2456, DOI 10.1128/jb.172.5.2456-2461.1990; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; Raivio TL, 1999, J BACTERIOL, V181, P5263, DOI 10.1128/JB.181.17.5263-5272.1999; Raivio TL, 2000, MOL MICROBIOL, V37, P1186, DOI 10.1046/j.1365-2958.2000.02074.x; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Schneider TD, 1996, METHOD ENZYMOL, V274, P445; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SNYDER WB, 1995, J BACTERIOL, V177, P4216, DOI 10.1128/jb.177.15.4216-4223.1995; THORBJARNARDOTTIR SH, 1978, MOL GEN GENET, V161, P89, DOI 10.1007/BF00266619	39	163	167	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26652	26661		10.1074/jbc.M203487200	http://dx.doi.org/10.1074/jbc.M203487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11953442	hybrid			2022-12-27	WOS:000176908700107
J	Feng, K; Zhou, XH; Oohashi, T; Morgelin, M; Lustig, A; Hirakawa, S; Ninomiya, Y; Engel, J; Rauch, U; Fassler, R				Feng, K; Zhou, XH; Oohashi, T; Morgelin, M; Lustig, A; Hirakawa, S; Ninomiya, Y; Engel, J; Rauch, U; Fassler, R			All four members of the Ten-m/Odz family of transmembrane proteins form dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR-RULE GENE; COLLAGEN-VI; ODD OZ; EXPRESSION; TISSUES; TENASCIN; HOMOLOGS; LAMININ; BINDING; VIRUS	Ten-m/Odz/teneurins are a new family of four distinct type II transmembrane molecules. Their extracellular domains are composed of an array of eight consecutive EGF modules followed by a large globular domain. Two of the eight modules contain only 5 instead of the typical 6 cysteine residues and have the capability to dimerize in a covalent, disulfide-linked fashion. The structural properties of the extracellular domains of all four mouse Ten-m proteins have been analyzed using secreted, recombinant molecules produced by mammalian HEK-293 cells. Electron microscopic analysis supported by analytical ultracentrifugation data revealed that the recombinant extracellular domains of all Ten-m proteins formed homodimers. SDS-PAGE analysis under non-reducing conditions as well as negative staining after partial denaturation of the molecules indicated that the globular COOH-terminal domains of Ten-m1 and -m4 contained subdomains with a pronounced stability against denaturing agents, especially when compared with the homologous domains of Ten-m2 and -m3. Co-transfection experiments of mammalian cells with two different extracellular domains revealed that Ten-m molecules have also the ability to form heterodimers, a property that, combined with alternative splicing events, allows the formation of a multitude of molecules with different characteristics from a limited set of genes.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Lund Univ, Sect Connect Tissue Biol, Dept Expt Pathol, S-22185 Lund, Sweden; Lund Univ, Sect Connect Tissue Biol, Dept Cell & Mol Biol, S-22185 Lund, Sweden; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	Max Planck Society; Lund University; Lund University; Okayama University; University of Basel	Fassler, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Oohashi, Toshitaka/B-1599-2011	Oohashi, Toshitaka/0000-0002-9302-1913				BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; Ben-Zur T, 2000, DEV BIOL, V217, P107, DOI 10.1006/dbio.1999.9532; Brandau O, 1999, HUM MOL GENET, V8, P2407, DOI 10.1093/hmg/8.13.2407; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Levine A, 1997, DEV DYNAM, V209, P1, DOI 10.1002/(SICI)1097-0177(199705)209:1<1::AID-AJA1>3.0.CO;2-M; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Mieda M, 1999, MECH DEVELOP, V87, P223, DOI 10.1016/S0925-4773(99)00155-0; Minet AD, 1999, J CELL SCI, V112, P2019; Minet AD, 2000, GENE, V257, P87, DOI 10.1016/S0378-1119(00)00388-7; Oohashi T, 1999, J CELL BIOL, V145, P563, DOI 10.1083/jcb.145.3.563; Otaki JM, 1999, DEV BIOL, V212, P165, DOI 10.1006/dbio.1999.9310; RALSON G, 1993, INTRO ANAL ULTRACENT; Rubin BP, 1999, DEV BIOL, V216, P195, DOI 10.1006/dbio.1999.9503; Tucker RP, 2000, MECH DEVELOP, V98, P187, DOI 10.1016/S0925-4773(00)00444-5; Tucker RP, 2001, DEV DYNAM, V220, P27, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1084>3.0.CO;2-B; Van Holde K., 1971, PHYSICAL BIOCH, P98; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200	24	70	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26128	26135		10.1074/jbc.M203722200	http://dx.doi.org/10.1074/jbc.M203722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000766	hybrid			2022-12-27	WOS:000176908700040
J	Laboissiere, MCA; Young, MM; Pinho, RG; Todd, S; Fletterick, RJ; Kuntz, I; Craik, CS				Laboissiere, MCA; Young, MM; Pinho, RG; Todd, S; Fletterick, RJ; Kuntz, I; Craik, CS			Computer-assisted mutagenesis of ecotin to engineer its secondary binding site for urokinase inhibition.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; IN-VITRO SELECTION; PLASMINOGEN-ACTIVATOR; PEPTIDE LIBRARIES; 2-HYBRID SYSTEM; PHAGE DISPLAY; RNA; METASTASIS; MOLECULES; EVOLUTION	Inhibitors of urokinase-type plasminogen activator WPM were selected in vitro from two ecotin phage-display libraries to study the effect on binding of amino acid substitutions at critical positions 108, 110, 112, and 113 within the 100s loop (RNKL, respectively, in wild type ecotin). The first, a focused library, was the result of a computation-assisted approach using the three-dimensional structure of the ecotin-trypsin complex to guide the modeling of amino acid substitutions predicted to increase affinity for uPA. The second, a complete library, allowed for all substitutions at the above identified positions. The consensus sequences selected from the focused, and complete libraries were RRWS and R(R/N)QL, respectively. Inhibition constant determinations showed ecotin variants containing these sequences to be similarly potent (K-i = 1-2 nm). These substitutions were combined with previously identified substitutions in another critical region of ecotin. One of these combinations (D70R/M84R/RRQL) is the tightest (Ki = 50 pm) ecotin variant inhibitor of uPA. The blending of combinatorial methods and computer algorithms designed to predict stronger binders has allowed us to obtain protein derivatives that exhibit greatly increased affinity for a predetermined target. This technology can be applied to select for enhanced binding interactions at protein-protein interfaces and accelerate the process of protease inhibitor development.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Brasilia, Dept Ciencias Farmaceut, Fac Ciencias Saude, BR-70910900 Brasilia, DF, Brazil	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.			Young, Malin/0000-0001-8343-4469	NCI NIH HHS [CA72006] Funding Source: Medline; NIDDK NIH HHS [DK39304] Funding Source: Medline; NIGMS NIH HHS [GM31497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GULBA DC, 1996, ANN HEMATOL S1, V73, P9; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Hoogenboom HR, 1997, TRENDS BIOTECHNOL, V15, P62, DOI 10.1016/S0167-7799(97)84205-9; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; LEE HR, 1991, FEBS LETT, V287, P53, DOI 10.1016/0014-5793(91)80014-T; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Reuning U, 1998, INT J ONCOL, V13, P893; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WANG CI, 1995, J BIOL CHEM, V270, P12250, DOI 10.1074/jbc.270.20.12250; WELLS J A, 1992, Current Opinion in Biotechnology, V3, P355, DOI 10.1016/0958-1669(92)90163-D; Yang SQ, 1998, J MOL BIOL, V279, P945, DOI 10.1006/jmbi.1998.1748; Yang SQ, 1998, J MOL BIOL, V279, P1001, DOI 10.1006/jmbi.1998.1749; Zou XQ, 1999, J AM CHEM SOC, V121, P8033, DOI 10.1021/ja984102p	31	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26623	26631		10.1074/jbc.M203076200	http://dx.doi.org/10.1074/jbc.M203076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11959867	hybrid			2022-12-27	WOS:000176908700104
J	Rao, MK; Maiti, S; Ananthaswamy, HN; Wilkinson, MF				Rao, MK; Maiti, S; Ananthaswamy, HN; Wilkinson, MF			A highly active homeobox gene promoter regulated by Ets and Sp1 family members in normal granulosa cells and diverse tumor cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS SP1; REPRESS TRANSCRIPTION; NECROSIS-FACTOR; ONCOFETAL GENE; SERTOLI CELLS; STEM-CELLS; EXPRESSION; PEM; ACTIVATION	One mechanism by which normal cells become converted to tumor cells involves the aberrant transcriptional activation of genes that are normally silent. We characterize a promoter that normally exhibits highly tissue- and stage-specific expression but displays ubiquitous expression when cells become immortalized or malignant, regardless of their lineage or tissue origin. This promoter normally drives the expression of the Pem homeobox gene in specific cell types in ovary and placenta but is aberrantly expressed in lymphomas, neuroblastomas, retinoblastomas, carcinomas, and sarcomas. By deletion analysis we identified a region between nucleotides -80 and -104 that was absolutely critical for the expression from this distal Pem promoter (Pem Pd). Site-specific mutagenesis and transection studies revealed that this region contains two consensus Ets sites and a single Sp1 site that were necessary for Pem Pd expression. Gel shift analysis showed that Ets and Sp1 family members bound to these sites. Transfection studies demonstrated that the Ets family members Elf1 and Gabp and the Sp1 family members Sp1 and Sp3 transactivated the Pem Pd. Surprisingly, we found that Sp3 was a more potent activator of the Pem Pd than was Sp1; this is unusual, because Sp3 is either a weak activator or a repressor of most other promoters. Activation by either Elf1 or Gabp required an intact Sp1 family member binding site, suggesting that Ets and Sp1 family members cooperate to activate Pent Pd transcription. Expression from the Pem Pd (either transiently transfected or endogenous) depended on the Ras pathway, which could explain both its Ets- and Sp1-dependent expression in normal cells and its aberrant expression in tumor cells, in which ras protooncogenes are frequently mutated. We suggest that the Pem Pd may be a useful model system to understand the molecular mechanism by which a tissue-specific promoter can be corrupted in tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org						Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Bassuk AG, 1998, MOL MED, V4, P392, DOI 10.1007/BF03401746; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Caldas C, 1999, CANCER METAST REV, V18, P313, DOI 10.1023/A:1006333610078; CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Fan Y, 1999, DEV BIOL, V210, P481, DOI 10.1006/dbio.1999.9279; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; GALANG CK, 1994, ONCOGENE, V9, P2913; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Krikun G, 2000, MOL ENDOCRINOL, V14, P393, DOI 10.1210/me.14.3.393; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lindsey JS, 1996, DEV BIOL, V179, P471, DOI 10.1006/dbio.1996.0276; Lindsey JS, 1996, BIOL REPROD, V55, P975, DOI 10.1095/biolreprod55.5.975; Maiti S, 1996, J BIOL CHEM, V271, P17536, DOI 10.1074/jbc.271.29.17536; Maiti S, 2001, ENDOCRINOLOGY, V142, P1567, DOI 10.1210/en.142.4.1567; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Ono T, 2000, INT J CANCER, V88, P845, DOI 10.1002/1097-0215(20001215)88:6<845::AID-IJC1>3.0.CO;2-N; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Pitman JL, 1998, DEV BIOL, V202, P196, DOI 10.1006/dbio.1998.8978; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Rao M, 2002, EPIDIDYMIS MOL CLIN, P269, DOI 10.1007/978-1-4615-0679-9_15; Rieber M, 1999, INT J CANCER, V83, P359, DOI 10.1002/(SICI)1097-0215(19991029)83:3<359::AID-IJC11>3.0.CO;2-6; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SASAKI AW, 1991, MECH DEVELOP, V34, P155, DOI 10.1016/0925-4773(91)90052-8; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Serio KJ, 2000, AM J RESP CELL MOL, V23, P234, DOI 10.1165/ajrcmb.23.2.4042; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Sutton KA, 1997, GENOMICS, V45, P447, DOI 10.1006/geno.1997.4946; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Tomaras GD, 1999, J LEUKOCYTE BIOL, V66, P183, DOI 10.1002/jlb.66.1.183; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zachos G, 1997, CRIT REV ONCOL HEMAT, V26, P65, DOI 10.1016/S1040-8428(97)00013-9; Zannetti A, 2000, CANCER RES, V60, P1546	70	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26036	26045		10.1074/jbc.M203374200	http://dx.doi.org/10.1074/jbc.M203374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986330	hybrid			2022-12-27	WOS:000176908700029
J	Greene, BT; Thorburn, J; Willingham, MC; Thorburn, A; Planalp, RP; Brechbiel, MW; Jennings-Gee, J; Wilkinson, J; Torti, FM; Torti, SV				Greene, BT; Thorburn, J; Willingham, MC; Thorburn, A; Planalp, RP; Brechbiel, MW; Jennings-Gee, J; Wilkinson, J; Torti, FM; Torti, SV			Activation of caspase pathways during iron chelator-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; ISONICOTINOYL HYDRAZONE; NEUROBLASTOMA-CELLS; SIGNALING PATHWAY; NECROSIS-FACTOR; CYTOCHROME-C; PROTEIN P35; DEPRIVATION; CIS,CIS-1,3,5-TRIAMINOCYCLOHEXANE; INHIBITION	Iron chelators have traditionally been used in the treatment of iron overload. Recently, chelators have also been explored for their ability to limit oxidant damage in cardiovascular, neurologic, and inflammatory disease as well as to serve as anti-cancer agents. To determine the mechanism of cell death induced by iron chelators, we assessed the time course and pathways of caspase activation during apoptosis induced by iron chelators. We report that the chelator tachpyridine sequentially activates caspases 9, 3, and 8. These caspases were also activated by the structurally unrelated chelators dipyridyl and desferrioxamine. The critical role of caspase activation in cell death was supported by micro-injection experiments demonstrating that p35, a broad spectrum caspase inhibitor, protected HeLa cells from chelator-induced cell death. Apoptosis mediated by tachpyridine was not prevented by blocking the CD95 death receptor pathway with a Fas-associated death domain protein (FADD) dominant-negative mutant. In contrast, chelator-mediated cell death was blocked in cells microinjected with Bcl-XL and completely inhibited in cells microinjected with a dominant-negative caspase 9 expression vector. Caspase activation was not observed in cells treated with N-methyl tachpyridine, an N-alkylated derivative of tachpyridine which lacks an ability to react with iron. These results suggest that activation of a mitochondrial caspase pathway is an important mechanism by which iron chelators induce cell death.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; NIH, Radiat Oncol Branch, Bethesda, MD 20892 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; University System Of New Hampshire; University of New Hampshire; National Institutes of Health (NIH) - USA	Torti, SV (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Hanes Bldg,Rm 4057,Med Ctr Blvd, Winston Salem, NC 27157 USA.	storti@vfubmc.edu	Planalp, Roy/E-7115-2012	Planalp, Roy/0000-0001-5673-8694	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057781] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 57781] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe RD, 2001, CARCINOGENESIS, V22, P1607, DOI 10.1093/carcin/22.10.1607; Bowen T, 1996, BIOORG MED CHEM LETT, V6, P807, DOI 10.1016/0960-894X(96)00110-2; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fan LJ, 2001, CANCER RES, V61, P1073; Franchini M, 2000, HAEMATOLOGICA, V85, P1122; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Galanello R, 2001, SEMIN HEMATOL, V38, P73, DOI 10.1053/shem.2001.20147; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; HENNING RS, 2000, METHOD ENZYMOL, V322, P91; HILETI D, 1995, BRIT J HAEMATOL, V89, P181, DOI 10.1111/j.1365-2141.1995.tb08927.x; Horackova M, 2000, CARDIOVASC RES, V47, P529, DOI 10.1016/S0008-6363(00)00088-2; Ido Y, 1999, CELL PROLIFERAT, V32, P63, DOI 10.1046/j.1365-2184.1999.00133.x; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kovar J, 1997, PATHOBIOLOGY, V65, P61, DOI 10.1159/000164105; Kulp KS, 1996, EXP CELL RES, V229, P60, DOI 10.1006/excr.1996.0343; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZD, 2002, MED RES REV, V22, P26, DOI 10.1002/med.1027; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martelius T, 1999, TRANSPLANTATION, V68, P1753, DOI 10.1097/00007890-199912150-00020; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Park G, 1998, J BIOL INORG CHEM, V3, P449, DOI 10.1007/s007750050254; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Rakba N, 2000, CARCINOGENESIS, V21, P943, DOI 10.1093/carcin/21.5.943; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RIAZULHAQ, 1995, EXP HEMATOL, V23, P428; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Simonart T, 2000, J INVEST DERMATOL, V115, P893, DOI 10.1046/j.1523-1747.2000.00119.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Tetef ML, 2001, CLIN CANCER RES, V7, P1569; Thompson KJ, 2001, BRAIN RES BULL, V55, P155, DOI 10.1016/S0361-9230(01)00510-X; Torti SV, 1998, BLOOD, V92, P1384, DOI 10.1182/blood.V92.4.1384; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Weinberg ED, 1999, CANCER INVEST, V17, P507, DOI 10.3109/07357909909032860; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; Wilson MR, 1998, BIOCHEM CELL BIOL, V76, P573, DOI 10.1139/bcb-76-4-573; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	45	76	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25568	25575		10.1074/jbc.M110345200	http://dx.doi.org/10.1074/jbc.M110345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980894	hybrid			2022-12-27	WOS:000176747000094
J	Lopez-Carballo, G; Moreno, L; Masia, S; Perez, P; Barettino, D				Lopez-Carballo, G; Moreno, L; Masia, S; Perez, P; Barettino, D			Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ACHAETE-SCUTE HOMOLOG-1; LOOP-HELIX PROTEINS; GROWTH FACTOR-I; NEURONAL DIFFERENTIATION; BLASTOMA CELLS; NEURITE OUTGROWTH; ESTROGEN-RECEPTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION	Retinoic acid (RA) induces neural differentiation of SH-SY5Y neuroblastoma cells. We show that the mRNA levels of the differentiation-inhibiting basic helix-loop-helix transcription factors ID1, ID2, and ID3 are down-regulated during RA-induced differentiation of SHSY5Y cells. The levels of ID proteins decreased in parallel to the observed transcriptional repression. The expression of other basic helix-loop-helix genes changed during RA-induced differentiation: expression of neuroblast-specific ASCL1 (HASH-1) gene was promptly reduced after RA treatment, whereas expression of differentiation-promoting genes NEUROD6 (NEX-1, HATH-2) and NEUROD1 was increased. Treatments with 12-O-tetradecanoylphorbol-13-acetate, another inducer of neuroblastoma cell differentiation, also resulted in coordinated down-regulation of ID gene expression, underscoring the role of ID genes in differentiation. Downregulation of ID gene expression by RA involves a complex mechanism because full transcriptional repression required newly synthesized proteins and signaling by phosphatidylinositol 3-kinase (PI3K). RA treatment activates the PI3K/Akt signaling pathway, resulting in increased PI3K activity in extracts from RA-treated cells and a rapid increase in phosphorylation of Akt in Ser-473. Inhibition of PI3K by LY294002 impaired RA-induced differentiation, as assessed by morphological and biochemical criteria. We propose that RA, by activating the PI3K/Akt signaling pathway, plays an important role in the regulation of neuronal cell survival.	CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Barettino, D (corresponding author), CSIC, Inst Biomed Valencia, Jaime Roig 11, E-46010 Valencia, Spain.		Perez, Paloma/K-8841-2017; Moreno Royo, Lucrecia/A-8648-2017	Perez, Paloma/0000-0002-7166-2824; Moreno Royo, Lucrecia/0000-0002-9456-9649; Masia, Susana/0000-0002-9807-140X				Alexander F, 2000, UROL CLIN N AM, V27, P383, DOI 10.1016/S0094-0143(05)70087-2; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Asano T, 2000, J BIOL CHEM, V275, P17671, DOI 10.1074/jbc.M910391199; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chiaramello A, 1996, J BIOL CHEM, V271, P22035, DOI 10.1074/jbc.271.36.22035; Cho JH, 2001, J NEUROCHEM, V77, P103, DOI 10.1046/j.1471-4159.2001.t01-1-00230.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dragnev K H, 2000, Oncologist, V5, P361, DOI 10.1634/theoncologist.5-5-361; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Gestblom C, 1999, LAB INVEST, V79, P67; Ghigo D, 1998, J CELL PHYSIOL, V174, P99; Glass CK, 2000, GENE DEV, V14, P121; Grynfeld A, 2000, INT J CANCER, V88, P401, DOI 10.1002/1097-0215(20001101)88:3<401::AID-IJC12>3.3.CO;2-M; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HANADA M, 1993, CANCER RES, V53, P4978; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Ichimiya S, 2001, MED PEDIATR ONCOL, V36, P132, DOI 10.1002/1096-911X(20010101)36:1<132::AID-MPO1031>3.0.CO;2-A; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASORELLA A, 1995, CANCER RES, V55, P4711; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; MATTSSON MEK, 1986, J CELL BIOL, V102, P1949, DOI 10.1083/jcb.102.5.1949; Matz M, 1997, NUCLEIC ACIDS RES, V25, P2541, DOI 10.1093/nar/25.12.2541; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; Persson P, 2000, BIOCHEM BIOPH RES CO, V274, P22, DOI 10.1006/bbrc.2000.3090; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIDELL N, 1982, J NATL CANCER I, V68, P589; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Soderholm H, 1999, BIOCHEM BIOPH RES CO, V256, P557, DOI 10.1006/bbrc.1999.0314; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAHIRA T, 1991, ONCOGENE, V6, P2333; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; TAKEUCHI T, 1986, J CLIN INVEST, V77, P1038, DOI 10.1172/JCI112357; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WUARIN L, 1991, DEV BIOL, V144, P429, DOI 10.1016/0012-1606(91)90435-6; WUARIN L, 1990, INT J DEV NEUROSCI, V8, P317, DOI 10.1016/0736-5748(90)90038-4; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zile MH, 1998, J NUTR, V128, p455S, DOI 10.1093/jn/128.2.455S	80	208	215	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25297	25304		10.1074/jbc.M201869200	http://dx.doi.org/10.1074/jbc.M201869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000752	Green Submitted, hybrid			2022-12-27	WOS:000176747000060
J	Sepulveda, JL; Vlahopoulos, S; Iyer, D; Belaguli, N; Schwartz, RJ				Sepulveda, JL; Vlahopoulos, S; Iyer, D; Belaguli, N; Schwartz, RJ			Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; TINMAN HOMOLOG NKX-2.5; DNA-BINDING TARGETS; TRANSCRIPTION FACTORS; PROTEINS SP1; ACTIVATION; HOMEODOMAIN; PROMOTER; ELEMENTS; INTERACT	Herein, the restricted expression of serum response factors (SRF) closely overlapped with Nkx2-5 and GATA4 transcripts in early chick embryos coinciding with the earliest appearance of cardiac alpha-actin (alphaCA) transcripts and nascent myocardial cells. The combinatorial expression of SRF, a MADS box factor Nkx2-5 (a NK4 homeodomain), and/or GATA4, a dual C4 zinc finger protein, in heterologous CV1 fibroblasts and Schneider 2 insect cells demonstrated synergistic induction of alphaCA promoter activity. These three factors induced endogenous alphaCA mRNA over a 100-fold in murine embryonic stem cells. In addition, the DNA-binding defective mutant N-kx2-5pm efficiently coactivated the alphaCA promoter in the presence of SRF and GATA4 in the presence of all four SREs and was substantially weakened when individual SREs were mutated and or serially deleted. In contrast, the introduction of SRFpm, a SRF DNA-binding mutant, blocked the activation with all of the alphaCA promoter constructions. These assays indicated a dependence upon cooperative SRF binding for facilitating the recruitment of Nkx2-5 and GATA4 to the alphaCA promoter. Furthermore, the recruitment of Nkx2-5 and GATA4 by SRF was observed to strongly enhance SRF DNA binding affinity. This mechanism allowed for the formation of higher ordered alphaCA promoter DNA binding complexes, led to a model of SRF physical association with Nkx2-5 and GATA4.	Baylor Coll Med, Dept Mol & Cellular Biol, Div Cardiovasc Sci, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Div Cardiovasc Sci, Ctr Cardiovasc Dev, 1 Baylor Plaza,Rm 145E, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu	Vlahopoulos, Spiros/AAK-6362-2020; Vlahopoulos, Spiros A/A-1186-2014	Vlahopoulos, Spiros/0000-0001-6245-3863; Vlahopoulos, Spiros A/0000-0001-6245-3863	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albrecht BE, 1997, EUR J NEUROSCI, V9, P2414, DOI 10.1111/j.1460-9568.1997.tb01658.x; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; BODMER R, 1993, DEVELOPMENT, V118, P719; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MA JT, 1994, BIOCHEM BIOPH RES CO, V200, P1742, DOI 10.1006/bbrc.1994.1654; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Simon KJ, 1997, MOL CELL BIOL, V17, P6653, DOI 10.1128/MCB.17.11.6653; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Uetz P, 1996, ANAL BIOCHEM, V237, P161, DOI 10.1006/abio.1996.0220; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4	46	127	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25775	25782		10.1074/jbc.M203122200	http://dx.doi.org/10.1074/jbc.M203122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983708	hybrid			2022-12-27	WOS:000176747000120
J	Angata, T; Kerr, SC; Greaves, DR; Varki, NM; Crocker, PR; Varki, A				Angata, T; Kerr, SC; Greaves, DR; Varki, NM; Crocker, PR; Varki, A			Cloning and characterization of human Siglec-11 - A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PROTEIN-TYROSINE PHOSPHATASES; ACID-BINDING-SITE; SIALIC ACIDS; INHIBITORY RECEPTOR; SIALOADHESIN FAMILY; OLIGOSIALIC ACIDS; PRIMATE EVOLUTION; CELL-ADHESION; HUMAN CD33	Siglecs are sialic acid-recognizing animal lectins of the immunoglobulin superfamily. We have cloned and characterized a novel human molecule, Siglec-11, that belongs to the subgroup of CD33/Siglec-3-related Siglees. As with others in this subgroup, the cytosolic domain of Siglec-11 is phosphorylated at tyrosine residue(s) upon pervanadate treatment of cells and then recruits the protein-tyrosine phosphatases SHP-1 and SHP-2. However, Siglec-11 has several novel features relative to the other CD33/Siglec-3-related Siglecs. First, it binds specifically to alpha2-8-linked sialic acids. Second, unlike other CD33/Siglec-3-related Siglecs, Siglec-11 was not found on peripheral blood leukocytes. Instead, we observed its expression on macrophages in various tissues, such as liver Kupffer cells. Third, it was also expressed on brain microglia, thus becoming the second Siglec to be found in the nervous system. Fourth, whereas the Siglec-11 gene is on human chromosome 19, it lies outside the previously described CD33/Siglec-3-related Siglec cluster on this chromosome. Fifth, analyses of genome data bases indicate that Siglec-11 has no mouse ortholog and that it is likely to be the last canonical human Siglec to be reported. Finally, although Siglec-11 shows marked sequence similarity to human Siglec-10 in its extracellular domain, the cytosolic tail appears only distantly related. Analysis of genomic regions surrounding the Siglec-11 gene suggests that it is actually a chimeric molecule that arose from relatively recent gene duplication and recombination events, involving the extracellular domain of a closely related ancestral Siglec gene (which subsequently became a pseudogene) and a transmembrane and cytosolic tail derived from another ancestral Siglec.	Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Dundee, Sch Life Sci, Div Mol Cell Biol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Dundee; University of Oxford	Varki, A (corresponding author), Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	avarki@ucsd.edu		Crocker, Paul/0000-0001-6230-0293; Greaves, David/0000-0003-2856-9410	NHLBI NIH HHS [P01 HL57345-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Angata T, 2001, J BIOL CHEM, V276, P45128, DOI 10.1074/jbc.M108573200; Brand-Arpon V, 1999, GENOMICS, V56, P98, DOI 10.1006/geno.1998.5690; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Canavez F, 2001, J IMMUNOL, V167, P5786, DOI 10.4049/jimmunol.167.10.5786; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Gough PJ, 2001, IMMUNOLOGY, V103, P351, DOI 10.1046/j.1365-2567.2001.01256.x; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Ito A, 2001, FEBS LETT, V498, P116, DOI 10.1016/S0014-5793(01)02476-0; Johnson ME, 2001, NATURE, V413, P514, DOI 10.1038/35097067; KANTOR AB, 1997, WEIRS HDB EXPT IMMUN, V2; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KOOP BF, 1986, NATURE, V319, P234, DOI 10.1038/319234a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li N, 2001, J BIOL CHEM, V276, P28106, DOI 10.1074/jbc.M100467200; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; Nei M, 1997, P NATL ACAD SCI USA, V94, P7799, DOI 10.1073/pnas.94.15.7799; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Ohno S., 1970, EVOLUTION GENE DUPLI; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Paul SP, 2000, BLOOD, V96, P483; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Schnaar RL, 1998, ANN NY ACAD SCI, V845, P92, DOI 10.1111/j.1749-6632.1998.tb09664.x; Sharon D, 1999, GENOMICS, V61, P24, DOI 10.1006/geno.1999.5900; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; Stewart CB, 1998, CURR BIOL, V8, pR582, DOI 10.1016/S0960-9822(07)00367-3; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; TAYLOR CR, 1994, HUM PATHOL, V25, P263, DOI 10.1016/0046-8177(94)90198-8; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Ulyanova T, 2001, J BIOL CHEM, V276, P14451, DOI 10.1074/jbc.M011650200; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; Whitney G, 2001, EUR J BIOCHEM, V268, P6083, DOI 10.1046/j.0014-2956.2001.02543.x; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200; [No title captured]	63	145	153	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24466	24474		10.1074/jbc.M202833200	http://dx.doi.org/10.1074/jbc.M202833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986327	hybrid			2022-12-27	WOS:000176611800066
J	Mihalik, SJ; Steinberg, SJ; Pei, ZT; Park, J; Kim, DG; Heinzer, AK; Dacremont, G; Wanders, RJA; Cuebas, DA; Smith, KD; Watkins, PA				Mihalik, SJ; Steinberg, SJ; Pei, ZT; Park, J; Kim, DG; Heinzer, AK; Dacremont, G; Wanders, RJA; Cuebas, DA; Smith, KD; Watkins, PA			Participation of two members of the very long-chain acyl-CoA synthetase family in bile acid synthesis and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; X-LINKED ADRENOLEUKODYSTROPHY; COENZYME-A-LIGASE; FATTY-ACID; SUBCELLULAR-DISTRIBUTION; SUBSTRATE SPECIFICITIES; N-ACYLTRANSFERASE; CHOLIC-ACID; BIOSYNTHESIS; METABOLISM	Bile acids are synthesized de novo in the liver from cholesterol and conjugated to glycine or taurine via a complex series of reactions involving multiple organelles. Bile acids secreted into the small intestine are efficiently reabsorbed and reutilized. Activation by thio-esterification to CoA is required at two points in bile acid metabolism. First, 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid, the 27-carbon precursor of cholic acid, must be activated to its CoA derivative before side chain cleavage via peroxisomal beta-oxidation. Second, reutilization of cholate and other C-24 bile acids requires reactivation prior to re-conjugation. We reported previously that homolog 2 of very long-chain acyl-CoA synthetase (VLCS) can activate cholate (Steinberg, S. J., Mihalik, S. J., Kim, D. G., Cuebas, D. A., and Watkins, P. A. (2000) J. Biol. Chem. 275, 15605-15608). We now show that this enzyme also activates chenodeoxycholate, the secondary bile acids deoxycholate and lithocholate, and 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. In contrast, VLCS activated 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoate, but did not utilize any of the C-24 bile acids as substrates. We hypothesize that the primary function of homolog 2 is in the reactivation and recycling of C-24 bile acids, whereas VLCS participates in the de novo synthesis pathway. Results of in situ hybridization, topographic orientation, and inhibition studies are consistent with the proposed roles of these enzymes in bile acid metabolism.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; State Univ Ghent, Sch Med, Dept Pediat, B-9000 Ghent, Belgium; Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; SW Missouri State Univ, Dept Chem, Springfield, MO 65804 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Ghent University; University of Amsterdam; Academic Medical Center Amsterdam; Missouri State University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981, HD24061] Funding Source: Medline; NINDS NIH HHS [NS10533, NS37355] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Carey Martin C., 1994, P719; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Hofmann Alan F., 1994, P677; KASE BF, 1989, J BIOL CHEM, V264, P9220; KASE F, 1983, J LIPID RES, V24, P1560; KATZ N, 1989, EUR J BIOCHEM, V180, P185, DOI 10.1111/j.1432-1033.1989.tb14631.x; KATZ NR, 1983, EUR J BIOCHEM, V135, P103, DOI 10.1111/j.1432-1033.1983.tb07623.x; KILLENBERG PG, 1978, J LIPID RES, V19, P24; Kurosawa T, 1998, ANAL CHIM ACTA, V365, P249, DOI 10.1016/S0003-2670(97)00601-6; LIM WC, 1981, BIOCHEM J, V197, P611, DOI 10.1042/bj1970611; LOWRY OH, 1951, J BIOL CHEM, V193, P265; POLOKOFF MA, 1977, J BIOL CHEM, V252, P1167; ROST B, 1995, PROTEIN SCI, V4, P521; SCHEPERS L, 1989, BIOCHEM J, V257, P221, DOI 10.1042/bj2570221; Setchell KDR, 2001, LIVER DIS CHILDREN, P701; Smith BT, 2000, EXP CELL RES, V254, P309, DOI 10.1006/excr.1999.4757; Solaas K, 2000, J LIPID RES, V41, P1154; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Steinberg SJ, 1999, ANN NEUROL, V46, P409, DOI 10.1002/1531-8249(199909)46:3<409::AID-ANA18>3.0.CO;2-9; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; TSERNG KY, 1977, J LIPID RES, V18, P400; TWISK J, 1995, J CLIN INVEST, V95, P1235, DOI 10.1172/JCI117773; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; WATKINS PA, 1995, AM J HUM GENET, V57, P292; Wheeler JB, 1997, ARCH BIOCHEM BIOPHYS, V348, P15, DOI 10.1006/abbi.1997.0391; Xu RF, 1996, BIOCHEM BIOPH RES CO, V221, P271, DOI 10.1006/bbrc.1996.0585	35	86	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24771	24779		10.1074/jbc.M203295200	http://dx.doi.org/10.1074/jbc.M203295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980911	hybrid, Green Published			2022-12-27	WOS:000176611800104
J	Miura, S; Karnik, SS				Miura, S; Karnik, SS			Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; HELICES; MUTATION; AT(1); MECHANISMS; RHODOPSIN; BINDING; DOMAIN; ACID; VI	A key step in transmembrane (TM) signal transduction by G-protein-coupled receptors (GPCRs) is the ligand-induced conformational change of the receptor, which triggers the activation of a guanine nucleotide-binding protein. GPCRs contain a seven-TM helical structure essential for signal transduction in response to a large variety of sensory and hormonal signals. Primary structure comparison of GPCRs has shown that the second TM helix contains a highly conserved Asp residue, which is critical for agonist activation in these receptors. How conformational changes in TM2 relate to signal transduction by a GPCR is not known, because activation-induced conformational changes in TM2 helix have not been measured. Here we use modification of reporter cysteines to measure water accessibility at specific residues in TM2 of the type I receptor for the octapeptide hormone angiotensin II. Activation-dependent changes in the accessibility of Cys(76) on TM2 were measured in constitutively activated mutants. These changes were directly correlated with measurement of function, establishing the link between physical changes in TM2 and function. Accessibility changes were measured at several consecutive residues on TM2, which suggest that TM2 undergoes a transmembrane movement in response to activation. This is the first report of in situ measurement of TAU movement in a GPCR.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Karnik, SS (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	karniks@ccf.org	Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057470] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL064845, R01 HL057470, HL57470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Karnik SS, 2000, V CH MO CAR, V1, P117; Laporte SA, 1999, MOL ENDOCRINOL, V13, P578, DOI 10.1210/me.13.4.578; MARIE J, 1994, J BIOL CHEM, V269, P20815; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492	27	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24299	24305		10.1074/jbc.M202743200	http://dx.doi.org/10.1074/jbc.M202743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983705	hybrid			2022-12-27	WOS:000176611800044
J	Nakamura, J; Tajima, G; Sato, C				Nakamura, J; Tajima, G; Sato, C			Substrate regulation of calcium binding in Ca2+-ATPase molecules of the sarcoplasmic reticulum II. Effect of CTP, GTP, ITP, and UTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE; PUMP PROTEIN; ATP-BINDING; ION; PHOSPHORYLATION; STOICHIOMETRY; MODULATION; HYDROLYSIS; KINETICS	To examine the effect of CTP, GTP, ITP, and UTP on calcium binding of Ca2+-ATPase molecules of the sarcoplasmic reticulum, the calcium dependence of the Ca2+-activated hydrolysis activities of these NTPs of the enzyme molecules was examined by comparison with that of calcium binding of the molecules in the absence of the NTPs at pH 7.40. In the sarcoplasmic reticulum membrane, CTP, GTP, and ITP did not affect the noncooperative (Hill value (n(H)) of similar to1, apparent calcium affinity (K-0.5) of 2-6 mum)) and cooperative (n(H) similar to 2, K-0.5 similar to 0.2 mum) calcium binding of the molecules, whereas UTP caused the molecules to highly cooperatively (n(H) similar to 4) bind calcium ions with a lowered K-0.5 of similar to0.04 mum. When the enzyme molecules were solubilized with detergent, all of these NTPs reversibly degraded the calcium affinity of the molecule (from K-0.5 = 3-5 to >40 mum), although the effect of the NTPs on the negatively cooperative manner (n(H) similar to 0.5) of calcium binding was not experimentally obtained. Taking into account the first part of this study (Nakamura, J., Tajima, G., Sato, C., Furukohri, T., and Konishi, K. (2002) J. Biol. Chem. 277, 24180-24190) showing the improving effect of ATP on calcium binding of the membranous and solubilized molecules, the results show that ATP is the only intrinsic substrate for the enzyme molecule. This NTP regulation is discussed in terms of the oligomeric structure of the molecules.	Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808578, Japan; Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Tsukuba, Ibaraki 3058568, Japan	Tohoku University; National Institute of Advanced Industrial Science & Technology (AIST)	Nakamura, J (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808578, Japan.	jun-n@mail.cc.tohoku.ac.jp	Sato, Chikara/M-7183-2016	Sato, Chikara/0000-0001-5543-4496				BONTING SL, 1961, ARCH BIOCHEM BIOPHYS, V95, P416, DOI 10.1016/0003-9861(61)90170-9; de Meis L, 1973, J Biol Chem, V248, P3691; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; FERREIRA ST, 1988, J BIOL CHEM, V263, P9973; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2307; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1967, J BIOL CHEM, V242, P4637; KHAN MMT, 1966, J AM CHEM SOC, V88, P668; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAKINOSE M, 1965, BIOCHEM Z, V343, P383; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Nakamura J, 2002, J BIOL CHEM, V277, P24180, DOI 10.1074/jbc.M111834200; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TADA M, 1978, PHYSIOL REV, V58, P1; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANWINKLE WB, 1981, J BIOL CHEM, V256, P2268; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	32	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24191	24196		10.1074/jbc.M111836200	http://dx.doi.org/10.1074/jbc.M111836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976322	hybrid			2022-12-27	WOS:000176611800029
J	Miyajima, H; Miyaso, H; Okumura, M; Kurisu, J; Imaizumi, K				Miyajima, H; Miyaso, H; Okumura, M; Kurisu, J; Imaizumi, K			Identification of a cis-acting element for the regulation of SMN exon 7 splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; MOTOR-NEURON GENE; MOLECULAR ANALYSIS; HNRNP A1; SEVERITY; PROTEIN; DUPLICATION; EXPRESSION; ENHANCERS; DELETIONS	Spinal muscular atrophy results from the loss of functional survival motor neuron (SMN1) alleles. Two nearly identical copies of SMN exist and differ only by a single non-polymorphic C to T transition in exon 7. This transition leads to alteration of exon 7 splicing; that is, SMN1 produces a full-length transcript, whereas SMN2 expresses a low level of full-length transcript and predominantly an isoform lacking exon 7. The truncated transcript of SMN encodes a less stable protein with reduced self-oligomerization activity that fails to compensate for the loss of SMN1. In this paper, we identified a cis-acting element (element 1), which is composed of 45 bp in intron 6 responsible for the regulation of SMN exon 7 splicing. Mutations in element 1 or treatment with antisense oligonucleotides directed toward element 1 caused an increase in exon 7 inclusion. An similar to33-kDa protein was demonstrated to associate with a pre-mRNA sequence containing both element 1 and the C to T transition in SMN exon 7 but not with the sequence containing mutated element 1, suggesting that the binding of the similar to33-kDa protein plays crucial roles in the skipping of S3LV exon 7 containing the C to T transition.	NAIST, Div Struct Cellular Biol, Nara 6300101, Japan	Nara Institute of Science & Technology	Imaizumi, K (corresponding author), NAIST, Div Struct Cellular Biol, 8916-5 Takayama, Nara 6300101, Japan.			Miyaso, Hidenobu/0000-0003-2212-1500				Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brahe C, 1996, HUM MOL GENET, V5, P1971, DOI 10.1093/hmg/5.12.1971; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DiDonato CJ, 1997, ANN NEUROL, V41, P230, DOI 10.1002/ana.410410214; Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; PEARN J, 1980, LANCET, V1, P919; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Rochette CF, 2001, HUM GENET, V108, P255, DOI 10.1007/s004390100473; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Simard LR, 1997, AM J MED GENET, V72, P51, DOI 10.1002/(SICI)1096-8628(19971003)72:1<51::AID-AJMG11>3.0.CO;2-T; Tange TO, 2001, EMBO J, V20, P5748; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	30	84	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23271	23277		10.1074/jbc.M200851200	http://dx.doi.org/10.1074/jbc.M200851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956196	hybrid			2022-12-27	WOS:000176475700024
J	Sanchez-Chapula, JA; Navarro-Polanco, RA; Culberson, C; Chen, J; Sanguinetti, MC				Sanchez-Chapula, JA; Navarro-Polanco, RA; Culberson, C; Chen, J; Sanguinetti, MC			Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; POTASSIUM CHANNEL; RECEPTOR-SITE; CARDIAC-ARRHYTHMIA; CHLOROQUINE; RECTIFIER; MECHANISM; BINDING; RECTIFICATION; DOFETILIDE	The structural determinants for the voltage-dependent block of ion channels are poorly understood. Here we investigate the voltage-dependent block of wild-type and mutant human ether-a-go-go related gene (HERG) K+ channels by the antimalarial compound chloroquine. The block of wild-type HERG channels expressed in Xenopus oocytes was enhanced as the membrane potential was progressively depolarized. The IC50 was 8.4 +/- 0.9 muM when assessed during 4-s voltage clamp pulses to 0 mV. Chloroquine also slowed the apparent rate of HERG deactivation, reflecting the inability of drug-bound channels to close. Mutation to alanine of aromatic residues (Tyr-652 or Phe-656) located in the S6 domain of HERG greatly reduced the potency of channel block by chloroquine (IC50 > 1 mM at 0 mV). However, mutation of Tyr-652 also altered the voltage dependence of the block. In contrast to wild-type HERG, block of Y652A HERG channels was diminished by progressive membrane depolarization, and complete relief from block was observed at +40 mV. HERG channel block was voltage-independent when the hydroxyl group of Tyr-652 was removed by mutating the residue to Phe. Together these findings indicate a critical role for Tyr-652 in voltage dependent block of HERG channels. Molecular modeling was used to define energy-minimized dockings of chloroquine to the central cavity of HERG. Our experimental findings and modeling suggest that chloroquine preferentially blocks open HERG channels by cation-pi and v-stacking interactions with Tyr-652 and Phe-656 of multiple subunits.	Univ Utah, Eccles Inst Human Genet, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Univ Colima, Unidad Invest Carlos Mendez, Ctr Univ Invest Biomed, Colima 23000, Mexico; Merck Res Labs, Mol Syst, West Point, PA 19486 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Universidad de Colima; Merck & Company	Sanguinetti, MC (corresponding author), Univ Utah, Eccles Inst Human Genet, Eccles Program Human Mol Biol & Genet, 15 N 2030 E,Rm 4220, Salt Lake City, UT 84112 USA.	michael.sanguinetti@hmbg.utah.edu	Navarro-Polanco, Ricardo/AAQ-6152-2021; Sanguinetti, Michael/AAN-2615-2020		FOGARTY INTERNATIONAL CENTER [R03TW001211] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055236] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW001211] Funding Source: Medline; NHLBI NIH HHS [R01HL55236] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BUSTOS MDG, 1994, TROP MED PARASITOL, V45, P83; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ElSherif N, 1996, CIRC RES, V79, P474, DOI 10.1161/01.RES.79.3.474; FAUCHIER JP, 1993, ARCH MAL COEUR VAISS, V86, P757; FURUKAWA T, 1989, J PHARMACOL EXP THER, V251, P756; HARRIS L, 1988, CAN J CARDIOL, V4, P295; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; HONDEGHEM LM, 1984, ANNU REV PHARMACOL, V24, P387, DOI 10.1146/annurev.pa.24.040184.002131; Kamiya K, 2001, MOL PHARMACOL, V60, P244, DOI 10.1124/mol.60.2.244; Kang JS, 2001, MOL PHARMACOL, V59, P122, DOI 10.1124/mol.59.1.122; Kang JS, 2001, J PHARMACOL EXP THER, V299, P290; Katayama Y, 2000, J PHARMACOL EXP THER, V294, P339; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; MILLER MD, 1994, J COMPUT AID MOL DES, V8, P153, DOI 10.1007/BF00119865; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Roden DM, 1998, AM J CARDIOL, V82, p49I, DOI 10.1016/S0002-9149(98)00472-X; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437; SANGHVI LM, 1965, CIRCULATION, V32, P281, DOI 10.1161/01.CIR.32.2.281; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; STARMER CF, 1985, J THEOR BIOL, V115, P337, DOI 10.1016/S0022-5193(85)80196-X; STARMER CF, 1987, BIOPHYS J, V52, P405, DOI 10.1016/S0006-3495(87)83229-0; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YEH JZ, 1978, NATURE, V273, P387, DOI 10.1038/273387a0; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	41	157	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23587	23595		10.1074/jbc.M200448200	http://dx.doi.org/10.1074/jbc.M200448200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960982	hybrid			2022-12-27	WOS:000176475700064
J	Arakawa, R; Yokoyama, S				Arakawa, R; Yokoyama, S			Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR LIPID EFFLUX; TANGIER-DISEASE; CHOLESTEROL EFFLUX; ABCA1 TRANSPORTER; INHIBITION; ALPHA; FIBROBLASTS; MACROPHAGES; GENERATION	ATP-binding cassette transporter (ABC) A1 was increased by apolipoprotein A-I without an increase of its message in THP-1 cells. The pulse label study demonstrated that apoA-I retarded degradation of ABCA1. Similar changes were demonstrated by apoA-II, but the effect of high density lipoprotein was almost negligible on the basis of equivalent protein concentration. Thiol protease inhibitors (leupeptin and N-acetyl-Leu-Leu-norleucinal (ALLN)) increased ABCA1 and slowed its decay in the cells, whereas none of the proteosome-specific inhibitor lactacystin, other protease inhibitors, or the lysosomal inhibitor NH4Cl showed such effects. The effects of apoA-I and ALLN were additive for the increase of ABC.,U,, and the apoA-I-mediated cellular lipid release was enhanced by ALLN. The data suggest that ABCA1 is rapidly degraded by a thiol protease(s) in the cells unless helical apolipoproteins in their lipid-free form stabilize ABCA1 by protecting it from protease-mediated degradation.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem Cell Biol & Metab, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Grelan Pharmaceut Co Ltd, Div Res & Dev, Tokyo 2050002, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem Cell Biol & Metab, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.							Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2000, J LIPID RES, V41, P1952; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; Costet P, 2000, J BIOL CHEM, V275, P28240; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; LIANG HQ, 1995, BBA-LIPID LIPID MET, V1257, P31, DOI 10.1016/0005-2760(95)00055-H; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; TAJIMA S, 1983, J BIOL CHEM, V258, P73; Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	31	173	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22426	22429		10.1074/jbc.M202996200	http://dx.doi.org/10.1074/jbc.M202996200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950847	hybrid			2022-12-27	WOS:000176313600042
J	Tanoue, T; Yamamoto, T; Nishida, E				Tanoue, T; Yamamoto, T; Nishida, E			Modular structure of a docking surface on MAPK phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHATASES; SUBSTRATE SELECTIVITY; CRYSTAL-STRUCTURE; IN-VIVO; PTP-SL; ERK2; TRANSCRIPTION	Mitogen-activated protein kinases (MAPKs) must be precisely inactivated to achieve proper functions in the cells. Ten members of dual specificity phosphatases specifically acting on MAPKs, termed MAPK phosphatases (MKPs), have been reported. Each member has its own substrate specificity that should be tightly regulated. However, the molecular mechanism underlying the regulation of the specificity is largely unknown. In the MAPK signaling pathways, docking interactions, which are different from transient enzyme-substrate interaction, are known to regulate the enzymatic specificity. Here we have identified and characterized a docking surface of MKPs. Our results show that a docking surface is composed of a tandem alignment of three subregions (modules): a cluster of positively charged amino acids, a cluster of hydrophobic amino acids, and a cluster of positively charged amino acids (positive-hydrophobic-positive). This modular structure well fits the docking groove on MAPKs that we have previously identified and may contribute to regulating the docking specificity of the MKP family. The position, number, and species of charged amino acids in each module including the central hydrophobic subregion are important factors in regulation of docking to specific MAPKs. This modular structure in the docking interaction may define a novel model of protein-protein interaction that would also regulate other systems.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Yamamoto, Takuya/H-2792-2017	Yamamoto, Takuya/0000-0002-0022-3947				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811; Zhan XL, 2001, CHEM REV, V101, P2477, DOI 10.1021/cr000245u; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	52	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22942	22949		10.1074/jbc.M202096200	http://dx.doi.org/10.1074/jbc.M202096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953434	hybrid			2022-12-27	WOS:000176313600107
J	Powell, DW; Rane, MJ; Chen, QD; Singh, S; McLeish, KR				Powell, DW; Rane, MJ; Chen, QD; Singh, S; McLeish, KR			Identification of 14-3-3 zeta as a protein kinase B/Akt substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT; PHOSPHORYLATION; 14-3-3-PROTEINS; ACTIVATION; INHIBITION; APOPTOSIS; ISOFORMS; SURVIVAL; PKB/AKT; CELLS	Protein kinase B/Akt (PKB/Akt) is a member of the ACG kinase family, which also includes protein kinase C, that phosphorylates a number of 14-3-3-binding proteins. 14-3-3 protein regulation of protein kinase C activity is modulated by 14-3-3 phosphorylation. We examined the hypothesis that PKB/Akt interacts with and phosphorylates 14-3-3zeta, leading to modulation of dimerization. By glutathione S-transferase pull-down, Akt precipitated recombinant 14-3-3zeta and endogenous 14-3-3zeta from HEK293 cell lysates. Recombinant active PKB/ Akt phosphorylated recombinant 14-3-3zeta in an in vitro kinase assay. Transfection of active PKB/Akt into HEK293 cells resulted in phosphorylation of 14-3-3zeta. Based on a motif search of 14-3-3zeta, a potential PKB/Akt phosphorylation site, Ser-58, was mutated to alanine. PKB/Akt was unable to phosphorylate this mutant protein. Incubation of 14-3-3zeta with recombinant active PKB/ Akt resulted in phosphorylation of 45% of the protein, as determined by a pI shift on two-dimensional electrophoresis, but 14-3-3zeta dimerization was not altered. These data indicate that PKB/Akt phosphorylates Ser-58 on 14-3-3zeta both in vitro and in intact cells. The functional relevance of this phosphorylation remains to be determined.	Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McLeish, KR (corresponding author), Univ Louisville, Mol Signaling Grp, Kidney Dis Program, 615 S Preston St, Louisville, KY 40202 USA.		McLeish, Kenneth R./B-9819-2013; Powell, David W/E-9288-2013	McLeish, Kenneth R./0000-0002-7816-3286; 				ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; Autieri MV, 1999, DNA CELL BIOL, V18, P555, DOI 10.1089/104454999315105; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; HAUAAER A, 1999, J BIOL CHEM, V274, P9258; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lawlor MA, 2001, J CELL SCI, V114, P2903; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Meller N, 1996, MOL CELL BIOL, V16, P5782; Montano X, 2001, FEBS LETT, V507, P237, DOI 10.1016/S0014-5793(01)02903-9; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	23	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21639	21642		10.1074/jbc.M203167200	http://dx.doi.org/10.1074/jbc.M203167200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11956222	hybrid			2022-12-27	WOS:000176286000070
J	Deroo, BJ; Archer, TK				Deroo, BJ; Archer, TK			Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; GLUCOCORTICOID RECEPTOR; HEAT-SHOCK; PROTEIN DENATURATION; CHROMATIN STRUCTURE; MAMMALIAN-CELLS; 26S PROTEASOME; DEGRADATION; PROGESTINS; APOPTOSIS	Reporter enzymes are commonly used in cell biology to study transcriptional activity of genes. Recently, reporter enzymes in combination with compounds that inhibit proteasome function have been used to study the effect of blocking transcription factor degradation on gene activation. While investigating the effect of proteasome inhibition on steroid receptor activation of the mouse mammary tumor virus (MMTV) promoter, we found that treatment with proteasome inhibitors enhanced glucocorticoid activation of the promoter attached to a chloramphenicol acetyltransferase (CAT) reporter, but inhibited activation of MMTV attached to a firefly luciferase or beta-galactosidase reporter. MMTV RNA levels under these conditions correlated with the promoter activity observed using the CAT reporter, suggesting that proteasome inhibitor treatment interfered with luciferase or beta-galactosidase reporter assays. Washout experiments demonstrated that the majority of luciferase activity was lost if the proteasome inhibitor was added at the same time luciferase was produced, not once the functional protein was made, suggesting that proteasome inhibition interferes with production of luciferase protein. Indeed, we found that proteasome inhibitor treatment dramatically reduced the levels of luciferase and beta-galactosidase protein produced, as determined by Western blot. Thus, treatment with proteasome inhibitors interferes with luciferase and beta-galactosidase reporter assays, possibly by inhibiting production of a functional reporter protein.	NIEHS, Reprod & Dev Toxicol Lab, Chromatin & Gene Express Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Chromatin & Gene Express Sect, NIH, MD E4-06, Res Triangle Pk, NC 27709 USA.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Bush KT, 1997, J BIOL CHEM, V272, P9086; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DERON BJ, 2002, IN PRESS MOL CELL BI, V22; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lee PH, 1998, INT J ROBUST NONLIN, V8, P39; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Morley SJ, 2001, FEBS LETT, V503, P206, DOI 10.1016/S0014-5793(01)02735-1; Naylor LH, 1999, BIOCHEM PHARMACOL, V58, P749, DOI 10.1016/S0006-2952(99)00096-9; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; Nollen EAA, 2001, P NATL ACAD SCI USA, V98, P12038, DOI 10.1073/pnas.201112398; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; PINTO M, 1991, J BIOL CHEM, V266, P13941; Roussou I, 2000, CELL STRESS CHAPERON, V5, P8, DOI 10.1379/1466-1268(2000)005<0008:EPDIIT>2.0.CO;2; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	27	42	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20120	20123		10.1074/jbc.C200173200	http://dx.doi.org/10.1074/jbc.C200173200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11959849	hybrid			2022-12-27	WOS:000176204500003
J	Keller, C; Ladenburger, EM; Kremer, M; Knippers, R				Keller, C; Ladenburger, EM; Kremer, M; Knippers, R			The origin recognition complex marks a replication origin in the human TOP1 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA-REPLICATION; EUKARYOTIC DNA; MCM PROTEINS; IN-VIVO; SACCHAROMYCES-CEREVISIAE; INITIATION SITES; HNRNP-U; CHROMATIN; YEAST; ORC	The locations of the origin recognition complex (ORC) in mammalian genomes have been elusive. We have therefore analyzed the DNA sequences associated with human ORC via in vivo cross-linking and chromatin immunoprecipitation. Antibodies specific for hOrc2 protein precipitate chromatin fragments that also contain other ORC proteins, suggesting that the proteins form multisubunit complexes on chromatin in vivo. A binding region for ORC was identified at the CpG island upstream of the human TOP1 gene. Nascent strand abundance assays show that the ORC binding region coincides with an origin of bidirectional replication. The TOP1 gene includes two well characterized matrix attachment regions. The matrix attachment region elements analyzed contain no ORC and constitute no sites for replication initiation. In initial attempts to use the chromatin immunoprecipitation technique for the identification of additional ORC sites in the human genome, we isolated a sequence close to another actively transcribed gene (TOM1) and an alphoid satellite sequence that underlies centromeric heterochromatin. Nascent strand abundance assays gave no indication that the heterochromatin sequence serves as a replication initiation site, suggesting that an ORC on this site may perform functions other than replication initiation.	Univ Konstanz, Dept Biol, D-78464 Constance, Germany	University of Konstanz	Keller, C (corresponding author), Univ Konstanz, Dept Biol, D-78464 Constance, Germany.	Christian.Keller@uni-konstanz.de						Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Boulikas T, 1996, J CELL BIOCHEM, V60, P297, DOI 10.1002/(SICI)1097-4644(19960301)60:3<297::AID-JCB2>3.0.CO;2-R; BREWER BJ, 1993, COLD SPRING HARB SYM, V58, P425, DOI 10.1101/SQB.1993.058.01.049; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P31; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; Gencheva M, 1996, J BIOL CHEM, V271, P2608, DOI 10.1074/jbc.271.5.2608; Giacca M, 1997, METHODS, V13, P301, DOI 10.1006/meth.1997.0529; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; GUGGENHEIMER RA, 1984, P NATL ACAD SCI-BIOL, V81, P3069, DOI 10.1073/pnas.81.10.3069; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HEILAND S, 1995, MOL CELL BIOL, V15, P6623; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; Jorgensen AL, 1997, DAN MED BULL, V44, P522; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; KUNZE N, 1991, J BIOL CHEM, V266, P9610; KUNZE N, 1990, EUR J BIOCHEM, V194, P323, DOI 10.1111/j.1432-1033.1990.tb15620.x; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mechali M, 2001, NAT REV GENET, V2, P640, DOI 10.1038/35084598; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; Nickerson JA, 2001, J CELL SCI, V114, P463; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; ROMIG H, 1994, EUR J BIOCHEM, V221, P411, DOI 10.1111/j.1432-1033.1994.tb18753.x; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; Shareef MM, 2001, MOL BIOL CELL, V12, P1671, DOI 10.1091/mbc.12.6.1671; Simon I, 2001, EMBO J, V20, P6150, DOI 10.1093/emboj/20.21.6150; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Stagljar I, 1999, BIOL CHEM, V380, P525, DOI 10.1515/BC.1999.067; TODOROVIC V, 1999, FRONT BIOSCI, V4, P859; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; YOON Y, 1995, MOL CELL BIOL, V15, P2482; Zink D, 1999, EXP CELL RES, V247, P176, DOI 10.1006/excr.1998.4311	76	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31430	31440		10.1074/jbc.M202165200	http://dx.doi.org/10.1074/jbc.M202165200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12004060	hybrid			2022-12-27	WOS:000177718700020
J	Zhang, XW; Shu, LL; Hosoi, H; Murti, KG; Houghton, PJ				Zhang, XW; Shu, LL; Hosoi, H; Murti, KG; Houghton, PJ			Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MESSENGER-RNA; TRANSLATION INITIATION; ORNITHINE-DECARBOXYLASE; CYCLIN D1; PROTEIN; GROWTH; INHIBITION; EXPRESSION; RECEPTOR	Mammalian target of rapamycin (mTOR) controls initiation of translation through regulation of ribosomal p70S6 kinase (S6K1) and eukaryotic translation initiation factor-4E (eIF4E) binding protein (4E-BP). mTOR is considered to be located predominantly in cytosolic or membrane fractions and may shuttle between the cytoplasm and nucleus. In most previous studies a single cell line, E1A-immortalized human embryonic kidney cells (HEK293), has been used. Here we show that in human malignant cell lines, human fibroblasts, and murine myoblasts mTOR is predominantly nuclear. In contrast, mTOR is largely excluded from the nucleus in HEK293 cells. Hybrids between HEK293 and Rh30 rhabdomyosarcoma cells generated cells co-expressing markers unique to HEK293 (E1A) and Rh30 (MyoD). mTOR distribution was mainly nuclear with detectable levels in the cytoplasm. mTOR isolated from Rh30 nuclei phosphorylated recombinant GST-4E-BP1 (Thr-46) in vitro and thus has kinase activity. We next investigated the cellular distribution of mTOR substrates 4E-BP, S6K1, and eIF4E. 4E-BP was exclusively detected in cytoplasmic fractions in all cell lines. S6K1 was localized in the cytoplasm in colon carcinoma, HEK293 cells, and IMR90 fibroblasts. S6K1 was readily detected in all cellular fractions derived from rhabdomyosarcoma cells. eIF4E was detected in all fractions derived from rhabdomyosarcoma cells but was not detectable in nuclear fractions from colon carcinoma HEK293 or IMR90 cells.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N LauderdaleSt,Mail Stop 230, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Houghton, Peter/E-3265-2011		NCI NIH HHS [CA28765, CA77776, CA23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, R01CA077776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DILLING MB, 1994, CANCER RES, V54, P903; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Morton CL, 1998, J PHARMACOL EXP THER, V286, P1066; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; SOSINSKI J, 1994, MOL PHARMACOL, V45, P962; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; WRIGHT WE, 1978, EXP CELL RES, V112, P395, DOI 10.1016/0014-4827(78)90222-7	36	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28127	28134		10.1074/jbc.M202625200	http://dx.doi.org/10.1074/jbc.M202625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12000755	hybrid			2022-12-27	WOS:000177189800069
J	Shields, RL; Lai, J; Keck, R; O'Connell, LY; Hong, K; Meng, YG; Weikert, SHA; Presta, LG				Shields, RL; Lai, J; Keck, R; O'Connell, LY; Hong, K; Meng, YG; Weikert, SHA; Presta, LG			Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN SECRETION; GLYCOSYLATION PATTERN; RHEUMATOID-ARTHRITIS; EFFECTOR FUNCTIONS; RECEPTOR-II; AMINO-ACID; CARBOHYDRATE; RAT; COMPLEX	Lec13 cells, a variant Chinese hamster ovary cell line, were used to produce human IgG1 that were deficient in fucose attached to the Asn(297)-Iinked carbohydrate but were otherwise similar to that found in IgG1 produced in normal Chinese hamster ovary cell lines and from human serum. Lack of fucose on the IgG1 had no effect on binding to human FcgammaRI, C1q, or the neonatal Fc receptor. Although no change in affinity was found for the His(131) polymorphic form of human FcgammaRIIA, a slight improvement in binding was evident for FcgammaRIIB and the Arg(131) FcgammaRIIA polymorphic form. In contrast, binding of the fucose-deficient IgG1 to human FcgammaRIIIA was improved up to 50-fold. Antibody-dependent cellular cytotoxicity assays using purified peripheral blood monocytes or natural killer cells from several donors showed enhanced cytotoxicity, especially evident at lower antibody concentrations. When combined with an IgG1 Fc protein variant that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fucose was synergistic.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Cell Culture & Fermentat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Presta, LG (corresponding author), DNAX Res Inst Molec & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	leonard.presta@dnax.org						Anderson DR, 1997, BIOCHEM SOC T, V25, P705, DOI 10.1042/bst0250705; Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J; Boyd PN, 1995, MOL IMMUNOL, V32, P1311, DOI 10.1016/0161-5890(95)00118-2; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CLARK MR, 1989, J IMMUNOL, V143, P1731; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119.abs; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Gavin A, 1998, IMMUNOL MED, V26, P11; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Groenink J, 1996, EUR J IMMUNOL, V26, P1404, DOI 10.1002/eji.1830260634; HAND PH, 1992, CANCER IMMUNOL IMMUN, V35, P165, DOI 10.1007/BF01756183; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; HASHIM OH, 1987, MOL IMMUNOL, V24, P1087, DOI 10.1016/0161-5890(87)90077-0; HASHIM OH, 1988, IMMUNOLOGY, V63, P383; HOBBS SM, 1992, MOL IMMUNOL, V29, P949, DOI 10.1016/0161-5890(92)90133-I; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Jassal R, 2001, BIOCHEM BIOPH RES CO, V286, P243, DOI 10.1006/bbrc.2001.5382; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; KAUSHAL GP, 1994, METHOD ENZYMOL, V230, P316; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Kumpel Belinda M., 1994, Human Antibodies and Hybridomas, V5, P143; Lifely MR, 1995, GLYCOBIOLOGY, V5, P813, DOI 10.1093/glycob/5.8.813; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; Makrides SC, 1998, PHARMACOL REV, V50, P59; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; MATHER JP, 1992, Patent No. 5122469; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; Okafo GN, 1996, ANAL BIOCHEM, V240, P68, DOI 10.1006/abio.1996.0332; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Penichet ML, 2001, J IMMUNOL METHODS, V248, P91, DOI 10.1016/S0022-1759(00)00345-8; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; ROTHMAN RJ, 1989, MOL IMMUNOL, V26, P1113, DOI 10.1016/0161-5890(89)90055-2; Routier FH, 1997, GLYCOCONJUGATE J, V14, P201, DOI 10.1023/A:1018589704981; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Sampson JH, 2000, P NATL ACAD SCI USA, V97, P7503, DOI 10.1073/pnas.130166597; Segal DM, 2001, J IMMUNOL METHODS, V248, P1, DOI 10.1016/S0022-1759(00)00338-0; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; TAO MH, 1989, J IMMUNOL, V143, P2595; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WAWRZYNCZAK EJ, 1992, MOL IMMUNOL, V29, P213, DOI 10.1016/0161-5890(92)90102-4; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wright A, 1998, J IMMUNOL, V160, P3393; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616	65	1287	2142	3	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26733	26740		10.1074/jbc.M202069200	http://dx.doi.org/10.1074/jbc.M202069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11986321	hybrid			2022-12-27	WOS:000177055900006
J	Min, GS; Kemper, JK; Kemper, B				Min, GS; Kemper, JK; Kemper, B			Glucocorticoid receptor-interacting protein 1 mediates ligand-independent nuclear translocation and activation of constitutive androstane receptor in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-RESPONSIVE ENHANCER; XENOBIOTIC INDUCTION; CYP2B GENE; FACTOR-I; CAR; COACTIVATOR; ELEMENTS; BINDING; BETA; TIF2	Phenobarbital (PB) induction of CYP2B genes is mediated by translocation of the constitutively active androstane receptor (CAR) to the nucleus. Interaction of CAR with p160 coactivators and enhancement of CAR transactivation by the coactivators have been shown in cultured cells. In the present studies, the interaction of CAR with the p160 coactivator glucocorticoid receptor-interacting protein 1 (GRIP1) was examined in vitro and in vivo. Binding of GRIP1 to CAR was shown by glutathione S-transferase (GST) pull-down and affinity DNA binding. N- or C-terminal fragments of GRIP1 that contained the central receptor-interacting domain bound to GST-CAR, but the presence of ligand increased the binding to GST-CAR of only the fragments containing the C-terminal region. In gel shift analysis, binding to was observed only with GRIP1 fragments containing the C-terminal region, and the binding was increased by a CAR agonist and decreased by a CAR antagonist. Expression of GRIP1 enhanced CAR-mediated transactivation in cultured hepatic-derived cells 2-3-fold. In hepatocytes transfected in vivo, expression of exogenous GRIP1 alone induced transactivation of the CYP2B1 PB-dependent enhancer 15-fold, whereas CAR expression alone resulted in only a 3-fold enhancement in untreated mice. Remarkably, CAR and GRIP1 together synergistically transactivated the enhancer about 150-fold, which is approximately equal to activation by PB treatment. In PB-treated mice, expression of exogenous CAR alone had little effect, expression of GRIP1 increased transactivation about 2-fold, and with CAR and GRIP, a 4-fold activation was observed. In untreated mice, expression of GRIP resulted in nuclear translocation of green fluorescent protein-CAR. These results strongly suggest that a p160 coactivator functions in CAR-mediated transactivation in vivo in response to PB treatment and that the synergistic activation of CAR by GRIP in untreated animals results from both nuclear translocation and activation of CAR.	Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM39360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; ESTABROOK RW, 1971, BIOCHEM BIOPH RES CO, V42, P132, DOI 10.1016/0006-291X(71)90372-X; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Gervois P, 2001, J BIOL CHEM, V276, P33471, DOI 10.1074/jbc.M102839200; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HAGSTROM JE, 1999, PANVERA POSTINGS, V5, P2; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; Paquet Y, 2000, J BIOL CHEM, V275, P38427, DOI 10.1074/jbc.M005776200; Puustinen R, 2001, EUR J ENDOCRINOL, V145, P323, DOI 10.1530/eje.0.1450323; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TANAKA H, 1993, J BIOL CHEM, V268, P1854; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557	35	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26356	26363		10.1074/jbc.M200051200	http://dx.doi.org/10.1074/jbc.M200051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000748	hybrid			2022-12-27	WOS:000176908700071
J	Rattenholl, A; Pappano, WN; Koch, M; Keene, DR; Kadler, KE; Sasaki, T; Timpl, R; Burgeson, RE; Greenspan, DS; Bruckner-Tuderman, L				Rattenholl, A; Pappano, WN; Koch, M; Keene, DR; Kadler, KE; Sasaki, T; Timpl, R; Burgeson, RE; Greenspan, DS; Bruckner-Tuderman, L			Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOLLOID-LIKE; C-PROTEINASE; I PROCOLLAGEN; MATRIX METALLOPROTEINASES; EPIDERMOLYSIS-BULLOSA; EXTRACELLULAR-MATRIX; FIBROGENIC CELLS; GAMMA-2 CHAIN; TISSUE FORM; SHORT ARM	Collagen VII is the major structural component of the anchoring fibrils at the dermal-epidermal junction in the skin. It is secreted by keratinocytes as a precursor, procollagen VII, and processed into mature collagen during polymerization of the anchoring fibrils. We show that bone morphogenetic protein-1 (BMP-1), which exhibits procollagen C-proteinase activity, cleaves the C-terminal propeptide from human procollagen VII. The cleavage occurs at the BMP-1 consensus cleavage site SYAA down arrow DTAG within the NC-2 domain. Mammalian tolloid-like (mTLL)-1 and -2, two other proteases of the astacin enzyme family, were able to process procollagen VII at the same site in vitro. Immunohistochemical and genetic evidence supported the involvement of these enzymes in cleaving type VII procollagen in vivo. Both BMP-1 and mTLL-1 are expressed in the skin and in cultured cutaneous cells. A naturally occurring deletion in the human COL7A1 gene, 8523del14, which is associated with dystrophic epidermolysis bullosa and eliminates the BMP-1 consensus sequence, abolished processing of procollagen VII, and in mutant skin procollagen VII accumulated at the dermal-epidermal junction. On the other hand, deficiency of BMP-1 in the skin of knockout mouse embryos did not prevent processing of procollagen VII to mature collagen, suggesting that mTLL-1 and/or mTLL-2 can substitute for BMP-1 in the processing of procollagen VII in situ.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Cambridge, MA 02139 USA; Shriners Hosp Children, Portland, OR 97201 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munster; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital; University of Manchester; Max Planck Society	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany.	tuderma@uni-muenster.de	KADLER, KARL/ABI-2403-2020; Koch, Manuel/AAG-9914-2021	KADLER, KARL/0000-0003-4977-4683; Koch, Manuel/0000-0002-2962-7814; Greenspan, Daniel/0000-0001-8096-7446; Pappano, William/0000-0003-2848-2219	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM63471] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Arnold U, 1999, ANAL BIOCHEM, V271, P197, DOI 10.1006/abio.1999.4149; Betts CM, 1999, BRIT J DERMATOL, V141, P833, DOI 10.1046/j.1365-2133.1999.03155.x; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Bruckner-Tuderman L, 1999, J DERMATOL SCI, V20, P122, DOI 10.1016/S0923-1811(99)00018-3; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; Chen M, 2001, J BIOL CHEM, V276, P21649, DOI 10.1074/jbc.M100180200; Chen M, 2000, J BIOL CHEM, V275, P24429, DOI 10.1074/jbc.M003440200; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; Clark TG, 1999, DEVELOPMENT, V126, P2631; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Gagnoux-Palacios L, 2001, J CELL BIOL, V153, P835, DOI 10.1083/jcb.153.4.835; Gardella R, 1996, AM J HUM GENET, V59, P292; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; HOJIMA Y, 1994, ANAL BIOCHEM, V223, P173, DOI 10.1006/abio.1994.1569; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; KONIG A, 1994, LAB INVEST, V70, P203; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Tunggal L, 2002, AM J PATHOL, V160, P459, DOI 10.1016/S0002-9440(10)64865-1; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Yamada H, 2001, HUM MOL GENET, V10, P1563, DOI 10.1093/hmg/10.15.1563	58	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26372	26378		10.1074/jbc.M203247200	http://dx.doi.org/10.1074/jbc.M203247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986329	hybrid			2022-12-27	WOS:000176908700073
J	Toth, M; Hernandez-Barrantes, S; Osenkowski, P; Bernardo, MM; Gervasi, DC; Shimura, Y; Meroueh, O; Kotra, LP; Galvez, BG; Arroyo, AG; Mobashery, S; Fridman, R				Toth, M; Hernandez-Barrantes, S; Osenkowski, P; Bernardo, MM; Gervasi, DC; Shimura, Y; Meroueh, O; Kotra, LP; Galvez, BG; Arroyo, AG; Mobashery, S; Fridman, R			Complex pattern of membrane type 1 matrix metalloproteinase shedding - Regulation by autocatalytic cell surface inactivation of active enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; TISSUE INHIBITOR; PROGELATINASE-A; GELATINASE-A; 1-MATRIX METALLOPROTEINASE; PRO-MMP-2 ACTIVATION; FIBROSARCOMA CELLS; 72-KDA GELATINASE; CATALYTIC DOMAIN; IV COLLAGENASE	Membrane type I matrix metalloproteinase (MT1-MMP) is a type I transmembrane AIMP shown to play a critical role in normal development and in malignant processes. Emerging evidence indicates that MT1-MMP is regulated by a process of ectodomain shedding. Active MT1-MMP undergoes autocatalytic processing on the cell surface, leading to the formation of an inactive 44kDa fragment and release of the entire catalytic domain. Analysis of the released MT1-MMP forms in various cell types revealed a complex pattern of shedding involving two major fragments of 50 and 18 kDa and two minor species of 56 and 31-35 kDa. Protease inhibitor studies and a catalytically inactive MT1-MMP mutant revealed both autocatalytic (18 kDa) and non-autocatalytic (56, 50, and 31-35 kDa) shedding mechanisms. Purification and sequencing of the 18-kDa fragment indicated that it extends from Tyr(112) to Ala(255). Structural and sequencing data indicate that shedding of the 18-kDa fragment is initiated at the Gly(284)-Gly(285) site, followed by cleavage between the conserved Ala(255) and Ile(256) residues near the conserved methionine turn, a structural feature of the catalytic domain of all MMPs. Consistently, a recombinant 18-kDa fragment had no catalytic activity and did not bind TIMP-2. Thus, autocatalytic shedding evolved as a specific mechanism to terminate MT1-MMP activity on the cell surface by disrupting enzyme integrity at a vital structural site. In contrast, functional data suggest that the non-autocatalytic shedding generates soluble active MT1-MMP species capable of binding TIMP-2. These studies suggest that ectodomain shedding regulates the pericellular and extracellular activities of MT1-MMP through a delicate balance of active and inactive enzyme-soluble fragments.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Chem, Detroit, MI 48201 USA; Hosp Princesa, Dept Inmunol, Madrid 28006, Spain	Wayne State University; Wayne State University; Hospital de La Princesa	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Arroyo, Alicia G./L-2796-2014; Gálvez, Beatriz G./H-1644-2015	Arroyo, Alicia G./0000-0002-1536-3846; Gálvez, Beatriz G./0000-0002-8082-9323; Kotra, Lakshmi P./0000-0002-7071-4637	NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Bigg HF, 2001, CANCER RES, V61, P3610; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brown PD, 1997, MED ONCOL, V14, P1, DOI 10.1007/BF02990939; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CASE DA, 1997, AMBER 5 0 COMPUTER P; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Dolo V, 1998, CANCER RES, V58, P4468; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Foda HD, 1996, LAB INVEST, V74, P538; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Harayama T, 1999, JPN J CANCER RES, V90, P942, DOI 10.1111/j.1349-7006.1999.tb00839.x; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Imai K, 1996, CANCER RES, V56, P2707; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kiessling LL, 1998, CHEM BIOL, V5, pR49, DOI 10.1016/S1074-5521(98)90056-4; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Li H, 1998, MOL CARCINOGEN, V22, P84; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Toth M, 1999, J CELL PHYSIOL, V180, P131, DOI 10.1002/(SICI)1097-4652(199907)180:1<131::AID-JCP15>3.0.CO;2-S; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 1997, CANCER RES, V57, P3159; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; YU M, 1995, CANCER RES, V55, P3272	62	102	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26340	26350		10.1074/jbc.M200655200	http://dx.doi.org/10.1074/jbc.M200655200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004057	hybrid			2022-12-27	WOS:000176908700069
J	Chantret, I; Dupre, T; Delenda, C; Bucher, S; Dancourt, J; Barnier, A; Charollais, A; Heron, D; Bader-Meunier, B; Danos, O; Seta, N; Durand, G; Oriol, R; Codogno, P; Moore, SEH				Chantret, I; Dupre, T; Delenda, C; Bucher, S; Dancourt, J; Barnier, A; Charollais, A; Heron, D; Bader-Meunier, B; Danos, O; Seta, N; Durand, G; Oriol, R; Codogno, P; Moore, SEH			Congenital disorders of glycosylation type ig is defined by a deficiency in dolichyl-P-mannose : Man(7)GlcNAc(2)-PP-dolichyl mannosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	International Symposium on Protein Traffic Glycosylation and Human Health	MAY 12-16, 2001	INTERLAKEN, SWITZERLAND				ALPHA-D-MANNOSIDASE; N-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; LINKED OLIGOSACCHARIDES; PROTEIN GLYCOSYLATION; GENE; DEGRADATION; MUTATIONS; YEAST	Type I congenital disorders of glycosylation (CDGI) are diseases presenting multisystemic lesions including central and peripheral nervous system deficits. The disease is characterized by under-glycosylated serum glycoproteins and is caused by mutations in genes encoding proteins involved in the stepwise assembly of dolichol-oligosaccharide used for protein N-glycosylation. We report that fibroblasts from a type I CDG patient, born of consanguineous parents, are deficient in their capacity to add the eighth mannose residue onto the lipid-linked oligosaccharide precursor. We have characterized cDNA corresponding to the human ortholog of the yeast gene ALG12 that encodes the dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl alpha6-mannosyltransferase that is thought to accomplish this reaction, and we show that the patient is homozygous for a point mutation (T571G) that causes an amino acid substitution (F142V) in a conserved region of the protein. As the pathological phenotype of the fibroblasts of the patient was largely normalized upon transduction with the wild type gene, we demonstrate that the F142V substitution is the underlying cause of this new CDG, which we suggest be called CDG Ig. Finally, we show that the fibroblasts of the patient are capable of the direct transfer of Man(7)GlcNAc(2) from dolichol onto protein and that this N-linked structure can be glucosylated by UDP-glucose: glycoprotein glucosyltransferase in the endoplasmic reticulum.	INSERM, U504, Unite Glycobiol & Signalisat Cellulaire, 16 Ave Paul Vaillant Couturier,Batiment INSERM, F-94807 Villejuif, France; Hop Bichat Claude Bernard, Biochim A, Paris, France; Assistance Publ Hop Paris, Hop Bicetre, Paris, France; Assistance Publ Hop Paris, Hop La Pitie Salpetriere, Paris, France; CNRS, URA 1923, Genethon 3, F-91002 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)	Moore, SEH (corresponding author), INSERM, U504, Unite Glycobiol & Signalisat Cellulaire, 16 Ave Paul Vaillant Couturier,Batiment INSERM, F-94807 Villejuif, France.	moore@vjf.inserm.fr	Codogno, Patrice/G-1384-2013; Dancourt, Julia/U-1533-2017; CHANTRET, Isabelle/AAF-7134-2021; Moore, Stuart/AAF-3920-2021; Seta, Nathalie S/F-1824-2018	Codogno, Patrice/0000-0002-5492-3180; Dancourt, Julia/0000-0002-6237-1566; CHANTRET, Isabelle/0000-0002-0896-1274; Moore, Stuart/0000-0002-1020-2242; Seta, Nathalie S/0000-0002-9240-8630; bader-meunier, brigitte/0000-0001-8476-8196				ABEIJON C, 1990, J BIOL CHEM, V265, P14691; Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; CHANTRET I, 1994, J CELL SCI, V107, P213; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cipollo JF, 2001, J BIOL CHEM, V276, P21828, DOI 10.1074/jbc.M010896200; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; de Koning TJ, 2000, VIRCHOWS ARCH, V437, P101, DOI 10.1007/s004280000185; Dupre T, 2000, GLYCOBIOLOGY, V10, P1277, DOI 10.1093/glycob/10.12.1277; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Freeze HH, 2001, GLYCOBIOLOGY, V11, p129R, DOI 10.1093/glycob/11.12.129R; Freeze HH, 1998, J PEDIATR-US, V133, P593, DOI 10.1016/S0022-3476(98)70096-4; Freeze HH, 1999, BIOCHEM BIOPH RES CO, V255, P189, DOI 10.1006/bbrc.1998.9945; Grunewald S, 2000, ANN NEUROL, V47, P776; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; JAEKEN J, 1993, J INHERIT METAB DIS, V16, P813, DOI 10.1007/BF00714272; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Kim S, 2000, J CLIN INVEST, V105, P191, DOI 10.1172/JCI7302; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1999, EMBO J, V18, P6816, DOI 10.1093/emboj/18.23.6816; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kornfeld S, 1998, J CLIN INVEST, V101, P1293, DOI 10.1172/JCI3140; Kranz C, 2001, J CLIN INVEST, V108, P1613, DOI 10.1172/JCI200113635; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MARQUARDT T, 1995, EUR J CELL BIOL, V66, P268; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; ROMERO PA, 1986, J BIOL CHEM, V261, P5936; Schachter H, 2001, J CLIN INVEST, V108, P1579, DOI 10.1172/JCI200114498; Schachter H, 2001, CELL MOL LIFE SCI, V58, P1085, DOI 10.1007/PL00000923; Schenk B, 2001, J CLIN INVEST, V108, P1687, DOI 10.1172/JCI200113419; Seta N, 1996, CLIN CHIM ACTA, V254, P131, DOI 10.1016/0009-8981(96)06379-6; Sharma CB, 2001, BIOL CHEM, V382, P321, DOI 10.1515/BC.2001.039; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO MJ, 1976, J BIOL CHEM, V251, P6420; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	55	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25815	25822		10.1074/jbc.M203285200	http://dx.doi.org/10.1074/jbc.M203285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	11983712	hybrid			2022-12-27	WOS:000176747000124
J	Xiao, C; Yang, BF; Asadi, N; Beguinot, F; Hao, CH				Xiao, C; Yang, BF; Asadi, N; Beguinot, F; Hao, CH			Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE-C; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; INTRACELLULAR REGULATION; CASPASE-8 ACTIVATION; RECEPTOR; FADD; PEA-15; EXPRESSION; RECRUITMENT	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can trigger apoptosis in some tumor cells but not other tumor cells. To explore the signal transduction events in TRAIL-triggered apoptosis and its modulation in nontransfected tumor cells, we analyzed TRAIL-induced death-inducing signaling complex (DISC) in TRAIL-sensitive and -resistant glioma cells. Caspase-8 and caspase-10 were recruited to the DISC, where they were proteolytically activated to initiate apoptosis in TRAIL-sensitive glioma cells. Caspase-8 and caspase-10 were also recruited to the DISC in TRAIL-resistant cells, but their further activation was inhibited by two antiapoptotic proteins termed cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes-15kDa (PED/PEA-15). Both long and short forms of c-FLIP were recruited to the DISC, where the long form c-FLIP was cleaved to produce intermediate fragments. Of the three isoforms of PED/PEA-15 proteins, only the doubly phosphorylated form was expressed and recruited to the DISC in TRAIL-resistant cells, indicating that the phosphorylation status of PED/PEA-15 determines its recruitment in the cells. Treatment with calcium/calmodulin-dependent protein kinase inhibitor rescued TRAIL sensitivity in TRAIL-resistant cells, providing a potential new approach to sensitize the cells to TRAIL-induced apoptosis.	Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada; Univ Naples Federico II, CNR, Sch Med, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Sch Med, Ctr Endocrinol Sperimentale, I-80131 Naples, Italy	University of Alberta; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Hao, CH (corresponding author), Univ Alberta, Dept Lab Med & Pathol, 261HMRC, Edmonton, AB T6G 2S2, Canada.	chao@ualberta.ca			Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hao CH, 2001, CANCER RES, V61, P1162; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kubes M, 1998, J NEUROCHEM, V71, P1307; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Zhang XD, 1999, CANCER RES, V59, P2747	41	161	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25020	25025		10.1074/jbc.M202946200	http://dx.doi.org/10.1074/jbc.M202946200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976344	hybrid			2022-12-27	WOS:000176747000025
J	Schutyser, E; Struyf, S; Proost, P; Opdenakker, G; Laureys, G; Verhasselt, B; Peperstraete, L; Van de Putte, I; Saccani, A; Allavena, P; Mantovani, A; Van Damme, J				Schutyser, E; Struyf, S; Proost, P; Opdenakker, G; Laureys, G; Verhasselt, B; Peperstraete, L; Van de Putte, I; Saccani, A; Allavena, P; Mantovani, A; Van Damme, J			Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC PROTEINS MCP-2; C-C CHEMOKINES; DENDRITIC CELLS; MALIGNANT ASCITES; UP-REGULATION; T-CELLS; IN-VIVO; EXPRESSION; CANCER; RECEPTOR	Chemokines are important in leukocyte homeostasis, inflammation, angiogenesis, and metastasis. Here, the molecular diversity of chemokines present in ovarian carcinoma was studied by purifying the proteins to homogeneity from ascitic fluid. Biologically active intact CCL2 and processed CXCL8, CCL3, and CCL18 isoforms were recovered. CCL7 and CCL20 were also purified, but their levels were 10-fold lower compared with CXCLS, CCL2, and CCL3 and even 100-fold lower than the amounts of CCL18 isolated. In ascitic fluids from patients with ovarian carcinoma (n = 12), significantly higher levels of CXCL8 and CCL18 (2.0 versus 0.7 ng/ml p = 0.01) and 120 versus 44 ng/ml (p = 0.0002), respectively) were detected compared with those in nonovarian carcinoma patients (n = 12). In contrast to CXCLS, CCL18 was not inducible in carcinoma cell lines. Immunostaining showed CCL18 expression in tumor-infiltrating cells with monocyte/macrophage morphology but not in the ovarian carcinoma cells. Our data demonstrate that biochemically heterogenous but biologically active forms of several chemokines are present at different concentrations in ovarian carcinoma ascitic fluid. This points to a delicate balance of chemokines in epithelial ovarian cancer and to a potentially major role for CXCLS and CCL18 in this tumor.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; State Univ Ghent Hosp, B-9000 Ghent, Belgium; Reg Hosp Heilig Hart, B-3000 Louvain, Belgium; Ist Ric Farmacol Mario Negri, Immunol Lab, I-20157 Milan, Italy	KU Leuven; Ghent University; Ghent University Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Van Damme, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.		Proost, Paul/V-3052-2017; Opdenakker, Ghislain/Q-3130-2017; Allavena, Paola/HHM-5218-2022; Struyf, Sofie/U-2455-2017; laureys, genevieve/AAG-2390-2021; Opdenakker, Ghislain/V-8562-2019; Mantovani, Alberto/HCI-7449-2022	Proost, Paul/0000-0002-0133-5545; Opdenakker, Ghislain/0000-0003-1714-2294; Allavena, Paola/0000-0002-6697-6028; Struyf, Sofie/0000-0003-4558-0769; Opdenakker, Ghislain/0000-0003-1714-2294; Mantovani, Alberto/0000-0001-5578-236X; Verhasselt, Bruno/0000-0002-4645-1144; Van Damme, Jo/0000-0002-6707-1167				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; BALKWILL FR, 1994, EUR CYTOKINE NETW, V5, P379; Burke F, 1996, CYTOKINE, V8, P578, DOI 10.1006/cyto.1996.0077; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Guan P, 1999, GENOMICS, V56, P296, DOI 10.1006/geno.1998.5635; Hieshima K, 1997, J IMMUNOL, V159, P1140; Ivarsson K, 1998, GYNECOL ONCOL, V71, P420, DOI 10.1006/gyno.1998.5198; Ivarsson K, 2000, ACTA OBSTET GYN SCAN, V79, P777, DOI 10.1034/j.1600-0412.2000.079009777.x; Kleeff J, 1999, INT J CANCER, V81, P650, DOI 10.1002/(SICI)1097-0215(19990517)81:4<650::AID-IJC23>3.0.CO;2-#; Kodelja V, 1998, RES IMMUNOL, V149, P633, DOI 10.1016/S0923-2494(99)80029-7; Kodelja V, 1998, J IMMUNOL, V160, P1411; Kusano F, 2000, LAB INVEST, V80, P415, DOI 10.1038/labinvest.3780046; Lindhout E, 2001, J IMMUNOL, V166, P3284, DOI 10.4049/jimmunol.166.5.3284; Loercher AE, 1999, J IMMUNOL, V163, P6251; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 1999, CONT CANC RES, P35; Melichar B, 1998, CLIN CANCER RES, V4, P799; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1999, CONT CANC RES, P193; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Opdenakker G, 1999, CONT CANC RES, P51; Pardo A, 2001, J LEUKOCYTE BIOL, V70, P610; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; PROOST P, 1995, CYTOKINE, V7, P97, DOI 10.1006/cyto.1995.1013; Proost P, 1998, J IMMUNOL, V160, P4034; Punnonen R, 1998, CANCER, V83, P788, DOI 10.1002/(SICI)1097-0142(19980815)83:4<788::AID-CNCR24>3.0.CO;2-N; Radke J, 1996, GEBURTSH FRAUENHEILK, V56, P83, DOI 10.1055/s-2007-1022247; Reape TJ, 1999, AM J PATHOL, V154, P365, DOI 10.1016/S0002-9440(10)65283-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schutyser E, 2000, J IMMUNOL, V165, P4470, DOI 10.4049/jimmunol.165.8.4470; Schutyser E, 2001, EUR J IMMUNOL, V31, P3755, DOI 10.1002/1521-4141(200112)31:12<3755::AID-IMMU3755>3.0.CO;2-O; Scotton C, 2001, BRIT J CANCER, V85, P891, DOI 10.1054/bjoc.2001.2020; Scotton CJ, 2001, CANCER RES, V61, P4961; Sica A, 2000, J IMMUNOL, V164, P733, DOI 10.4049/jimmunol.164.2.733; Strieter RM, 1996, J IMMUNOL, V156, P3583; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; VANDAMME J, 1988, J IMMUNOL, V140, P1534; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vissers JLM, 2001, J LEUKOCYTE BIOL, V69, P785; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	50	169	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24584	24593		10.1074/jbc.M112275200	http://dx.doi.org/10.1074/jbc.M112275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978786	hybrid			2022-12-27	WOS:000176611800081
J	Soroka, V; Kiryushko, D; Novitskaya, V; Ronn, LCB; Poulsen, FM; Holm, A; Bock, E; Berezin, V				Soroka, V; Kiryushko, D; Novitskaya, V; Ronn, LCB; Poulsen, FM; Holm, A; Bock, E; Berezin, V			Induction of neuronal differentiation by a peptide corresponding to the homophilic binding site of the second Ig module of the neural cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; HEPARIN-BINDING; SYNTHETIC PEPTIDES; NCAM; OUTGROWTH; DOMAIN; IDENTIFICATION; RECEPTOR; ACTIVATION; PATHWAY	NCAM plays a key role in neural development and plasticity-mediating cell adhesion and differentiation mainly through homophilic binding. Until recently, attempts to modulate neuronal differentiation and plasticity through NCAM have been impeded by the absence of small synthetic agonists mimicking homophilic inter. actions of NCAM. We show here that a peptide, P2, corresponding to a 12-amino acid sequence localized in the FG loop of the second Ig module of NCAM, binds to the first Ig module, which is the natural binding partner of the second Ig module, with an apparent K-d of 4.7 +/- 0.9 x 10(-6) m. P2 inhibits cell aggregation and induces neurite outgrowth from hippocampal neurons, maximal neuritogenic effect being obtained at a concentration of 0.8 mum. The neuritogenic effect was inhibited by preincubation of P2 with the recombinant NCAM-IgI. Both the length of P2 and the basic amino acid residues at the N and C termini are important for its neuritogenic activity. Treatment of hippocampal cultures with P2 results in induction of phosphorylation of the mitogen-activated protein kinases ERK1 and ERK2. Thus, P2 is a potent mimetic of NCAM, and therefore, an attractive compound for the development of drugs for the treatment of neurodegenerative diseases.	Univ Copenhagen, Panum Inst, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen, Denmark; Dniepropetrovsk State Univ, Lab Biophys & Bioelect, UA-49050 Dnepropetrovsk, Ukraine; Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark	University of Copenhagen; Ministry of Education & Science of Ukraine; Oles Honchar Dnipro National University; University of Copenhagen; University of Copenhagen	Berezin, V (corresponding author), Univ Copenhagen, Panum Inst, Inst Mol Pathol, Prot Lab, Bldg 6-2,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.		Poulsen, Flemming M/E-6848-2010					Atkins AR, 1999, FEBS LETT, V451, P162, DOI 10.1016/S0014-5793(99)00554-2; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Berezin V, 2000, Curr Opin Drug Discov Devel, V3, P605; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Jensen PH, 1999, NAT STRUCT BIOL, V6, P486; KALLAPUR SG, 1992, J NEUROSCI RES, V33, P538, DOI 10.1002/jnr.490330406; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Kolkova K, 2000, J NEUROSCI, V20, P2238; MAAR T, 1995, INT J DEV NEUROSCI, V13, P491, DOI 10.1016/0736-5748(95)00068-R; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.3.CO;2-T; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	23	68	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24676	24683		10.1074/jbc.M109694200	http://dx.doi.org/10.1074/jbc.M109694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983682	hybrid			2022-12-27	WOS:000176611800093
J	Jacob, A; Cooney, D; Pradhan, M; Coggeshall, KM				Jacob, A; Cooney, D; Pradhan, M; Coggeshall, KM			Convergence of signaling pathways on the activation of ERK in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHOLIPASE C-GAMMA; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASE; CROSS-LINKING; RAS; INHIBITION; PHOSPHORYLATION	The B cell receptor (BCR) initiates three major signaling pathways: the Ras pathway, which leads to extracellular signal-regulated kinase (ERR) activation; the phospholipase C-gamma pathway, which causes calcium mobilization; and the phosphoinositide 3-kinase (PI 3-kinase) pathway. These combine to induce different biological responses depending on the context of the BCR signal. Both the Ras and PI 3-kinase pathways are important for B cell development and activation. Several model systems show evidence of cross-regulation between these pathways. Here we demonstrate through the use of PI 3-kinase inhibitors and a dominant-negative PI 3-kinase construct that the BCR-induced phosphorylation and activation of ERK is dependent on PI 3-kinase. PI 3-kinase feeds into the Ras signaling cascade at multiple points, both upstream and downstream of Ras. We also show that ERK activation is dependent on phospholipase C-gamma, in keeping with its dependence on calcium mobilization. Last, the activation of PI 3-kinase itself is completely dependent on Ras. We conclude that the PI 3-kinase and Ras signaling cascades are intimately connected in B cells and that the activation of ERK is a signal integration point, since it requires simultaneous input from all three major signaling pathways.	Oklahoma Med Res Fdn, Immunobiol & Canc Program, Oklahoma City, OK 73104 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Oklahoma Medical Research Foundation; University System of Ohio; Ohio State University	Coggeshall, KM (corresponding author), Oklahoma Med Res Fdn, Immunobiol & Canc Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.		Cooney, Damon/J-4762-2014	Cooney, Damon/0000-0002-2786-287X	NCI NIH HHS [CA64268] Funding Source: Medline; NIAID NIH HHS [AI49264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064268, R29CA064268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; GOLD MR, 1994, J IMMUNOL, V152, P42; Gold MR, 2000, CURR TOP MICROBIOL, V245, P77; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kawauchi K, 1996, MOL IMMUNOL, V33, P287, DOI 10.1016/0161-5890(95)00134-4; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li XL, 2000, EUR J IMMUNOL, V30, P1576, DOI 10.1002/1521-4141(200006)30:6<1576::AID-IMMU1576>3.0.CO;2-0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Montessuit C, 1999, J BIOL CHEM, V274, P9006, DOI 10.1074/jbc.274.13.9006; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Reth M, 2000, IMMUNOL REV, V176, P10; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SAXTON TM, 1994, J IMMUNOL, V153, P623; SMIT L, 1994, J BIOL CHEM, V269, P20209; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1997, J IMMUNOL, V158, P1125; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	56	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23420	23426		10.1074/jbc.M202485200	http://dx.doi.org/10.1074/jbc.M202485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976336	hybrid			2022-12-27	WOS:000176475700043
J	Lee, SH; Hannink, M				Lee, SH; Hannink, M			Characterization of the nuclear import and export functions of I kappa B epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; REL PROTEINS; DNA-BINDING; PEST DOMAIN; ALPHA; PHOSPHORYLATION; ACTIVATION; FAMILY; BETA; EXPRESSION	Control over the nuclear localization of nuclear factor kappaB/Rel proteins is accomplished in large part through association with members of the inhibitor of kappaB (IkappaB) protein family. For example, the well studied IkappaBalpha protein actively shuttles between the nucleus and the cytoplasm and both inhibits nuclear import and mediates nuclear export of NF-kappaB/Rel proteins. In contrast, the IkappaBbeta protein can inhibit nuclear import of NF-kappaB/Rel proteins but does not remove NF-kappaB/Rel proteins from the nucleus. To further understand how the IkappaB proteins control the nuclear-cytoplasmic distribution of NF-kappaB/Rel proteins, we have characterized the nuclear import and nuclear export functions of IkappaBepsilon. Our results indicate that the IkappaBepsilon protein, like the IkappaBalpha protein, actively shuttles between the nucleus and the cytoplasm. Similar to IkappaBalpha, nuclear import of IkappaBepsilon is mediated by its ankyrin repeat domain and is not blocked by the dominant-negative RanQ69L protein. However, the nuclear import function of the IkappaBepsilon ankyrin repeat domain is markedly less efficient than that of IkappaBalpha, with the result that nuclear shuttling of IkappaBepsilon between the nucleus and the cytoplasm is significantly slower than IkappaBalpha. Nuclear export of IkappaBepsilon is mediated by a short leucine-rich nuclear export sequence (NES)-like sequence ((VLLPFDDLKI352)-V-343), located between amino acids 343 and 352. This NES-like sequence is required for RanGTP-dependent binding of IkappaBepsilon to CRM1. Nuclear accumulation of IkappaBepsilon is increased by either leptomycin B treatment or alanine substitutions within the IkappaBepsilon-derived NES. A functional NES is required for both efficient cytoplasmic retention and post-induction control of c-Rel by IkappaBepsilon, consistent with the notion that IkappaBepsilon-mediated nuclear export contributes to control over the nucleocytoplasmic distribution of NF-kappaB/Rel proteins.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Hannink, M (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65212 USA.				NIGMS NIH HHS [GM59213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059213] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AREZANASEISDEDO.F, 1997, J CELL SCI, V110, P369; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee SH, 2001, J BIOL CHEM, V276, P23599, DOI 10.1074/jbc.M011197200; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; Memet S, 1999, J IMMUNOL, V163, P5994; O'Neill RE, 1998, EMBO J, V17, P288, DOI 10.1093/emboj/17.1.288; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SACHDEV S, 1995, ONCOGENE, V11, P811; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON J, 1995, CELL, V61, P255; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	41	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23358	23366		10.1074/jbc.M111559200	http://dx.doi.org/10.1074/jbc.M111559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970947	hybrid			2022-12-27	WOS:000176475700035
J	Skjerpen, CS; Wesche, J; Olsnes, S				Skjerpen, CS; Wesche, J; Olsnes, S			Identification of ribosome-binding protein p34 as an intracellular protein that binds acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH-REPEAT; FACTOR-I; KINASE CK2; HEPARIN-BINDING; TRANSLOCATION; SYNAPTOTAGMIN-1; PROLIFERATION; INTERACTS; DOMAIN; LOCALIZATION	With the aim of identifying new intracellular binding partners for acidic fibroblast growth factor (aFGF), proteins from U2OS human osteosarcoma cells were adsorbed to immobilized aFGF. One of the adsorbed proteins is a member of the leucine-rich repeat protein family termed ribosome-binding protein p34 (p34). This protein has previously been localized to endoplasmic reticulum membranes and is thought to span the membrane with the N terminus on the cytosolic side. Confocal microscopy of cells transfected with Myc-p34 confirmed the endoplasmic reticulum. localization, and Northern blotting determined p34 mRNA to be present in a multitude of different tissues. Cross-linking experiments indicated that the protein is present in the cell as a dimer. In vitro translated p34 was found to interact with maltose-binding protein-aFGF through its cytosolic coiled-coil domain. The interaction between aFGF and p34 was further characterized by surface plasmon resonance, giving a K-D of 1.4 +/- 0.3 mum. Even though p34 interacted with mitogenic aFGF, it bound poorly to the non-mitogenic aFGF(K132E) mutant, indicating a possible involvement of p34 in intracellular signaling by aFGF.	Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway.	sjur.olsnes@labmed.uio.no	Wesche, Jorgen/ABH-7524-2020	Wesche, Jorgen/0000-0002-9200-9162				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Gotz C, 2000, BIOCHEM BIOPH RES CO, V268, P882, DOI 10.1006/bbrc.2000.2230; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mizukoshi E, 1999, BIOCHEM J, V343, P461, DOI 10.1042/0264-6021:3430461; OHSUMI T, 1993, BIOCHEM J, V294, P465, DOI 10.1042/bj2940465; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Russo K, 2002, J BIOL CHEM, V277, P1284, DOI 10.1074/jbc.M108858200; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270	40	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23864	23871		10.1074/jbc.M112193200	http://dx.doi.org/10.1074/jbc.M112193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964394	hybrid			2022-12-27	WOS:000176475700100
J	Zhou, TQ; Shen, J; Liu, Y; Rosen, BP				Zhou, TQ; Shen, J; Liu, Y; Rosen, BP			Unisite and multisite catalysis in the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING SITE; ESCHERICHIA-COLI; CONFORMATIONAL-CHANGES; PUMP; MECHANISM; FLUORESCENCE; MUTAGENESIS; SUBSTRATE; SEQUENCE	The ars operon of plasmid R773 encodes an As(III)/Sb(III) extrusion pump. The catalytic subunit, the ArsA ATPase, has two homologous halves, A1 and A2, each with a consensus nucleotide-binding sequence. ATP hydrolysis is slow in the absence of metalloid and is accelerated by metalloid binding. ArsA M446W has a single tryptophan adjacent to the A2 nucleotide-binding site. Tryptophan fluorescence increased upon addition of ATP, ADP, or a nonhydrolyzable ATP analogue. Mg2+ and Sb(III) produced rapid quenching of fluorescence with ADP, no quenching with a nonhydrolyzable analogue, and slow quenching with ATP. The results suggest that slow quenching with ATP reflects hydrolysis of ATP to ADP in the A2 nucleotide-binding site. In an A2 nucleotide-binding site mutant, nucleotides had no effect. In contrast, in an A1 nucleotide-binding mutant, nucleotides still increased fluorescence, but there was no quenching with Mg2+ and Sb(III). This suggests that the A2 site hydrolyzes ATP only when Sb(III) or As(III) is present and when the A1 nucleotide-binding domain is functional. These results support previous hypotheses in which only the A1 nucleotide-binding domain hydrolyzes ATP in the absence of activator (unisite catalysis), and both the A1 and A2 sites hydrolyze ATP when activated (multisite catalysis).	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bhattacharjee H, 2000, BIOMETALS, V13, P281, DOI 10.1023/A:1009200215328; Bhattacharjee H, 2000, BIOCHEM SOC T, V28, P520, DOI 10.1042/0300-5127:0280520; CHEN CM, 1986, J BIOL CHEM, V261, P5030; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KARKARIA CE, 1991, ARCH BIOCHEM BIOPHYS, V288, P107, DOI 10.1016/0003-9861(91)90170-N; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kaur P, 1999, J BIOL CHEM, V274, P25849, DOI 10.1074/jbc.274.36.25849; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Rouviere N, 1997, BIOCHEMISTRY-US, V36, P7339, DOI 10.1021/bi962289w; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; Walmsley AR, 2001, BIOCHEM J, V360, P589, DOI 10.1042/0264-6021:3600589; Walmsley AR, 2001, J BIOL CHEM, V276, P6378, DOI 10.1074/jbc.M008105200; WEBER J, 1997, BIOCHIM BIOPHYS ACTA, V1318, P19; Zhou T, 2000, EMBO J, V19, P1; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731; Zhou TQ, 2001, J BIOL CHEM, V276, P30414, DOI 10.1074/jbc.M103671200	29	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23815	23820		10.1074/jbc.M203432200	http://dx.doi.org/10.1074/jbc.M203432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964412	hybrid			2022-12-27	WOS:000176475700094
J	Liedtke, CM; Yun, CHC; Kyle, N; Wang, DD				Liedtke, CM; Yun, CHC; Kyle, N; Wang, DD			Protein kinase C epsilon-dependent regulation of cystic fibrosis transmembrane regulator involves binding to a receptor for activated C kinase (RACK1) and RACK1 binding to Na+/H+ exchange regulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTIF-CONTAINING PROTEIN; CONDUCTANCE REGULATOR; INTRACELLULAR RECEPTORS; CRYSTAL-STRUCTURE; BETA; DOMAIN; PKC; CFTR; REGION; TRANSLOCATION	Protein kinase C (PKC) regulation of cystic fibrosis transmembrane regulator (CFTR) chloride function has been demonstrated in several cell lines, including Calu-3 cells that express native, wild-type CFTR. We demonstrated previously that PKCepsilon was required for cAMP-dependent CFTR function. The goal of this study was to determine whether PKCepsilon interacts directly with CFTR. Using overlay assay, immunoprecipitation, pulldown and binding assays, we show that PKCepsilon does not bind to CFTR, but does bind to a receptor for activated C kinase (RACK1), a 37-kDa scaffold protein, and that RACK1 binds to Na+/H+ exchange regulatory factor (NHERF1), a binding partner of CFTR. In vitro binding assays demonstrate dose-dependent binding of PKCepsilon to RACK1 which is inhibited by an 8-amino acid peptide based on the sequence of the sixth Trp-Asp repeat in RACK1 or by an 8-amino acid sequence in the V1 region of PKCepsilon, epsilonV1-2. A 4-amino acid sequence INAL (70-73) expressed in CFTR shares 50% homology to the RACK1 inhibitory peptide, but it does not bind PKCepsilon. NHERF1 and RACK1 bind in a dose-dependent manner. Immunofluorescence and confocal microscopy of RACK1 and CFTR revealed colocalization of the proteins to the apical and lateral regions of Calu-3 cells. The results indicate the RACK1 binds PKCepsilon and NHERF1, thus serving as a scaffold protein to anchor the enzyme in proximity to CFTR.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Warren Alan Bernbaum MD Ctr Cyst Fibrosis Res, Cleveland, OH 44106 USA; Emory Univ, Dept Gastroenterol, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Dept Med, Atlanta, GA 30322 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Emory University; Emory University	Liedtke, CM (corresponding author), BRB, Rm 824,2109 Adelbert Rd, Cleveland, OH 44106 USA.	cxl7@po.cwru.edu			NHLBI NIH HHS [HL67190, HL58598] Funding Source: Medline; NIDDK NIH HHS [DK27651, DK44484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067190, R01HL058598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, P01DK044484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Brandon NJ, 1999, J NEUROSCI, V19, P9228; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; FranchiGazzola R, 1996, J BIOL CHEM, V271, P26124, DOI 10.1074/jbc.271.42.26124; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liedtke CM, 2001, AM J PHYSIOL-LUNG C, V280, pL739, DOI 10.1152/ajplung.2001.280.4.L739; Liedtke CM, 1998, AM J PHYSIOL-CELL PH, V275, pC1357, DOI 10.1152/ajpcell.1998.275.5.C1357; Liedtke CM, 1997, AM J PHYSIOL-CELL PH, V273, pC1632, DOI 10.1152/ajpcell.1997.273.5.C1632; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Middleton LM, 1998, AM J PHYSIOL-CELL PH, V275, pC293, DOI 10.1152/ajpcell.1998.275.1.C293; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yeon SW, 2001, BIOCHEM BIOPH RES CO, V280, P782, DOI 10.1006/bbrc.2000.4181; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	52	77	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22925	22933		10.1074/jbc.M201917200	http://dx.doi.org/10.1074/jbc.M201917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956211	hybrid			2022-12-27	WOS:000176313600105
J	Pelletier, B; Beaudoin, J; Mukai, Y; Labbe, S				Pelletier, B; Beaudoin, J; Mukai, Y; Labbe, S			Fep1, an iron sensor regulating iron transporter gene expression in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ENCODING GENE; METAL-ION TRANSPORT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; USTILAGO-MAYDIS; GATA FACTOR; FERRIC REDUCTASE; SIDEROPHORE BIOSYNTHESIS; PENICILLIUM-CHRYSOGENUM; MOLECULAR-BIOLOGY	Schizosaccharomyces pombe cells acquire iron under high affinity conditions through the action of a cell surface ferric reductase encoded by the frp1(+) gene and a two-component iron-transporting complex encoded by the fip1(+) and fio1(+) genes. When cells are grown in the presence of iron, transcription of all three genes is blocked. A conserved regulatory element, 5'-(A/T)GATAA-3', located upstream of the frp1(+), fip1(+), and fio1(+) genes, is necessary for iron repression. We have cloned a novel gene, termed fep1(+), which encodes an iron-sensing transcription factor. Binding studies reveal that the putative DNA binding domain of Fep1 expressed as a fusion protein in Escherichia coli specifically interacts with the 5'-(A/T)GATAA-3' sequence in an iron-dependent manner. In a fep1Delta mutant strain, the fio1(+) gene is highly expressed and is unregulated by iron. Furthermore, the fep1Delta mutation increases activity of the cell surface iron reductase and renders cells hypersensitive to the iron-dependent free radical generator phleomycin. Mutations in the transcriptional co-repressors tup11(+) and tup12(+) are phenocopies to fep1(+). Indeed, strains with both tup11Delta and tup12Delta deletions fail to sense iron. This suggests that in the presence of iron and Fep1, the Tup11 and Tup12 proteins may act as co-repressors for down-regulation of genes encoding components of the reductive iron transport machinery.	Univ Sherbrooke, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Osaka Univ, Dept Biotechnol, Suita, Osaka 5650871, Japan	University of Sherbrooke; Osaka University	Labbe, S (corresponding author), Univ Sherbrooke, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada.			Mukai, Yukio/0000-0003-1265-0839; Labbe, Simon/0000-0002-4947-523X				Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; ALFA C, 1993, EXPT FISSION YEASTS; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; Ardon O, 2001, J BIOL CHEM, V276, P43049, DOI 10.1074/jbc.M108701200; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DANCIS A, 1998, J PEDIAT 2, V132, P524; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FOX KR, 1987, BIOCHEM J, V243, P847, DOI 10.1042/bj2430847; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; Haas H, 1999, J BIOL CHEM, V274, P4613, DOI 10.1074/jbc.274.8.4613; Haas H, 1997, J BIOL CHEM, V272, P22576, DOI 10.1074/jbc.272.36.22576; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hoe KL, 1996, BIOCHEM MOL BIOL INT, V39, P127; KEENEY JB, 1994, GENETICS, V136, P849; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; Koch KA, 1996, MOL CELL BIOL, V16, P724; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Ostling J, 1996, MOL CELL BIOL, V16, P753; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; SANTORO N, 1997, YEAST STRESS RESPONS, P165; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VASSAROTTI A, 1985, J BIOL CHEM, V260, P6348; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; Wessling-Resnick M, 2000, ANNU REV NUTR, V20, P129, DOI 10.1146/annurev.nutr.20.1.129; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YAMAGUCHIIWAI Y, 2002, J BIOL CHEM     0304; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200; Zhou LW, 1998, MOL GEN GENET, V259, P532, DOI 10.1007/s004380050845	67	99	101	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22950	22958		10.1074/jbc.M202682200	http://dx.doi.org/10.1074/jbc.M202682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956219	hybrid			2022-12-27	WOS:000176313600108
J	Siskind, LJ; Kolesnick, RN; Colombini, M				Siskind, LJ; Kolesnick, RN; Colombini, M			Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; INDUCED APOPTOSIS; CELL-DEATH; CASPASE ACTIVATION; LNCAP CELLS; GENERATION; MECHANISM; RESISTANCE; RELEASE; BCL-2	Ceramides are known to play a major regulatory role in apoptosis by inducing cytochrome c release from mitochondria. We have previously reported that C-2- and C-16-ceramide, but not dihydroceramide, form large channels in planar membranes (Siskind, L. J., and Colombini, M. (2001) J. Biol. Chem. 275, 38640 -38644). Here we show that ceramides do not trigger a cytochrome c secretion or release mechanism, but simply raise the permeability of the mitochondrial outer membrane, via ceramide channel formation, to include small proteins. Exogenously added reduced cytochrome c was able to freely permeate the mitochondrial outer membrane with entry to and exit from the intermembrane space facilitated by ceramides in a dose- and time-dependent manner. The permeability pathways were eliminated upon removal of C-2-ceramide by bovine serum albumin, thus ruling out a detergent-like effect of C2-ceramide on membranes. Ceramide channels were not specific to cytochrome c, as ceramides induced release of adenylate kinase, but not fumerase from isolated mitochondria, showing some specificity of these channels for the outer mitochondrial membrane. SDS-PAGE results show that ceramides allow release of intermembrane space proteins with a molecular weight cut-off of about 60,000. These results indicate that the ceramide-induced membrane permeability increases in isolated mitochondria are via ceramide channel formation and not a release mechanism, as the channels that allow cytochrome c to freely permeate are reversible, and are not specific to cytochrome c.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University System of Maryland; University of Maryland College Park; Memorial Sloan Kettering Cancer Center	Colombini, M (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	mc34@umail.umd.edu	Colombini, Marco/A-1540-2014	Siskind, Leah/0000-0001-5026-5187	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042467, R01NS042025] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS042467, F31 NS042467-02, R01 NS042025, R01 NS042025-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Ardail D, 2001, FEBS LETT, V488, P160, DOI 10.1016/S0014-5793(00)02332-2; Ariga T, 1998, J LIPID RES, V39, P1; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; Castedo M, 1996, J IMMUNOL, V157, P512; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Gannes FMP, 1998, CYTOMETRY, V33, P333; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garzotto M, 1999, CANCER RES, V59, P5194; Garzotto M, 1998, CANCER RES, V58, P2260; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; Hofmann K, 1999, TRENDS BIOCHEM SCI, V24, P227, DOI 10.1016/S0968-0004(99)01410-3; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; Kawatani M, 2000, EXP CELL RES, V259, P389, DOI 10.1006/excr.2000.4986; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LI LY, 2001, CELL, V412, P95; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; Muriel MP, 2000, J COMP NEUROL, V426, P297, DOI 10.1002/1096-9861(20001016)426:2<297::AID-CNE10>3.0.CO;2-O; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Polster BM, 2001, J BIOL CHEM, V276, P37887; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Radin NS, 2001, EUR J BIOCHEM, V268, P193, DOI 10.1046/j.1432-1033.2001.01845.x; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Simon CG, 1998, BIOCHEMISTRY-US, V37, P2059, DOI 10.1021/bi9710636; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Sotocassa G.L., 1967, METHOD ENZYMOL, V10, P448; SPECTOR AA, 1969, J LIPID RES, V10, P56; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; TUBOI S, 1990, ADV ENZYME REGUL, V30, P289; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	71	278	285	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26796	26803		10.1074/jbc.M200754200	http://dx.doi.org/10.1074/jbc.M200754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12006562	hybrid, Green Accepted			2022-12-27	WOS:000177055900013
J	Warton, K; Tonini, R; Fairlie, WD; Matthews, JM; Valenzuela, SM; Qiu, MR; Wu, WM; Pankhurst, S; Bauskin, AR; Harrop, SJ; Campbell, TJ; Curmi, PMG; Breit, SN; Mazzanti, M				Warton, K; Tonini, R; Fairlie, WD; Matthews, JM; Valenzuela, SM; Qiu, MR; Wu, WM; Pankhurst, S; Bauskin, AR; Harrop, SJ; Campbell, TJ; Curmi, PMG; Breit, SN; Mazzanti, M			Recombinant CLIC1 (NCC27) assembles in lipid bilayers via a pH-dependent two-state process to form chloride ion channels with identical characteristics to those observed in Chinese hamster ovary cells expressing CLIC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEIN; P64	CLIC1 (NCC27) is an unusual, largely intracellular, ion channel that exists in both soluble and membrane-associated forms. The soluble recombinant protein can be expressed in Escherichia coli, a property that has made possible both detailed electrophysiological studies in lipid bilayers and an examination of the mechanism of membrane integration. Soluble E. coli-derived CLIC1 moves from solution into artificial bilayers and forms chloride-selective ion channels with essentially identical conductance, pharmacology, and opening and closing kinetics to those observed in CLIC1-transfected Chinese hamster ovary cells. The process of membrane integration of CLIC1 is pH-dependent. Following addition of protein to the trans solution, small conductance channels with slow kinetics (SCSK) appear in the bilayer. These SCSK modules then appear to undergo a transition to form a high conductance channel with fast kinetics. This has four times the conductance of the SCSK and fast kinetics that characterize the native channel. This suggests that the CLIC1 ion channel is likely to consist of a tetrameric assembly of subunits and indicates that despite its size and unusual properties, it is able to form a completely functional ion channel in the absence of any other ancillary proteins.	Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia; Univ New S Wales, Dept Med, Sydney, NSW 2052, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ Roma La Sapienza, Dipartimento Fisiol, I-00185 Rome, Italy; Fdn Cenci Bolognetti, Inst Pasteur, I-00185 Rome, Italy; Univ New S Wales, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Darlinghurst, NSW 2010, Australia	Sapienza University Rome; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; Sapienza University Rome; Fondazione Cenci Bolognetti; University of New South Wales Sydney; St Vincents Hospital Sydney	Mazzanti, M (corresponding author), Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Ple Aldo Moro 5, I-00185 Rome, Italy.	michele.mazzanti@uniroma1.it	Mazzanti, Michele/A-8941-2011; Matthews, Jacqueline/A-7322-2013; Curmi, Paul/G-7185-2011; Valenzuela, Stella/R-6387-2019; Fairlie, Walter/M-8401-2015; Tonini, Raffaella/J-2960-2012	Curmi, Paul/0000-0001-5762-7638; Valenzuela, Stella/0000-0001-5934-6047; Fairlie, Walter/0000-0002-2498-1160; Mazzanti, Michele/0000-0002-1819-3811; Matthews, Jacqueline/0000-0001-8518-3472; Campbell, Terry/0000-0003-0055-4137; TONINI, Raffaella/0000-0003-1652-4709				CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575	14	94	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26003	26011		10.1074/jbc.M203666200	http://dx.doi.org/10.1074/jbc.M203666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11978800	hybrid			2022-12-27	WOS:000176908700025
J	Buhman, KK; Smith, SJ; Stone, SJ; Repa, JJ; Wong, JS; Knapp, FF; Burri, BJ; Hamilton, RL; Abumrad, NA; Farese, RV				Buhman, KK; Smith, SJ; Stone, SJ; Repa, JJ; Wong, JS; Knapp, FF; Burri, BJ; Hamilton, RL; Abumrad, NA; Farese, RV			DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; MONOACYLGLYCEROL ACYLTRANSFERASE; APOLIPOPROTEIN-B; CHOLESTEROL; LIVER; MICE; ACID	Dietary triacylglycerols are a major source of energy for animals. The absorption of dietary triacylglycerols involves their hydrolysis to free fatty acids and monoacylglycerols in the intestinal lumen, the uptake of these products into enterocytes, the resynthesis of triacylgylcerols, and the incorporation of newly synthesized triacylglycerols into nascent chylomicrons for secretion. In enterocytes, the final step in triacylglycerol synthesis is believed to be catalyzed primarily through the actions of acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes. In this study, we analyzed intestinal triacylglycerol absorption and chylomicron synthesis and secretion in DGAT1-deficient (Dgat1(-/-)) mice. Surprisingly, DGAT1 was not essential for quantitative dietary triacylglycerol absorption, even in mice fed a high fat diet, or for the synthesis of chylomicrons. However, Dgat1(-/-)mice had reduced postabsorptive chylomicronemia (1 h after a high fat challenge) and accumulated neutrallipid droplets in the cytoplasm of enterocytes when chronically fed a high fat diet. These results suggest a reduced rate of triacylglycerol absorption in Dgat1(-/-)mice. Analysis of intestine from Dgat1(-/-) mice revealed activity for two other enzymes, DGAT2 and diacylglycerol transacylase, that catalyze triacylglycerol synthesis and apparently help to compensate for the absence of DGAT1. Our findings indicate that multiple mechanisms for triacylglycerol synthesis in the intestine facilitate triacylglycerol absorption.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Dept Anat, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Oak Ridge Natl Lab, Nucl Med Program, Oak Ridge, TN 37831 USA; USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11793 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Agriculture (USDA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Farese, RV (corresponding author), Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA.		Buhman, Kimberly/AAV-3111-2021	Buhman, Kimberly/0000-0002-3784-1028; Repa, Joyce/0000-0001-5740-1954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056084, R01DK056084] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056084, DK56084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGERMULLER S, 1982, HISTOCHEM J, V14, P823, DOI 10.1007/BF01033631; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; Knapp FF, 1999, INT J CARDIAC IMAG, V15, P1, DOI 10.1023/A:1006147228352; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; LEHNER R, 1993, J BIOL CHEM, V268, P8781; MANSBACH CM, 1973, BIOCHIM BIOPHYS ACTA, V296, P386, DOI 10.1016/0005-2760(73)90097-0; Meiner V, 1997, J LIPID RES, V38, P1928; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; RODGERS JB, 1970, BIOCHIM BIOPHYS ACTA, V202, P426, DOI 10.1016/0005-2760(70)90113-X; Schwarz M, 1998, J LIPID RES, V39, P1833; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; WILSON MD, 1994, J LIPID RES, V35, P943; YANG LY, 1991, J LIPID RES, V32, P1173; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	20	187	230	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25474	25479		10.1074/jbc.M202013200	http://dx.doi.org/10.1074/jbc.M202013200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11959864	hybrid			2022-12-27	WOS:000176747000082
J	Kruger, C; Berkowitz, O; Stephan, UW; Hell, R				Kruger, C; Berkowitz, O; Stephan, UW; Hell, R			A metal-binding member of the late embryogenesis abundant protein family transports iron in the phloem of Ricinus communis L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GELS; NICOTIANAMINE; ACID; ELECTROPHORESIS; MICRONUTRIENTS; STAIN	The transport of metal micronutrients to developing organs in a plant is mediated primarily by the sieve elements. Ligands are thought to form complexes with the free ions in order to prevent cellular damage, but no binding partners have been unequivocally identified from plants so far. This study has used the phloem-mediated transport of micronutrients during the germination of the castor bean seedling to identify an iron transport protein (ITP). It is demonstrated that essentially all Fe-55 fed to seedlings is associated with the protein fraction of phloem exudate. It is shown that ITP carries iron in vivo and binds additional iron in vitro. ITP was purified to homogeneity from minute amounts of phloem exudate using immobilized metal ion affinity chromatography. It preferentially binds to Fe3+ but not to Fe2+ and also complexes Cu2+, Zn2+, and Mn2+ in vitro. The corresponding cDNA of ITP was cloned using internal peptide fragments. The deduced protein of 96 amino acids shows high similarity to the stress-related family of late embryogenesis abundant proteins. Its predicted characteristics and its RNA expression pattern are consistent with a function in metal ion binding. The ITP from Ricinus provides the first identified micronutrient binding partner for phloem-mediated long distance transport in plants and is the first member of the late embryogenesis abundant protein family shown to have such a function.	Leibniz Inst, Inst Pflanzengent & Kulturpflanzenforsch Gatersle, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Hell, R (corresponding author), Leibniz Inst, Inst Pflanzengent & Kulturpflanzenforsch Gatersle, Corrensstr 3, D-06466 Gatersleben, Germany.	hell@ipk-gatersleben.de	Berkowitz, Oliver/AAE-7979-2019; Berkowitz, Oliver/A-7854-2008; Hell, Ruediger/E-5436-2014	Berkowitz, Oliver/0000-0002-7671-6983; Berkowitz, Oliver/0000-0002-7671-6983; Hell, Ruediger/0000-0002-6238-4818				ANDEREGG G, 1989, J CHEM SOC CHEM COMM, P647, DOI 10.1039/c39890000647; Atkins C, 2000, AUST J PLANT PHYSIOL, V27, P531, DOI 10.1071/PP99129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brait JF, 2002, OXIDATIVE STRESS PLA, P171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG MCM, 1985, ANAL BIOCHEM, V148, P498, DOI 10.1016/0003-2697(85)90258-1; Cuming AC, 1999, SEED PROTEINS, P753; Fox TC, 1998, ANNU REV PLANT PHYS, V49, P669, DOI 10.1146/annurev.arplant.49.1.669; Fritsche K, 1999, FEBS LETT, V462, P249, DOI 10.1016/S0014-5793(99)01541-0; GALAU GA, 1992, PLANT PHYSIOL, V98, P1523, DOI 10.1104/pp.98.4.1523; Garay-Arroyo A, 2000, J BIOL CHEM, V275, P5668, DOI 10.1074/jbc.275.8.5668; Herbik A, 1999, EUR J BIOCHEM, V265, P231, DOI 10.1046/j.1432-1327.1999.00717.x; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; JUNGBLUT PR, 1990, J BIOCHEM BIOPH METH, V21, P47, DOI 10.1016/0165-022X(90)90044-D; KALLARACKAL J, 1989, PLANTA, V177, P327, DOI 10.1007/BF00403590; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAAS FM, 1988, PLANT PHYSIOL, V87, P167, DOI 10.1104/pp.87.1.167; Marentes E, 1997, 9 INT S IR NUTR INT, P74; Marschner H, 1997, BOT ACTA, V110, P265, DOI 10.1111/j.1438-8677.1997.tb00639.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATE JS, 1975, PHLOEM TRANSPORT, P451; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDKE I, 1995, PHYSIOL PLANTARUM, V95, P147, DOI 10.1111/j.1399-3054.1995.tb00821.x; Schmidke I, 1999, PHYSIOL PLANTARUM, V106, P82, DOI 10.1034/j.1399-3054.1999.106112.x; Stephan UW, 1996, BIOMETALS, V9, P84, DOI 10.1007/BF00188095; STEPHAN UW, 1993, PHYSIOL PLANTARUM, V88, P522, DOI 10.1111/j.1399-3054.1993.tb01367.x; STEPHAN UW, 2002, IN PRESS PLANT SOIL; Takahashi R, 1997, PLANT SCI, V123, P93, DOI 10.1016/S0168-9452(96)04568-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGOOR BJ, 1976, PHYSIOL PLANTARUM, V36, P213, DOI 10.1111/j.1399-3054.1976.tb03938.x; von Wiren N, 1999, PLANT PHYSIOL, V119, P1107, DOI 10.1104/pp.119.3.1107; WANG HL, 1999, AM SOC PLANT PHYSL A, P105; WANG HL, 2000, 10 INT S IR NUTR INT, P105; Zhong W, 1996, PLANT CELL ENVIRON, V19, P471, DOI 10.1111/j.1365-3040.1996.tb00339.x	37	181	205	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25062	25069		10.1074/jbc.M201896200	http://dx.doi.org/10.1074/jbc.M201896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983700	hybrid			2022-12-27	WOS:000176747000031
J	Abraham, MR; Selivanov, VA; Hodgson, DM; Pucar, D; Zingman, LV; Wieringa, B; Dzeja, PP; Aleksee, AE; Terzic, A				Abraham, MR; Selivanov, VA; Hodgson, DM; Pucar, D; Zingman, LV; Wieringa, B; Dzeja, PP; Aleksee, AE; Terzic, A			Coupling of cell energetics with membrane metabolic sensing - Integrative signaling through creatine kinase phosphotransfer disrupted by M-CK gene knock-out	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNELS; ADENYLATE KINASE; CATALYZED PHOSPHOTRANSFER; SULFONYLUREA RECEPTOR; SARCOPLASMIC-RETICULUM; PROTECTIVE ROLE; MICE DEFICIENT; MUSCLE; HEART	Transduction of metabolic signals is essential in preserving cellular homeostasis. Yet, principles governing integration and synchronization of membrane metabolic sensors with cell metabolism remain elusive. Here, analysis of cellular nucleotide fluxes and nucleotide-dependent gating of the ATP-sensitive K+ (K-ATP) channel, a prototypic metabolic sensor, revealed a diffusional barrier within the submembrane space, preventing direct reception of cytosolic signals. Creatine kinase phosphotransfer, captured by O-18-assisted P-31 NMR, coordinated tightly with ATP turnover, reflecting the cellular energetic status. The dynamics of high energy phosphoryl transfer through the creatine kinase relay permitted a high fidelity transmission of energetic signals into the submembrane compartment synchronizing K-ATP channel activity with cell metabolism. Knock-out of the creatine kinase M-CK gene disrupted signal delivery to K-ATP channels and generated a cellular phenotype with increased electrical vulnerability. Thus, in the compartmentalized cell environment, phosphotransfer systems shunt diffusional barriers and secure regimented signal transduction integrating metabolic sensors with the cellular energetic network.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; Univ Nijmegen, Med Ctr, Ctr Mol Life Sci, NL-6500 HE Nijmegen, Netherlands	Mayo Clinic; Mayo Clinic; Mayo Clinic; Radboud University Nijmegen	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, 200 1st St SW,Guggenheim 7, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Wieringa, Berend/A-5346-2011; Zingman, Leonid V/GXG-0136-2022	Wieringa, Berend/0000-0001-9192-8020; Zingman, Leonid V/0000-0002-7566-4616; Selivanov, Vitaly/0000-0002-7937-9249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64822, HL-07111] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 1999, FASEB J, V13, P1901; Aguilar-Bryan L, 2001, RECENT PROG HORM RES, V56, P47, DOI 10.1210/rp.56.1.47; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; Boehm E, 2000, J MOL CELL CARDIOL, V32, P891, DOI 10.1006/jmcc.2000.1130; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Chazov E I, 1980, Adv Myocardiol, V1, P139; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; de Groof AJC, 2002, J BIOL CHEM, V277, P5275, DOI 10.1074/jbc.M108157200; DECKING UKM, 1995, AM J PHYSIOL-HEART C, V269, pH734, DOI 10.1152/ajpheart.1995.269.2.H734; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; GOLHABER JI, 1997, MYOCARDIUM, P325; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Kabakov AY, 1998, BIOPHYS J, V75, P2858, DOI 10.1016/S0006-3495(98)77728-8; Kinsey ST, 1999, NMR BIOMED, V12, P1, DOI 10.1002/(SICI)1099-1492(199902)12:1<1::AID-NBM539>3.0.CO;2-V; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Koster JC, 2001, CIRC RES, V89, P1022, DOI 10.1161/hh2301.100342; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; Li RA, 2000, CIRC RES, V87, P837, DOI 10.1161/01.RES.87.10.837; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Mihm MJ, 2001, CIRCULATION, V104, P174, DOI 10.1161/01.CIR.104.2.174; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Pucar D, 2001, J BIOL CHEM, V276, P44812, DOI 10.1074/jbc.M104425200; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; Sasaki N, 2001, AM J PHYSIOL-HEART C, V280, pH1882, DOI 10.1152/ajpheart.2001.280.4.H1882; Saupe KW, 1998, CIRC RES, V82, P898; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Stockler S, 1996, AM J HUM GENET, V58, P914; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WEISS JN, 1992, J PHYSIOL-LONDON, V447, P649, DOI 10.1113/jphysiol.1992.sp019022; WEISS JN, 1993, CARDIOVASC DRUG THER, V7, P499, DOI 10.1007/BF00877614; Weiss JN, 2001, CIRC RES, V89, P108, DOI 10.1161/res.89.2.108; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; Yamada K, 2001, SCIENCE, V292, P1543, DOI 10.1126/science.1059829; Zingman LV, 2002, J BIOL CHEM, V277, P14206, DOI 10.1074/jbc.M109452200; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	64	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24427	24434		10.1074/jbc.M201777200	http://dx.doi.org/10.1074/jbc.M201777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967264	hybrid, Green Published			2022-12-27	WOS:000176611800061
J	Kraus, RJ; Ariazi, EA; Farrell, ML; Mertz, JE				Kraus, RJ; Ariazi, EA; Farrell, ML; Mertz, JE			Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; STEROID-HORMONE RECEPTORS; ACTIVATED PROTEIN-KINASE; HUMAN LACTOFERRIN GENE; RESPONSE ELEMENTS; BREAST-CANCER; PROMOTER; BINDING; PHOSPHORYLATION; COACTIVATOR	The estrogen-related receptor alpha (ERRalpha) is an orphan member of the nuclear receptor superfamily. We show that the major isoform of the human ERRalpha gene, ERRalpha1, can sequence-specifically bind a consensus palindromic estrogen response element (ERE) and directly compete with estrogen receptor alpha (ERalpha) for binding. ERRalpha1 activates or represses ERE-regulated transcription in a cell type-dependent manner, repressing in ER-positive MCF-7 cells while activating in ER-negative HeLa cells. Thus, ERRalpha1 can function both as a modulator of estrogen responsiveness and as an estrogen-independent activator. Repression likely occurs in the absence of exogenous ligand since charcoal treatment of the serum had no effect on silencing activity. Mutational analysis revealed that repression is not simply the result of competition between ERalpha and ERRalpha1 for binding to the DNA, Rather, it also requires the presence of sequences within the carboxyl-terminal E/F domain of ERRalpha1. Thus, ERRalpha1 can function as either an active repressor or a constitutive activator of ERE-dependent transcription. We hypothesize that ERRalpha1 can play a critical role in the etiology of some breast cancers, thereby providing a novel therapeutic target in their treatment.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mertz, JE (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA.				NATIONAL CANCER INSTITUTE [P01CA022443, T32CA009681, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA09135, CA07175, CA09681, CA22443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA JC, 1980, EUR J CANCER, V16, P323, DOI 10.1016/0014-2964(80)90348-5; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CATHERINO WH, 1995, CANCER LETT, V92, P39, DOI 10.1016/0304-3835(95)03755-L; Chen F, 1999, GENE, V228, P101, DOI 10.1016/S0378-1119(98)00619-2; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; CLARK GM, 1983, BREAST CANCER RES TR, V3, P69; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN JA, 1973, BIOCHEMISTRY-US, V12, P4085, DOI 10.1021/bi00745a010; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KNIGHT WA, 1977, CANCER RES, V37, P4669; Kraus RJ, 2001, VIROLOGY, V287, P89, DOI 10.1006/viro.2001.1024; Kraus RJ, 2001, J VIROL, V75, P867, DOI 10.1128/JVI.75.2.867-877.2001; Lu DS, 2001, CANCER RES, V61, P6755; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Murphy C S, 1990, Receptor, V1, P65; OREILLEY GH, 2000, THESIS U WISCONSIN M; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang ZP, 2001, MOL CELL ENDOCRINOL, V172, P223, DOI 10.1016/S0303-7207(00)00372-5; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	52	99	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24826	24834		10.1074/jbc.M202952200	http://dx.doi.org/10.1074/jbc.M202952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986328	hybrid			2022-12-27	WOS:000176611800110
J	Gloe, T; Sohn, HY; Meininger, GA; Pohl, U				Gloe, T; Sohn, HY; Meininger, GA; Pohl, U			Shear stress-induced release of basic fibroblast growth factor from endothelial cells is mediated by matrix interaction via integrin alpha(V)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN SULFATE COMPLEXES; KAPOSIS-SARCOMA KS; SMOOTH-MUSCLE; INFLAMMATORY CYTOKINES; EXTRACELLULAR-MATRIX; LESION FORMATION; BINDING PROTEIN; ANGIOGENESIS; PROLIFERATION; RESPONSES	Considering that chronic elevation of shear stress results in remodeling of the vasculature, we analyzed whether mechanical load could mediate basic fibroblast growth factor (bFGF) release and whether bFGF would act as mediator of shear stress-induced endothelial proliferation and differentiation. Supernatant media of shear stress-exposed endothelial cells (EC) contained significantly higher amounts of bFGF than medium from static cells. Released bFGF was fully intact with regard to its function as an inductor of proliferation and differentiation. Shear stress-conditioned media induced capillary-like structure formation, whereas static control medium did not. Likewise, only shear stress-conditioned medium induced proliferation of serum starved EC. Both capillary-like structure formation and proliferation could be inhibited by neutralization of bFGF or its receptor. The release of bFGF was subject to specific, integrin-mediated control, since inhibition of alpha(v)beta(3) integrin prevented it, whereas inhibition of alpha(5)beta(1) integrin had no effect. We conclude that shear stress induces the release of bFGF from EC in a tightly controlled manner. The release is dependent on specific cell-matrix interactions via alpha(v)beta(3) integrins. The effects on cell proliferation and differentiation suggest that release of bFGF is functionally significant and may represent a necessary initial step in adaptive remodeling processes induced by shear stress.	Univ Munich, Inst Vegetat Physiol, D-80336 Munich, Germany; Univ Munich, Klinikum Innenstadt, Dept Cardiol, D-80336 Munich, Germany; Texas A&M Univ, Dept Med Physiol, College Stn, TX 77843 USA	University of Munich; University of Munich; Texas A&M University System; Texas A&M University College Station	Gloe, T (corresponding author), Univ Munich, Inst Vegetat Physiol, Schillerstr 44, D-80336 Munich, Germany.	gloe@lrz.uni-muenchen.de						ACEVEDO AD, 1993, J CELL PHYSIOL, V157, P603, DOI 10.1002/jcp.1041570321; Acosta JA, 1996, MOL MED, V2, P755, DOI 10.1007/BF03401659; Albuquerque MLC, 1998, EXP CELL RES, V245, P163, DOI 10.1006/excr.1998.4243; Ambalavanan N, 1999, BIOL NEONATE, V76, P311, DOI 10.1159/000014173; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, BLOOD, V81, P3324; Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BUSHKINHARAV I, 1995, J BIOL CHEM, V270, P13422, DOI 10.1074/jbc.270.22.13422; Cenni E, 1999, J BIOMAT SCI-POLYM E, V10, P891, DOI 10.1163/156856299X00513; Cenni E, 1999, J BIOMAT SCI-POLYM E, V10, P989, DOI 10.1163/156856299X00577; Chen CH, 1997, P ASSOC AM PHYSICIAN, V109, P351; COZZOLINO F, 1993, J CLIN INVEST, V91, P2504, DOI 10.1172/JCI116486; Cucina A, 1999, BIOCHEM BIOPH RES CO, V257, P306, DOI 10.1006/bbrc.1999.0478; Deschenes MR, 1999, MED SCI SPORT EXER, V31, P1599, DOI 10.1097/00005768-199911000-00016; EGUCHI K, 1992, J RHEUMATOL, V19, P1925; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Fajardo LF, 1996, LAB INVEST, V74, P600; Garcia-Martinez C, 1999, GENE THER, V6, P1210, DOI 10.1038/sj.gt.3300950; Gavin TP, 2000, J APPL PHYSIOL, V88, P1192, DOI 10.1152/jappl.2000.88.4.1192; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Gloe T, 1999, J BIOL CHEM, V274, P15996, DOI 10.1074/jbc.274.23.15996; Gu JW, 1997, CIRCULATION, V95, P1165; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Hudlicka O, 1998, MICROCIRCULATION, V5, P7; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JOSEPHSILVERSTEIN J, 1987, SEMIN THROMB HEMOST, V13, P504, DOI 10.1055/s-2007-1003526; Kohno M, 1998, CIRCULATION, V98, P353, DOI 10.1161/01.CIR.98.4.353; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li ZH, 1995, EXP MOL PATHOL, V63, P77, DOI 10.1006/exmp.1995.1032; Lopez JJ, 1998, AM J PHYSIOL-HEART C, V274, pH930, DOI 10.1152/ajpheart.1998.274.3.H930; Mogford JE, 1997, J CLIN INVEST, V100, P1647, DOI 10.1172/JCI119689; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.3.CO;2-R; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; Pepper MS, 1998, EXP CELL RES, V241, P414, DOI 10.1006/excr.1998.4072; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Rainger GE, 1999, AM J PHYSIOL-HEART C, V276, pH858, DOI 10.1152/ajpheart.1999.276.3.H858; REIDY MA, 1992, CIRCULATION, V86, P43; RIFKIN DB, 1990, CELL DIFFER DEV, V32, P313, DOI 10.1016/0922-3371(90)90045-X; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAMANIEGO F, 1995, J IMMUNOL, V154, P3582; Samaniego F, 1997, J IMMUNOL, V158, P1887; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sapienza P, 1998, Minerva Cardioangiol, V46, P141; Sapienza P, 1998, J SURG RES, V75, P24, DOI 10.1006/jsre.1997.5260; SARZANI R, 1989, J CLIN INVEST, V83, P1404, DOI 10.1172/JCI114029; SATO Y, 1989, MOL ENDOCRINOL, V3, P744, DOI 10.1210/mend-3-4-744; SCHULTZ G S, 1991, Eye (London), V5, P170; Shyy JYJ, 2001, BIORHEOLOGY, V38, P109; VILLASCHI S, 1993, AM J PATHOL, V143, P181; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Yang HT, 1998, AM J PHYSIOL-HEART C, V274, pH2053, DOI 10.1152/ajpheart.1998.274.6.H2053; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643	59	91	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23453	23458		10.1074/jbc.M203889200	http://dx.doi.org/10.1074/jbc.M203889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976347	hybrid			2022-12-27	WOS:000176475700048
J	Gonzalez-Santos, JM; Wang, A; Jones, J; Ushida, C; Liu, J; Hu, J				Gonzalez-Santos, JM; Wang, A; Jones, J; Ushida, C; Liu, J; Hu, J			Central region of the human splicing factor Hprp3p interacts with Hprp4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; ISOTHERMAL TITRATION CALORIMETRY; SACCHAROMYCES-CEREVISIAE; 2ND STEP; MUTATIONAL ANALYSIS; SNRNP PROTEIN; RNA; YEAST; PRP4; U4	Human splicing factors Hprp3p and Hprp4p are associated with the U4/U6 small nuclear ribonucleoprotein particle, which is essential for the assembly of an active spliceosome. Currently, little is known about the specific roles of these factors in splicing. In this study, we characterized the molecular interaction between Hprp3p and Hprp4p. Constructs were created for expression of Hprp3p or its mutants in bacterial or mammalian cells. We showed that antibodies against either Hprp3p or Hprp4p were able to pull-down the Hprp3p-Hprp4p complex formed in Escherichia coli lysates. By co-immunoprecipitation and isothermal titration calorimetry, we demonstrated that purified Hprp3p and its mutants containing the central region, but lacking either the N-terminal 194 amino acids or the C-terminal 240 amino acids, were able to interact with Hprp4p. Conversely, Hprp3p mutants containing only the N- or C-terminal region did not interact with Hprp4p. In addition, by co-immunoprecipitation, we showed that intact Hprp3p and its mutants containing the central region interacted with Hprp4p in HeLa cell nuclear extracts. Primer extension analysis illustrated that the central region of Hprp3p is required to maintain the association of Hprp3p-Hprp4p with U4/U6 small nuclear RNAs, suggesting that this Hprp3p/Hprp4p interaction allows the recruitment of Hprp4p, and perhaps other protein(s), to the U4/U6 small nuclear ribonucleoprotein particle.	Hosp Sick Children, Program Lung Biol Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Hu, J (corresponding author), Hosp Sick Children, Program Lung Biol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jhu@sickkids.on.ca	Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733; Hu, Jim/0000-0001-9134-7103				Ast G, 2001, NUCLEIC ACIDS RES, V29, P1741, DOI 10.1093/nar/29.8.1741; Ayadi L, 1997, RNA, V3, P197; Ayadi L, 1998, J MOL BIOL, V284, P673, DOI 10.1006/jmbi.1998.2183; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; Blencowe BJ, 1999, TRENDS BIOCHEM SCI, V24, P179, DOI 10.1016/S0968-0004(99)01387-0; Blencowe BJ, 1999, METH MOL B, V118, P275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; Horowitz DS, 1997, RNA, V3, P1374; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; HU J, 1994, NUCLEIC ACIDS RES, V22, P1724, DOI 10.1093/nar/22.9.1724; HU J, 1995, MOL CELL BIOL, V15, P1274; Johnson TL, 2001, GENE DEV, V15, P1957, DOI 10.1101/gad.895601; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; Kim M, 2001, J MOL BIOL, V312, P711, DOI 10.1006/jmbi.2001.4980; KONARSKA MM, 1988, P NATL ACAD SCI USA, V85, P5459, DOI 10.1073/pnas.85.15.5459; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAMER A, 1990, METHOD ENZYMOL, V181, P3; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LAST RL, 1987, GENETICS, V117, P619; Lauber J, 1997, RNA, V3, P926; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; Maroney PA, 2000, MOL CELL, V6, P317, DOI 10.1016/S1097-2765(00)00032-0; Meister G, 2001, EMBO J, V20, P2304, DOI 10.1093/emboj/20.9.2304; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; NOTTROTT S, 2001, 6 ANN M RNA SOC MAY, P5; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Rappsilber J, 2001, J BIOL CHEM, V276, P31142, DOI 10.1074/jbc.M103620200; Reidt U, 2000, J BIOL CHEM, V275, P7439, DOI 10.1074/jbc.275.11.7439; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Teigelkamp S, 1998, RNA, V4, P127; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; Umen JG, 1995, RNA, V1, P869; Vidovic I, 2000, MOL CELL, V6, P1331, DOI 10.1016/S1097-2765(00)00131-3; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Walhout AJM, 2000, YEAST, V17, P88, DOI 10.1002/1097-0061(20000630)17:2<88::AID-YEA20>3.0.CO;2-Y; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wang A, 1997, HUM MOL GENET, V6, P2117, DOI 10.1093/hmg/6.12.2117; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; XU Y, 1990, MOL CELL BIOL, V10, P1217, DOI 10.1128/MCB.10.3.1217	53	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23764	23772		10.1074/jbc.M111461200	http://dx.doi.org/10.1074/jbc.M111461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971898	hybrid			2022-12-27	WOS:000176475700087
J	Simon, MF; Rey, A; Castan-Laurel, I; Gres, S; Sibrac, D; Valet, P; Saulnier-Blache, JS				Simon, MF; Rey, A; Castan-Laurel, I; Gres, S; Sibrac, D; Valet, P; Saulnier-Blache, JS			Expression of ectolipid phosphate phosphohydrolases in 3T3F442A preadipocytes and adipocytes - Involvement in the control of lysophosphatidic acid production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; SIGNAL-TRANSDUCTION; LYSOPHOSPHOLIPASE-D; ADIPOSE-TISSUE; RAT PLASMA; RECEPTOR; IDENTIFICATION; CLONING; CELLS; GROWTH	Because of its production by adipocytes and its ability to increase preadipocyte proliferation, lysophosphatidic acid (LPA) could participate in the paracrine control of adipose tissue development. The aim of the present study was to determine which enzyme activities are involved in exogenous LPA hydrolysis by preadipocytes and adipocytes. Using a quantitative method, we observed that extracellular LPA rapidly disappeared from the culture medium of 3T3F442A preadipocytes. This disappearance was strongly slowed down in the presence of the phosphatase inhibitors, sodium vanadate and sodium pervanadate. By using [P-33]LPA on intact 3T3F442A preadipocytes, we found that 90% of LPA hydrolysis resulted from LPA phosphatase activity biochemically related to previously described ectolipid phosphate phosphohydrolases (LPPs). Quantitative real time reverse transcriptase-PCR revealed that 3T3F442A preadipocytes expressed mRNAs of three known Lpp gene subtypes (1, 2, and 3), with a predominant expression of Lpp1 and Lpp3. Differentiation of 3T3F442A preadipocytes into adipocytes led to an 80% reduction in ecto-LPA phosphatase activity, with a concomitant down-regulation in Lpp1, Lpp2, and Lpp3 mRNA expression. Despite this regulation, treatment of 3T3F442A adipocytes with sodium vanadate increased LPA production in the culture medium, suggesting the involvement of ecto-LPA phosphatase activity in the control of extracellular production of LPA by adipocytes. In conclusion, these data demonstrate that hydrolysis of extracellular LPA by preadipocytes and adipocytes mainly results from a dephosphorylation activity. This activity M occurs at the extracellular face of cell membrane, (ii) exhibits biochemical characteristics similar to those of the LPP, (iii) is negatively regulated during adipocyte differentiation, and (iv) plays an important role in the control of extracellular LPA production by adipocytes. Ecto-LPA phosphatase activity represents a potential target to control adipose tissue development.	Univ Toulouse 3, CHU Rangueil, INSERM U317, Inst Louis Bugnard, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Saulnier-Blache, JS (corresponding author), Univ Toulouse 3, CHU Rangueil, INSERM U317, Inst Louis Bugnard, Batiment L3, F-31403 Toulouse 04, France.		Saulnier-Blache, Jean Sebastien/X-7729-2018; Valet, Philippe/N-7472-2017	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				AILHAUD G, 2000, INT J OBES RELAT  S2, V24, P1; Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GESTA S, 2002, IN PRESS J LIPID RES; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Ishikawa T, 2000, J BIOCHEM-TOKYO, V127, P645, DOI 10.1093/oxfordjournals.jbchem.a022652; JAMAL Z, 1992, INT J OBESITY, V16, P789; JAMDAR SC, 1994, BIOCHEM J, V301, P793, DOI 10.1042/bj3010793; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; Kanoh H, 1999, CHEM PHYS LIPIDS, V98, P119, DOI 10.1016/S0009-3084(99)00024-9; Liliom K, 1998, J BIOL CHEM, V273, P13461, DOI 10.1074/jbc.273.22.13461; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; MAURIEGE P, 1987, EUR J CLIN INVEST, V17, P156, DOI 10.1111/j.1365-2362.1987.tb02395.x; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; PAGES C, 2001, PROSTAG OTH LIPID M, V1, P1; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tokumura A, 1999, BBA-MOL CELL BIOL L, V1437, P235, DOI 10.1016/S1388-1981(99)00011-6; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; Xu J, 2000, ANN NY ACAD SCI, V905, P81; Xu J, 2000, J BIOL CHEM, V275, P27520; Zhang NA, 2000, GENOMICS, V63, P142, DOI 10.1006/geno.1999.6055	33	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23131	23136		10.1074/jbc.M201530200	http://dx.doi.org/10.1074/jbc.M201530200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956205	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000176475700006
J	Kane, S; Sano, H; Liu, SCH; Asara, JM; Lane, WS; Garner, CC; Lienhard, GE				Kane, S; Sano, H; Liu, SCH; Asara, JM; Lane, WS; Garner, CC; Lienhard, GE			A method to identify serine kinase substrates - Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; S6 KINASE; INSULIN; TRANSPORT; 3-KINASE	This study describes a method for the identification of the substrates of specific serine kinases. An antibody specific for the phosphomotif generated by the kinase is used to isolate phosphorylated substrates by immunoprecipitation, and the isolated proteins are identified by tandem mass spectrometry of peptides. This method was applied to the identification of substrates for the protein kinase Akt, which specifically phosphorylates the RXRXYS/T motif. 3T3-L1 adipocytes were treated with insulin to activate Akt, and the putative Akt substrate proteins were isolated by immunoprecipitation with an antibody against the phospho form of this motif. This led to the identification of a novel 160-kDa substrate for Akt. The 160-kDa substrate for Akt, which was designated AS160, has a Rab GAP domain. Recombinant AS160 was shown to be a substrate for Akt, and two sites of phosphorylation, both in RXRXXS/T motifs, were identified by mass spectrometry and mutation. Insulin treatment of adipocytes caused AS160 to redistribute from the low density microsomes to the cytosol.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Harvard Univ, Dept Mol & Cellular Biol, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Dartmouth College; Harvard University	Lienhard, GE (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Vail Bldg, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK025336, R55DK025336, R01DK042816, R56DK042816, R01DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42816, DK25336, R01 DK042816, R01 DK025336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clifford GM, 1998, FEBS LETT, V435, P125, DOI 10.1016/S0014-5793(98)01052-7; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FROST SC, 1985, J BIOL CHEM, V260, P2646; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Lawlor MA, 2001, J CELL SCI, V114, P2903; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	18	400	425	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22115	22118		10.1074/jbc.C200198200	http://dx.doi.org/10.1074/jbc.C200198200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11994271	hybrid			2022-12-27	WOS:000176313600003
J	Schroeder, JA; Adriance, MC; McConnell, EJ; Thompson, MC; Pockaj, B; Gendler, SJ				Schroeder, JA; Adriance, MC; McConnell, EJ; Thompson, MC; Pockaj, B; Gendler, SJ			ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu Transgenic carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIN-BUNDLING PROTEIN; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; MOUSE MAMMARY; CELL MOTILITY; CYCLIN D1; PROGNOSTIC MARKER; FACTOR-ALPHA; E-CADHERIN	Simultaneous deregulation of both Wnt and ErbB growth factors has previously been shown to result in the cooperative induction of mammary gland tumors. Using the murine mammary tumor virus (MMTV)-Wnt-1 transgenic model of mammary carcinoma, we have identified an unvarying association between beta-catenin and epidermal growth factor receptor/c-Neu (ErbB1/ErbB2) heterodimers in mammary gland tumors, indicating a requirement for ErbB signaling in Wnt-mediated tumorigenesis. Expansion of these observations to a second transgenic model, MMTV-c-Neu, demonstrated similar tumor-specific interactions, including an ErbB1 ligand-inducible phosphorylation of both beta-catenin and c-Neu. Direct relevance of these findings to human breast cancer was established upon examination of a set of human infiltrating ductal breast adenocarcinoma and lymph node metastasis tissues taken at surgery. These data revealed increased levels of beta-catenin in tumors and metastases versus normal breast as well as an association between beta-catenin and c-Neu that measurably occurs only in neoplasia, most strongly in metastatic lesions. These studies have identified a seemingly indispensable interaction between beta-catenin and epidermal growth factor receptor/c-Neu heterodimers in Wnt-1-mediated breast tumorigenesis that may indicate a fundamental signaling event in human metastatic progression.	Mayo Clin Scottsdale, Mayo Med Grad Sch, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Mayo Med Grad Sch, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Mayo Med Grad Sch, Tumor Biol Program, Scottsdale, AZ 85259 USA.			schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA90204, CA64389, CA81703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA090204, R01CA064389, F32CA081703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Bonvini P, 2001, CANCER RES, V61, P1671; Brandt R, 2000, ONCOGENE, V19, P2129, DOI 10.1038/sj.onc.1203520; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grothey A, 2000, BRIT J CANCER, V83, P870, DOI 10.1054/bjoc.2000.1395; Grothey A, 2000, ONCOGENE, V19, P4864, DOI 10.1038/sj.onc.1203838; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Polakis P, 2000, GENE DEV, V14, P1837; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 2000, ONCOGENE, V19, P3193, DOI 10.1038/sj.onc.1203652; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simon R, 2001, J NATL CANCER I, V93, P1141, DOI 10.1093/jnci/93.15.1141; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomlinson JS, 2001, CANCER RES, V61, P5231; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993	37	68	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22692	22698		10.1074/jbc.M201975200	http://dx.doi.org/10.1074/jbc.M201975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950845	hybrid			2022-12-27	WOS:000176313600077
J	Gu, JJ; Kawai, H; Nie, LG; Kitao, H; Wiederschain, D; Jochemsen, AG; Parant, J; Lozano, G; Yuan, ZM				Gu, JJ; Kawai, H; Nie, LG; Kitao, H; Wiederschain, D; Jochemsen, AG; Parant, J; Lozano, G; Yuan, ZM			Mutual dependence of MDM2 and MDMX in their functional inactivation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								MDMX, an MDM2-related protein, has emerged as yet another essential negative regulator of p53 tumor suppressor, since loss of MDMX expression results in p53-ependent embryonic lethality in mice. However, it remains unknown why neither homologue can compensate for the loss of the other. In addition, results of biochemical studies have suggested that MDMX inhibits MDM2-mediated p53 degradation, thus contradicting its role as defined in gene knockout experiments. Using cells deficient in either MDM2 or MDMX, we demonstrated that these two p53 inhibitors are in fact functionally dependent on each other. In the absence of MDMX, MDM2 is largely ineffective in down-regulating p53 because of its extremely short half-life. MDMX renders MDM2 protein sufficiently stable to function at its full potential for p53 degradation. On the other hand, MDMX, which is a cytoplasmic protein, depends on MDM2 to redistribute into the nucleus and be able to inactivate p53. We also showed that MDMX, when exceedingly overexpressed, inhibits MDM2-mediated p53 degradation by competing with MDM2 for p53 binding. Our findings therefore provide a molecular basis for the nonoverlapping activities of these two p53 inhibitors previously revealed in genetic studies.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Harvard University; Harvard T.H. Chan School of Public Health; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Texas System; UTMD Anderson Cancer Center	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.			Kawai, Hidehiko/0000-0003-2213-7166	NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA85679-01A] Funding Source: Medline; NIEHS NIH HHS [T32 ES07155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9	10	204	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19251	19254		10.1074/jbc.C200150200	http://dx.doi.org/10.1074/jbc.C200150200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11953423	hybrid			2022-12-27	WOS:000175894800003
J	Creuzenet, C; Urbanic, RV; Lam, JS				Creuzenet, C; Urbanic, RV; Lam, JS			Structure-function studies of two novel UDP-GlcNAc C6 Dehydratases/C4 Reductases - Variation from the SYK dogma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE 4,6-DEHYDRATASE; PATHOGEN HELICOBACTER-PYLORI; X-RAY STRUCTURE; GDP-L-FUCOSE; GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ACTIVE-SITE; STAPHYLOCOCCUS-AUREUS; GDP-4-KETO-6-DEOXY-D-MANNOSE EPIMERASE/REDUCTASE	Two subfamilies of UDP-GlcNAc C6 dehydratases were recently identified. FlaA1, a short soluble protein that exhibits a typical SYK catalytic triad, characterizes one of these subfamilies, and WbpM, a large membrane protein that harbors an altered SMK triad that was not predicted to sustain activity, represents the other subfamily. This study focuses on investigating the structure and function of these C6 dehydratases and the role of the altered triad as well as additional amino acid residues involved in catalysis. The significant activity retained by the FlaA1 Y141M triad mutant and the low activity of the WbpM M438Y mutant indicated that the methionine residue was involved in catalysis. A Glu 589 residue, which is conserved only within the large homologues, was shown to be essential for activity in WbpM. Introduction of this residue in FlaA1 enhanced the activity of the corresponding V266E mutant. Hence, this glutamate residue might be responsible for the retention of catalytic efficiency in the large homologues despite alteration of their catalytic triad. Mutations of residues specific for the short homologues (AsP70, Asp(149) Lys(150), Cys(103)) abolished the activity of FlaA1. Among them, C103M prevented dimerization but did not significantly affect the secondary structure. The fact that we could identify subfamily-specific residues that are essential for catalysis suggested an independent evolution for each subfamily of C6 dehydratases. Finally, the loss of activity of the FlaAl G20A mutant provided evidence that a cofactor is involved in catalysis, and kinetic study of the FlaAl H86A mutant revealed that this conserved histidine is involved in substrate binding. None of the mutations investigated altered the substrate, product, and function specificity of these enzymes.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	Western University (University of Western Ontario); University of Guelph	Lam, JS (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.							Allard STM, 2000, ACTA CRYSTALLOGR D, V56, P222, DOI 10.1107/S0907444999016200; Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; Bisso A, 1999, FEBS LETT, V456, P370, DOI 10.1016/S0014-5793(99)00982-5; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; COLEMAN WG, 1979, J BACTERIOL, V139, P899, DOI 10.1128/JB.139.3.899-910.1979; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; Dean CR, 1999, J BACTERIOL, V181, P4275, DOI 10.1128/JB.181.14.4275-4284.1999; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; He XM, 1996, BIOCHEMISTRY-US, V35, P4721, DOI 10.1021/bi952706p; Jornvall H, 1999, ADV EXP MED BIOL, V463, P359; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Leclerc G, 1998, J BACTERIOL, V180, P5010, DOI 10.1128/JB.180.19.5010-5019.1998; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; Liu YJ, 1996, BIOCHEMISTRY-US, V35, P7615, DOI 10.1021/bi960102v; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MUKHERJI S, 1992, J BIOL CHEM, V267, P11709; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; Rosano C, 2000, J MOL BIOL, V303, P77, DOI 10.1006/jmbi.2000.4106; Sau S, 1996, J BACTERIOL, V178, P2118, DOI 10.1128/jb.178.7.2118-2126.1996; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SNIPES CE, 1977, J BIOL CHEM, V252, P8113; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P20617, DOI 10.1074/jbc.M101304200; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; THOMPSON MW, 1992, J GEN MICROBIOL, V138, P779, DOI 10.1099/00221287-138-4-779; THORSON JS, 1993, J AM CHEM SOC, V115, P5827, DOI 10.1021/ja00066a062; THORSON JS, 1993, J AM CHEM SOC, V115, P6993, DOI 10.1021/ja00068a075; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tonetti M, 1998, BIOCHIMIE, V80, P923, DOI 10.1016/S0300-9084(00)88889-6; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P354, DOI 10.1128/AAC.37.2.354; WANG SF, 1969, J BIOL CHEM, V244, P3430; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933; YU Y, 1992, J BIOL CHEM, V267, P5868	56	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26769	26778		10.1074/jbc.M202882200	http://dx.doi.org/10.1074/jbc.M202882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004063	hybrid			2022-12-27	WOS:000177055900010
J	Kohn, EA; Ruth, ND; Brown, MK; Livingstone, M; Eastman, A				Kohn, EA; Ruth, ND; Brown, MK; Livingstone, M; Eastman, A			Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; HAMSTER OVARY CELLS; PROTEIN KINASE-C; G(2) CHECKPOINT; RADIOSENSITIZING AGENT; SELECTIVE INHIBITORS; UCN-01; P53; ARREST; REPLICATION	DNA damage causes cell cycle arrest in G(1), S, or G(2) to prevent replication on damaged DNA or to prevent aberrant mitosis. The G(1) arrest requires the p53 tumor suppressor, yet the topoisomerase I inhibitor SN38 induces p53 after the G(1) checkpoint such that the cells only arrest in S or G(2). Hence, SN38 facilitates comparison of p53 wild-type and mutant cells with regard to the efficacy of drugs such as 7-hydroxystaurosporine (UCN-01) that Abrogate S and G(2) arrest. UCN-01 abrogated S and G(2) arrest in the p53 mutant breast tumor cell line MDA-MB-231 but not in the p53 wild-type breast line, MCF10a. This resistance to UCN-01 in the p53 wild-type cells correlated with suppression of cyclins A and B. In the p53 mutant cells, low concentrations of UCN-01 caused S phase cells to progress to G(2) before undergoing mitosis and death, whereas high concentrations caused rapid premature mitosis and death of S phase cells. UCN-01 inhibits Chk1/2, which should activate the mitosis-inducing phosphatase Cdc25C, yet this phosphatase remained inactive during S phase progression induced by low concentrations of UCN-01, probably because Cdc25C is also inhibited by the constitutive kinase, G TAK1. High concentrations of UCN-01 caused rapid activation of Cdc25C, which is attributed to inhibition of C-TAK1, as well as Chk1/2. Hence, UCN-01 has multiple effects depending on concentration and cell phenotype that must be considered when investigating mechanisms of checkpoint regulation.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Dartmouth College	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.		Livingstone, Mark/H-1709-2011	Livingstone, Mark/0000-0002-2757-7008	NCI NIH HHS [CA82220, CA23108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082220, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; Busby EC, 2000, CANCER RES, V60, P2108; Cholody WM, 2001, CANCER CHEMOTH PHARM, V47, P241, DOI 10.1007/s002800000234; DARZYNKIEWICZ Z, 1984, CYTOMETRY, V5, P355, DOI 10.1002/cyto.990050411; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Husain A, 1997, CLIN CANCER RES, V3, P2089; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Lammer C, 1998, J CELL SCI, V111, P2445; LAU CC, 1982, P NATL ACAD SCI USA, V79, P2943; Lee SI, 1999, BIOCHEM PHARMACOL, V58, P1713, DOI 10.1016/S0006-2952(99)00258-0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; POWELL SN, 1995, CANCER RES, V55, P1643; Rhind N, 2000, J CELL SCI, V113, P3889; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shao RG, 1997, CANCER RES, V57, P4029; Shi Z, 2001, CANCER RES, V61, P1065; SORENSON CM, 1988, CANCER RES, V48, P6703; STAUSFELD UP, 1994, J BIOL CHEM, V269, P5989; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TAKAHASHI I, 1989, J ANTIBIOT, V42, P564, DOI 10.7164/antibiotics.42.564; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yin XY, 2001, CANCER RES, V61, P6487; Yu Qiang, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P800; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	42	92	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26553	26564		10.1074/jbc.M202040200	http://dx.doi.org/10.1074/jbc.M202040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11953432	hybrid			2022-12-27	WOS:000176908700096
J	Lener, D; Budihas, SR; Le Grice, SFJ				Lener, D; Budihas, SR; Le Grice, SFJ			Mutating conserved residues in the ribonuclease H domain of Ty3 reverse transcriptase affects specialized cleavage events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND TRANSFER; RNA SECONDARY STRUCTURE; YEAST RETROTRANSPOSON TY1; PRIMER TRANSFER-RNA; ESCHERICHIA-COLI; ACTIVE-SITE; NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE; POLYPURINE TRACT; POLYMERASE	The reverse transcriptase-associated ribonuclease H (RT/RNase H) domains from the gypsy group of retrotransposons, of which Ty3 is a member, share considerable sequence homology with their retroviral counterparts. However, the gypsy elements have a conserved tyrosine (position 459 in Ty3 RT) instead of the conserved histidine in the catalytic center of retroviral RTs such as at position 539 of HIV-1. In addition, the gypsy group shows conservation of histidine adjacent to the third of the metal-chelating carboxylate residues, which is Asp-426 of Ty3 RT. The role of these and additional catalytic residues was assessed with purified recombinant enzymes and through the ability of Ty3 mutants to support transposition in Saccaromyces cerevisiae. Although all mutations had minimal impact on DNA polymerase function, amidation of Asp-358, Glu-401, and Asp-426 eliminated Me2+ and Mn2+-dependent RNase H function. Replacing His-427 and Tyr-459 with Ala and Asp-469 with Asn resulted in reduced RNase H activity in the presence of Mg2+, whereas in the presence of Mn2+ these mutants displayed a lack of turnover. Despite this, mutations at all positions were lethal for transposition. To reconcile these apparently contradictory findings, the efficiency of specialized RNase H-mediated events was examined for each enzyme. Mutants retaining RNase H activity on a heteropolymeric RNA-DNA hybrid failed to support DNA strand transfer and release of the (+) strand polypurine tract primer from (+) RNA, suggesting that interrupting one or both of these events might account for the transposition defect.	NCI, Reverse Transcriptase Biochem Sect, Resistance Mechanisms Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), NCI, Reverse Transcriptase Biochem Sect, Resistance Mechanisms Lab, HIV Drug Resistance Program,NIH, 1050 Boyles St,POB B, Frederick, MD 21702 USA.			Lener, Daniela/0000-0001-8266-8810				Baldwin GS, 1999, J MOL BIOL, V288, P87, DOI 10.1006/jmbi.1999.2672; BLAIN SW, 1995, J VIROL, V69, P5113, DOI 10.1128/JVI.69.8.5113-5116.1995; Boutabout M, 2001, NUCLEIC ACIDS RES, V29, P2217, DOI 10.1093/nar/29.11.2217; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CAO WG, 1995, BIOCHEMISTRY-US, V34, P2276, DOI 10.1021/bi00007a023; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 2001, J BIOL CHEM, V276, P32515, DOI 10.1074/jbc.M103958200; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Friant S, 1996, BIOCHIMIE, V78, P674, DOI 10.1016/S0300-9084(96)80013-7; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; Goedken ER, 2001, J BIOL CHEM, V276, P7266, DOI 10.1074/jbc.M009626200; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HANSEN LJ, 1990, J VIROL, V64, P2599, DOI 10.1128/JVI.64.6.2599-2607.1990; Haruki M, 2000, BIOCHEMISTRY-US, V39, P13939, DOI 10.1021/bi001469+; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kanaya S, 1996, J BIOL CHEM, V271, P32729, DOI 10.1074/jbc.271.51.32729; KANAYA S, 1990, J BIOL CHEM, V265, P4615; Kashiwagi T, 1996, PROTEIN ENG, V9, P857, DOI 10.1093/protein/9.10.857; Ke N, 1999, RNA, V5, P929, DOI 10.1017/S1355838299990015; KEENEY JB, 1995, MOL CELL BIOL, V15, P217, DOI 10.1128/MCB.15.1.217; KINSEY PT, 1995, GENETICS, V139, P81; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYARATSKHELIA M, 2002, J BIOL CHEM, V277, P16689; LAUERMANN V, 1994, P NATL ACAD SCI USA, V91, P9847, DOI 10.1073/pnas.91.21.9847; Lauermann V, 1997, EMBO J, V16, P6603, DOI 10.1093/emboj/16.21.6603; Malik HS, 2001, GENOME RES, V11, P1187, DOI 10.1101/gr.185101; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; Nymark-McMahon MH, 1999, J VIROL, V73, P453, DOI 10.1128/JVI.73.1.453-465.1999; ODA Y, 1993, J BIOL CHEM, V268, P88; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2002, BIOCHEMISTRY-US, V41, P4856, DOI 10.1021/bi015970t; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SCHATZ O, 1990, ONCOGENESIS AIDS, P293; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Smith CM, 1999, J VIROL, V73, P6573, DOI 10.1128/JVI.73.8.6573-6581.1999; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; Uzun O, 2001, J VIROL, V75, P6337, DOI 10.1128/JVI.75.14.6337-6347.2001; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wilhelm M, 2001, J BIOL CHEM, V276, P47695, DOI 10.1074/jbc.M106067200; Wilhelm M, 1997, NUCLEIC ACIDS RES, V25, P2161, DOI 10.1093/nar/25.11.2161; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q	60	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26486	26495		10.1074/jbc.M200496200	http://dx.doi.org/10.1074/jbc.M200496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994277	hybrid			2022-12-27	WOS:000176908700087
J	Lingbeek, ME; Jacobs, JJL; van Lohuizen, M				Lingbeek, ME; Jacobs, JJL; van Lohuizen, M			The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14(ARF) via a variant T-site in the initiator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLT-ORAM-SYNDROME; CELL IMMORTALIZATION; DNA-BINDING; TRANSCRIPTION; SENESCENCE; EXPRESSION; MUTATIONS; P19(ARF); TRANSFORMATION; PROLIFERATION	The murine tumor suppressor p19(ARF) (p14(ARF) in humans) is thought to fulfill an important protective role in preventing primary cells from oncogenic transformation via its action in the p53 pathway. Several disease-implicated regulators of p19(ARF) are known to date, among which are the T-box genes TBX2, which resides on an amplicon in primary breast tumors, and TBX3, which is mutated in the human developmental disorder Ulnar-Mammary syndrome. Here we identify a variant T-site, matching 13 of 20 nucleotides of a consensus T-site, as the essential TBX2/TBX3-binding element in the human p14(ARF) promoter. Mutant analysis indicates that both the consensus T-box and a C-terminal conserved repression domain are essential for p14(ARF) repression. Whereas the core nucleotides required for interaction of the archetypal T-box protein Brachyury with a consensus T-site are conserved in the variant site, additional flanking nucleotides contribute to the specificity of TBX2 binding. This is illustrated by the inability of TBX1A or Xbra to activate via the variant p14(ARF) T-site. Importantly, this suggests a hitherto unsuspected level of specificity associated with T-box factors and corresponding recognition sites in regulating their target genes in vivo.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.v.lohuizen@nki.nl	Pillay, Nischalan/F-9536-2012; Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795				Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Casey ES, 1998, DEVELOPMENT, V125, P3887; Casey ES, 1999, DEVELOPMENT, V126, P4193; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Conlon FL, 2001, DEVELOPMENT, V128, P3749; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Gregorio A, 1999, DEVELOPMENT, V126, P5599; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Kusch T, 2002, GENE DEV, V16, P518, DOI 10.1101/gad.213002; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Li QY, 1997, NAT GENET, V15, P21; Liu JX, 2001, P NATL ACAD SCI USA, V98, P8674, DOI 10.1073/pnas.141234898; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Papaioannou VE, 2001, INT REV CYTOL, V207, P1; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sinha S, 2000, GENE, V258, P15, DOI 10.1016/S0378-1119(00)00417-0; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Tada M, 2001, DEV GROWTH DIFFER, V43, P1; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	45	135	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26120	26127		10.1074/jbc.M200403200	http://dx.doi.org/10.1074/jbc.M200403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000749	hybrid			2022-12-27	WOS:000176908700039
J	Niiranen, K; Pietila, M; Pirttila, TJ; Jarvinen, A; Halmekyto, M; Korhonen, VP; Keinanen, TA; Alhonen, L; Janne, J				Niiranen, K; Pietila, M; Pirttila, TJ; Jarvinen, A; Halmekyto, M; Korhonen, VP; Keinanen, TA; Alhonen, L; Janne, J			Targeted disruption of spermidine/spermine N-1-acetyltransferase gene in mouse embryonic stem cells - Effects on polyamine homeostasis and sensitivity to polyamine analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMINE N1-ACETYLTRANSFERASE; TRANSGENIC MICE; LUNG-CANCER; BIS(ETHYL)POLYAMINE ANALOGS; GROWTH; CATABOLISM; N-1,N-11-DIETHYLNORSPERMINE; METABOLISM; OXIDASE; LINES	We have generated mouse embryonic stem cells with targeted disruption of spermidine/spermine N-1-acetyltransferase (SSAT) gene. The targeted cells did not contain any inducible SSAT activity, and the SSAT protein was not present. The SSAT-deficient cells proliferated normally and appeared to maintain otherwise similar polyamine pools as did the wild-type cells, with the possible exception of constantly elevated (about 30%) cellular spermidine. As expected, the mutated cells were significantly more resistant toward the growth-inhibitory action of polyamine analogues, such as N-1,N-11-diethylnorspermine. However, this resistance was not directly attributable to cellular depletion of the higher polyamines spermidine and spermine, as the analogue depleted the polyamine pools almost equally effectively in both wild-type and SSAT-deficient cells. Tracer experiments with [C-14]-labeled spermidine revealed that SSAT activity is essential for the back-conversion of spermidine to putrescine as radioactive N-acetylspermidine and putrescine were readily detectable in N-1,N-11-diethylnorspermine-exposed wild-type cells but not in SSAT-deficient cells. Similar experiments with [C-14]spermine indicated that the latter polyamine was converted to spermidine in both cell lines and, unexpectedly, more effectively in the targeted cells than in the parental cells. This back-conversion was only partly inhibited by MDL72527, an inhibitor of polyamine oxidase. These results indicated that SSAT does not play a major role in the maintenance of polyamine homeostasis, and the toxicity exerted by polyamine analogues is largely not based on SSAT-induced depletion of the natural polyamines. Moreover, embryonic stem cells appear to operate an SSAT-independent system for the back-conversion of spermine to spermidine.	Univ Kuopio, Inst Appl Biotechnol, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland	Janne, J (corresponding author), Univ Kuopio, Inst Appl Biotechnol, POB 1627, FIN-70211 Kuopio, Finland.		Keinänen, Tuomo/AAC-5630-2019					Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Alhonen L, 2000, P NATL ACAD SCI USA, V97, P8290, DOI 10.1073/pnas.140122097; Alhonen L, 1999, MOL PHARMACOL, V55, P693; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; KUMAZAWA T, 1990, ANAL BIOCHEM, V188, P105, DOI 10.1016/0003-2697(90)90535-H; LIBBY PR, 1987, BIOCHEM BIOPH RES CO, V144, P528, DOI 10.1016/S0006-291X(87)80541-7; Mank-Seymour AR, 1998, CLIN CANCER RES, V4, P2003; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; PORTER CW, 1991, CANCER RES, V51, P3715; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Wang YL, 2001, CANCER RES, V61, P5370	20	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25323	25328		10.1074/jbc.M203599200	http://dx.doi.org/10.1074/jbc.M203599200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000764	hybrid			2022-12-27	WOS:000176747000063
J	Que, XC; Ngo, HA; Lawton, J; Gray, M; Liu, Q; Engel, J; Brinen, L; Ghosh, P; Joiner, KA; Reed, SL				Que, XC; Ngo, HA; Lawton, J; Gray, M; Liu, Q; Engel, J; Brinen, L; Ghosh, P; Joiner, KA; Reed, SL			The cathepsin B of Toxoplasma gondii, toxopain-1, is critical for parasite invasion and rhoptry protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	11th Molecular Parasitology Meeting	2000	WOODS HOLE, MA				HOST-CELL INVASION; ORGANELLES; RECEPTOR; IDENTIFICATION; SEQUENCES; BINDING; COMPARTMENTS; TRAFFICKING; BIOGENESIS; PREDICTION	Cysteine proteinases play a major role in invasion and intracellular survival of a number of pathogenic parasites. We cloned a single copy gene, tgcp1, from Toxoplasma gondii and refolded recombinant enzyme to yield active proteinase. Substrate specificity of the enzyme and homology modeling identified the proteinase as a cathepsin B. Specific cysteine proteinase inhibitors interrupted invasion by tachyzoites. The T. gondii cathepsin B localized to rhoptries, secretory organelles required for parasite invasion into cells. Processing of the pro-rhoptry protein 2 to mature rhoptry proteins was delayed by incubation of extracellular parasites with a cathepsin B inhibitor prior to pulse-chase immunoprecipitation. Delivery of cathepsin B to mature rhoptries was impaired in organisms with disruptions in rhoptry formation by expression of a dominant negative mu1-adaptin. Similar disruption of rhoptry formation was observed when infected fibroblasts were treated with a specific inhibitor of cathepsin B, generating small and poorly developed rhoptries. This first evidence for localization of a cysteine proteinase to the unusual rhoptry secretory organelle of an apicomplexan parasite suggests that the rhoptries may be a prototype of a lysosome-related organelle and provides a critical link between cysteine proteinases and parasite invasion for this class of organism.	Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem, La Jolla, CA 92093 USA; Univ Calif San Francisco, Vet Adm Med Ctr, Dept Pathol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Yale University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Reed, SL (corresponding author), Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Pathol, 200 W Arbor Dr, San Diego, CA 92103 USA.	slreed@ucsd.edu	Que, Xuchu/H-2741-2019; Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X; Que, Xuchu/0000-0002-6751-5493	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060, R01AI041903, P30AI036214] Funding Source: NIH RePORTER; NIAID NIH HHS [5 P30 AI36214, R01 AI41903, AI30060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn HJ, 2001, BIOCHEM BIOPH RES CO, V287, P630, DOI 10.1006/bbrc.2001.5637; Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; Armstrong N, 1999, PROTEIN SCI, V8, P1475, DOI 10.1110/ps.8.7.1475; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Bradley PJ, 1999, MOL BIOCHEM PARASIT, V100, P103, DOI 10.1016/S0166-6851(99)00035-3; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Denzer K, 2000, J CELL SCI, V113, P3365; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; Dubremetz JF, 1998, INT J PARASITOL, V28, P1007, DOI 10.1016/S0020-7519(98)00076-9; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; FOUSSARD F, 1991, PARASITOLOGY, V102, P367, DOI 10.1017/S0031182000064313; FULLER AL, 1990, J PARASITOL, V76, P464, DOI 10.2307/3282822; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Huete-Perez JA, 1999, J BIOL CHEM, V274, P16249, DOI 10.1074/jbc.274.23.16249; JOINER KA, 1993, INFECT IMMUN, V61, P1169, DOI 10.1128/IAI.61.4.1169-1172.1993; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LYCKE E, 1965, BRIT J EXP PATHOL, V46, P189; MAYER R, 1991, J MED CHEM, V34, P3029, DOI 10.1021/jm00114a011; MERCKELBACH A, 1994, TROP MED PARASITOL, V45, P193; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ngo HM, 1998, J EUKARYOT MICROBIOL, V45, P323, DOI 10.1111/j.1550-7408.1998.tb04543.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OGUN SA, 1994, EXP PARASITOL, V79, P270, DOI 10.1006/expr.1994.1090; PAMER EG, 1989, MOL BIOCHEM PARASIT, V33, P27, DOI 10.1016/0166-6851(89)90038-8; Que XC, 2002, MOL BIOCHEM PARASIT, V119, P23, DOI 10.1016/S0166-6851(01)00387-5; REED S, 1993, J CLIN INVEST, V91, P1532, DOI 10.1172/JCI116359; Reichmann G, 2002, MOL BIOCHEM PARASIT, V119, P43, DOI 10.1016/S0166-6851(01)00397-8; Robibaro B, 2002, CELL MICROBIOL, V4, P139, DOI 10.1046/j.1462-5822.2002.00178.x; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; Shaw MK, 1998, PARASITOLOGY, V117, P435, DOI 10.1017/S0031182098003278; Sinai AP, 2001, J CELL BIOL, V154, P95, DOI 10.1083/jcb.200101073; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; TAKAHASHI N, 1993, FEBS LETT, V334, P153, DOI 10.1016/0014-5793(93)81702-2	41	85	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25791	25797		10.1074/jbc.M202659200	http://dx.doi.org/10.1074/jbc.M202659200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	12000756	hybrid			2022-12-27	WOS:000176747000122
J	Mishra, RS; Gu, YP; Bose, S; Verghese, S; Kalepu, S; Singh, N				Mishra, RS; Gu, YP; Bose, S; Verghese, S; Kalepu, S; Singh, N			Cell surface accumulation of a truncated transmembrane prion protein in Gerstmann-Straussler-Scheinker disease P102L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; TRANSGENIC MICE; NEURODEGENERATION; PRP; HETEROGENEITY; DEGRADATION; INHIBITION; MUTATION; PEPTIDES; GENETICS	A familial prion disorder with a proline to leucine substitution at residue 102 of the prion protein (PrP102L) is typically associated with protease-resistant PrP fragments (PrPSc) in the brain parenchyma that are infectious to recipient animals. When modeled in transgenic mice, a fatal neurodegenerative disease develops, but, unlike the human counterpart, PrPSc is lacking and transmission to recipient animals is questionable. Alternate mice expressing a single copy of PrP102L (mouse PrP101L) do not develop spontaneous disease, but show dramatic susceptibility to PrPSc isolates from different species. To understand these discrepant results, we studied the biogenesis of human PrP102L in a cell model. Here, we report that cells expressing PrP 1121 show decreased expression of the normal 18-kDa fragment on the plasma membrane. Instead, a 20-kDa fragment, probably derived from transmembrane PrP ((PrP)-Pr-Ctm), accumulates on the cell surface. Because the 20-kDa fragment includes an amyloidogenic region of PrP that is disrupted in the 18-kDa form, increased surface expression of 20-kDa fragment may enhance the susceptibility of these cells to PrPSc infection by providing an optimal substrate, or by amplifying the neurotoxic signal of PrPSc. Thus, altered susceptibility of PrP101L Mice to exogenous PrPSc may be mediated by the 20-kDa (PrP)-Pr-Ctm fragment, rather than PrP102L per se.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Singh, N (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	nxs2@po.cwru.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035962, R29NS035962] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35962] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbanti P, 1996, NEUROLOGY, V47, P734, DOI 10.1212/WNL.47.3.734; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 1998, J VIROL, V72, P1153; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Piccardo P, 1998, J NEUROPATH EXP NEUR, V57, P979, DOI 10.1097/00005072-199810000-00010; Prusiner SB, 1996, COLD SPRING HARB SYM, V61, P473; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Yamada M, 1999, NEUROLOGY, V52, P260, DOI 10.1212/WNL.52.2.260; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	30	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24554	24561		10.1074/jbc.M200213200	http://dx.doi.org/10.1074/jbc.M200213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967261	hybrid			2022-12-27	WOS:000176611800077
J	Seo, M; Lee, YI; Cho, CH; Bae, CD; Kim, IH; Juhnn, YS				Seo, M; Lee, YI; Cho, CH; Bae, CD; Kim, IH; Juhnn, YS			Bi-directional regulation of UV-induced activation of p38 kinase and c-Jun N-terminal kinase by G protein beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; MAP KINASE; KAPPA-B; PATHWAY; EXPRESSION; APOPTOSIS; CELLS; CASCADES	Ultraviolet (UV) irradiation induces various cellular responses by activating many UV-responsive enzymes including mitogen-activated protein kinases (MAPKs). Various G protein-coupled receptor agonists also activate MAPKs, but it is not known whether or not G proteins also mediate the UV-induced activation of MAPKs. Therefore, this study was undertaken to determine whether the G protein betagamma-subunit (Gbetagamma) mediates the UV-induced activation of p38 and JNK. Gbetagamma overexpression in COS-1 cells amplified the UV-induced activation of p38 but reduced JNK activation. The overexpression of the C-terminal region of beta-adrenergic receptor kinase (betaARKct) decreased the UV-induced activation of p38 but increased JNK activation. Gbeta(1)gamma(2) expression increased MKK3/6 phosphorylation with a concomitant decrease in MKK4 phosphorylation, which contrasts with betaARKct expression. Gbeta(1)gamma(2) or betaARKct expression resulted in corresponding changes in the transcriptional activity of CHOP and c-Jun. Treatment with a p38 inhibitor, SB203580, or the expression of a kinase-inactive p38 increased the UV-induced JNK activation. Expression of the constitutively active MKK6 decreased the UV-induced JNK activation. In summary, although the endogenous Gbetagamma was found to mediate about half of the UV-induced activation of p38, it was found that exogenous Gbetagamma mediates the bi-directional regulation of UV-induced p38 and JNK activation, and that this bidirectional regulation results from the inhibition of JNK activation by the p38 activated via Gbetagamma in the COS-1 cells.	Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Inst Canc Res, Seoul 110799, South Korea; Natl Canc Ctr, Div Basic Sci, Koyang 411764, South Korea; Sungkyunkwan Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 440746, South Korea	Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC); Sungkyunkwan University (SKKU)	Juhnn, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.	juhnn@snu.ac.kr	Juhnn, Yong-Sung/J-2790-2012					ARUFFO A, 1991, CURRENT PROTOCOLS MO; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COFFER PJ, 1995, ONCOGENE, V11, P561; Coso OA, 1996, J BIOL CHEM, V271, P3963; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233; FAURE M, 1994, J BIOL CHEM, V269, P7851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	30	24	25	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24197	24203		10.1074/jbc.M201717200	http://dx.doi.org/10.1074/jbc.M201717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978790	hybrid			2022-12-27	WOS:000176611800030
J	Siu, F; Bain, PJ; LeBlanc-Chaffin, R; Chen, H; Kilberg, MS				Siu, F; Bain, PJ; LeBlanc-Chaffin, R; Chen, H; Kilberg, MS			ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; AMINO-ACID REGULATION; EXPRESSION; TRANSCRIPTION; PROTEIN; CELLS; ELEMENTS	Transcription from the asparagine synthetase (A.S.) gene is increased in response to either amino acid (amino acid response) or glucose (endoplasmic reticulum stress response) deprivation. These two independent pathways converge on the same set of genomic cis-elements within the A.S. promoter referred to as nutrient-sensing response elements (NSRE) 1 and 2, both of which are necessary for gene activation. The NSRE-1 sequence was used to screen ATF/CREB family members by electrophoresis mobility shift assays and supershift by specific antibodies. The results indicated that ATF4 binds to the NSRE-1 sequence and that the amount of the ATF4 complex was increased when extracts from amino acid-deprived or glucose-deprived cells were tested. Using electrophoresis mobility shift assay experiments and a probe that contained both NSRE-1 and NSRE-2, mutation of the NSRE-1 sequence completely prevented formation of the ATF4-containing complexes, whereas mutation of the NSRE-2 sequence did not. Overexpression of ATF4 increased A.S. promoter-driven transcription, whereas an inhibitory dominant negative ATF4 mutant blocked both basal and starvation-enhanced transcription. Collectively, the results provide both in vitro and in vivo evidence for a role of ATF4 in the transcriptional activation of the A.S. gene in response to nutrient deprivation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Nutr Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Box 100245, Gainesville, FL 32610 USA.				NIDDK NIH HHS [DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRULIS IL, 1979, J BIOL CHEM, V254, P629; ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hutson RG, 1996, CLIN NUTR, V15, P327, DOI 10.1016/S0261-5614(96)80009-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Jousse C, 1999, Curr Opin Clin Nutr Metab Care, V2, P297, DOI 10.1097/00075197-199907000-00008; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700	22	196	202	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24120	24127		10.1074/jbc.M201959200	http://dx.doi.org/10.1074/jbc.M201959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11960987	hybrid			2022-12-27	WOS:000176611800020
J	Dangoria, NS; DeLay, ML; Kingsbury, DJ; Mear, JP; Uchanska-Ziegler, B; Ziegler, A; Colbert, RA				Dangoria, NS; DeLay, ML; Kingsbury, DJ; Mear, JP; Uchanska-Ziegler, B; Ziegler, A; Colbert, RA			HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; COMPLEX CLASS-I; HEAVY-CHAINS; MONOCLONAL-ANTIBODIES; ANTIGEN PRESENTATION; PEPTIDE BINDING; QUALITY-CONTROL; CUTTING EDGE; EXPRESSION; RECOGNITION	The class I protein HLA-B27 confers susceptibility to inflammatory arthritis in humans and when overexpressed in rodents for reasons that remain unclear. We demonstrated previously that HIA-B27 heavy chains (HQ undergo endoplasmic reticulum (ER)-associated degradation. We report here that HLA-B27 HC also forms two types of aberrant disulfide-linked complexes (dimers) during the folding and assembly process that can be distinguished by conformation-sensitive antibodies W6/32 and HC10. HC10-reactive dimers form immediately after HC synthesis in the ER and constitute at least 25% of the HC pool, whereas W6/32-reactive dimers appear several hours later and represent less than 10% of the folded HC. HC10-reactive dimers accumulate in the absence of tapasin or beta(2)-microglobulin, whereas W6/32-reactive dimers are not detected. Efficient formation of W6/32-reactive dimers appears to depend on the transporter associated with antigen processing, tapasin, and beta(2)-microglobulin. The unpaired Cys(67) and residues at the base of the B pocket that dramatically impair HTA-B27 HC folding are critical for the formation of HC10-reactive ER dimers. Although certain other alleles also form dimers late in the assembly pathway, ER dimerization of HLA-B27 may be unique. These results demonstrate that residues comprising the HIA-B27 B pocket result in aberrant HC folding and disuffide bond formation, and thus confer unusual properties on this molecule that are unrelated to peptide selection per se, yet may be important in disease pathogenesis.	Childrens Hosp, Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA; Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, D-14050 Berlin, Germany	Cincinnati Children's Hospital Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Colbert, RA (corresponding author), Childrens Hosp, Med Ctr, Div Rheumatol, PAV 2-129,3333 Burnet Ave, Cincinnati, OH 45229 USA.	bob.colbert@chmcc.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR044059, R01AR046177] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60 AR-44059, R01 AR-46177] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; CAPPS GG, 1993, J IMMUNOL, V151, P159; CARRENO BM, 1994, EUR J IMMUNOL, V24, P1285, DOI 10.1002/eji.1830240607; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Colbert RA, 2000, J RHEUMATOL, V27, P1107; COLBERT RA, 1993, P NATL ACAD SCI USA, V90, P6879, DOI 10.1073/pnas.90.14.6879; Copeman J, 1998, EUR J IMMUNOL, V28, P3783, DOI 10.1002/(SICI)1521-4141(199811)28:11<3783::AID-IMMU3783>3.0.CO;2-9; CRESSWELL P, 1975, J IMMUNOL, V114, P523; Cresswell P, 1999, IMMUNOL RES, V19, P191, DOI 10.1007/BF02786487; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Gur H, 1999, CELL IMMUNOL, V191, P105, DOI 10.1006/cimm.1998.1417; HAKEM R, 1989, J IMMUNOL, V142, P297; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Ikawa T, 1998, J CLIN INVEST, V101, P263, DOI 10.1172/JCI471; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Khan MA, 1998, SPONDYLARTHRITIDES, P17; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6; Kostyu DD, 1997, HUM IMMUNOL, V57, P1, DOI 10.1016/S0198-8859(97)00175-4; Laitio P, 1997, EUR J IMMUNOL, V27, P1331, DOI 10.1002/eji.1830270606; LARSSON LG, 1992, INT J CANCER, V52, P759, DOI 10.1002/ijc.2910520515; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Lindquist JA, 2001, FASEB J, V15, P1448, DOI 10.1096/fj.00-0720fje; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LOZANO F, 1993, LEUKEMIA RES, V17, P9, DOI 10.1016/0145-2126(93)90135-8; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Malik P, 1999, TISSUE ANTIGENS, V53, P576, DOI 10.1034/j.1399-0039.1999.530609.x; Mear JP, 1999, J IMMUNOL, V163, P6665; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Parham P, 1996, IMMUNOL REV, V154, P137, DOI 10.1111/j.1600-065X.1996.tb00932.x; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; PERARNAU BM, 1988, J IMMUNOL, V141, P1383; PIOUS D, 1977, IMMUNOGENETICS, V4, P437, DOI 10.1007/BF01575679; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Rehm A, 2000, HUM IMMUNOL, V61, P408, DOI 10.1016/S0198-8859(99)00176-7; Reinelt S, 2001, J BIOL CHEM, V276, P18472, DOI 10.1074/jbc.M101282200; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SMITH DM, 1994, J IMMUNOL, V153, P1054; SPRINGER TA, 1977, J BIOL CHEM, V252, P4694; STAM NJ, 1986, J IMMUNOL, V137, P2299; Taurog JD, 1999, IMMUNOL REV, V169, P209; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; Virtala M, 1997, INFECT IMMUN, V65, P4236, DOI 10.1128/IAI.65.10.4236-4242.1997; WARBURTON RJ, 1994, HUM IMMUNOL, V39, P261, DOI 10.1016/0198-8859(94)90269-0; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WHELAN MA, 1993, EUR J IMMUNOL, V23, P3278, DOI 10.1002/eji.1830231233; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	68	179	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23459	23468		10.1074/jbc.M110336200	http://dx.doi.org/10.1074/jbc.M110336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11978783	hybrid			2022-12-27	WOS:000176475700049
J	Nelson, LM; Rose, RC; Moroianu, J				Nelson, LM; Rose, RC; Moroianu, J			Nuclear import strategies of high risk HPV16 L1 major capsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; HUMAN-PAPILLOMAVIRUS TYPE-11; VESICULAR STOMATITIS-VIRUS; RNA-BINDING-PROTEINS; HNRNP A1; LOCALIZATION SIGNALS; MATRIX PROTEIN; INSECT CELLS; RAN; IDENTIFICATION	During the late phase of human papillomavirus (HPV) infection, the L1 major capsid proteins enter the nuclei of host epithelial cells and, together with the L2 minor capsid proteins, assemble the replicated viral DNA into virions. We investigated the nuclear import of the L1 major capsid protein of high risk HPV16. When digitonin-permeabilized HeLa cells were incubated with HPV16 L1 capsomeres, the L1 protein was imported into the nucleus in a receptor-mediated manner. HPV16 L1 capsomeres formed complexes with Kap alpha2beta1 heterodimers via interaction with Kap alpha2. Accordingly, nuclear import of HPV16 L1 capsomeres was mediated by Kap alpha2beta1 heterodimers, required RanGDP and free GTP, and was independent of GTP hydrolysis. Remarkably, HPV16 L1 capsomeres also interacted with Kap 132 and binding of RanGTP to Kap 192 did not dissociate the HPV16 L1.Kap beta2 complex. Significantly, HPV16 L1 capsomeres inhibited the nuclear import of Kap 132 and of a Kap beta2-specific M9-containing cargo. These data suggest that, during the productive stage of infection, while the HPV16 L1 major capsid protein enters the nucleus via the Kap alpha2beta1-mediated pathway to assemble the virions, it also inhibits the Kap beta2-mediated nuclear import of host hnRN-P A1 protein and, in this way, favors virion formation.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Univ Rochester, Sch Med & Dent, Dept Med & Microbiol & Immunol, Infect Dis Unit, Rochester, NY 14642 USA	Boston College; University of Rochester	Moroianu, J (corresponding author), Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA.	moroianu@bc.edu						ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Belnap DM, 1996, J MOL BIOL, V259, P249, DOI 10.1006/jmbi.1996.0317; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gustin KE, 2001, EMBO J, V20, P240, DOI 10.1093/emboj/20.1.240; HAGENSEE ME, 1994, J VIROL, V68, P4503, DOI 10.1128/JVI.68.7.4503-4505.1994; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Li ML, 1998, J VIROL, V72, P2160, DOI 10.1128/JVI.72.3.2160-2167.1998; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; MICHAEL WM, 1995, CELL, V83, P415; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Moroianu J, 1999, J CELL BIOCHEM, P76; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nelson LM, 2000, J CELL BIOCHEM, V79, P225, DOI 10.1002/1097-4644(20001101)79:2<225::AID-JCB60>3.0.CO;2-A; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; ROSE RC, 1994, J GEN VIROL, V75, P2075, DOI 10.1099/0022-1317-75-8-2075; ROSE RC, 1993, J VIROL, V67, P1936, DOI 10.1128/JVI.67.4.1936-1944.1993; ROSE RC, 1994, J GEN VIROL, V75, P2445, DOI 10.1099/0022-1317-75-9-2445; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; VOLPERS C, 1994, VIROLOGY, V200, P504, DOI 10.1006/viro.1994.1213; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; ZHOU J, 1993, J GEN VIROL, V74, P763, DOI 10.1099/0022-1317-74-4-763; ZHOU J, 1991, VIROLOGY, V185, P625, DOI 10.1016/0042-6822(91)90533-H; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	52	29	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23958	23964		10.1074/jbc.M200724200	http://dx.doi.org/10.1074/jbc.M200724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971900	hybrid			2022-12-27	WOS:000176475700111
J	Keshamouni, VG; Mattingly, RR; Reddy, KB				Keshamouni, VG; Mattingly, RR; Reddy, KB			Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; STEROID-HORMONE RECEPTORS; SIGNAL-TRANSDUCTION; MAP KINASE; ESTROGEN-RECEPTOR; MCF-7 CELLS; DEPENDENT ACTIVATION; ESTRADIOL-RECEPTOR; FACTOR SECRETION	Activation of mitogen-activated protein kinase (Erk/ MAPK) is a critical signal transduction event for estrogen (E-2)-mediated cell proliferation. Recent studies from our group and others have shown that persistent activation of Erk plays a major role in cell migration and tumor progression. The signaling mechanism(s) responsible for persistent Erk activation are not fully characterized, however. In this study, we have shown that E-2 induces a slow but persistent activation of Erk in MCF-7 breast carcinoma cells. The E-2-induced Erk activation is dependent on new protein synthesis, suggesting that E-2-induced growth factors play a major role in Erk activation. When MCF-7 cells were treated with E-2 in the presence of an anti-HER-2 monoclonal antibody (herceptin), 60-70% of E-2-induced Erk activation is blocked. In addition, when untreated MCF-7 cells were exposed to conditioned medium from E-2-treated cells, Erk activity was significantly enhanced. Furthermore Erk activity was blocked by an antibody against HER-2 or by heregulin (HRG) depletion from the conditioned medium through immunoprecipitation. In contrast, epidermal growth factor receptor (Ab528) antibody only blocked 10-20% of E-2-induced Erk activation, suggesting that E-2-induced Erk activation is predominantly mediated through the secretion of HRG and activation of HER-2 by an autoctine/paracrine mechanism. Inhibition of PKC-delta-mediated signaling by a dominant negative mutant or the relatively specific PKC-delta inhibitor rottlerin blocked most of the E-2-induced Erk activation but had no effect on TGFalpha-induced Erk activation. By contrast inhibition of Ras, by inhibition of farnesyl transferase (Ftase-1) or dominant negative (N17)-Ras, significantly inhibited both E-2- and TGFalpha-induced Erk activation. This evaluation of downstream signaling revealed that E-2-induced Erk activation is mediated by a In HRG/HER-2/PKC-delta/Ras pathway that could be crucial for E-2-dependent growth-promoting effects in early stages of tumor progression.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.			Keshamouni, Venkateshwar/0000-0003-1947-791X	NATIONAL CANCER INSTITUTE [R01CA081150, R01CA083964] Funding Source: NIH RePORTER; NCI NIH HHS [R01 NCA81150, R01 CA 83964-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DUBIK D, 1987, CANCER RES, V47, P6517; Elledge RM, 1998, CLIN CANCER RES, V4, P7; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FABBRO D, 1986, CANCER RES, V46, P2720; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Hornia A, 1999, MOL CELL BIOL, V19, P7672; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kurokawa H, 2000, CANCER RES, V60, P5887; LACROIX H, 1989, ONCOGENE, V4, P145; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPPMAN ME, 1987, J CELL BIOCHEM, V35, P1, DOI 10.1002/jcb.240350102; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mattingly RR, 2001, TOXICOL APPL PHARM, V176, P162, DOI 10.1006/taap.2001.9272; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miles DW, 2001, BREAST CANCER RES, V3, P380, DOI 10.1186/bcr326; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moasser MM, 2001, CANCER RES, V61, P7184; MORRISON P, 1996, J BIOL CHEM, V271, P12691; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Normanno N, 1997, J MAMMARY GLAND BIOL, V2, P143, DOI 10.1023/A:1026351730785; OBRIAN CA, 1989, CANCER RES, V49, P3215; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; REDDY KB, 1992, CANCER RES, V52, P3636; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rusnak DW, 2001, CANCER RES, V61, P7196; Sato J D, 1983, Mol Biol Med, V1, P511; SEGER R, 1992, J BIOL CHEM, V267, P25628; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tang CK, 1996, CANCER RES, V56, P3350; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Treish I, 2000, AM J HEALTH-SYST PH, V57, P2063, DOI 10.1093/ajhp/57.22.2063; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	78	142	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22558	22565		10.1074/jbc.M202351200	http://dx.doi.org/10.1074/jbc.M202351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960991	hybrid			2022-12-27	WOS:000176313600061
J	Zhang, LQ; Hartshorn, KL; Crouch, EC; Ikegami, M; Whitsett, JA				Zhang, LQ; Hartshorn, KL; Crouch, EC; Ikegami, M; Whitsett, JA			Complementation of pulmonary abnormalities in SP-D(-/-) mice with an SP-D/conglutinin fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TARGETED MICE; CARBOHYDRATE-RECOGNITION DOMAIN; INFLUENZA-A VIRUSES; ALVEOLAR MACROPHAGES; IN-VIVO; TRANSGENIC MICE; HOST-DEFENSE; SURFACTANT; EXPRESSION; BINDING	Surfactant protein D (SP-D) and serum conglutinin are closely related members of the collectin family of host defense lectins. Although normally synthesized at different anatomic sites, both proteins participate in the innate immune response to microbial challenge. To discern the roles of specific domains in the function of SP-D in vivo, a fusion protein (SP-D/Cong(neck+CRD)) consisting of the NH2-terminal and collagenous domains of rat SP-D (rSP-D) and the neck and carbohydrate recognition domains (CRDs) of bovine conglutinin (Cong) was expressed in the respiratory epithelium of SP-D gene-targeted (SP-D(-/-)) mice. While SP-D/Cong(neck+CRD) fusion protein did not affect lung morphology and surfactant phospholipid levels in the lungs of wild type mice, the chimeric protein substantially corrected the increased lung phospholipids in SP-D(-/-) mice. The SP-D/Cong(neck+CRD) fusion protein also completely corrected defects in influenza A clearance and inhibited the exaggerated inflammatory response that occurs following viral infection. However, the chimeric protein did not ameliorate the ongoing lung inflammation, enhanced metalloproteinase expression, and alveolar destruction that characterize this model of SP-D deficiency. By contrast, a single arm mutant (RrSP-D-Ser15,D-20) partially restored antiviral activity but otherwise failed to rescue the deficient phenotype. Our findings directly implicate the CRDs of both SP-D and conglutinin in host defense in vivo. Our findings also strongly suggest that the molecular mechanisms underlying impaired pulmonary host defense and abnormal lipid metabolism are distinct from those that promote ongoing inflammation and the development of emphysema.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Cincinnati Children's Hospital Medical Center; Boston University; Boston University; Washington University (WUSTL)	Whitsett, JA (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@chmcc.org		Hartshorn, Kevan/0000-0002-7196-7433	NHLBI NIH HHS [HL29594, HL5891, HL63329-03, HL44015, HL61646-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL061646, P01HL029594, R01HL044015, R01HL063329] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; Elhalwagi BM, 1999, AM J RESP CELL MOL, V21, P380, DOI 10.1165/ajrcmb.21.3.3676; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; HARTSHORN KL, 1993, J IMMUNOL, V151, P6265; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156, DOI 10.1152/ajplung.1997.273.6.L1156; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Hartshorn KL, 2000, AM J PHYSIOL-LUNG C, V278, pL90, DOI 10.1152/ajplung.2000.278.1.L90; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; Holmskov UL, 2000, APMIS, V108, P7; HULL W, 2000, AM J RESP CRIT CARE, V161, pA42; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Reid KBM, 1998, BBA-MOL BASIS DIS, V1408, P290, DOI 10.1016/S0925-4439(98)00074-X; REID KBM, 1994, SPRINGER SEMIN IMMUN, V15, P307, DOI 10.1007/BF01837363; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	35	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22453	22459		10.1074/jbc.M201632200	http://dx.doi.org/10.1074/jbc.M201632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956209	hybrid			2022-12-27	WOS:000176313600046
J	Tanimura, A; Nezu, A; Morita, T; Hashimoto, N; Tojyo, Y				Tanimura, A; Nezu, A; Morita, T; Hashimoto, N; Tojyo, Y			Interplay between calcium, diacylglycerol, and phosphorylation in the spatial and temporal regulation of PKC alpha-GFP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL ESTERS; SIGNAL-TRANSDUCTION; MEMBRANE-BINDING; PHAGOCYTOSIS; LOCALIZATION; ACTIVATION; CA2+; AUTOPHOSPHORYLATION; TRANSLOCATION	The function of protein kinase C (PKC) is closely regulated by its subcellular localization. We expressed PKCalpha fused to green fluorescent protein (PKCalpha-GFP) and examined its translocation in living and permeabilized cells of the human parotid cell line, HSY-EB. ATP induced an oscillatory translocation of PKCalpha-GFP to and from the plasma membrane that paralleled the appearance of repetitive Ca2+ spikes. Staurosporine attenuated the relocation of PKCalpha-GFP to the cytosol and caused a stepwise accumulation of PKCalpha-GFP at the plasma membrane during ATP stimulation. Diacylglycerol enhanced the amplitude and duration of the ATP-induced oscillatory translocation of PKCalpha-GFP. lonomycin induced a transient translocation of PKCalpha-GFP to the plasma membrane despite the continuous elevation of cytosolic Ca2+. The ionomycin-induced transient translocation of PKCalpha-GFP was prolonged by staurosporine, diacylglycerol, and phorbol myristate acetate. Experiments using permeabilized cells showed that staurosporine or the elimination of ATP and Mg2+ decreases the rate of dissociation of PKCalpha-GFP from the membrane. Diacylglycerol slowed the dissociation of PKCalpha-GFP from the membrane regardless of the Ca2+ concentration. The effect of diacylglycerol was attenuated by ATP plus Mg2+ at low concentrations of Ca2+ (< 500 nM) but not at high concentrations of Ca2+ (> 1000 nM). These data suggest a complex interplay between Ca2+, diacylglycerol, and phosphorylation in the regulation of the membrane binding of PKCalpha.	Hlth Sci Univ Hokkaido, Dept Dent Pharmacol, Sch Dent, Ishikari, Hokkaido 0610293, Japan; Hlth Sci Univ Hokkaido, Dept Integrated Human Sci, Sch Dent, Ishikari, Hokkaido 0610293, Japan	Health Sciences University of Hokkaido; Health Sciences University of Hokkaido	Tanimura, A (corresponding author), Hlth Sci Univ Hokkaido, Dept Dent Pharmacol, Sch Dent, Ishikari, Hokkaido 0610293, Japan.							ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Brumell JH, 1999, J IMMUNOL, V163, P3388; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; SCHAEFER M, 2001, FASEB J; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Tojyo Y, 2001, BBA-MOL CELL RES, V1539, P114, DOI 10.1016/S0167-4889(01)00098-2; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	32	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29054	29062		10.1074/jbc.M201130200	http://dx.doi.org/10.1074/jbc.M201130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11997388	hybrid			2022-12-27	WOS:000177342600092
J	Bennin, DA; Don, ASA; Brake, T; McKenzie, JL; Rosenbaum, H; Ortiz, L; DePaoli-Roach, AA; Horne, MC				Bennin, DA; Don, ASA; Brake, T; McKenzie, JL; Rosenbaum, H; Ortiz, L; DePaoli-Roach, AA; Horne, MC			Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B ' subunits in active complexes and induces nuclear aberrations and a G(1)/S phase cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GROWTH ARREST; TUMOR-ANTIGEN; A-SUBUNIT; IDENTIFICATION; EXPRESSION; FAMILY; KINASE; PP2A	Cyclin G2, together with cyclin G1 and cyclin 1, defines a novel cyclin family expressed in terminally differentiated tissues including brain and muscle. Cyclin G2 expression is up-regulated as cells undergo cell cycle arrest or apoptosis in response to inhibitory stimuli independent of p53 (Horne, M., Donaldson, K., Goolsby, G., Tran, D., Mulheisen, M., Hell, J. and Wahl, A. (1997) J. Biol. Chem. 272, 12650-12661). We tested the hypothesis that cyclin G2 may be a negative regulator of cell cycle progression and found that ectopic expression of cyclin G2 induces the formation of aberrant nuclei and cell cycle arrest in HEK293 and Chinese hamster ovary cells. Cyclin G2 is primarily partitioned to a detergent-resistant compartment, suggesting an association with cytoskeletal elements. We determined that cyclin G2 and its homolog cyclin G1 directly interact with the catalytic subunit of protein phosphatase 2A (PP2A). An okadaic acid-sensitive (<2 nM) phosphatase activity coprecipitates with endogenous and ectopic cyclin G2. We found that cyclin G2 also associates with various PP2A B' regulatory subunits, as previously shown for cyclin G1. The PP2A/A subunit is not detectable in cyclin G2-PP2A-B'-C complexes. Notably, cyclin G2 colocalizes with both PP2A/C and B' subunits in detergent-resistant cellular compartments, suggesting that these complexes form in living cells. The ability of cyclin G2 to inhibit cell cycle progression correlates with its ability to bind PP2A/B' and C subunits. Together, our findings suggest that cyclin G2-PP2A complexes inhibit cell cycle progression.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Indiana Univ, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Iowa; Indiana University System; Indiana University-Purdue University Indianapolis	Horne, MC (corresponding author), Univ Iowa, Dept Pharmacol, 2-530 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	mary-horne@uiowa.edu		Horne, Mary/0000-0002-2799-3212	NIGMS NIH HHS [R01 GM 56900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; Bates S, 1996, ONCOGENE, V13, P1103; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Bras A, 1999, FASEB J, V13, P931, DOI 10.1096/fasebj.13.8.931; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Cheng AY, 1998, CANCER RES, V58, P3611; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; Galadari S, 1998, BIOCHEMISTRY-US, V37, P11232, DOI 10.1021/bi980911+; Gao CY, 1997, BIOESSAYS, V19, P307, DOI 10.1002/bies.950190408; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Horne MC, 1996, IMMUNITY, V4, P145, DOI 10.1016/S1074-7613(00)80679-2; Jackman MR, 1997, CANCER SURV, V29, P47; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jensen MR, 1999, GENE, V230, P171, DOI 10.1016/S0378-1119(99)00057-8; Jiang W, 2000, GENETICS, V154, P1025; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; LEE TH, 1995, SEMIN CANCER BIOL, V6, P203, DOI 10.1006/scbi.1995.0027; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Mills JC, 1998, J CELL SCI, V111, P625; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Reed SI, 1997, CANCER SURV, V29, P7; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; Snaith HA, 1996, J CELL SCI, V109, P3001; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1998, J COMP NEUROL, V392, P515; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAMURA K, 1993, ONCOGENE, V8, P2113; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	93	171	180	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27449	27467		10.1074/jbc.M111693200	http://dx.doi.org/10.1074/jbc.M111693200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11956189	hybrid			2022-12-27	WOS:000177055900095
J	Dobson, GP; Hitchins, S; Teague, WE				Dobson, GP; Hitchins, S; Teague, WE			Thermodynamics of the pyruvate kinase reaction and the reversal of glycolysis in heart and skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROCNEMIUS IN-VIVO; CREATINE-KINASE; GLYCOGEN-SYNTHESIS; LACTATE; METABOLISM; EXERCISE; FROG; PH	The effect of temperature, pH, and free [Mg2+] on the apparent equilibrium constant of pyruvate kinase (phosphoenol transphosphorylase) (EC 2.7.1.40) was investigated. The apparent equilibrium constant, K', for the biochemical reaction P-enolpyruvate + ADP = ATP + Pyr was defined as K' = [ATP][Pyr]/[ADP][P-enolpyruvatel] where each reactant represents the sum of all the ionic and metal complexed species in M. The K' at pH 7.0, 1.0 mm free Mg2+ and I of 0.25 m was 3.89 X 10(4) (n = 8) at 25 degreesC. The standard apparent enthalpy (DeltaH'degrees) for the biochemical reaction was -4.31 kJmol(-1) in the direction of ATP formation. The corresponding standard apparent entropy (DeltaS'degrees) was +73.4 J K-1 mol(-1). The DeltaHdegrees and AS' values for the reference reaction, P-enolpyruvate(3-) + ADp(3-) + H+ = ATp(4-) + Pyr(1-), were -6.43 kJmol(-1) and + 180 J K-1 mol(-1), respectively (5 to 38 degreesC). We examined further the mass action ratio in rat heart and skeletal muscle at rest and found that the pyruvate kinase reaction in vivo was close to equilibrium i.e. within a factor of about 3 to 6 of K' in the direction of ATP at the same pH, free [Mg2+], and T. We conclude that the pyruvate kinase reaction may be reversed under some conditions in vivo, a finding that challenges the long held dogma that the reaction is displaced far from equilibrium.	James Cook Univ N Queensland, Sch Biomed & Mol Sci, Div Physiol & Pharmacol, Townsville, Qld 4811, Australia; NIAAA, Sect Nucl Magnet Resonacne Studies, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	James Cook University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Dobson, GP (corresponding author), James Cook Univ N Queensland, Sch Biomed & Mol Sci, Div Physiol & Pharmacol, Townsville, Qld 4811, Australia.							BENDALL JR, 1970, BIOCHEM J, V118, P887, DOI 10.1042/bj1180887; CHEER RL, 1980, BIOPHYS CHEM, V12, P73, DOI 10.1016/0301-4622(80)80041-X; Cieslar J, 1998, AM J PHYSIOL-REG I, V275, pR1530, DOI 10.1152/ajpregu.1998.275.5.R1530; Cieslar JH, 2001, AM J PHYSIOL-REG I, V281, pR511, DOI 10.1152/ajpregu.2001.281.2.R511; Cieslar JH, 2000, J BIOL CHEM, V275, P6129, DOI 10.1074/jbc.275.9.6129; CONNETT RJ, 1996, SECTION 12 HDB PHYSL, P870; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Donovan CM, 2000, MED SCI SPORT EXER, V32, P772, DOI 10.1097/00005768-200004000-00009; DYSON RD, 1975, J BIOL CHEM, V250, P3316; GOLDBERG RN, 1994, J PHYS CHEM REF DATA, V23, P547, DOI 10.1063/1.555948; GOLDING EM, 1995, J EXP BIOL, V198, P1775; GOLDING EM, 1995, MAGNET RESON MED, V33, P467, DOI 10.1002/mrm.1910330403; HERMANSEN L, 1977, AM J PHYSIOL, V233, pE422, DOI 10.1152/ajpendo.1977.233.5.E422; Hill AV, 1923, Q J MED, V16, P135, DOI 10.1093/qjmed/os-16.62.135; Hitchins S, 2001, AM J PHYSIOL-HEART C, V281, pH882, DOI 10.1152/ajpheart.2001.281.2.H882; HOCHACHKA PW, 1988, CAN J ZOOL, V66, P1128, DOI 10.1139/z88-165; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; KREBS HA, 1965, BIOCHEM J, V94, P436, DOI 10.1042/bj0940436; KREBS HA, 1964, P R SOC LOND B, V159, P544; KRIMSKY I, 1959, J BIOL CHEM, V234, P232; LARDY HA, 1945, J BIOL CHEM, V159, P343; LARDY HA, 1949, RESP ENZYMES, P179; Lehninger A L, 1982, PRINCIPLES BIOCH; MCLANE JA, 1979, J BIOL CHEM, V254, P6548; MCQUATE JT, 1959, J BIOL CHEM, V234, P2151; Meyerhof O, 1919, PFLUG ARCH GES PHYS, V175, P88, DOI 10.1007/BF01722141; Meyerhof O, 1938, BIOCHEM Z, V298, P396; Newsholme EA, 1973, REGULATION METABOLIS; Parnas JK, 1934, BIOCHEM Z, V272, P64; Pascoe DD, 1996, SPORTS MED, V21, P98, DOI 10.2165/00007256-199621020-00003; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; SCHULTE PM, 1992, J EXP BIOL, V166, P181; SCRUTTON MC, 1968, ANNU REV BIOCHEM, V37, P249, DOI 10.1146/annurev.bi.37.070168.001341; SHIOTA M, 1984, BIOCHEM J, V222, P281, DOI 10.1042/bj2220281; Teague WE, 1999, J BIOL CHEM, V274, P22459, DOI 10.1074/jbc.274.32.22459; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; Voet D, 1999, FUNDAMENTALS BIOCH; ZAMMIT VA, 1978, BIOCHEM J, V174, P979, DOI 10.1042/bj1740979	40	23	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27176	27182		10.1074/jbc.M111422200	http://dx.doi.org/10.1074/jbc.M111422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11986306	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000177055900062
J	Huang, LP; Kirschke, CP; Gitschier, J				Huang, LP; Kirschke, CP; Gitschier, J			Functional characterization of a novel mammalian zinc transporter, ZnT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DI-LEUCINE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; CONFERS RESISTANCE; SYNAPTIC VESICLES; PLASMA-MEMBRANE; MENKES PROTEIN; EXPRESSION; MOUSE; IDENTIFICATION	We describe ZnT6, a new member of the CDF (cation diffusion facilitator) family of heavy metal transporters. The human ZNT6 gene was mapped at 2p21-22, while the mouse Znt6 was localized to chromosome 17. Overexpression of ZnT6 in both wild-type yeast and mutants that are deficient in cytoplasmic zinc causes growth inhibition, but this inhibition is abolished in mutant cells with high cytoplasmic zinc. ZnT6 may function in transporting the cytoplasmic zinc into the Golgi apparatus as well as the vesicular compartment, as evidenced by its overlapping intracellular localization with TGN38 and transferrin receptor in the normal rat kidney cells. We also demonstrate that the intracellular distributions of ZnT6 as well as ZnT4 are regulated by zinc in the normal rat kidney cells. The results from this report, combined with those from other studies, suggest that the intracellular zinc homeostasis is mediated by many ZnT proteins, which act in tissue-, cell-, and organelle-specific manners.	Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA; USDA ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California Davis; United States Department of Agriculture (USDA); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, LP (corresponding author), Univ Calif Davis, Rowe Program Genet, 4445 Tupper Hall, Davis, CA 95616 USA.							BURGUNDER JM, 1984, J HERED, V75, P480; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; DASILVA FDF, 1991, BIOL CHEM ELEMENTS, P299; DICHIE MM, 1969, MOUSE NEWS LETT, V41, P30; Francis MJ, 1999, J CELL SCI, V112, P1721; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Lioumi M, 1999, GENOMICS, V62, P272, DOI 10.1006/geno.1999.5993; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MURGIA C, 1999, J PHYSL, V277, pG1231; NIES DH, 1992, J BACTERIOL, V174, P8102, DOI 10.1128/JB.174.24.8102-8110.1992; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; PILETZ JE, 1978, SCIENCE, V199, P181, DOI 10.1126/science.619449; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	25	172	181	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26389	26395		10.1074/jbc.M200462200	http://dx.doi.org/10.1074/jbc.M200462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11997387	hybrid			2022-12-27	WOS:000176908700075
J	Richardson, TH; Tan, XQ; Frey, G; Callen, W; Cabell, M; Lam, D; Macomber, J; Short, JM; Robertson, DE; Miller, C				Richardson, TH; Tan, XQ; Frey, G; Callen, W; Cabell, M; Lam, D; Macomber, J; Short, JM; Robertson, DE; Miller, C			A novel, high performance enzyme for starch liquefaction - Discovery and optimization of a low pH, thermostable alpha-amylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO RECOMBINATION; BACILLUS-LICHENIFORMIS; PYROCOCCUS-FURIOSUS; DIRECTED EVOLUTION; BIOCHEMICAL-CHARACTERIZATION; THERMOCOCCUS-PROFUNDUS; NUCLEOTIDE-SEQUENCE; MOLECULAR EVOLUTION; CLONING; EXPRESSION	High throughput screening of microbial DNA libraries was used to identify alpha-amylases with phenotypic characteristics compatible with large scale corn wet milling process conditions. Single and multiorganism DNA libraries originating from various environments were targeted for activity and sequence-based screening approaches. After initial screening, 15 clones were designated as primary hits based upon activity at pH 4.5 or 95 degreesC without addition of endogenous Ca2+. After further characterization, three enzyme candidates were chosen each with an exceptional expression of one or more aspects of the necessary phenotype: temperature stability, pH optimum, lowered reliance on Ca2+ and/or enzyme rate. To combine the best aspects of the three phenotypes to optimize process compatibility, the natural gene homologues were used as a parental sequence set for gene reassembly. Approximately 21,000 chimeric daughter sequences were generated and subsets screened using a process-specific, high throughput activity assay. Gene reassembly resulted in numerous improved mutants with combined optimal phenotypes of expression, temperature stability, and pH optimum. After biochemical and process-specific characterization of these gene products, one a-amylase with exceptional process compatibility and economics was identified. This paper describes the synergistic approach of combining environmental discovery and laboratory evolution for identification and optimization of industrially important biocatalysts.	Diversa Corp, San Diego, CA 92121 USA		Richardson, TH (corresponding author), Diversa Corp, 4955 Directors Pl, San Diego, CA 92121 USA.		Short, Jay/GQY-7343-2022					Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; CHUNG YC, 1995, APPL ENVIRON MICROB, V61, P1502, DOI 10.1128/AEM.61.4.1502-1506.1995; Coco WM, 2001, NAT BIOTECHNOL, V19, P354, DOI 10.1038/86744; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Dong GQ, 1997, APPL ENVIRON MICROB, V63, P3569, DOI 10.1128/AEM.63.9.3569-3576.1997; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; Frillingos S, 2000, J APPL MICROBIOL, V88, P495, DOI 10.1046/j.1365-2672.2000.00988.x; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Hashida M, 2000, TRENDS GLYCOSCI GLYC, V12, P389, DOI 10.4052/tigg.12.389; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Holden JF, 2001, FEMS MICROBIOL ECOL, V36, P51, DOI 10.1016/S0168-6496(01)00118-0; IMANAKA T, 1996, Patent No. 96191138; Jorgensen S, 1997, J BIOL CHEM, V272, P16335, DOI 10.1074/jbc.272.26.16335; KOCH R, 1991, ARCH MICROBIOL, V155, P572, DOI 10.1007/BF00245352; Lee JT, 1996, J FERMENT BIOENG, V82, P432, DOI 10.1016/S0922-338X(97)86978-4; Leveque E, 2000, ENZYME MICROB TECH, V26, P3, DOI 10.1016/S0141-0229(99)00142-8; Leveque E, 2000, FEMS MICROBIOL LETT, V186, P67, DOI 10.1016/S0378-1097(00)00117-8; Linden A, 2000, J CHROMATOGR B, V737, P253, DOI 10.1016/S0378-4347(99)00364-3; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUZAKI H, 1974, BIOCHIM BIOPHYS ACTA, V365, P235, DOI 10.1016/0005-2795(74)90268-2; Ness JE, 1999, NAT BIOTECHNOL, V17, P893, DOI 10.1038/12884; Ostermeier M, 1999, NAT BIOTECHNOL, V17, P1205, DOI 10.1038/70754; ROBERTSON DE, 1996, SIM NEWS, V46, P3; SAITO N, 1973, ARCH BIOCHEM BIOPHYS, V155, P290, DOI 10.1016/0003-9861(73)90117-3; Schmidt-Dannert Claudia, 1999, Trends in Biotechnology, V17, P135, DOI 10.1016/S0167-7799(98)01283-9; SHORT JM, 1996, Patent No. 96657409; Sieber V, 2001, NAT BIOTECHNOL, V19, P456, DOI 10.1038/88129; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Tachibana Y, 1996, J FERMENT BIOENG, V82, P224, DOI 10.1016/0922-338X(96)88812-X; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665; YUUKI T, 1985, J BIOCHEM-TOKYO, V98, P1147, DOI 10.1093/oxfordjournals.jbchem.a135381; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	34	148	194	1	68	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26501	26507		10.1074/jbc.M203183200	http://dx.doi.org/10.1074/jbc.M203183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994309	hybrid			2022-12-27	WOS:000176908700089
J	Stahelin, RV; Long, F; Diraviyam, K; Bruzik, KS; Murray, D; Cho, WH				Stahelin, RV; Long, F; Diraviyam, K; Bruzik, KS; Murray, D; Cho, WH			Phosphatidylinositol 3-phosphate induces the membrane penetration of the FYVE domains of Vps27p and Hrs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; KINASE-C-ALPHA; CRYSTAL-STRUCTURE; PROTEIN-KINASE; PHOSPHOLIPASE A(2); BINDING DOMAIN; LOCALIZATION; ROLES; TRAFFICKING; PRESSURE	involved in membrane trafficking and cell signaling to phosphatidylinositol 3-phosphate (PtdIns(3)P)-containing membranes. To elucidate the mechanism by which the FYVE domain interacts with PtdIns(3)P-containing membranes, we measured the membrane binding of the FYVE domains of yeast Vps27p and Drosophila hepatocyte growth factor-regulated tyrosine kinase substrate and their mutants by surface plasmon resonance and monolayer penetration analyses. These measurements as well as electrostatic potential calculation show that PtdIns(3)P specifically induces the membrane penetration of the FYVE domains and increases their membrane residence time by decreasing the positive charge surrounding the hydrophobic tip of the domain and causing local conformational changes. Mutations of hydrophobic residues located close to the PtdIns(3)P-binding pocket or an Arg residue directly involved in PtdIns(3)P binding abrogated the penetration of the FYVE domains into the monolayer, the packing density of which is comparable with that of biological membranes and large unilamellar vesicles. Based on these results, we propose a mechanism of the membrane binding of the FYVE domain in which the domain first binds to the PtdIns(3)P-containing membrane by specific PtdIns(3)P binding and nonspecific electrostatic interactions, which is then followed by the PtdIns(3)P-induced partial membrane penetration of the domain.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University	Cho, WH (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987, GM57568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Kutateladze TG, 2000, J BIOMOL NMR, V17, P89, DOI 10.1023/A:1008394731942; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Momsen WE, 1997, METHOD ENZYMOL, V286, P292; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 2001, SEMIN CELL DEV BIOL, V12, P193, DOI 10.1006/scdb.2000.0236; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	45	127	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26379	26388		10.1074/jbc.M201106200	http://dx.doi.org/10.1074/jbc.M201106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006563	hybrid			2022-12-27	WOS:000176908700074
J	Gummadi, SN; Menon, AK				Gummadi, SN; Menon, AK			Transbilayer movement of dipalmitoylphosphatidylcholine in proteoliposomes reconstituted from detergent extracts of endoplasmic reticulum - Kinetics of transbilayer transport mediated by a single flippase and identification of protein fractions enriched in flippase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TRANSMEMBRANE MOVEMENT; PHOSPHOLIPID FLIPPASE; MEMBRANE; PHOSPHATIDYLCHOLINE; BILAYER; SEPARATION; DENSITY; MOTION; LIPIDS; PHASE	Phospholipid translocation (flip-flop) across membrane bilayers is typically assessed via assays utilizing partially water-soluble phospholipid analogs as transport reporters. These assays have been used in previous work to show that phospholipid translocation in biogenic (self-synthesizing) membranes such as the endoplasmic reticulum is facilitated by specific membrane proteins (flippases). To extend these studies to natural phospholipids while providing a framework to guide the purification of a flippase, we now describe an assay to measure the transbilayer translocation of dipalmitoylphosphatidylcholine, a membrane-embedded phospholipid, in proteoliposomes generated from detergent-solubilized rat liver endoplasmic reticulum. Translocation was assayed using phospholipase A(2) under conditions where the vesicles were determined to be intact. Phospholipase A(2), rapidly hydrolyzed phospholipids in the outer leaflet of liposomes and proteoliposomes with a half-time of similar to0.1 min. However, for flippase-containing proteoliposomes, the initial rapid hydrolysis phase was followed by a slower phase reflecting flippase-mediated translocation of phospholipids from the inner to the outer leaflet. The amplitude of the slow phase was decreased in trypsin-treated proteoliposomes. The kinetic characteristics of the slow phase were used to assess the rate of transbilayer equilibration of phospholipids. For 250-nm diameter vesicles containing a single flippase, the half-time was 3.3 min. Proportionate reductions in equilibration half-time were observed for preparations with a higher average number of flippases/vesicle. Preliminary purification steps indicated that flippase activity could be enriched similar to15-fold by sequential adsorption of the detergent extract onto anion and cation exchange resins.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Menon, AK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	menon@biochem.wisc.edu	Gummadi, Sathyanarayana Naidu/K-2303-2019; Gummadi, Sathyanarayana/W-5354-2019	Gummadi, Sathyanarayana Naidu/0000-0003-0707-5710; Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM063117] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63117] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELL GB, 1964, PHOSPHOLIPIDS CHEM M, P264; BACKER JM, 1987, NATURE, V327, P341, DOI 10.1038/327341a0; BELL RM, 1981, J LIPID RES, V22, P391; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRETSCHER MS, 1973, CELL SURFACE DEV, P17; BURACK WR, 1993, BIOCHEMISTRY-US, V32, P583, DOI 10.1021/bi00053a025; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Devaux P F, 1993, Subcell Biochem, V21, P273; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GOLDSTEIN B, 1981, P NATL ACAD SCI-BIOL, V78, P5695, DOI 10.1073/pnas.78.9.5695; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Hrafnsdottir S, 2000, J BACTERIOL, V182, P4198, DOI 10.1128/JB.182.15.4198-4206.2000; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1998, J BIOL CHEM, V273, P18936, DOI 10.1074/jbc.273.30.18936; JAIN MK, 1980, NATURE, V284, P486, DOI 10.1038/284486a0; Janssen MJFW, 1999, BBA-BIOMEMBRANES, V1421, P64, DOI 10.1016/S0005-2736(99)00113-3; KAWASHIMA Y, 1987, J BIOL CHEM, V262, P16495; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; LENARD J, 1976, P NATL ACAD SCI USA, V73, P391, DOI 10.1073/pnas.73.2.391; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Marx U, 2000, BIOPHYS J, V78, P2628, DOI 10.1016/S0006-3495(00)76807-X; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MENON A, 1995, TRENDS CELL BIOL, V5, P355, DOI 10.1016/S0962-8924(00)89069-8; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROTHMAN JE, 1975, BIOCHEMISTRY-US, V14, P2809, DOI 10.1021/bi00684a004; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; SANO H, 1981, J CHEM PHYS, V75, P2870, DOI 10.1063/1.442360; SUNDLER R, 1978, J BIOL CHEM, V253, P5299; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; Webb W W, 1981, Biochem Soc Symp, P191; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSCHUT JC, 1979, FEBS LETT, V98, P181, DOI 10.1016/0014-5793(79)80179-9	43	44	44	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25337	25343		10.1074/jbc.M203809200	http://dx.doi.org/10.1074/jbc.M203809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000768	hybrid			2022-12-27	WOS:000176747000065
J	Lemmers, C; Medina, E; Delgrossi, MH; Michel, D; Arsanto, JP; Le Bivic, A				Lemmers, C; Medina, E; Delgrossi, MH; Michel, D; Arsanto, JP; Le Bivic, A			hINADI/PATJ, a homolog of discs lost, interacts with crumbs and localizes to tight junctions in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAIN PROTEIN; ZONULA ADHERENS FORMATION; DROSOPHILA STARDUST; KINASE-C; POLARITY; MEMBRANE; COMPLEX; MUPP1; FORM; INAD	dCrumbs is an apical organizer crucial for the maintenance of epithelial polarity in Drosophila (1). It is known that dCrumbs interacts with Discs lost (Dlt), a protein with four PDZ (PSD95/Dises Large/ZO-1) domains (2), and Stardust (Sdt), a protein of the NIAGUK (membrane-associated guanylate kinase) family (3, 4). We have searched for potential homologs of Dlt in human epithelial cells and characterized one of them in intestinal epithelial cells. Human INAD-like (hINADl) contains 8 PDZ domains, is concentrated in tight junctions, and is also found at the apical plasma membrane. Overexpression of hINADl disrupted the tight junctions localization of ZO-1 and 3. We also identified a partial cDNA coding the transmembrane and cytoplasmic domains of a new human crumbs (CRB3) expressed in Caco-2 cells. This CRB3 was able to interact through its C-terminal end with the N-terminal domain of hINADl. Taken together, the data indicate that hINADl is likely to represent a Dlt homolog in mammalian epithelial cells and might be involved in regulating the integrity of tight junctions. We thus propose to rename hINADl ATJ for protein associated to tight junctions.	Univ Mediterranee, Fac Sci Luminy, Inst Biol Dev Marseille, UMR 6165,Lab Neurogenese & Morphogenese Dev Adult, F-13288 Marseille 09, France	UDICE-French Research Universities; Aix-Marseille Universite	Le Bivic, A (corresponding author), Univ Mediterranee, Fac Sci Luminy, Inst Biol Dev Marseille, UMR 6165,Lab Neurogenese & Morphogenese Dev Adult, Case 907, F-13288 Marseille 09, France.	lebivic@ibdm.univ-mrs.fr						Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Balda MS, 1998, J CELL SCI, V111, P541; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; Delgrossi MH, 1997, J CELL SCI, V110, P2207; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GARCIA M, 1993, J CELL SCI, V104, P1281; Grawe F, 1996, DEVELOPMENT, V122, P951; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; Knoblich JA, 2000, CURR BIOL, V10, pR791, DOI 10.1016/S0960-9822(00)00761-2; Knust E, 2000, CURR OPIN GENET DEV, V10, P471, DOI 10.1016/S0959-437X(00)00115-5; Kramer H, 2000, J CELL BIOL, V151, pF15, DOI 10.1083/jcb.151.4.F15; LEBIVIC A, 1988, EUR J CELL BIOL, V46, P113; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; QUARONI A, 1985, DEV BIOL, V111, P267, DOI 10.1016/0012-1606(85)90482-8; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Soejima H, 2001, GENOMICS, V74, P115, DOI 10.1006/geno.2001.6527; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	39	133	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25408	25415		10.1074/jbc.M202196200	http://dx.doi.org/10.1074/jbc.M202196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964389	hybrid			2022-12-27	WOS:000176747000074
J	Spitkovsky, D; Hehner, SP; Hofmann, TG; Moller, A; Schmitz, ML				Spitkovsky, D; Hehner, SP; Hofmann, TG; Moller, A; Schmitz, ML			The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BINDING-PROTEIN; IMMUNE EVASION; TYPE-16; TRANSCRIPTION; E6; CANCER; ALPHA; CELLS; IKK	Infection with high-risk human papillomaviruses (HPV) can lead to the development of cervical carcinomas. This process critically depends on the virus-encoded E6 and E7 oncoproteins, which stimulate proliferation by manipulating the function of a variety of host key regulatory proteins. Here we show that both viral proteins dose-dependently interfere with the transcriptional activity of NF-kappaB. A variety of experimental approaches revealed that a fraction of the E7 proteins is found in association with the IkappaB kinase complex and attenuates induced kinase activity of IkappaB kinase alpha (IKKalpha) and IKKbeta, thus resulting in impaired IkappaBalpha phosphorylation and degradation. Indirect immunofluorescence shows that E7 impairs TNFalpha-induced nuclear translocation of NF-kappaB, thus preventing NF-kappaB from binding to its cognate DNA. While E7 obviates IKK activation in the cytoplasm, the E6 protein reduces NF-kappaB p65-dependent transcriptional activity within the nucleus. We suggest that HPV oncogene-mediated suppression of NF-kappaB activity contributes to HPV escape from the immune system.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany; German Canc Res Ctr, Div Immunochem G0200, D-69120 Heidelberg, Germany; Univ Cologne, Inst Vegetat Physiol, D-50931 Cologne, Germany	University of Bern; Heinrich Pette Institute; Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Schmitz, ML (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	Lienhard.Schmitz@ibc.unibe.ch	Schmitz, M. Lienhard/D-9328-2017; Möller, Andreas/O-1063-2015	Schmitz, M. Lienhard/0000-0002-6984-7192; Möller, Andreas/0000-0002-8618-6998				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Boyer SN, 1996, CANCER RES, V56, P4620; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; CHINAMI M, 1994, J GEN VIROL, V75, P277, DOI 10.1099/0022-1317-75-2-277; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fontaine V, 2000, VIROLOGY, V272, P40, DOI 10.1006/viro.2000.0363; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; GILMORE TD, 1992, CANCER SURV, V15, P69; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KYO S, 1994, VIROLOGY, V200, P130, DOI 10.1006/viro.1994.1171; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; MALEJCZYK J, 1994, INT J CANCER, V56, P593, DOI 10.1002/ijc.2910560421; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spitkovsky D, 1996, ONCOGENE, V13, P1027; Tait SWG, 2000, J BIOL CHEM, V275, P34656, DOI 10.1074/jbc.M000320200; TARTOUR E, 1994, CANCER RES, V54, P6243; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; Vancurova I, 2002, J VIROL, V76, P1533, DOI 10.1128/JVI.76.3.1533-1536.2002; Vikhanskaya F, 2002, INT J CANCER, V97, P732, DOI 10.1002/ijc.10114; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	55	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25576	25582		10.1074/jbc.M201884200	http://dx.doi.org/10.1074/jbc.M201884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986318	hybrid			2022-12-27	WOS:000176747000095
J	Bernett, MJ; Blaber, SI; Scarisbrick, IA; Dhanarajana, P; Thomspon, SM; Blaber, M				Bernett, MJ; Blaber, SI; Scarisbrick, IA; Dhanarajana, P; Thomspon, SM; Blaber, M			Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MOUSE SUBMANDIBULAR-GLAND; RAT SPINAL-CORD; SERINE-PROTEASE; GENE FAMILY; ZYME/PROTEASE M/NEUROSIN; ALZHEIMERS-DISEASE; SEQUENCE; IDENTIFICATION; BIOMARKER	The human kallikreins are a large multigene family of closely related serine-type proteases. In this regard, they are similar to the multigene kallikrein families characterized in mice and rats. There is a much more extensive body of knowledge regarding the function of mouse and rat kallikreins in comparison with the human kallikreins. Human kallikrein 6 has been proposed as the homologue to rat myelencephalon-specific protease, an arginine-specific degradative-type protease abundantly expressed in the central nervous system and implicated in demyelinating disease. We present the x-ray crystal structure of mature, active recombinant human kallikrein 6 at 1.75-Angstrom resolution. This high resolution model provides the first three-dimensional view of one of the human kallikreins and one of only a few structures of serine proteases predominantly expressed in the central nervous system. Enzymatic data are presented that support the identification of human kallikrein 6 as the functional homologue of rat myelencephalon-specific protease and are corroborated by a molecular phylogenetic analysis. Furthermore, the x-ray data provide support for the characterization of human kallikrein 6 as a degradative protease with structural features more similar to trypsin than the regulatory kallikreins.	Florida State Univ, Inst Mol Biophys, Dept Chem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Dept Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Dept Biol Sci, Tallahassee, FL 32306 USA; Florida State Univ, Sch Computat Sci & Informat Technol, Tallahassee, FL 32306 USA; Mayo Clin, Mayo Med & Grad Sch, Dept Neurol, Rochester, MN 55905 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; Mayo Clinic	Blaber, M (corresponding author), Florida State Univ, Inst Mol Biophys, Dept Chem, 307-DRS-4380, Tallahassee, FL 32306 USA.	blaber@sb.fsu.edu	Blaber, Michael/E-7478-2011; Blaber, Michael/ABA-5031-2021; Blaber, Michael/N-1083-2019	Blaber, Michael/0000-0002-6856-1643; 				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; BIRKTOFT JJ, 1976, BIOCHEMISTRY-US, V15, P4481, DOI 10.1021/bi00665a023; BLABER M, 1989, BIOCHEMISTRY-US, V28, P7813, DOI 10.1021/bi00445a043; BLABER M, 1993, PROTEIN SCI, V2, P1210, DOI 10.1002/pro.5560020803; BLABER M, 1987, BIOCHEMISTRY-US, V26, P6742, DOI 10.1021/bi00395a025; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; BOCK CW, 1994, INORG CHEM, V33, P419, DOI 10.1021/ic00081a007; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAYHUFF TJ, 1992, BIOTECHNIQUES, V13, P499; Diamandis EP, 2000, CLIN BIOCHEM, V33, P369, DOI 10.1016/S0009-9120(00)00145-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Diamandis EP, 2002, CANCER RES, V62, P295; Diamandis EP, 2000, CLIN BIOCHEM, V33, P663, DOI 10.1016/S0009-9120(00)00185-5; Diamandis EP, 2000, CLIN BIOCHEM, V33, P579, DOI 10.1016/S0009-9120(00)00182-X; DRINKWATER CC, 1987, BIOCHEMISTRY-US, V26, P6750, DOI 10.1021/bi00395a026; ETZOLD T, 1993, COMPUT APPL BIOSCI, V9, P49; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FELSENSTEIN J, 2001, PHYLIP VERSION 3 5 P; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONGSTRABILEN J, 1989, MOL BRAIN RES, V5, P159, DOI 10.1016/0169-328X(89)90007-7; KIM WS, 1991, J BIOL CHEM, V266, P19283; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Luo LY, 2001, CLIN CHIM ACTA, V306, P111, DOI 10.1016/S0009-8981(01)00401-6; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; Matsui H, 2000, J BIOL CHEM, V275, P11050, DOI 10.1074/jbc.275.15.11050; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meier N, 1999, BIOCHEM BIOPH RES CO, V258, P374, DOI 10.1006/bbrc.1999.0600; Nakajima N, 1999, BIOSCI BIOTECH BIOCH, V63, P2031, DOI 10.1271/bbb.63.2031; Ogawa K, 2000, PSYCHIAT CLIN NEUROS, V54, P419, DOI 10.1046/j.1440-1819.2000.00731.x; Oka T, 2002, J BIOL CHEM, V277, P14724, DOI 10.1074/jbc.M110725200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Scarisbrick IA, 2000, GLIA, V30, P219, DOI 10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 2001, J COMP NEUROL, V431, P347; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 2001, PAUP ASTERISK VERSIO; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; WILSON WH, 1979, J BIOL CHEM, V254, P6002; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; Yamanaka H, 1999, MOL BRAIN RES, V71, P217, DOI 10.1016/S0169-328X(99)00187-4; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yousef GM, 2001, CANCER RES, V61, P7811; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	62	149	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24562	24570		10.1074/jbc.M202392200	http://dx.doi.org/10.1074/jbc.M202392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983703	hybrid			2022-12-27	WOS:000176611800078
J	Chen, ZH; Alcayaga, C; Suarez-Isla, BA; O'Rourke, B; Tomaselli, G; Marban, E				Chen, ZH; Alcayaga, C; Suarez-Isla, BA; O'Rourke, B; Tomaselli, G; Marban, E			A "minimal" sodium channel construct consisting of ligated S5-P-S6 segments forms a toxin-activatable ionophore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; NA+-CHANNEL; EXCITABLE-MEMBRANES; BREVETOXIN RECEPTOR; SAXITOXIN BINDING; STRUCTURAL MODEL; POINT MUTATIONS; CELL-DEATH; SITE; PORE	The large size (six membrane-spanning repeats in each of four domains) and asymmetric architecture of the voltage-dependent Na+ channel has hindered determination of its structure. With the goal of determining the minimum structure of the Na+ channel permeation pathway, we created two stable cell lines expressing the voltage-dependent rat skeletal muscle Na+ channel (mu1) with a polyhistidine tag on the C terminus (muHis) and pore-only mu1 (muPore) channels with S1-S4 in all domains removed. Both constructs were recognized by a Na+ channel-specific antibody on a Western blot. muHis channels exhibited the same functional properties as wildtype mu1. In contrast, muPore channels did not conduct Na+ currents nor did they bind [H-3]saxitoxin. Veratridine caused 40 and 54% cell death in muHis- and muPore-expressing cells, respectively. However, veratridine-induced cell death could only be blocked by tetrodotoxin in cells expressing muHis, but not muPore. Furthermore, using a fluorescent Na+ indicator, we measured changes in intracellular Na+ induced by veratridine and a brevotoxin analogue, pumiliotoxin. When calibrated to the maximum signal after addition of gramicidin, the maximal percent increases in fluorescence (DeltaF) were 35 and 31% in cells expressing muHis and muPore, respectively. Moreover, in the presence of 1 mum tetrodotoxin, DeltaF decreased significantly to 10% in muHis- but not in muPore-expressing cells (43%). In conclusion, S5-P-S6 segments of mu1 channels form a toxin-activable ionophore but do not reconstitute the Na+ channel permeation pathway with full fidelity.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Univ Chile, Fac Med, Inst Biomed Sci, Program Physiol & Biophys, Santiago 6530499, Chile	Johns Hopkins University; Universidad de Chile	Marban, E (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R01 HL52768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; Balser JR, 1996, J PHYSIOL-LONDON, V494, P431, DOI 10.1113/jphysiol.1996.sp021503; BARNES S, 1988, J GEN PHYSIOL, V91, P421, DOI 10.1085/jgp.91.3.421; Benitah JP, 1999, J NEUROSCI, V19, P1577; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen ZH, 2000, J PHYSIOL-LONDON, V524, P37, DOI 10.1111/j.1469-7793.2000.t01-1-00037.x; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DOYLE DD, 1993, J GEN PHYSIOL, V101, P153, DOI 10.1085/jgp.101.2.153; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Hille B., 1992, IONIC CHANNELS EXCIT; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; Jeglitsch G, 1998, J PHARMACOL EXP THER, V284, P516; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUTRO JB, 1986, J GEN PHYSIOL, V87, P1, DOI 10.1085/jgp.87.1.1; Takahashi S, 1999, EUR J PHARMACOL, V372, P297, DOI 10.1016/S0014-2999(99)00208-3; Takahashi S, 2000, EUR J PHARMACOL, V408, P127, DOI 10.1016/S0014-2999(00)00790-1; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TRAINER VL, 1991, MOL PHARMACOL, V40, P988; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; Velez P, 2001, TOXICON, V39, P929, DOI 10.1016/S0041-0101(00)00230-0; WADA A, 1992, J PHARMACOL EXP THER, V263, P1347; Wang SY, 1999, BIOPHYS J, V76, P3141, DOI 10.1016/S0006-3495(99)77465-5; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Yotsu-Yamashita M, 2000, BIOCHEM BIOPH RES CO, V267, P403, DOI 10.1006/bbrc.1999.1974	37	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24653	24658		10.1074/jbc.M111862200	http://dx.doi.org/10.1074/jbc.M111862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11973330	hybrid			2022-12-27	WOS:000176611800090
J	Pietsch, M; Gutschow, M				Pietsch, M; Gutschow, M			Alternate substrate inhibition of cholesterol esterase by Thieno[2,3-d][1,3]oxazin-4-ones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PARA-NITROPHENYL; CATALYZED-HYDROLYSIS; BINDING INHIBITION; SLOW-BINDING; MECHANISM; SITE; LIPASE	In a kinetic study, the interaction of bovine pancreatic cholesterol esterase (CEase) with fused 1,3-oxazin-4-ones and 1,3-thiazin-4-ones was investigated, and the compounds were characterized as alternate substrate inhibitors. Inhibition assays were performed in the presence of sodium taurocholate with p-nitrophenyl butyrate as chromogenic substrate. Strong active site-directed inhibition was detected for 2-diethylaminothieno[2,3-d][1,3]oxazin-4-ones with a cycloaliphatic chain at positions 5,6. The most potent inhibitors, compounds 3 and 4, exhibited K-i values of 0.58 and 1.86 muM, respectively. An exchange of the ring oxygen by sulfur and the removal of the cycloaliphatic moiety as well as the replacement of the thiophene ring by benzene led to a loss of inhibitory potency. CEase has the capability to catalyze the hydrolysis of representatives of fused 1,3-oxazin-4-ones as well as the highly stable 1,3-thiazin-4-ones by using an acylation-deacylation mechanism. Hydrolyses were performed in the presence of a high enzyme concentration, and products were identified spectrophotometrically and by means of high performance liquid chromatography. The kinetic parameters V-max(I) and V-max(I)/K-m(I) for the CEase-catalyzed turnover were determined. The compounds whose enzyme-catalyzed hydrolysis followed first-order kinetics (K-m(I) > 25 muM) failed to inhibit CEase. On the other hand, inhibitors 3 (initial concentration of 25 muM) and 4 (20 muM) were hydrolyzed by CEase under steady-state conditions in the first phase of the reaction. Rate-limiting deacylation was demonstrated in nucleophilic competition experiments with ethanol as acyl acceptor wherein the conversion of compound 3 was accelerated up to an ethanol concentration of 1.5 m. The characterization of these compounds (i.e. 3 and 4) as alternate substrate inhibitors is not only based on the verification of the CEase-catalyzed hydrolysis. It also rests upon the concurrence of corresponding K-i values obtained in the inhibition assay compared with separately determined K-m(I) values of their enzyme-catalyzed consumption, as could be predicted from the kinetic model used in this study.	Univ Bonn, Inst Pharmaceut, D-53115 Bonn, Germany	University of Bonn	Gutschow, M (corresponding author), Univ Bonn, Inst Pharmaceut, Kreuzbergweg 26, D-53115 Bonn, Germany.	guetschow@uni-bonn.de						BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; CYGLER M, 1993, PROTEIN SCI, V2, P366; Deck LM, 1999, J MED CHEM, V42, P4250, DOI 10.1021/jm990309x; Feaster SR, 1996, BIOCHEMISTRY-US, V35, P16723, DOI 10.1021/bi961677v; Feaster SR, 1997, METHOD ENZYMOL, V286, P231; Gutschow M, 1999, J MED CHEM, V42, P5437, DOI 10.1021/jm991108w; Gutschow M, 1998, J MED CHEM, V41, P1729, DOI 10.1021/jm9708341; Gutschow M, 1999, J ORG CHEM, V64, P5109, DOI 10.1021/jo9900634; HLASTA DJ, 1994, ANNU REP MED CHEM, V29, P195; HOSIE L, 1987, J BIOL CHEM, V262, P260; KRANTZ A, 1992, BIOORG MED CHEM LETT, V2, P1327, DOI 10.1016/S0960-894X(00)80507-7; KRANTZ A, 1990, J MED CHEM, V33, P464, DOI 10.1021/jm00164a002; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; Lin GL, 1999, BIOCHEMISTRY-US, V38, P9971, DOI 10.1021/bi982775e; Lin GL, 1999, BBA-PROTEIN STRUCT M, V1431, P500, DOI 10.1016/S0167-4838(99)00073-4; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; LOMBARDO D, 1981, BIOCHIM BIOPHYS ACTA, V657, P425, DOI 10.1016/0005-2744(81)90328-4; Martyn DC, 1999, CURR PHARM DESIGN, V5, P405; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MYERSPAYNE SC, 1995, BIOCHEMISTRY-US, V34, P3942, DOI 10.1021/bi00012a011; NEUMANN U, 1995, BIOORG CHEM, V23, P72, DOI 10.1006/bioo.1995.1006; NEUMANN U, 1994, J BIOL CHEM, V269, P21561; Neumann U, 2001, BIOORGAN MED CHEM, V9, P947, DOI 10.1016/S0968-0896(00)00310-2; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Powers J C, 1993, Agents Actions Suppl, V42, P3; Quinn D. M., 1998, COMPREHENSIVE BIOL C, P455; SINNOTT M, 1998, COMPREHENSIVE BIOL C, V4, P93; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P4126, DOI 10.1021/bi00387a057; STOUT JS, 1985, BIOCHIM BIOPHYS ACTA, V837, P6, DOI 10.1016/0005-2760(85)90079-7; SUTTON LD, 1990, J AM CHEM SOC, V112, P8398, DOI 10.1021/ja00179a025; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G	31	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24006	24013		10.1074/jbc.M112252200	http://dx.doi.org/10.1074/jbc.M112252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959857	hybrid			2022-12-27	WOS:000176611800007
J	Wang, XT; Grammatikakis, N; Hu, JM				Wang, XT; Grammatikakis, N; Hu, JM			Role of p50/CDC37 in hepadnavirus assembly and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; HEPATITIS-B VIRUSES; HEAT-SHOCK-PROTEIN; KINASE-TARGETING SUBUNIT; DNA-SYNTHESIS; ENCAPSIDATION SIGNAL; RECEPTOR COMPLEXES; CHAPERONE COMPLEX; TYROSINE RESIDUE; HSP90	The cellular chaperone Hsp90 has been shown to associate with the reverse transcriptase (RT) of the duck hepatitis B virus and is required for RT functions. However, the molecular basis for the specific interaction between the RT and Hsp90 remains unknown. Comparison of protein compositional properties suggests that the RT is highly related to the protein kinase c-Raf, which interacts with Hsp90 via the cochaperone p50 (CDC37). We tested whether the RT, like c-Raf, is specifically recognized by p50. Immunoprecipitation and pull-down assays showed that p50 or p50deltaC, a p50 mutant defective in Hsp90 binding, could interact specifically with the RT both in vitro and in vivo, indicating that p50 can bind the RT independently of Hsp90. Furthermore, purified p50 and p50deltaC interacted directly with purified RT. The importance of p50-RT interaction for RT functions was underscored by 1) inhibition of protein-primed initiation of reverse transcription by p50deltaC in vitro and 2) stimulation of viral DNA replication and RNA packaging by p50 and their inhibition by p50deltaC in transfected cells. These results suggest that p50 can function as a cellular cofactor for the hepadnavirus RT by mediating the interaction between the RT and Hsp90.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	Boston University; Queens University - Canada	Hu, JM (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Rm R516,80 E Concord St, Boston, MA 02118 USA.		Hu, Jianming/A-6928-2009		NIAID NIH HHS [R01 AI43453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043453, R37AI043453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Fliss AE, 1997, MOL BIOL CELL, V8, P2501, DOI 10.1091/mbc.8.12.2501; Goes FS, 2001, EUR J BIOCHEM, V268, P2281, DOI 10.1046/j.1432-1327.2001.02105.x; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; HIRSCH RC, 1991, J VIROL, V65, P3309, DOI 10.1128/JVI.65.6.3309-3316.1991; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; Hu JM, 1997, SEMIN VIROL, V8, P205, DOI 10.1006/smvy.1997.0123; Hu JM, 1996, METHOD ENZYMOL, V275, P195; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hu JM, 2000, J VIROL, V74, P11447, DOI 10.1128/JVI.74.24.11447-11455.2000; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; JILBERT AR, 1992, J VIROL, V66, P1377, DOI 10.1128/JVI.66.3.1377-1388.1992; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; Kumar R, 2001, J BIOL CHEM, V276, P11371, DOI 10.1074/jbc.M010480200; LANFORD RE, 1995, J VIROL, V69, P4431, DOI 10.1128/JVI.69.7.4431-4439.1995; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Nassal M, 1996, J VIROL, V70, P2764, DOI 10.1128/JVI.70.5.2764-2773.1996; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PUGH JC, 1988, J VIROL, V62, P3513, DOI 10.1128/JVI.62.9.3513-3516.1988; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; Scholz GM, 2001, J BIOL CHEM, V276, P30971, DOI 10.1074/jbc.M103889200; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; SEEGER C, 1989, J VIROL, V63, P1907, DOI 10.1128/JVI.63.5.1907-1915.1989; SEEGER C, 1990, J VIROL, V64, P16, DOI 10.1128/JVI.64.1.16-23.1990; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 1997, METHOD ENZYMOL, V283, P220; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1994, J VIROL, V68, P8437, DOI 10.1128/JVI.68.12.8437-8442.1994; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; WU TT, 1991, J VIROL, V65, P2155, DOI 10.1128/JVI.65.5.2155-2163.1991; Yao EM, 2000, J VIROL, V74, P8648, DOI 10.1128/JVI.74.18.8648-8657.2000; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; YU MS, 1994, J VIROL, V68, P4341, DOI 10.1128/JVI.68.7.4341-4348.1994; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	54	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24361	24367		10.1074/jbc.M202198200	http://dx.doi.org/10.1074/jbc.M202198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986322	hybrid			2022-12-27	WOS:000176611800052
J	Hieta, R; Myllyharju, J				Hieta, R; Myllyharju, J			Cloning and characterization of a low molecular weight prolyl 4-hydroxylase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DISULFIDE-ISOMERASE SUBUNIT; SITE-DIRECTED MUTAGENESIS; CELL WALL PROTEINS; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; PROLINE HYDROXYLATION; BETA-SUBUNIT; PHASEOLUS-VULGARIS; HISTIDINE-RESIDUES	4-Hydroxyproline is found in collagens and collagen-like proteins in animals and in many glycoproteins in plants. Animal prolyl 4-hydroxylases (P4Hs) have been cloned and characterized from many sources, but no plant P4H has been cloned so far. We report here that the genome of Arabidopsis thaliana encodes six P4H-like polypeptides, one of which, a 283-residue soluble monomer, was cloned and characterized here as a recombinant protein. Catalytically critical residues identified in animal P4Hs are conserved in this P4H, and their mutagenesis led to complete or almost complete inactivation. The recombinant P4H effectively hydroxylated poly(L-proline) and many synthetic peptides corresponding to proline-rich repeats present in plant glycoproteins and other proteins. Surprisingly, collagen-like peptides were also good substrates, the V-max with (Pro-Pro-Gly)(10) being similar to that with poly(L-proline). The enzyme acted in this peptide preferentially on prolines in Y positions in the X-Y-Gly triplets. Correspondingly, (Gly-Pro-4Hyp)(5) and (ProAla-Gly)(5) were poor substrates, with V-max values less than 5 and 20% of that obtained with (Pro-Pro-Gly)(10), respectively, the K-m for the latter also being high. Peptides representing the N- and C-terminal hydroxylation sites present in hypoxia-inducible transcription factor a also served as substrates. As these peptides contain only one proline residue, a poly(L-proline) type II conformation was clearly not required for hydroxylation.	Univ Oulu, Dept Biochem & Mol Biol, FIN-90014 Oulu, Finland; Bioctr Oulu, Collagen Res Unit, Oulu, Finland	University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Dept Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.			Hieta, Reija/0000-0001-5724-6253				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; BERG RA, 1977, BIOCHEMISTRY-US, V16, P1615, DOI 10.1021/bi00627a014; BOLWELL GP, 1985, BIOCHEM J, V229, P693, DOI 10.1042/bj2290693; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; COHEN PB, 1983, PLANT PHYSIOL, V72, P754, DOI 10.1104/pp.72.3.754; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HPAK E, 2001, J BIOL CHEM, V276, P11272; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KASKA DD, 1987, BIOCHEM J, V241, P483, DOI 10.1042/bj2410483; KASKA DD, 1988, BIOCHEM J, V256, P257, DOI 10.1042/bj2560257; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1969, J BIOL CHEM, V244, P2755; KIVIRIKKO KI, 1971, BIOCHEM BIOPH RES CO, V45, P1591, DOI 10.1016/0006-291X(71)90203-8; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; SADAVA D, 1971, BIOCHIM BIOPHYS ACTA, V227, P278, DOI 10.1016/0005-2744(71)90060-X; SAUER A, 1985, PLANTA, V164, P287, DOI 10.1007/BF00396094; Serpe MD, 1999, ADV BOT RES, V30, P207; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Sommer-Knudsen J, 1998, PHYTOCHEMISTRY, V47, P483, DOI 10.1016/S0031-9422(97)00724-3; TANAKA M, 1981, J BIOL CHEM, V256, P1397; TANAKA M, 1980, BIOCHIM BIOPHYS ACTA, V616, P188, DOI 10.1016/0005-2744(80)90137-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Wojtaszek P, 1999, INT J BIOCHEM CELL B, V31, P463, DOI 10.1016/S1357-2725(98)00126-5	51	92	97	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23965	23971		10.1074/jbc.M201865200	http://dx.doi.org/10.1074/jbc.M201865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976332	hybrid			2022-12-27	WOS:000176475700112
J	Lellek, H; Welker, S; Diehl, I; Kirsten, R; Greeve, J				Lellek, H; Welker, S; Diehl, I; Kirsten, R; Greeve, J			Reconstitution of mRNA editing in yeast using a Gal4-ApoB-Gal80 fusion transcript as the selectable marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE DEAMINASE AID; APOBEC-1 COMPLEMENTATION FACTOR; MOLECULAR-CLONING; CATALYTIC SUBUNIT; PROTEIN; ENZYME; HYPERMUTATION; GENE; IDENTIFICATION; EXPRESSION	We describe a fusion transcript of Gal4 linked to its specific inhibitor protein Gal80 by 276 nucleotides of apolipoprotein (apo) B sequence as a selectable marker for mRNA editing. Editing of apoB mRNA is catalyzed by an editing enzyme complex that introduces a stop codon by deamination of C to U. The catalytic subunit APOBEC-1 is a cytidine deaminase and requires a second essential component recently cloned and termed APOBEC-1 complementing factor (ACF) or APOBEC-1-stimulating protein (ASP). The aim of this study was to demonstrate that APOBEC-1 plus ACF/ASP comprise all that is required for editing of apoB mRNA in vivo. Expression of APOBEC-l and Gal4 fused to its inhibitor Gal80 by an intervening unedited apoB sequence (Gal4-apoB(C)-Gal80) did not result in the Gal4-dependent expression of HIS3 and beta-galactosidase in the yeast strain CG1945. Co-expression of APOBEC-1 and ACF/ASP induced editing of the apoB site in up to 13% of the Gal4-apoB(C)-Gal80 transcripts and enabled selection of yeast cells for robust expression of HIS3 and beta-galactosidase. Additional expression of the alternative splicing regulatory protein KSRP increased the editing of the apoB site by APOBEC-1 and ACF/ASP to 21%. Thus, APOBEC-1 and ACF/ASP represent the core apoB mRNA editing enzyme in vivo. This study demonstrates for the first time the successful use of a selectable marker for mRNA editing. The Ga14-Gal80 system is analogous to the two-hybrid assay and may have broader applications for the study of other mRNA processing reactions.	Univ Klinikum Hamburg Eppendorf, Kernklin & Poliklin, Klin & Poliklin Innere Med, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Greeve, J (corresponding author), Univ Klinikum Hamburg Eppendorf, Kernklin & Poliklin, Klin & Poliklin Innere Med, Martinstr 52, D-20246 Hamburg, Germany.	greeve@uke.uni-hamburg.de						Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Dance GSC, 2002, J BIOL CHEM, V277, P12703, DOI 10.1074/jbc.M111337200; Dance GSC, 2000, NUCLEIC ACIDS RES, V28, P424, DOI 10.1093/nar/28.2.424; Dance GSC, 2001, NUCLEIC ACIDS RES, V29, P1772, DOI 10.1093/nar/29.8.1772; Greeve J, 1996, J LIPID RES, V37, P2001; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GREEVE J, 1993, J LIPID RES, V34, P1367; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Henderson JO, 2001, BBA-GENE STRUCT EXPR, V1522, P22, DOI 10.1016/S0167-4781(01)00295-0; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Tian M, 2000, NATURE, V407, P31, DOI 10.1038/35024189; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	37	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23638	23644		10.1074/jbc.M203517200	http://dx.doi.org/10.1074/jbc.M203517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976346	hybrid			2022-12-27	WOS:000176475700070
J	Liu, Y; Li, JL; Kim, BO; Pace, BS; He, JJ				Liu, Y; Li, JL; Kim, BO; Pace, BS; He, JJ			HIV-1 tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear tat-interacting protein of 110 kDa, Tip110	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR TRANSCRIPTION FACTOR; RNA RECOGNITION; HISTONE ACETYLTRANSFERASE; TYPE-1 TAT; IN-VITRO; ELONGATION; BINDING; IDENTIFICATION; ACTIVATION	Human immunodeficiency virus type 1 (HIV-1) gene expression and replication is highly dependent on and modulated by interactions between viral and host cellular factors. Tat protein, encoded by one of the HTV-1 regulatory genes, tat, is essential for HIV-1 gene expression. A number of host cellular factors have been shown to interact with Tat in this process. During our attempts to determine the molecular mechanisms of Tat interaction with brain cells, we isolated a cDNA clone that encodes a novel Tat-interacting protein of 110 kDa or Tip110 from a human fetal brain cDNA library. Gen-Bank(TM) BLAST search revealed that Tip110 was almost identical to a previously cloned KIAA0156 gene with unknown functions. In vivo binding of Tip110 with Tat was confirmed by immunoprecipitation and Western blotting, in combination with mutagenesis. The yeast three-hybrid RNA-protein interaction assay indicated no direct interaction of Tip110 with Tat transactivating response element RNA. Nevertheless, Tip110 strongly synergized with Tat on Tat-mediated chloramphenicol acetyltransferase reporter gene expression and HIV-1 virus production, whereas down-modulation of constitutive Tip110 expression inhibited HIV-1 virus production. Northern blot analysis showed that Tip110 mRNA was expressed in a variety of human tissues and cells. Moreover, digital fluorescence microscopic imaging revealed that Tip110 was expressed exclusively in the nucleus, and within a nuclear speckle structure that has recently been described for human cyclin T and CDK9, two critical components for Tat transactivation function on HIV-1 long terminal repeat promoter. Taken together, these data demonstrate that Tip110 regulates Tat transactivation activity through direct interaction, and suggest that Tip110 is an important cellular factor for HIV-1 gene expression and viral replication.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of South Alabama	He, JJ (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, R4 302,1044 W Walnut St, Indianapolis, IN 46202 USA.	jjhe@iupui.edu		Pace, Betty/0000-0002-1275-4112	NINDS NIH HHS [R01NS39804] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039804] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gu JA, 1998, BBA-GENE STRUCT EXPR, V1399, P1, DOI 10.1016/S0167-4781(98)00082-7; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Herrmann CH, 2001, J CELL SCI, V114, P1491; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MILLER JG, 1972, SHORT COURSE BACTERI; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Whitesell L, 1999, METHODS, V18, P296, DOI 10.1006/meth.1999.0787; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu L, 2000, GENE THER, V7, P438, DOI 10.1038/sj.gt.3301106; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang D, 1999, CANCER RES, V59, P4056; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605	57	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23854	23863		10.1074/jbc.M200773200	http://dx.doi.org/10.1074/jbc.M200773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959860	hybrid			2022-12-27	WOS:000176475700099
J	Muller, M; Panke, O; Junge, W; Engelbrecht, S				Muller, M; Panke, O; Junge, W; Engelbrecht, S			F-1-ATPase, the C-terminal end of subunit gamma is not required for ATP hydrolysis-driven rotation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; SITE-DIRECTED MUTAGENESIS; ROTARY F-ATPASE; BETA-SUBUNIT; VISCOELASTIC DYNAMICS; NONCATALYTIC SITES; SYNTHASE; CATALYSIS; TRANSPORT; TORQUE	ATP hydrolysis by the isolated F-1-ATPase drives the rotation of the central shaft, subunit gamma, which is located within a hexagon formed by subunits (alphabeta)(3). The C-terminal end of gamma forms an alpha-helix which properly fits into the "hydrophobic bearing" provided by loops of subunits alpha and beta. This "bearing" is expected to be essential for the rotary function. We checked the importance of this contact region by successive C-terminal deletions of 3, 6, 9, 12, 15, and 18 amino acid residues (Escherichia coli F-1-ATPase). The ATP hydrolysis activity of a load-free ensemble of F-1 with 12 residues deleted decreased to 24%, of the control. EF1 with deletions of 15 or 18 residues was inactive, probably because it failed to assemble. The average torque generated by a single molecule of EF1 when loaded by a fluorescent actin filament was, however, unaffected by deletions of up to 12 residues, as was their rotational behavior (all samples rotated during 60 +/- 19% of the observation time). Activation energy analysis with the ensemble revealed a moderate decrease from 54 kJ/mol for EF1 (full-length gamma) to 34 kJ/mol for EF1(gamma-12). These observations imply that the intactness of the C terminus of subunit gamma provides structural stability and/or routing during assembly of the enzyme, but that it is not required for the rotary action under load, proper.	Univ Osnabruck, Fachbereich Biol, Biophys Abt, D-49076 Osnabruck, Germany	University Osnabruck	Engelbrecht, S (corresponding author), Univ Osnabruck, Fachbereich Biol, Biophys Abt, Barbarastr 11, D-49076 Osnabruck, Germany.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; *APPL BIOS, 2000, ABI PRISM BIGD TERM; Boyer PD, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1058, DOI 10.1023/A:1012420610963; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cherepanov DA, 2001, BIOPHYS J, V81, P1234, DOI 10.1016/S0006-3495(01)75781-5; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 2000, J EXP BIOL, V203, P9; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; Gumbiowski K, 2001, J BIOL CHEM, V276, P42287, DOI 10.1074/jbc.M106884200; Happel, 2012, LOW REYNOLDS NUMBER; Hara KY, 2000, J BIOL CHEM, V275, P14260, DOI 10.1074/jbc.275.19.14260; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JEANTEURDEBEUKELAER C, 1995, J BIOL CHEM, V270, P22850; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Ketchum CJ, 1998, J BIOL CHEM, V273, P22292, DOI 10.1074/jbc.273.35.22292; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 1996, FEBS LETT, V383, P196, DOI 10.1016/0014-5793(96)00246-3; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHIN K, 1992, J BIOL CHEM, V267, P20835; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1995, J BIOL CHEM, V270, P21045, DOI 10.1074/jbc.270.36.21045; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WISE JG, 1990, J BIOL CHEM, V265, P10403; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	45	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23308	23313		10.1074/jbc.M201998200	http://dx.doi.org/10.1074/jbc.M201998200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964400	hybrid			2022-12-27	WOS:000176475700029
J	Ziros, PG; Gil, APR; Georgakopoulos, T; Habeos, I; Kletsas, D; Basdra, EK; Papavassiliou, AG				Ziros, PG; Gil, APR; Georgakopoulos, T; Habeos, I; Kletsas, D; Basdra, EK; Papavassiliou, AG			The bone-specific transcriptional regulator Cbfa1 is a target of mechanical signals in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; PERIODONTAL-LIGAMENT; I COLLAGEN; MORPHOGENETIC PROTEIN-2; CLEIDOCRANIAL DYSPLASIA; MESSENGER-RNA; C-JUN; DIFFERENTIATION; KINASE	A primary goal of bone research is to understand the mechanism(s) by which mechanical forces dictate the cellular and metabolic activities of osteoblasts, the bone-forming cells. Several studies indicate that osteblastic cells respond to physical loading by transducing signals that alter gene expression patterns. Accumulated data have documented the fundamental role of the osteoblast-specific transcription factor Cbfa1 (core-binding factor) in osteoblast differentiation and function. Here, we demonstrate that low level mechanical deformation (stretching) of human osteoblastic cells directly up-regulates the expression and DNA binding activity of Cbfa1. This effect seems to be fine tuned by stretch-triggered induction of distinct mitogen-activated protein kinase cascades. Our novel finding that activated extracellular signal-regulated kinase mitogen-activated protein kinase physically interacts and phosphorylates endogenous Cbfa1 in vivo (ultimately potentiating this transcription factor) provides a molecular link between mechanostressing and stimulation of osteoblast differentiation. Elucidation of the specific modifiers and cofactors that operate in this mechanotranscription circuitry will contribute to a better understanding of mechanical load-induced bone formation which may set the basis for nonpharmacological intervention in bone loss pathologies.	Univ Patras, Sch Med, Dept Biochem, GR-26110 Patras, Greece; Heidelberg Univ, Dept Orthodont, D-69120 Heidelberg, Germany; Natl Ctr Sci Res Demokritos, Inst Biol, GR-15310 Athens, Greece	University of Patras; Ruprecht Karls University Heidelberg; National Centre of Scientific Research "Demokritos"	Papavassiliou, AG (corresponding author), Univ Patras, Sch Med, Dept Biochem, GR-26110 Patras, Greece.	papavas@med.upatras.gr	Karamouzis, Michalis/AAD-2860-2020; Kletsas, Dimitris/F-6953-2010; ziros, panos/C-7289-2009; Gil, Andrea Paola Rojas/AAS-8328-2021	Rojas Gil, Andrea Paola/0000-0002-9812-2131; Kletsas, Dimitris/0000-0002-9828-3963				ARCEO N, 1991, J PERIODONTOL, V62, P499, DOI 10.1902/jop.1991.62.8.499; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASDRA EK, 1995, BBA-MOL CELL RES, V1268, P209, DOI 10.1016/0167-4889(95)00090-F; Basdra EK, 1997, EUR J ORTHODONT, V19, P615, DOI 10.1093/ejo/19.6.615; Bronckers ALJJ, 2001, MECH DEVELOP, V101, P255, DOI 10.1016/S0925-4773(00)00562-1; Carnes DL, 1997, J PERIODONTOL, V68, P701, DOI 10.1902/jop.1997.68.7.701; CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052; Kletsas D, 1998, FEBS LETT, V430, P358, DOI 10.1016/S0014-5793(98)00695-4; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; LANYON LE, 1987, J BIOMECH, V20, P1083, DOI 10.1016/0021-9290(87)90026-1; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lekic P, 1996, ANAT REC, V245, P327; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Massague J, 2000, GENE DEV, V14, P627; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Pavlin D, 2000, CALCIFIED TISSUE INT, V67, P163, DOI 10.1007/s00223001105; Peverali FA, 2001, MOL MED, V7, P68, DOI 10.1007/BF03401840; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; ZAMAN G, 1992, CALCIFIED TISSUE INT, V51, P132, DOI 10.1007/BF00298501	59	190	236	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23934	23941		10.1074/jbc.M109881200	http://dx.doi.org/10.1074/jbc.M109881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960980	hybrid			2022-12-27	WOS:000176475700108
J	Bouyain, S; Silk, NJ; Fabini, G; Drickamer, K				Bouyain, S; Silk, NJ; Fabini, G; Drickamer, K			An endogenous Drosophila receptor for glycans bearing alpha 1,3-linked core fucose residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LECTIN-LIKE DOMAINS; CARBOHYDRATE-RECOGNITION; HORSERADISH-PEROXIDASE; GRASSHOPPER EMBRYOS; EPITOPE; SEQUENCE; SELECTIN; OLIGOSACCHARIDES; GLYCOPROTEINS	The genome of Drosophila melanogaster encodes several proteins that are predicted to contain Ca2+-dependent, C-type carbohydrate-recognition domains. The CG2958 gene encodes a protein containing 359 amino acid residues. Analysis of the CG2958 sequence suggests that it consists of an N-terminal domain found in other Drosophila proteins, a middle segment that is unique, and a C-terminal C-type carbohydrate-recognition domain. Expression studies show that the full-length protein is a tetramer formed by noncovalent association of disulfide-linked dimers that are linked through cysteine residues in the N-terminal domain. The expressed protein binds to immobilized yeast invertase through the C-terminal carbohydrate-recognition domain. Competition binding studies using monosaccharides demonstrate that CG2958 interacts specifically with fucose and mannose. Fucose binds similar to5-fold better than mannose. Blotting studies reveal that the best glycoprotein ligands are those that contain N-linked glycans bearing alpha1,3-linked fucose residues. Binding is enhanced by the additional presence of alpha1,6-linked fucose. It has previously been proposed that labeling of the Drosophila neural system by anti-horseradish peroxidase antibodies is a result of the presence of difucosylated N-linked glycans. CG2958 is a potential endogenous receptor for such neural-specific carbohydrate epitopes.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Agr Univ Vienna, Inst Chem, Glycobiol Div, A-1190 Vienna, Austria	University of Oxford; University of Natural Resources & Life Sciences, Vienna	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.							Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Blanck O, 1996, J BIOL CHEM, V271, P7289, DOI 10.1074/jbc.271.13.7289; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Bouyain S, 2001, GLYCOBIOLOGY, V11, P989, DOI 10.1093/glycob/11.11.989; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARR SA, 1986, ANAL BIOCHEM, V157, P396, DOI 10.1016/0003-2697(86)90643-3; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GRAYEB J, 1984, EMBO J, V3, P2437; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SNOW PM, 1987, J NEUROSCI, V7, P4137; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651	36	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22566	22572		10.1074/jbc.M202825200	http://dx.doi.org/10.1074/jbc.M202825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960993	hybrid			2022-12-27	WOS:000176313600062
J	Donaldson, JC; Dise, RS; Ritchie, MD; Hanks, SK				Donaldson, JC; Dise, RS; Ritchie, MD; Hanks, SK			Nephrocystin-conserved domains involved in targeting to epithelial cell-cell junctions, interaction with filamins, and establishing cell polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; FAMILIAL JUVENILE NEPHRONOPHTHISIS; TYROSINE PHOSPHORYLATION; GENE; DIFFERENTIATION; IDENTIFICATION; TRANSLOCATION; EXPRESSION; P130(CAS); CLEAVAGE	Nephrocystin is the protein product of the gene mutated in juvenile nephronophthisis, an autosomal recessive cystic kidney disease afflicting children and young adults. Because the normal cellular function of nephrocystin is largely unknown, the molecular defects underlying disease pathogenesis remain obscure. Analysis of nephrocystin amino acid sequences from human and other species revealed three distinct conserved domains including Src homology 3 and coil-coil domains in the N-terminal region, as well as a large highly conserved C-terminal region bearing no obvious homology to other proteins and hence referred to as the "nephrocystin homology domain" (NHD). The objective of this study was to gain insight into nephrocystin function by defining functional properties of the conserved domains. We analyzed a series of nephrocystin deletion mutants expressed in Madin-Darby canine kidney and COS-7 cells. This analysis revealed previously unrecognized functional attributes of the NHD, including abilities to promote both self-association and epithelial cell-cell junctional targeting. We further observed that Madin-Darby canine kidney cell lines stably expressing a nephrocystin mutant with a deletion of the Src homology 3 domain have reduced ability to establish tight junctions as measured by transepithelial electrical resistance. Finally, from a two-hybrid screen and coimmunoprecipitation studies we identified members of the filamin family of actin-binding proteins as having the capacity to interact with the (NHD). These findings support a functional role for nephrocystin as a docking protein involved in organizing a protein complex to regulate the actin cytoskeleton at sites of epithelial cell-cell adhesion and further suggest that these properties are important for establishing epithelial cell polarity.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hanks, SK (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, B-2211 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	steve.hanks@vanderbilt.edu	Ritchie, Marylyn/C-1114-2012		NIDDK NIH HHS [DK56018] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Caridi G, 2000, AM J KIDNEY DIS, V35, P44, DOI 10.1016/S0272-6386(00)70300-3; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hildebrandt F, 2000, J AM SOC NEPHROL, V11, P1753, DOI 10.1681/ASN.V1191753; HILDEBRANDT F, 1992, CLIN INVESTIGATOR, V70, P802; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Hildebrandt F, 2001, KIDNEY INT, V59, P434, DOI 10.1046/j.1523-1755.2001.059002434.x; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Konrad M, 1998, J MOL MED-JMM, V76, P310, DOI 10.1007/s001090050222; KWAK KB, 1993, FEBS LETT, V323, P151, DOI 10.1016/0014-5793(93)81468-F; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lo SH, 1997, J CELL BIOL, V136, P1349, DOI 10.1083/jcb.136.6.1349; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Otto E, 2000, J AM SOC NEPHROL, V11, P270, DOI 10.1681/ASN.V112270; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; PATCH LA, 1995, J CELL SCI, V108, P1371; Saunier S, 1997, HUM MOL GENET, V6, P2317, DOI 10.1093/hmg/6.13.2317; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WALDHERR R, 1982, VIRCHOWS ARCH A, V394, P235, DOI 10.1007/BF00430668; Wang Q, 1996, J CELL BIOCHEM, V62, P383, DOI 10.1002/(SICI)1097-4644(199609)62:3<383::AID-JCB8>3.0.CO;2-N; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919	33	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29028	29035		10.1074/jbc.M111697200	http://dx.doi.org/10.1074/jbc.M111697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12006559	hybrid			2022-12-27	WOS:000177342600089
J	Jurado, LA; Song, SL; Roesler, WJ; Park, EA				Jurado, LA; Song, SL; Roesler, WJ; Park, EA			Conserved amino acids within CCAAT enhancer-binding proteins (C/EBP alpha and beta) regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; DEPENDENT ACTIVATION; TRANSCRIPTION; CAMP; GTP; PROMOTER; ELEMENT; INDUCTION; MECHANISM; ISOFORMS	Thyroid hormone and cAMP stimulate transcription of the gene for phosphoenolpyruvate carboxykinase (PEPCK). CCAAT enhancer-binding proteins (C/EBPalpha and beta) are involved in multiple aspects of the nutritional, developmental and hormonal regulation of PEPCK gene expression. Previously, we have identified a thyroid hormone response element in the PEPCK promoter and demonstrated that C/EBP proteins bound to the P3(I) site are participants in the induction of PEPCK gene expression by thyroid hormone and cAMP. Here, we identify several peptide regions within the transactivation domain of C/EBPa that enhance the ability of T-3 to stimulate gene transcription. We also demonstrate that several conserved amino acids in the transactivation domain of C/EBPalpha and C/EBPbeta are required for the stimulation of basal gene expression and identify amino acids within C/EBPbeta that participate in the CAMP induction of the PEPCK gene. Finally, we show that the CREB-binding protein (CBP) enhanced the induction of PEPCK gene transcription by thyroid hormone and that CBP is associated with the PEPCK gene in vivo. Our results indicate that both C/EBP proteins and CBP participate in the regulation of PEPCK gene transcription by thyroid hormone.	Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Tennessee System; University of Tennessee Health Science Center; University of Saskatchewan	Park, EA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu						BOESLER WJ, 2001, ANNU REV NUTR, V21, P141; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chung SS, 1999, ARCH BIOCHEM BIOPHYS, V364, P30, DOI 10.1006/abbi.1998.1089; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lee SJ, 1999, INTERMETALLICS, V7, P11, DOI 10.1016/S0966-9795(98)00004-1; Liu XD, 2001, AM J PHYSIOL-RENAL, V281, pF649, DOI 10.1152/ajprenal.2001.281.4.F649; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Monroy MA, 2001, J BIOL CHEM, V276, P40721, DOI 10.1074/jbc.M103615200; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1993, J BIOL CHEM, V268, P613; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RUNGE D, 1991, EUR J BIOCHEM, V198, P641, DOI 10.1111/j.1432-1033.1991.tb16062.x; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	43	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27606	27612		10.1074/jbc.M201429200	http://dx.doi.org/10.1074/jbc.M201429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11997389	hybrid			2022-12-27	WOS:000177189800006
J	Walther, M; Anton, M; Wiedmann, M; Fletterick, R; Kuhn, H				Walther, M; Anton, M; Wiedmann, M; Fletterick, R; Kuhn, H			The N-terminal domain of the reticulocyte-type 15-lipoxygenase is not essential for enzymatic activity but contains determinants for membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOXYGENASE; 5-LIPOXYGENASE; CALCIUM; OXYGENATION; TRANSLOCATION; LOCALIZATION; PROTEIN	The rabbit reticulocyte-type 15-lipoxygenase is capable of oxygenating biomembranes and lipoproteins without the preceding action of ester lipid cleaving enzymes. This reaction requires an efficient membrane binding, and the N-terminal beta-barrel domain of the enzyme has been implicated in this process. To obtain detailed information on the structural requirements for membrane oxygenation, we expressed the rabbit wildtype 15-lipoxygenase, its beta-barrel deletion mutant (catalytic domain), and several lipoxygenase point mutations as His-tagged fusion proteins in Escherichia coli and tested their membrane binding characteristics. We found that: (i) the beta-barrel deletion mutant was catalytically active and its enzymatic properties (K-m, V-max, pH optimum, substrate specificity) were similar to those of the wild-type enzyme; (ii) when compared with the wildtype lipoxygenase, the membrane binding properties of the N-terminal truncation mutant were impaired but not abolished, suggesting a role of the catalytic domain in membrane binding; and (iii) Phe-70 and Leu-71 (constituents of the beta-barrel domain) but also Trp-181, which is located in the catalytic domain, were identified as sequence determinants for membrane binding. Mutation of these amino acids to more polar residues (F70H, L71K, W181E) impaired the membrane binding capacity of the recombinant enzyme. These data indicate that the C-terminal catalytic domain of the rabbit 15-lipoxygenase is enzymatically active and that the membrane binding properties of the enzyme are determined by a concerted action of the N-terminal beta-barrel and the C-terminal catalytic domain.	Humboldt Univ, Clin Charite, Inst Biochem, D-10117 Berlin, Germany; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Humboldt University of Berlin; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco	Kuhn, H (corresponding author), Humboldt Univ, Clin Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	hartmut.kuehn@charite.de			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060889] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60889] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; BROCK TG, 1994, J BIOL CHEM, V269, P22059; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; CRANE FL, 1956, BIOCHIM BIOPHYS ACTA, V22, P475, DOI 10.1016/0006-3002(56)90058-0; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; KUHN H, 1990, J BIOL CHEM, V265, P18351; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PUERINGER RJ, 1992, AM J PHYSIOL, V262, pL454, DOI 10.1152/ajplung.1992.262.4.L454; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Tatulian SA, 1998, BIOCHEMISTRY-US, V37, P15481, DOI 10.1021/bi981062t; Upston JM, 1997, J BIOL CHEM, V272, P30067, DOI 10.1074/jbc.272.48.30067; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	40	63	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27360	27366		10.1074/jbc.M203234200	http://dx.doi.org/10.1074/jbc.M203234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004065	hybrid			2022-12-27	WOS:000177055900085
J	Mazurkiewicz, P; Konings, WN; Poelarends, GJ				Mazurkiewicz, P; Konings, WN; Poelarends, GJ			Acidic residues in the lactococcal multidrug efflux pump LmrP play critical roles in transport of lipophilic cationic compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; CYSTEINE-SCANNING MUTAGENESIS; CONTROLLED GENE-EXPRESSION; ESCHERICHIA-COLI; RESISTANCE; SYSTEMS; RECOGNITION; MECHANISMS; BACTERIA; TOPOLOGY	The proton motive force-driven efflux pump LmrP confers multidrug resistance on Lactococcus lactis cells by extruding a wide variety of lipophilic cationic compounds from the inner leaflet of the cytoplasmic membrane to the exterior of the cell. LmrP contains one cysteine (Cys(270)), which was replaced by alanine. This cysteine-less variant was used in a cysteine scanning accessibility approach. All 19 acidic residues in LmrP were replaced one by one by cysteine and subsequently challenged with the large thiol reagent fluorescein maleimide. The labeling pattern strongly indicates that only three acidic residues (Asp(142), Glu(327), and Glu(388)) are membrane-embedded. The roles of these residues in drug recognition were evaluated based on transport experiments with two cationic substrates, ethidium and Hoechst 33342, after replacing each of these residues with cysteine, alanine, lysine, glutamate, or aspartate. The obtained results suggest that the negative charges at positions 142 and 327 are not critical for the transport function but are important for drug recognition by LmrP. Surprisingly, the residues Cys(142) and Cys(327) become accessible for fluorescein maleimide upon binding of substrates, indicating a movement of these residues from a nonpolar to a polar environment. Substrate binding apparently results in a conformational change in this region of the protein and a reorientation of a lipid-embedded, hydrophobic substrate-binding site to an,aqueous substrate translocation pathway.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Groningen	Konings, WN (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Konings, Wilhelmus N./C-7063-2013	Poelarends, Gerrit/0000-0002-6917-6368				Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Meuller J, 1999, J BIOL CHEM, V274, P19072, DOI 10.1074/jbc.274.27.19072; NIKKADO H, 1909, CURR OPIN MICROBIOL, V1, P516; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 1999, BIOCHEMISTRY-US, V38, P13900, DOI 10.1021/bi991262k; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Roberts MC, 1996, FEMS MICROBIOL REV, V19, P1, DOI 10.1111/j.1574-6976.1996.tb00251.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; van Veen HW, 1997, SEMIN CANCER BIOL, V8, P183, DOI 10.1006/scbi.1997.0064; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	26	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26081	26088		10.1074/jbc.M203141200	http://dx.doi.org/10.1074/jbc.M203141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994308	hybrid, Green Published			2022-12-27	WOS:000176908700034
J	Stubbs, VEL; Schratl, P; Hartnell, A; Williams, TJ; Peskar, BA; Heinemann, A; Sabroe, I				Stubbs, VEL; Schratl, P; Hartnell, A; Williams, TJ; Peskar, BA; Heinemann, A; Sabroe, I			Indomethacin causes prostaglandin D-2-like and eotaxin-like selective responses in eosinophils and basophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CCR3; PLATELET-ACTIVATING-FACTOR; OXYGEN RADICAL PRODUCTION; CD11B UP-REGULATION; MAST-CELLS; IN-VITRO; ACTIN REORGANIZATION; HUMAN NEUTROPHILS; CUTTING EDGE; G-PROTEIN	We investigated the actions of a panel of nonsteroidal anti-inflammatory drugs on eosinophils, basophils, neutrophils, and monocytes. Indomethacin alone was a potent and selective inducer of eosinophil and basophil shape change. In eosinophils, indomethacin induced chemotaxis, CD11b up-regulation, respiratory burst, and L-selectin shedding but did not cause up-regulation of CD63 expression. Pretreatment of eosinophils with indomethacin also enhanced subsequent eosinophil shape change induced by eotaxin, although treatment with higher concentrations of indomethacin resulted in a decrease in the expression of the major eosinophil chemokine receptor, CCR3. Indomethacin activities and cell selectivity closely resembled those of prostaglandin D-2 (PGD(2)). Eosinophil shape change in response to eotaxin was inhibited by pertussis toxin, but indomethacin- and PGD(2)-induced shape change responses were not. Treatment of eosinophils with specific inhibitors of phospholipase C (U-73122), phosphatidylinositol 3-kinase (LY-294002), and p38 mitogen-activated protein kinase (SB-202190) revealed roles for these pathways in indomethacin signaling. Indomethacin and its analogues may therefore provide a structural basis from which selective PGD(2) receptor small molecule antagonists may be designed and which may have utility in the treatment of allergic inflammatory disease.	Dept Expt & Clin Pharmacol, A-8010 Graz, Austria; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Heinemann, A (corresponding author), Dept Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@kfunigraz.ac.at	Sabroe, Ian/I-5981-2013; Sabroe, Ian/AAE-5858-2019	Sabroe, Ian/0000-0001-9750-8975; Heinemann, Akos/0000-0002-8554-2372				Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; ANTHONY A, 1993, ALIMENT PHARM THER, V7, P29; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Boehme SA, 1999, J IMMUNOL, V163, P1611; BRYAN SA, 2002, IN PRESS AM J RESP C; Culley FJ, 2000, J IMMUNOL, V165, P6447, DOI 10.4049/jimmunol.165.11.6447; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DEMERSON CA, 1976, J MED CHEM, V19, P391, DOI 10.1021/jm00225a010; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; EMMENDORFFER A, 1990, J IMMUNOL METHODS, V131, P269, DOI 10.1016/0022-1759(90)90198-5; Fiorucci S, 1997, ALIMENT PHARM THERAP, V11, P619, DOI 10.1046/j.1365-2036.1997.00190.x; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; FUREDER W, 1995, ANN HEMATOL, V70, P251; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; Gomez-Gaviro MV, 2000, BLOOD, V96, P3592, DOI 10.1182/blood.V96.10.3592.h8003592_3592_3600; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirai H, 2002, J IMMUNOL, V168, P981, DOI 10.4049/jimmunol.168.3.981; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Laufer S, 1999, INFLAMM RES, V48, P133, DOI 10.1007/s000110050436; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Liu LX, 1998, J IMMUNOL, V161, P3064; Monneret G, 1999, CLIN EXP IMMUNOL, V115, P393; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; NOWAK D, 1993, EUR RESPIR J, V6, P405; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; Okada S, 1997, AM J RESP CELL MOL, V16, P455, DOI 10.1165/ajrcmb.16.4.9115757; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Prasit P, 1999, BIOORG MED CHEM LETT, V9, P1773, DOI 10.1016/S0960-894X(99)00288-7; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sabroe I, 1999, J IMMUNOL, V162, P2946; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stellato C, 2001, J IMMUNOL, V166, P1457, DOI 10.4049/jimmunol.166.3.1457; Struyf S, 2001, EUR J IMMUNOL, V31, P2170, DOI 10.1002/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D; Tanaka Y, 1999, J IMMUNOL, V163, P6209; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tenscher K, 1997, BIOCHEM BIOPH RES CO, V240, P32, DOI 10.1006/bbrc.1997.7601; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Wu DQ, 2000, J CELL SCI, V113, P2935; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Ying S, 1999, J IMMUNOL, V163, P3976; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	59	71	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26012	26020		10.1074/jbc.M201803200	http://dx.doi.org/10.1074/jbc.M201803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11980903	hybrid			2022-12-27	WOS:000176908700026
J	Yamazaki, K; Guo, LM; Sugahara, K; Zhang, C; Enzan, H; Nakabeppu, Y; Kitajima, S; Aso, T				Yamazaki, K; Guo, LM; Sugahara, K; Zhang, C; Enzan, H; Nakabeppu, Y; Kitajima, S; Aso, T			Identification and biochemical characterization of a novel transcription elongation factor, Elongin A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; FACTOR-SIII; BC COMPLEX; GENE; PURIFICATION; SUBUNIT; DISEASE; DOMAINS; BINDING	The Elongin complex stimulates the rate of transcription elongation by RNA polymerase 11 by suppressing the transient pausing of the polymerase at many sites along the DNA template. Elongin is composed of a transcriptionally active A subunit and two small regulatory B and C subunits, the latter binding stably to each other to form a binary complex that interacts with Elongin A and strongly induces its transcriptional activity. To further understand the role of Elongin A in transcriptional regulation by RNA polymerase 11, we are attempting to identify Elongin A-related proteins. Here, we report on the molecular cloning, expression, and biochemical characterization of human Elongin A3, a novel transcription elongation factor that exhibits 49 and 81% identity to Elongin A and the recently identified Elongin A2, respectively. The mRNA of Elongin A3 is ubiquitously expressed, and the protein is localized to the nucleus of cells. Mechanistic studies have demonstrated that Elongin A3 possesses similar biochemical features to Elongin A2. Both stimulate the rate of transcription elongation by RNA polymerase II and are capable of forming a stable complex with Elongin BC. In contrast to Elongin A, however, their transcriptional activities are not activated by Elongin BC. Structure-function analyses using fusion proteins composed of Elongin A3 and Elongin A revealed that the COOH-terminal region of Elongin A is important for the activation by Elongin BC.	Kochi Med Sch, Fac Med, Dept Chem, Nankoku, Kochi 7838505, Japan; Kochi Med Sch, Fac Med, Dept Pathol, Nankoku, Kochi 7838505, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan	Kochi University; Kochi University; Tokyo Medical & Dental University (TMDU); Kyushu University; Japan Science & Technology Agency (JST)	Aso, T (corresponding author), Kochi Med Sch, Fac Med, Dept Chem, Oko Cho, Nankoku, Kochi 7838505, Japan.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Aso T, 1996, GENE, V168, P277, DOI 10.1016/0378-1119(95)00750-4; Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; Aso T, 1999, CYTOGENET CELL GENET, V86, P259, DOI 10.1159/000015355; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Koth CM, 2000, J BIOL CHEM, V275, P11174, DOI 10.1074/jbc.275.15.11174; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Stuhlmuller B, 2000, ARTHRITIS RHEUM, V43, P775, DOI 10.1002/1529-0131(200004)43:4<775::AID-ANR8>3.0.CO;2-7; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956	33	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26444	26451		10.1074/jbc.M202859200	http://dx.doi.org/10.1074/jbc.M202859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994304	hybrid			2022-12-27	WOS:000176908700082
J	Kelm, O; Wind, M; Lehmann, WD; Nigg, EA				Kelm, O; Wind, M; Lehmann, WD; Nigg, EA			Cell cycle-regulated phosphorylation of the Xenopus polo-like kinase Plx1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; PROGNOSTIC-SIGNIFICANCE; MPF AMPLIFICATION; FAMILY MEMBERS; PLK EXPRESSION; EGG EXTRACTS; MITOSIS	Polo-like kinases (Plks) control multiple important events during M phase progression, but little is known about their activation during the cell cycle. The activities of both mammalian Plk1 and Xenopus Plx1 peak during M phase, and this activation has been attributed to phosphorylation. However, no phosphorylation sites have previously been identified in any member of the Plk family. Here we have combined tryptic phosphopeptide mapping with mass spectrometry to identify four major phosphorylation sites in Xenopus Plx1. All four sites appear to be phosphorylated in a cell cycle-dependent manner. Phosphorylations at two sites (Ser-260 and Ser-326) most likely represent autophosphorylation events, whereas two other sites (Thr-201 and Ser-340) are targeted by upstream kinases. Several recombinant kinases were tested for their ability to phosphorylate Plx1 in vitro. Whereas xPlkk1 phosphorylated primarily Thr-10, Thr-201 was readily phosphorylated by protein kinase A, and Cdk1/cyclin B was identified as a likely kinase acting on Ser-340. Phosphorylation of Ser-340 was shown to be responsible for the retarded electrophoretic mobility of Plx1 during M phase, and phosphorylation of Thr-201 was identified as a major activating event.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ)	Nigg, EA (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany.	nigg@biochem.mpg.de		nigg, erich/0000-0003-4835-5719				Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL SCI, V114, P2357; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karaiskou A, 1998, EXP CELL RES, V244, P491, DOI 10.1006/excr.1998.4220; Kinter M, 2000, PROTEIN SEQUENCING I, V1st, P152; Knecht R, 1999, CANCER RES, V59, P2794; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; WIND M, 2002, IN PRESS PROTEOMICS, V2; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	56	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25247	25256		10.1074/jbc.M202855200	http://dx.doi.org/10.1074/jbc.M202855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994303	hybrid			2022-12-27	WOS:000176747000053
J	Sengupta, PK; Fargo, J; Smith, BD				Sengupta, PK; Fargo, J; Smith, BD			The RFX family interacts at the collagen (COL1A2) start site and represses transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II TRANSACTIVATOR; GROWTH-FACTOR-BETA; BARE LYMPHOCYTE SYNDROME; HUMAN SKIN FIBROBLASTS; NECROSIS-FACTOR-ALPHA; DNA-BINDING PROTEIN; REGULATORY FACTOR-X; GENE-EXPRESSION; INTERFERON-GAMMA; NF-Y	The transcription start site of the collagen alpha2(1) gene (COL1A2) has a sequence-specific binding site for a DNA methylation-responsive binding protein called regulatory factor for X-box 1 (RFX1) (Sengupta, P. K., Erhlich, M., and Smith, B. D. (1999) J. Biol. Chem. 274, 3664936655). In this report, we demonstrate that RFX1 forms homodimers as well as heterodimers with RFX2 spanning the collagen transcription start site. Methylation at +7 on the coding strand increases RFX1 complex formation in gel shift assays. Methylation on the template strand, however, does not increase RFX1 complex formation. DNA from human fibroblasts contains minimal methylation on the coding strand (<4%) with variable methylation on the template strand. RFX1 acts as a repressor of collagen transcription as judged by in vitro transcription and co-transfection assays with an un-methylated collagen promoter-reporter construct. In addition, an RFX5 complex present in human fibroblasts interacts with the collagen RFX site, which is not sensitive to methylation. This is the first demonstration of RFX5 complex formation on a gene other than major histocompatibility complex (MHC) promoters. Also, RFX5 represses transcription of a collagen promoter-reporter construct in rat fibroblasts that have no detectable RFX5 complex formation or protein. RFX5 complex activates MHC 11 transcription by interacting with an interferon-gamma (IFN-gamma)-inducible protein, major histocompatibility class 11 trans-activator (CIITA). Collagen transcription is repressed by IFN-gamma in a dose-dependent manner in human but not in rat fibroblasts. IFN-gamma enhances RFX5 binding activity, and CIITA is present in the RFX5 complex of IFN-gamma-treated human fibroblasts. CIITA repressed collagen gene transcription more effectively in human fibroblasts than in rat fibroblasts, suggesting that the RFX5 complex may, in part, recruit CIITA protein to the collagen transcription start site. Thus the RFX family may be important repressors of collagen gene transcription through a RFX binding site spanning the transcription start site.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Vet Adm Med Ctr, Boston, MA 02118 USA	Boston University	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386, R01HL068094] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL68094, P01-HL56386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Biegalke BJ, 1998, J VIROL, V72, P5457, DOI 10.1128/JVI.72.7.5457-5463.1998; BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Brickey WJ, 1999, J IMMUNOL, V163, P6622; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; CATANIA J, 1991, MUTAT RES, V256, P283, DOI 10.1016/0921-8734(91)90019-8; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GOLDSTEIN RH, 1991, AM J PHYSIOL, V261, pL29, DOI 10.1152/ajplung.1991.261.2.L29; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Iwama A, 1999, MOL CELL BIOL, V19, P3940; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Katan-Khaykovich Y, 1999, J MOL BIOL, V294, P121, DOI 10.1006/jmbi.1999.3245; KHAN R, 1988, J BIOL CHEM, V263, P14374; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Mach B, 1999, SCIENCE, V285, P1367, DOI 10.1126/science.285.5432.1367; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Masternak K, 2002, EMBO J, V21, P1379, DOI 10.1093/emboj/21.6.1379; Moreno CS, 1997, J IMMUNOL, V158, P5841; Mori-Aoki A, 2000, BIOCHEM BIOPH RES CO, V278, P58, DOI 10.1006/bbrc.2000.3769; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; Pieper RO, 1999, NUCLEIC ACIDS RES, V27, P3229, DOI 10.1093/nar/27.15.3229; Piskurich JF, 1998, J IMMUNOL, V160, P233; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Samac S, 1998, BIOL CHEM, V379, P541; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; SENGUPTA PK, 1994, AM J HEMATOL, V46, P169, DOI 10.1002/ajh.2830460302; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; SMITH BD, 1988, BIOCHEM J, V253, P269, DOI 10.1042/bj2530269; SMITH GJ, 1981, CANCER RES, V41, P1373; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Tierney R, 2000, J VIROL, V74, P10458, DOI 10.1128/JVI.74.22.10458-10467.2000; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; WILSON VL, 1983, SCIENCE, V220, P1054; Ying AK, 2000, CARDIOVASC RES, V46, P172, DOI 10.1016/S0008-6363(00)00004-3; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	90	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24926	24937		10.1074/jbc.M111712200	http://dx.doi.org/10.1074/jbc.M111712200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986307	hybrid			2022-12-27	WOS:000176747000014
J	Shah, S; Pishvaian, MJ; Easwaran, V; Brown, PH; Byers, SW				Shah, S; Pishvaian, MJ; Easwaran, V; Brown, PH; Byers, SW			The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; EPITHELIAL TUMOR-CELLS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; 9-CIS-RETINOIC ACID; GROWTH-INHIBITION; COLON-CARCINOMA; ALPHA-CATENIN; ADHESION	Vitamin A derivatives (retinoids) are potent regulators of cell proliferation and differentiation. Retinoids inhibit the function of the oncogenic AP-1 and beta-catenin/TCF pathways and also stabilize components of the adherens junction, a tumor suppressor complex. When treated with retinoic acid (RA), the breast cancer cell line, SKBR3, undergoes differentiation and reduction in cell proliferation. The present work demonstrates that in SKBR3 cells, which exhibit high AP-1 activity, RA-regulation of cadherin expression and function, but not changes in AP-1 (or beta-catenin/TCF) signaling, is responsible for the epithelial differentiation. However, cadherin function and recruitment of beta-catenin to the membrane is not required for RA to regulate DNA synthesis in these cells. RA also reduces the activity of an AP-1 and TCF-sensitive cyclin D1 reporter in SKBR3 cells in a manner that is independent of the TCF site. In contrast, in SW480 cells, which have high levels of beta-catenin/TCF signaling, the activity and retinoid responsiveness of the cyclin D1 promoter was markedly inhibited by mutation of the TCF site. These data indicate that the remarkably broad effects of RA on the growth and differentiation of many different epithelial cancers may well be explained by the ability of RA to differentially regulate the activity of RAR/RXR, AP-1, and beta-catenin/TCF pathways.	Georgetown Univ, Ctr Med, Sch Med, Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Ctr Med, Sch Med, Dept Oncol & Cell Biol, Washington, DC 20007 USA; Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, San Antonio, TX 78284 USA	Georgetown University; Georgetown University; University of Texas System; University of Texas Health San Antonio	Byers, SW (corresponding author), Georgetown Univ, Ctr Med, Sch Med, Lombardi Canc Res Ctr, E415 Res Bldg,3970 Reservoir Rd, Washington, DC 20007 USA.	byerss@georgetown.edu						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANZANO MA, 1994, CANCER RES, V54, P4614; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1993, J CELL SCI, P159; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BOYER B, 1989, J MEMBRANE BIOL, V112, P97, DOI 10.1007/BF01871271; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Byers S, 1996, ENDOCRINOLOGY, V137, P3265, DOI 10.1210/en.137.8.3265; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EDWARD M, 1992, CLIN EXP METASTAS, V10, P61, DOI 10.1007/BF00163577; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Fitzgerald P, 1997, CANCER RES, V57, P2642; FLIGIEL SEG, 1992, J CUTAN PATHOL, V19, P27, DOI 10.1111/j.1600-0560.1992.tb01555.x; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hong Waun Ki, 1994, P597; HOOSEIN NM, 1988, CANCER LETT, V40, P219, DOI 10.1016/0304-3835(88)90014-6; HOULE JD, 1989, NEUROSCI LETT, V103, P253, DOI 10.1016/0304-3940(89)90108-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li JJ, 1996, CANCER RES, V56, P483; Mangelsdorf David J., 1994, P319; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OYAMA T, 1994, CANCER RES, V54, P6282; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Pishvaian MJ, 1999, CANCER RES, V59, P947; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Sellin JH, 2001, CANCER RES, V61, P2899; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Shimazui T, 1996, CANCER RES, V56, P3234; SHIMOYAMA Y, 1995, CANCER RES, V55, P2206; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Szeto W, 2001, CANCER RES, V61, P4197; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Truica CI, 2000, CANCER RES, V60, P4709; VERMA AK, 1980, CANCER RES, V40, P2367; VERMA AK, 1983, CANCER RES, V43, P3045; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	57	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25313	25322		10.1074/jbc.M203158200	http://dx.doi.org/10.1074/jbc.M203158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000762	hybrid			2022-12-27	WOS:000176747000062
J	Yusta, B; Estall, J; Drucker, DJ				Yusta, B; Estall, J; Drucker, DJ			Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CELL-SURVIVAL; SIGNALING PATHWAY; GLP-2 RECEPTOR; CARDIAC MYOCYTES; NEURONAL DEATH; CYTOCHROME-C; BH3 DOMAIN; KAPPA-B; IN-VIVO	Activation of glucagon-like peptide-2 receptor (GLP-2R) signaling promotes expansion of the mucosal epithelium indirectly via activation of growth and anti-apoptotic pathways; however, the cellular mechanisms coupling direct GLP-2R activation to cell survival remain poorly understood. We now demonstrate that GLP-2, in a cycloheximide-insensitive manner, enhanced survival in baby hamster kidney cells stably transfected with the rat GLP-2R; reduced mitochondrial cytochrome c efflux; and attenuated the caspase-dependent cleavage of Akt, poly(ADP-ribose) polymerase, and beta-catenin following inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002. The prosurvival effects of GLP-2 on LY294002-induced cell death were independent of Akt, P90(Rsk), or p70 S6 kinase activation; were mimicked by forskolin; and were abrogated by inhibition of protein kinase A (PKA) activity. GLP-2 inhibited activation of glycogen synthase kinase-3 (GSK-3) through phosphorylation at Ser(21) in GSK-3alpha and at Ser(9) in GSK-3beta in a PI3K-independent, PKA-dependent manner. GLP-2 reduced LY294002-induced mitochondrial association of endogenous Bad and Bax and stimulated phosphorylation of a transfected Bad fusion protein at Ser(155) in a PI3K-independent, but H89-sensitive manner, a modification known to suppress Bad pro-apoptotic activity. These results suggest that GLP-2R signaling enhances cell survival independently of PI3K/Akt by inhibiting the activity of a subset of pro-apoptotic downstream targets of Akt in a PKA-dependent manner.	Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, 200 Elizabeth St, Toronto, ON M5G 1L7, Canada.		Drucker, Daniel J/A-4092-2010	Estall, Jennifer/0000-0002-9838-1440				Araki M, 2000, J AM COLL CARDIOL, V36, P1411, DOI 10.1016/S0735-1097(00)00822-6; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boushey RP, 1999, AM J PHYSIOL-ENDOC M, V277, pE937, DOI 10.1152/ajpendo.1999.277.5.E937; Boushey RP, 2001, CANCER RES, V61, P687; BREGENHOLT S, 2001, 61 ANN M AM DIAB ASS, V50, pOR125; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burrin DG, 2000, AM J PHYSIOL-GASTR L, V279, pG1249, DOI 10.1152/ajpgi.2000.279.6.G1249; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Delgado M, 1996, BLOOD, V87, P5152, DOI 10.1182/blood.V87.12.5152.bloodjournal87125152; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Drucker DJ, 2001, J CLIN ENDOCR METAB, V86, P1759, DOI 10.1210/jc.86.4.1759; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; Goswami R, 2000, J NEUROSCI RES, V59, P136, DOI 10.1002/(SICI)1097-4547(20000101)59:1<136::AID-JNR16>3.0.CO;2-F; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; HANSOTIA T, 2001, 61 ANN M AM DIAB ASS, V50, pP1457; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hetman M, 2000, J NEUROSCI, V20, P2567; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Oka JI, 2000, BRAIN RES, V878, P194, DOI 10.1016/S0006-8993(00)02741-4; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Singh K, 2000, CARDIOVASC RES, V45, P713, DOI 10.1016/S0008-6363(99)00370-3; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Thangaraju M, 1999, CANCER RES, V59, P1649; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Wang XD, 2001, GENE DEV, V15, P2922; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yan LZ, 2000, AM J PHYSIOL-CELL PH, V279, pC1665, DOI 10.1152/ajpcell.2000.279.5.C1665; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459; Yusta B, 2000, GASTROENTEROLOGY, V119, P744, DOI 10.1053/gast.2000.16489; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	64	71	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24896	24906		10.1074/jbc.M201358200	http://dx.doi.org/10.1074/jbc.M201358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978789	hybrid			2022-12-27	WOS:000176747000011
J	Henderson, BR; Galea, M; Schuechner, S; Leung, L				Henderson, BR; Galea, M; Schuechner, S; Leung, L			Lymphoid enhancer factor-1 blocks adenomatous polyposis coli-mediated nuclear export and degradation of beta-catenin - Regulation by histone deacetylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR LEF-1; MALIGNANT-MELANOMA; GENE-EXPRESSION; DOWN-REGULATION; LOCALIZATION; ACTIVATION; CANCER; TRANSACTIVATION; TRANSFORMATION	The oncogenic protein beta-catenin is overexpressed in many cancers, frequently accumulating in nuclei where it forms active complexes with lymphoid enhancer factor-1 (LEF-1)/T-cell transcription factors, inducing genes such as c-myc and cyclin D1. In normal cells, nuclear beta-catenin levels are controlled by the adenomatous polyposis coli (APC) protein through nuclear export and cytoplasmic degradation. Transient expression of LEF-1 is known to increase nuclear beta-catenin levels by an unknown mechanism. Here, we show that A-PC and LEF-1 compete for nuclear beta-catenin with opposing consequences. APC can export nuclear beta-catenin to the cytoplasm for degradation. In contrast, LEF-1 anchors beta-catenin in the nucleus by blocking APC-mediated nuclear export. LEF-1 also prevented the APC/CRM1-independent nuclear export of beta-catenin as revealed by in vitro assays. Importantly, LEF-1-bound beta-catenin was protected from degradation by APC and axin in SW480 colon cancer cells. The ability of LEF-1 to trap beta-catenin in the nucleus was down-regulated by histone deacetylase 1, and this correlated with a decrease in LEF1 transcription activity. Our findings identify LEF-1 as key regulator of beta-catenin nuclear localization and stability and suggest that overexpression of LEF-1 in colon cancer and melanoma cells may contribute to the accumulation of oncogenic beta-catenin in the nucleus.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.		Galea, Melanie A/I-2236-2014					Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOVANES K, 2001, NAT GENET, V28, P53; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Neufeld KL, 2000, EMBO REP, V1, P519; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Orsulic S, 1999, J CELL SCI, V112, P1237; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SMITH KJ, 1994, CANCER RES, V54, P3672; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2	33	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24258	24264		10.1074/jbc.M110602200	http://dx.doi.org/10.1074/jbc.M110602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986304	hybrid			2022-12-27	WOS:000176611800038
J	Kim, J; Kim, JH; Lee, SH; Kim, DH; Kang, HY; Bae, SH; Pan, ZQ; Seo, YS				Kim, J; Kim, JH; Lee, SH; Kim, DH; Kang, HY; Bae, SH; Pan, ZQ; Seo, YS			The novel human DNA helicase hFBH1 is an F-box protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVATING KINASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEOLYSIS; IDENTIFICATION; METABOLISM; SEQUENCE; ENGINE; MOTIF; SGS1	We have identified a novel DNA helicase in humans that belongs to members of the superfamily I helicase and found that it contains a well conserved F-box motif at its N terminus. We have named the enzyme hFBH1 (human F-box DNA helicase 1). Recombinant hFBH1, containing glutathione S-transferase at the N terminus, was expressed in Sf9 cells and purified. In this report, we show that hFBH1 exhibited DNA-dependent ATPase and DNA unwinding activities that displace duplex DNA in the 3' to 5' direction. The hFBH1 enzyme interacted with human SKP1 and formed an SCF ((S) under bar KP1/(C) under bar ullin/(F) under bar -box) complex together with human Cullin and ROC1. In addition, the SCF complex containing hFBH1 as an F-box protein displayed ubiquitin ligase activity. We demonstrate that hFBH1 is the first F-box protein that possesses intrinsic enzyme activity. The potential role of the F-box motif and the helicase activity of the enzyme are discussed with regard to regulation of DNA metabolism.	Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, Suwon 440746, Kyunggi, South Korea; Dong A Univ, Coll Med, Dept Pharmacol, Seo Gu, Pusan 602103, South Korea; Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Sungkyunkwan University (SKKU); Dong A University; Icahn School of Medicine at Mount Sinai	Seo, YS (corresponding author), Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, 300 Chunchun Dong, Suwon 440746, Kyunggi, South Korea.	ysseo@med.skku.ac.kr	Kim, Jaehoon/G-2711-2011; Seo, Yeonsoo/C-1605-2011	Kim, Jaehoon/0000-0003-4035-0438; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; KAIS, 1994, METHODS YEAST GENETI, P169; Kang HY, 2000, GENETICS, V155, P1055; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; McVey M, 2001, GENETICS, V157, P1531; Miller J.H., 1972, EXPT MOL GENETICS; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Yee A, 1996, J BIOL CHEM, V271, P471, DOI 10.1074/jbc.271.1.471; YEE A, 1995, CANCER RES, V55, P6058	33	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24530	24537		10.1074/jbc.M201612200	http://dx.doi.org/10.1074/jbc.M201612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956208	hybrid			2022-12-27	WOS:000176611800074
J	Maeda, T; Mazzulli, JR; Farrance, IKG; Stewart, AFR				Maeda, T; Mazzulli, JR; Farrance, IKG; Stewart, AFR			Mouse DTEF-1 (ETFR-1, TEF-5) is a transcriptional activator in alpha(1)-adrenergic agonist-stimulated cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; PROTEIN-KINASE-C; HEAVY-CHAIN GENE; RAT-HEART MYOCYTES; M-CAT ELEMENTS; RECEPTOR STIMULATION; MULTIGENE FAMILY; FACTOR RTEF-1; DNA-BINDING; HYPERTROPHY	alpha(1)-Adrenergic signaling in cardiac myocytes activates the skeletal muscle alpha-actin gene through an MCAT cis-element, the binding site of the transcriptional enhancer factor-1 (TEF-1) family of transcription factors. TEF-1 accounts for more than 85% of the MCAT binding activity in neonatal rat cardiac myocytes. Other TEF-1 family members account for the rest. Although TEF-1 itself has little effect on the alpha(1)-adrenergic activation of skeletal muscle alpha-actin, the related factor RTEF-1 augments the response and is a target of alpha(1)-adrenergic signaling. Here, we examined another TEF-1 family member expressed in cardiac muscle, DTEF-1, and observed that it also augmented the alpha(1)-adrenergic response of skeletal muscle alpha-actin. A DTEF-1 peptide-specific antibody revealed that endogenous DTEF-1 accounts for up to 5% of the MCAT binding activity in neonatal rat cardiac myocytes. A TEF-1/DTEF-1 chimera suggests that alpha(1)-adrenergic signaling modulates DTEF-1 function. Orthophosphate labeling and immunoprecipitation of an epitope-tagged DTEF-1 showed that DTEF-1 is phosphorylated in vivo. alpha(1)-Adrenergic stimulation increased while phosphatase treatment lowered the MCAT binding by DTEF-1 and the endogenous non-TEF-1 MCAT-binding factor. In contrast, alpha(1)-adrenergic stimulation did not alter, and phosphatase treatment increased, MCAT binding of TEF-1 and RTEF-1. Taken together, these results suggest that DTEF-1 is a target for alpha(1)-adrenergic activation of the skeletal muscle alpha-actin gene in neonatal rat cardiac myocytes.	Univ Pittsburgh, Sch Med, Cardiovasc Inst, Pittsburgh, PA 15213 USA; Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Maryland; University of Maryland Baltimore	Stewart, AFR (corresponding author), Univ Pittsburgh, Sch Med, Cardiovasc Inst, BST 1704-3,200 Lothrop St, Pittsburgh, PA 15213 USA.		Stewart, Alexandre F.R./A-5677-2011	Stewart, Alexandre/0000-0003-2673-9164	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867, R29HL057211] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL57211, P01 HL27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aihara Y, 2000, HYPERTENSION, V36, P48, DOI 10.1161/01.HYP.36.1.48; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; Brunskill EW, 2001, DEV BIOL, V235, P507, DOI 10.1006/dbio.2001.0313; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; GUPTA MP, 1991, BIOCHEM BIOPH RES CO, V174, P1196, DOI 10.1016/0006-291X(91)91548-Q; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Jacquemin P, 1998, DEV DYNAM, V212, P423, DOI 10.1002/(SICI)1097-0177(199807)212:3<423::AID-AJA10>3.0.CO;2-1; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 1999, MOL ENDOCRINOL, V13, P879, DOI 10.1210/me.13.6.879; Jiang SW, 2001, J BIOL CHEM, V276, P23464, DOI 10.1074/jbc.M010934200; Kaneko KJ, 1997, DEVELOPMENT, V124, P1963; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V228, P365, DOI 10.1006/bbrc.1996.1667	37	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24346	24352		10.1074/jbc.M201171200	http://dx.doi.org/10.1074/jbc.M201171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986313	hybrid			2022-12-27	WOS:000176611800050
J	Meigs, TE; Fedor-Chaiken, M; Kaplan, DD; Brackenbury, R; Casey, PJ				Meigs, TE; Fedor-Chaiken, M; Kaplan, DD; Brackenbury, R; Casey, PJ			G alpha(12) and G alpha(13) negatively regulate the adhesive functions of cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; STRESS FIBER FORMATION; HETEROTRIMERIC G-PROTEINS; RHO-FAMILY GTPASES; BETA-CATENIN; ALPHA-SUBUNIT; CYTOPLASMIC DOMAIN; CARCINOMA-CELLS; PHOSPHOLIPASE-D; NIH3T3 CELLS	Cadherins function to promote adhesion between adjacent cells and play critical roles in such cellular processes as development, tissue maintenance, and tumor suppression. We previously demonstrated that heterotrimeric G proteins of the G(12) subfamily comprised of Galpha(12) and Galpha(13) interact with the cytoplasmic domain of cadherins and cause the release of the transcriptional activator beta-catenin (Meigs, T. E., Fields, T. A., McKee, D. D., and Casey, P. J. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 519-524). Because of the importance of beta-catenin in cadherin-mediated cell-cell adhesion, we examined whether G(12) subfamily proteins could also regulate cadherin function. The introduction of mutationally activated G(12) proteins into K562 cells expressing E-cadherin blocked cadherin-mediated cell adhesion in steady-state assays. Also, in breast cancer cells, the introduction of activated G(12) proteins blocked E-cadherin function in a fast aggregation assay. Aggregation mediated by a mutant cadherin that lacks G(12) binding ability was not affected by activated G(12) proteins, indicating a requirement for direct G(12)-cadherin interaction. Furthermore, in wound-filling assays in which ectopic expression of E-cadherin inhibits cell migration, the expression of activated G(12) proteins reversed the inhibition via a mechanism that was independent of G(12)-mediated Rho activation. These results validate the G(12)-cadherin interaction as a potentially important event in cell biology and suggest novel roles for G(12) proteins in the regulation of cadherin-mediated developmental events and in the loss of cadherin function that is characteristic of metastatic tumor progression.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Duke University; University System of Ohio; University of Cincinnati	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.			Kaplan, Daniel/0000-0001-8297-560X; Casey, Patrick/0000-0002-7366-9309; Brackenbury, Robert/0000-0002-1332-4018	NCI NIH HHS [CA91159] Funding Source: Medline; NIAMS NIH HHS [AR44713] Funding Source: Medline; NIGMS NIH HHS [GM55717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR044713, R01AR044713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055717, R55GM055717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; BRACKENBURY R, 1981, P NATL ACAD SCI-BIOL, V78, P387, DOI 10.1073/pnas.78.1.387; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen HY, 1997, J CELL SCI, V110, P345; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dermott JM, 2001, J CELL BIOCHEM, V81, P1; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLERNINCKX K, 1991, CELL, V66, P107; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	63	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24594	24600		10.1074/jbc.M201984200	http://dx.doi.org/10.1074/jbc.M201984200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976333	hybrid			2022-12-27	WOS:000176611800082
J	Fauconnet, S; Lascombe, I; Chabannes, E; Adessi, GL; Desvergne, B; Wahli, W; Bittard, H				Fauconnet, S; Lascombe, I; Chabannes, E; Adessi, GL; Desvergne, B; Wahli, W; Bittard, H			Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; ACID-BINDING PROTEIN; SMOOTH-MUSCLE-CELLS; PPAR-GAMMA; FATTY-ACIDS; GENE-EXPRESSION; HYPOLIPIDEMIC DRUGS; HUMAN GLIOBLASTOMA; URINARY-BLADDER; MESSENGER-RNA	The growth of any solid tumor depends on angiogenesis. Vascular endothelial growth factor (VEGF) plays a prominent role in vesical tumor angiogenesis regulation. Previous studies have shown that the peroxisome proliferator-activated receptor gamma (PPARgamma) was involved in the angiogenesis process. Here, we report for the first time that in two different human bladder cancer cell lines, RT4 (derived from grade I tumor) and T24 (derived from grade III tumor), VEGF (mRNA and protein) is differentially up-regulated by the three PPAR isotypes. Its expression is increased by PPARalpha, beta, and gamma in RT4 cells and only by PPARbeta in T24 cells via a transcriptional activation of the VEGF promoter through an indirect mechanism. This effect is potentiated by an RXR (retinoid-X-receptor), selective retinoid LG10068 providing support for a PPAR agonist-specific action on VEGF expression. While investigating the downstream signaling pathways involved in PPAR agonist-mediated up-regulation of VEGF, we found that only the MER inhibitor PD98059 reduced PPAR ligand-induced expression of VEGF. These data contribute to a better understanding of the mechanisms by which PPARs regulate VEGF expression. They may lead to a new therapeutic approach to human bladder cancer in which excessive angiogenesis is a negative prognostic factor.	Ctr Hosp Univ Jean Minjoz, Serv Urol & Androl, Hop St Jacques, F-25000 Besancon, France; Ctr Hosp Univ Jean Minjoz, INSERM, F-25000 Besancon, France; Ctr Hosp Univ Jean Minjoz, Serv Endocrinol & Oncol Mol, F-25000 Besancon, France; Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland	Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; University of Lausanne	Bittard, H (corresponding author), Ctr Hosp Univ Jean Minjoz, Serv Urol & Androl, Hop St Jacques, 2 Pl St Jacques, F-25000 Besancon, France.	urologie@chu-besancon.fr	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; Auwerx J, 1999, CELL, V97, P161; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Bernardini S, 2001, J UROLOGY, V166, P1275, DOI 10.1016/S0022-5347(05)65752-7; BROWN LF, 1993, AM J PATHOL, V143, P1255; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; Celis JE, 1996, CANCER RES, V56, P4782; Chabannes E, 2001, CELL SIGNAL, V13, P585, DOI 10.1016/S0898-6568(01)00184-X; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Crew JP, 1999, J UROLOGY, V161, P799, DOI 10.1016/S0022-5347(01)61772-5; Crew JP, 1997, CANCER RES, V57, P5281; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Diep QN, 2000, HYPERTENSION, V36, P851, DOI 10.1161/01.HYP.36.5.851; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FRIEDELL GH, 1983, PATHOLOGY BLADDER CA, V1, P11; Fujimoto J, 1998, CANCER LETT, V134, P15, DOI 10.1016/S0304-3835(98)00232-8; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jones A, 2001, CLIN CANCER RES, V7, P1263; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVI F, 1993, INT J CANCER, V55, P419, DOI 10.1002/ijc.2910550316; Michalik L, 2002, INT J DEV BIOL, V46, P105; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Miyake H, 1999, UROLOGY, V53, P302, DOI 10.1016/S0090-4295(98)00486-5; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OBRIEN T, 1995, CANCER RES, V55, P510; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PAULI BU, 1983, PATHOLOGY BLADDER CA, V2, P41; Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	64	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23534	23543		10.1074/jbc.M200172200	http://dx.doi.org/10.1074/jbc.M200172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980898	hybrid			2022-12-27	WOS:000176475700058
J	Ilari, A; Bonamore, A; Farina, A; Johnson, KA; Boffi, A				Ilari, A; Bonamore, A; Farina, A; Johnson, KA; Boffi, A			The X-ray structure of ferric Escherichia coli flavohemoglobin reveals an unexpected geometry of the distal heme pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DIOXYGENASE; BINDING PROPERTIES; DIFFRACTION DATA; PROGRAM; STRESS; LIGAND	The x-ray structure of ferric unliganded lipid-free Escherichia coli flavohemoglobin has been solved to a resolution of 2.2 Angstrom and refined to an R-factor of 19%. The overall fold is similar to that of ferrous lipid-bound Alcaligenes eutrophus flavohemoglobin with the notable exception of the E helix positioning within the globin domain and a rotation of the NAD binding module with respect to the FAD-binding domain accompanied by a substantial rearrangement of the C-terminal region. An inspection of the heme environment in E. coli flavohemoglobin reveals an unexpected architecture of the distal pocket. In fact, the distal site is occupied by the isopropyl side chain Leu-E11 that shields the heme iron from the residues in the topological positions predicted to interact with heme iron-bound ligands, namely Tyr-B10 and Gln-E7, and stabilizes a pentacoordinate ferric iron species. Ligand binding properties are consistent with the presence of a pentacoordinate species in solution as indicated by a very fast second order combination rates with imidazole and azide. Surprisingly, imidazole, cyanide, and azide binding profiles at equilibrium are not accounted for by a single site titration curve but are biphasic and strongly suggest the presence of two distinct conformers within the liganded species.	Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Boffi, A (corresponding author), Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy.	alberto.boffi@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Bonamore, Alessandra/AAB-2587-2019; Ilari, Andrea/T-5501-2017	Ilari, Andrea/0000-0002-7754-399X; Bonamore, Alessandra/0000-0002-3940-4657; Ilari, Andrea/0000-0002-7754-399X				Boffi A, 1999, BIOPHYS J, V77, P1143, DOI 10.1016/S0006-3495(99)76965-1; Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; Bonamore A, 2001, BBA-PROTEIN STRUCT M, V1549, P174, DOI 10.1016/S0167-4838(01)00256-4; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Collaborative Computational Project No. 4, 1994, ACTA CRYSTALLOGR D, V50, P750; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; JAKOB W, 1992, ARCH BIOCHEM BIOPHYS, V292, P29, DOI 10.1016/0003-9861(92)90046-Y; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mansy SS, 1998, BIOCHEMISTRY-US, V37, P12452, DOI 10.1021/bi980516j; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	28	115	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23725	23732		10.1074/jbc.M202228200	http://dx.doi.org/10.1074/jbc.M202228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964402	hybrid			2022-12-27	WOS:000176475700082
J	Jelenska, J; Sirikhachornkit, A; Haselkorn, R; Gornicki, P				Jelenska, J; Sirikhachornkit, A; Haselkorn, R; Gornicki, P			The carboxyltransferase activity of the apicoplast acetyl-CoA carboxylase of Toxoplasma gondii is the target of aryloxyphenoxypropionate inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PLASMODIUM-FALCIPARUM; APICOMPLEXA; RESISTANCE; HERBICIDES; PATHWAY; GROWTH; DOMAIN	Inhibition of growth of the apicomplexan parasite Toxoplasma gondii by aryloxyphenoxypropionate herbicides has been correlated with the inhibition of its acetyl-CoA carboxylase (ACC) by these compounds. Here, full-length and C-terminal fragments of T. gondii apicoplast ACC as well as C-terminal fragments of the cytosolic ACC were expressed in Escherichia coli. The recombinant proteins that were soluble showed the expected enzymatic activities. Yeast gene-replacement strains depending for growth on the expressed T. gondii ACC were derived by complementation of a yeast ACC1 null mutation. In vitro and in vivo tests with noxyphenoxypropionates showed that the carboxyltransferase domain of the apicoplast T. gondii ACC is the target for this class of inhibitors. The cytosolic T. gondii ACC is resistant to aryloxyphenoxypropionates. Both T. gondii isozymes are resistant to cyclohexanediones, another class of inhibitors targeting the ACC of grass plastids.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Gornicki, P (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.							Devine MD, 1997, PESTIC SCI, V51, P259, DOI 10.1002/(SICI)1096-9063(199711)51:3&lt;259::AID-PS644&gt;3.0.CO;2-S; Devine MD, 2000, CROP PROT, V19, P881, DOI 10.1016/S0261-2194(00)00123-X; Gleeson MT, 2000, INT J PARASITOL, V30, P1053, DOI 10.1016/S0020-7519(00)00100-4; GORNICKI P, 1993, PLANT MOL BIOL, V22, P547, DOI 10.1007/BF00015984; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; Herbert D, 1997, PESTIC SCI, V50, P67, DOI 10.1002/(SICI)1096-9063(199705)50:1&lt;67::AID-PS552&gt;3.0.CO;2-#; Incledon BJ, 1997, PESTIC BIOCHEM PHYS, V57, P255, DOI 10.1006/pest.1997.2279; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Joachimiak M, 1997, P NATL ACAD SCI USA, V94, P9990, DOI 10.1073/pnas.94.18.9990; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kozaki A, 2000, J BIOL CHEM, V275, P10702, DOI 10.1074/jbc.275.14.10702; Macreadie I, 2000, PARASITOL TODAY, V16, P438, DOI 10.1016/S0169-4758(00)01758-0; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; Nikolskaya T, 1999, P NATL ACAD SCI USA, V96, P14647, DOI 10.1073/pnas.96.25.14647; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1997, MICROBIOL MOL BIOL R, V61, P1; Zagnitko O, 2001, P NATL ACAD SCI USA, V98, P6617, DOI 10.1073/pnas.121172798; Zuther E, 1999, P NATL ACAD SCI USA, V96, P13387, DOI 10.1073/pnas.96.23.13387	21	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23208	23215		10.1074/jbc.M200455200	http://dx.doi.org/10.1074/jbc.M200455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980900	hybrid			2022-12-27	WOS:000176475700016
J	Osada, M; Imaoka, S; Sugimoto, T; Hiroi, T; Funae, Y				Osada, M; Imaoka, S; Sugimoto, T; Hiroi, T; Funae, Y			NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; B-CELL LINES; PROLINE HYDROXYLATION; DIPHENYLENE IODONIUM; PROLYL HYDROXYLATION; HUMAN ERYTHROPOIETIN; CARBON-MONOXIDE	Hypoxia induces a group of physiologically important genes that include erythropoietin (EPO) and vascular endothelial growth factor (VEGF). Hypoxia-inducible factor 1 (HIF-1) was identified as a hypoxia-activated transcription factor; however, the molecular mechanisms that underlie hypoxia signal transduction in mammalian cells remain undefined. In this study, we found that a flavoprotein, NADPH-P450 reductase (NPR), could regulate the induction of EPO mRNA under hypoxic conditions. Hypoxic EPO mRNA induction in Hep3B cells was inhibited by diphenyleneiodonium. chloride, which is an inhibitor of NADPH-dependent enzymes. NPR antisense cDNA was transfected into Hep3B cells, and NPR-deficient hepatocyte cells (NPR- cells) were established. NPR- cells lacked EPO induction under hypoxia, and HIF-1alpha in NPR- cells did not respond to either transcriptional activation or translocation to the nucleus based on electrophoretic mobility shift assays and reporter gene assay including hypoxia response element. In contrast, NPR overexpression in Hep3B cells enhanced the DNA binding activity of HIF-1alpha by luciferase reporter gene assay. A study with HeLa S3 cells produced the same results. Furthermore, anti-NPR IgG inhibited EPO induction. EPO induction inhibited by diphenyleneiodonium chloride was recovered by bovine serum albumin-NADPH (a covalent binding complex of bovine serum albumin and NADPH) as well as NADPH. These results suggested that NPR located at the plasma membrane regulates EPO expression in hypoxia, including HIF-1 activation and translocation. We further studied the expression of NPR and VEGF mRNAs in human tumor tissues and found that the NPR mRNA levels were correlated with the VEGF mRNA levels, suggesting that NPR might be an important factor in the hypoxic induction of genes such as VEGF in vivo.	Osaka City Univ, Sch Med, Dept Chem Biol, Abeno Ku, Osaka 5458585, Japan; Osaka City Gen Hosp, Miyakojima Ku, Osaka 5340021, Japan	Osaka Metropolitan University; Osaka City General Hospital	Imaoka, S (corresponding author), Kwansei Gakuin Univ, Sch Sci & Technol, 2-1 Gakuen, Sanda 6691337, Japan.	imaoka@ksc.kwansei.ac.jp						ACKER H, 1994, RESP PHYSIOL, V95, P1, DOI 10.1016/0034-5687(94)90043-4; Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FUNAE Y, 1987, BIOCHIM BIOPHYS ACTA, V926, P349, DOI 10.1016/0304-4165(87)90221-2; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GORLACH A, 1993, BIOCHEM J, V290, P771; Harder DR, 1996, CIRC RES, V79, P54, DOI 10.1161/01.RES.79.1.54; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Imaoka S, 1997, BIOCHEM PHARMACOL, V54, P677, DOI 10.1016/S0006-2952(97)00216-5; IMAOKA S, 1990, ARCH BIOCHEM BIOPHYS, V278, P168, DOI 10.1016/0003-9861(90)90245-T; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li D, 2001, J UROLOGY, V166, P2500, DOI 10.1016/S0022-5347(05)65624-8; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; MALY FE, 1988, J IMMUNOL, V140, P2334; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; ZOU AP, 1994, AM J PHYSIOL, V266, pF275, DOI 10.1152/ajprenal.1994.266.2.F275	44	33	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23367	23373		10.1074/jbc.M112413200	http://dx.doi.org/10.1074/jbc.M112413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971899	hybrid			2022-12-27	WOS:000176475700036
J	Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M				Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M			A novel dual specificity phosphatase SKRP1 interacts with the MAPK kinase MKK7 and inactivates the JNK MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; TYROSINE-PHOSPHATASE; CATALYTIC ACTIVATION; SIGNAL-TRANSDUCTION; CELL-LINES; SELECTIVELY DEPHOSPHORYLATES; MOLECULAR-CLONING; STRESS; P38	Mitogen-activated protein kinases (MAPKs) are activated in response to various extracellular stimuli, and their activities are regulated by upstream activating kinases and protein phosphatases such as MAPK phosphatases (MKPs). We report the identification and characterization of a novel MKP termed SKRP1 (SAPK pathway-regulating phosphatase 1). It contains an extended active site sequence motif conserved in all MKPs but lacks a Cdc25 homology domain. Immunoblotting analysis revealed that SKRP1 is constitutively expressed, and its transcripts of 4.0 and 1.0 kb were detected in almost tissues examined. SKRP1 was highly specific for c-Jun N-terminal kinase (JNK) in vitro and effectively suppressed the JNK activation in response to tumor necrosis factor a or thapsigargin. Endogenous SKRP1 was present predominantly in the cytoplasm and colocalized with JNK. However, SKRP1 does not bind directly to its target JNK, but co-precipitation of SKRP1 with the MAPK kinase MKK7, a JNK activator, was found in vitro and in vivo. Furthermore, we found that SKRP1 did not interfere with the co-precipitation of MKK7 with JNK. Together, our findings indicate that SKRP1 interacts with its physiological substrate JNK through MKK7, thereby leading to the precise regulation of JNK activity in vivo.	Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan	Tokyo Medical & Dental University (TMDU); Keio University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dowd S, 1998, J CELL SCI, V111, P3389; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hansson T, 1997, J MOL BIOL, V265, P118, DOI 10.1006/jmbi.1996.0716; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kolmodin K, 2001, FEBS LETT, V498, P208, DOI 10.1016/S0014-5793(01)02479-6; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; QU Z, 1997, MOL CELL BIOL, V17, P7407; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	64	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23909	23918		10.1074/jbc.M200837200	http://dx.doi.org/10.1074/jbc.M200837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959861	hybrid			2022-12-27	WOS:000176475700105
J	Gascon, I; Carrascosa, JL; Villar, L; Lazaro, JM; Salas, M				Gascon, I; Carrascosa, JL; Villar, L; Lazaro, JM; Salas, M			Importance of the N-terminal region of the phage GA-1 single-stranded DNA-binding protein for its self-interaction ability and functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; ESCHERICHIA-COLI; HELICASE-PRIMASE; SSB PROTEINS; RECA PROTEIN; UL8 SUBUNIT; REPLICATION; PHI-29; POLYMERASE; ORIGIN	The single-stranded DNA-binding protein (SSB) of phage GA-1 displays higher efficiency than the SSBs of the related phages phi29 and Nf. In this work, the self-interaction ability of GA-1 SSB has been analyzed by visualization of the purified protein by electron microscopy, glycerol gradient sedimentation, and in vivo cross-linking of bacterial cultures infected with phage GA-1. GA-1 SSB contains an insert at its N-terminal region that is not present in the SSBs of 029 and Nf. Three deletion mutant proteins have been characterized, DeltaN19, DeltaN26, and DeltaN33, which lack the 19, 26 or 33 amino acids, respectively, that follow the initial methionine of GA-1 SSB. Mutant protein DeltaN19 retains the structural and functional behavior of GA-1 SSB, whereas mutant proteins DeltaN26 and DeltaN33 no longer stimulate viral DNA replication or display helix-destabilizing activity. Analysis of the mutant proteins by ultracentrifugation in glycerol gradients and electron microscopy indicates that deletion of 26 or 33 but not of 19 amino acids of the N-terminal region of GA-1 SSB results in the loss of the oligomerization ability of this protein. Our data support the importance of the N-terminal region of GA-1 SSB for the differential self-interaction ability and functional behavior of this protein.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01 GM27242-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARWERT F, 1974, J VIROL, V13, P584, DOI 10.1128/JVI.13.3.584-589.1974; Beernink HTH, 1998, BIOCHEMISTRY-US, V37, P5673, DOI 10.1021/bi9800956; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; CARTHEW RW, 1985, CELL, V43, P438; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; FOLMER RHA, 1994, EUR J BIOCHEM, V224, P663, DOI 10.1111/j.1432-1033.1994.00663.x; Gascon I, 2000, J MOL BIOL, V296, P989, DOI 10.1006/jmbi.2000.3521; Gascon I, 2000, NUCLEIC ACIDS RES, V28, P2034, DOI 10.1093/nar/28.10.2034; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Lazaro JM, 1995, METHOD ENZYMOL, V262, P42; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LITTLER E, 1983, J GEN VIROL, V64, P983, DOI 10.1099/0022-1317-64-5-983; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Mapelli M, 2000, J VIROL, V74, P8812, DOI 10.1128/JVI.74.19.8812-8822.2000; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; Masui R, 1998, BIOCHEMISTRY-US, V37, P14788, DOI 10.1021/bi981296c; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; Pecenkova T, 1999, J MOL EVOL, V48, P197, DOI 10.1007/PL00006458; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; Revzin A., 1990, BIOL NONSPECIFIC DNA; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1999, GENETIC ENG, V21; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SOENGAS MS, 1994, J MOL BIOL, V239, P213, DOI 10.1006/jmbi.1994.1364; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STUIVER MH, 1990, J VIROL, V64, P379, DOI 10.1128/JVI.64.1.379-386.1990; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VAUGHAN PJ, 1984, J GEN VIROL, V65, P2033, DOI 10.1099/0022-1317-65-11-2033; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIKAWA H, 1986, J GEN APPL MICROBIOL, V32, P39, DOI 10.2323/jgam.32.39; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353	50	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22534	22540		10.1074/jbc.M202430200	http://dx.doi.org/10.1074/jbc.M202430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956216	hybrid			2022-12-27	WOS:000176313600057
J	Scott, RO; Thelin, WM; Milgram, SL				Scott, RO; Thelin, WM; Milgram, SL			A novel PDZ protein regulates the activity of guanylyl cyclase C, the heat-stable enterotoxin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMAIN-MEDIATED INTERACTION; ESCHERICHIA-COLI; NA+/H+-EXCHANGER; INTESTINAL MEMBRANES; EPITHELIAL-CELLS; STRUCTURAL BASIS; MESSENGER-RNA; KINASE-A; PEPTIDE	Secretory diarrhea is the leading cause of infectious diarrhea in humans. Secretory diarrhea may be caused by binding of heat-stable enterotoxins to the intestinal receptor guanylyl cyclase C (GCC). Activation of GCC catalyzes the formation of cGMP, initiating a signaling cascade that opens the cystic fibrosis transmembrane conductance regulator chloride channel at the apical cell surface. To identify proteins that regulate the trafficking or function of GCC, we used the unique COOH terminus of GCC as the "bait" to screen a human intestinal yeast two-hybrid library. We identified a novel protein, IKEPP (intestinal and kidney-enriched PDZ protein) that associates with the COOH terminus of GCC in biochemical assays and by co-immunoprecipitation. IKEPP is expressed in the intestinal epithelium, where it is preferentially accumulated at the apical surface. The GCC-IKEPP interaction is not required for the efficient targeting of GCC to the apical cell surface. Rather, the association with IKEPP significantly inhibits heat-stable enterotoxin-mediated activation of GCC. Our findings are the first to identify a regulatory protein that associates with GCC to modulate the catalytic activity of the enzyme and provides new insights in mechanisms that regulate GCC activity in response to bacterial toxin.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050744] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63755] Funding Source: Medline; NIDDK NIH HHS [R29DK50744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakre MM, 2000, EUR J BIOCHEM, V267, P179, DOI 10.1046/j.1432-1327.2000.00986.x; BENHAROUGA M, 2001, 15 ANN N AM CYST FIB; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carrithers SL, 2000, REGUL PEPTIDES, V95, P65, DOI 10.1016/S0167-0115(00)00139-7; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN MB, 1992, BIOCHEM BIOPH RES CO, V186, P483, DOI 10.1016/S0006-291X(05)80833-2; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DESHMANE SP, 1995, BIOCHEMISTRY-US, V34, P9095, DOI 10.1021/bi00028a019; Deshmane SP, 1997, BIOCHEMISTRY-US, V36, P12921, DOI 10.1021/bi971077b; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Forte LR, 1999, ENDOCRINOLOGY, V140, P1800, DOI 10.1210/en.140.4.1800; FORTE LR, 2000, J PHYSL, V278, pF180; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; HAKKI S, 1993, INT J BIOCHEM, V25, P557, DOI 10.1016/0020-711X(93)90664-Z; HAKKI S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P1, DOI 10.1016/0005-2736(93)90224-N; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; HIRAYAMA T, 1993, MICROB PATHOGENESIS, V15, P283, DOI 10.1006/mpat.1993.1078; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kocher O, 1999, LAB INVEST, V79, P1161; LI ZP, 1993, AM J PHYSIOL, V265, pG394, DOI 10.1152/ajpgi.1993.265.2.G394; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nandi A, 1997, J CELL BIOCHEM, V66, P500, DOI 10.1002/(SICI)1097-4644(19970915)66:4<500::AID-JCB9>3.0.CO;2-P; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG1307, DOI 10.1152/ajpgi.2000.279.6.G1307; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Schulz S, 1997, J CLIN INVEST, V100, P1590, DOI 10.1172/JCI119683; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swenson ES, 1996, BIOCHEM BIOPH RES CO, V225, P1009, DOI 10.1006/bbrc.1996.1286; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; Vijayachandra K, 2000, BIOCHEMISTRY-US, V39, P16075, DOI 10.1021/bi0013849; Wada A, 1996, FEBS LETT, V384, P75; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	56	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22934	22941		10.1074/jbc.M202434200	http://dx.doi.org/10.1074/jbc.M202434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950846	hybrid, Green Published			2022-12-27	WOS:000176313600106
J	Babinski, KJ; Kanjilal, SJ; Raetz, CRH				Babinski, KJ; Kanjilal, SJ; Raetz, CRH			Accumulation of the lipid A precursor UDP-2,3-diacylglucosamine in an Escherichia coli mutant lacking the lpxH gene.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; GRAM-NEGATIVE ENDOTOXIN; AGROBACTERIUM-TUMEFACIENS C58; CDP-DIGLYCERIDE HYDROLASE; PURPLE ACID-PHOSPHATASE; X-RAY STRUCTURE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BIOSYNTHESIS; PROTEIN	The lpxH gene encodes the UDP-2,3-diacylglucosamine-specific pyrophosphatase that catalyzes the fourth step of lipid A biosynthesis in Escherichia coli. To confirm the function of lpxH, we constructed KB321/pKJB5. This strain contains a kanamycin insertion element in the chromosomal copy of lpxH, complemented by plasmid pKJB5, which is temperature-sensitive for replication and harbors lpxH(+). KB21/pKJB5 grows at 30 degreesC but loses viability at 44 degreesC, demonstrating that lpxH is essential. CDP-diglyceride hydrolase (Cdh) catalyzes the same reaction as LpxH in vitro but is nonessential and cannot compensate for the absence of LpxH. The presence of Cdh in cell extracts interferes with the LpxH assay. We therefore constructed KB25/ pKJB5, which contains both an in-frame deletion of cdh and a kanamycin insertion mutation in lpxH, covered by pKJB5. When KB25/pKJB5 cells are grown at 44 degreesC, viability is lost, and all in vitro LpxH activity is eliminated. A lipid migrating with synthetic UDP-2,3-diacylglucosamine accumulates in KB25/pKJB5 following loss of the covering plasmid at 44 degreesC. This material was converted to the expected products, 2,3-diacylglucosamine 1-phosphate and UMP, by LpxH. Pseudomonas aeruginosa contains two proteins with sequence similarity to E. coli LpxH. The more homologous protein catalyzes UDP-2,3-diacylglucosamine hydrolysis in vitro. The corresponding gene complements YB25/pKJB5 at 44 degreesC, but the less homologous gene does not. The accumulation of UDP-2,3-diacylglucosamine in our lpxH mutant is consistent with the observation that the lipid A disaccharide synthase LpxB, the next enzyme in the pathway, cannot condense two UDP-2,3-diacylglucosamine molecules, but instead utilizes UDP-2,3-diacylglucosamine as its donor and 2,3-diacylglucosamine 1-phosphate as its acceptor.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.				NIGMS NIH HHS [GM-51310, GM07184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; Ausubel FM, 1988, MOL REPROD DEV; Babinski KJ, 2002, J BIOL CHEM, V277, P25937, DOI 10.1074/jbc.M204067200; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H., 1999, ENDOTOXIN HLTH DIS; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BULAWA CE, 1984, J BIOL CHEM, V259, P1257; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; GANONG BR, 1980, J BIOL CHEM, V255, P1623; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; ICHO T, 1985, J BIOL CHEM, V260, P2092; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; JOHZUKA K, 1995, GENETICS, V139, P1521; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Miller J.H., 1972, EXPT MOL GENETICS; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1972, J BIOL CHEM, V247, P2245; RAETZ CRH, 1976, J BACTERIOL, V125, P855, DOI 10.1128/JB.125.3.855-863.1976; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rusnak F, 1996, J BIOL INORG CHEM, V1, P388, DOI 10.1007/s007750050070; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Sambrook J., 2002, MOL CLONING LAB MANU; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; TAVASSOLI M, 1995, NUCLEIC ACIDS RES, V23, P383, DOI 10.1093/nar/23.3.383; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	48	52	55	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25947	25956		10.1074/jbc.M204068200	http://dx.doi.org/10.1074/jbc.M204068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000771	hybrid			2022-12-27	WOS:000176908700018
J	Behre, G; Singh, SM; Liu, HT; Bortolin, LT; Christopeit, M; Radomska, HS; Rangatia, J; Hiddemann, W; Friedman, AD; Tenen, DG				Behre, G; Singh, SM; Liu, HT; Bortolin, LT; Christopeit, M; Radomska, HS; Rangatia, J; Hiddemann, W; Friedman, AD; Tenen, DG			Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; CELL-PROLIFERATION; TRANSCRIPTION FACTOR; C-JUN; PU.1; EXPRESSION; KINASE; GROWTH; GENE	The transcription factor C/EBPalpha regulates early steps of normal granulocyte differentiation since mice with a disruption of the C/EBPalpha gene do not express detectable levels of the granulocyte colony-stimulating factor receptor and produce no neutrophils. We have recently shown that C/EBPalpha function is also impaired in acute myeloid leukemias. However, how the transcriptional activity of C/EBPalpha is regulated both in myelopoiesis and leukemogenesis is not fully understood. The current study demonstrates that activated Ras enhances the ability of C/EBPalpha to transactivate the granulocyte colony-stimulating factor receptor promoter and a minimal promoter containing only C/EBP DNA binding sites. Ras signaling activates C/EBPalpha via the transactivation domain because it enhances the transactivation function of a fusion protein containing a Gal4 DNA binding domain and the C/EBPalpha transactivation domain and does not change C/EBPalpha DNA binding. Ras acts on serine 248 of the C/EBPalpha transactivation domain, because it does not enhance the transactivation function of a C/EBPalpha serine 248 to alanine point mutant. Interestingly, serine 248 of C/EBPa is a protein kinase C (PKC) consensus site, and a PKC inhibitor blocks the activation of C/EBPalpha by Ras. Ras signaling leads to phosphorylation of C/EBPa in vivo. Finally, mutation of serine 248 to alanine obviates the ability of C/EBPalpha to induce granulocytic differentiation. These data suggest a model where Ras signaling enhances the activity of C/EBPalpha to induce granulocytic differentiation by phosphorylation of serine 248.	Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; MIT, Lincoln Lab, Lexington, MA 02420 USA; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Johns Hopkins University; Johns Hopkins Medicine; Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.	gerdbehre@aol.com		Christopeit, Maximilian/0000-0003-4627-0412; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [P01CA072009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72009] Funding Source: Medline; NHLBI NIH HHS [HL 56745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HIBI S, 1993, BLOOD, V81, P1841; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Iida H, 2000, INT J HEMATOL, V71, P153; JIN DI, 1995, MOL CELL BIOL, V15, P693; Johnson R, 1996, MOL CELL BIOL, V16, P4504; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Maher J, 1996, LEUKEMIA, V10, P83; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; REDDY VA, 2002, IN PRESS BLOOD; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Schaich M, 2001, BRIT J HAEMATOL, V112, P300, DOI 10.1046/j.1365-2141.2001.02562.x; SCOTT LM, 1992, BLOOD, V80, P1725; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; WASYLYK C, 1994, ONCOGENE, V9, P3665; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	41	66	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26293	26299		10.1074/jbc.M202301200	http://dx.doi.org/10.1074/jbc.M202301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11978795	hybrid			2022-12-27	WOS:000176908700063
J	Krnajski, Z; Gilberger, TW; Walter, RD; Cowman, AF; Muller, S				Krnajski, Z; Gilberger, TW; Walter, RD; Cowman, AF; Muller, S			Thioredoxin reductase is essential for the survival of Plasmodium falciparum erythrocytic stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE GLUTATHIONE-REDUCTASE; MALARIA-INFECTED ERYTHROCYTES; DISULFIDE BOND FORMATION; RED-BLOOD-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; OXIDATIVE STRESS; GENE-EXPRESSION; ACTIVE-SITE	The human malaria parasite Plasmodium falciparum poses an increasing threat to human health in the tropical regions of the world, and the validation and assessment of possible drug targets is required for the development of new antimalarials. It has been shown that the erythrocytic stages of the parasites, which are responsible for the pathology of the disease in humans, are under enhanced oxidative stress and are particularly vulnerable to exogenous challenges by reactive oxygen species. Therefore it is postulated that the disruption of the antioxidant and/or redox systems of the parasite is a feasible way to interfere with their development during erythrocytic schizogony. In order to test this suggestion thioredoxin reductase (TrxR), an enzyme heavily involved in maintenance of redox homeostasis and antioxidant defense, was knocked out in P. falciparum. was impossible to generate parasites with a disrupted trxR gene suggesting that TrxR is essential for P. falciparum erythrocytic stages. Technical problems were excluded by transfecting a 3' replacement construct, which recombined correctly and transfectants did not show any phenotypic alterations. In order to prove that the trxR knockout was responsible for the lethal phenotype of the null mutants, a co-transfection with both the knockout construct and a construct containing the trxR coding region under the control of the calmodulin promoter was conducted. Despite the disruption of the trxR gene, parasites were viable. In a Southern blot analysis a complicated restriction pattern was obtained, but it was shown by pulse field gel electrophoresis and field inverse gel electrophoreses that only the trxR gene locus on chromosome 9 was targeted by the constructs. It was found that the co-transfected constructs form concatemeric structures prior to integration into the trxR gene locus, which is further supported by plasmid rescue followed by restriction analyses of the plasmids. Northern and Western blot analyses proved that the co-transfectants highly overexpress TrxR from the introduced gene. Our results demonstrate that TrxR is essential for the survival of the erythrocytic stages of P. falciparum.	Univ Dundee, Sch Life Sci, Div Biochem & Mol Microbiol, Dundee DD1 5EH, Scotland; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Bernhard Nocht Inst Trop Med, Dept Biochem Parasitol, D-20359 Hamburg, Germany	University of Dundee; Walter & Eliza Hall Institute; Bernhard Nocht Institut fur Tropenmedizin	Muller, S (corresponding author), Univ Dundee, Sch Life Sci, Div Biochem & Mol Microbiol, MSI-WTB Complex, Dundee DD1 5EH, Scotland.		Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004; Gilberger, Tim-Wolf/0000-0002-7965-8272				Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Buettner C, 1999, J BIOL CHEM, V274, P21598, DOI 10.1074/jbc.274.31.21598; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN G, 1993, J BACTERIOL, V175, P5159, DOI 10.1128/JB.175.16.5159-5167.1993; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Gilberger TW, 1998, FEBS LETT, V425, P407, DOI 10.1016/S0014-5793(98)00270-1; GINSBURG H, 1994, PARASITE, V1, P5, DOI 10.1051/parasite/1994011005; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1977, BIOCHEM SOC T, V5, P611, DOI 10.1042/bst0050611; HUNT NH, 1990, BLOOD CELLS, V16, P499; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kadekoppala M, 2001, MOL BIOCHEM PARASIT, V112, P211, DOI 10.1016/S0166-6851(00)00368-6; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kawazu S, 2001, MOL BIOCHEM PARASIT, V116, P73, DOI 10.1016/S0166-6851(01)00308-5; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kreimer S, 1997, ARCH MICROBIOL, V168, P328, DOI 10.1007/s002030050506; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V113, P303, DOI 10.1016/S0166-6851(01)00219-5; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Luersen K, 2000, BIOCHEM J, V346, P545, DOI 10.1042/0264-6021:3460545; Luersen K, 1999, MOL BIOCHEM PARASIT, V98, P131, DOI 10.1016/S0166-6851(98)00161-3; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Meierjohann S, 2002, BIOCHEM J, V363, P833, DOI 10.1042/0264-6021:3630833; Missirlis F, 2001, CURR BIOL, V11, P1272, DOI 10.1016/S0960-9822(01)00393-1; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; O'Donnell RA, 2001, NUCLEIC ACIDS RES, V29, P716, DOI 10.1093/nar/29.3.716; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; Patankar S, 2001, MOL BIOL CELL, V12, P3114, DOI 10.1091/mbc.12.10.3114; Rahlfs S, 2001, EUR J BIOCHEM, V268, P1404, DOI 10.1046/j.1432-1327.2001.02005.x; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Sambrook J., 2002, MOL CLONING LAB MANU; SIES H, 1989, NATURWISSENSCHAFTEN, V76, P57, DOI 10.1007/BF00396705; Sies H, 1986, ANGEW CHEMIE, V98, P1061, DOI [10.1002/ange.19860981203, DOI 10.1002/ANGE.19860981203]; Thompson JK, 1997, MOL BIOCHEM PARASIT, V87, P49, DOI 10.1016/S0166-6851(97)00041-8; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trenholme KR, 2000, P NATL ACAD SCI USA, V97, P4029, DOI 10.1073/pnas.040561197; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; UMLAS J, 1971, AM J TROP MED HYG, V20, P527, DOI 10.4269/ajtmh.1971.20.527; VENNERSTROM JL, 1988, J MED CHEM, V31, P1269, DOI 10.1021/jm00402a001; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	53	91	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25970	25975		10.1074/jbc.M203539200	http://dx.doi.org/10.1074/jbc.M203539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004069	hybrid			2022-12-27	WOS:000176908700021
J	Seyhan, AA; Vitiello, D; Shields, MT; Burke, JM				Seyhan, AA; Vitiello, D; Shields, MT; Burke, JM			Ribozyme inhibition of Alphavirus replication.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HAIRPIN RIBOZYME; IN-VITRO; EXPRESSION; CLEAVAGE; MECHANISM; LIGATION; SEQUENCE; SINDBIS	A model system to examine the expression and antiviral activity of trans-acting ribozymes in mammalian cells has been developed and evaluated. Hairpin ribozymes were engineered to cleave a specific site, identified by a combinatorial activity-based selection method, within genomic and subgenomic RNA species of Sindbis virus. Transiently transfected cells expressed moderate levels of ribozyme (similar to50,000 molecules/cell) with predominant nuclear localization and a short half-life (23 min). Stable cell lines expressed ribozymes at modest levels (similar to2,000 molecules/cell). Ribozyme-mediated RNA cleavage activity was detected in cell extracts. Clonal cell lines were challenged with recombinant Sindhis virus, and viral replication was examined using plaque formation and green fluorescent protein assays. Significant inhibition of viral replication was observed in cells expressing the active antiviral ribozyme, and lower levels of inhibition in control cells expressing inactive or irrelevant ribozymes. These findings are consistent with a model in which inhibition of viral replication occurs via ribozyme cleavage of viral RNAs, suggesting that ribozymes may represent useful antiviral agents.	Somagen Inc, Santa Cruz, CA 95060 USA; Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Burke, JM (corresponding author), Somagen Inc, Santa Cruz, CA 95060 USA.	John.Burke@uvm.edu	Seyhan, Attila/G-3603-2017	Seyhan, Attila/0000-0002-6264-1482; Seyhan, Attila A/0000-0003-1276-8466	NIAID NIH HHS [AI30534] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030534] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Bertrand E, 1997, RNA, V3, P75; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; Donahue CP, 2000, J MOL BIOL, V295, P693, DOI 10.1006/jmbi.1999.3380; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; HEIDNER HW, 1994, J VIROL, V68, P2683, DOI 10.1128/JVI.68.4.2683-2692.1994; Mahy BWJ, 1996, VIROLOGY METHODS MAN, P35; NOONBERG SB, 1994, NUCLEIC ACIDS RES, V22, P2830, DOI 10.1093/nar/22.14.2830; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; Pinard R, 2001, EMBO J, V20, P6434, DOI 10.1093/emboj/20.22.6434; Pulitz JZ, 1999, J VIROL, V73, P5381, DOI 10.1128/JVI.73.7.5381-5387.1999; Sargueil B, 2000, J BIOL CHEM, V275, P32157, DOI 10.1074/jbc.M005591200; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; Seyhan AA, 1998, NUCLEIC ACIDS RES, V26, P3494, DOI 10.1093/nar/26.15.3494; Simpson DA, 1996, VIROLOGY, V222, P464, DOI 10.1006/viro.1996.0445; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Sun LQ, 2000, PHARMACOL REV, V52, P325; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; Vitiello D, 2000, RNA, V6, P628, DOI 10.1017/S1355838200990964; WENGLER G, 1980, TOGAVIRUSES; Yadava RS, 2001, J MOL BIOL, V309, P893, DOI 10.1006/jmbi.2001.4713; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; Yu Q, 1998, J BIOL CHEM, V273, P23524, DOI 10.1074/jbc.273.36.23524; Yu Q, 1997, Methods Mol Biol, V74, P161	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25957	25962		10.1074/jbc.M111360200	http://dx.doi.org/10.1074/jbc.M111360200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006558	hybrid			2022-12-27	WOS:000176908700019
J	Klein, ATJ; van den Berg, M; Bottger, G; Tabak, HF; Distel, B				Klein, ATJ; van den Berg, M; Bottger, G; Tabak, HF; Distel, B			Saccharomyces cerevisiae acyl-CoA oxidase follows a novel, non-PTS1, import pathway into peroxisomes that is dependent on Pex5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; TARGETING SIGNAL-RECEPTOR; MEMBRANE-PROTEIN PEX13P; ALANINE-GLYOXYLATE AMINOTRANSFERASE-1; PRIMARY HYPEROXALURIA TYPE-1; YEAST YARROWIA-LIPOLYTICA; COENZYME-A OXIDASE; PICHIA-PASTORIS; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE	The peroxisomal protein acyl-CoA oxidase (Pox1p) of Saccharomyces cerevisiae lacks either of the two well characterized peroxisomal targeting sequences known as PTS1 and PTS2. Here we demonstrate that peroxisomal import of Pox1p is nevertheless dependent on binding to Pex5p, the PTS1 import receptor. The interaction between Pex5p and Pox1p, however, involves novel contact sites in both proteins. The interaction region in Pex5p is located in a defined area of the amino-terminal part of the protein outside of the tetratricopeptide repeat domain involved in PTS1 recognition; the interaction site in Pox1p is located internally and not at the carboxyl terminus where a PTS1 is normally found. By making use of pex5 mutants that are either specifically disturbed in binding of PTS1 proteins or in binding of Pox1p, we demonstrate the existence of two independent, Pex5p-mediated import pathways into peroxisomes in yeast as follows: a classical PTS1 pathway and a novel, non-PTS1 pathway for Pox1p.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl						Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; BRUINENBERG PG, 1990, YEAST, V6, P245, DOI 10.1002/yea.320060309; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; deVet ECJM, 1997, BBA-LIPID LIPID MET, V1346, P25, DOI 10.1016/S0005-2760(97)00014-3; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hettema EH, 1998, J CELL BIOL, V142, P421, DOI 10.1083/jcb.142.2.421; HILL DE, 1988, NUCLEIC ACIDS RES, V16, P365, DOI 10.1093/nar/16.1.365; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Klein ATJ, 2001, J BIOL CHEM, V276, P15034, DOI 10.1074/jbc.M010776200; Koller A, 1999, YEAST, V15, P1035, DOI 10.1002/(SICI)1097-0061(199908)15:11<1035::AID-YEA432>3.0.CO;2-1; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lee MS, 1997, PLANT CELL, V9, P185, DOI 10.1105/tpc.9.2.185; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; Luck H, 1963, METHODS ENZYMATIC AN, P885; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Miller J. H, 1972, EXPT MOL GENETICS; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; Motley AM, 2000, EMBO REP, V1, P40, DOI 10.1093/embo-reports/kvd010; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Nohammer C, 2000, EUR J BIOCHEM, V267, P1254, DOI 10.1046/j.1432-1327.2000.01128.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; Wang HJ, 1998, YEAST, V14, P1373, DOI 10.1002/(SICI)1097-0061(199811)14:15<1373::AID-YEA332>3.0.CO;2-1; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Will GK, 1999, MOL CELL BIOL, V19, P2265; Yang XD, 2001, EUR J CELL BIOL, V80, P126, DOI 10.1078/0171-9335-00144; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	81	104	105	3	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25011	25019		10.1074/jbc.M203254200	http://dx.doi.org/10.1074/jbc.M203254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11967269	hybrid			2022-12-27	WOS:000176747000024
J	Ouzzine, M; Gulberti, S; Levoin, N; Netter, P; Magdalou, J; Fournel-Gigleux, S				Ouzzine, M; Gulberti, S; Levoin, N; Netter, P; Magdalou, J; Fournel-Gigleux, S			The donor substrate specificity beta 1,3-glucuronosyltransferase I toward UDP-glucoronic acid is determined by two crucial histidine and arginine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GLUCURONOSYLTRANSFERASE-I; MOLECULAR-CLONING; BIOSYNTHESIS; EXPRESSION; MECHANISM; GLYCOSYLTRANSFERASES; STRUCTURE/FUNCTION; PROTEINS; COMPLEX	The human beta1,3-glucuronosyltransferase I (GlcAT-I) plays a key role in proteoglycan biosynthesis by catalyzing the transfer of glucuronic acid onto the trisaccharide-protein linkage structure Galbeta1,3Galbeta1,4Xylbeta-O-Ser, a prerequisite step for polymerization of glycosaminoglycan chains. In this study, we identified His(308) and Arg(277) residues as essential determinants for the donor substrate (UDP-glucuronic acid) selectivity of the human GleAT-I. Analysis of the UDP-glucuronic acid-binding site by computational modeling in conjunction with site-directed mutagenesis indicated that both residues interact with glucuronic acid. Substitution of His(308) by arginine induced major changes in the donor substrate specificity of GlcAT-I. Interestingly, the H308R mutant was able to efficiently utilize nucleotide sugars LTDP-glucose, LTDP-mannose, and LTDP-N-acetylglucosamine, which are not naturally accepted by the wild-type enzyme, as co-substrate in the transfer reaction. To gain insight into the role of Arg277, site-directed mutagenesis in combination with chemical modification was carried out. Substitution of Are 77 with alanine abrogated the activity of GlcAT-I. Furthermore, the arginine-directed reagent 2,3-butanedione irreversibly inhibited GlcAT-I, which was effectively protected against inactivation by UDP-glucuronic acid but not by UDP-glucose. It is noteworthy that the activity of the H308R mutant toward UDP-glucose was unaffected by the arginine-directed reagent. Our results are consistent with crucial interactions between the His(308). and Arg(277) residues and the glucuronic acid moiety that governs the specificity of GlcAT-1 toward the nucleotide sugar donor substrate.	Univ Henri Poincare Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Henri Poincare Nancy 1, Fac Med, CNRS, UMR 7561, BP 184, F-54505 Vandoeuvre Les Nancy, France.		Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950; levoin, nicolas/0000-0002-7731-736X; GULBERTI, Sandrine/0000-0002-9378-4697				Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Beier L, 2000, PROTEIN ENG, V13, P509, DOI 10.1093/protein/13.7.509; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gouze JN, 2001, ARTHRITIS RHEUM, V44, P351, DOI 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.3.CO;2-D; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Ouzzine M, 2000, MOL PHARMACOL, V58, P1609, DOI 10.1124/mol.58.6.1609; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PLANT AR, 1988, ARCH BIOCHEM BIOPHYS, V262, P181, DOI 10.1016/0003-9861(88)90180-4; Pless D, 1999, DRUG METAB DISPOS, V27, P588; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Senay C, 1997, MOL PHARMACOL, V51, P406; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SURLES MC, 1994, PROTEIN SCI, V3, P198; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VERTEL BM, 1995, TRENDS CELL BIOL, V5, P458, DOI 10.1016/S0962-8924(00)89115-1; Wakarchuk WW, 2001, J BIOL CHEM, V276, P12785, DOI 10.1074/jbc.M011293200; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; ZAKIM D, 1983, J BIOL CHEM, V258, P6430	36	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25439	25445		10.1074/jbc.M201912200	http://dx.doi.org/10.1074/jbc.M201912200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986319	hybrid			2022-12-27	WOS:000176747000078
J	Ueda, H; Matsumoto, H; Takahashi, N; Ogawa, H				Ueda, H; Matsumoto, H; Takahashi, N; Ogawa, H			Psathyrella velutina mushroom lectin exhibits high affinity toward sialocrlycoproteins possessing terminal N-acetylneuraminic acid alpha 2,3-linked to penultimate galactose residues of trisialyl N-glycans - Comparison with other sialic acid-specific lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING-SPECIFICITY; WHEAT-GERM-AGGLUTININ; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEFICIENT GLYCOPROTEIN SYNDROME; LINKED OLIGOSACCHARIDES; MAACKIA-AMURENSIS; SUGAR CHAINS; GLYCOSYLATION ABNORMALITY; H-1-NMR SPECTROSCOPY; RHEUMATOID-ARTHRITIS	A lectin from the fruiting body of the Psathyrella velutina mushroom (PVL) was found to bind specifically to N-acetylneuraminic acid, as well as to GlcNAc (Ueda, H., Kojima, K., Saitoh, T., and Ogawa, H. (1999) FEBS Lett. 448, 75-80). In this study, the glycan sequences that PVL recognizes with high affinity on sialoglycoproteins were revealed. Among sialic acid-specific lectins only PVL could reveal the sialylated N-acetyllactosamine structure of glycoproteins in blotting studies, based on the dual specificity. The affinity of PVL to fetuin was measured by surface plasmon resonance to be 10(7) M-1, which is an order of magnitude higher than those of Sambucus nigra agglutinin and Maackia amurensis mitogen, whereas affinity to asialofetuin was similar to0 and to asialoagalactofetuin was 10(8) M-1, suggesting that PVL exhibits remarkably high affinities toward glycoproteins possessing trisialo- or GlcNAc-exposed glycans. Transferrin was separated into fractions that correspond to the sialylation states on an immobilized PVL column. Transferrin-possessing trisialoglycans containing alpha2,3-linked N-acetylneuraminic acid on the beta1,4-linked GlcNAc branch bound to the PVL column and eluted with GlcNAc; those containing only alpha2,6-linked sialic acids were retarded, whereas other transferrin fractions passed through the column. These results indicate that PVL is a lectin with potential for separation and detection of sialoglycoproteins because of its dual specificity toward sialoglycans and GlcNAc exposed glycans.	Ochanomizu Univ, Grad Sch Humanities & Sci, Dept Adv Biosci, Bunkyo Ku, Tokyo 1128610, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan	Ochanomizu University; Nagoya City University	Ogawa, H (corresponding author), Ochanomizu Univ, Grad Sch Humanities & Sci, Dept Adv Biosci, Bunkyo Ku, 2-1-1 Otsuka, Tokyo 1128610, Japan.							BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; ENDO T, 1992, J BIOL CHEM, V267, P707; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GOLDSTEIN IJ, 1975, BIOCHIM BIOPHYS ACTA, V405, P53, DOI 10.1016/0005-2795(75)90313-X; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; Haseley SR, 1999, ANAL BIOCHEM, V274, P203, DOI 10.1006/abio.1999.4277; Helander A, 2001, CLIN CHEM, V47, P1225; IshiiKarakasa I, 1997, EUR J BIOCHEM, V247, P709, DOI 10.1111/j.1432-1033.1997.00709.x; JAEKEN J, 1996, N COMP BIOC, V30, P457; KAWAGISHI H, 1994, FEBS LETT, V340, P56, DOI 10.1016/0014-5793(94)80172-X; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KOBATA A, 1994, METHOD ENZYMOL, V247, P228; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; KONAMI Y, 1994, FEBS LETT, V342, P334, DOI 10.1016/0014-5793(94)80527-X; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDAL C, 1990, EXPERIENTIA, V46, P433, DOI 10.1007/BF01954221; MATSUKI T, 1992, EXP CLIN IMMUNOGENET, V9, P125; MILLER RL, 1987, METHOD ENZYMOL, V138, P527; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; MONTREUIL J, 1997, GLYCOPROTEINS 2 B, V29, P203; NAKAGAWA H, 1995, ANAL BIOCHEM, V226, P130, DOI 10.1006/abio.1995.1200; Nakane P K, 1975, Methods Enzymol, V37, P133; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; ROTH J, 1996, N COMP BIOC, V30, P413; Rousseau C, 1997, J CELL BIOCHEM, V66, P370, DOI 10.1002/(SICI)1097-4644(19970901)66:3<370::AID-JCB9>3.0.CO;2-M; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; Shiyan SD, 1997, GLYCOCONJUGATE J, V14, P631, DOI 10.1023/A:1018544711767; TAKAHASHI N, 1995, ANAL BIOCHEM, V226, P139, DOI 10.1006/abio.1995.1201; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TSUCHIYA N, 1994, CLIN IMMUNOL IMMUNOP, V70, P47, DOI 10.1006/clin.1994.1009; TSUCHIYA N, 1993, J IMMUNOL, V151, P1137; TURNER GA, 1995, GLYCOCONJUGATE J, V12, P211, DOI 10.1007/BF00731322; Ueda H, 1999, J BIOCHEM-TOKYO, V126, P530, DOI 10.1093/oxfordjournals.jbchem.a022482; Ueda H, 1999, FEBS LETT, V448, P75, DOI 10.1016/S0014-5793(99)00334-8; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; WANG WC, 1988, J BIOL CHEM, V263, P4576; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; YAMASHITA K, 1983, CANCER RES, V43, P5059; YAMASHITA K, 1996, N COMP BIOC, V30, P445; YONEDA A, 1993, EUR J BIOCHEM, V218, P797, DOI 10.1111/j.1432-1033.1993.tb18434.x	47	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24916	24925		10.1074/jbc.M110727200	http://dx.doi.org/10.1074/jbc.M110727200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986305	hybrid			2022-12-27	WOS:000176747000013
J	Waldmann, T; Eckerich, C; Baack, M; Gruss, C				Waldmann, T; Eckerich, C; Baack, M; Gruss, C			The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; MESSENGER-RNA; BINDING; ENHANCER; TRANSLOCATION; MAINTENANCE; REPLICATION; AUTOANTIGEN; ONCOPROTEIN; NUCLEUS	We have investigated the molecular mechanism by which the proto-oncogene protein DEK, an abundant chromatin-associated protein, changes the topology of DNA in chromatin in vitro. Band-shift assays and electron microscopy revealed that DEK induces both intra-and intermolecular interactions between DNA molecules. Binding of the DEK protein introduces constrained positive supercoils both into protein-free DNA and into DNA in chromatin. The induced change in topology is reversible after removal of the DEK protein. As shown by sedimentation analysis and electron microscopy, the DEK-induced positive supercoiling causes distinct structural changes of DNA and chromatin. The observed direct effects of DEK on chromatin folding help to understand the function that this major chromatin protein performs in the nucleus.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Gruss, C (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Claudia.Gruss@uni-konstanz.de	Waldmann, Tanja/A-5145-2010	Waldmann, Tanja/0000-0001-9276-1592				Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Alexiadis V, 2000, GENE DEV, V14, P1308; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GRUSS C, 1995, METH MOL G, V7, P101; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; VOLLENWEIDER HJ, 1975, P NATL ACAD SCI USA, V72, P83, DOI 10.1073/pnas.72.1.83; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wichmann I, 2000, CLIN EXP IMMUNOL, V119, P530, DOI 10.1046/j.1365-2249.2000.01154.x; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	37	81	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24988	24994		10.1074/jbc.M204045200	http://dx.doi.org/10.1074/jbc.M204045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997399	hybrid			2022-12-27	WOS:000176747000021
J	Schwalbe, RA; Rudin, A; Xia, SL; Wingo, CS				Schwalbe, RA; Rudin, A; Xia, SL; Wingo, CS			Site-directed glycosylation tagging of functional Kir2.1 reveals that the putative pore-forming segment is extracellular	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNELS; ASPARAGINE-LINKED OLIGOSACCHARIDES; POTASSIUM CHANNEL; SELECTIVITY FILTER; SIGNATURE SEQUENCE; INWARD RECTIFICATION; UNITARY CONDUCTANCE; MUTATIONS; EXPRESSION; SPERMINE	Inwardly rectifying K+ channels or Kirs are a large gene family and have been predicted to have two transmembrane segments, M1 and M2, intracellular N and C termini, and two extracellular loops, E1 and E2, separated by an intramembranous pore-forming segment, H5. H5 contains a stretch of eight residues that are similar in voltage-dependent K+ channels, Kvs, and this stretch is called the signature sequence of K+ channels. Because mutations in this sequence altered selectivity in Kvs, it has been designated as the selectivity filter. Previously, we used N-glycosylation substitution mutants to map the extracellular topology of a weak inwardly rectifying K+ channel, Kir1.1 or ROMR1, and found that the entire H5 segment was extracellular. We now report utilization of introduced N-glycosylation sites, NX(S/T), at positions Ser(128) in El, and Gln(140), Ileu(143), and Phe(147) in the H5 sequence of a strong inwardly rectifying K+ channel, Kir2.1. Furthermore, we show that biotinylated channel proteins with N-linked oligosaccharides attached at positions 140 and 143 in the signature sequence are located at the cell surface. Mutant channels were functional as detected by whole-cell and single-channel recordings. Unlike Kir1.1, position Lys(117) was not occupied. We conclude that, for yet another K+ channel, the invariant G(Y/F)G sequence is extracellular rather than intramembranous.	Univ Florida, Dept Med, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA; Dept Vet Affairs Med Ctr, Nephrol Sect, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Schwalbe, RA (corresponding author), Univ Florida, Dept Med, Div Nephrol Hypertens & Transplantat, Box 100224, Gainesville, FL 32610 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055404, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052990] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55404, HL36930] Funding Source: Medline; NIDDK NIH HHS [DK52990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bianchi L, 1996, J BIOL CHEM, V271, P6114, DOI 10.1074/jbc.271.11.6114; Dart C, 1998, J PHYSIOL-LONDON, V511, P25, DOI 10.1111/j.1469-7793.1998.025bi.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kubo Y, 1998, FEBS LETT, V435, P69, DOI 10.1016/S0014-5793(98)01038-2; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Picones A, 2001, BIOPHYS J, V81, P2035, DOI 10.1016/S0006-3495(01)75853-5; Repunte VP, 1999, EMBO J, V18, P3317, DOI 10.1093/emboj/18.12.3317; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SAMBROOK J, 1992, MOL CLONING LAB MANU; Schwalbe RA, 1996, J BIOL CHEM, V271, P24201, DOI 10.1074/jbc.271.39.24201; Schwalbe RA, 1997, J BIOL CHEM, V272, P25217, DOI 10.1074/jbc.272.40.25217; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; So I, 2001, J PHYSIOL-LONDON, V531, P37, DOI 10.1111/j.1469-7793.2001.0037j.x; Splitt H, 2000, FEBS LETT, V472, P83, DOI 10.1016/S0014-5793(00)01429-0; Wischmeyer E, 2000, FEBS LETT, V466, P115, DOI 10.1016/S0014-5793(99)01769-X; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24382	24389		10.1074/jbc.M201668200	http://dx.doi.org/10.1074/jbc.M201668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11991952	hybrid			2022-12-27	WOS:000176611800055
J	Chavakis, T; Boeckel, N; Santoso, S; Voss, R; Isordia-Salas, I; Pixley, RA; Morgenstern, E; Colman, RW; Preissner, KT				Chavakis, T; Boeckel, N; Santoso, S; Voss, R; Isordia-Salas, I; Pixley, RA; Morgenstern, E; Colman, RW; Preissner, KT			Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIB-IIIA; UROKINASE RECEPTOR; BINDING-PROTEIN; CLOT FORMATION; LIGHT CHAIN; VITRONECTIN BINDS; ANIONIC SURFACE; S-PROTEIN	Proteolytic cleavage of single chain high molecular weight kininogen (HK) by kallikrein releases the short-lived vasodilator bradykinin and leaves behind two-chain high molecular weight kininogen (HKa). HKa and particularly its His-Gly-Lys-rich domain 5 have been previously reported to exert anti-adhesive properties by binding to the extracellular matrix protein vitronectin (VN). In this study the ability of HKa and domain 5 to interfere with platelet adhesion and aggregation was investigated. In a purified system HKa and particularly domain 5 but not HK inhibited the binding of VN to the alpha(IIb)beta(3) integrin, whereas the binding of fibrinogen to this integrin was not affected. The region Gly-486-Lys-502 from the carboxyl terminus of the domain 5 was identified as responsible for inhibition of the VN-alpha(IIb)beta(3)-integrin interaction, as this portion was also found to mediate kininogen binding to VN. Through these interactions, HKa, the isolated domain 5, and the peptide Gly-486-Lys502 abrogated the alphaIIbbeta(3)-integrin-dependent adhesion of human platelets to VN but not to fibrinogen. The codistribution of VN and HKa at sites of ex vivo platelet aggregation was demonstrated by transmission immune electron microscopy, indicating that the described interaction is likely to take place in vivo. Moreover, domain 5 and the peptide Gly-486-Lys-502 dose-dependently blocked platelet aggregation, resembling the inhibitory effect of monoclonal antibody 13111 against multimeric VN. Finally, treatment of mice with isolated domain 5 resulted in a significantly prolonged tail bleeding time. Taken together, our data emphasize the inhibitory role of HK domain 5 on platelet adhesion and aggregation; new antithrombotic compounds may become available on the basis of peptide Gly-486-Lys-502 of HK domain 5.	Univ Giessen, Fachbereich Humanmed, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med, D-35392 Giessen, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany; Univ Saarland, Dept Med Biol, D-66421 Homburg, Germany; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen; Saarland University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Preissner, KT (corresponding author), Univ Giessen, Fachbereich Humanmed, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	klaus.t.preissner@biochemie.med.uni-giessen.de	Chavakis, Triantafyllos/ABE-8845-2020		NCI NIH HHS [CA63938] Funding Source: Medline; NHLBI NIH HHS [HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BRADFORD HN, 1993, J BIOL CHEM, V268, P26546; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; COLLINS WE, 1987, ANN NY ACAD SCI, V516, P291, DOI 10.1111/j.1749-6632.1987.tb33049.x; Colman RW, 1999, ARTERIOSCL THROM VAS, V19, P2245, DOI 10.1161/01.ATV.19.9.2245; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; deBoer HC, 1995, J BIOL CHEM, V270, P30733, DOI 10.1074/jbc.270.51.30733; DEGROOT PG, 1996, VASCULAR CONTROL HAE, P147; DELACADENA RA, 1994, THROMB HAEMOSTASIS, V72, P125; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Eitzman DT, 2000, BLOOD, V95, P577, DOI 10.1182/blood.V95.2.577; Fay WP, 1999, BLOOD, V93, P1825, DOI 10.1182/blood.V93.6.1825.406k37_1825_1830; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Fox JEB, 1999, THROMB HAEMOSTASIS, V82, P385; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Hasan AAK, 1996, CIRCULATION, V94, P517, DOI 10.1161/01.CIR.94.3.517; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HESS S, 1995, THROMB HAEMOSTASIS, V74, P258; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Konstantinides S, 2001, CIRCULATION, V103, P576, DOI 10.1161/01.CIR.103.4.576; KOST C, 1992, J BIOL CHEM, V267, P12098; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; MOHRI H, 1991, AM J CLIN PATHOL, V96, P605, DOI 10.1093/ajcp/96.5.605; Morgenstern E, 2001, ANN NY ACAD SCI, V936, P449; Morgenstern E, 2001, EUR J CELL BIOL, V80, P87, DOI 10.1078/0171-9335-00138; NICULESCU F, 1987, ATHEROSCLEROSIS, V65, P1, DOI 10.1016/0021-9150(87)90002-5; NISHIKAWA K, 1992, BLOOD, V80, P1980; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; Phillips DR, 1998, ARCH PATHOL LAB MED, V122, P811; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SCHMAIER AH, 1986, BLOOD, V67, P119; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; Sheng N, 2000, BLOOD, V95, P3788; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TAIT JF, 1987, J BIOL CHEM, V262, P11651; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; Verheul HMW, 2000, BLOOD, V96, P4216, DOI 10.1182/blood.V96.13.4216; WATKINS SC, 1990, HISTOCHEM J, V22, P507, DOI 10.1007/BF01007236; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; Wohn KD, 1999, BRIT J HAEMATOL, V104, P901, DOI 10.1046/j.1365-2141.1999.01242.x; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com	57	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23157	23164		10.1074/jbc.M202529200	http://dx.doi.org/10.1074/jbc.M202529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970955	hybrid			2022-12-27	WOS:000176475700010
J	Colston, JT; Chandrasekar, B; Freeman, GL				Colston, JT; Chandrasekar, B; Freeman, GL			A novel peroxide-induced calcium transient regulates interleukin-6 expression in cardiac-derived fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; MYOCARDIAL-ISCHEMIA; GENE-EXPRESSION; PROINFLAMMATORY CYTOKINE; STUNNED MYOCARDIUM; RAT-HEART; REPERFUSION; ENTRY	Reperfusion of ischemic myocardium leads to a local burst of free radicals, increased [Ca2+](i) and the release of proinflammatory cytokines. The purpose of this study was to determine whether brief exposure of cardiac fibroblasts to H2O2 is associated with transient changes in [Ca2+](i) levels and whether this stimulus is sufficient to induce interleukin-6 (IL-6) expression. Cardiac derived fibroblasts were isolated from adult male rats and cultured under standard conditions. Individual coverslip-attached fibroblasts were loaded with the calcium probe Fura-2/AM and exposed to a single 3-min pulse of 100 mum H2O2. In addition, low passage cultures were exposed to a pulse of H2O2 and assayed for IL-6 expression. A brief exposure of H2O2 led to a large intracellular Ca2+ transient with a mean transient magnitude of 318 +/- 28 nm (mean +/- S.D., n = 12). Stimulation in the absence of [Ca2+](o) led to a 59% reduction in mean transient magnitude (129 +/- 23 nm, n = 10, p < 0.001), whereas pretreatment with the inositol 1,4,5-trisphosphate receptor blocker xestospongin C resulted in a 37% reduction (199 +/- 25 nM, n = 10, p < 0.01). Cells treated with xestospongin C and stimulated in the absence of [Ca2+](o) did not exhibit a Ca2+ transient. Time-dependent IL-6 release was significantly elevated by 4 h (368 +/- 64 pg/mg protein, p < 0.01) and increased further by 24 h (1030 +/- 76 pg/mg protein). The depletion of cellular Ca2+ by pretreatment with thapsigargin in the absence of [Ca2+](o). attenuated H2O2-induced IL-6 mRNA expression while blocking protein release. These data show that the exposure of cardiac fibroblasts to a brief pulse of physiological levels of H2O2 resulted in a large Ca2+ transient with intracellular and extracellular Ca2+ contributions. Furthermore, brief H2O2 exposure led to calcium-dependent IL-6 expression.	Univ Texas, Hlth Sci Ctr, Div Cardiol, Audie L Murphy Div, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Freeman, GL (corresponding author), Univ Texas, Dept Med Cardiol, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.							BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOLLI R, 1987, AM J PHYSIOL, V253, pH1372, DOI 10.1152/ajpheart.1987.253.6.H1372; Chandrasekar B, 1998, BBA-MOL BASIS DIS, V1406, P91, DOI 10.1016/S0925-4439(97)00062-8; Chandrasekar B, 1997, CLIN EXP IMMUNOL, V108, P346, DOI 10.1046/j.1365-2249.1997.d01-1017.x; Chandrasekar B, 2001, CIRCULATION, V103, P2296; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; CHARLAT ML, 1989, J AM COLL CARDIOL, V13, P185, DOI 10.1016/0735-1097(89)90569-X; Chen JJ, 2001, J MOL CELL CARDIOL, V33, P1919, DOI 10.1006/jmcc.2001.1454; Colston JT, 2000, J AM COLL CARDIOL, V35, p331A; Colston JT, 1998, CARDIOVASC RES, V38, P158, DOI 10.1016/S0008-6363(97)00323-4; DIGLIO CA, 1988, TISSUE CELL, V20, P477, DOI 10.1016/0040-8166(88)90051-1; EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183; Frangogiannis N G, 1996, EXS, V76, P263; GROSS GJ, 1986, AM J PHYSIOL, V250, P372; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; McDonough JL, 1999, CIRC RES, V84, P9; NAG AC, 1980, CYTOBIOS, V28, P41; National Institute of Health (NIH), 1985, DHEW PUBL; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Rosado JA, 2000, J PHYSIOL-LONDON, V529, P159, DOI 10.1111/j.1469-7793.2000.00159.x; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V280, pH344, DOI 10.1152/ajpheart.2001.280.1.H344; Shivakumar K, 2001, J MOL CELL CARDIOL, V33, P373, DOI 10.1006/jmcc.2000.1309; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; VARANI J, 1989, AM J PATHOL, V135, P435; Wollert K C, 2001, Heart Fail Rev, V6, P95; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	33	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23477	23483		10.1074/jbc.M108676200	http://dx.doi.org/10.1074/jbc.M108676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11983681	hybrid			2022-12-27	WOS:000176475700051
J	Yasukawa, K; Sawamura, D; McMillan, JR; Nakamura, H; Shimizu, H				Yasukawa, K; Sawamura, D; McMillan, JR; Nakamura, H; Shimizu, H			Dominant and recessive compound heterozygous mutations in epidermolysis bullosa simplex demonstrate the role of the stutter region in keratin intermediate filament assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-STRUCTURE; POINT MUTATIONS; TRANSGENIC MICE; DOWLING-MEARA; EXPRESSION; DISEASE; SEVERITY; GENE; HYPERKERATOSIS; ABNORMALITIES	Keratin intermediate filaments are important cytoskeletal structural proteins involved in maintaining cell shape and function. Mutations in the epidermal keratin genes, keratin 5 or keratin 14 lead to the disruption of keratin filament assembly, resulting in an autosomal dominant inherited blistering skin disease, epidermolysis bullosa simplex (EBS). We investigated a large EBS kindred who exhibited a markedly heterogeneous clinical presentation and detected two distinct keratin 5 mutations in the proband, the most severely affected. One missense mutation (E170K) in the highly conserved helix initiation peptide sequence of the 1A rod domain was found in all the affected family members. In contrast, the other missense mutation (E418K) was found only in the proband. The E418K mutation was located in the stutter region, an interruption in the heptad repeat regularity, whose function as yet remains unclear. We hypothesized that this mutated stutter allele was clinically silent when combined with the wild type allele but aggravates the clinical severity of EBS caused by the E170K mutation on the other allele. To confirm this in vitro, we transfected mutant keratin 5 cDNA into cultured cells. Although only 12.7% of the cells transfected with the E170K mutation alone showed disrupted keratin filament aggregations, significantly more cells (30-0% cotransfected with both E170K and E418K mutations demonstrated keratin aggregation p < 0.05). These transfection assay results corresponded to the heterogeneous clinical findings of the EBS patient in this kindred. We have identified the first case of both compound heterozygous dominant (E170K) and recessive (E418K) mutations in any keratin gene and confirmed the significant involvement of the stutter region in the assembly and organization of the keratin intermediate filament network in vitro.	Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Shimizu, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	shimizu@med.hokudai.ac.jp						ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BEAUDET AL, 2000, METABOLIC MOL BASES, V1, P3; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Brown JH, 1996, PROTEINS, V26, P134; CHAN YM, 1994, J CELL SCI, V107, P765; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Fine JD, 2000, J AM ACAD DERMATOL, V42, P1051, DOI 10.1016/S0190-9622(00)90302-5; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1994, J INVEST DERMATOL, V103, pS25, DOI 10.1111/1523-1747.ep12398924; FUCHS EV, 1999, EPIDERMOLYSIS BULLOS, P280; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 1998, Subcell Biochem, V31, P319; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; Hu ZL, 1997, J INVEST DERMATOL, V109, P360, DOI 10.1111/1523-1747.ep12336051; Hut PHL, 2000, J INVEST DERMATOL, V114, P616, DOI 10.1046/j.1523-1747.2000.00928.x; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; Kobayashi S, 1996, FEBS LETT, V386, P149, DOI 10.1016/0014-5793(96)00393-6; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; Liovic M, 2001, J INVEST DERMATOL, V116, P964, DOI 10.1046/j.1523-1747.2001.01334.x; Livingston RJ, 2001, J INVEST DERMATOL, V116, P970, DOI 10.1046/j.1523-1747.2001.01324.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NORTH ACT, 1994, PROTEINS, V20, P174, DOI 10.1002/prot.340200207; RUGG EL, 1993, NAT GENET, V5, P294, DOI 10.1038/ng1193-294; Sato-Matsumura KC, 2002, ARCH DERMATOL, V138, P269, DOI 10.1001/archderm.138.2.269; Shimizu H, 1999, J INVEST DERMATOL, V113, P419, DOI 10.1046/j.1523-1747.1999.00713.x; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1994, J INVEST DERMATOL, V103, pS19, DOI 10.1111/1523-1747.ep12398900; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stephens K, 1997, J INVEST DERMATOL, V108, P349, DOI 10.1111/1523-1747.ep12286486; STEPHENS K, 1993, J INVEST DERMATOL, V101, P240, DOI 10.1111/1523-1747.ep12365079; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563	42	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23670	23674		10.1074/jbc.M200974200	http://dx.doi.org/10.1074/jbc.M200974200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973334	hybrid			2022-12-27	WOS:000176475700075
J	Fujita, T; Meguro, T; Fukuyama, R; Nakamuta, H; Koida, M				Fujita, T; Meguro, T; Fukuyama, R; Nakamuta, H; Koida, M			New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells - Checkpoint of modulation by cyclic AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-DEPENDENT ACTIVATION; NERVE GROWTH-FACTOR; B-RAF; OSTEOBLASTIC CELLS; MAP KINASE; PTH/PTHRP RECEPTOR; COUPLED RECEPTORS; TRANSGENIC MICE; IN-VITRO	cAMP signaling, activated by extracellular stimuli such as parathyroid hormone, has cell type-specific effects important for cellular proliferation and differentiation in bone cells. Recent evidence of a second enzyme target for cAMP suggests divergent effects on extracellular-regulated kinase (ERK) activity depending on Epac/Rap1/B-Raf signaling. We investigated the molecular mechanism of the dual functionality of cAMP on cell proliferation in clonal bone cell types. MC3T3-E1 and ATDC5, but not MG63, express a 95-kDa isoform of B-Raf. cAMP stimulated Ras-independent and Rap1-dependent ERK phosphorylation and cell proliferation in B-Raf-expressing cells, but inhibited growth in B-Raf-lacking cells. The mitogenic action of cAMP was blocked by the ERK pathway inhibitor PD98059. In B-Raf-transduced MG63 cells, cAMP stimulated ERK activation and cell proliferation. Thus, B-Raf is the dominant molecular switch that permits differential cAMP-dependent regulation of ERK with important implications for cell proliferation in bone cells. These findings might explain the dual functionality of parathyroid hormone on osteoblastic cell proliferation.	Setsunan Univ, Fac Pharmaceut Sci, Dept Pharmacol, Hirakata, Osaka 5730101, Japan	Setsunan University	Fujita, T (corresponding author), Setsunan Univ, Fac Pharmaceut Sci, Dept Pharmacol, Nagaotoge Cho 45-1, Hirakata, Osaka 5730101, Japan.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1983, EMBO J, V14, P3475; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Dempster DW, 1999, J CLIN ENDOCR METAB, V84, P1562, DOI 10.1210/jc.84.5.1562; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Fujita T, 2001, JPN J PHARMACOL, V86, P405, DOI 10.1254/jjp.86.405; Fujita T, 2001, JPN J PHARMACOL, V86, P86, DOI 10.1254/jjp.86.86; Fujita T, 2001, JPN J PHARMACOL, V85, P278, DOI 10.1254/jjp.85.278; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HABENER JF, 1984, PHYSIOL REV, V64, P985, DOI 10.1152/physrev.1984.64.3.985; Hilliker S, 1996, BONE, V19, P469, DOI 10.1016/S8756-3282(96)00230-X; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1999, MOL CELL BIOL, V19, P6057; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756-3282(95)00427-0; Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10304; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Takuma K, 2000, EUR J PHARMACOL, V399, P1, DOI 10.1016/S0014-2999(00)00334-4; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; WANG ZQ, 1995, CANCER RES, V55, P6244; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	59	103	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22191	22200		10.1074/jbc.M110364200	http://dx.doi.org/10.1074/jbc.M110364200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956184	hybrid			2022-12-27	WOS:000176313600013
J	Guillen, C; Martinez, P; de Gortazar, AR; Martinez, ME; Esbrit, P				Guillen, C; Martinez, P; de Gortazar, AR; Martinez, ME; Esbrit, P			Both n- and c-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ENDOCHONDRAL BONE-FORMATION; KINASE-C; OSTEOSARCOMA CELLS; IN-VIVO; TRANSCRIPTION FACTOR; OVARIECTOMIZED RATS; PTH/PTHRP RECEPTOR; GENE-EXPRESSION; PEPTIDE	Parathyroid hormone (PTH)-related protein (PTHrP) seems to affect bone resorption by interaction with bone cytokines, among them interleukin-6 (IL-6). Recent studies suggest that nuclear factor (NF)-kappaB activation has an important role in bone resorption. We assessed whether the N-terminal fragment of PTHrP, and its C-terminal region, unrelated to PTH, can activate NF-kappaB, and its relationship with IL-6 gene induction in different rat and human osteoblastic cell preparations. Here we present molecular data demonstrating that both PTHrP (136) and PTHrP (107-139) activate NF-kappaB, leading to an increase in IL-6 mRNA, in these cells. Using anti-p65 and anti-p50 antibodies, we detected the presence of both proteins in the activated NF-kappaB complex. This effect induced by either the N- or C-terminal PTHrP domain in osteoblastic cells appears to occur by different intracellular mechanisms, involving protein kinase A or intracellular Ca2+/protein kinase C activation, respectively. However, the effect of each peptide alone did not increase further when added together. Our findings lend support to the hypothesis that the C-terminal domain of PTHrP, in a manner similar to its N-terminal fragment, might stimulate bone resorption. These studies also provide further insights into the putative role of PTHrP as a modulator of bone remodeling.	Fdn Jimeenez Diaz, Res Unit, Bone & Mineral Metab Lab, Madrid 28040, Spain; Hosp La Paz, Div Biochem, Madrid 28046, Spain	Hospital Universitario La Paz	Esbrit, P (corresponding author), Fdn Jimeenez Diaz, Res Unit, Bone & Mineral Metab Lab, Avda Reyes Catolicos 2, Madrid 28040, Spain.		Guillén, Carlos/J-9728-2014; Gortazar, Arancha/G-5385-2017	Guillén, Carlos/0000-0002-9370-6314; Gortazar, Arancha/0000-0001-5072-3141; Guillen, Carlos/0000-0003-2717-1929				Ali NN, 1999, FEBS LETT, V460, P315, DOI 10.1016/S0014-5793(99)01370-8; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bilbe G, 1996, BONE, V19, P437, DOI 10.1016/S8756-3282(96)00254-2; Cornish J, 1997, ENDOCRINOLOGY, V138, P1299, DOI 10.1210/en.138.3.1299; De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096; de Miguel F, 1999, J AM SOC NEPHROL, V10, P796; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo-129-4-1762; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Frolik CA, 1999, J BONE MINER RES, V14, P163, DOI 10.1359/jbmr.1999.14.2.163; GAGNON L, 1993, J BONE MINER RES, V8, P497; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENFIELD EM, 1995, J CLIN INVEST, V96, P1238, DOI 10.1172/JCI118157; Hehner SP, 1999, J IMMUNOL, V163, P5617; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Itoh K, 2000, J BONE MINER RES, V15, P1766, DOI 10.1359/jbmr.2000.15.9.1766; Jimi E, 1996, J BIOL CHEM, V271, P4605; KAJI H, 1995, ENDOCRINOLOGY, V136, P842, DOI 10.1210/en.136.3.842; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756-3282(97)00180-4; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kozawa O, 1998, BONE, V22, P355, DOI 10.1016/S8756-3282(97)00293-7; Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; Martinez ME, 1997, J BONE MINER RES, V12, P778, DOI 10.1359/jbmr.1997.12.5.778; Nagy Z, 2001, J BONE MINER RES, V16, P1220, DOI 10.1359/jbmr.2001.16.7.1220; Onyia JE, 1997, J CELL BIOCHEM, V67, P265, DOI 10.1002/(SICI)1097-4644(19971101)67:2<265::AID-JCB12>3.0.CO;2-E; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Quinn CO, 2000, ENDOCRINE, V12, P227, DOI 10.1385/ENDO:12:3:227; RIXON RH, 1994, J BONE MINER RES, V9, P1179; ROUFFET J, 1994, REPROD NUTR DEV, V34, P473, DOI 10.1051/rnd:19940508; Sanders JL, 2000, J BONE MINER RES, V15, P885, DOI 10.1359/jbmr.2000.15.5.885; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; SUGIMOTO T, 1993, J BONE MINER RES, V8, P451; Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Valin A, 1997, J CELL PHYSIOL, V170, P209, DOI 10.1002/(SICI)1097-4652(199702)170:2<209::AID-JCP13>3.3.CO;2-Y; Valin A, 1999, CALCIFIED TISSUE INT, V65, P148, DOI 10.1007/s002239900674; Valin A, 2001, ENDOCRINOLOGY, V142, P2752, DOI 10.1210/en.142.7.2752; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WHITFIELD JF, 1994, J CELL PHYSIOL, V158, P518, DOI 10.1002/jcp.1041580317; Yang CH, 1997, PROBABILIST ENG MECH, V12, P1, DOI 10.1016/S0266-8920(96)00009-4	53	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28109	28117		10.1074/jbc.M111013200	http://dx.doi.org/10.1074/jbc.M111013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12000745	hybrid			2022-12-27	WOS:000177189800067
J	Chang, TS; Jeong, W; Choi, SY; Yu, SQ; Kang, SW; Rhee, SG				Chang, TS; Jeong, W; Choi, SY; Yu, SQ; Kang, SW; Rhee, SG			Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN-TYROSINE PHOSPHATASES; MAMMALIAN PEROXIREDOXIN; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; REVERSIBLE INACTIVATION; THIOREDOXIN PEROXIDASE; REDUCE PEROXIDES; OXYGEN; CDC2	Hydrogen peroxide is implicated as an intracellular messenger in various cellular responses such as proliferation and differentiation. Peroxiredoxin (Prx) I is a member of the peroxiredoxin family of peroxidases and contains a consensus site (Thr(90)-Pro-Lys-Lys) for phosphorylation by cyclin-dependent kinases (CDKs). This protein has now been shown to be phosphorylated specifically on Thr(90) by several CDKs, including Cdc2, in vitro. Phosphorylation of Prx I on Thr(90) reduced the peroxidase activity of this protein by 80%. The phosphorylation of Prx I in HeLa cells was monitored with the use of antibodies specific for Prx I phosphorylated on Thr(90). Immunoblot analysis with these antibodies of HeLa cells arrested at various stages of the cell cycle revealed that Prx I phosphorylation occurs in parallel with the activation of Cdc2; Prx I phosphorylation was thus marked during mitosis but virtually undetectable during interphase. Furthermore, when Cdc2 expression was reduced by RNA interference with cognate small interfering RNAs, Prx I phosphorylation was not observed in the cells synchronized in mitotic phase. The cytosolic location of Prx I likely prevents its interaction with activated CDKs until after the breakdown of the nuclear envelope during mitosis, when Cdc2 is the CDK that is most active. Phosphorylation of Prx I on Thr90 both in vitro and in vivo was blocked by roscovitine, an inhibitor of CDKs. These results suggest that Cdc2-mediated phosphorylation and inactivation of Prx I and the resulting intracellular accumulation of H2O2 might be important for progression of the cell cycle.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University	Rhee, SG (corresponding author), Bldg 50,Rm 3523,S Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov						Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cunnick JM, 1998, BIOCHEM MOL BIOL INT, V45, P887; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Harborth J, 2001, J CELL SCI, V114, P4557; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Ichimiya S, 1997, DNA CELL BIOL, V16, P311, DOI 10.1089/dna.1997.16.311; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREK W, 1995, METHOD ENZYMOL, V254, P114; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mizusawa H, 2000, NEUROSCI LETT, V283, P57, DOI 10.1016/S0304-3940(00)00910-1; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oberley TD, 2001, FREE RADICAL BIO MED, V30, P412, DOI 10.1016/S0891-5849(00)00486-X; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rhee S.G., 2000, SCI STKE; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; RIME H, 1995, EXP CELL RES, V219, P29, DOI 10.1006/excr.1995.1201; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YOU JS, 1995, J CELL PHYSIOL, V164, P424, DOI 10.1002/jcp.1041640223; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	55	200	222	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25370	25376		10.1074/jbc.M110432200	http://dx.doi.org/10.1074/jbc.M110432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986303	hybrid			2022-12-27	WOS:000176747000069
J	Hess, MT; Gupta, RD; Kolodner, RD				Hess, MT; Gupta, RD; Kolodner, RD			Dominant Saccharomyces cerevisiae msh6 mutations cause increased mispair binding and decreased dissociation from mispairs by Msh2-Msh6 in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; ESCHERICHIA-COLI MUTS; CELL NUCLEAR ANTIGEN; HMUTS-ALPHA; BASE PAIRS; DUPLEX OLIGONUCLEOTIDES; TRANSLOCATION MECHANISM; SUBUNIT INTERACTIONS; RECOGNITION COMPLEX; SPECIFICALLY BINDS	A previous study described four dominant msh6 mutations that interfere with both the Msh2-Msh6 and Msh2-Msh3 mismatch recognition complexes (Das Gupta, R., and Kolodner, R. D. (2000) Nat. Genet. 24, 53-56). Modeling predicted that two of the amino acid substitutions (G1067D and G1142D) interfere with protein-protein interactions at the ATP-binding site-associated dimer interface, one (S1036P) similarly interferes with protein-protein interactions and affects the Msh2 ATP-binding site, and one (H1096A) affects the Msh6 ATP-binding site. The ATPase activity of the Msh2-Msh6-G1067D and Msh2-Msh6-G1142D complexes was inhibited by GT, +A, and +AT mispairs, and these complexes showed increased binding to GT and +A mispairs in the presence of ATP. The ATPase activity of the Msh2-Msh6-S1036P complex was inhibited by a GT mispair, and it bound the GT mispair in the presence of ATP, whereas its interaction with insertion mispairs was unchanged compared with the wild-type complex. The ATPase activity of the Msh2-Msh6-H1096A complex was generally attenuated, and its mispair-binding behavior was unaffected. These results are in contrast to those obtained with the wild-type Msh2-Msh6 complex, which showed mispair-stimulated ATPase activity and ATP inhibition of mispair binding. These results indicate that the dominant msh6 mutations cause more stable binding to mispairs and suggest that there may be differences in how base base and insertion mispairs are recognized.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.		Classen, Scott/AAY-8176-2020		NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA92584] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Das Gupta R, 2000, NAT GENET, V24, P53, DOI 10.1038/71684; Drotschmann K, 2001, J BIOL CHEM, V276, P46225, DOI 10.1074/jbc.C100450200; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dufner P, 2000, J BIOL CHEM, V275, P36550, DOI 10.1074/jbc.M005987200; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lynch HT, 1999, J MED GENET, V36, P801; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Schofield MJ, 2001, J BIOL CHEM, V276, P45505, DOI 10.1074/jbc.C100449200; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Yamamoto A, 2000, NUCLEIC ACIDS RES, V28, P3564, DOI 10.1093/nar/28.18.3564	68	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25545	25553		10.1074/jbc.M202282200	http://dx.doi.org/10.1074/jbc.M202282200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986324	hybrid			2022-12-27	WOS:000176747000091
J	Inoue, Y; Hayhurst, GP; Inoue, J; Mori, M; Gonzalez, FJ				Inoue, Y; Hayhurst, GP; Inoue, J; Mori, M; Gonzalez, FJ			Defective ureagenesis in mice carrying a liver-specific disruption of he-datocvte nuclear factor 4 alpha (HNF4 alpha) - HNF4 alpha regulates ornithine transcarbamylase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTORS; HEMOPHILIA-B LEYDEN; FACTOR-IX PROMOTER; GENE-EXPRESSION; BINDING-SITE; CYCLE ENZYMES; VISCERAL ENDODERM; RESPONSE ELEMENT; C/EBP-BETA; CELL	Hepatocyte nuclear factor 4alpha (HNF4alpha) regulates the expression of many genes preferentially expressed in liver. HNF4alpha-null mice die during embryogenesis precluding the analysis of its function in the adult. To circumvent this problem, liver-specific HNF4alpha-null mice were produced. Mice lacking hepatic HNF4alpha expression exhibited increased serum ammonia and reduced serum urea. This disruption in ureagenesis may be explained by a marked decrease in expression and activity of hepatic ornithine transcarbamylase (OTC). To determine the molecular mechanisms involved in transcriptional regulation of the mouse OTC gene, the OTC promoter region was analyzed. Sequence analysis revealed the presence of two putative HNF4alpha-binding sites in the mouse OTC promoter region. By using transient transfection analysis, it was established that high levels of promoter activity were dependent on both HNF4alpha-binding sites and the expression of HNF4alpha. Furthermore, the proximal HNF4alpha-binding site was found to be more important than the distal. one for transactivating OTC promoter. These data demonstrate that HNF4alpha is critical for urea homeostasis by direct regulation of the OTC gene in vivo.	NCI, Div Basic Sci, Lab Metab, NIH, Bethesda, MD 20892 USA; Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kumamoto University	Gonzalez, FJ (corresponding author), NCI, Div Basic Sci, Lab Metab, NIH, 9000 Rockville Pike,Rm 3E-24,Bldg 37, Bethesda, MD 20892 USA.		Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482				[Anonymous], 2001, NUCL RECEPTORS GENET; Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; Bailly A, 1998, J CELL SCI, V111, P2411; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; BULLA GA, 1994, MOL CELL BIOL, V14, P7086, DOI 10.1128/MCB.14.11.7086; CARTER ME, 1993, J BIOL CHEM, V268, P13805; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Duncan SA, 1997, DEVELOPMENT, V124, P279; Garnier G, 1996, J BIOL CHEM, V271, P30205, DOI 10.1074/jbc.271.47.30205; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; GRISOLIA S, 1952, J BIOL CHEM, V198, P561; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HODGES PE, 1989, P NATL ACAD SCI USA, V86, P4142, DOI 10.1073/pnas.86.11.4142; IKEMOTO M, 1990, BIOCHEM J, V270, P697, DOI 10.1042/bj2700697; Inoue Y, 2001, INT J MOL MED, V8, P481; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Kimura T, 2001, FEBS LETT, V494, P105, DOI 10.1016/S0014-5793(01)02320-1; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LARGILLIERE C, 1995, LANCET, V345, P1113, DOI 10.1016/S0140-6736(95)90843-9; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Matsuda I, 1997, AM J MED GENET, V71, P378, DOI 10.1002/(SICI)1096-8628(19970905)71:4<378::AID-AJMG2>3.0.CO;2-Q; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MORI M, 1979, P NATL ACAD SCI USA, V76, P5071, DOI 10.1073/pnas.76.10.5071; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; Naka H, 1996, BRIT J HAEMATOL, V92, P231, DOI 10.1046/j.1365-2141.1995.269804.x; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; Qureshi IA, 1997, ADV EXP MED BIOL, V420, P143; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; Tuchman M, 1996, HUM GENET, V97, P274, DOI 10.1007/BF02185751; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; VERES G, 1986, J BIOL CHEM, V261, P7588; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Ye XH, 1996, J BIOL CHEM, V271, P3639; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826	57	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25257	25265		10.1074/jbc.M203126200	http://dx.doi.org/10.1074/jbc.M203126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994307	hybrid			2022-12-27	WOS:000176747000054
J	Kassenbrock, CK; Hunter, S; Garl, P; Johnson, GL; Anderson, SM				Kassenbrock, CK; Hunter, S; Garl, P; Johnson, GL; Anderson, SM			Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SYK TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; SIGNALING PATHWAY; T-CELLS; ADAPTER PROTEINS; BREAST-CANCER; RING FINGER; IN-VIVO	Stimulation of T47D cells with epidermal growth factor (EGF) results in the activation of the intrinsic tyrosine kinases of the receptor and the phosphorylation of multiple cellular proteins including the receptor, scaffold molecules such as c-Cbl, adapter molecules such as Shc, and the serine/threonine protein kinase Akt. We demonstrate that EGF stimulation of T47D cells results in the activation of the Src protein-tyrosine kinase and that the Src kinase inhibitor PP1 blocks the EGF-induced phosphorylation of c-Cbl but not the activation/phosphorylation of the EGF receptor itself. PP1 also blocks EGF-induced ubiquitination of the EGF receptor, which is presumably mediated by phosphorylated c-Cbl. Src is associated with c-Cbl, and we have previously demonstrated that the Src-like kinase Fyn can phosphorylate c-Cbl at a preferred binding site for the p85 subunit of phosphatidylinositol 3'-kinase. PP1 treatment blocks EGF-induced activation of the anti-apoptotic protein kinase Akt suggesting that Src may regulate activation of Akt, perhaps by a Src --> c-Cbl --> phosphatidylinositol 3'-kinase --> Akt pathway.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Anderson, SM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Box B-216,200 E 9th Ave, Denver, CO 80262 USA.	steve.anderson@uchsc.edu			NIDDK NIH HHS [DK48879] Funding Source: Medline; NIGMS NIH HHS [GM55754] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055754] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1996, ONCOGENE, V12, P2491; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smit L, 1996, ONCOGENE, V13, P381; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	95	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24967	24975		10.1074/jbc.M201026200	http://dx.doi.org/10.1074/jbc.M201026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994282	hybrid			2022-12-27	WOS:000176747000018
J	Pendleton, LC; Goodwin, BL; Flam, BR; Solomonson, LP; Eichler, DC				Pendleton, LC; Goodwin, BL; Flam, BR; Solomonson, LP; Eichler, DC			Endothelial argininosuccinate synthase mRNA 5 '-untranslated region diversity - Infrastructure for tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; L-ARGININE; MESSENGER-RNA; TRANSLATIONAL CONTROL; L-CITRULLINE; CELLS; INITIATION; METABOLISM; TRANSPORT; SEQUENCES	Based on the integral role that argininosuccinate synthase (AS) plays in the production of nitric oxide in vascular endothelial cells and urea in liver, an analysis was carried out to determine whether signals reside in the AS mRNA to account for tissue differences in AS function and location. Reverse transcriptase-PCR and sequence analysis showed that the AS mRNA coding region was the same for both endothelial cells and liver; however, 5'-RACE analysis (rapid amplification of cDNA ends) identified AS mRNA species in endothelial cells in addition to a major 43-nucleotide (nt) 5'-untranslated region (UTR) AS mRNA with overlapping extended 5'-UTRs of 66 and 92 nt. Comparison to the genomic sequence immediately upstream of the reported transcription start site for the human and mouse AS gene suggested that expression of all three species of bovine endothelial AS mRNA are driven by a common promoter and that 5'-UTR diversity in endothelial cells results from three transcriptional initiation sites within exon 1. RNase protection analysis and real-time reverse transcriptase-PCR verified and quantitated the differential expression of the extended 5'-UTR species relative to the major 43-nt 5'-UTR AS mRNA. In vitro translation studies showed a less pronounced but similar discordant expression. Sequential deletions starting from the 5' terminus of the 92-nt 5'-UTR construct resulted in a corresponding increase in translational efficiency, but the most pronounced effect resulted from mutation of an upstream open reading frame, which restored translational efficiency of the 92-nt 5'-UTR AS mRNA. When the different AS mRNA 5'-UTRs, cloned in front of a luciferase reporter gene, were transfected into endothelial cells, the pattern of luciferase expression was nearly identical to that observed for the different 5'-UTR AS mRNAs in endothelial cells. Given the different roles ascribed for argininosuccinate synthase, urea versus NO production, these results suggest that sequence in the AS gene represented by position -92 to -43 nt from the translation start site in the extended AS mRNA 5'UTRs plays an important role in differential and tissue-specific expression.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Eichler, DC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA.		Flam, Brenda/I-5625-2012; Eichler, Duane/A-1906-2012					BAYDOUN AR, 1990, BIOCHEM BIOPH RES CO, V173, P940, DOI 10.1016/S0006-291X(05)80876-9; BLOCK ER, 1995, AM J PHYSIOL-LUNG C, V269, pL574, DOI 10.1152/ajplung.1995.269.5.L574; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Moor CH, 2001, INT REV CYTOL, V203, P567; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FAKLER CR, 1995, ACTA PAEDIATR, V84, P460, DOI 10.1111/j.1651-2227.1995.tb13673.x; Flam BR, 2001, NITRIC OXIDE-BIOL CH, V5, P187, DOI 10.1006/niox.2001.0340; FREYTAG SO, 1984, J BIOL CHEM, V259, P3160; FREYTAG SO, 1984, MOL CELL BIOL, V4, P1978, DOI 10.1128/MCB.4.10.1978; GOLD ME, 1989, BIOCHEM BIOPH RES CO, V164, P714, DOI 10.1016/0006-291X(89)91518-0; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; JINNO Y, 1985, J BIOCHEM-TOKYO, V98, P1395, DOI 10.1093/oxfordjournals.jbchem.a135407; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; McDonald KK, 1997, BBA-BIOMEMBRANES, V1324, P133, DOI 10.1016/S0005-2736(96)00226-X; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; Sonenberg Nahum, 1993, Gene Expression, V3, P317; SURH LC, 1991, GENE, V99, P181, DOI 10.1016/0378-1119(91)90125-U; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25363	25369		10.1074/jbc.M111677200	http://dx.doi.org/10.1074/jbc.M111677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11967259	hybrid			2022-12-27	WOS:000176747000068
J	Zhao, HX; Kinnunen, PKJ				Zhao, HX; Kinnunen, PKJ			Binding of the antimicrobial peptide temporin L to liposomes assessed by Trp fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN FLUORESCENCE; MODEL MEMBRANES; MAGAININ 2; DEPTH; PROTEIN; PENETRATION; ORIENTATION; ANALOGS; CHARGE; PORES	The structure and membrane topology of the antimicrobial peptide temporin L (FVQWFSKFLGRILNH(2)) were studied using liposomes as model bilayers. Circular dichroic spectra revealed temporin L to adopt an alpha-helical conformation when bound to liposomes. Binding of temporin L to liposomes induced significant blue shifts of the emission spectra of the single Trp residue (Trp(4)) and also changed its quantum yield. The observed changes in the characteristics of the Trp(4) fluorescence are in keeping with the insertion of this residue into the hydrophobic region of the liposomal bilayers. Access of the aqueous quencher acrylamide to Trp(4) decreased in the sequence 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC)/cholesterol (X-chol = 0.1) > SOPC > SOPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG, X-POPG = 0.1) > SOPC/POPG (X-POPG = 0.2) approximate to SOPC/POPG (X-POPG = 0.4), where X represents molar fraction of the indicated lipid. Whereas quenching of Trp(4) by brominated phospholipids was significant in SOPC liposomes, the quenching efficiency was enhanced when the vesicles contained POPG. The depth of insertion of Trp(4) into lipid bilayers was calculated by both the parallax method and distribution analysis and revealed this residue to reside at an average distance of d approximate to 8.0 +/- 0.5 Angstrom from the center of both SOPC and SOPC/POPG bilayers. However, in the presence of cholesterol, d was increased to 9.5 +/- 0.5 Angstrom, thus revealing Trp(4) to become accommodated more superficially in the bilayer. The above data suggest the presence of two populations of temporin L in SOPC- and POPG-containing membranes with parallel and perpendicular orientation with respect to the plane of the membrane surface.	Univ Helsinki, Helsinki Biophys & Biomembrane Grp, Inst Biomed, FIN-00014 Helsinki, Finland	University of Helsinki	Kinnunen, PKJ (corresponding author), Univ Helsinki, Helsinki Biophys & Biomembrane Grp, Inst Biomed, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Paavo.Kinnunen@Helsinki.fi		Zhao, Hongxia/0000-0002-1606-5621				ARGIOLAS A, 1984, J BIOL CHEM, V259, P106; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P21, DOI 10.1016/0005-2736(78)90108-6; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; Ladokhin A S, 1993, J Fluoresc, V3, P195, DOI 10.1007/BF00862742; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Ladokhin AS, 1997, METHOD ENZYMOL, V278, P462; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MCELHANEY RN, 1999, BIOCHIM BIOPHYS ACTA, V1462, P1; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Oren Z, 1998, BIOPOLYMERS, V47, P451; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; VANGINKEL G, 1989, BIOCHIMIE, V71, P23, DOI 10.1016/0300-9084(89)90127-2; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173; Zhao HX, 2002, BIOCHEMISTRY-US, V41, P4425, DOI 10.1021/bi011929e; Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3	42	86	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25170	25177		10.1074/jbc.M203186200	http://dx.doi.org/10.1074/jbc.M203186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991956	hybrid			2022-12-27	WOS:000176747000043
J	Hekman, M; Hamm, H; Villar, AV; Bader, B; Kuhlmann, J; Nickel, J; Rapp, UR				Hekman, M; Hamm, H; Villar, AV; Bader, B; Kuhlmann, J; Nickel, J; Rapp, UR			Associations of B- and C-raf with cholesterol, phosphatidylserine, and lipid second messengers - Preferential binding of Raf to artificial lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; INTEGRAL MEMBRANE-PROTEINS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CELL-SURFACE; H-RAS; CAVEOLAE MEMBRANE; STRUCTURAL BASIS; ZINC-FINGER; KINASE	The serine/threonine kinase C-Raf is a key mediator in cellular signaling. Translocation of Raf to membranes has been proposed to be facilitated by Ras proteins in their GTP-bound state. In this study we provide evidence that both purified B- and C-Raf kinases possess lipophilic properties and associate with phospholipid membranes. In the presence of phosphatidylserine and lipid second messengers such as phosphatidic acid and ceramides these associations were very specific with affinity constants (K-D) in the range of 0.5-50 nM. Raf association with liposomes was accompanied by displacement of 14-3-3 proteins and inhibition of Raf kinase activities. Interactions of Raf with cholesterol are of particular interest, since cholesterol has been shown to be involved, together with sphingomyelin and glycero-phospholipids in the formation of specialized lipid microdomains called rafts. We demonstrate here that purified Raf proteins have moderate binding affinity for cholesterol. However, under conditions of lipid raft formation, Raf association with cholesterol (or rafts) increased dramatically. Since ceramides also support formation of rafts and interact with Raf we propose that Raf may be present at the plasma membrane in two distinct microdomains: in raft regions via association with cholesterol and ceramides and in non-raft regions due to interaction with phosphatidylserine and phosphatidic acid. At either location Raf kinase activity was inhibited by lipid binding in the absence or presence of Ras. Ras-Raf interactions with full-length C-Raf were studied both in solution and in phospholipid environment. Ras association with Raf was GTP dependent as previously demonstrated for C-Raf-RBD fragments. In the presence of liposomes the recruitment of C-Raf by reconstituted Ras-farnesyl was only marginal, since almost 70% of added C-Raf was bound by the lipids alone. Thus Ras-Raf binding in response to activation of Ras-coupled receptors may utilize Raf protein that is already present at the membrane.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Basque Country, Dept Bioquim, Grp Biomembranas, E-48080 Bilbao, Spain; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Wurzburg, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany	University of Wurzburg; University of Basque Country; Max Planck Society; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de	Villar, Ana/I-5190-2015	Villar, Ana/0000-0003-4588-9598; Bader, Benjamin/0000-0002-5299-396X				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cooper MA, 2000, ANAL BIOCHEM, V277, P196, DOI 10.1006/abio.1999.4389; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Danelian E, 2000, J MED CHEM, V43, P2083, DOI 10.1021/jm991156g; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Marco MD, 2001, J BIOL CHEM, V276, P23009; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gennis R.B., 1988, BIOMEMBRANES MOL STR; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kerkhoff E, 2001, ADV ENZYME REGUL, V41, P261, DOI 10.1016/S0065-2571(00)00023-6; KOLCH W, 1990, ONCOGENE, V5, P713; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LIU Z, 1995, EUR BIOPHYS J, V24, P31, DOI 10.1007/BF00216828; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Massey JB, 2001, BBA-BIOMEMBRANES, V1510, P167, DOI 10.1016/S0005-2736(00)00344-8; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Morre DJ, 1999, BIOFACTORS, V9, P179, DOI 10.1002/biof.5520090213; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Schulte T, 1997, DEVELOPMENT, V124, P577; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	77	72	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24090	24102		10.1074/jbc.M200576200	http://dx.doi.org/10.1074/jbc.M200576200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11953426	hybrid			2022-12-27	WOS:000176611800017
J	Lindqvist, A; Andersson, S				Lindqvist, A; Andersson, S			Biochemical properties of purified recombinant human beta-carotene 15,15'-monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; BETA,BETA-CAROTENE 15,15'-DIOXYGENASE; SUBSTRATE-SPECIFICITY; EXPRESSION; CLEAVAGE; IDENTIFICATION; PROTEINS; ENZYMES; CLONING	beta-Carotene 15,15'-monooxygenase (BCO), formerly known as beta-carotene 15,15'-dioxygenase, catalyzes the first step in the synthesis of vitamin A from dietary carotenoids. We have biochemically and enzymologically characterized the purified recombinant human BCO enzyme. A highly active BCO enzyme was expressed and purified to homogeneity from baculovirus-infected Spodoptera frugiperda 9 insect cells. The K-m and V-max of the enzyme for beta-carotene were 7 mum and 10 nmol retinal/mg x min, respectively, values that corresponded to a turnover number (k(cat)) of 0.66 min(-1) and a catalytic efficiency (k(cat)/K-m) of similar to10(5) m(-1.)min(-1). The enzyme existed as a tetramer in solution, and substrate specificity analyses suggested that at least one unsubstituted beta-ionone ring half-site was imperative for efficient cleavage of the carbon 15,15'-double bond in carotenoid substrates. High levels of BCO mRNA were observed along the whole intestinal tract, in the liver, and in the kidney, whereas lower levels were present in the prostate, testis, ovary, and skeletal muscle. The current data suggest that the human BCO enzyme may, in addition to its well established role in the digestive system, also play a role in peripheral vitamin A synthesis from plasma-borne provitamin A carotenoids.	Univ Texas, SW Med Ctr, Dept Obstet Gynecol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Andersson, S (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet Gynecol, F2106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stefan.andersson@utsouthwestern.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052167] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11149] Funding Source: Medline; NIDDK NIH HHS [DK52167] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENDICH A, 1989, FASEB J, V3, P1927, DOI 10.1096/fasebj.3.8.2656356; Blaner William S., 1994, P229; BLOMSTRA.R, 1967, SCAND J CLIN LAB INV, V19, P339, DOI 10.3109/00365516709090648; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; FIDGE NH, 1969, BIOCHEM J, V114, P689, DOI 10.1042/bj1140689; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; GOODMAN DS, 1967, J BIOL CHEM, V242, P3543; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; GRISWOLD MD, 1989, ANN NY ACAD SCI, V564, P154, DOI 10.1111/j.1749-6632.1989.tb25895.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; KIM KH, 1990, MOL ENDOCRINOL, V4, P1679, DOI 10.1210/mend-4-11-1679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMAN.MR, 1972, J LIPID RES, V13, P477; LAKSHMANAN MR, 1968, BIOCHEM BIOPH RES CO, V33, P347, DOI 10.1016/0006-291X(68)90791-2; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; Moghrabi N, 1997, J CLIN ENDOCR METAB, V82, P3872, DOI 10.1210/jc.82.11.3872; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Rock CL, 1997, PHARMACOL THERAPEUT, V75, P185, DOI 10.1016/S0163-7258(97)00054-5; Sambrook J., 2001, MOL CLONING LAB MANU; SINGH H, 1974, BIOCHIM BIOPHYS ACTA, V370, P49, DOI 10.1016/0005-2744(74)90030-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wirtz GM, 2001, HELV CHIM ACTA, V84, P2301, DOI 10.1002/1522-2675(20010815)84:8<2301::AID-HLCA2301>3.0.CO;2-U; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	32	193	204	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23942	23948		10.1074/jbc.M202756200	http://dx.doi.org/10.1074/jbc.M202756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960992	hybrid			2022-12-27	WOS:000176475700109
J	Greenwood, IA; Miller, LJ; Ohya, S; Horowitz, B				Greenwood, IA; Miller, LJ; Ohya, S; Horowitz, B			The large conductance potassium channel beta-subunit can interact with and modulate the functional properties of a calcium-activated chloride channel, CLCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNELS; CLONING; PROTEINS; TRACHEA; FAMILY; CELLS; LUNG	We have recently compared the biophysical and pharmacological properties of native Ca2+-activated Cl- currents in murine portal vein with mCLCA1 channels cloned from murine portal vein myocytes (Britton, F. C., Ohya, S., Horowitz, B., and Greenwood, I. A (2002) J. Physiol. (Lond.) 539,107-117). These channels shared a similar relative permeability to various anions, but the expressed channel current lacked the marked time dependence of the native current. In addition, the expressed channel showed a lower Ca2+ sensitivity than the native channel. As non-pore-forming regulatory beta-subunits alter the kinetics and increase the Ca2+ sensitivity of Ca2+-dependent K+ channels (BK channels) we investigated whether co-expression of beta-subunits with CLCA1 would alter the kinetics/Ca2+ sensitivity of mCLCA1. Internal dialysis of human embryonic kidney cells stably expressing CLCA1 with 500 nM Ca2+ evoked a significantly larger current when the beta-subunit KC-NMB1 was co-expressed. In a small number of co-transfected cells marked time dependence to the activation kinetics was observed. Interaction studies using the mammalian two-hybrid technique demonstrated a physical association between CLCA1 and KCNMB1 when coexpressed in human embryonic kidney cells. These data suggest that activation of CLCA1 can be modified by accessory subunits.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Horowitz, B (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, MS352 Anderson Med Bldg, Reno, NV 89557 USA.		Ohya, Susumu/AAB-3618-2020	Ohya, Susumu/0000-0002-5765-0667; Greenwood, Iain/0000-0002-0603-0492	NCRR NIH HHS [P20 RR15581] Funding Source: Medline; NHLBI NIH HHS [HL 49524] Funding Source: Medline; NIDDK NIH HHS [DK 41315] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041315] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Britton FC, 2002, J PHYSIOL-LONDON, V539, P107, DOI 10.1113/jphysiol.2001.013170; Collier ML, 1996, CIRC RES, V78, P936, DOI 10.1161/01.RES.78.5.936; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; ELBLE RC, 2002, J BIOL CHEM, V10, P1074; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Fuller CM, 2001, PFLUG ARCH EUR J PHY, V443, pS107, DOI 10.1007/s004240100655; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Greenwood IA, 1999, J PHYSIOL-LONDON, V516, P365, DOI 10.1111/j.1469-7793.1999.0365v.x; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ji HL, 1998, AM J PHYSIOL-CELL PH, V274, pC455, DOI 10.1152/ajpcell.1998.274.2.C455; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Nilius B, 1997, J VASC RES, V34, P220, DOI 10.1159/000159226; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Wang Q, 1997, AM J PHYSIOL-CELL PH, V273, pC520, DOI 10.1152/ajpcell.1997.273.2.C520; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971	19	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22119	22122		10.1074/jbc.C200215200	http://dx.doi.org/10.1074/jbc.C200215200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11994272	hybrid			2022-12-27	WOS:000176313600004
J	Molotkov, A; Duester, G				Molotkov, A; Duester, G			Retinol/ethanol drug interaction during acute alcohol intoxication in mice involves inhibition of retinol metabolism to retinoic acid by alcohol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; ETHANOL INHIBITION; MUTANT MICE; RAT-LIVER; MOUSE; EXPRESSION; HINDBRAIN; IDENTIFICATION; INITIATION; MECHANISM	Substantial evidence indicates that one consequence of alcohol intoxication is a reduction in retinoic acid (RA) levels. Studies on the mechanism have shown that chronic ethanol consumption induces P450 enzymes that increase RA degradation, thus accounting for much but not all of the observed decrease in RA. A reduction in RA synthesis may also be involved as ethanol competitively inhibits retinol oxidation catalyzed by alcohol dehydrogenase (ADH) in vitro. This may be important during acute ethanol intoxication and may contribute to adverse retinol/ethanol drug interactions. Here we have examined mice for the effect of either acute ethanol intoxication or Adh1 gene disruption on RA synthesis and degradation. RA produced following a dose of retinol (50 mg/kg) was reduced 87% by pretreatment with an intoxicating dose of ethanol (3.5 g/kg). RA produced in Adh1-null mutant mice following a 50-mg/kg dose of retinol was reduced 82% relative to wild-type mice, thus similar to wild-type mice pretreated with ethanol. Reduced RA production was associated with increased retinol levels in both ethanol-treated wild-type mice and Adh1-null mutant mice, indicating reduced clearance of the retinol dose. RA degradation following a dose of RA (10 mg/kg) was increased only 42% by ethanol pretreatment (3.5 g/kg) and only 26% in Adh1-null mutant mice relative to wild-type mice. These findings demonstrate that the reduced RA levels observed during acute retinol/ethanol drug interaction are due primarily to a decrease in ADH-catalyzed RA synthesis and secondarily to an increase in RA degradation.	Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Gene Regulat Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Armstrong Robert B., 1994, P545; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; De Luca LM, 1997, J NUTR BIOCHEM, V8, P426, DOI 10.1016/S0955-2863(97)00063-6; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; FROLIK CA, 1984, RETINOIDS, V2, P177; Gavalas A, 2000, CURR OPIN GENET DEV, V10, P380, DOI 10.1016/S0959-437X(00)00100-3; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Helms JA, 1996, DEVELOPMENT, V122, P1385; Kastner P., 1994, Vitamin A in health and disease., P189; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Lieber CS, 1997, CLIN CHIM ACTA, V257, P59, DOI 10.1016/S0009-8981(96)06434-0; LINDBLAD B, 1976, JAMA-J AM MED ASSOC, V236, P1600, DOI 10.1001/jama.236.14.1600; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; Malpel S, 2000, DEVELOPMENT, V127, P3057; Mangelsdorf David J., 1994, P319; McSorley LC, 2000, BIOCHEM PHARMACOL, V60, P517, DOI 10.1016/S0006-2952(00)00356-7; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Misner DL, 2001, P NATL ACAD SCI USA, V98, P11714, DOI 10.1073/pnas.191369798; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Niederreither K, 2000, DEVELOPMENT, V127, P75; Power SC, 1999, DEV DYNAM, V216, P469, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<469::AID-DVDY15>3.0.CO;2-3; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; SATRE MA, 1992, BIOL REPROD, V46, P802, DOI 10.1095/biolreprod46.5.802; Stratford T, 1996, CURR BIOL, V6, P1124, DOI 10.1016/S0960-9822(02)70679-9; Szalai G, 2002, EUR J BIOCHEM, V269, P224, DOI 10.1046/j.0014-2956.2001.02642.x; Wagner E, 2000, DEV BIOL, V222, P460, DOI 10.1006/dbio.2000.9719; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	43	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22553	22557		10.1074/jbc.M201603200	http://dx.doi.org/10.1074/jbc.M201603200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960985	hybrid			2022-12-27	WOS:000176313600060
J	Srinivasula, SM; Poyet, JL; Razmara, M; Datta, P; Zhang, ZJ; Alnemri, ES				Srinivasula, SM; Poyet, JL; Razmara, M; Datta, P; Zhang, ZJ; Alnemri, ES			The PYRIN-CARD protein ASC is an activating adaptor for caspase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECRUITMENT DOMAIN; FAMILY MEMBER; CROHNS-DISEASE; APOPTOSIS; KINASE; NOD2; SUSCEPTIBILITY; IDENTIFICATION; INFLAMMATION	The PYRIN and CARD domains are members of the six-helix bundle death domain-fold superfamily that mediates assembly of large signaling complexes in the apoptotic and inflammatory signaling pathways. Here we show that the PYRIN-CARD protein ASC functions as a caspase-1-activating adaptor. ASC interacted specifically with procaspase-1 via CARD-CARD interactions and induced its oligomerization. Consistent with these results ectopic expression of full-length ASC, but not its isolated CARD or PYRIN domain, with procaspase-1 induced activation of procaspase-1 and processing of prointerleukin-1beta in transfected cells. Substitution of the PYRIN domain of ASC with an inducible FKBP12 oligomerization domain produced a molecule that can induce caspase-1 activation in response to stimulation with the oligomerization drug AP20187, suggesting that the PYRIN domain functions as an oligomerization domain, whereas the CARD domain functions as the effector domain in the caspase-1 activation pathway. Furthermore stable expression of an isolated CARD of ASC in THP-1 cells diminished interleukin-1beta generation in response to pro-inflammatory cytokines. These results indicate that ASC is involved in the caspase-1 signaling pathway by mediating the assembly of a caspase-1-inflammasome signaling complex in response to pro-inflammatory cytokine stimulation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NCI NIH HHS [CA85421] Funding Source: Medline; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aksentijevich I, 1997, CELL, V90, P797; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1	27	422	441	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21119	21122		10.1074/jbc.C200179200	http://dx.doi.org/10.1074/jbc.C200179200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11967258	hybrid			2022-12-27	WOS:000176286000003
J	Han, YP; Nien, YD; Garner, WL				Han, YP; Nien, YD; Garner, WL			Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; 92-KD GELATINASE; IV COLLAGENASE; WOUND FLUID; EXPRESSION; CYTOKINES; MATRIX-METALLOPROTEINASE-9; STROMELYSIN; PROGRESSION; METASTASIS	The proteolytic activation of pro-matrix metalloproteinase (MMP)-9 by conversion of the 92-kDa precursor into an 82-kDa active form has been observed in chronic wounds, tumor metastasis, and many inflammation-associated diseases, yet the mechanistic pathway to control this process has not been identified. In this report, we show that the massive expression and activation of MMP-9 in skin tissue from patients with chronically unhealed wounds could be reconstituted in vitro with cultured normal human skin by stimulation with transforming growth factor-beta and tumor necrosis factor (TNF)-alpha. We dissected the mechanistic pathway for TNF-alpha induced activation of pro-MMP-9 in human skin. We found that proteolytic activation of pro-MMP-9 was mediated by a tissue-associated chymotrypsin-like proteinase, designated here as pro-MMP-9 activator (pM9A). This unidentified activator specifically converted pro-MMP-9 but not pro-MMP-2, another member of the gelatinase family. The tissue-bound pM9A was steadily expressed and not regulated by TNF-alpha, which indicated that the cytokine-mediated activation of pro-MMP-9 might be regulated at the inhibitor level. Indeed, the skin constantly secreted tissue inhibitor of metalloproteinase-1 at the basal state. TNF-alpha, but not transforming growth factor-beta, down-regulated this inhibitor. The TNF-alpha-mediated activation of pro-MMP-9 was tightly associated with down-regulation of tissue inhibitor of metalloproteinase-1 in a dose-dependent manner. To establish this linkage, we demonstrate that the recombinant tissue inhibitor of metalloproteinase-1 could block the activation of pro-MMP-9 by either the intact skin or skin fractions. Thus, these studies suggest a novel regulation for the proteolytic activation of MMP-9 in human tissue, which is mediated by tissue-bound activator and controlled by down-regulation of a specific inhibitor.	Univ So Calif, Keck Sch Med, Div Plast & Reconstruct Surg, Dept Surg, Los Angeles, CA 90033 USA	University of Southern California	Han, YP (corresponding author), Univ So Calif, Keck Sch Med, Div Plast & Reconstruct Surg, Dept Surg, 1450 San Pablo St,Suite 2000, Los Angeles, CA 90033 USA.	yhan@surgery.usc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050967, R01GM050967] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050967-08, R29 GM050967, R01 GM050967, R01 GM050967-07, GM 50967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Cooney R, 1997, J TRAUMA, V42, P415, DOI 10.1097/00005373-199703000-00008; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; GARNER WL, 1993, J INVEST DERMATOL, V101, P875, DOI 10.1111/1523-1747.ep12371710; GIAVAZZI R, 1990, CANCER RES, V50, P4771; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Han YP, 2001, J CELL SCI, V114, P131; JORDON RE, 1985, J INVEST DERMATOL, V85, pS72, DOI 10.1111/1523-1747.ep12275497; Kleer CG, 2000, BREAST CANCER RES, V2, P423, DOI 10.1186/bcr89; Kurtzman SH, 1999, ONCOL REP, V6, P65; LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x; Lijnen HR, 1998, BLOOD, V91, P2045, DOI 10.1182/blood.V91.6.2045.2045_2045_2053; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Nash MA, 1999, ENDOCR-RELAT CANCER, V6, P93, DOI 10.1677/erc.0.0060093; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; REMICK DG, 1992, IMMUNOL INVEST, V21, P321, DOI 10.3109/08820139209069371; Rha SY, 1997, BREAST CANCER RES TR, V43, P175; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stadelmann WK, 1998, AM J SURG, V176, p39S, DOI 10.1016/S0002-9610(98)00184-6; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; Tarlton JF, 1997, BRIT J DERMATOL, V137, P506, DOI 10.1111/j.1365-2133.1997.tb03779.x; Trengove NJ, 2000, WOUND REPAIR REGEN, V8, P13, DOI 10.1046/j.1524-475x.2000.00013.x; TUAN TL, 1994, J CELL SCI, V107, P2285; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wielockx B, 2001, NAT MED, V7, P1202, DOI 10.1038/nm1101-1202; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; Wysocki AB, 1999, WOUND REPAIR REGEN, V7, P154, DOI 10.1046/j.1524-475X.1999.00154.x; Yager DR, 1996, J INVEST DERMATOL, V107, P743, DOI 10.1111/1523-1747.ep12365637; YOUNG PK, 1994, J INVEST DERMATOL, V103, P660, DOI 10.1111/1523-1747.ep12398424; Zeng ZS, 1998, BRIT J CANCER, V78, P349, DOI 10.1038/bjc.1998.497; ZUCKER S, 1989, INVAS METAST, V9, P167	41	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27319	27327		10.1074/jbc.M202842200	http://dx.doi.org/10.1074/jbc.M202842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004062	Green Accepted, hybrid			2022-12-27	WOS:000177055900080
J	Dai, MS; Chevallier, N; Stone, S; Heinrich, MC; McConnell, M; Reuter, T; Broxmeyer, HE; Licht, JD; Lu, L; Hoatlin, ME				Dai, MS; Chevallier, N; Stone, S; Heinrich, MC; McConnell, M; Reuter, T; Broxmeyer, HE; Licht, JD; Lu, L; Hoatlin, ME			The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; GROUP-C GENE; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR; ENCODING GENE; PROTEIN; EXPRESSION; PLZF; GROWTH; COMPLEX	FAZF, a member of the BTB/POZ family of transcriptional repressor proteins, has been shown to bind to FANCC, the protein defective in patients with the bone marrow failure syndrome Fanconi anemia complementation group C. Because bone marrow failure in Fanconi anemia has been attributed to a failure of the hematopoietic stem cell population to produce sufficient progeny, we documented the expression of FAZF in human CD34(+) hematopoietic progenitor cells. FAZF was expressed at high levels in early stages of differentiation but declined during subsequent differentiation into erythroid and myeloid lineages. Consistent with its presumed role as a transcriptional repressor, FAZF was found in the nuclear compartment, where it resides in distinct nuclear speckles at or near sites of DNA replication. Using a FAZF-inducible myeloid cell line, we found that enforced expression of FAZF was accompanied by accumulation in the G, phase of the cell cycle followed later by apoptosis. These results suggest an essential role for FAZF during the proliferative stages of primitive hematopoietic progenitors, possibly acting in concert with (a subset of) the Fanconi anemia proteins.	Oregon Hlth Sci Univ, Div Mol Med, Portland, OR 97201 USA; Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA; Portland Vet Adm Med Ctr, Portland, OR 97201 USA	Oregon Health & Science University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hoatlin, ME (corresponding author), Oregon Hlth Sci Univ, Div Mol Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Ittershagen, Stacie/X-7658-2019; Licht, Jonathan/L-4239-2019; Heinrich, Michael/AAC-6745-2019	Chevallier, Nathalie/0000-0002-1800-2579; Heinrich, Michael/0000-0003-3790-0478; Ittershagen, Stacie (Stone)/0000-0003-3834-176X; Licht, Jonathan/0000-0002-3942-1369; McConnell, Melanie J./0000-0003-3840-1347	NCI NIH HHS [CA59936] Funding Source: Medline; NHLBI NIH HHS [HL56045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056045, R29HL056045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; BAGBY GC, 1993, BLOOD, V82, P183; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; BRADY G, 1995, CURR BIOL, V5, P909, DOI 10.1016/S0960-9822(95)00181-3; Carreau M, 1999, EXP HEMATOL, V27, P1667, DOI 10.1016/S0301-472X(99)00102-2; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; De Kerviler E, 2000, CLIN RADIOL, V55, P340, DOI 10.1053/crad.2000.0445; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haneline LS, 1999, BLOOD, V94, P1; Haneline LS, 1998, BLOOD, V91, P4092; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; HOATLIN ME, 1987, J VIROL, V61, P1442, DOI 10.1128/JVI.61.5.1442-1447.1987; Huynh KD, 2000, GENE DEV, V14, P1810; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kruyt FAE, 1997, CANCER RES, V57, P2244; Kupfer GM, 1996, BLOOD, V88, P1019; Lin WC, 1999, BIOCHEM BIOPH RES CO, V264, P789, DOI 10.1006/bbrc.1999.1594; Liu JM, 1997, HUM GENE THER, V8, P1715, DOI 10.1089/hum.1997.8.14-1715; Lu L, 1996, BLOOD, V87, P525, DOI 10.1182/blood.V87.2.525.bloodjournal872525; Lu L, 1999, BLOOD, V94, P2319, DOI 10.1182/blood.V94.7.2319.419k14_2319_2332; Matkovic ME, 2001, AM J HUM GENET, V69, P355; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SEGAL GM, 1994, J CLIN INVEST, V94, P846, DOI 10.1172/JCI117405; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Tang CJC, 2001, J BIOL CHEM, V276, P19631, DOI 10.1074/jbc.M100170200; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tower PA, 1998, EXP HEMATOL, V26, P19; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; WALSH CE, 1994, BLOOD, V84, P453; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	42	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26327	26334		10.1074/jbc.M201834200	http://dx.doi.org/10.1074/jbc.M201834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986317	hybrid			2022-12-27	WOS:000176908700067
J	Ariga, T; Masaike, T; Noji, H; Yoshida, M				Ariga, T; Masaike, T; Noji, H; Yoshida, M			Stepping rotation of F-1-ATPase with one, two, or three altered catalytic sites that bind ATP only slowly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; CHANGE MECHANISM; MOLECULAR MOTOR; SYNTHASE; NUCLEOTIDES; RESOLUTION; EFFICIENCY; HYDROLYSIS; SUBUNITS	F-1-ATPase is an ATP hydrolysis-driven motor in which the gamma subunit rotates in the stator cylinder alpha(3)beta(3). To know the coordination of three catalytic beta subunits during catalysis, hybrid F-1-ATPases, each containing one, two, or three "slow" mutant beta subunits that bind ATP very slowly, were prepared, and the rotations were observed with a single molecule level. Each hybrid made one, two, or three steps per 360degrees revolution, respectively, at 5 muM ATP where the wild-type enzyme rotated continuously without step under the same observing conditions. The observed dwell times of the steps are explained by the slow binding rate of ATP. Except for the steps, properties of rotation, such as the torque forces exerted during rotary movement, were not significantly changed from those of the wild-type enzyme. Thus, it appears that the presence of the slow beta subunit(s) does not seriously affect other normal beta subunit(s) in the same F-1-ATPase molecule and that the order of sequential catalytic events is faithfully maintained even when ATP binding to one or two of the catalytic sites is retarded.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; JSP, Precursory Res Embryon Sci & Technol, Yokohama, Kanagawa 3320012, Japan; JSP, Exploratory Res Adv Technol, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; University of Tokyo	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Ariga, Takayuki/ACM-3092-2022	Masaike, Tomoko/0000-0003-3290-1893; Ariga, Takayuki/0000-0002-2045-5761				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; Boyer PD, 2002, FEBS LETT, V512, P29, DOI 10.1016/S0014-5793(02)02293-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kinosita K, 2000, PHILOS T R SOC B, V355, P473, DOI 10.1098/rstb.2000.0589; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P25480, DOI 10.1074/jbc.M102200200; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; Oster G, 2000, J BIOENERG BIOMEMBR, V32, P459, DOI 10.1023/A:1005660807157; Ren HM, 2000, J BIOL CHEM, V275, P10057, DOI 10.1074/jbc.275.14.10057; Ren HM, 2000, BBA-BIOENERGETICS, V1458, P221, DOI 10.1016/S0005-2728(00)00075-X; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	27	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24870	24874		10.1074/jbc.M202582200	http://dx.doi.org/10.1074/jbc.M202582200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964408	hybrid			2022-12-27	WOS:000176747000007
J	Behera, AK; Kumar, M; Lockey, RF; Mohapatra, SS				Behera, AK; Kumar, M; Lockey, RF; Mohapatra, SS			2 '-5 ' oligoadenylate synthetase plays a critical role in interferon-7 inhibition of respiratory syncytial virus infection of human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-INDUCIBLE GENES; OLIGO-A SYNTHETASE; RNASE-L INHIBITOR; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; 2-5A-DEPENDENT RNASE; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; 2-5A SYNTHETASE; ACTIVATION	Respiratory syncytial virus (RSV), associated with bronchiolitis and asthma, is resistant to the antiviral effects of type-I interferons (IFN), but not IFN-gamma. However, the antiviral mechanism of IFN-gamma action against RSV infection is unknown. The molecular mechanism of IFN-gamma-induced antiviral activity was examined in this study using human epithelial cell lines HEp-2 and A549. Exposure of these cells to 100-1000 units/ml of IFN-gamma, either before or after RSV infection, results in a significant decrease in RSV infection. After 1 h of exposure, IFN-gamma induces protein expression of IFN regulatory factor-1 (IRF-1) but not IRF-2, double-stranded RNA-activated protein kinase, and inducible nitric-oxide synthase in these cells. The mRNA for IRF-1, p40, and p69 isoforms of 2'-5' oligoadenylate synthetase (2-5 AS) are detectable, respectively, at 1 and 4 h of IFN-gamma exposure. Studies using cycloheximide and antisense oligonucleotides to IRF-1 indicate a direct role of IRF-1 in activating 2-5 AS. Cells transfected with 2-5 AS antisense oligonucleotides inhibit the antiviral effect of IFN-gamma. A stable cell line of HEp-2 overexpressing RNase L inhibitor, RLI-14, which exhibits an IFN-gamma-induced gene expression pattern similar to that of the parent cell line, shows a significant reduction in RNase L activity and IFN-gamma-mediated antiviral effect, compared with HEp-2 cells. These results provide direct evidence of the involvement of 2-5 AS in IFN-gamma-mediated antiviral activity in these cells.	Univ S Florida, Coll Med, Div Allergy Immunol,Dept Internal Med, Joy McCann Culverhouse Airway Dis Ctr, Tampa, FL 33612 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Mohapatra, SS (corresponding author), Univ S Florida, Coll Med, Div Allergy Immunol,Dept Internal Med, Joy McCann Culverhouse Airway Dis Ctr, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	smohapat@hsc.usf.edu	Mohapatra, Shyam/C-2500-2012					Atreya PL, 1999, VIROLOGY, V261, P227, DOI 10.1006/viro.1999.9835; Aubert M, 1999, J VIROL, V73, P2803, DOI 10.1128/JVI.73.4.2803-2813.1999; Behera AK, 2001, BIOCHEM BIOPH RES CO, V280, P188, DOI 10.1006/bbrc.2000.4093; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Bukreyev A, 1999, P NATL ACAD SCI USA, V96, P2367, DOI 10.1073/pnas.96.5.2367; Byrd LG, 1997, CLIN INFECT DIS, V25, P1363, DOI 10.1086/516152; Carbonell-Estrany X, 2001, PEDIATR INFECT DIS J, V20, P874, DOI 10.1097/00006454-200109000-00010; CHA Y, 1994, J BIOL CHEM, V269, P5279; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Floyd-Smith G, 1999, EXP CELL RES, V246, P138, DOI 10.1006/excr.1998.4296; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hall CB, 2000, CLIN INFECT DIS, V31, P590, DOI 10.1086/313960; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Lehtonen A, 1997, J IMMUNOL, V159, P794; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAVLOVIC J, 1993, CIBA F SYMP, V176, P233; Player MR, 1998, METHODS, V15, P243, DOI 10.1006/meth.1998.0628; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEN GC, 1992, J BIOL CHEM, V267, P5017; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Tristram DA, 1998, ARCH OTOLARYNGOL, V124, P777, DOI 10.1001/archotol.124.7.777; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	46	53	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25601	25608		10.1074/jbc.M200211200	http://dx.doi.org/10.1074/jbc.M200211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980899	hybrid			2022-12-27	WOS:000176747000098
J	Hirai, I; Wang, HG				Hirai, I; Wang, HG			A role of the C-terminal region of human Rad9 (hRad9) in nuclear transport of the hRad9 checkpoint complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; SLIDING CLAMP; CONTROL GENE; PROTEIN; PCNA; INTERACTS; HUS1; ATR	Rad9, Rad1, and Hus1 are members of the Rad family of checkpoint proteins that are required for both DNA replication and DNA damage checkpoints and are thought to function as sensors in the DNA integrity checkpoint control. These proteins can interact with each other and form a stable proliferating cell nuclear antigen-related Rad9-Rad1-Hus1 heterotrimeric complex that might encircle DNA at or near the damaged sites. In this study, we demonstrate that the human Rad9 (hRad9) protein contains a predicted nuclear localization sequence (NLS) near its C terminus, which plays an essential role in the hRad9-mediated G2 checkpoint. Deletion experiments indicate that the NLS-containing region of hRad9 is critical for the nuclear transport of not only hRad9 but also human Rad1 (hRad1) and human Hus1 (hHus1), although this region is not required for hRad9-hRad1-hHus1 complex formation. In support of the role that hRad9 NI'S plays in the nuclear targeting of the hRad9-hRad1-hHus1 complex, overexpression of a deletion mutant of hRad9 lacking the NLS-containing C-terminal region can bypass the G(2) checkpoint and result in cell death after ionizing radiation or hydroxyurea treatment. Moreover, knockdown of hRad9 expression by small interfering RNA (siRNA) results in hRad1 accumulation in the cytoplasm and significantly abrogates the G, checkpoint in the presence of damaged DNA or incomplete DNA replication. Thus, the C-terminal region of human Rad9 protein is important for G(2) checkpoint control by operating the transport of the hRad9-hRad1-hHus1 checkpoint complex into the nucleus.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA090315, R01CA082197] Funding Source: NIH RePORTER; NCI NIH HHS [CA90315, CA82197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cai RL, 2000, J BIOL CHEM, V275, P27909; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Humphrey T, 2000, MUTAT RES-FUND MOL M, V451, P211, DOI 10.1016/S0027-5107(00)00051-8; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu QH, 2000, GENE DEV, V14, P1448; Melo JA, 2001, GENE DEV, V15, P2809; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; TSURIMOTO T, 1999, FRONT BIOSCI, V4, pD649; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25722	25727		10.1074/jbc.M203079200	http://dx.doi.org/10.1074/jbc.M203079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994305	hybrid			2022-12-27	WOS:000176747000114
J	Knockaert, M; Wieking, K; Schmitt, S; Leost, M; Grant, KM; Mottram, JC; Kunick, C; Meijer, L				Knockaert, M; Wieking, K; Schmitt, S; Leost, M; Grant, KM; Mottram, JC; Kunick, C; Meijer, L			Intracellular targets of paullones - Identification following affinity purification on immobilized inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; MITOCHONDRIAL MALATE-DEHYDROGENASE; GLYCOGEN-SYNTHASE KINASE-3; REFINED CRYSTAL-STRUCTURE; SMALL-MOLECULE INHIBITORS; LEISHMANIA-MEXICANA; PROTEIN-KINASES; PLASMODIUM-FALCIPARUM; TRYPANOSOMA-BRUCEI; CANCER-THERAPY	Numerous inhibitors of cyclin-dependent kinases and glycogen synthase kinase-3 (GSK-3) are being developed in view of their potential applications against cancers and neurodegenerative disorders. Among these, paullones constitute a family of potent and apparently selective cyclin-dependent kinase and GSK-3 inhibitors. However, their actual intracellular targets remain to be identified. To address this issue we have immobilized a paullone, gwennpaullone, on an agarose matrix. Extracts from various cell types and tissues were screened for proteins interacting with this matrix. This approach validated GSK-3alpha and GSK-3beta as major intracellular paullone targets and also mitochondrial, but not cytoplasmic, malate dehydrogenase (MDH). Mitochondrial MDH was indeed inhibited by micromolar concentrations of paullones. Mitochondrial MDH was the major paullone-binding protein in the parasitic protozoon Leishmania mexicana, and paullones inhibited growth of the parasite. This simple batchwise affinity chromatography approach constitutes a straightforward method for the identification of intracellular targets of this particular class of novel anti-mitotic compounds. It has revealed an unexpected target, mitochondrial MDH, the inhibition of which may participate in the pharmacological effects of paullones.	CNRS, Biol Stn, F-29682 Roscoff, France; Univ Hamburg, Inst Pharm, D-20146 Hamburg, Germany; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	Centre National de la Recherche Scientifique (CNRS); University of Hamburg; University of Glasgow	Meijer, L (corresponding author), CNRS, Biol Stn, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr		Kunick, Conrad/0000-0001-7041-5322; Mottram, Jeremy/0000-0001-5574-3766; Grant, Karen/0000-0002-0934-3873				Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96; Anderson SA, 1998, EXP PARASITOL, V89, P63, DOI 10.1006/expr.1998.4260; Anderson SA, 1998, MOL BIOCHEM PARASIT, V96, P185, DOI 10.1016/S0166-6851(98)00116-9; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1989, BIOCHEM SOC T, V17, P301, DOI 10.1042/bst0170301; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Fischer PM, 2000, CURR MED CHEM, V7, P1213, DOI 10.2174/0929867003374048; Garcia-Echeverria C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.3.CO;2-U; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GLEASON WB, 1994, BIOCHEMISTRY-US, V33, P2078, DOI 10.1021/bi00174a014; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; Grant KM, 1998, J BIOL CHEM, V273, P10153, DOI 10.1074/jbc.273.17.10153; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Gussio R, 2000, ANTI-CANCER DRUG DES, V15, P53; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hooijberg JH, 1999, BRIT J CANCER, V81, P269, DOI 10.1038/sj.bjc.6690687; Hooijberg JH, 1997, FEBS LETT, V413, P344, DOI 10.1016/S0014-5793(97)00940-X; Hunter GR, 2000, MOL BIOCHEM PARASIT, V105, P203, DOI 10.1016/S0166-6851(99)00176-0; JOH T, 1987, J BIOL CHEM, V262, P15127; Kaiser A, 2001, ARCH BIOCHEM BIOPHYS, V386, P179, DOI 10.1006/abbi.2000.2220; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; KNOCKAERT M, 2002, IN PRESS ONCOGENE; KREBS H. A., 1937, Enzymologia, V4, P148; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUNNASCH N, 1995, EXP PARASITOL, V80, P357, DOI 10.1006/expr.1995.1047; LANGUNNASCH N, 1992, MOL BIOCHEM PARASIT, V50, P17, DOI 10.1016/0166-6851(92)90240-K; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Mani S, 2000, EXPERT OPIN INV DRUG, V9, P1849, DOI 10.1517/13543784.9.8.1849; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; MOTTRAM JC, 1985, BIOCHIM BIOPHYS ACTA, V827, P310, DOI 10.1016/0167-4838(85)90216-X; MOTTRAM JC, 1985, EXP PARASITOL, V59, P265, DOI 10.1016/0014-4894(85)90081-5; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Musrati RA, 1998, GEN PHYSIOL BIOPHYS, V17, P193; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; Primot A, 2000, PROTEIN EXPRES PURIF, V20, P394, DOI 10.1006/prep.2000.1321; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; ROSANIA GR, 2000, EXPERT OPIN THER PAT, V10, P1; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2001, LEUKEMIA, V15, P1, DOI 10.1038/sj.leu.2401994; SHRAGO E, 1965, ARCH BIOCHEM BIOPHYS, V109, P57, DOI 10.1016/0003-9861(65)90286-9; SHRAGO E, 1963, BIOCHIM BIOPHYS ACTA, V73, P7; Sielecki TM, 2000, J MED CHEM, V43, P1, DOI 10.1021/jm990256j; Smith DG, 2001, BIOORG MED CHEM LETT, V11, P635, DOI 10.1016/S0960-894X(00)00721-6; Sridhar R, 2000, PHARM RES-DORDR, V17, P1345, DOI 10.1023/A:1007507224529; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WIEKING K, 2002, IN PRESS ARCH PHARM; Zaharevitz DW, 1999, CANCER RES, V59, P2566	59	126	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25493	25501		10.1074/jbc.M202651200	http://dx.doi.org/10.1074/jbc.M202651200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964410	hybrid			2022-12-27	WOS:000176747000085
J	Lubetsky, JB; Dios, A; Han, JL; Aljabari, B; Ruzsicska, B; Mitchell, R; Lolis, E; Al-Abed, Y				Lubetsky, JB; Dios, A; Han, JL; Aljabari, B; Ruzsicska, B; Mitchell, R; Lolis, E; Al-Abed, Y			The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MIF; CRYSTAL-STRUCTURE; PHENYLPYRUVATE TAUTOMERASE; RHEUMATOID-ARTHRITIS; MOLECULAR-CLONING; REGULATORY ROLE; HIGH EXPRESSION; CYTOKINE; ANGIOGENESIS; RESOLUTION	Macrophage migration inhibitory factor (MIF) is an immunoregulatory protein that is a potential therapeutic target for a number of inflammatory diseases. Evidence exists that an unexpected catalytic active site of MIF may have a biological function. To gain further insight into the role of the catalytic active site, a series of mutational, structural, and biological activity studies were performed. The insertion of an alanine between Pro-1 and Met-2 (PAM) abolishes a non-physiological catalytic activity, and this mutant is defective in the in vitro glucocorticoid counter-regulatory activity of MIF. The crystal structure of MIF complexed to (SR)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an inhibitor of MIF D-dopachrome tautomerase activity, reveals that ISO-1 binds to the same position of the active site as p-hydroxyphenylpyruvic acid, a substrate of MIF. ISO-1 inhibits several MIF biological activities, further establishing a role for the catalytic active site of MIF.	N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Northwell Health; Yale University; Yale University	Lolis, E (corresponding author), N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA.			Lolis, Elias/0000-0002-7902-7868				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; Benigni F, 2000, J CLIN INVEST, V106, P1291, DOI 10.1172/JCI9900; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1997, X PLOR 3 851 EDITION; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GEORGE M, 1962, P SOC EXP BIOL MED, V111, P514; Hermanowski-Vosatka A, 1999, BIOCHEMISTRY-US, V38, P12841, DOI 10.1021/bi991352p; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; Lan HY, 1996, AM J PATHOL, V149, P1119; Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B; Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Matsunaga J, 1999, J BIOL CHEM, V274, P3268, DOI 10.1074/jbc.274.6.3268; Matsunaga J, 1999, CELL MOL BIOL, V45, P1035; MIKAYAMA T, 1993, P NATL ACAD SCI USA, V90, P10056, DOI 10.1073/pnas.90.21.10056; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Onodera S, 1999, CYTOKINE, V11, P163, DOI 10.1006/cyto.1998.0402; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Sampey AV, 2001, ARTHRITIS RHEUM-US, V44, P1273, DOI 10.1002/1529-0131(200106)44:6<1273::AID-ART219>3.0.CO;2-8; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Swope MD, 1998, J BIOL CHEM, V273, P14877, DOI 10.1074/jbc.273.24.14877; Swope MD, 1999, REV PHYSIOL BIOCH P, V139, P1, DOI 10.1007/BFb0033647; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wityak J, 1997, J MED CHEM, V40, P50, DOI 10.1021/jm960626t; Xue CB, 1997, J MED CHEM, V40, P2064, DOI 10.1021/jm960799i	52	228	248	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24976	24982		10.1074/jbc.M203220200	http://dx.doi.org/10.1074/jbc.M203220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997397	hybrid			2022-12-27	WOS:000176747000019
J	Somanna, A; Mundodi, V; Gedamu, L				Somanna, A; Mundodi, V; Gedamu, L			Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex - Evidence for the activation of latent transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EXPRESSION; PROTEINASES; MECHANISMS; CELLS; GENE; ORGANIZATION; SUPPRESSION; INFECTION; RELEASE	Cathepsin B-like genes from Leishmania donovani and Leishmania chagasi have been isolated and characterized. It is a single gene, which is constitutively expressed in all the life cycle stages of the parasite. Studies using cathepsin B-specific inhibitor treatment suggested that cathepsin B does not seem to play a role in the promastigote stages of the parasite, however it aids in the parasite survival within the host macrophages. Antisense mRNA inhibition of cathepsin B gene also revealed that it plays an important role in the parasite survival within the host macrophages. Furthermore, for the first time, we have shown that Leishmania whole cell lysates as well as the recombinant cathepsin B protein cleaved human recombinant latent transforming growth factor (TGF)-beta1 into a mature peptide releasing the latency associated protein, in a cell-free incubation system. Mink lung epithelial cell growth inhibition assay revealed that the cleaved TGF-beta1 was biologically active, suggesting that Leishmania cathepsin B can cleave latent TGF-beta1 into mature and active form. These results suggest that cathepsin B plays an important role in Leishmania survival within the host macrophages by activating latent TGF-beta1.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Gedamu, L (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	lgedamu@ucalgary.ca						Adam PJ, 2000, CYTOKINE, V12, P348, DOI 10.1006/cyto.1999.0559; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Ankri S, 1999, INFECT IMMUN, V67, P421, DOI 10.1128/IAI.67.1.421-422.1999; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Bart G, 1997, MOL BIOCHEM PARASIT, V88, P53, DOI 10.1016/S0166-6851(97)00072-8; Bogdan C, 1997, Behring Inst Mitt, P58; Bogdan C, 1999, PARASITOL TODAY, V15, P22, DOI 10.1016/S0169-4758(98)01362-3; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535; Chan VJ, 1999, BIOCHEM J, V340, P113, DOI 10.1042/0264-6021:3400113; Chen DQ, 2000, INFECT IMMUN, V68, P80, DOI 10.1128/IAI.68.1.80-86.2000; CHU M, 2002, J BIOL CHEM, V277, P14829; Chu TM, 1998, BIOCHEM BIOPH RES CO, V253, P128, DOI 10.1006/bbrc.1998.9760; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Farrell PJ, 1998, BIOTECHNOL BIOENG, V60, P656, DOI 10.1002/(SICI)1097-0290(19981220)60:6<656::AID-BIT2>3.0.CO;2-9; Farrell PJ, 2000, PROTEINS, V41, P144, DOI 10.1002/1097-0134(20001001)41:1<144::AID-PROT160>3.3.CO;2-8; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; HUNTER CA, 1995, EUR J IMMUNOL, V25, P994, DOI 10.1002/eji.1830250420; Maekawa Y, 1998, J IMMUNOL, V161, P2120; MANIATIS F, 1989, MOL CLONING LAB MANU; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Mundodi V, 2002, GENE, V282, P257, DOI 10.1016/S0378-1119(01)00851-4; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; SchultzCherry S, 1996, J VIROL, V70, P8624, DOI 10.1128/JVI.70.12.8624-8629.1996; Spano F, 1998, MOL BIOCHEM PARASIT, V92, P147, DOI 10.1016/S0166-6851(97)00243-0; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; TSELENTIS Y, 1994, LANCET, V343, P1635, DOI 10.1016/S0140-6736(94)93085-6; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wilson ME, 1998, J IMMUNOL, V161, P6148	36	86	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25305	25312		10.1074/jbc.M203034200	http://dx.doi.org/10.1074/jbc.M203034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000761	Green Submitted, hybrid			2022-12-27	WOS:000176747000061
J	Romeo, AA; Capobianco, JA; English, AM				Romeo, AA; Capobianco, JA; English, AM			Heme nitrosylation of deoxyhemoglobin by S-nitrosoglutathione requires copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ELECTRON-TRANSFER; BLOOD; HEMOGLOBIN; NITROSOHEMOGLOBIN; GLUTATHIONE; MYOGLOBIN; OXIDATION; RELEASE; PROTEIN	NO reactions with hemoglobin (Hb) likely play a role in blood pressure regulation. For example, NO exchange between Hb and S-nitrosoglutathione (GSNO) has been reported in vitro. Here we examine the reaction between GSNO and deoxyHb (HbFe(II)) in the presence of both Cu(I) (2,9-dimethyl-1, 10-phenanthroline (neocuproine)) and Cu(II) (diethylenetriamine-N,N,N',N",N"-pentaacetic acid) chelators using a copper-depleted Hb solution. Spectroscopic analysis of deoxyHb (HbFe(II))/GSNO incubates shows prompt formation (<5 min) of similar to100% hemenitrosylated Hb (HbFe(II)NO) in the absence of chelators, 46% in the presence of diethylenetriamine-N,N,N',N",N"-pentaacetic acid, and 25% in the presence of neocuproine. Negligible (<2%) HbFe(II)NO was detected when neocuproine was added to copper-depleted HbFe(II)/GSNO incubates. Thus, HbFe(II)NO formation via a mechanism involving free NO generated by Cu(I) catalysis of GSNO breakdown is proposed. GSH is a source of reducing equivalents because extensive GSSG was detected in HbFe(II)/GSNO incubates in the absence of metal chelators. No S-nitrosation of HbFe(II) was detected under any conditions. In contrast, the NO released from GSNO is directed to Cysbeta(93) of oxyHb in the absence of chelators, but only metHb formation is observed in the presence of chelators. Our findings reveal that the reactions of GSNO and Hb are controlled by copper and that metal chelators do not fully inhibit NO release from GSNO in Hb-containing solutions.	Concordia Univ, Dept Biochem & Chem, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	English, AM (corresponding author), Concordia Univ, Dept Biochem & Chem, 1455 Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	english@vax2.concordia.ca	Romeo, Andrea Antonino/AAY-2175-2021	Romeo, Andrea Antonino/0000-0002-1579-2480				Abbyad P, 2001, J ANAL ATOM SPECTROM, V16, P464, DOI 10.1039/b100672j; ANTONINI E, 1964, J BIOL CHEM, V239, P907; Artz JD, 1998, CHEM RES TOXICOL, V11, P1393, DOI 10.1021/tx980205+; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; GARTNER A, 1983, FEBS LETT, V155, P15, DOI 10.1016/0014-5793(83)80199-9; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; IORIO EED, 1981, METHOD ENZYMOL, V76, P57; JAMES BR, 1961, J CHEM SOC, P2007, DOI 10.1039/jr9610002007; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kandori H, 1998, J AM CHEM SOC, V120, P5828, DOI 10.1021/ja980837i; KUMA F, 1981, J BIOL CHEM, V256, P5518; LEI YB, 1995, INORG CHEM, V34, P1083, DOI 10.1021/ic00109a014; Mahalingam TR, 1997, BIOL TRACE ELEM RES, V57, P223, DOI 10.1007/BF02785291; MAUK AG, 1979, BIOCHEM BIOPH RES CO, V86, P206, DOI 10.1016/0006-291X(79)90401-7; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; Noble DR, 2000, NITRIC OXIDE-BIOL CH, V4, P392, DOI 10.1006/niox.2000.0291; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pezacki JP, 2001, J AM CHEM SOC, V123, P4615, DOI 10.1021/ja015716o; Romeo AA, 2001, J AM CHEM SOC, V123, P1782, DOI 10.1021/ja005612y; SAMPATH V, 1994, BIOCHEM BIOPH RES CO, V198, P281, DOI 10.1006/bbrc.1994.1039; Scorza G, 1997, FREE RADICAL BIO MED, V22, P633, DOI 10.1016/S0891-5849(96)00378-4; Sheu FS, 2000, BIOPHYS J, V78, P1216, DOI 10.1016/S0006-3495(00)76679-3; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Spencer NY, 2000, J BIOL CHEM, V275, P36562, DOI 10.1074/jbc.M005347200; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Tsikas D, 2001, BBA-PROTEIN STRUCT M, V1546, P422, DOI 10.1016/S0167-4838(01)00166-2; Upmacis RK, 1997, J AM CHEM SOC, V119, P10424, DOI 10.1021/ja964249l; VANASSENDELFT OW, 1975, ANAL BIOCHEM, V69, P43, DOI 10.1016/0003-2697(75)90563-1; Williams DLH, 1999, ACCOUNTS CHEM RES, V32, P869, DOI 10.1021/ar9800439; WILLIAMS WJ, 1972, HEMATOLOGY, P11; [No title captured]	37	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24135	24141		10.1074/jbc.M202221200	http://dx.doi.org/10.1074/jbc.M202221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11970954	Green Accepted, hybrid			2022-12-27	WOS:000176611800022
J	Han, JH; Hajjar, DP; Zhou, XY; Gotto, AM; Nicholson, AC				Han, JH; Hajjar, DP; Zhou, XY; Gotto, AM; Nicholson, AC			Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression - A new mechanism of action for high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SCAVENGER RECEPTOR; PPAR-GAMMA; CELLULAR CHOLESTEROL; FATTY-ACIDS; IN-VITRO; SR-BI; PROTEIN; CD36; DIFFERENTIATION; BINDING	Cellular cholesterol content reflects a balance of lipid influx by lipoprotein receptors and endogenous synthesis and efflux to cholesterol acceptor particles. The beneficial effect of high density lipoprotein (HDL) in protecting against the development of cardiovascular disease is thought to be mediated predominately through its induction of cellular cholesterol efflux and reverse cholesterol transport" from peripheral tissues to the liver. We tested the hypothesis that HDL could inhibit cellular lipid accumulation by modulating expression of peroxisome proliferator-activated receptor-gamma (PPARgamma)-responsive genes. To this end, we, evaluated expression of two PPARgamma-responsive genes, CD36, a receptor for oxidized low density lipoprotein, and aP2, a fatty acid-binding protein. HDL decreased expression of macrophage CD36 and aP2 in a dose-dependent manner. HDL also decreased aP2 expression in fibroblasts, reduced accumulation of lipid, and slowed differentiation of fibroblasts into adipocytes. HDL stimulated mitogen-activated protein (MAP) kinase activity, and inhibition of CD36 expression was blocked by co-incubation with a MAP kinase inhibitor. HDL increased expression of PPARgamma mRNA and protein, induced translocation of PPARgamma from the cytoplasm to the nucleus, and increased PPARgamma phosphorylation. Our data demonstrate that despite induction and translocation of PPARgamma in response to HDL, ALAP kinase-mediated phosphorylation of PPARgamma inhibited expression of PPARgamma-responsive genes and suggest mechanisms by which HDL may inhibit cellular lipid accumulation.	Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Ctr Vasc Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Nicholson, AC (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol, 1300 York Ave, New York, NY 10021 USA.	nicholso@mail.med.cornell.edu			NHLBI NIH HHS [P50-HL56987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; AMRI EZ, 1991, J LIPID RES, V32, P1449; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; CALVO D, 1993, J BIOL CHEM, V268, P18929; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Fu YC, 2000, J LIPID RES, V41, P2017; GREENWALT DE, 1992, BLOOD, V80, P1105; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Han JH, 1999, J LIPID RES, V40, P830; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Xue JC, 1996, MOL CELL BIOL, V16, P1567; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	45	53	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23582	23586		10.1074/jbc.M200685200	http://dx.doi.org/10.1074/jbc.M200685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953427	hybrid			2022-12-27	WOS:000176475700063
J	Tanno, B; Negroni, A; Vitali, R; Pirozzoli, MC; Cesi, V; Mancini, C; Calabretta, B; Raschella, G				Tanno, B; Negroni, A; Vitali, R; Pirozzoli, MC; Cesi, V; Mancini, C; Calabretta, B; Raschella, G			Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; MESSENGER-RNA; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR (IGF)-I; CDNA CLONES; DIFFERENTIATION; ACTIVATION; RECEPTOR	Neuroblastoma (NB), a malignant childhood tumor deriving from the embryonic neural crest, is sensitive to the growth-stimulating effects of insulin-like growth factors (IGFs). Aggressive cases of this disease often acquire autocrine loops of IGF production, but the mechanisms through which the different components of the IGF axis are regulated in tumor cells remain unclear. Upon conditional expression of c-Myb in a NB cell line, we detected up-regulation of IGF1, IGF1 receptor, and insulin-like growth factor-binding protein 5 (IGFBP-5) expression. Analysis of the IGFBP-5 promoter revealed two potential Myb binding sites at position -59 to -54 (M1) and -429 to -424 (M2) from the transcription start site; both sites were bound by c-Myb and BMyb in vitro and in vivo. Reporter assays carried out using the proximal region of the human IGFBP-5 promoter demonstrated that c-Myb and B-Myb enhanced transcription. However, site-directed mutagenesis and deletion of the Myb binding sites coupled with reporter assays revealed that M2 but not M1 was important for Myb-dependent transactivation of the IGFBP-5 promoter. The double mutant M1/M2 was still transactivated by c-Myb, suggesting the existence of Myb binding-independent mechanisms of IGFBP-5 promoter regulation. A constitutively active AKT transactivated the IGFBP-5 promoter, whereas the phosphatidylinositol 3-kinase inhibitor LY294002 suppressed it. Moreover, the kinase dead dominant negative K179M AHT mutant was able to inhibit transcription from the M2 and M1/M2 IGFBP-5 mutant promoters. Deletion analysis of the IGFBP-5 promoter revealed that the AKT-responsive region lies between nucleotides -334 and -83. Together, these data suggest that the Myb binding-independent transactivation of the IGFBP-5 promoter was due to the activation of the phosphatidylinositol 3-kinase/AKT pathway likely mediated by IGF1 receptor-dependent signals. Finally, IGFBP-5 was able to modulate proliferation of NB cells in a manner dependent on its concentration and on the presence of IGFs.	ENEA, Sect Toxicol & Biomed Sci, I-00060 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Italian National Agency New Technical Energy & Sustainable Economics Development; Jefferson University	Raschella, G (corresponding author), ENEA, Sect Toxicol & Biomed Sci, Via Anguillarese 301, I-00060 Rome, Italy.	raschella@casaccia.enea.it	Vitali, Roberta/K-2509-2016; Negroni, Anna/GLS-2306-2022	Vitali, Roberta/0000-0003-4203-0163; Negroni, Anna/0000-0002-2273-8837				ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Andress DL, 2001, AM J PHYSIOL-ENDOC M, V281, pE283, DOI 10.1152/ajpendo.2001.281.2.E283; Baxter RC, 2001, J CLIN PATHOL-MOL PA, V54, P145, DOI 10.1136/mp.54.3.145; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; el-Badry O M, 1992, Cancer Treat Res, V63, P105; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; ELBADRY OM, 1991, PROG CLIN BIOL RES, V366, P257; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FIELDER PJ, 1993, GROWTH REGULAT, V3, P226; Franchimont N, 1997, ENDOCRINOLOGY, V138, P3380, DOI 10.1210/en.138.8.3380; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Gabbitas B, 1996, J BIOL CHEM, V271, P9033, DOI 10.1074/jbc.271.15.9033; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KOGNER P, 1993, CANCER RES, V53, P2044; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; MATSUMOTO K, 1992, ENDOCRINOLOGY, V130, P3669, DOI 10.1210/en.130.6.3669; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; PAGTERHOLTHUIZE.P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Pash JM, 1996, ENDOCRINOLOGY, V137, P2375, DOI 10.1210/en.137.6.2375; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1999, CANCER RES, V59, P3365; RASCHELLA G, 1992, CANCER RES, V52, P4221; Raschella G, 1996, EXP CELL RES, V222, P395, DOI 10.1006/excr.1996.0049; REISS K, 1991, CANCER RES, V51, P5997; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Rousse S, 2001, J BIOL CHEM, V276, P46961, DOI 10.1074/jbc.M104440200; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SAWADA T, 1987, MED PEDIATR ONCOL, V15, P14, DOI 10.1002/mpo.2950150104; SCHULLER AGP, 1993, ENDOCRINOLOGY, V132, P2544, DOI 10.1210/en.132.6.2544; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; Tonner E, 2000, ADV EXP MED BIOL, V480, P45; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wulbrand U, 2000, EUR J CLIN INVEST, V30, P729; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Yeh LCC, 1998, J CELL PHYSIOL, V175, P78, DOI 10.1002/(SICI)1097-4652(199804)175:1<78::AID-JCP9>3.0.CO;2-9; Yeh LCC, 2000, ENDOCRINOLOGY, V141, P3278, DOI 10.1210/en.141.9.3278; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	68	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23172	23180		10.1074/jbc.M200141200	http://dx.doi.org/10.1074/jbc.M200141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973331	hybrid			2022-12-27	WOS:000176475700012
J	Boll, M; Foltz, MT; Rubio-Aliaga, I; Kottra, G; Daniel, H				Boll, M; Foltz, MT; Rubio-Aliaga, I; Kottra, G; Daniel, H			Functional characterization of two novel mammalian electrogenic proton-dependent amino acid cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL-MEMBRANE-VESICLES; CACO-2 CELL MONOLAYERS; ELECTROCHEMICAL GRADIENT; RENAL TRANSPORT; VESICULAR GABA; L-ALANINE; SYSTEM-N; LOCALIZATION; IDENTIFICATION; ABSORPTION	We cloned two cDNAs encoding proton/amino acid co-transporters, designated as mPAT1 and mPAT2, from murine tissues. They were identified by sequence similarity to the amino acid/auxin permease family member of lower eukaryotes. We functionally characterized both transporters by flux studies and electrophysiology after expression in Xenopus laevis oocytes. Both mPAT1 and mPAT2 induced a pH-dependent electrogenic transport activity for small amino acids (glycine, alanine, and proline) that is altered by membrane potential. Direct evidence for amino acid/H+-symport was shown by intracellular acidification, and a flux coupling stoichiometry for proline/H+-symport of 1:1 was determined for both transporters. Besides small apolar L-amino acids, the transporters also recognize their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid. The mPAT1 transporter, the marine orthologue of the recently cloned rat LYAAT-1 transporter, can be considered as a low affinity system when compared with mPAT2. The mRNA of mPAT1 is highly expressed in small intestine, colon, kidney, and brain; the mPAT2-mRNA is mainly found in heart and lung. Phenotypically, the PAT1 transporter possesses the same functional characteristics as the previously described proton-dependent amino acid transport process in apical membranes of intestinal and renal epithelial cells.	Tech Univ Munich, Inst Nutr Sci, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Daniel, H (corresponding author), Tech Univ Munich, Inst Nutr Sci, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany.		Daniel, Hannelore/B-8982-2009	Rubio-Aliaga, Isabel/0000-0003-1051-9511				Bockman DE, 1997, INT J PANCREATOL, V22, P221; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; JESSEN H, 1988, BIOCHIM BIOPHYS ACTA, V942, P262; JORGENSEN KE, 1987, BIOCHEM J, V248, P533, DOI 10.1042/bj2480533; Kottra G, 2001, J PHYSIOL-LONDON, V536, P495, DOI 10.1111/j.1469-7793.2001.0495c.xd; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Ogihara H, 1996, BIOCHEM BIOPH RES CO, V220, P848, DOI 10.1006/bbrc.1996.0493; PISONI RL, 1987, J BIOL CHEM, V262, P6010; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; ROIGAARDPETERSEN H, 1989, BIOCHIM BIOPHYS ACTA, V984, P231, DOI 10.1016/0005-2736(89)90221-6; ROIGAARDPETERSEN H, 1990, AM J PHYSIOL, V258, pF388, DOI 10.1152/ajprenal.1990.258.2.F388; Russnak R, 2001, J BIOL CHEM, V276, P23849, DOI 10.1074/jbc.M008028200; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; Saier MH, 2000, MICROBIOL-SGM, V146, P1775, DOI 10.1099/00221287-146-8-1775; Shen H, 1999, AM J PHYSIOL-RENAL, V276, pF658, DOI 10.1152/ajprenal.1999.276.5.F658; THWAITES DT, 1994, J MEMBRANE BIOL, V140, P143; THWAITES DT, 1993, FEBS LETT, V333, P78, DOI 10.1016/0014-5793(93)80378-8; Thwaites DT, 2000, BRIT J PHARMACOL, V129, P457, DOI 10.1038/sj.bjp.0703069; THWAITES DT, 1995, J MEMBRANE BIOL, V145, P245; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5	24	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22966	22973		10.1074/jbc.M200374200	http://dx.doi.org/10.1074/jbc.M200374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959859	hybrid			2022-12-27	WOS:000176313600110
J	Cook, SA; Matsui, T; Li, L; Rosenzweig, A				Cook, SA; Matsui, T; Li, L; Rosenzweig, A			Transcriptional effects of chronic Akt activation in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; BETA SUPERFAMILY MEMBER; IGF-BINDING PROTEIN-5; NF-KAPPA-B; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CARDIOVASCULAR-SYSTEM; NEURONAL SURVIVAL; SIGNALING PATHWAY; CARDIAC MYOCYTES	Akt activation reduces cardiomyocyte death and induces cardiac hypertrophy. To help identify effector mechanisms, gene expression profiles in hearts from transgenic mice with cardiac-specific expression of activated Akt (myr-Akt) were compared with littermate controls. 40 genes were identified as differentially expressed. Quantitative reverse transcription-PCR confirmed qualitative results of transcript profiling for 9 of 10 genes examined, however, there were notable quantitative discrepancies between the quantitative reverse transcription-PCR and microarray data sets. Interestingly Akt induced significant up-regulation of insulin-like growth factor-binding protein-5 (IGFBP-5), which could contribute to its anti-apoptotic effects in the heart. In addition, Akt-mediated down-regulation of peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 (PGC-1) and PPAR-alpha may shift myocytes toward glycolytic metabolism shown to preserve cardiomyocyte function and survival during transient ischemia. IGFBP-5 transcripts also increased after adenoviral gene transfer of myr-Akt to cultured cardiomyocytes, suggesting that this represents a direct effect of Akt activation. In contrast, substantial induction of growth differentiation factor-8 (GDF-8), a highly conserved inhibitor of skeletal muscle growth, was observed in transgenic hearts but not after acute Akt activation in vitro, suggesting that GDF-8 induction may represent a secondary effect perhaps related to the cardiac hypertrophy seen in these mice. Thus, microarray analysis reveals previously unappreciated Akt regulation of genes that could contribute to the effects of Akt on cardiomyocyte survival, metabolism, and growth.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Program Cardiovasc Gene Therap, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Rosenzweig, A (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Program Cardiovasc Gene Therapy, 114 16th St,Rm 2600, Charlestown, MA 02129 USA.	Rosenzweig@helix.mgh.harvard.edu	Cook, Stuart/G-9567-2011	Cook, Stuart/0000-0001-6628-194X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061557, K08HL004250, R01HL059521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-04250, HL-59521, HL-61557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APSTEIN CS, 1983, CIRC RES, V52, P515, DOI 10.1161/01.RES.52.5.515; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cook SA, 1999, CIRC RES, V85, P940; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fishman GI, 1998, CIRC RES, V82, P837; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; Godecke A, 2000, BASIC RES CARDIOL, V95, P492, DOI 10.1007/s003950070026; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jonassen AK, 2001, CIRC RES, V89, P1191, DOI 10.1161/hh2401.101385; Kerr SM, 1996, HUM MOL GENET, V5, P1139, DOI 10.1093/hmg/5.8.1139; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Knight J, 2001, NATURE, V410, P860, DOI 10.1038/35073680; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; MATSUI T, 2002, IN PRESS J BIOL CHEM, V277; McCaig C, 2002, J CELL BIOCHEM, V84, P784, DOI 10.1002/jcb.10093; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Neville C, 1996, DEV GENET, V19, P157, DOI 10.1002/(SICI)1520-6408(1996)19:2<157::AID-DVG7>3.0.CO;2-8; Ozes ON, 1999, NATURE, V401, P82; Perks CM, 2000, J CELL BIOCHEM, V80, P248; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Proud CG, 1997, BIOCHEM J, V328, P329; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roschier M, 2001, J NEUROCHEM, V76, P11, DOI 10.1046/j.1471-4159.2001.00002.x; Sharma M, 1999, J CELL PHYSIOL, V180, P1; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	164	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22528	22533		10.1074/jbc.M201462200	http://dx.doi.org/10.1074/jbc.M201462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956204	hybrid			2022-12-27	WOS:000176313600056
J	Musib, R; Wang, GF; Geng, L; Rubenstein, PA				Musib, R; Wang, GF; Geng, L; Rubenstein, PA			Effect of polymerization on the subdomain 3/4 loop of yeast actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; SACCHAROMYCES-CEREVISIAE; MYOSIN; FILAMENTS; DYNAMICS; MODEL; REFINEMENT; STABILITY; MUTATION; TERMINUS	The Holmes F-actin model predicts a polymerization-dependent conformation change of a subdomain 3/4 loop with a hydrophobic tip (residues 266-269), allowing interaction with a hydrophobic surface on the opposing strand of the filament producing filament stabilization. We introduced cysteines in place of Val(266), Leu(267), and Leu(269) in yeast actin to allow attachment of pyrene maleimide. Pyrene at each of these positions produced differing fluorescence spectra in G-actin. Polymerization decreased the fluorescence for the 266 and 267 probes and increased that for the 269 probe. The direction of the fluorescence change was mirrored with a smaller and less hydrophobic probe, acrylodan, when attached to 266 or 269. Following polymerization, increased acrylamide quenching was observed for pyrene at 266 or 267 but not 269. The 267 probe was the least accessible of the three in G- and F-actin. F-actin quenching was biphasic for the 265, 266, and 269 but not 267 probes, suggesting that in F-actin, the pyrene samples multiple environments. Finally, in F-actin the probe at 266 interacts with one at Cys(374) on a monomer in the opposing strand, producing a pyrene excimer band. These results indicate a polymerization-dependent movement of the subdomain 3/4 loop partially consistent with Holmes' model.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Wang, Gufeng/B-3972-2011	Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; COOK RK, 1991, J BIOL CHEM, V266, P16825; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P8; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Prochniewicz E, 1997, BIOCHEMISTRY-US, V36, P12845, DOI 10.1021/bi971201r; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; TAO T, 1979, BIOCHEMISTRY-US, V18, P2759, DOI 10.1021/bi00580a011; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; Wriggers W, 1997, BIOPHYS J, V73, P624, DOI 10.1016/S0006-3495(97)78098-6; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	26	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22699	22709		10.1074/jbc.M203096200	http://dx.doi.org/10.1074/jbc.M203096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959868	hybrid			2022-12-27	WOS:000176313600078
J	Rautavuoma, K; Takaluoma, K; Passoja, K; Pirskanen, A; Kvist, AP; Kivirikko, KI; Myllyharju, J				Rautavuoma, K; Takaluoma, K; Passoja, K; Pirskanen, A; Kvist, AP; Kivirikko, KI; Myllyharju, J			Characterization of three fragments that constitute the monomers of the human lysyl hydroxylase isoenzymes 1-3 - The 30-kDa N-terminal fragment is not required for lysyl hydroxylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; HUMAN PROLYL 4-HYDROXYLASE; COLLAGEN; IDENTIFICATION; CLONING; ISOFORM; TISSUE; GENE; EXPRESSION; CARTILAGE	Lysyl hydroxylase (LH) catalyzes the formation of hydroxylysine in collagens; three human isoenzymes have been cloned so far. We report here on the purification of all three recombinant isoenzymes to homogeneity from the medium of cultured insect cells, and we demonstrate that they are all homodimers. Limited proteolysis experiments identified two main protease-sensitive regions in the monomers of about 80-85 kDa, corresponding to three fragments A-C (from the N to C terminus), with molecular masses of about 30, 37, and 16 kDa, respectively. Fragment A was found to play no role in LH activity as a recombinant B-C polypeptide constituted a fully active hydroxylase with K-m values for cosubstrates and the peptide substrate that were identical to those of the full-length enzyme. LH3, but not LH1 and LH2, has also been reported recently (Heikkinen, J., Risteli, M., Wang, C., Latvala, J., Rossi, M., Valtavaara, M., and Myllyla, R. (2000) J. Biol, Chem. 275, 36158-36163) to possess collagen glucosyltransferase activity. We confirm this highly surprising finding here and extend it by demonstrating that LH3 may also possess trace amounts of collagen galactosyltransferase activity. All the glucosyltransferase and galactosyltransferase activity of LH3 was found to reside in fragment A, which played no role in the hydroxylase activity of the polypeptide. This fragment is about 55% identical and 80% similar to the corresponding fragments of LH1 and LH2. However, the levels of the glycosyltransferase activities are so low that they may be of little biological significance. It is thus evident that human tissues must have additional glycosyltransferases that are responsible for most of the collagen glycosylation in vivo.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.							ANTTINEN H, 1978, BIOCHEM J, V175, P737, DOI 10.1042/bj1750737; Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BYERS PH, 1995, METABOLIC MOL BASES, P4029; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; Krol BJ, 1996, J INVEST DERMATOL, V106, P11, DOI 10.1111/1523-1747.ep12326956; KUUTTISAVOLAINEN ER, 1979, CLIN CHIM ACTA, V96, P53, DOI 10.1016/0009-8981(79)90051-2; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; MYLLYLA R, 1988, BIOCHEM J, V253, P489, DOI 10.1042/bj2530489; MYLLYLA R, 1975, EUR J BIOCHEM, V52, P401, DOI 10.1111/j.1432-1033.1975.tb04008.x; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Notbohm H, 1999, J BIOL CHEM, V274, P8988, DOI 10.1074/jbc.274.13.8988; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P40, DOI 10.1016/0005-2744(80)90040-6; TURPEENNIEMIHUJANEN TM, 1980, BIOCHEM J, V189, P247, DOI 10.1042/bj1890247; TURPEENNIEMIHUJANEN TM, 1981, COLLAGEN REL RES, V1, P355; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Wingfield P. T., 1998, CURRENT PROTOCOLS PR; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; YEOWELL HN, 1992, J INVEST DERMATOL, V99, P864, DOI 10.1111/1523-1747.ep12614840; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	35	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23084	23091		10.1074/jbc.M112077200	http://dx.doi.org/10.1074/jbc.M112077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956192	hybrid			2022-12-27	WOS:000176313600124
J	van Tiel, CM; Westerman, J; Paasman, MA; Hoebens, MM; Wirtz, KWA; Snoek, GT				van Tiel, CM; Westerman, J; Paasman, MA; Hoebens, MM; Wirtz, KWA; Snoek, GT			The Golgi localization of phosphatidylinositol transfer protein beta requires the protein kinase C-dependent phosphorylation of serine 262 and is essential for maintaining plasma membrane sphingomyelin levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEINS; BOVINE BRAIN; HL-60 CELLS; RAT-BRAIN; YEAST; ALPHA; TRANSPORT; ISOFORM; BINDING	Recombinant mouse phosphatidylinositol transfer protein (PI-TP)beta is a substrate for protein kinase C (PKC)-dependent phosphorylation in vitro. Based on site-directed mutagenesis and two-dimensional tryptic peptide mapping, Ser(262) was identified as the major site of phosphorylation and Ser(165) as a minor phosphorylation site. The phospholipid transfer activities of wild-type PI-TPbeta and PI-TPbeta(S262A) were identical, whereas PI-TPbeta(S165A) was completely inactive. PKC-dependent phosphorylation of Ser(262) also had no effect on the transfer activity of PI-TPbeta. To investigate the role of Ser(262) in the function in of PI-TPO, wtPI-TPbeta and PI-TPbeta(S262A) were overexpressed in NIH3T3 fibroblast cells. Two-dimensional PAGE analysis of cell lysates was used to separate PI-TPbeta from its phosphorylated form. After Western blotting, wtPI-TPbeta was found to be 85% phosphorylated, whereas PI-TPbeta(S262A) was not phosphorylated. In the presence of the PKC inhibitor GF 109203X, the phosphorylated form of wtPI-TPbeta was strongly reduced. Immunolocalization showed that wtPI-TPbeta was predominantly associated with the Golgi membranes. In the presence of the PKC inhibitor, w-tPI-TPbeta was distributed throughout the cell similar to what was observed for PI-TPbeta(S262A). In contrast to wtPI-TPbeta overexpressors, cells overexpressing PI-TPbeta(S262A) were unable to rapidly replenish sphingomyelin in the plasma membrane upon degradation by sphingomyelinase. This implies that PKC-dependent association with the Golgi complex is a prerequisite for PI-TPbeta to express its effect on sphingomyelin metabolism.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Lipid Biochem, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	van Tiel, CM (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Lipid Biochem, Inst Biomembranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	c.vantiel@chem.uu.nl						Alb JG, 2002, MOL BIOL CELL, V13, P739, DOI 10.1091/mbc.01-09-0457; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; DeVries KJ, 1996, EXP CELL RES, V227, P33, DOI 10.1006/excr.1996.0246; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; HELMKAMP GM, 1985, CHEM PHYS LIPIDS, V38, P3, DOI 10.1016/0009-3084(85)90053-2; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HUANG KP, 1986, J BIOL CHEM, V261, P2134; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mwanjewe J, 2001, BIOCHEM J, V359, P211, DOI 10.1042/0264-6021:3590211; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Snoek GT, 1999, J BIOL CHEM, V274, P35393, DOI 10.1074/jbc.274.50.35393; SNOEK GT, 1993, BIOCHEM J, V291, P649, DOI 10.1042/bj2910649; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TIMMERMANSHEREIJGERS JLPM, 1995, J BIOL CHEM, V270, P14263, DOI 10.1074/jbc.270.24.14263; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; van Tiel CM, 2000, BIOCHEM J, V346, P537, DOI 10.1042/0264-6021:3460537; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200	30	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22447	22452		10.1074/jbc.M201532200	http://dx.doi.org/10.1074/jbc.M201532200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953429	hybrid			2022-12-27	WOS:000176313600045
J	Gil-Parrado, S; Fernandez-Montalvan, A; Assfalg-Machleidt, I; Popp, O; Bestvater, F; Holloschi, A; Knoch, TA; Auerswald, EA; Welsh, K; Reed, JC; Fritz, H; Fuentes-Prior, P; Spiess, E; Salvesen, GS; Machleidt, W				Gil-Parrado, S; Fernandez-Montalvan, A; Assfalg-Machleidt, I; Popp, O; Bestvater, F; Holloschi, A; Knoch, TA; Auerswald, EA; Welsh, K; Reed, JC; Fritz, H; Fuentes-Prior, P; Spiess, E; Salvesen, GS; Machleidt, W			Lonomycin-activated calpain triggers apoptosis - A probable role for Bcl-2 family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE DOWN-REGULATION; CELL-DEATH; CASPASE ACTIVATION; CYTOCHROME-C; T-CELLS; PROTEIN; CALCIUM; MITOCHONDRIA; CLEAVAGE; BAX	Ubiquitous calpains (mu- and m-calpain) have been repeatedly implicated in apoptosis, but the underlying mechanism(s) remain(s) to be elucidated. We examined ionomycin-induced cell death in LCLC 103H cells, derived from a human large cell lung carcinoma. We detected hallmarks of apoptosis such as membrane blebbing, nuclear condensation, DNA ladder formation, caspase activation, and poly-(ADP-ribose)polymerase cleavage. Apoptosis was prevented by preincubation of the cells with the calpain inhibitor acetyl-calpastatin 27-peptide and the caspase inhibitor Z-DEVD-fmk, implicating both the calpains and caspases in the apoptotic process. The apoptotic events correlated in a calpastatin-inhibitable manner with Bid and Bcl-2 decrease and with activation of caspases-9, -3, and -7. In vitro both ubiquitous calpains cleaved recombinant Bcl-2, Bid, and Bcl-X-L at single sites truncating their N-terminal regions. Binding studies revealed diminished interactions of calpain-truncated Bcl-2 and Bid with immobilized intact Bcl-2 family proteins. Moreover, calpain-cleaved Bcl-2 and Bid induced cytochrome c release from isolated mitochondria. We conclude that ionomycin-induced calpain activation promotes decrease of Bcl-2 proteins thereby triggering the intrinsic apoptotic pathway.	Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Fachhsch Mannheim, Inst Molekularbiol & Zellkulturtech, D-68163 Mannheim, Germany; Burnham Inst, La Jolla, CA 92037 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Sanford Burnham Prebys Medical Discovery Institute; Max Planck Society	Gil-Parrado, S (corresponding author), Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	shirgilpa@web.de		Fuentes-Prior, Pablo/0000-0002-6618-3204; Fernandez-Montalvan, Amaury/0000-0001-9156-0000				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Buki A, 2000, J NEUROSCI, V20, P2825; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; FURUYA Y, 1994, CANCER RES, V54, P6167; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAFNER M, 1988, CELL MOTIL CYTOSKEL, V9, P271, DOI 10.1002/cm.970090309; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsumura Y, 2001, J MOL CELL CARDIOL, V33, P1133, DOI 10.1006/jmcc.2001.1373; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Squier MKT, 1997, J IMMUNOL, V158, P3690; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Xie ZH, 2000, METHOD ENZYMOL, V322, P266; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	67	168	176	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27217	27226		10.1074/jbc.M202945200	http://dx.doi.org/10.1074/jbc.M202945200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12000759	Green Published, hybrid			2022-12-27	WOS:000177055900067
J	Radeke, HH; Janssen-Graalfs, I; Sowa, EN; Chouchakova, N; Skokowa, J; Loscher, F; Schmidt, RE; Heeringa, P; Gessner, JE				Radeke, HH; Janssen-Graalfs, I; Sowa, EN; Chouchakova, N; Skokowa, J; Loscher, F; Schmidt, RE; Heeringa, P; Gessner, JE			Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIII; AUTOIMMUNE-DISEASE; DEFICIENT MICE; IN-VIVO; IGG; EXPRESSION; CHEMOKINE; COMPLEMENT; COMPLEXES; INJURY	We examined the capacity of mouse glomerular mesangial cells (MC) to express and function through two different low affinity FcgammaRs, the activating FcgammaRIII and the inhibitory FcgammaRII. Immunohistochemistry identified FcgammaRII as the prominent FcgammaR in the kidney, and low levels of FcgammaRIIb2-specific mRNA were also detected in primary cultures of growth-arrested MC. Activation by tumor necrosis factor-alpha/interleukin-1beta induced substantial FcgammaRII expression in proliferating MC. Importantly, however, stimulation with interferon-gamma (IFN-gamma)/lipopolysaccharide or IFN-gamma alone resulted in a complete down-regulation of FcgammaRII, which was accompanied by a strong increase in FcRgamma chain mRNA and a surface appearance of FcgammaRIII. Activating FcgammaRIII triggered mRNA synthesis for monocyte chemoattractant protein-1 (MCP-1), MCP-5, cytokine-induced neutrophil chemoattractant, and RANTES, whereas FcgammaRIII-deficient MC failed to respond to immune complex (IC) activation as shown by impaired production of MCP-1 mRNA/protein. In a passive model of acute anti-glomerular basement membrane (GBM) nephritis, induction of FcgammaRIII and suppression of FcgammaRII occurred in kidney tissues. Blockade of FcgammaRII, when induced selectively in the kidney, resulted in enhanced inflammation. Taken together, our results define a novel regulatory pathway with opposite regulation of FcgammaRII (suppressed) and FcgammaRIII (induced) by IFN-gamma on MCs in vitro and anti-GBM IgG in vivo. Herein is provided the first evidence that glomerular FcgammaRII plays an important immunoregulatory role in the initiation of IC glomerulonephritis.	Hannover Med Sch, Abt Klin Immunol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Clin Goethe Univ, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; Univ Maastricht, Dept Immunol, NL-6221 ER Maastricht, Netherlands	Hannover Medical School; Hannover Medical School; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Maastricht University	Gessner, JE (corresponding author), Hannover Med Sch, Abt Klin Immunol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Gessner.Johannes@MH-Hannover.de	Radeke, Heinfried H/E-3772-2013; Heeringa, Peter/A-6008-2009; Skokowa, Julia/AAU-3622-2021	Radeke, Heinfried H/0000-0002-4499-2510; Heeringa, Peter/0000-0001-8684-763X; Skokowa, Julia/0000-0002-4399-2324				Ambrus JL, 1997, JAMA-J AM MED ASSOC, V278, P1938, DOI 10.1001/jama.278.22.1938; Anders HJ, 2001, J AM SOC NEPHROL, V12, P919, DOI 10.1681/ASN.V125919; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; Baumann U, 2001, J IMMUNOL, V167, P1022, DOI 10.4049/jimmunol.167.2.1022; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; BRINI AT, 1993, J BIOL CHEM, V268, P1355; Chouchakova N, 2001, J IMMUNOL, V166, P5193, DOI 10.4049/jimmunol.166.8.5193; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Coxon A, 2001, IMMUNITY, V14, P693, DOI 10.1016/S1074-7613(01)00150-9; DAERON M, 1992, J IMMUNOL, V149, P1365; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FLOEGE J, 1990, KIDNEY INT, V37, P859, DOI 10.1038/ki.1990.59; FLOEGE J, 1994, KIDNEY INT, V45, P360, DOI 10.1038/ki.1994.46; Fossati-Jimack L, 2000, J EXP MED, V191, P1293, DOI 10.1084/jem.191.8.1293; FRANCKI A, 1995, AM J PATHOL, V147, P1372; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; GUYRE PM, 1989, J IMMUNOL, V143, P1650; Hazenbos WLW, 1998, J IMMUNOL, V161, P3026; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Heller T, 1999, J IMMUNOL, V162, P5657; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P7706, DOI 10.1073/pnas.82.22.7706; HORA K, 1992, P NATL ACAD SCI USA, V89, P1745, DOI 10.1073/pnas.89.5.1745; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Luo Y, 1999, J IMMUNOL, V163, P3985; Madaio MP, 1999, SEMIN NEPHROL, V19, P48; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; Meyer D, 1998, BLOOD, V92, P3997, DOI 10.1182/blood.V92.11.3997.423k52_3997_4002; Mitchell DA, 1999, J IMMUNOL, V162, P5676; Moore KJ, 1998, KIDNEY INT, V53, P1631, DOI 10.1046/j.1523-1755.1998.00911.x; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; Quigg RJ, 1998, KIDNEY INT, V53, P320, DOI 10.1046/j.1523-1755.1998.00723.x; RA C, 1989, J BIOL CHEM, V264, P15323; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; RADEKE HH, 1994, KIDNEY INT, V45, P763, DOI 10.1038/ki.1994.101; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; SANTIAGO A, 1991, KIDNEY INT, V39, P87, DOI 10.1038/ki.1991.11; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Schiller C, 2000, EUR J IMMUNOL, V30, P481; SCHRIJVER G, 1990, KIDNEY INT, V38, P86, DOI 10.1038/ki.1990.171; SEARS DW, 1990, J IMMUNOL, V144, P371; Suzuki Y, 1998, KIDNEY INT, V54, P1166, DOI 10.1046/j.1523-1755.1998.00108.x; Sylvestre DL, 1996, IMMUNITY, V5, P387, DOI 10.1016/S1074-7613(00)80264-2; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; Uciechowski P, 1998, EUR J IMMUNOL, V28, P2928, DOI 10.1002/(SICI)1521-4141(199809)28:09<2928::AID-IMMU2928>3.0.CO;2-8; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187; Zernecke A, 2001, J IMMUNOL, V166, P5755, DOI 10.4049/jimmunol.166.9.5755	59	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27535	27544		10.1074/jbc.M200419200	http://dx.doi.org/10.1074/jbc.M200419200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11983693	hybrid			2022-12-27	WOS:000177055900104
J	Guo, WN; Malin, SA; Johns, DC; Jeromin, A; Nerbonne, JM				Guo, WN; Malin, SA; Johns, DC; Jeromin, A; Nerbonne, JM			Modulation of Kv4-encoded K+ currents in the mammalian myocardium by neuronal calcium sensor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; ADRENAL CHROMAFFIN CELLS; CHANNEL BETA-SUBUNITS; LONG-QT SYNDROME; BINDING-PROTEIN; GENE-TRANSFER; POTASSIUM CHANNELS; NERVOUS-SYSTEM; ALPHA-SUBUNITS; RAT VENTRICLE	Voltage-gated K+ channels are multimeric proteins, consisting of four pore-forming alpha-subunits alone or in association with accessory subunits. Recently, for example, it was shown that the accessory Kv channel interacting proteins form complexes with Kv4 alpha-subunits and modulate Kv4 channel activity. The experiments reported here demonstrate that the neuronal calcium sensor protein-1 (NCS-1), another member of the recoverin-neuronal calcium sensor superfamily, is expressed in adult mouse ventricles and that NCS-1 co-immunoprecipitates with Kv4.3 from (adult mouse) ventricular extracts. In addition, co-expression studies in HEK-293 cells reveal that NCS-1 increases membrane expression of Kv4 a-subunits and functional Kv4-encoded K+ current densities. Co-expression of NCS-1 also decreases the rate of inactivation of Kv4 a-subunit-encoded K+ currents. In contrast to the pronounced effects of Kv channel interacting proteins on Kv4 channel gating, however, NCS-1 co-expression does not measurably affect the voltage dependence of steady-state inactivation or the rate of recovery from inactivation of Kv4-encoded K+ currents. Taken together, these results suggest that NCS-1 is an accessory subunit of Kv4-encoded I-to,I-f channels that functions to regulate Ito,f density in the mammalian myocardium.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Washington University (WUSTL); Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Nerbonne, JM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066388] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66388, HL34161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Antzelevitch C, 1999, J ELECTROCARDIOL, V32, P158, DOI 10.1016/S0022-0736(99)90074-2; Antzelevitch C, 2002, HDB PHYSL 2, P654; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Guo WN, 2002, CIRC RES, V90, P586, DOI 10.1161/01.RES.0000012664.05949.E0; Guo WN, 2001, CIRCULATION, V104, P78; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Johns DC, 1999, J NEUROSCI, V19, P1691; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Nerbonne JM, 1998, J NEUROBIOL, V37, P37, DOI 10.1002/(SICI)1097-4695(199810)37:1<37::AID-NEU4>3.0.CO;2-9; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Romero MI, 1998, GENE THER, V5, P1612, DOI 10.1038/sj.gt.3300774; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Xu HD, 1996, J GEN PHYSIOL, V108, P405, DOI 10.1085/jgp.108.5.405; Xu HD, 1999, J GEN PHYSIOL, V113, P661, DOI 10.1085/jgp.113.5.661; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	41	74	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26436	26443		10.1074/jbc.M201431200	http://dx.doi.org/10.1074/jbc.M201431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994284	hybrid			2022-12-27	WOS:000176908700081
J	Ketteler, R; Heinrich, AC; Offe, JK; Becker, V; Cohen, J; Neumann, D; Klingmuller, U				Ketteler, R; Heinrich, AC; Offe, JK; Becker, V; Cohen, J; Neumann, D; Klingmuller, U			A functional green fluorescent protein-tagged erythropoietin receptor despite physical separation of JAK2 binding site and tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TRANSMEMBRANE DOMAIN; CYTOKINE RECEPTORS; ACTIVATION; IDENTIFICATION; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION; PROGENITORS; HORMONE	Signaling through hematopoietic cytokine receptors such as the erythropoietin receptor (EpoR) depends on the activation of a receptor-bound Janus kinase (JAK) and tyrosine phosphorylation of the cytoplasmic domain. To visualize the EpoR and elucidate structural requirements coordinating signal transduction, we probed the EpoR by inserting the green fluorescent protein (GFP) at various positions. We show that insertion of GFP in proximity to the transmembrane domain, either in the extracellular or the cytoplasmic domain, results in EpoR-GFP receptors incompetent to elicit biological responses in a factor-dependent cell line or in erythroid progenitor cells. Surprisingly, a receptor harboring GFP insertion in the middle of the cytoplasmic domain, and thereby separating the JAK2 binding site from the tyrosine residues, is capable of supporting signal transduction in response to ligand binding. Comparable with the wild type EpoR, but more efficient than a C-terminal EpoR-GFP fusion, this chimeric receptor promotes the maturation of erythroid progenitor cells and is localized in punctated endosome-like structures. We conclude that the extracellular, transmembrane, and membrane-proximal segment of the cytoplasmic domain form a rigid structural entity whose precise orientation is essential for the initiation of signal transduction, whereas the cytoplasmic domain possesses flexibility in adopting an activated conformation.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Tel Aviv Univ, Sackler Fac Med, Dept Cell Biol & Histol, IL-69978 Tel Aviv, Israel	Max Planck Society; Tel Aviv University; Sackler Faculty of Medicine	Klingmuller, U (corresponding author), Max Planck Inst Immunbiol, Stubeweg 51, D-79108 Freiburg, Germany.		Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099; Neumann, Drorit/0000-0002-4805-7511; Ketteler, Robin/0000-0002-2786-7291				Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ketteler R, 2002, GENE THER, V9, P477, DOI 10.1038/sj.gt.3301653; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Silverman MA, 2001, P NATL ACAD SCI USA, V98, P7051, DOI 10.1073/pnas.111146198; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	30	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26547	26552		10.1074/jbc.M202287200	http://dx.doi.org/10.1074/jbc.M202287200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11997394	hybrid			2022-12-27	WOS:000176908700095
J	Masiero, S; Imbriano, C; Ravasio, F; Favaro, R; Pelucchi, N; Gorla, MS; Mantovani, R; Colombo, L; Kater, MM				Masiero, S; Imbriano, C; Ravasio, F; Favaro, R; Pelucchi, N; Gorla, MS; Mantovani, R; Colombo, L; Kater, MM			Ternary complex formation between MADS-box transcription factors and the histone fold protein NF-YB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOWER DEVELOPMENT; HOMEOTIC GENES; ANTIRRHINUM-MAJUS; OVULE DEVELOPMENT; RNA-POLYMERASE; HOST STRAIN; CCAAT BOXES; ARABIDOPSIS; DOMAIN; FAMILY	MADS-box proteins are transcription factors present in different eukaryotic kingdoms. In contrast to plants, for mammalian and yeast MADS-box proteins ternary complex formation with unrelated transcription factors was reported. We show here the first identification of such ternary interaction in plants. A rice seed-specific NF-YB was identified as partner of OsMADS18 by two-hybrid screening. NF-YB contains a histone fold motif, HFM,(1) and is part of the trimeric CCAAT-binding NF-Y complex. OsMADS18, alone or in combination with a natural partner, interacts with OsNF-YB1 through the MADS and I regions. The mouse NF-YB also associates with OsMADS18 in vivo and in vitro as a NF-YB-NF-YC dimer. Other rice MADS-box proteins do not interact in these assays, indicating specificity for the interaction. OsNF-YB1 is capable of heterodimerizing with NF-YC, but not trimerizing with NF-YA, thus precluding CCAAT binding. Mutation of the variant Asp at position 99 of the HFM alpha2-helix into a conserved serine recovers the capacity to interact with NF-YA, but not with DNA. This is the first indication that members of the NF-YB family work through mechanisms independent of the CCAAT box.	Univ Milan, Dipartimento Genet & BIol Microrganismi, I-20133 Milan, Italy; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Modena & Reggio Emilia, Dept Anim Biol, I-41100 Modena, Italy	University of Milan; University of Milan; Universita di Modena e Reggio Emilia	Kater, MM (corresponding author), Univ Milan, Dipartimento Genet & BIol Microrganismi, Via Celoria 26, I-20133 Milan, Italy.	martin.kater@unimi.it	Imbriano, Carol/C-9376-2015; Imbriano, Carol/ABD-8204-2021; Masiero, Simona/J-2898-2013; Favaro, Rebecca/HHZ-8978-2022; Kater, Martin M/M-9381-2017	Imbriano, Carol/0000-0003-2864-4820; Imbriano, Carol/0000-0003-2864-4820; Favaro, Rebecca/0000-0002-6195-5711; Kater, Martin M/0000-0003-1155-2575; masiero, simona/0000-0002-7563-7634; Colombo, Lucia/0000-0001-8415-1399				ANGENENT GC, 1995, PLANT CELL, V7, P1569, DOI 10.1105/tpc.7.10.1569; ANGENENT GC, 1992, PLANT CELL, V4, P983, DOI 10.1105/tpc.4.8.983; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Coen Enrico S., 1992, Current Opinion in Cell Biology, V4, P929, DOI 10.1016/0955-0674(92)90120-2; Colombo L, 1997, PLANT CELL, V9, P703, DOI 10.1105/tpc.9.5.703; Colombo L, 1998, PLANT J, V16, P355, DOI 10.1046/j.1365-313x.1998.00300.x; Davies B, 1996, EMBO J, V15, P4330, DOI 10.1002/j.1460-2075.1996.tb00807.x; Davies B, 1994, Results Probl Cell Differ, V20, P235; Edwards D, 1998, PLANT PHYSIOL, V117, P1015, DOI 10.1104/pp.117.3.1015; Egea-Cortines M, 1999, EMBO J, V18, P5370, DOI 10.1093/emboj/18.19.5370; Fan HY, 1997, PLANT J, V12, P999, DOI 10.1046/j.1365-313X.1997.12050999.x; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fernandez DE, 2000, PLANT CELL, V12, P183, DOI 10.1105/tpc.12.2.183; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Gusmaroli G, 2001, GENE, V264, P173, DOI 10.1016/S0378-1119(01)00323-7; Gusmaroli G, 2002, GENE, V283, P41, DOI 10.1016/S0378-1119(01)00833-2; Hartmann U, 2000, PLANT J, V21, P351, DOI 10.1046/j.1365-313x.2000.00682.x; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Immink RGH, 1999, DEVELOPMENT, V126, P5117; James P, 1996, GENETICS, V144, P1425; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Lopez-Dee ZP, 1999, DEV GENET, V25, P237, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;237::AID-DVG6&gt;3.0.CO;2-L; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Moon YH, 1999, PLANT PHYSIOL, V120, P1193, DOI 10.1104/pp.120.4.1193; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; PURUGGANAN MD, 1995, GENETICS, V140, P345; Richert J, 1996, PLANT SCI, V114, P93, DOI 10.1016/0168-9452(95)04308-X; Riechmann JL, 1996, NUCLEIC ACIDS RES, V24, P3134, DOI 10.1093/nar/24.16.3134; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sinha S, 1996, MOL CELL BIOL, V16, P328; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; Zemzoumi K, 1999, J MOL BIOL, V286, P327, DOI 10.1006/jmbi.1998.2496; Zhang HM, 1998, SCIENCE, V279, P407, DOI 10.1126/science.279.5349.407	52	87	108	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26429	26435		10.1074/jbc.M202546200	http://dx.doi.org/10.1074/jbc.M202546200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11971906	hybrid			2022-12-27	WOS:000176908700080
J	Figueiredo-Pereira, ME; Li, ZM; Jansen, M; Rockwell, P				Figueiredo-Pereira, ME; Li, ZM; Jansen, M; Rockwell, P			N-acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; OXIDATIVE STRESS; PROTEIN; ALZHEIMERS; INHIBITION; IMPAIRMENT; DISEASE; INCLUSIONS; HYPOTHESIS; INDUCTION	In many neurodegenerative disorders, aggregates of ubiquitinated proteins are detected in neuronal inclusions, but their role in neurodegeneration remains to be defined. To identify intracellular mechanisms associated with the appearance of ubiquitin-protein aggregates, mouse neuronal HT4 cells were treated with cadmium. This heavy metal is a potent cell poison that mediates oxidative stress and disrupts the ubiquitin/ proteasome pathway. In the current studies, the following intracellular events were found to be also induced by cadmium: (i) a specific rise in cyclooxygenase-2 (COX-2) gene expression but not COX-1; (ii) an increase in the extracellular levels of the proinflammatory prostaglandin E2, a product of COX-2; and (iii) production of 4-hydroxy-2-nonenal-protein adducts, which result from lipid peroxidation. In addition, cadmium treatment led to the accumulation of high molecular weight ubiquitin COX-2 conjugates and perturbed COX-2 glycosylation. The thiol-reducing antioxidant N-acetylcysteine, and, to a lesser extent, the COX-2 inhibitor celecoxib, attenuated the loss of cell viability induced by cadmium demonstrating that oxidative stress and COX-2 activation contribute to cadmium cytotoxicity. These findings establish that disruption of the ubiquitin/proteasome pathway is not the only event triggered by cadmium. This oxidative stressor also activates COX-2 function. Both events could be triggered by formation of 4-hydroxy-2-nonenal as a result of cadmium-induced lipid peroxidation. Proinflammatory responses stimulated by oxidative stressors that mimic the cadmium effects may, therefore, be important initiators of the neurodegenerative process and exacerbate its progress.	CUNY Hunter Coll, Dept Sci Biol, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Figueiredo-Pereira, ME (corresponding author), CUNY Hunter Coll, Dept Sci Biol, 695 Pk Ave, New York, NY 10021 USA.	pereira@genectr.hunter.cuny.edu			NINDS NIH HHS [NS34018] Funding Source: Medline; PHSPO CDC HHS [SO66054] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034018] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHSPO CDC HHS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACAN NL, 1995, BIOCHEM MOL MED, V54, P33, DOI 10.1006/bmme.1995.1005; Andersen JK, 2000, MECH AGEING DEV, V118, P15, DOI 10.1016/S0047-6374(00)00150-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; FIGUEIREDOPEREI.ME, 2001, PROTEOLYSIS PATHOLPH, P137; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Martinez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5; Martinez M, 1999, LIFE SCI, V64, P1253, DOI 10.1016/S0024-3205(98)00472-X; Minekura H, 2001, BIOCHEM BIOPH RES CO, V282, P557, DOI 10.1006/bbrc.2001.4586; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYTILINEOU C, 1993, J NEUROCHEM, V61, P1470, DOI 10.1111/j.1471-4159.1993.tb13642.x; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Oka A, 1999, NEUROPEDIATRICS, V30, P34, DOI 10.1055/s-2007-973454; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stohs Sidney J., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P201; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203	42	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25283	25289		10.1074/jbc.M109145200	http://dx.doi.org/10.1074/jbc.M109145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997384	hybrid			2022-12-27	WOS:000176747000058
J	Sterling, D; Alvarez, BV; Casey, JR				Sterling, D; Alvarez, BV; Casey, JR			The extracellular component of a transport metabolon - Extracellular loop 4 of the human AE1 Cl-/HCO(3)(-)exchanger binds carbonic anhydrase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGER; CDNA CLONING; ERYTHROCYTE BAND-3; INTRACELLULAR PH; LOCALIZATION; EXPRESSION; PROTEINS; CELLS; CA; RABBIT	Cytosolic carbonic anhydrase II (CAII) and the cytoplasmic C-terminal tails of chloride/bicarbonate anion exchange (AE) proteins associate to form a bicarbonate transport metabolon, which maximizes the bicarbonate transport rate. To determine whether cell surface-anchored carbonic anhydrase IV (CAIV) interacts with AE proteins to accelerate the bicarbonate transport rate, AE1-mediated bicarbonate transport was monitored in transfected HEK293 cells. Expression of the inactive CAII V143Y mutant blocked the interaction between endogenous cytosolic CAII and AE1, AE2, and AE3 and inhibited their transport activity (53 +/- 3, 49 +/- 10, and 35 +/- 1% inhibition, respectively). However, in the presence of V143Y CAII, expression of CAIV restored full functional activity to AE1, AE2, and AE3 (AE1, 101 3; AE2, 85 +/- 5; AE3, 108 +/- 1%). In Triton X-100 extracts of transfected HEK293 cells, resolved by sucrose gradient ultracentrifugation, CAIV recruitment to the position of AE1 suggested a physical interaction between CAIV and AE1. Gel overlay assays showed a specific interaction between CAIV and AE1, AE2, and AE3. Glutathione S-transferase pull-down assays revealed that the interaction between CAIV and AE1 occurs on the large fourth extracellular loop of AE1. We conclude that AE1 and CAIV interact on extracellular loop 4 of AE 1, forming the extracellular component of a bicarbonate transport metabolon, which accelerates the rate of AE-mediated bicarbonate transport.	Univ Alberta, Dept Physiol, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	Institute for Work & Health; University of Alberta; Institute for Work & Health; University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; Bagnis C, 2001, AM J PHYSIOL-RENAL, V280, pF437, DOI 10.1152/ajprenal.2001.280.3.F437; Baird TT, 1997, BIOCHEMISTRY-US, V36, P2669, DOI 10.1021/bi962663s; BRECHUE WF, 1991, BIOCHIM BIOPHYS ACTA, V1066, P201, DOI 10.1016/0005-2736(91)90187-D; BRION LP, 1994, AM J PHYSIOL, V266, pF185, DOI 10.1152/ajprenal.1994.266.2.F185; BROSIUS FC, 1995, AM J PHYSIOL-RENAL, V269, pF461, DOI 10.1152/ajprenal.1995.269.4.F461; BROWN D, 1990, P NATL ACAD SCI USA, V87, P7457, DOI 10.1073/pnas.87.19.7457; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUCE LJ, 1995, BLOOD, V85, P541; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; COUSIN JL, 1976, J PHYSIOL-LONDON, V256, P61, DOI 10.1113/jphysiol.1976.sp011311; COUSIN JL, 1975, J PHYSIOL-LONDON, V253, P385, DOI 10.1113/jphysiol.1975.sp011195; DODGSON SJ, 1988, J APPL PHYSIOL, V65, P1472, DOI 10.1152/jappl.1988.65.4.1472; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; GEERS C, 1992, BIOCHEM J, V282, P165, DOI 10.1042/bj2820165; GHANDOUR MS, 1992, P NATL ACAD SCI USA, V89, P6823, DOI 10.1073/pnas.89.15.6823; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716; Jarolim P, 1998, BLOOD, V92, P4836, DOI 10.1182/blood.V92.12.4836.424k24_4836_4843; KIFOR G, 1993, J MEMBRANE BIOL, V134, P169; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINN SC, 1992, J BIOL CHEM, V267, P7927; LINN SC, 1995, CIRC RES, V76, P584, DOI 10.1161/01.RES.76.4.584; LONNERHOLM G, 1991, ACTA PHYSIOL SCAND, V141, P231, DOI 10.1111/j.1748-1716.1991.tb09072.x; MAREN TH, 1993, J BIOL CHEM, V268, P26233; MCKINLEY DN, 1976, BIOCHIM BIOPHYS ACTA, V445, P780, DOI 10.1016/0005-2744(76)90128-5; Mori K, 1999, J BIOL CHEM, V274, P15701, DOI 10.1074/jbc.274.22.15701; OKUYAMA T, 1992, P NATL ACAD SCI USA, V89, P1315, DOI 10.1073/pnas.89.4.1315; PARKES JL, 1989, ARCH BIOCHEM BIOPHYS, V275, P459, DOI 10.1016/0003-9861(89)90392-5; PUCEAT M, 1995, J BIOL CHEM, V270, P1315, DOI 10.1074/jbc.270.3.1315; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; Richards SM, 1999, J CELL SCI, V112, P1519; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; RUETZ S, 1993, SOC GEN PHY, V48, P193; Schwartz GJ, 2000, AM J PHYSIOL-RENAL, V278, pF894, DOI 10.1152/ajprenal.2000.278.6.F894; Schwartz GJ, 1999, AM J PHYSIOL-RENAL, V276, pF510, DOI 10.1152/ajprenal.1999.276.4.F510; Scozzafava A, 2002, BIOORG MED CHEM LETT, V12, P1177, DOI 10.1016/S0960-894X(02)00121-X; Sender S, 1998, J HISTOCHEM CYTOCHEM, V46, P855, DOI 10.1177/002215549804600709; SLY WS, 1985, PEDIATR RES, V19, P1033, DOI 10.1203/00006450-198510000-00017; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Sterling D, 1999, BIOCHEM J, V344, P221, DOI 10.1042/0264-6021:3440221; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, BIOPHYS J, V82, p570A; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tong CK, 2000, J NEUROSCI, V20, P8247, DOI 10.1523/JNEUROSCI.20-22-08247.2000; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuganezawa H, 2001, J BIOL CHEM, V276, P8180, DOI 10.1074/jbc.M004513200; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; WAHEED A, 1992, ARCH BIOCHEM BIOPHYS, V294, P550, DOI 10.1016/0003-9861(92)90724-B; WHITNEY PL, 1982, J BIOL CHEM, V257, P2056; Wistrand PJ, 1999, ACTA PHYSIOL SCAND, V165, P211; WISTRAND PJ, 1989, KIDNEY INT, V35, P851, DOI 10.1038/ki.1989.63; Zolotarev AS, 1996, BIOCHEMISTRY-US, V35, P10367, DOI 10.1021/bi9526084	67	128	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25239	25246		10.1074/jbc.M202562200	http://dx.doi.org/10.1074/jbc.M202562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994299	hybrid			2022-12-27	WOS:000176747000052
J	Zako, M; Iwaki, M; Yoneda, M; Miyaishi, O; Zhao, JS; Suzuki, Y; Takeuchi, M; Miyake, G; Ikagawa, H; Kimata, K				Zako, M; Iwaki, M; Yoneda, M; Miyaishi, O; Zhao, JS; Suzuki, Y; Takeuchi, M; Miyake, G; Ikagawa, H; Kimata, K			Molecular cloning and characterization of chick sialoprotein associated with cones and rods, a developmentally regulated glycoprotein of interphotoreceptor matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HUMAN RETINA; PG-M; HYALURONAN; PHOTORECEPTORS; LOCALIZATION; PROTEINS; ADHESION; VERSICAN; BINDING	MY-174 is an IgM class monoclonal antibody originally established against chick PG-M/versican. The antibody specifically stains the photoreceptor layer, where we recently reported an absence of PG-M/versican. In this study, we re-characterized the antibody and identified the molecule that reacts to MY-174 at the photoreceptor layer. Immunohistochemistry localized the antigen to the matrix surrounding photoreceptors. A variety of glycosidase digestions showed that the antigen is the 150-kDa glycoprotein that has sialylated N- and O-linked glycoconjugates having a molecular mass of more than 30-kDa. The peptide sequences obtained from purified MY-174 antigen showed we had sequenced a full-length cDNA with an open reading frame of 2787 base pairs, encoding a polypeptide of 928 amino acids, with 56 and 54% identities to human and mouse sialoprotein associated with cones and rods (SPACRs), respectively, and with the structural features observed in SPACRs. The specific sialylated O-glycoconjugates here are involved in the epitope structure for MY-174. SPACR first appeared by embryonic days 15-16, and expression increased with developmental age, paralleling the adhesion between neural retina and retinal pigment epithelium. Thus, we concluded that the MY-174 antigen at the photoreceptor layer, a developmentally regulated glycoprotein, is identical to chick SPACR and may be involved in a novel system mediating adhesion between neural retina and retinal pigment epithelium.	Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Dept Pathol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Prefectural Coll Nursing & Hlth, Nagoya, Aichi 4638502, Japan; Tosei Municipal Hosp, Aichi 4890803, Japan	Aichi Medical University; Aichi Medical University; Aichi Medical University	Zako, M (corresponding author), Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.							Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997; Adler A J, 1982, Curr Eye Res, V2, P743, DOI 10.3109/02713688209020006; ADLER AJ, 1982, EXP EYE RES, V34, P423, DOI 10.1016/0014-4835(82)90088-4; ADLER AJ, 1981, EXP EYE RES, V32, P755, DOI 10.1016/0014-4835(81)90025-7; BISHOP PN, 1993, GLYCOBIOLOGY, V3, P403, DOI 10.1093/glycob/3.4.403; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; ENDO EG, 1988, INVEST OPHTH VIS SCI, V29, P1390; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HAGEMAN GS, 1991, PROGR RETINAL RES, V10, P207; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYFIELD JG, 1989, RETINA-J RET VIT DIS, V9, P59, DOI 10.1097/00006982-198909010-00008; Hollyfield JG, 1997, EXP EYE RES, V65, P603, DOI 10.1006/exer.1997.0369; Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422; HOLLYFIELD JG, 1990, EXP EYE RES, V51, P107, DOI 10.1016/0014-4835(90)90177-V; Isogai Z, 1996, CANCER RES, V56, P3902; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LAZARUS HS, 1992, INVEST OPHTH VIS SCI, V33, P364; Lee JW, 2000, EXP EYE RES, V71, P341, DOI 10.1006/exer.2000.0888; MARMOR MF, 1993, PROG RETIN RES, V12, P179, DOI 10.1016/0278-4327(93)90009-I; PORRELLO K, 1986, CURR EYE RES, V5, P981, DOI 10.3109/02713688608995180; Russell SR, 1997, AM J OPHTHALMOL, V123, P386, DOI 10.1016/S0002-9394(14)70135-7; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; TIEN LF, 1992, EXP EYE RES, V55, P297, DOI 10.1016/0014-4835(92)90194-W; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YAO XY, 1990, INVEST OPHTH VIS SCI, V31, P2051; YAO XY, 1992, INVEST OPHTH VIS SCI, V33, P498; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 1997, J NEUROCHEM, V69, P2155; ZAUBERMAN H, 1969, EXP EYE RES, V8, P276, DOI 10.1016/S0014-4835(69)80039-4; Zauberman H, 1979, RETINAL PIGMENT EPIT, P192; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	34	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25592	25600		10.1074/jbc.M201279200	http://dx.doi.org/10.1074/jbc.M201279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991949	hybrid			2022-12-27	WOS:000176747000097
J	Chou, CJ; Haluzik, M; Gregory, C; Dietz, KR; Vinson, C; Gavrilova, O; Reitman, ML				Chou, CJ; Haluzik, M; Gregory, C; Dietz, KR; Vinson, C; Gavrilova, O; Reitman, ML			WY14,643, a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-OXIDATION; ADIPOSE-TISSUE; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE; SKELETAL-MUSCLE; LIPODYSTROPHY; LEPTIN; OBESITY; MOUSE; OVEREXPRESSION	WY14,643 is a specific peroxisome proliferator-activated receptor a (PPARalpha) agonist with strong hypolipidemic effects. Here we have examined the effect of WY14,643 in the A-ZIP/F-1 mouse, a model of severe lipoatrophic diabetes. With I week of treatment, all doses of WY14,643 that were tested normalized serum triglyceride and fatty acid levels. Glucose and insulin levels also improved but only with high doses and longer treatment duration. WY14,643 reduced liver and muscle triglyceride content and increased levels of mRNA encoding fatty acid oxidation enzymes. In liver, the elevated lipogenic mRNA profile (including PPARgamma) in A-ZIP/F-1 mice remained unchanged. These results suggest that WY14,643 acts by increasing beta-oxidation rather by than decreasing lipogenesis or lipid uptake. Hyperinsulinemic euglycemic clamp studies indicated that WY14,643 treatment improved liver more than muscle insulin sensitivity and that hepatic mRNA levels of gluconeogenic enzymes were reduced. Combination treatment with both WY14,643 and a PPARgamma ligand, rosiglitazone, did not lower glucose levels more effectively than did treatment with WY14,643 alone. These data support the hypothesis that reducing intracellular triglycerides in non-adipose tissues improves insulin sensitivity and suggest that further investigation of the role of PPARa agonists in the treatment of lipoatrophic diabetes is warranted.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reitman, ML (corresponding author), Merck Res Labs, POB 2000,RY80M-213, Rahway, NJ 07065 USA.		Dietz, Kelly/AAE-3074-2021; Reitman, Marc/B-4448-2013; Haluzik, Martin/I-8190-2017	Reitman, Marc/0000-0002-0426-9475; Haluzik, Martin/0000-0002-0201-6888; Dietz, Kelly/0000-0003-3670-2912				Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Cook WS, 2000, BIOCHEM BIOPH RES CO, V278, P250, DOI 10.1006/bbrc.2000.3739; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Gavrilova O, 2000, NATURE, V403, P850, DOI 10.1038/35002663; GRASSO P, 1993, PEROXISOMES BIOL IMP, P639; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Minnich A, 2001, AM J PHYSIOL-ENDOC M, V280, pE270, DOI 10.1152/ajpendo.2001.280.2.E270; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Panz VR, 1997, CLIN ENDOCRINOL, V46, P365, DOI 10.1046/j.1365-2265.1997.970912.x; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; ROBBINS DC, 1979, METABOLISM, V28, P908, DOI 10.1016/0026-0495(79)90090-8; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Vantyghem MC, 1999, DIABETES CARE, V22, P1374, DOI 10.2337/diacare.22.8.1374; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	34	153	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24484	24489		10.1074/jbc.M202449200	http://dx.doi.org/10.1074/jbc.M202449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11994294	hybrid			2022-12-27	WOS:000176611800068
J	Kashiwagi, K; Innami, A; Zenda, R; Tomitori, H; Igarashi, K				Kashiwagi, K; Innami, A; Zenda, R; Tomitori, H; Igarashi, K			The ATPase activity and the functional domain of PotA, a component of the spermidine-preferential uptake system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYAMINE TRANSPORT; MALTOSE TRANSPORT; CRYSTAL-STRUCTURE; HISTIDINE PERMEASE; ABC TRANSPORTER; BINDING SUBUNIT; INDUCER EXCLUSION; PROTEIN; PUTRESCINE; MALK	The ATPase activity of PotA, a component of the spermidine-preferential uptake system consisting of PotA, -B, -C, and -D, was studied using purified PotA and a PotABC complex on inside-out membrane vesicles. It was found that PotA can form a dimer by disulfide cross-linking but that each PotA molecule functions independently. When PotA was associated with the membrane proteins PotB and PotC, the K-m value for ATP increased and PotA became much more sensitive to inhibition by spermidine. It was also shown that spermidine uptake in cells was gradually inhibited in parallel with spermidine accumulation in cells. The results suggest that spermidine functions as a feedback inhibitor of spermidine transport. The function of PotA was analyzed using PotA mutants obtained by random mutagenesis. There are two domains in PotA. The NH2-terminal domain (residues 1-250) contains the ATP binding pocket formed in part by residues Cys(26), Phe(27), Phe(45), Cys(54), Leu(60), and Leu(76), the active center of ATPase that includes Val(135) and Asp(172), and amino acid residues necessary for the interaction with a second PotA subunit (Cys(26)) and with PotB (Cys(54)). The COOH-terminal domain (residues 251-378) of PotA contains a site that regulates ATPase activity and a site involved in the spermidine inhibition of ATPase activity.	Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	iga16077@p.chiba-u.ac.jp	Laureys, Steven/A-3349-2011; Bonhomme, Vincent/J-7144-2019; Laureys, Steven/AAN-2097-2021	Bonhomme, Vincent/0000-0001-6356-547X; Laureys, Steven/0000-0002-3096-3807; Igarashi, Kazuei/0000-0003-3751-3187				Antognoni F, 1999, J BIOL CHEM, V274, P1942, DOI 10.1074/jbc.274.4.1942; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 2000, J BACTERIOL, V182, P1432, DOI 10.1128/JB.182.5.1432-1436.2000; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P250; NEEDLEMAN SB, 1970, J MOL BIOL, V157, P105; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099	44	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24212	24219		10.1074/jbc.M202849200	http://dx.doi.org/10.1074/jbc.M202849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976340	hybrid			2022-12-27	WOS:000176611800032
J	Kawano, M; Igarashi, K; Yamato, I; Kakinuma, Y				Kawano, M; Igarashi, K; Yamato, I; Kakinuma, Y			Arginine residue at position 573 in Enterococcus hirae vacuolar-type ATPase NtpI subunit plays a crucial role in Na+ translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; PROTON TRANSLOCATION; ALPHA-SUBUNIT; H+-ATPASE; SYNTHASE; GENE; PURIFICATION; (H+)-ATPASE	The 76-kDa NtpI subunit constitutes the membrane-embedded V-0 moiety of Enterococcus hirae vacuolar type Na+-ATPase with a 16-kDa NtpK hexamer containing Na+ binding sites. In this study, we investigated the role of an arginine residue, which is highly conserved among the corresponding subunits of bacterial vacuolar-type ATPases, at position 573 of NtpI. Substitution of Glu, Leu, or Gln for Arg-573 abolished sodium transport and sodium-stimulated ATP hydrolysis of the enzyme. The conservative replacement of Arg by Lys lowered both activities about one-fifth of those of the wild type enzyme. We have reported previously on ATP-dependent negative cooperativity for Na+ coupling of this enzyme (Murata, T., Kakinuma, Y., and Yamato, 1. (2001) J. Biol. Chem. 276, 48337-48340). The negative cooperativity for the Na+ dependence of ATPase activity was weakened by the mutation R573K, the Hill coefficients for the wild type and mutant enzymes at a saturated ATP concentration were 0.22 +/- 0.03 and 0.40 +/- 0.05, respectively. The Hill coefficients of both enzymes at limited ATP concentrations approached 1. These results indicate that NtpI Arg-573 is indispensable for sodium translocation and for the cooperative features of E. hirae vacuolar-type ATPase.	Muroran Inst Technol, Dept Appl Chem, Muroran, Hokkaido 0508585, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Muroran Institute of Technology; Chiba University; Tokyo University of Science	Kakinuma, Y (corresponding author), Muroran Inst Technol, Dept Appl Chem, 27-1 Mizumoto Cho, Muroran, Hokkaido 0508585, Japan.			Igarashi, Kazuei/0000-0003-3751-3187; KAWANO-KAWADA, Miyuki/0000-0002-1168-9291				Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fillingame RH, 2000, J EXP BIOL, V203, P9; HEEFNER DL, 1980, J BIOL CHEM, V255, P1403; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Murata T, 2000, J BIOL CHEM, V275, P13415, DOI 10.1074/jbc.275.18.13415; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 2001, J BIOL CHEM, V276, P48337, DOI 10.1074/jbc.M106821200; Murata T, 1999, J BIOCHEM, V125, P414, DOI 10.1093/oxfordjournals.jbchem.a022302; NAKAYAMA T, 1993, CHEM PHARM BULL, V41, P117; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oster G, 2000, PHILOS T ROY SOC B, V355, P523, DOI 10.1098/rstb.2000.0593; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUZUKI T, 1993, MOL MICROBIOL, V9, P111, DOI 10.1111/j.1365-2958.1993.tb01673.x; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Takase K, 1999, BIOSCI BIOTECH BIOCH, V63, P1125, DOI 10.1271/bbb.63.1125; TAKASE K, 1998, 71 ANN M JAP BIOCH S, P1099; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1994, J BIOL CHEM, V269, P30364; WASER M, 1992, J BIOL CHEM, V267, P5396; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZUBENTRUP KH, 1997, J BACTERIOL, V179, P1274	41	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24405	24410		10.1074/jbc.M200973200	http://dx.doi.org/10.1074/jbc.M200973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983695	hybrid			2022-12-27	WOS:000176611800058
J	Mukherjee, SB; Das, M; Sudhandiran, G; Shaha, C				Mukherjee, SB; Das, M; Sudhandiran, G; Shaha, C			Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; BUTHIONINE SULFOXIMINE; NERVE-TERMINALS; CALCIUM-UPTAKE; MEMBRANE; RELEASE; NA+; GLUTATHIONE	Reactive oxygen species are important regulators of protozoal infection. Promastigotes of Leishmania donovani, the causative agent of Kala-azar, undergo an apoptosis-like death upon exposure to H2O2. The present study shows that upon activation of death response by H2O2, a dose- and time-dependent loss of mitochondrial membrane potential occurs. This loss is accompanied by a depletion of cellular glutathione, but cardiolipin content or thiol oxidation status remains unchanged. ATP levels are reduced within the first 60 min of exposure as a result of mitochondrial membrane potential loss. A tight link exists between changes in cytosolic Ca2+ homeostasis and collapse of the mitochondrial membrane potential, but the dissipation of the potential is independent of elevation of cytosolic Na+ and mitochondrial Ca2+. Partial inhibition of cytosolic Ca2+ increase achieved by chelating extracellular or intracellular Ca2+ by the use of appropriate agents resulted in significant rescue of the fall of the mitochondrial membrane potential and apoptosis-like death. It is further demonstrated that the increase in cytosolic Ca2+ is an additive result of release of Ca2+ from intracellular stores as well as by influx of extracellular Ca2+ through flufenamic acid-sensitive non-selective cation channels; contribution of the latter was larger. Mitochondrial changes do not involve opening of the mitochondrial transition pore as cyclosporin A is unable to prevent mitochondrial membrane potential loss. An antioxidant like N-acetylcysteine is able to inhibit the fall of the mitochondrial membrane potential and prevent apoptosis-like death. Together, these findings show the importance of non-selective cation channels in regulating the response of L. donovani promastigotes to oxidative stress that triggers downstream signaling cascades leading to apotosis-like death.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	cshaha@nii.res.in	Sudhandiran, G/AAG-9967-2019; Ganapasam, Sudhandiran/AAD-4264-2021	Sudhandiran, G/0000-0003-0066-7801; Das, Manika/0000-0001-8639-7165				Anderson CP, 1999, EXP CELL RES, V246, P183, DOI 10.1006/excr.1998.4303; Anuradha CD, 2001, FREE RADICAL BIO MED, V31, P367, DOI 10.1016/S0891-5849(01)00591-3; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Basselin M, 1998, PARASITOL RES, V84, P78, DOI 10.1007/s004360050361; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CHANG KP, 1983, INT REV CYTOL, P267; Chinopoulos C, 1999, ANN NY ACAD SCI, V893, P269, DOI 10.1111/j.1749-6632.1999.tb07834.x; Chinopoulos C, 2000, J NEUROSCI, V20, P2094; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Das M, 2001, J CELL SCI, V114, P2461; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Diaz G, 1999, J CELL SCI, V112, P1077; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; Ehlers RA, 1999, SURGERY, V126, P148, DOI 10.1067/msy.1999.98725; ERIC C, 2001, J BIOL CHEM, V276, P5384; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Geller HM, 2001, J NEUROCHEM, V78, P265, DOI 10.1046/j.1471-4159.2001.00395.x; Gonzalez A, 2000, J BIOL CHEM, V275, P38680, DOI 10.1074/jbc.M005667200; Gottlieb RA, 2001, BIOL SIGNAL RECEPT, V10, P147; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Kim JA, 2000, FREE RADICAL RES, V33, P267, DOI 10.1080/10715760000301431; Kim JA, 2001, BIOCHEM BIOPH RES CO, V281, P511, DOI 10.1006/bbrc.2001.4371; Kowaltowski AJ, 2000, FEBS LETT, V473, P177, DOI 10.1016/S0014-5793(00)01526-X; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KRICKA LJ, 1988, ANAL BIOCHEM, V175, P14, DOI 10.1016/0003-2697(88)90354-5; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li X, 2000, EXP CELL RES, V257, P290, DOI 10.1006/excr.2000.4901; Meyer TN, 1996, KIDNEY INT, V49, P388, DOI 10.1038/ki.1996.57; NABI ZF, 1984, MOL BIOCHEM PARASIT, V10, P297, DOI 10.1016/0166-6851(84)90028-8; Nicole A, 1998, BIOMED PHARMACOTHER, V52, P349, DOI 10.1016/S0753-3322(99)80001-8; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Overly CC, 1996, J CELL SCI, V109, P971; Panaretakis T, 2001, TOXICOL APPL PHARM, V173, P56, DOI 10.1006/taap.2001.9159; Pariente JA, 2001, J MEMBRANE BIOL, V179, P27, DOI 10.1007/s002320010034; Rais S, 2000, ANTIMICROB AGENTS CH, V44, P2406, DOI 10.1128/AAC.44.9.2406-2410.2000; Satoh T, 1997, J NEUROSCI RES, V50, P413, DOI 10.1002/(SICI)1097-4547(19971101)50:3<413::AID-JNR7>3.0.CO;2-L; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; Simpson PB, 1998, J PHYSIOL-LONDON, V508, P413, DOI 10.1111/j.1469-7793.1998.413bq.x; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P37, DOI 10.1006/abbi.2000.2194; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463; Ward MW, 2000, J NEUROSCI, V20, P7208; Weldrick DP, 1999, FEMS MICROBIOL LETT, V173, P139, DOI 10.1111/j.1574-6968.1999.tb13495.x; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V374, P142, DOI 10.1006/abbi.1999.1574; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhang GH, 1996, J BIOL CHEM, V271, P29067, DOI 10.1074/jbc.271.46.29067	59	174	178	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24717	24727		10.1074/jbc.M201961200	http://dx.doi.org/10.1074/jbc.M201961200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983701	hybrid			2022-12-27	WOS:000176611800098
J	Hagen, T; Di Daniel, E; Culbert, AA; Reith, AD				Hagen, T; Di Daniel, E; Culbert, AA; Reith, AD			Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; NEGATIVE REGULATOR; XENOPUS EMBRYOS; SUBSTRATE-SPECIFICITY; WNT; AXIN; PATHWAY; COMPLEX; DEPHOSPHORYLATION; INHIBITION	Glycogen synthase kinase-3 (GSK-3) is a serine-threo. nine kinase that is involved in multiple cellular signaling pathways, including the Wnt signaling cascade where it phosphorylates beta-catenin, thus targeting it for proteasome-mediated degradation. Unlike phosphorylation of glycogen synthase, phosphorylation of beta-catenin by GSK-3 does not require priming in vitro, i.e. it is not dependent on the presence of a phosphoserine, four residues C-terminal to the GSK-3 phosphorylation site. Recently, a means of dissecting GSK-3 activity toward primed and non-primed substrates has been made possible by identification of the R96A mutant of GSK-3beta. This mutant is unable to phosphorylate primed but can still phosphorylate unprimed substrates (Frame, S., Cohen, P., and Biondi R. M. (2001) Mol. Cell 7,1321-1327). Here we have investigated whether phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin requires priming through prior phosphorylation at Ser(41) in intact cells. We have shown that the Are mutant does not induce beta-catenin degradation but instead stabilizes beta-catenin, indicating that it is unable to phosphorylate beta-catenin in intact cells. Furthermore, if Ser(45) in beta-catenin is mutated to Ala, beta-catenin is markedly stabilized, and phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin by wild type GSK-3beta is prevented in intact cells. In addition, we have shown that the L128A mutant, which is deficient in phosphorylating Axin in vitro, is still able to phosphorylate beta-catenin in intact cells although it has reduced activity. Mutation of Tyr(216) to Phe markedly reduces the ability of GSK-3beta to phosphorylate and down-regulate beta-catenin. In conclusion, we have found that the Are mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).	GlaxoSmithKline Inc, Syst Res Kinase Biol Discovery Res, Harlow CM19 5AD, Essex, England; GlaxoSmithKline Inc, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AD, Essex, England; GlaxoSmithKline Inc, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AD, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hagen, T (corresponding author), UCL, Wolfson Inst Biomed Res, Mortimer St, London WC1E 6BT, England.	t.hagen@ucl.ac.uk						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dale TC, 1998, BIOCHEM J, V329, P209; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Koesters R, 2001, CARCINOGENESIS, V22, P1885, DOI 10.1093/carcin/22.11.1885; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200	38	76	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23330	23335		10.1074/jbc.M201364200	http://dx.doi.org/10.1074/jbc.M201364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967263	hybrid			2022-12-27	WOS:000176475700032
J	Gukovskaya, AS; Gukovsky, I; Jung, Y; Mouria, M; Pandol, SJ				Gukovskaya, AS; Gukovsky, I; Jung, Y; Mouria, M; Pandol, SJ			Cholecystokinin induces caspase activation and mitochondrial dysfunction in pancreatic acinar cells - Roles in cell injury processes of pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; PERMEABILITY TRANSITION; INDUCED APOPTOSIS; ENZYME-SECRETION; CYCLOSPORINE-A; UP-REGULATION; DEATH; INDUCTION; CERULEIN	Apoptosis and necrosis are critical parameters of pancreatitis, the mechanisms of which remain unknown. Many characteristics of pancreatitis can be studied in vitro in pancreatic acini treated with high doses of cholecystokinin (CCK). We show here that CCK stimulates apoptosis and death signaling pathways in rat pancreatic acinar cells, including caspase activation, cytochrome c release, and mitochondrial depolarization. The mitochondrial dysfunction is mediated by upstream caspases (possibly caspase-8) and, in turn, leads to activation of caspase-3. CCK causes mitochondrial alterations through both permeability transition pore-dependent (cytochrome c release) and permeability transition pore-independent (mitochondrial depolarization) mechanisms. Caspase activation and mitochondrial alterations also occur in untreated pancreatic acinar cells; however, the underlying mechanisms are different. In particular, caspases protect untreated acinar cells from mitochondrial damage. We found that caspases not only mediate apoptosis but also regulate other parameters of CCK-induced acinar cell injury that are characteristic of pancreatitis; in particular, caspases negatively regulate necrosis and trypsin activation in acinar cells. The results suggest that the observed signaling pathways regulate parenchymal cell injury and death in CCK-induced pancreatitis. Protection against necrosis and trypsin activation by caspases can explain why the severity of pancreatitis in experimental models correlates inversely with the extent of apoptosis.	Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Gukovskaya, AS (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Med, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.			Gukovskaya, Anna/0000-0003-3737-5335	PHS HHS [P50-A11999] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASTANI B, 1995, BBA-MOL CELL RES, V1269, P307, DOI 10.1016/0167-4889(95)00120-0; Beil M, 2002, AM J PHYSIOL-GASTR L, V282, pG450, DOI 10.1152/ajpgi.00042.2001; Bhatia M, 2000, J PATHOL, V190, P117; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; BROCKEMEIER KM, 1995, BIOCHEMISTRY-US, V34, P16440; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fujimoto K, 1997, DIGESTION, V58, P421, DOI 10.1159/000201478; Gaisano HY, 2001, J CLIN INVEST, V108, P1597; Gorelick FS, 1999, BEST PRACT RES CL GA, V13, P227, DOI 10.1053/bega.1999.0021; Gukovsaya AS, 1996, GASTROENTEROLOGY, V110, P875, DOI 10.1053/gast.1996.v110.pm8608898; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Halangk W, 1998, PANCREAS, V16, P88, DOI 10.1097/00006676-199801000-00014; Han B, 1999, AM J PHYSIOL-CELL PH, V277, pC74, DOI 10.1152/ajpcell.1999.277.1.C74; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LERCH MM, 1994, INT J PANCREATOL, V15, P159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu D, 2000, J BIOL CHEM, V275, P9244, DOI 10.1074/jbc.275.13.9244; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nguyen NSD, 1999, FREE RADICAL BIO MED, V27, P1267, DOI 10.1016/S0891-5849(99)00160-4; NIEDERAU C, 1990, GASTROENTEROLOGY, V99, P1120, DOI 10.1016/0016-5085(90)90633-C; Norman J, 1998, AM J SURG, V175, P76, DOI 10.1016/S0002-9610(97)00240-7; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1989, CELL CALCIUM, V10, P255, DOI 10.1016/0143-4160(89)90008-0; PANDOL SJ, 1986, J BIOL CHEM, V261, P4438; Pandol SJ, 1999, GASTROENTEROLOGY, V117, P706, DOI 10.1016/S0016-5085(99)70465-8; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; REISINE T, 1995, CIBA F SYMP, V190, P160; Saluja AK, 1999, AM J PHYSIOL-GASTR L, V276, pG835, DOI 10.1152/ajpgi.1999.276.4.G835; SALUJA AK, 1989, P NATL ACAD SCI USA, V86, P8968, DOI 10.1073/pnas.86.22.8968; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schild L, 1999, MOL CELL BIOCHEM, V195, P191, DOI 10.1023/A:1006988625831; Steer ML, 1999, BEST PRACT RES CL GA, V13, P213, DOI 10.1053/bega.1999.0020; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Terzian AR, 1996, BIOCHEM PHARMACOL, V52, P569, DOI 10.1016/0006-2952(96)00308-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOPAZIAN M, 1999, TXB GASTROENTEROLOGY, P2121; Vercesi AE, 1997, BIOSCIENCE REP, V17, P43, DOI 10.1023/A:1027335217774; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WILLEMS PHGM, 1995, CELL CALCIUM, V18, P471, DOI 10.1016/0143-4160(95)90010-1; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zaninovic V, 2000, AM J PHYSIOL-GASTR L, V279, pG666, DOI 10.1152/ajpgi.2000.279.4.G666	63	113	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22595	22604		10.1074/jbc.M202929200	http://dx.doi.org/10.1074/jbc.M202929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11964411	hybrid			2022-12-27	WOS:000176313600066
J	Bae, SH; Kim, DW; Kim, J; Kim, JH; Kim, DH; Kim, HD; Kang, HY; Seo, YS				Bae, SH; Kim, DW; Kim, J; Kim, JH; Kim, DH; Kim, HD; Kang, HY; Seo, YS			Coupling of DNA helicase and endonuclease activities of yeast Dna2 facilitates Okazaki fragment processing.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESSENTIAL IN-VIVO; REPLICATION FORK; SV40 ORIGIN; PROTEIN; HELICASE/ENDONUCLEASE; NUCLEASES; SUGGESTS; MACHINES; ENCODES	Saccharomyces cerevisiae Dna2 possesses both helicase and endonuclease activities. Its endonuclease activity is essential and well suited to remove RNA-DNA primers of Okazaki fragments. In contrast, its helicase activity, although required for optimal growth, is not essential when the rate of cell growth is reduced. These findings suggest that DNA unwinding activity of Dna2 plays an auxiliary role in Okazaki fragment processing. To address this issue, we examined whether the Dna2 helicase activity influenced its intrinsic endonuclease activity using two mutant proteins, Dna2D657A and Dna2K1080E, which contain only helicase or endonuclease activity, respectively. Experiments performed with a mixture of Dna2D657A and Dna2K1080E enzymes revealed that cleavage of a single-stranded DNA by endonuclease activity of Dna2 occurs while the enzyme translocates along the substrate. In addition, DNA unwinding activity efficiently removed the secondary structure formed in the flap structure, which was further aided by replication protein A. Our results suggest that the Dna2 unwinding activity plays a role in facilitating the removal of the flap DNA by its intrinsic endonuclease activity.	Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Natl Creat Res Initiat Ctr Cell Cycle Control, Suwon 440746, South Korea; Dong A Univ, Coll Med, Dept Pharmacol, Seo Gu, Pusan 602103, South Korea; Chungbuk Prov Univ Sci & Technol, Dept Biotechnol & Bioinformat, Okchon 373807, Chungbuk, South Korea	Sungkyunkwan University (SKKU); Dong A University	Seo, YS (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Natl Creat Res Initiat Ctr Cell Cycle Control, Changan Ku, Suwon 440746, South Korea.	ysseo@med.skku.ac.kr	Seo, Yeonsoo/C-1605-2011; Kim, Dong Wook/H-8253-2015	Kim, Dong Wook/0000-0001-5351-7597				Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2001, NUCLEIC ACIDS RES, V29, P3069, DOI 10.1093/nar/29.14.3069; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Kang HY, 2000, GENETICS, V155, P1055; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0	24	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26632	26641		10.1074/jbc.M111026200	http://dx.doi.org/10.1074/jbc.M111026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004053	hybrid			2022-12-27	WOS:000176908700105
J	Griffiths, SW; King, J; Cooney, CL				Griffiths, SW; King, J; Cooney, CL			The reactivity and oxidation pathway of cysteine 232 in recombinant human alpha 1-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALPHA-1-PROTEINASE INHIBITOR; HYDROGEN-PEROXIDE; SULFENIC ACID; ACTIVE-SITE; DISULFIDE EXCHANGE; ION-PAIR; MECHANISM; ALPHA(1)-ANTITRYPSIN; INACTIVATION; GLUTATHIONE	Oxidative damage to the sulfur-containing amino acids, methionine and cysteine, is a major concern in biotechnology and medicine. alpha1-Antitrypsin, which is a metastable and conformationally flexible protein that belongs to the serpin family of protease inhibitors, contains nine methionines and a single cysteine in its primary sequence. Although it is known that methionine oxidation in the protein active site results in a loss of biological activity, there is little specific knowledge regarding the reactivity of its unpaired thiol, Cys-232. In this study, the thiol-modifying reagent NBD-Cl (7-chloro-4-nitrobenz-2-oxa-1,3-diazole) was used to label peroxide-modified alpha1-antitrypsin and demonstrate that the Cys-232 in vitro oxidation pathway begins with a stable sulfenic acid intermediate and is followed by the formation of sulfinic and cysteic acid in successive steps. pH-dependent reactivity with hydrogen peroxide showed that Cys-232 has a pK(a) of 6.86 +/- 0.05, a value that is more than 1.5 pH units lower than that of a typical protein thiol. pH-induced conformational changes in the region surrounding Cys-232 were also examined and indicate that mildly acidic conditions induce a conformation that enhances Cys-232 reactivity. In summary, this work provides new insights into alpha1-antitrypsin reactivity in oxidizing environments and shows that a unique structural environment renders its unpaired thiol, Cys-232, its most reactive amino acid.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Griffiths, SW (corresponding author), 77 Massachusetts Ave,Bldg 56,Rm 456, Cambridge, MA 02139 USA.	swgriffi@mit.edu		Griffiths, Steven/0000-0002-9593-4724				Barrett GC, 1990, CHEM SULPHENIC ACIDS, P1; BARTON JP, 1973, J CHEM SOC PERK T 2, P1547, DOI 10.1039/p29730001547; BEATTY K, 1982, J LAB CLIN MED, V100, P186; Beynon R., 1996, BASICS BUFFER SOLUTI; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CLAIBORNE A, 2001, BIOCHEMISTRY-US, V58, P215; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Griffiths SW, 2002, BIOCHEMISTRY-US, V41, P6245, DOI 10.1021/bi025599p; Griffiths SW, 2002, J CHROMATOGR A, V942, P133, DOI 10.1016/S0021-9673(01)01350-4; HOLMAN CM, 1994, BIOCHEMISTRY-US, V33, P2672, DOI 10.1021/bi00175a041; HOYLAERTS M, 1987, J BIOTECHNOL, V5, P181, DOI 10.1016/0168-1656(87)90015-0; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JANOFF A, 1986, AM REV RESPIR DIS, V133, P353; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; LAURELL CB, 1970, IMMUNOCHEMISTRY, V7, P461, DOI 10.1016/0019-2791(70)90228-4; LAURELL CB, 1974, IMMUNOCHEMISTRY, V11, P703, DOI 10.1016/0019-2791(74)90269-9; LEUNG PSK, 1985, J PHYS CHEM-US, V89, P5267, DOI 10.1021/j100270a029; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; Miyamoto Y, 2000, BBA-PROTEIN STRUCT M, V1477, P90, DOI 10.1016/S0167-4838(99)00264-2; MUSIANI P, 1978, CLIN CHIM ACTA, V85, P61, DOI 10.1016/0009-8981(78)90101-8; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PARENTE A, 1985, BIOCHEMISTRY-US, V24, P1098, DOI 10.1021/bi00326a005; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; POLGAR L, 1973, EUR J BIOCHEM, V39, P421, DOI 10.1111/j.1432-1033.1973.tb03140.x; SAKLATVALA J, 1976, BIOCHEM J, V157, P339, DOI 10.1042/bj1570339; Scott LJ, 1999, BIOCHEM BIOPH RES CO, V255, P562, DOI 10.1006/bbrc.1999.0247; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Taggart C, 2000, J BIOL CHEM, V275, P27258; Tyagi SC, 1996, BIOCHEM CELL BIOL, V74, P391, DOI 10.1139/o96-042; TYAGI SC, 1992, BIOCHEMISTRY-US, V31, P10584, DOI 10.1021/bi00158a022; Wang PF, 2001, BIOCHEMISTRY-US, V40, P11698, DOI 10.1021/bi011208f; WILSON JM, 1980, J AM CHEM SOC, V102, P359, DOI 10.1021/ja00521a058; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8	47	70	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25486	25492		10.1074/jbc.M203089200	http://dx.doi.org/10.1074/jbc.M203089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991955	hybrid			2022-12-27	WOS:000176747000084
J	He, B; Lee, LW; Minges, JT; Wilson, EM				He, B; Lee, LW; Minges, JT; Wilson, EM			Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; PROBASIN GENE; REGULATED EXPRESSION; RESPONSIVE ENHANCER; STRUCTURAL BASIS; TRANSGENIC MICE; MESSENGER-RNA; MOUSE	The agonist-induced androgen receptor NH2- and COOH-terminal (N/C) interaction is mediated by the FXXLF and WXXLF NH2-terminal motifs. Here we demonstrate that agonist-dependent transactivation of prostate-specific antigen (PSA) and probasin enhancer/promoter regions requires the N/C interaction, whereas the sex-limited protein gene and mouse mammary tumor virus long terminal repeat do not. Transactivation of PSA and probasin response regions also depends on activation function 1 (AF1) in the NH2-terminal region but can be increased by binding an overexpressed p160 coactivator to activation function 2 (AF2) in the ligand binding domain. The dependence of the PSA and probasin enhancer/promoters on the N/C interaction for transactivation allowed us to demonstrate that in the presence of androgen, the WXXLF motif with the sequence (WHTLF437)-W-433 contributes as an inhibitor to AR transactivation. We further show that like the FXXLF and LXXLL motifs, the WXXLF motif interacts in the presence of androgen with AF2 in the ligand binding domain. Sequence comparisons among species indicate greater conservation of the FXXLF motif compared with the WXXLF motif, paralleling the functional significance of these binding motifs. The data provide evidence for promoter-specific differences in the requirement for the androgen receptor N/C interaction and in the contributions of AF1 and AF2 in androgen-induced gene regulation.	Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA.				NICHD NIH HHS [HD16910, U54-HD35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, R01HD016910, U54HD035041] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; CARPET F, 1988, NUCLEIC ACIDS RES, V16, P10881; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHALEPAKIS G, 1988, NUCLEIC ACIDS RES, V16, P10237, DOI 10.1093/nar/16.21.10237; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; Choong CS, 1998, J MOL EVOL, V47, P334, DOI 10.1007/PL00006391; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FISCHER LM, 1995, DEV BIOL, V170, P115, DOI 10.1006/dbio.1995.1200; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Gregory CW, 2001, CANCER RES, V61, P4315; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; HE WW, 1990, BIOCHEM BIOPH RES CO, V171, P697, DOI 10.1016/0006-291X(90)91202-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; KASPER S, 1994, J BIOL CHEM, V269, P31763; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeo J, 1999, J BIOL CHEM, V274, P5674, DOI 10.1074/jbc.274.9.5674; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Todo T, 1999, BIOCHEM BIOPH RES CO, V254, P378, DOI 10.1006/bbrc.1998.9919; Touhata K, 1999, BBA-MOL CELL RES, V1450, P481, DOI 10.1016/S0167-4889(99)00055-5; WONG CI, 1993, J BIOL CHEM, V268, P19004; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	41	130	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25631	25639		10.1074/jbc.M202809200	http://dx.doi.org/10.1074/jbc.M202809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000757	hybrid, Green Published			2022-12-27	WOS:000176747000102
J	Konstas, AA; Koch, JP; Tucker, SJ; Korbmacher, C				Konstas, AA; Koch, JP; Tucker, SJ; Korbmacher, C			Cystic fibrosis transmembrane conductance regulator-dependent up-regulation of Kir1.1 (ROMK) renal K+ channels by the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; NA+ CHANNEL; SURFACE EXPRESSION; XENOPUS OOCYTES; CFTR; ENAC; MUTATIONS; MEMBRANE; PROTEINS; DOMAINS	The epithelial sodium channel (ENaC) and the secretory potassium channel (Kir1.1/ROMK) are expressed in the apical membrane of renal collecting duct principal cells where they provide the rate-limiting steps for Na+ absorption and K+ secretion. The cystic fibrosis transmembrane conductance regulator (CFTR) is thought to regulate the function of both ENaC and Kir1.1. We hypothesized that CFTR may provide a regulatory link between ENaC and Kir1.1. In Xenopus laevis oocytes co-expressing both ENaC and CFTR, the CFTR currents were 3-fold larger than those in oocytes expressing CFTR alone due to an increased expression of CFTR in the plasma membrane. ENaC was also able to increase Kir1.1 currents through an increase in surface expression, but only in the presence of CFTR. In the absence of CFTR, co-expression of ENaC was without effect on Kir1.1. ENaC-mediated CFTR-dependent up-regulation of Kir1.1 was reduced with a Liddle's syndrome mutant of ENaC. Furthermore, ENaC co-expressed with CFTR was without effect on the closely related K+ channel Kir4.1. We conclude that ENaC up-regulates Kir1.1 in a CFTR-dependent manner. CFTR may therefore provide the mechanistic link that mediates the coordinated upregulation of Kir1.1 during the stimulation of ENaC by hormones such as aldosterone or antidiuretic hormone.	Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England	University of Oxford	Korbmacher, C (corresponding author), Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de	Tucker, Stephen J./ABE-7468-2020; Tucker, Stephen J./ABE-6741-2020	Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000				BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Cahill P, 2000, J BIOL CHEM, V275, P16697, DOI 10.1074/jbc.M910205199; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF723, DOI 10.1152/ajprenal.1996.271.3.F723; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Ito M, 1996, FEBS LETT, V388, P11, DOI 10.1016/0014-5793(96)00502-9; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kibble JD, 2000, J PHYSIOL-LONDON, V526, P27, DOI 10.1111/j.1469-7793.2000.00027.x; Koch JP, 1999, J MEMBRANE BIOL, V168, P131, DOI 10.1007/s002329900503; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; KORBMACHER C, 1995, J MEMBRANE BIOL, V146, P29; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Letz B, 1997, AM J PHYSIOL-CELL PH, V272, pC657, DOI 10.1152/ajpcell.1997.272.2.C657; MALNIC G, 2000, KIDNEY PHYSL PATHOPH, P1575; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SCHAFER JA, 1990, AM J PHYSIOL, V258, pF199, DOI 10.1152/ajprenal.1990.258.1.F199; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; ToddTurla KM, 1996, AM J PHYSIOL-RENAL, V270, pF237, DOI 10.1152/ajprenal.1996.270.1.F237; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang WH, 1999, AM J PHYSIOL-RENAL, V277, pF826, DOI 10.1152/ajprenal.1999.277.6.F826; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Welling P. A., 1999, Journal of the American Society of Nephrology, V10, p49A; Wilson PD, 1999, EXP NEPHROL, V7, P284; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	49	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25377	25384		10.1074/jbc.M201925200	http://dx.doi.org/10.1074/jbc.M201925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994290	hybrid			2022-12-27	WOS:000176747000070
J	Adachi, H; Tsujimoto, M				Adachi, H; Tsujimoto, M			Characterization of the human gene encoding the scavenger receptor expressed by endothelial cell and its regulation by a novel transcription factor, endothelial zinc finger protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER; CLONING; BINDING; ATHEROSCLEROSIS; IDENTIFICATION	The scavenger receptor expressed by endothelial cell (SREC), mediates the selective uptake of modified low density lipoprotein (LDL), such as acetylated LDL and oxidized LDL, into endothelial cells. The SREC gene spans 12 kilobase pairs and contains 11 exons. Analysis of full-length cDNA clones of SREC from a peripheral blood leukocyte cDNA library revealed that at least five alternatively spliced cDNAs were present, and two of them encoded soluble forms of SREC. The transcription start site of the SREC gene was mapped, and DNA sequence analysis revealed an Sp1 binding site in its proximal region. Deletion analysis of the 5'-flanking sequence revealed that sequence between base pairs -108 and -98 was critical for the promoter activity. This region contained half of an inverted repeat (111) sequence with a triple nucleotide spacer (IR-3). A protected sequence between base pairs -268 and +17 was defined by in vitro DNase I footprinting analysis using human umbilical vein endothelial cell (HUVEC) nuclear extract. A novel transcription factor, endothelial zinc finger protein-2 (EZF-2), that binds to the 5'-flanking critical region of the SREC promoter activity was cloned from a HUVEC cDNA library employing a one-hybrid system. Whereas purified recombinant Sp1. alone produced similar protection in in vitro DNase I footprinting analysis, EZF-2 also bound to the 5'-flanking region SREC promoter. Co-transfection of SREC promoter and Sp1 or EZF-2 expression plasmids in HUVEC revealed that EZF-2 but not Sp1 increased SREC promoter activity. On the other hand, the mutation of either the Sp1 motif or IR-3 motif resulted in a decrease in the promoter activity. These results suggest that whereas Sp1 is the major nuclear protein bound to the regulatory region of the promoter, both EZF-2 and Sp1 are responsible for its regulation.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	RIKEN	Adachi, H (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; ADACHI H, 1995, J BIOCHEM-TOKYO, V118, P555, DOI 10.1093/oxfordjournals.jbchem.a124945; AMARAVADI L, 1994, BIOTECHNIQUES, V16, P98; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Han ZG, 1999, J BIOL CHEM, V274, P35741, DOI 10.1074/jbc.274.50.35741; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 2001, J CLIN INVEST, V108, P645, DOI 10.1172/JCI13932; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARUYAMA K, 1994, GENE, V138, P171; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OZMEN L, 1993, J IMMUNOL, V150, P2698; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; RICHTERICH P, 1993, METHOD ENZYMOL, V218, P187; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; Sander TL, 2000, J BIOL CHEM, V275, P12857, DOI 10.1074/jbc.275.17.12857; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; YET SF, 1998, J BIOL CHEM, V273, P1056	29	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24014	24021		10.1074/jbc.M201854200	http://dx.doi.org/10.1074/jbc.M201854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978792	hybrid			2022-12-27	WOS:000176611800008
J	Velthuis, JHL; Rouschop, KMA; de Bont, HJGM; Mulder, GJ; Nagelkerke, JF				Velthuis, JHL; Rouschop, KMA; de Bont, HJGM; Mulder, GJ; Nagelkerke, JF			Distinct intracellular signaling in tumor necrosis factor-related apoptosis-inducing ligand- and CD95 ligand-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; DEATH RECEPTORS; IN-VIVO; CELLS; BCL-2; FAS; MITOCHONDRIA; MECHANISMS; EXPRESSION; CASPASE-8	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in tumor cells but not in healthy cells. Similar to CD95 ligand (CD95L), TRAIL signaling requires ligand-receptor interaction; the downstream signaling molecules, such as Fas-associated death domain and caspase-8, also seem similar. Using cells stably expressing TRAIL and CD95L, we show that both TRAIL and CD95L induce apoptosis in the rat colon carcinoma cell line CC531. The mitochondrial damage (loss of mitochondrial membrane potential (MMP) and release of cytochrome c) observed after co-incubation with TRAIL-expressing cells occurs much earlier than that observed with CD95L-expressing cells. The decrease in MMP induced by both ligands was caspase-8-mediated; no difference in caspase-8 activation by TRAIL and CD95L was found. TRAIL, but not CD95L, induced activation of caspase-10. bcl-2 overexpression could not prevent TRAIL-induced mitochondrial dysfunction, whereas it completely prevented CD95L-mediated loss of MMP and cytochrome c release. The selective effect of TRAIL on tumor cells and the apparent inability of bcl-2 to block TRAIL-induced apoptosis suggest that TRAIL may offer a lead for cancer therapy in the future.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Velthuis, JHL (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, Wassenaarseweg 72, NL-2300 RA Leiden, Netherlands.	velthuis@lacdr.leidenuniv.nl		Rouschop, Kasper/0000-0002-4208-5415				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; Degli-Esposti M, 1999, J LEUKOCYTE BIOL, V65, P535, DOI 10.1002/jlb.65.5.535; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Krammer P H, 1999, Adv Immunol, V71, P163; Krammer PH, 1998, TOXICOL LETT, V103, P131, DOI 10.1016/S0378-4274(98)00297-5; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Seol DW, 2001, CANCER RES, V61, P1138; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Tanaka M, 1997, J IMMUNOL, V158, P2303; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANDEWATER B, 1993, BIOCHEM PHARMACOL, V45, P2259, DOI 10.1016/0006-2952(93)90197-5; Vermijlen D, 1999, HEPATOLOGY, V29, P51, DOI 10.1002/hep.510290143; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	41	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24631	24637		10.1074/jbc.M111572200	http://dx.doi.org/10.1074/jbc.M111572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980895	hybrid, Green Published			2022-12-27	WOS:000176611800087
J	Xia, Y; Wen, HY; Kellems, RE				Xia, Y; Wen, HY; Kellems, RE			Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAI-1 GENE-EXPRESSION; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; PROGNOSTIC IMPACT; BOUND UROKINASE; AT(1) RECEPTOR; TYPE-1 PAI-1; CELLS; CALCINEURIN; MECHANISMS	Trophoblast implantation depends, in part, on the controlled production of plasmin from plasminogen, a process regulated by plasminogen activators and plasminogen activator inhibitors. We have determined that angiotensin II (Ang II) stimulates plasminogen activator inhibitor-1 (PAI-1) synthesis and secretion in human trophoblasts in a time- and concentration-dependent manner. Our results indicate that Ang II activates PAI-1 gene expression through the AT1 receptor and involves the calcium-dependent activation of calcineurin and the nuclear translocation of NFAT. Increased PAI-1 synthesis and secretion is associated with reduced trophoblast invasion as judged by an in vitro invasion assay. These studies are the first to link the renin-angiotensin system with the fibrinolytic system to regulate trophoblast invasion.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System	Kellems, RE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin, Houston, TX 77030 USA.	Rodney.E.Kellems@uth.tmc.edu						Ahn JD, 2001, DIABETOLOGIA, V44, P713, DOI 10.1007/s001250051680; Alhenc-Gelas F, 1986, Adv Nephrol Necker Hosp, V15, P25; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; Burgle M, 1997, BIOL CHEM, V378, P231, DOI 10.1515/bchm.1997.378.3-4.231; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chen HC, 2000, ARTERIOSCL THROM VAS, V20, P2297, DOI 10.1161/01.ATV.20.10.2297; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DEBOER K, 1988, AM J OBSTET GYNECOL, V158, P518, DOI 10.1016/0002-9378(88)90016-6; Dechend R, 2000, CIRCULATION, V101, P2382, DOI 10.1161/01.CIR.101.20.2382; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Estelles A, 1998, THROMB HAEMOSTASIS, V79, P500; FEENER EP, 1995, J CLIN INVEST, V95, P1353, DOI 10.1172/JCI117786; FEINBERG RF, 1989, LAB INVEST, V61, P20; Fitzpatrick TE, 1998, EXP CELL RES, V245, P155, DOI 10.1006/excr.1998.4240; Fogo AB, 2000, AM J KIDNEY DIS, V35, P179, DOI 10.1016/S0272-6386(00)70324-6; GRAHAM CH, 1992, BIOCHEM CELL BIOL, V70, P867, DOI 10.1139/o92-135; GRAHAM CH, 1991, J CELL PHYSIOL, V148, P228, DOI 10.1002/jcp.1041480207; Granger JP, 2001, AM J HYPERTENS, V14, p178S, DOI 10.1016/S0895-7061(01)02086-6; HAGEMANN A, 1994, EXP CLIN ENDOCRINOL, V102, P252, DOI 10.1055/s-0029-1211289; HAHN AWA, 1993, BIOCHEM BIOPH RES CO, V192, P189, DOI 10.1006/bbrc.1993.1399; HOFMANN GE, 1994, AM J OBSTET GYNECOL, V170, P671, DOI 10.1016/S0002-9378(94)70246-2; KETTELER M, 1995, ANNU REV PHYSIOL, V57, P279; Khoo NKS, 1998, INT J CANCER, V77, P429, DOI 10.1002/(SICI)1097-0215(19980729)77:3<429::AID-IJC20>3.0.CO;2-1; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; Lala PK, 2000, PLACENTA, V21, P593, DOI 10.1053/plac.1999.0545; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; Matsusaka T, 1996, J AM SOC NEPHROL, V7, P2025; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Motojima M, 1999, BBA-MOL CELL RES, V1449, P217, DOI 10.1016/S0167-4889(99)00014-2; Motojima M, 2000, BIOCHEM J, V349, P435, DOI 10.1042/0264-6021:3490435; Nakamura S, 2000, KIDNEY INT, V58, P251, DOI 10.1046/j.1523-1755.2000.00160.x; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; Poisner AM, 1998, FRONT NEUROENDOCRIN, V19, P232, DOI 10.1006/frne.1998.0166; QUEENAN JT, 1987, J BIOL CHEM, V262, P10903; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; Schmitt M, 1997, BRIT J CANCER, V76, P306, DOI 10.1038/bjc.1997.383; Shaarawy M, 1996, INT J GYNECOL OBSTET, V55, P135, DOI 10.1016/S0020-7292(96)02755-5; SKINNER SL, 1972, CLIN SCI, V42, P479, DOI 10.1042/cs0420479; STRICKLAND S, 1976, J BIOL CHEM, V251, P5694; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wallukat G, 1999, J CLIN INVEST, V103, P945, DOI 10.1172/JCI4106; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wolf G, 1998, NEPHROLOGIE, V19, P451; WOLF G, 1992, AM J PATHOL, V140, P95; WUN TC, 1987, J BIOL CHEM, V262, P3646; Xia Y, 2002, BIOL REPROD, V66, P135, DOI 10.1095/biolreprod66.1.135; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855	58	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24601	24608		10.1074/jbc.M201369200	http://dx.doi.org/10.1074/jbc.M201369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983698	hybrid			2022-12-27	WOS:000176611800083
J	Yengo, CM; De la Cruz, EM; Chrin, LR; Gaffney, DP; Berger, CL				Yengo, CM; De la Cruz, EM; Chrin, LR; Gaffney, DP; Berger, CL			Actin-induced closure of the actin-binding cleft of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MYOSIN; X-RAY STRUCTURE; MOTOR DOMAIN; ADP RELEASE; ACTOMYOSIN; COMPLEX; HEAD; SUBFRAGMENT-1; PURIFICATION; CONTRACTION	The putative actin-binding interface of myosin is separated by a large cleft that extends into the base of the nucleotide binding pocket, suggesting that it may be important for mediating the nucleotide-dependent changes in the affinity for myosin on actin. We have genetically engineered a truncated version of smooth muscle myosin containing the motor domain and the essential light chain-binding region (MDE), with a single tryptophan residue at position 425 (F425W-MDE) in the actin-binding cleft. Steady-state fluorescence of F425W-MDE demonstrates that Trp-425 is in a more solvent-exposed conformation in the presence of MgATP than in the presence of MgADP or absence of nucleotide, consistent with closure of the actin-binding cleft in the strongly bound states of MgATPase cycle for myosin. Transient kinetic experiments demonstrate a direct correlation between the rates of strong actin binding and the conformation of Trp-425 in the actin-binding cleft, and suggest the existence of a novel conformation of myosin not previously seen in solution or by x-ray crystallography. Thus, these results directly demonstrate that: 1) the conformation of the actin-binding cleft mediates the affinity of myosin for actin in a nucleotide-dependent manner, and 2) actin induces conformational changes in myosin required to generate force and motion during muscle contraction.	Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Vermont; University of Pennsylvania; University of Pennsylvania	Berger, CL (corresponding author), Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044219] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63798] Funding Source: Medline; NIAMS NIH HHS [AR44219] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHOCK SP, 1976, BIOCHEMISTRY-US, V15, P3244, DOI 10.1021/bi00660a013; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1991, BIOCHEM J, V274, P1; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; MORNET D, 1981, BIOCHEMISTRY-US, V20, P2110, DOI 10.1021/bi00511a007; Onishi H, 1995, P NATL ACAD SCI USA, V92, P11965, DOI 10.1073/pnas.92.26.11965; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sellers J. R., 1999, MYOSINS; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P2110; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l; Yengo CM, 1998, P NATL ACAD SCI USA, V95, P12944, DOI 10.1073/pnas.95.22.12944	28	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24114	24119		10.1074/jbc.M111253200	http://dx.doi.org/10.1074/jbc.M111253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959853	hybrid			2022-12-27	WOS:000176611800019
J	Corzo, G; Villegas, E; Gomez-Lagunas, F; Possani, LD; Belokoneva, OS; Nakajima, T				Corzo, G; Villegas, E; Gomez-Lagunas, F; Possani, LD; Belokoneva, OS; Nakajima, T			Oxyopinins, large amphipathic peptides isolated from the venom of the wolf spider Oxyopes kitabensis with cytolytic properties and positive insecticidal cooperativity with spider neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PHONEUTRIA-NIGRIVENTER KEYS; SCORPION PANDINUS-IMPERATOR; ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL PEPTIDE; LIPID BILAYERS; CHANNELS; TOXINS; MODEL; MAGAININ-2	Five amphipathic peptides with antimicrobial, hemolytic, and insecticidal activity were isolated from the crude venom of the wolf spider Oxyopes kitabensis. The peptides, named oxyopinins, are the largest linear cationic amphipathic peptides from the venom of a spider that have been chemically characterized at present. According to their primary structure Oxyopinin 1 is composed of 48 amino acid residues showing extended sequence similarity to the ant insecticidal peptide ponericinL2 and to the frog antimicrobial peptide dermaseptin. Oxyopinins 2a, 2b, 2c, and 2d have highly similar sequences. At least 27 out of 37 amino acid residues are conserved. They also show a segment of sequence similar to ponericinL2. Circular dichroism analyses showed that the secondary structure of the five peptides is essentially a-helical. Oxyopinins showed disrupting activities toward both biological membranes and artificial vesicles, particularly to those rich in phosphatidylcholine. Electrophysiological recordings performed on insect cells (Sf9) showed that the oxyopinins produce a drastic reduction of cell membrane resistance by opening non-selective ion channels. Additionally, a new paralytic neurotoxin named Oxytoxin 1 was purified from the same spider venom. It contains 69 amino acid residue cross-linked by five disulfide bridges. Application of mixtures containing oxyopinins and Oxytoxin 1 to insect larvae showed a potentiation phenomenon, by which an increase lethality effect is observed. These results suggest that the linear amphipathic peptides in spider venoms and neuropeptides cooperate to capture insects efficiently.	Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Univ Nacl Autonoma Mexico, Dept Physiol, Sch Med, Mexico City 04510, DF, Mexico; Inst Biotechnol, Dept Mol Recognit & Struct Biol, Cuernavaca 62210, Morelos, Mexico	Suntory Holdings Ltd; Universidad Nacional Autonoma de Mexico	Corzo, G (corresponding author), Suntory Inst Bioorgan Res, Wakayamadai 1-1-1, Shimamoto, Osaka 6188503, Japan.	corzo@sunbor.or.jp	Corzo, Gerardo/B-3778-2014; Possani, Lourival D/J-2397-2013	Corzo, Gerardo/0000-0002-9513-1622; Villegas Villarreal, Elba Cristina/0000-0003-1795-0427				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; AGAWA Y, 1991, J BIOL CHEM, V266, P20218; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Batista CVF, 1999, PEPTIDES, V20, P679, DOI 10.1016/S0196-9781(99)00050-9; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; CHAN TK, 1975, TOXICON, V13, P61, DOI 10.1016/0041-0101(75)90159-2; Chen FY, 2002, BIOPHYS J, V82, P908, DOI 10.1016/S0006-3495(02)75452-0; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G; Corzo G, 2000, EUR J BIOCHEM, V267, P5783, DOI 10.1046/j.1432-1327.2000.01653.x; Corzo G, 2001, BIOCHEM J, V359, P35, DOI 10.1042/0264-6021:3590035; de Lima ME, 2002, J INSECT PHYSIOL, V48, P53, DOI 10.1016/S0022-1910(01)00143-3; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; Elazar M, 2001, J EXP BIOL, V204, P2637; Escoubas P, 1995, TOXICON, V33, P1549, DOI 10.1016/0041-0101(95)00107-7; FENNELL JF, 1968, P SOC EXP BIOL MED, V127, P707; FIGUEIREDO SG, 1995, TOXICON, V33, P83, DOI 10.1016/0041-0101(94)00130-Z; FINNEY DJ, 1962, PROBIT ANAL, P318; FOELIX RF, 1996, BIOL SPIDERS, P7; FRIEDEL T, 1989, TOXICON, V27, P305, DOI 10.1016/0041-0101(89)90178-5; GomezLagunas F, 1996, J MEMBRANE BIOL, V152, P49, DOI 10.1007/s002329900084; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; Hara T, 2001, BIOCHEMISTRY-US, V40, P12395, DOI 10.1021/bi011413v; Heller WT, 1997, BIOPHYS J, V73, P239, DOI 10.1016/S0006-3495(97)78064-0; HERRMANN R, 1995, TOXICON, V33, P1099, DOI 10.1016/0041-0101(95)98053-X; HERRMANN R, 1990, INSECT BIOCHEM, V20, P625, DOI 10.1016/0020-1790(90)90075-6; Higashimoto Y, 1999, J BIOCHEM-TOKYO, V125, P705, DOI 10.1093/oxfordjournals.jbchem.a022340; Hille B., 1992, IONIC CHANNELS EXCIT; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; IWAI H, 1993, EUR J BIOCHEM, V217, P639, DOI 10.1111/j.1432-1033.1993.tb18287.x; Kuhn-Nentwig L, 2002, J BIOL CHEM, V277, P11208, DOI 10.1074/jbc.M111099200; Lamberty M, 2001, J BIOL CHEM, V276, P4085, DOI 10.1074/jbc.M002998200; Mak DOD, 1995, BIOPHYS J, V69, P2323, DOI 10.1016/S0006-3495(95)80102-5; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P2104, DOI 10.1021/bi961870p; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NAKAJIMA T, 1990, ADV EXP MED BIOL, V247, P215; NELSON GJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P221, DOI 10.1016/0005-2760(67)90152-X; OKADA M, 1985, J BIOL CHEM, V260, P7174; Orivel J, 2001, J BIOL CHEM, V276, P17823, DOI 10.1074/jbc.M100216200; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; Silva PI, 2000, J BIOL CHEM, V275, P33464, DOI 10.1074/jbc.M001491200; Silvestro L, 1997, BIOCHEMISTRY-US, V36, P11452, DOI 10.1021/bi9630826; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SODERHALL K, 1983, DEV COMP IMMUNOL, V7, P229, DOI 10.1016/0145-305X(83)90004-6; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TAKLE G, 1985, J CELL SCI, V75, P207; Torres-Larios A, 2000, EUR J BIOCHEM, V267, P5023, DOI 10.1046/j.1432-1327.2000.01556.x; Veiga SS, 2001, BRAZ J MED BIOL RES, V34, P843, DOI 10.1590/S0100-879X2001000700002; WHITE DA, 1973, FORM FUNCTION PHOSPH, P454; Wieprecht T, 2000, BIOPHYS CHEM, V85, P187, DOI 10.1016/S0301-4622(00)00120-4; Wong H, 1997, EUR J BIOCHEM, V247, P545, DOI 10.1111/j.1432-1033.1997.00545.x; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	57	110	121	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23627	23637		10.1074/jbc.M200511200	http://dx.doi.org/10.1074/jbc.M200511200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976325	hybrid			2022-12-27	WOS:000176475700069
J	Knuefermann, P; Chen, P; Misra, A; Shi, SP; Abdellatif, M; Sivasubramanian, N				Knuefermann, P; Chen, P; Misra, A; Shi, SP; Abdellatif, M; Sivasubramanian, N			Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NF kappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE GENE; DNA-BINDING; DEPENDENT ACTIVATION; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION; ALPHA; SIGNAL; CELLS; SUBUNIT	Myotrophin/V-1 is a cytosolic protein found at elevated levels in failing human hearts and in postnatal cerebellum. We have previously shown that it disrupts nuclear factor of kappaB (NFkappaB)-DNA complexes in vitro. In this study, we demonstrated that in HeLa cells native myotrophin/V-1 is predominantly present in the cytoplasm and translocates to the nucleus during sustained NFkappaB activation. Three-dimensional alignment studies indicate that myotrophin/V-1 resembles a truncated IkappaBalpha without the signal response domain (SRD) and PEST domains. Co-immunoprecipitation studies reveal that myotrophin/V-1 interacts with NFkappaB proteins in vitro; however, it remains physically associated only with p65 and c-Rel proteins in vivo during NFkappaB activation. In vitro studies indicate that myotrophin/V-1 can promote the formation of p50-p50 homodimers from monomeric p50 proteins and can convert the preformed p50-p65 heterodimers into p50-p50 and p65-p65 homodimers. Furthermore, adenovirus-mediated overexpression of myotrophin/V-1 resulted in elevated levels of both p5O-p5O and p65-p65 homodimers exceeding the levels of p50-p65 heterodimers compared with Adbetagal-infected cells, where the levels of p50-p65 heterodimers exceeded the levels of p5O-p5O and p65-p65 homodimers. Thus, overexpression of myotrophin/V-1 during NFkappaB activation resulted in a qualitative shift by quantitatively reducing the level of transactivating heterodimers while elevating the levels of repressive p50-p50 homodimers. Correspondingly, overexpression of myotrophin/V-1 resulted in significantly reduced kappaB-luciferase reporter activity. Because myotrophin/V-1 is found at elevated levels during NFkappaB activation in postnatal cerebellum and in failing human hearts, this study cumulatively suggests that myotrophin/V-1 is a regulatory protein for modulating the levels of activated NFkappaB dimers during this period.	Baylor Coll Med, Winters Ctr Heart Failure Res, Mol Cardiol Unit, Sect Dept Med,Vet Affairs Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sivasubramanian, N (corresponding author), Baylor Coll Med, Winters Ctr Heart Failure Res, Mol Cardiol Unit, Sect Dept Med,Vet Affairs Med Ctr, 6565 Fannin ST,MS524, Houston, TX 77030 USA.	nats@bcm.tmc.edu		Chen, Peter/0000-0002-5330-1718				Acarin L, 2000, NEUROSCI LETT, V288, P41, DOI 10.1016/S0304-3940(00)01202-7; Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Anderson KM, 1999, J MOL CELL CARDIOL, V31, P705, DOI 10.1006/jmcc.1998.0903; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Borgland SL, 2000, J VIROL, V74, P3941, DOI 10.1128/JVI.74.9.3941-3947.2000; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Brigelus-Flohe R, 1995, BIOFACTORS, V5, P169; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Clesham GJ, 1998, GENE THER, V5, P174, DOI 10.1038/sj.gt.3300576; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doerre S, 1999, J IMMUNOL, V163, P269; Farmer PK, 2000, AM J PHYSIOL-ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213; Goldring CE, 1998, EUR J IMMUNOL, V28, P2960, DOI 10.1002/(SICI)1521-4141(199809)28:09<2960::AID-IMMU2960>3.0.CO;2-B; GOLDRING CEP, 1995, BIOCHEM BIOPH RES CO, V209, P73, DOI 10.1006/bbrc.1995.1472; Guerrini L, 1997, J NEUROSCI, V17, P6057; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Haudek SB, 2001, J MOL CELL CARDIOL, V33, P1263, DOI 10.1006/jmcc.2001.1388; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Holm L, 1996, METHOD ENZYMOL, V266, P653; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kaltschmidt B, 2001, MECH DEVELOP, V101, P11, DOI 10.1016/S0925-4773(00)00542-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Koukouritaki SB, 1999, MOL MED, V5, P382, DOI 10.1007/BF03402127; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PENNICA D, 1995, GENE, V158, P305, DOI 10.1016/0378-1119(95)00131-O; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SEN S, 1990, J BIOL CHEM, V265, P16635; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIL P, 1995, CIRC RES, V76, P1020, DOI 10.1161/01.RES.76.6.1020; SIL P, 1993, CIRC RES, V73, P98, DOI 10.1161/01.RES.73.1.98; Sivasubramanian N, 1996, J BIOL CHEM, V271, P2812, DOI 10.1074/jbc.271.5.2812; SIVASUBRAMANIAN N, 1987, P NATL ACAD SCI USA, V84, P1, DOI 10.1073/pnas.84.1.1; Sohur US, 1999, GENE EXPRESSION, V8, P219; Song SY, 1996, ENDOCRINOLOGY, V137, P1423, DOI 10.1210/en.137.4.1423; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; TAOKA M, 1994, J BIOL CHEM, V269, P9946; TAOKA M, 1992, EUR J BIOCHEM, V207, P615, DOI 10.1111/j.1432-1033.1992.tb17088.x; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Vallejo JG, 2000, J IMMUNOL, V165, P419, DOI 10.4049/jimmunol.165.1.419; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Wilson L, 1999, GASTROENTEROLOGY, V117, P106, DOI 10.1016/S0016-5085(99)70556-1; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; Yamakuni T, 1998, J BIOL CHEM, V273, P27051, DOI 10.1074/jbc.273.42.27051; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yang YW, 1998, STRUCTURE, V6, P619, DOI 10.1016/S0969-2126(98)00063-X; Yang YW, 1997, PROTEIN SCI, V6, P1347, DOI 10.1002/pro.5560060625; Ziegler-Heitbrock L, 2001, J ENDOTOXIN RES, V7, P219, DOI 10.1177/09680519010070030401	78	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23888	23897		10.1074/jbc.M202937200	http://dx.doi.org/10.1074/jbc.M202937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971907	hybrid			2022-12-27	WOS:000176475700103
J	Yun, S; Jang, DS; Choi, G; Kim, KS; Choi, KY; Lee, HC				Yun, S; Jang, DS; Choi, G; Kim, KS; Choi, KY; Lee, HC			Trifluoroethanol increases the stability of Delta(5)-3-ketosteroid isomerase - N-15 NMR relaxation studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; CHEMICAL-SHIFT ANISOTROPY; PARTIALLY FOLDED STATE; HELICAL COILED-COILS; COLI RIBONUCLEASE HI; MODEL-FREE APPROACH; DNA-BINDING DOMAIN; BACKBONE DYNAMICS; QUATERNARY STRUCTURE; EQUILIBRIUM DISSOCIATION	In the equilibrium unfolding process of Delta(5)-3-ketosteroid isomerase from Pseudomonas testosteroni by urea, it was observed that the enzyme stability increases by 2.5 kcal/mol in the presence of 5% trifluoroethanol (TFE). To elucidate the increased enzyme stability by TFE, the backbone dynamics of Delta(5)-3-ketosteroid isomerase were studied in the presence and absence of 5% TFE by (15)'N NMR relaxation measurements, and the motional parameters (S-2,tau(e), and R-ex were extracted from the relaxation data using the model-free formalism. The presence of 5% TFE causes little change or a slight increase in the order parameters (S2) for a number of residues, which are located mainly in the dimer interface region. However, the majority of the residues exhibit reduced order parameters in the presence of 5% TFE, indicating that high frequency (pico- to nanosecond) motions are generally enhanced by TFE. The results suggest that the entropy can be an important factor for the enzyme stability, and the increase in entropy by TFE is partially responsible for the increased stability of Delta(5)-3-ketosteroid isomerase.	Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Superfunct Mat, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl Res Lab Prot Folding & Engn, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Lee, HC (corresponding author), Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea.		Kim, Kwang Soo/C-7538-2012	Kim, Kwang Soo/0000-0002-6929-5359				AKKE M, 1993, J AM CHEM SOC, V115, P9832, DOI 10.1021/ja00074a073; ALEXANDRESCU AT, 1994, J MOL BIOL, V235, P587, DOI 10.1006/jmbi.1994.1015; Arunkumar AI, 1996, J BIOMOL STRUCT DYN, V14, P381, DOI 10.1080/07391102.1996.10508133; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Beeser SA, 1997, J MOL BIOL, V269, P154, DOI 10.1006/jmbi.1997.1031; Bhakuni V, 1998, ARCH BIOCHEM BIOPHYS, V357, P274, DOI 10.1006/abbi.1998.0794; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BOYD J, 1990, CHEM PHYS LETT, V175, P477, DOI 10.1016/0009-2614(90)85567-V; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; CANN JR, 1987, INT J PEPT PROT RES, V29, P486; Cho HS, 1998, BIOCHEMISTRY-US, V37, P8325, DOI 10.1021/bi9801614; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; FAN P, 1993, BIOCHEMISTRY-US, V32, P13299, DOI 10.1021/bi00211a043; Fushman D, 1998, J AM CHEM SOC, V120, P7109, DOI 10.1021/ja980565j; Gast K, 1997, PROTEIN SCI, V6, P2578; HALLE B, 1981, J CHEM PHYS, V75, P1928, DOI 10.1063/1.442218; Hamada D, 2000, NAT STRUCT BIOL, V7, P58; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P15418, DOI 10.1021/bi00255a023; Ionescu RM, 1999, NAT STRUCT BIOL, V6, P304; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim DH, 2000, BIOCHEMISTRY-US, V39, P13084, DOI 10.1021/bi000872d; KIM SW, 1994, J BACTERIOL, V176, P6672, DOI 10.1128/JB.176.21.6672-6676.1994; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lu H, 1997, J MOL BIOL, V265, P112, DOI 10.1006/jmbi.1996.0715; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; Mackay JP, 1996, BIOCHEMISTRY-US, V35, P4867, DOI 10.1021/bi952761y; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MATTHEWS SJ, 1993, BIOCHEMISTRY-US, V32, P657, DOI 10.1021/bi00053a034; Mok YK, 1996, PROTEIN SCI, V5, P310; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PALMER AG, 1992, MOL PHYS, V75, P699, DOI 10.1080/00268979200100511; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RamirezAlvarado M, 1997, PROTEIN SCI, V6, P162; RISCHEL C, 1994, BIOCHEMISTRY-US, V33, P13997, DOI 10.1021/bi00251a006; Sahu SC, 2000, PROTEINS, V41, P460, DOI 10.1002/1097-0134(20001201)41:4<460::AID-PROT40>3.0.CO;2-X; SCHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452; Schonbrunner N, 1996, J MOL BIOL, V260, P432, DOI 10.1006/jmbi.1996.0412; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; Yamasaki K, 1998, J MOL BIOL, V277, P707, DOI 10.1006/jmbi.1997.1622; Yun SG, 2001, BIOCHEMISTRY-US, V40, P3967, DOI 10.1021/bi0023192; Zajicek J, 2000, J MOL BIOL, V301, P333, DOI 10.1006/jmbi.2000.3972; Zhang YX, 1996, J PROTEIN CHEM, V15, P631, DOI 10.1007/BF01886745; [No title captured]	56	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23414	23419		10.1074/jbc.M200147200	http://dx.doi.org/10.1074/jbc.M200147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973332	hybrid			2022-12-27	WOS:000176475700042
J	Bres, V; Kiernan, R; Emiliani, S; Benkirane, M				Bres, V; Kiernan, R; Emiliani, S; Benkirane, M			Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; RNA-POLYMERASE-II; NF-KAPPA-B; CELLULAR PROTEIN-KINASE; CREB-BINDING-PROTEIN; FACTOR P-TEFB; HIV-1 TAT; T-CELLS; TRANSCRIPTIONAL ACTIVATION; HISTONE-ACETYLTRANSFERASE	The human immunodeficiency virus type-1 trans-activator Tat is a transcription factor that activates the HIV-1 promoter through binding to the trans-activation-responsive region (TAR) localized at the 5'-end of all viral transcripts. We and others have recently shown that Tat is directly acetylated at lysine 28, within the activation domain, and lysine 50, in the TAR RNA binding domain, by Tat-associated histone acetyltransferases p300, p300/CBP-associating factor, and hGCN5. Here, we show that mutation of acetyl-acceptor lysines to arginine or glutamine affects virus replication. Interestingly, mutation of lysine 28 and lysine 50 differentially affected Tat trans-activation of integrated versus nonintegrated long terminal repeat. Our results highlight the importance of lysine 28 and lysine 50 of Tat in virus replication and Tat-mediated trans-activation.	Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Benkirane, M (corresponding author), Inst Genet Humaine, CNRS, UPR 1142, 141 Rue Cardonville, F-34396 Montpellier 5, France.		Kiernan, Rosemary/GXV-8695-2022	Kiernan, Rosemary/0000-0001-6645-0686				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cafaro A, 2000, J MED PRIMATOL, V29, P193, DOI 10.1034/j.1600-0684.2000.290313.x; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Ensoli B, 2000, J BIOL REG HOMEOS AG, V14, P22; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; JOSHI A, 1993, BIOTECHNIQUES, V14, P880; JOSHI A, 1993, BIOTECHNIQUES, V14, P884; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Osterhaus ADME, 1999, VACCINE, V17, P2713, DOI 10.1016/S0264-410X(98)00498-8; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Secchiero P, 1999, J IMMUNOL, V162, P2427; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	62	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22215	22221		10.1074/jbc.M201895200	http://dx.doi.org/10.1074/jbc.M201895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956210	hybrid			2022-12-27	WOS:000176313600016
J	Jones, LC; Okino, ST; Gonda, TJ; Whitlock, JP				Jones, LC; Okino, ST; Gonda, TJ; Whitlock, JP			Myb-binding protein 1a augments AhR-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN RECEPTOR; TRANSCRIPTION; TRANSACTIVATION; DOMAINS; IDENTIFICATION; CLONING; REVEALS; MOTIF; ARNT; PAS	We have studied the mechanism by which an acidic domain (amino acids 515-583) of the aromatic hydrocarbon receptor (AhR) transactivates a target gene. Studies with glutathione S-transferase fusion proteins demonstrate that the wild-type acidic domain associates in vitro with Myb-binding protein la, whereas a mutant domain (F542A, 1569A) does not. AhR-defective cells reconstituted with an AhR containing the wild-type acidic domain exhibit normal AhR function; however, cells reconstituted with an AhR containing the mutant acidic domain do not function normally. Transient transfection of Myb-binding protein la into mouse hepatoma cells is associated with augmentation of AhR-dependent gene expression. Such augmentation does not occur when Myb-binding protein la is transfected into AhR-defective cells that have been reconstituted with an AhR that lacks the acidic domain. We infer that 1) Myb-binding protein la associates with AhR, thereby enhancing transactivation, and 2) the presence of AhR's acidic domain is both necessary and sufficient for Myb-binding protein la to increase AhR-dependent gene expression.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Stanford University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Institute Medical & Veterinary Science Australia	Whitlock, JP (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Gonda, Thomas J/A-3620-2012		NCI NIH HHS [CA 53887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVIER D, 1994, ONCOGENE, V9, P305; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FISHER JM, 1990, J BIOL CHEM, V265, P9676; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Jones LC, 2001, J BIOL CHEM, V276, P25037, DOI 10.1074/jbc.M102910200; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; PERDEW GH, 1995, HYBRIDOMA, V14, P279, DOI 10.1089/hyb.1995.14.279; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SCAMMELL JG, 1995, MOL BRAIN RES, V33, P326, DOI 10.1016/0169-328X(95)00161-K; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWIFT S, 1999, CURRENT PROTOCOLS S, V31; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003	36	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22515	22519		10.1074/jbc.M200740200	http://dx.doi.org/10.1074/jbc.M200740200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956195	hybrid			2022-12-27	WOS:000176313600054
J	Li, JG; Chen, CG; Liu-Chen, LY				Li, JG; Chen, CG; Liu-Chen, LY			Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR MECHANISMS; OPIATE RECEPTOR; TERMINAL TAIL; BETA-ARRESTIN; PDZ PROTEINS; AGONIST; IDENTIFICATION	We have investigated whether Ezrin-radixin-moesin (ERM)-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF), a PDZ domain-containing phosphoprotein, is associated with the human kappa opioid receptor (hkor) and whether it regulates the trafficking and signaling of the hkor. When expressed in CHO cells stably transfected with the FLAG-tagged hkor (FLAG-hkor), EBP50/NHERF co-immunoprecipitated with FLAG-hkor, and the PDZ domain 1, but not the PDZ domain 11, of EBP50/NHERF was involved in the interaction. Treatment with the agonist (-)-(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclohexyl]benzeneacetamide (U50,488H) enhanced the association of EBP50/NHERF with FLAG-hkor. Expression of EBP50/NHERF, but not. a truncated form lacking the ERM-binding domain, abolished U50,488H-induced down-regulation of FLAG-hkor, which was apparently due to an increase in the recycling rate of internalized receptors. However, expression of EBP50/NHERF did not affect U50,488H binding affinity and U50,488H-stimulated [S-35]guanosine 5'-3-O-(thio)triphosphate binding and p42/p44 MAP kinase activation, nor did it affect U50,488H-induced desensitization and internalization of FLAG-hkor. To determine the motif of FLAG-hkor involved in EBP50/NHERF binding, we generated two mutants, FLAG-hkor-A and FLAG-hkor-EE, in which one Ala or two Glu residues were added to the C terminus, respectively. Neither FLAG-hkor-A nor FLAG-hkor-EE co-immunoprecipitated with EBP50/NHERF, and U50,488H-induced down-regulation of FLAG-hkor-A and FLAG-hkor-EE were not affected by expression of EBP50/NHERF. Thus, EBP50/NHERF binds to the C terminus of FLAG-hkor and blocks the down-regulation of FLAG-hkor. The C-terminal sequence of the hkor, NKPV, is distinctly different from the sequence D(S/T)XL, the optimal C-terminal motif in the beta(2)-adrenergic receptor for EBP50/NHERF binding. EBP50/NHERF may have a broader binding specificity and may interact with a subset of G protein-coupled receptors to serve as a recycling signal for these receptors.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Substance Abuse Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@astro.temple.edu						Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Bretscher A, 1997, J CELL SCI, V110, P3011; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hatzoglou A, 1996, J CELL BIOCHEM, V63, P410; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAW PY, 1984, J BIOL CHEM, V259, P4096; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu W, 2000, BIOCHEMISTRY-US, V39, P13904, DOI 10.1021/bi001099p; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	46	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27545	27552		10.1074/jbc.M200058200	http://dx.doi.org/10.1074/jbc.M200058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004055	hybrid			2022-12-27	WOS:000177055900105
J	Addona, GH; Husain, SS; Stehle, T; Miller, KW				Addona, GH; Husain, SS; Stehle, T; Miller, KW			Geometric isomers of a photoactivable general anesthetic delineate a binding site on adenylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTHANE; IDENTIFICATION; RESOLUTION; MECHANISM; XENON; PROTEINS; CAVITY	General anesthetics are a class of drugs whose mode of action is poorly understood. Here, two photoactivable general anesthetics, n-octan-1-ol geometric isomers bearing a diazirine group on either the third or seventh carbon (3- and 7-azioctanol, respectively), were used to locate and delineate an anesthetic site on adenylate kinase. Each photoincorporated at a mole ratio of 1:1 as determined by mass spectrometry. The photolabeled kinase was subjected to tryptic digest, and the fragments were separated by chromatography and sequenced by mass spectrometry. 3-Azioctanol photolabeled His-36, whereas its isomer, 7-azioctanol, photolabeled Asp-41. Inspection of the known structure of adenylate kinase shows that the side chains of these residues are within similar to5 Angstrom of each other. This distance matches the separation of the 3- and 7-positions of an extended aliphatic chain. The alkanol site so-defined spans two domains of adenylate kinase. His-36 is part of the CORE domain, and Asp-41 belongs to the nucleotide monophosphate binding domain. Upon ligand binding the nucleotide monophosphate binding domain rotates relative to the CORE domain, causing a conformational change that might be expected to affect alkanol binding. Indeed, the substrate-mimicking inhibitor adenosine-(5')-pentaphospho-(5')-adenosine (Ap5A) reduced the photoincorporation of 3- [H-3]azioctanol by 75%.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Lab Dev Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Miller, KW (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA.	k_miller@helix.mgh.harvard.edu			NIGMS NIH HHS [GM 58448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Addona GH, 2001, BIOPHYS J, V80, p314A; BAYLEY H, 1983, PHOTOGENERATED REAGE, P43; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BYEON IJL, 1993, BIOCHEMISTRY-US, V32, P12508, DOI 10.1021/bi00097a031; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chiara DC, 2000, BIOPHYS J, V78, p360A; CHURCH RFR, 1970, J ORG CHEM, V35, P2465, DOI 10.1021/jo00833a001; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; Dwyer DS, 2000, CELL MOL LIFE SCI, V57, P265, DOI 10.1007/PL00000689; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 2001, BIOPHYS J, V80, p335A; Eckenhoff RG, 2000, J BIOL CHEM, V275, P30439, DOI 10.1074/jbc.M005052200; Ferranti P, 1997, FEBS LETT, V400, P19, DOI 10.1016/S0014-5793(96)01258-6; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; GURSKY O, 1994, P NATL ACAD SCI USA, V91, P12388, DOI 10.1073/pnas.91.26.12388; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Kipp H, 1997, ANAL BIOCHEM, V245, P61, DOI 10.1006/abio.1996.9909; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; MARJANEN LA, 1982, CLIN CHIM ACTA, V122, P225, DOI 10.1016/0009-8981(82)90281-9; Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8564, DOI 10.1021/bi00027a006; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otting G, 1997, NAT STRUCT BIOL, V4, P396, DOI 10.1038/nsb0597-396; Prange T, 1998, PROTEINS, V30, P61, DOI 10.1002/(SICI)1097-0134(19980101)30:1<61::AID-PROT6>3.0.CO;2-N; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHNIEPP LE, 1946, J AM CHEM SOC, V68, P1646, DOI 10.1021/ja01212a085; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; TIAN G, 1988, BIOCHEMISTRY-US, V27, P5544, DOI 10.1021/bi00415a024; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	38	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25685	25691		10.1074/jbc.M201303200	http://dx.doi.org/10.1074/jbc.M201303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976328	hybrid			2022-12-27	WOS:000176747000108
J	Obst, M; Oppermann-Sanio, FB; Luftmann, H; Steinbuchel, A				Obst, M; Oppermann-Sanio, FB; Luftmann, H; Steinbuchel, A			Isolation of cyanophycin-degrading bacteria, cloning and characterization of an extracellular cyanophycinase gene (cphE) from Pseudomonas anguilliseptica strain BI - The cphE gene from P-anguilliseptica BI encodes a cyanophycin-hydrolyzing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC ACID CYANOPHYCIN; BACILLUS-SUBTILIS; ANABAENA-CYLINDRICA; RESERVE MATERIAL; MOLECULAR CHARACTERIZATION; DELETION MUTATION; ESCHERICHIA-COLI; NEUTRAL PROTEASE; CYANOBACTERIA; PURIFICATION	Eleven bacteria capable of utilizing cyanophycin (cyanophycin granule polypeptide (CGP)) as a carbon source for growth were isolated. One isolate was taxonomically affiliated as Pseudomonas anguilliseptica strain BI, and the extracellular cyanophycinase (CphE) was studied because utilization of cyanophycin as a carbon source and extracellular cyanophycinases were hitherto not described. CphE was detected in supernatants of CGP cultures and purified from a corresponding culture of strain BI employing chromatography on the anion exchange matrix Q-Sepharose and on an arginine-agarose affinity matrix. The mature form of the inducible enzyme consisted of one type of subunit with M-r = 43,000 and exhibited high specificity for CGP, whereas proteins and synthetic polyaspartic acid were not hydrolyzed or were only marginally hydrolyzed. Degradation products of the enzyme reaction were identified as aspartic acid-arginine dipeptides (beta-Asp-Arg) by high performance liquid chromatography and electrospray ionization mass spectrometry. The corresponding gene (cphE, 1254 base pairs) was identified in subclones of a cosmid gene library of strain BI by heterologous active expression in Escherichia coli, and its nucleotide sequence was determined. The enzyme exhibited only 27-28% amino acid sequence identity to intracellular cyanophycinases occurring in cyanobacteria. Analysis of the amino acid sequence of cphE revealed a putative catalytic triad consisting of the motif GXSXG plus a histidine and most probably a glutamate residue. In addition, the strong inhibition of the enzyme by Pefabloc(R) and phenylmethylsulfonyl fluoride indicated that the catalytic mechanism of CphE is related to that of serine type proteases. Quantitative analysis on the release of beta-Asp-Arg dipeptides from C-terminal labeled CGP gave evidence for an exo-degradation mechanism.	Univ Munster, Inst Mikrobiol, D-48149 Munster, Germany; Univ Munster, Inst Organ Chem, D-48149 Munster, Germany	University of Munster; University of Munster	Steinbuchel, A (corresponding author), Univ Munster, Inst Mikrobiol, Corrensstr 3, D-48149 Munster, Germany.	steinbu@uni-muenster.de						Aboulmagd E, 2000, ARCH MICROBIOL, V174, P297, DOI 10.1007/s002030000206; Alford Diana D., 1994, Journal of Environmental Polymer Degradation, V2, P225, DOI 10.1007/BF02071970; ALLEN MM, 1980, J BACTERIOL, V141, P959, DOI 10.1128/JB.141.2.959-962.1980; Berg H, 2000, EUR J BIOCHEM, V267, P5561, DOI 10.1046/j.1432-1327.2000.01622.x; BIRRER GA, 1994, INT J BIOL MACROMOL, V16, P265, DOI 10.1016/0141-8130(94)90032-9; Bovarnick M, 1942, J BIOL CHEM, V145, P415; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER TH, 1984, J BACTERIOL, V159, P453, DOI 10.1128/JB.159.2.453-459.1984; CLAUS D, 1964, J GEN MICROBIOL, V36, P107, DOI 10.1099/00221287-36-1-107; Cole R., 1997, ELECTROSPRAY IONIZAT; FREY KM, 2002, APPL ENVIRON MICROB, DOI DOI 10.1128/AE7.68.7.000-000.2002; Hai T, 2000, APPL MICROBIOL BIOT, V53, P383, DOI 10.1007/s002530051630; HANBY WE, 1946, BIOCHEM J, V40, P297, DOI 10.1042/bj0400297; HARA T, 1982, AGR BIOL CHEM TOKYO, V46, P2275, DOI 10.1080/00021369.1982.10865430; HE M, 1990, NUCLEIC ACIDS RES, V18, P1660, DOI 10.1093/nar/18.6.1660; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; JAY FT, 1976, NUCLEIC ACIDS RES, V3, P177, DOI 10.1093/nar/3.1.177; Krehenbrink M, 2002, ARCH MICROBIOL, V177, P371, DOI 10.1007/s00203-001-0396-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATCHINIANSADEK L, 1993, J BIOL CHEM, V268, P534; Liotenberg S, 1996, MICROBIOL-SGM, V142, P611, DOI 10.1099/13500872-142-3-611; MACKERRAS AH, 1990, J GEN MICROBIOL, V136, P2057, DOI 10.1099/00221287-136-10-2057; MILLER CG, 1998, HDB PROTEOLYTIC ENZY, P1557; Oppermann FB, 1998, POLYM DEGRAD STABIL, V59, P337, DOI 10.1016/S0141-3910(97)00175-4; Oppermann-Sanio FB, 2002, NATURWISSENSCHAFTEN, V89, P11, DOI 10.1007/s00114-001-0280-0; Rainey FA, 1996, INT J SYST BACTERIOL, V46, P1088, DOI 10.1099/00207713-46-4-1088; RAO RN, 1987, METHOD ENZYMOL, V153, P166; Richter R, 1999, EUR J BIOCHEM, V263, P163, DOI 10.1046/j.1432-1327.1999.00479.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RUFO GA, 1990, J BACTERIOL, V172, P1019, DOI 10.1128/jb.172.2.1019-1023.1990; Salamone PR, 1997, APPL MICROBIOL BIOT, V48, P317, DOI 10.1007/s002530051056; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Simon R.D., 1987, CYANOBACTERIA, P199; SIMON RD, 1971, P NATL ACAD SCI USA, V68, P265, DOI 10.1073/pnas.68.2.265; SIMON RD, 1976, BIOCHIM BIOPHYS ACTA, V420, P165, DOI 10.1016/0005-2795(76)90355-X; SIMON RD, 1980, BIOCHIM BIOPHYS ACTA, V626, P277, DOI 10.1016/0005-2795(80)90121-X; SLOMA A, 1988, J BACTERIOL, V170, P5557, DOI 10.1128/jb.170.12.5557-5563.1988; SLOMA A, 1990, J BACTERIOL, V172, P1470, DOI 10.1128/jb.172.3.1470-1477.1990; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TANGUYROUGEAU C, 1988, FEBS LETT, V234, P464, DOI 10.1016/0014-5793(88)80139-X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRAN L, 1991, J BACTERIOL, V173, P6364, DOI 10.1128/jb.173.20.6364-6372.1991; WEBER K, 1969, J BIOL CHEM, V244, P4406; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984; Ziegler K, 1998, EUR J BIOCHEM, V254, P154, DOI 10.1046/j.1432-1327.1998.2540154.x	51	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25096	25105		10.1074/jbc.M112267200	http://dx.doi.org/10.1074/jbc.M112267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986309	hybrid			2022-12-27	WOS:000176747000035
J	Bolster, DR; Crozier, SJ; Kimball, SR; Jefferson, LS				Bolster, DR; Crozier, SJ; Kimball, SR; Jefferson, LS			AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; INITIATION; EXERCISE; TRANSLATION; MECHANISM; INSULIN; GLUT-4	AMP-activated protein kinase (AMPK) is viewed as an energy sensor that acts to modulate glucose uptake and fatty acid oxidation in skeletal muscle. Given that protein synthesis is a high energy-consuming process, it may be transiently depressed during cellular energy stress. Thus, the intent of this investigation was to examine whether AMPK activation modulates the translational control of protein synthesis in skeletal muscle. Injections of 5-aminoimidazole-4-carboxamide 1-beta-D-ribonucleoside (AICAR) were used to activate AMPK in male rats. The activity of a, AMPK remained unchanged in gastrocnemius muscle from AICAR-treated animals compared with controls, whereas alpha(2) AMPK activity was significantly increased (51%). AICAR treatment resulted in a reduction in protein synthesis to 45%,, of the control value. This depression was associated with decreased activation of protein kinases in the mammalian target of rapamycin (mTOR) signal transduction pathway as evidenced by reduced phosphorylation. of protein kinase B on Ser(473), mTOR on Ser(2448), ribosomal protein S6 kinase on Thr(389), and eukaryotic initiation factor eIF4E-binding protein on Thr(37). A reduction in eIF4E associated with eIF4G to 10% of the control value was also noted. In contrast, eIF2B activity remained unchanged in response to AICAR treatment and therefore would not appear to contribute to the depression in protein synthesis. This is the first investigation to demonstrate changes in translation initiation and skeletal muscle protein synthesis in response to AMPK activation.	Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Jefferson, LS (corresponding author), Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, H166,500 Univ Dr, Hershey, PA 17033 USA.	jjefferson@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; CHEREL Y, 1991, CLIN SCI, V81, P611, DOI 10.1042/cs0810611; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DOHM GL, 1980, BIOCHEM J, V188, P255, DOI 10.1042/bj1880255; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2000, METH MOL B, V99, P63; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; KIMBALL SR, 1988, BIOCHEM BIOPH RES CO, V156, P706, DOI 10.1016/S0006-291X(88)80900-8; KIMBALL SR, 1992, BIOCHEM J, V286, P263, DOI 10.1042/bj2860263; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; KIMBALL SR, 1994, BIOCHIMIE, V76, P729, DOI 10.1016/0300-9084(94)90077-9; MERRIL G, 1997, AM J PHYSIOL, V2732, pE1107; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Musi N, 2001, AM J PHYSIOL-ENDOC M, V280, pE677, DOI 10.1152/ajpendo.2001.280.5.E677; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; RENNIE MJ, 1981, CLIN SCI, V61, P627, DOI 10.1042/cs0610627; Sekulic A, 2000, CANCER RES, V60, P3504; Tisdale MJ, 2000, NUTRITION, V16, P1013, DOI 10.1016/S0899-9007(00)00409-3; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; WOLFE RR, 1982, J APPL PHYSIOL, V52, P458, DOI 10.1152/jappl.1982.52.2.458; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	31	648	665	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					23977	23980		10.1074/jbc.C200171200	http://dx.doi.org/10.1074/jbc.C200171200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11997383	hybrid			2022-12-27	WOS:000176611800002
J	Chen, BC; Wu, WT; Ho, FM; Lin, WW				Chen, BC; Wu, WT; Ho, FM; Lin, WW			Inhibition of interleukin-1 beta-induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PROMOTES CELL-SURVIVAL; SIGNALING PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; PERITONEAL-MACROPHAGES; LIPOPOLYSACCHARIDE; IRAK; IL-1	Calcium/calmodulin-dependent protein kinase kinase (CaMKK) and Akt are two multifunctional kinases involved in many cellular responses. Although Akt and Ca2+ signals have been implicated in NF-kappaB activation in response to certain stimuli, these results are still controversial, and the mechanism(s) involved remains unknown. In this study, we show the roles that CaMKK and Akt play in regulating interleukin-1beta (IL-1beta)-induced NF-kappaB signaling. In human embryonic kidney 293 cells, IL-1beta induces IkappaB kinase beta (IKKbeta) activation, IkappaBalpha degradation, NF-kappaB transactivation, and weak Akt activation. A CaMKK inhibitor (KN-93) and phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002) do not inhibit IL-1beta-induced NF-kappaB activation. However, IL-1beta-induced NF-kappaB activity is attenuated by increased intracellular calcium in response to ionomycin, UTP, or thapsigargin or by overexpression of CaMKKc and/or Akt. Ionomycin and CaMKKc overexpression increases Akt phosphorylation on Thr(308) and enzyme activity. Under these conditions or upon overexpression of wild type Akt, IL-1beta-induced IKKbeta activity is diminished. Furthermore, a dominant negative mutant of Akt abolishes IKKbeta inhibition by CaMKKc and ionomycin, suggesting that Akt acts as a mediator of CaMKK signaling to inhibit IL-1beta-induced IKK activity at an upstream target site. We have also identified a novel interaction between CaMKK-stimulated Akt and interleukin-1 receptor-associated kinase 1 (IRAK1), which plays a key role in IL-1beta-induced NF-kappaB activation. CaMKKc and Akt overexpression decreases IRAK1-mediated NF-kappaB activity and its association with MyD88 in response to IL-1beta stimulation. Furthermore, CaMKKc and Akt overexpression increases IRAK1 phosphorylation at Thr(100), and point mutation of this site abrogates the inhibitory effect of Akt on IRAK1-mediated NF-kappaB activation. Taken together, these results indicate a novel regulatory mechanism for IL-1beta signaling and suggest that CaMKK-dependent Akt activation inhibits IL-1beta-induced NF-kappaB activation through interference with the coupling of IRAK1 to MyD88.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan; Tao Yuan Gen Hosp, Dept Hlth Execut Yuan, Taoyan 330, Taiwan	National Taiwan University	Lin, WW (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan.			Lin, Wan Wan/0000-0002-3207-734X				Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Chen BC, 1999, J BIOMED SCI, V6, P425, DOI 10.1159/000025418; Chen BC, 2001, J LEUKOCYTE BIOL, V69, P280; Chen BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/jbc.273.45.29754; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li XX, 1999, MOL CELL BIOL, V19, P4643; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Ozes ON, 1999, NATURE, V401, P82; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Park YC, 1997, BIOCHEM BIOPH RES CO, V240, P692, DOI 10.1006/bbrc.1997.7722; Rauch BH, 2000, FEBS LETT, V481, P3, DOI 10.1016/S0014-5793(00)01957-8; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	63	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24169	24179		10.1074/jbc.M106014200	http://dx.doi.org/10.1074/jbc.M106014200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976320	hybrid			2022-12-27	WOS:000176611800027
J	Iwaki, D; Mitsuzawa, H; Murakami, S; Sano, H; Konishi, M; Akino, T; Kuroki, Y				Iwaki, D; Mitsuzawa, H; Murakami, S; Sano, H; Konishi, M; Akino, T; Kuroki, Y			The extracellular toll-like receptor 2 domain directly binds peptidoglycan derived from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTTING EDGE; CELL ACTIVATION; LIPOPOLYSACCHARIDE; RECOGNITION; PROTEINS; TLR4; LIPOPROTEINS; MICE; CD14; EXPRESSION	Toll-like receptor 2 (TLR2) has been recognized to mediate cell signaling in response to peptidoglycan (PGN), a major cell wall component of Gram-positive bacteria. The mechanism by which TLR2 recognizes PGN is unknown. It is not even clear whether TLR2 directly binds to PGN. In this study, we generated a soluble form of recombinant TLR2 (sTLR2) possessing only its putative extracellular domain by using the baculovirus expression system to examine the direct interaction between sTLR2 and PGN. sTLR2 bound avidly to insoluble PGN (iPGN) from Staphylococcus aureus coated onto microtiter wells in a concentration-dependent manner. In contrast, sTLR2 exhibited a very weak binding to lipopolysaccharide. iPGN cosedimented sTLR2 after the mixture of iPGN and sTLR2 had been incubated and centrifuged. sTLR2 partially attenuated the iPGN-induced NF-kappaB activation in TLR2-transfected HEK 293 cells and the iPGN-induced IL-8 secretion in U937 cells. One of anti-human TLR2 monoclonal antibodies, which blocked iPGN-induced NF-kappaB activation in TLR2-transfected cells, inhibited the binding of sTLR2 to iPGN. In addition, we found that sCD14 interacted with sTLR2 and increased the binding of sTLR2 to iPGN. From these results, we conclude that the extracellular TLR2 domain directly binds to PGN.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Iwami K, 2000, J IMMUNOL, V165, P6682, DOI 10.4049/jimmunol.165.12.6682; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P139; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Stelter F, 1996, EUR J BIOCHEM, V236, P457, DOI 10.1111/j.1432-1033.1996.00457.x; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Yoshimura A, 1999, J IMMUNOL, V163, P1	39	140	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24315	24320		10.1074/jbc.M107057200	http://dx.doi.org/10.1074/jbc.M107057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986301	hybrid			2022-12-27	WOS:000176611800046
J	Jairajpuri, MA; Lu, AQ; Bock, SC				Jairajpuri, MA; Lu, AQ; Bock, SC			Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING SITE; REACTIVE CENTER LOOP; CONFORMATIONAL CHANGE; BETA-ANTITHROMBIN; ALPHA-THROMBIN; MECHANISM; AFFINITY; GLYCOSYLATION; ACCELERATION; CONVERSION	The mechanism for heparin activation of antithrombin III has been postulated to involve disruption of interactions between its reactive loop P1 residue and Glu(255) on the underlying protein surface. To test this hypothesis, the potential PI-constraining Arg(393)-Glu(255) hydrogen bond and ionic interactions were eliminated by converting Glu(255) to alanine. E255A and wild-type ATIIIs have identical reactive loop sequences (including ;the P1 and P14 residues), but differ in that Glu(255) -mediated, P1-constraining interactions with the underlying surface cannot form in the mutant. Relative to its wildtype parent, E255A had a 5-fold higher affinity for heparin and pentasaccharide. In the absence of cofactor, E255A exhibited a 5-fold activation of thrombin inhibition but no activation of factor Xa inhibition. Pentasaccharide addition elicited no further activation of thrombin inhibition but increased the factor Xa inhibition rate 100-fold. E255A heparin-dependent thrombin and factor Xa inhibition rates were 1000- and 2-fold faster, respectively, than pentasaccharide-catalyzed rates. Although "approximation" is the predominant factor in heparin activation of ATIII thrombin inhibition, and removal of the P1 constraint plays a distinct but minor role, the primary determinant for activation of factor Xa inhibition is the pentasaccharide-induced conformational change, with approximation making a further minor contribution, and removal of the P1 constraint playing no role at all.	Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bock, SC (corresponding author), Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Jairajpuri, Mohamad/AAS-2556-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030712] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL30712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHUANG Y, 2001, J BIOL CHEM, V40, P6670; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705; JACQUES LB, 1977, METHOD BIOCHEM ANAL, V24, P203; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; PICARD V, 1996, METHODS MOL BIOL PCR, P183; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492	26	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24460	24465		10.1074/jbc.M203127200	http://dx.doi.org/10.1074/jbc.M203127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11971909	hybrid			2022-12-27	WOS:000176611800065
J	Qiu, JZ; Bimston, DN; Partikian, A; Shen, BH				Qiu, JZ; Bimston, DN; Partikian, A; Shen, BH			Arginine residues 47 and 70 of human flap endonuclease-1 are involved in DNA substrate interactions and cleavage site determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN PCNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; REPLICATION FORK; IN-VITRO; BINDING; FEN-1; EXONUCLEASE; RECONSTITUTION; MECHANISM	Flap endonuclease-1 (FEN-1) is a critical enzyme for DNA replication and repair. Intensive studies have been carried out on its structure-specific nuclease activities and biological functions in yeast cells. However, its specific interactions with DNA substrates as an initial step of catalysis are not defined. An understanding of the ability of FEN-1 to recognize and bind a flap DNA substrate is critical for the elucidation of its molecular mechanism and for the explanation of possible pathological consequences resulting from its failure to bind DNA. Using human FEN-1 in this study, we identified two positively charged amino acid residues, Arg-47 and Arg-70 in human FEN-1, as candidates responsible for substrate binding. Mutation of the Arg-70 significantly reduced flap endonuclease activity and eliminated exonuclease activity. Mutation or protonation of Arg-47 shifted cleavage sites with flap substrate and significantly reduced the exonuclease activity. We revealed that these alterations are due to the defects in DNA-protein interactions. Although the effect of the single Arg-47 mutation on binding activities is not as severe as R70A, its double mutation with Asp-181 had a synergistic effect. Furthermore the possible interaction sites of these positively charged residues with DNA substrates were discussed based on FEN-1 cleavage patterns using different substrates. Finally data were provided to indicate that the observed negative effects of a high concentration of Mg2+ on enzymatic activity are probably due to the competition between the arginine residues an metal ions with DNA substrate since mutants were found to be less tolerant.	City Hope Natl Med Ctr, Div Mol Med, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Div Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.	bshen@coh.org		Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R29CA073764, R01CA081967, R01CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [CA81967, CA73764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Brosh RM, 2001, EMBO J, V20, P5791; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; Ma X, 2000, INT J CANCER, V88, P938, DOI 10.1002/1097-0215(20001215)88:6<938::AID-IJC16>3.0.CO;2-G; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 2001, J BIOL CHEM, V276, P30167, DOI 10.1074/jbc.M100985200; YOON JH, 1999, BIOCHEMISTRY-US, V39, P4909	44	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24659	24666		10.1074/jbc.M111941200	http://dx.doi.org/10.1074/jbc.M111941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986308	hybrid			2022-12-27	WOS:000176611800091
J	Friedle, H; Knochel, W				Friedle, H; Knochel, W			Cooperative interaction of Xvent-2 and GATA-2 in the activation of the ventral homeobox gene Xvent-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSOVENTRAL AXIS; XENOPUS EMBRYOS; BETA-CATENIN; WNT; EXPRESSION; INDUCTION; BMP-4; MESODERM; SUPPRESSION; PROTEINS	The Xvent family of homeobox transcription factors is essential for the establishment of the dorsal-ventral body axis during Xenopus embryogenesis. In contrast to Xvent-2B and other members of the Xvent-2 subfamily, Xvent-1B is not a direct response gene of bone morphogenetic protein-4 signaling. Xvent-1B is activated by Xvent-2, but CHX experiments revealed the requirement of additional factors. In this study, we report on the cooperative effect of Xvent-2 and the zinc finger transcription factor GATA-2 on the promoter of the Xvent-1B gene. We show that GATA-2 is a direct target gene of bone morphogenetic protein-4 and that GATA-2 interacts with Xvent-2 to activate transcription of Xvent-1B. Both transcription factors bind to distinct elements within the Xvent-1B promoter, and GATA-2 physically interacts with the C-terminal domain of Xvent-2. Promoter/reporter studies in Xenopus embryos revealed that full activation of Xvent-1B requires both Xvent-2 and GATA-2. Moreover, the two factors are sufficient to direct transcription of Xvent-1B in the presence of CHX at the ventral side of the embryo. The failure of both factors to activate Xvent-1B on the dorsal side suggests the existence of a dorsal inhibitor. This inhibitor is likely a component of the dorsal Wnt signaling pathway because nuclear translocation of beta-catenin before mid-blastula transition results in a suppression of Xvent-1B transcription.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Ulm University	Knochel, W (corresponding author), Univ Ulm, Biochem Abt, Albert Einstein Allee 11, D-89081 Ulm, Germany.	walter.knoechel@medizin.uni-ulm.de						Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; Baker JC, 1999, GENE DEV, V13, P3149, DOI 10.1101/gad.13.23.3149; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; Darken RS, 2001, DEV BIOL, V234, P42, DOI 10.1006/dbio.2001.0253; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Friedle H, 1998, EMBO J, V17, P2298, DOI 10.1093/emboj/17.8.2298; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamilton FS, 2001, DEVELOPMENT, V128, P2063; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Henningfeld KA, 2002, J BIOL CHEM, V277, P2097, DOI 10.1074/jbc.M108524200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Imai Y, 2001, DEVELOPMENT, V128, P2407; Kasahara H, 2001, J BIOL CHEM, V276, P4570, DOI 10.1074/jbc.M004995200; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Ladher R, 1996, DEVELOPMENT, V122, P2385; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Maxam A M, 1980, Methods Enzymol, V65, P499; Moretti PAB, 2001, GENOMICS, V76, P21, DOI 10.1006/geno.2001.6574; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Papalopulu N, 1996, DEV BIOL, V174, P104, DOI 10.1006/dbio.1996.0055; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; Schuler-Metz A, 2000, J BIOL CHEM, V275, P34365, DOI 10.1074/jbc.M003915200; Sykes TG, 1998, DEVELOPMENT, V125, P4595; Trindade M, 1999, DEV BIOL, V216, P442, DOI 10.1006/dbio.1999.9507; Xu RH, 1999, DEV BIOL, V208, P352, DOI 10.1006/dbio.1999.9205; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	42	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23872	23881		10.1074/jbc.M201831200	http://dx.doi.org/10.1074/jbc.M201831200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964398	hybrid			2022-12-27	WOS:000176475700101
J	Graham, DE; Xu, HM; White, RH				Graham, DE; Xu, HM; White, RH			Methanococcus jannaschii uses a pyruvoyl-dependent arginine decarboxylase in polyamine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; HISTIDINE-DECARBOXYLASE; ESCHERICHIA-COLI; CLOSTRIDIUM-PERFRINGENS; LACTOBACILLUS 30A; BOUND PYRUVATE; NITRIC-OXIDE; PURIFICATION; FAMILY; IDENTIFICATION	The genome sequence of the hyperthermophilic methanogen Methanococcus jannaschii contains homologs of most genes required for spermidine polyamine biosynthesis. Yet genomes from neither this organism nor any other euryarchaeon have orthologs of the pyridoxal 5'-phosphate-dependent ornithine or arginine decarboxylase genes, required to produce putrescine. Instead, as shown here, these organisms have a new class of arginine decarboxylase (Pv1ArgDC) formed by the self-cleavage of a proenzyme into a 5-kDa subunit and a 12-kDa subunit that contains a reactive pyruvoyl group. Although this extremely thermostable enzyme has no significant sequence similarity to previously characterized proteins, conserved active site residues are similar to those of the pyruvoyl-dependent histidine decarboxylase enzyme, and its subunits form a similar (alphabeta)(3) complex. Homologs of Pv1ArgDC are found in several bacterial genomes, including those of Chlamydia spp., which have no agmatine ureohydrolase enzyme to convert agmatine (decarboxylated arginine) into putrescine. In these intracellular pathogens, Pv1ArgDC may function analogously to pyruvoyl-dependent histidine decarboxylase; the cells are proposed to import arginine and export agmatine, increasing the pH and affecting the host cell's metabolism. Phylogenetic analysis of Pv1ArgDC proteins suggests that this gene has been recruited from the euryarchaeal polyamine biosynthetic pathway to function as a degradative enzyme in bacteria.	Virginia Polytech Inst & State Univ, Dept Biochem 0308, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	White, RH (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem 0308, Blacksburg, VA 24061 USA.	rhwhite@vt.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], PHYLIP PHYLOGENY INF; Begley TP, 2001, VITAM HORM, V61, P157; BELLEAU B, 1968, J AM CHEM SOC, V90, P1651, DOI 10.1021/ja01008a045; BLETHEN SL, 1968, J BIOL CHEM, V243, P1671; Boeker EA, 1971, METHODS ENZYMOLOGY B, V17B, P657; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CACCIAPUOTI G, 1986, EUR J BIOCHEM, V161, P263, DOI 10.1111/j.1432-1033.1986.tb10442.x; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Dixon H B, 1972, Methods Enzymol, V25, P409, DOI 10.1016/S0076-6879(72)25036-4; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FRIEDMAN SM, 1989, J BIOCHEM-TOKYO, V105, P1030, DOI 10.1093/oxfordjournals.jbchem.a122761; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Graham DE, 2002, J BIOL CHEM, V277, P13421, DOI 10.1074/jbc.M201011200; Hackert M.I., 1998, COMPREHENSIVE BIOL C, V2, P201; HEERSCHAP A, 1985, BIOPHYS CHEM, V22, P205, DOI 10.1016/0301-4622(85)80044-2; HUYNH QK, 1984, J BIOL CHEM, V259, P2833; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; JACOB F, 1960, CR HEBD ACAD SCI, V250, P1727; KELLER PJ, 1986, J AM CHEM SOC, V108, P344, DOI 10.1021/ja00262a053; Kim AD, 2000, J BACTERIOL, V182, P6667, DOI 10.1128/JB.182.23.6667-6672.2000; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Klein RD, 1999, MICROBIOL-UK, V145, P301, DOI 10.1099/13500872-145-2-301; Lu ZCJ, 2002, J BIOL CHEM, V277, P16624, DOI 10.1074/jbc.M110456200; MALMBERG RL, 1994, J BIOL CHEM, V269, P2703; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Piacenza L, 2001, P NATL ACAD SCI USA, V98, P7301, DOI 10.1073/pnas.121520398; PISHKO EJ, 1993, BIOCHEMISTRY-US, V32, P4943, DOI 10.1021/bi00069a032; Ramjee MK, 1997, BIOCHEM J, V323, P661, DOI 10.1042/bj3230661; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; RECSEI PA, 1983, J BIOL CHEM, V258, P439; RECSEI PA, 1970, BIOCHEMISTRY-US, V9, P1492, DOI 10.1021/bi00809a003; RECSEI PA, 1972, J BACTERIOL, V112, P624, DOI 10.1128/JB.112.1.624-626.1972; RILEY WD, 1970, BIOCHEMISTRY-US, V9, P1485, DOI 10.1021/bi00809a002; RILEY WD, 1968, BIOCHEMISTRY-US, V7, P3520, DOI 10.1021/bi00850a029; Schelp E, 2001, J MOL BIOL, V306, P727, DOI 10.1006/jmbi.2000.4430; SCHERER P, 1983, J BACTERIOL, V154, P1315, DOI 10.1128/JB.154.3.1315-1322.1983; Sekowska A, 2000, MICROBIOL-SGM, V146, P1815, DOI 10.1099/00221287-146-8-1815; Sekowska A, 2000, MOL MICROBIOL, V36, P1135, DOI 10.1046/j.1365-2958.2000.01930.x; Selkov E, 1997, GENE, V197, pGC11, DOI 10.1016/S0378-1119(97)00307-7; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Smith Bryan John, 1996, P369, DOI 10.1007/978-1-60327-259-9_63; SNELL EE, 1986, METHOD ENZYMOL, V122, P128; STAHL GL, 1978, J ORG CHEM, V43, P2285, DOI 10.1021/jo00405a045; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1976, J BACTERIOL, V128, P485, DOI 10.1128/JB.128.1.485-486.1976; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANASE S, 1985, J BIOL CHEM, V260, P6738; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Worley S, 2002, PROTEINS, V46, P321, DOI 10.1002/prot.10042; WU WH, 1973, J BIOL CHEM, V248, P1696; WU WH, 1973, J BIOL CHEM, V248, P1687	59	40	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23500	23507		10.1074/jbc.M203467200	http://dx.doi.org/10.1074/jbc.M203467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980912	hybrid			2022-12-27	WOS:000176475700054
J	Bakker, J; Lin, XH; Nelson, WG				Bakker, J; Lin, XH; Nelson, WG			Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA METHYLTRANSFERASE; MESSENGER-RNA EXPRESSION; DE-NOVO METHYLATION; HISTONE DEACETYLASE; CANCER-CELLS; COMPLEX; ISLAND; MECP2; HEPATOCARCINOGENESIS; NEOPLASIA	During the pathogenesis of human hepatocellular carcinoma (HCC), the CpG island encompassing the pi-class glutathione S-transferase gene (GSTP1) becomes hypermethylated. Repression of transcription accompanying CpG island hypermethylation has been proposed to be mediated by methyl-CpG binding domain (MBD) proteins. We report here that inhibition of transcription from hypermethylated GSTP1 promoters in Hep3B HCC cells, which fail to express GSTP1 mRNA or GSTP1 polypeptides, appears to be mediated by MBD2. Treatment of Hep3B cells with 5-azadeoxycytidine (5-aza-dC), a methyltransferase inhibitor, activated GSTP1 expression, whereas treatment with trichostatin A, a histone deacetylase inhibitor, had little effect. To more precisely assess the contribution of the pattern of GSTP1 CpG island methylation on GSTP1 mRNA expression, Hep3B cells were treated for 72 h with 5-aza-dC and then subjected to limiting dilution cloning. Bisulfite sequencing was used to map the methylation patterns of the GSTP1 promoter region in GSTP1-expressing and -non-expressing clones. In the clone that expressed GSTP1 mRNA determined by Northern blot analysis and quantitative reverse transcriptase (RT)-PCR, widespread demethylation of at least one GSTP1 allele was evident. Chromatin immunoprecipitation experiments revealed the presence of MBD2, but not Sp1, at the GSTP1 promoter in Hep3B cells. In contrast, Sp1 was detected at the GSTP1 promoter in a GSTP1-expressing Hep3B 5-aza-dC subclone. To test whether MBD2 might be responsible for the inhibition of GSTP1 transcription from hypermethylated GSTP1 promoters, siRNAs were used to reduce MED2 polypeptide levels in Hep3B cells. SssI-catalyzed methylation of GSTP1 promoter sequences resulted in diminished luciferase reporter activity after transfection into Hep3B cells. However, when hypermethylated GSTP1 promoter sequences were transfected into Hep3B cells that had been treated with siRNA-targeting MBD2 mRNA, no repression of luciferase reporter expression was evident. These findings implicate MBD2 in the repression of GSTP1 expression associated with GSTP1 CpG island hypermethylation in HCC cells.	Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Nelson, WG (corresponding author), Rm 151,Bunting Blaustein Canc Res Bldg,1650 Orlea, Baltimore, MD 21231 USA.				NCI NIH HHS [CA 70196] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Feng Q, 2001, GENE DEV, V15, P827; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Kanai Y, 1996, JPN J CANCER RES, V87, P1210, DOI 10.1111/j.1349-7006.1996.tb03135.x; Kanai Y, 1997, INT J CANCER, V71, P355; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN RIS, 1969, ANAL BIOCHEM, V27, P473, DOI 10.1016/0003-2697(69)90061-X; Lin XH, 2001, CANCER RES, V61, P8611; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Tchou JC, 2000, INT J ONCOL, V16, P663; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wong IHN, 1999, CANCER RES, V59, P71; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	47	90	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22573	22580		10.1074/jbc.M203009200	http://dx.doi.org/10.1074/jbc.M203009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960994	hybrid			2022-12-27	WOS:000176313600063
J	Miles, RD; Gorrell, A; Ferry, JG				Miles, RD; Gorrell, A; Ferry, JG			Evidence for a transition state analog, MgADP-aluminum fluoride-acetate, in acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE CONFORMATIONS; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; BINDING; HEXOKINASE; SITE; MECHANISM; FLUOROALUMINATE; IDENTIFICATION; TRANSDUCIN	Aluminum fluoride has become an important tool for investigating the mechanism of phosphoryl transfer, an essential reaction that controls a host of vital cell functions. Planar AlF3 or AlF4- molecules are proposed to mimic the phosphoryl group in the catalytic transition state. Acetate kinase catalyzes phosphoryl transfer of the ATP gamma-phosphate to acetate. Here we describe the inhibition of acetate kinase from Methanosarcina thermophila by preincubation with MgCl2, ADP, AlCl3, NaF, and acetate. Preincubation with butyrate in place of acetate did not significantly inhibit the enzyme. Several NTPs can substitute for ATP in the reaction, and the corresponding NDPs, in conjunction with MgCl2, AlCl3, NaF, and acetate, inhibit acetate kinase activity. Fluorescence quenching experiments indicated an increase in binding affinity of acetate kinase for MgADP in the presence of AlCl3, NaF, and acetate. These and other characteristics of the inhibition indicate that the transition state analog, MgADP-aluminum fluoride-acetate, forms an abortive complex in the active site. The protection from inhibition by a non-hydrolyzable ATP analog or acetylphosphate, in conjunction with the strict dependence of inhibition on the presence of both ADP and acetate, supports a direct in-line mechanism for acetate kinase.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 205 S Frear, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buss KA, 2001, J BACTERIOL, V183, P680, DOI 10.1128/JB.183.2.680-686.2001; Buss KA, 1997, PROTEIN SCI, V6, P2659; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FOX DK, 1986, J BIOL CHEM, V261, P3498; GARIN J, 1993, BIOCHEMISTRY-US, V32, P6821, DOI 10.1021/bi00078a004; Graham DL, 1999, BIOCHEMISTRY-US, V38, P14981, DOI 10.1021/bi991358e; Ingram-Smith C, 2000, J BIOL CHEM, V275, P33765, DOI 10.1074/jbc.M005303200; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; JANSON CA, 1974, J BIOL CHEM, V249, P2567; Lipmann F, 1944, J BIOL CHEM, V155, P55; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Miles RD, 2001, J BIOL CHEM, V276, P45059, DOI 10.1074/jbc.M108355200; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; PURICH DL, 1972, ARCH BIOCHEM BIOPHYS, V149, P307, DOI 10.1016/0003-9861(72)90326-8; ROSE IA, 1954, J BIOL CHEM, V211, P737; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SCRUTTON MC, 1965, J BIOL CHEM, V240, P3714; SECNIK J, 1992, BIOCHEMISTRY-US, V31, P2982, DOI 10.1021/bi00126a020; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; Singh-Wissmann K, 1998, J BACTERIOL, V180, P1129, DOI 10.1128/JB.180.5.1129-1134.1998; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPECTOR LB, 1980, P NATL ACAD SCI-BIOL, V77, P2626, DOI 10.1073/pnas.77.5.2626; STEITZ TA, 1981, PHILOS T ROY SOC B, V293, P43, DOI 10.1098/rstb.1981.0058; TAKASHI R, 1977, P NATL ACAD SCI USA, V74, P2334, DOI 10.1073/pnas.74.6.2334; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e	35	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22547	22552		10.1074/jbc.M105921200	http://dx.doi.org/10.1074/jbc.M105921200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960978	hybrid			2022-12-27	WOS:000176313600059
J	Zhyvoloup, A; Nemazanyy, I; Babich, A; Panasyuk, G; Pobigailo, N; Vudmaska, M; Naidenov, V; Kukharenko, O; Palchevskii, S; Savinska, L; Ovcharenko, G; Verdier, F; Valovka, T; Fenton, T; Rebholz, H; Wang, ML; Shepherd, P; Matsuka, G; Filonenko, V; Gout, IT				Zhyvoloup, A; Nemazanyy, I; Babich, A; Panasyuk, G; Pobigailo, N; Vudmaska, M; Naidenov, V; Kukharenko, O; Palchevskii, S; Savinska, L; Ovcharenko, G; Verdier, F; Valovka, T; Fenton, T; Rebholz, H; Wang, ML; Shepherd, P; Matsuka, G; Filonenko, V; Gout, IT			Molecular cloning of CoA synthase - The missing link in CoA biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANTOTHENATE KINASE GENE; COENZYME-A METABOLISM; ESCHERICHIA-COLI; RAT-LIVER; ADENYLYLTRANSFERASE; HEART; PURIFICATION; COMPLEX; MUSCLE; STATE	Coenzyme A functions as a carrier of acetyl and acyl groups in living cells and is essential for numerous biosynthetic, energy-yielding, and degradative metabolic pathways. There are five enzymatic steps in CoA biosynthesis. To date, molecular cloning of enzymes involved in the CoA biosynthetic pathway in mammals has been only reported for pantothenate kinase. In this study, we present cDNA cloning and functional characterization of CoA synthase. It has an open reading frame of 563 aa and encodes a protein of similar to60 kDa. Sequence alignments suggested that the protein possesses both phosphopantetheine adenylyltransferase and dephospho-CoA kinase domains. Biochemical assays using wild type recombinant protein confirmed the gene product indeed contained both these enzymatic activities. The presence of intrinsic phosphopantetheine adenylyltransferase activity was further confirmed by site-directed mutagenesis. Therefore, this study describes the first cloning and characterization of a mammalian CoA synthase and confirms this is a bifunctional enzyme containing the last two components of CoA biosynthesis.	Ludwig Inst Canc Res, London W1W 7BS, England; Inst Mol Biol & Genet, Dept Struct & Funct Nucl Acid, UA-143 Kiev, Ukraine; UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; University of London; University College London; UCL Medical School	Gout, IT (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	ivan@ludwig.ucl.ac.uk	Filonenko, Valeriy V/D-5447-2015; Panasyuk, Ganna/AAF-4350-2021; Palchevskyi, Sergii/K-5333-2016; Panasyuk, Ganna/A-4133-2018	Filonenko, Valeriy V/0000-0003-1839-3335; Panasyuk, Ganna/0000-0002-5591-848X; Palchevskyi, Sergii/0000-0001-6553-1513; Panasyuk, Ganna/0000-0002-5591-848X; Fenton, Tim/0000-0002-4737-8233; Rebholz, Heike/0000-0002-0400-7547				Abiko Y., 1975, METABOLIC PATHWAYS, V7, P1; BRASS EP, 1990, J NUTR, V120, P290, DOI 10.1093/jn/120.3.290; BUCOVAZ ET, 1980, MOL CELL BIOCHEM, V30, P7, DOI 10.1007/BF00215301; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; CORKEY BE, 1988, J CLIN INVEST, V82, P782, DOI 10.1172/JCI113679; FISHER MN, 1985, J BIOL CHEM, V260, P5745; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; MCALLISTER RA, 1988, BRIT J CANCER, V57, P83, DOI 10.1038/bjc.1988.14; Ni XH, 2002, INT J BIOCHEM CELL B, V34, P109, DOI 10.1016/S1357-2725(01)00114-5; RAPP GW, 1973, CANCER-AM CANCER SOC, V31, P357, DOI 10.1002/1097-0142(197302)31:2<357::AID-CNCR2820310214>3.0.CO;2-X; REIBEL DK, 1983, AM J PHYSIOL, V244, pH839, DOI 10.1152/ajpheart.1983.244.6.H839; REIBEL DK, 1981, AM J PHYSIOL, V240, pH606, DOI 10.1152/ajpheart.1981.240.4.H606; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; ROBISHAW JD, 1982, J BIOL CHEM, V257, P967; SKREDE S, 1983, EUR J BIOCHEM, V131, P57, DOI 10.1111/j.1432-1033.1983.tb07231.x; SMITH CM, 1980, BIOCHEM J, V188, P175, DOI 10.1042/bj1880175; SMITH CM, 1978, J NUTR, V108, P854, DOI 10.1093/jn/108.5.854; SMITH CM, 1978, J NUTR, V108, P863, DOI 10.1093/jn/108.5.863; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; TAHILIANI AG, 1991, VITAM HORM, V46, P165; TAHILIANI AG, 1991, BIOCHIM BIOPHYS ACTA, V1067, P29, DOI 10.1016/0005-2736(91)90022-Z; Vagelos P. R., 1973, ENZYMES, V8, P155; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; VOLTTI H, 1979, BIOCHEM J, V182, P95, DOI 10.1042/bj1820095; WORRALL DM, 1983, BIOCHEM J, V215, P153, DOI 10.1042/bj2150153; Yun M, 2000, J BIOL CHEM, V275, P28093	30	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22107	22110		10.1074/jbc.C200195200	http://dx.doi.org/10.1074/jbc.C200195200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11980892	Green Accepted, hybrid			2022-12-27	WOS:000176313600001
J	Bernards, AS; Miller, JK; Bao, KK; Wong, I				Bernards, AS; Miller, JK; Bao, KK; Wong, I			Flipping duplex DNA inside out - A double base-flipping reaction mechanism by Escherichia coli MutY adenine glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; MISMATCH REPAIR ENZYME; MITOCHONDRIAL DECAY; NUCLEOTIDE EXCISION; SUBSTRATE-ANALOGS; CRYSTAL-STRUCTURE; OXIDATIVE DAMAGE; RECOGNITION; FLUORESCENCE; SPECIFICITY	The Escherichia coli MutY adenine glycosylase plays a critical role in repairing mismatches in DNA between adenine and the oxidatively damaged guanine base 8-oxoguanine. Crystallographic studies of the catalytic core domain of MutY show that the scissile adenine is extruded from the DNA helix to be bound in the active site of the enzyme (Guan, Y., Manuel, R. C., Arvai, A. S., Parikh, S. S., Mol, C. D., Miller, J. H., Lloyd, S., and Tainer, J. A (1998) Nat. Struct. Biol. 5,1058-1064). However, the structural and mechanistic bases for the recognition of the 8-oxoguanine remain poorly understood. In experiments using a single-stranded 8-bromoguanine-containing synthetic oligodeoxyribonuclelotide alone and in a duplex construct mismatched to an adenine, we observed UV cross-linking between MutY and the 8-bromoguanine probe. We further observed enhanced cross-linking in the single strand experiments, suggesting that neither the duplex context nor the mismatch with adenine is required for recognition of the 8-oxoguanine moiety. Stopped-flow fluorescence studies using 2-aminopurine-containing oligodeoxyribonucleotides further revealed the sequential extrusion of the 8-oxoguanine at 108 s(-1) followed by the adenine at 16 s(-1). A protein isomerization step following base flipping at 1.9 s(-1) was also observed and is postulated to provide additional stabilization of the extruded adenine thereby facilitating its capture by the active site for excision.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Wong, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58771] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Bao KK, 2002, J BIOL CHEM, V277, P12089, DOI 10.1074/jbc.M111315200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GANNETT PM, 1993, CHEM RES TOXICOL, V6, P690, DOI 10.1021/tx00035a015; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hornby DP, 1998, CURR OPIN BIOTECH, V9, P354, DOI 10.1016/S0958-1669(98)80007-4; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; House PG, 2001, PROG NUCLEIC ACID RE, V68, P349; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Li XH, 2000, NUCLEIC ACIDS RES, V28, P4593, DOI 10.1093/nar/28.23.4593; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Lloyd RS, 1997, BIOPOLYMERS, V44, P139; Lu AL, 2000, METH MOL B, V152, P3; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; Morikawa K, 2000, MUTAT RES-DNA REPAIR, V460, P257, DOI 10.1016/S0921-8777(00)00031-8; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Porello SL, 1996, J AM CHEM SOC, V118, P10684, DOI 10.1021/ja9602206; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; WONG I, 2002, IN PRESS J BIOL CHEM, V277	43	48	51	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20960	20964		10.1074/jbc.C200181200	http://dx.doi.org/10.1074/jbc.C200181200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11964390	hybrid			2022-12-27	WOS:000176204500110
J	Hoff, KG; Ta, DT; Tapley, TL; Silberg, JJ; Vickery, LE				Hoff, KG; Ta, DT; Tapley, TL; Silberg, JJ; Vickery, LE			Hsc66 substrate specificity is directed toward a discrete region of the iron-sulfur cluster template protein IscU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE SYSTEM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PEPTIDE-BINDING; EXTINCTION COEFFICIENTS; HSP70 CHAPERONES; DNAK CHAPERONE; PHAGE DISPLAY; IDENTIFICATION; DOMAIN	Hsc66 and Hsc20 comprise a specialized chaperone system important for the assembly of iron-sulfur clusters in Escherchia coli. Only a single substrate, the Fe/S template protein IscU, has been identified for the Hsc66/Hsc20 system, but the mechanism by which Hsc66 selectively binds IscU is unknown. We have investigated Hsc66 substrate specificity using phage display and a peptide array of IscU. Screening of a heptameric peptide phage display library revealed that Hsc66 prefers peptides with a centrally located Pro-Pro motif. Using a cellulose-bound peptide array of IscU we determined that Hsc66 interacts specifically with a region (residues 99-103, LPPVK) that is invariant among all IscU family members. A synthetic peptide (ELPPVKIHC) corresponding to IscU residues 98106 behaves in a similar manner to native IscU, stimulating the ATPase activity of Hsc66 with similar affinity as IscU, preventing Hsc66 suppression of bovine rhodanese aggregation, and interacting with the peptide-binding domain of Hsc66. Unlike native IscU, however, the synthetic peptide is not bound by Hsc20 and does not synergistically stimulate Hsc66 ATPase activity with Hsc20. Our results indicate that Hsc66 and Hsc20 recognize distinct regions of IscU and further suggest that Hsc66 will not bind LPPVK motifs with high affinity in vivo unless they are in the context of native IscU and can be directed to Hsc66 by Hsc20.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Silberg, Jonathan J/A-3817-2010		NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA 09054] Funding Source: Medline; NIGMS NIH HHS [GM 07211, GM 54264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Atherton E., 1990, SOLID PHASE PEPTIDE; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cupp-Vickery JR, 2000, J MOL BIOL, V304, P835, DOI 10.1006/jmbi.2000.4252; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gisler SM, 1998, J MOL BIOL, V279, P833, DOI 10.1006/jmbi.1998.1815; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Levitan B, 1998, J MOL BIOL, V277, P893, DOI 10.1006/jmbi.1997.1555; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; OUZOUNIS C, 1994, TRENDS BIOCHEM SCI, V19, P199, DOI 10.1016/0968-0004(94)90021-3; *OXF MOL GROUP, 1996, MACV VERS 6 0 1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WANG TF, 1993, J BIOL CHEM, V268, P26049; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	46	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27353	27359		10.1074/jbc.M202814200	http://dx.doi.org/10.1074/jbc.M202814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994302	hybrid, Green Published, Green Accepted			2022-12-27	WOS:000177055900084
J	Bhattacharyya, R; Bhaumik, M; Raju, TS; Stanley, P				Bhattacharyya, R; Bhaumik, M; Raju, TS; Stanley, P			Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MGAT3 GENE; GLYCOPEPTIDE BETA-4-N-ACETYLGLUCOSAMINYLTRANSFERASE-III; HEPATIC NODULES; RECEPTOR GENE; GNT-III; EXPRESSION; GLYCOSYLATION; CELLS; LIVER; OLIGOSACCHARIDES	N-Acetylglucosaminyltransferase III (GlcNAc-TIII), the product of the Mgat3 gene, transfers the bisecting GlcNAe to the core mannose of complex N-glycans. The addition of this residue is regulated during development and has functional consequences for receptor signaling, cell adhesion, and tumor progression. Mice homozygous for a null mutation at the Mgat3 locus (Mgat3(Delta)) or for a targeted mutation in the Mgat3 gene (previously called Mgat3(neo), but herein renamed Mgat3(T37) because the allele generates inactive GlcNAc-TIII of similar to37 kDa) were found to exhibit retarded progression of liver tumors. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of neutral N-glycans from kidneys revealed no significant differences, and both mutants showed the expected lack of N-glycan species with an additional GlcNAc. However, the two mutants differed in several biological traits. Mgat3(T37/T37) homozygotes in a mixed or 129(SvJ) background were retarded in growth rate and exhibited an altered leg clasp reflex, an altered gait, and defective nursing behavior. Pups abandoned by Mgat3(T37/T37) mothers were rescued by wildtype foster mothers. None of these Mgat3(T37/T37) traits were exhibited by Mgat3(Delta/Delta) mice or by heterozygous mice carrying the Mgat3(T37) mutation. Similarly, no dominant-negative effect was observed in Chinese hamster ovary cells expressing truncated GIcNAc-TIII in the presence of wild-type GIcNAc-TIII. However, compound heterozygotes carrying both the Mgat3(T37) and Mgat3(Delta) mutations exhibited a marked leg clasp reflex, indicating that in the absence of wild-type GlcNAc-TIII, truncated GIcNAc-TIII causes this phenotype. The Mgat3 gene was expressed in brain at embryonic day 10.5 and thereafter and in neurons of adult cerebellum. The mutant Mgat3 gene was also highly expressed in Mgat3(T37/T37) brain. This may be the basis of the unexpected neurological phenotype induced by truncated, inactive GIcNAc-TIII in the mouse.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Genentech Inc, Analyt Chem, San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; Roche Holding; Genentech	Stanley, P (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	NCI NIH HHS [P01 CA13330, R01 CA30645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; Bhaumik M, 1998, CANCER RES, V58, P2881; BHAUMIK M, 1995, GENE, V164, P295, DOI 10.1016/0378-1119(95)00260-D; BHAUMIK M, 1996, GLYCOBIOLOGY, V6, P720; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; Chui D, 2001, P NATL ACAD SCI USA, V98, P1142, DOI 10.1073/pnas.98.3.1142; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Ihara H, 2002, EUR J BIOCHEM, V269, P193, DOI 10.1046/j.0014-2956.2001.02640.x; Ihara Y, 1998, P NATL ACAD SCI USA, V95, P2526, DOI 10.1073/pnas.95.5.2526; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Ioffe E, 1996, P NATL ACAD SCI USA, V93, P11041, DOI 10.1073/pnas.93.20.11041; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; Kohlhepp RL, 2001, MAMM GENOME, V12, P606, DOI 10.1007/s003350020042; Koyota S, 2001, J BIOL CHEM, V276, P32867, DOI 10.1074/jbc.M102371200; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; Miyagawa S, 2001, J BIOL CHEM, V276, P39310, DOI 10.1074/jbc.M104359200; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PASCALE R, 1989, CARCINOGENESIS, V10, P961, DOI 10.1093/carcin/10.5.961; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Scacheri PC, 2001, GENESIS, V30, P259, DOI 10.1002/gene.1072; Schachter H, 2001, CELL MOL LIFE SCI, V58, P1085, DOI 10.1007/PL00000923; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STEINBERG H, 1989, J PHARMACOL METHOD, V21, P103, DOI 10.1016/0160-5402(89)90028-4; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YANG J, 1994, GLYCOBIOLOGY, V4, P703, DOI 10.1093/glycob/4.5.703; Yang XP, 2000, CANCER RES, V60, P3313; Yoshimura M, 1996, CANCER RES, V56, P412; Yoshimura M, 1998, BIOCHEM J, V331, P733, DOI 10.1042/bj3310733; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOSHIMURA M, 1995, GLYCOCONJUGATE J, V12, P234, DOI 10.1007/BF00731325; Young WS, 1998, ADV EXP MED BIOL, V449, P231	52	44	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26300	26309		10.1074/jbc.M202276200	http://dx.doi.org/10.1074/jbc.M202276200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986323	hybrid			2022-12-27	WOS:000176908700064
J	Courtois-Coutry, N; Le Moellic, C; Boulkroun, S; Fay, M; Cluzeaud, F; Escoubet, B; Farman, N; Blot-Chabaud, M				Courtois-Coutry, N; Le Moellic, C; Boulkroun, S; Fay, M; Cluzeaud, F; Escoubet, B; Farman, N; Blot-Chabaud, M			Calcyclin is an early vasopressin-induced gene in the renal collecting duct - Role in the long term regulation of ion transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SODIUM-TRANSPORT; CELL-LINE; PERMEABILIZED CELLS; PLASMA-MEMBRANE; WATER CHANNELS; RAT-KIDNEY; TRANSLOCATION; DEOXYCORTICOSTERONE; ALDOSTERONE	Long-term effects of arginine vasopressin (AVP) in the kidney involve the transcription of unidentified genes. By subtractive hybridization experiments performed on the RCCD1 cortical collecting duct cell line, we identified calcyclin as an early AVP-induced gene (1 h). Calcyclin is a calcium-binding protein involved in the transduction of intracellular signals. In the kidney, calcyclin was localized at the mRNA level. in the glomerulus, all along the collecting duct, and in the epithelium lining the papilla. In RCCD, cells and in m-IMCD3 inner medullary collecting duct cells, calcyclin was evidence in the cytoplasm. Caleyelin mRNA levels were progressively increased by AVP treatment in RCCD1 (1.7-fold at 4 h) and m-IMCD3 (2-fold at 7.5 h) cells. In RCCD1 cells, calcyclin protein levels were increased by 4 h of AVP treatment. In vivo, treatment of genetically vasopressin-deficient Brattleboro rats with AVP for 4 days induced an increase in both calcyclin and aquaporin-2 mRNA expression. Finally, introduction of anti-calcyclin antibodies into RCCD1 cells by permeabilizing the plasma membrane prevented the long-term (but not short-term) increase in short-circuit current induced by AVP. Taken together, these results suggest that calcyclin is an early vasopressin-induced gene that participates in the late phase of the hormone response in transepithelial ion transport.	Univ Paris 07, INSERM, U478, Fac Med Xavier Bichat,Inst Federat Rech 02, F-75018 Paris, France; Univ Paris 07, INSERM, U426, Fac Med Xavier Bichat,Inst Federat Rech 02, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Blot-Chabaud, M (corresponding author), Univ Paris 07, INSERM, U478, Fac Med Xavier Bichat,Inst Federat Rech 02, F-75018 Paris, France.		COUTRY, Nathalie/O-9352-2017; Boulkroun, Sheerazed/M-4459-2017; Blot-Chabaud, Marcel/D-4064-2017; Boulkroun, Sheerazed/AAX-8348-2021	COUTRY, Nathalie/0000-0001-5830-4013; Boulkroun, Sheerazed/0000-0002-8796-7534; Boulkroun, Sheerazed/0000-0002-8796-7534				BINDELS RJM, 1988, BIOCHIM BIOPHYS ACTA, V972, P320, DOI 10.1016/0167-4889(88)90208-X; BlotChabaud M, 1996, KIDNEY INT, V50, P367, DOI 10.1038/ki.1996.325; CANESSA CM, 1992, AM J PHYSIOL, V262, pF454, DOI 10.1152/ajprenal.1992.262.3.F454; CHEN L, 1990, AM J PHYSIOL, V259, pF147, DOI 10.1152/ajprenal.1990.259.1.F147; Christensen BM, 1998, AM J PHYSIOL-RENAL, V275, pF285, DOI 10.1152/ajprenal.1998.275.2.F285; Djelidi S, 1999, FEBS LETT, V460, P533, DOI 10.1016/S0014-5793(99)01408-8; Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805; Djelidi S, 1997, J BIOL CHEM, V272, P32919, DOI 10.1074/jbc.272.52.32919; Ecelbarger CA, 2000, AM J PHYSIOL-RENAL, V279, pF46, DOI 10.1152/ajprenal.2000.279.1.F46; FARMAN N, 1991, AM J PHYSIOL, V260, pC468, DOI 10.1152/ajpcell.1991.260.3.C468; FERRARI S, 1987, J BIOL CHEM, V262, P8325; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; GHEZZO F, 1988, J BIOL CHEM, V263, P4758; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; Guerrero ML, 1997, AM J PHYSIOL-CELL PH, V272, pC697, DOI 10.1152/ajpcell.1997.272.2.C697; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HUTTON JC, 1986, CELL CALCIUM, V7, P339, DOI 10.1016/0143-4160(86)90037-0; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; Klussmann E, 2001, KIDNEY INT, V60, P446, DOI 10.1046/j.1523-1755.2001.060002446.x; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; Lewington AJP, 1997, AM J PHYSIOL-RENAL, V273, pF380, DOI 10.1152/ajprenal.1997.273.3.F380; Liu JM, 1999, METHODS, V19, P403, DOI 10.1006/meth.1999.0876; MANI RS, 1995, J BIOL CHEM, V270, P6658, DOI 10.1074/jbc.270.12.6658; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; MURPHY LC, 1988, J BIOL CHEM, V263, P2397; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; OKAZAKI K, 1994, J BIOL CHEM, V269, P6149; REIF MC, 1986, J CLIN INVEST, V77, P1291, DOI 10.1172/JCI112433; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; TOMITA K, 1985, J CLIN INVEST, V76, P132, DOI 10.1172/JCI111935; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; WILLS FL, 1994, PROTEIN SCI, V3, P2311, DOI 10.1002/pro.5560031216; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25728	25734		10.1074/jbc.M112435200	http://dx.doi.org/10.1074/jbc.M112435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000747	hybrid			2022-12-27	WOS:000176747000115
J	Vandenbroeck, K; Alloza, I; Brehmer, D; Billiau, A; Proost, P; McFerran, N; Rudiger, S; Walker, B				Vandenbroeck, K; Alloza, I; Brehmer, D; Billiau, A; Proost, P; McFerran, N; Rudiger, S; Walker, B			The conserved helix C region in the superfamily of interferon-gamma/interleukin-10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERFERON-GAMMA; DIFFERENTIATION-ASSOCIATED GENE; PROTEIN-PROTEIN INTERFACES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PEPTIDE-BINDING; INTERLEUKIN-10 REVEALS; SUBSTRATE-BINDING; DISEASE VIRUS; IFN-GAMMA	HSP70 chaperones mediate protein folding by ATP-dependent interaction with short linear peptide segments that are exposed on unfolded proteins. The mode of action of the Escherichia coli homolog DnaK is representative of all HSP70 chaperones, including the endoplasmic reticulum variant BiP/GRP78. DnaK has been shown to be effective in assisting refolding of a wide variety of prokaryotic and eukaryotic proteins, including the alpha-helical homodimeric secretory cytokine interferon-gamma (IFN-gamma). We screened solid-phase peptide libraries from human and mouse IFN-gamma to identify DnaK-binding sites. Conserved DnaK-binding sites were identified in the N-terminal half of helix B and in the C-terminal half of helix C, both of which are located at the IFN-gamma dimer interface. Soluble peptides derived from helices B and C bound DnaK with high affinity in competition assays. No DnalK-binding sites were found in the loops connecting the alpha-helices. The helix C DnaK-binding site appears to be conserved in most members of the superfamily of interleukin (IL)-10-related cytokines that comprises, apart from IL-10 and IFN-gamma, a series of recently discovered small secretory proteins, including IL-19, IL-20, IL-22/IL-TIF, IL-24/MDA-7 (melanoma differentiation-associated gene), IL-26/AK155, and a number of viral IL-10 homologs. These cytokines belong to a relatively small group of homodimeric proteins with highly interdigitated interfaces that exhibit the strongly hydrophobic character of the interior core of a single-chain folded domain. We propose that binding of DnaK to helix C in the superfamily of IL-10-related cytokines may constitute the hallmark of a novel conserved regulatory mechanism in which HSP70-like chaperones assist in the formation of a hydrophobic dimeric "folding" interface.	Queens Univ Belfast, Sch Pharm, Cytokine Biol & Genet Programme, Mcclay Res Ctr Pharmaceut Sci,Biomol Sci Res Grp, Belfast BT9 7BL, Antrim, North Ireland; Queens Univ Belfast, Ctr Prot & Peptide Engn, Belfast BT9 7BL, Antrim, North Ireland; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Univ Cambridge, MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	Queens University Belfast; Queens University Belfast; University of Freiburg; KU Leuven; University of Cambridge	Vandenbroeck, K (corresponding author), Queens Univ Belfast, Sch Pharm, Cytokine Biol & Genet Programme, Mcclay Res Ctr Pharmaceut Sci,Biomol Sci Res Grp, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	k.vandenbroeck@qub.ac.uk	Rüdiger, Stefan GD/G-4906-2012; Vandenbroeck, Koen/D-6845-2012; Proost, Paul/V-3052-2017; Walker, Brian/C-5263-2008	Rüdiger, Stefan GD/0000-0002-1807-2972; Vandenbroeck, Koen/0000-0002-6967-6485; Proost, Paul/0000-0002-0133-5545; Alloza, Iraide/0000-0002-8949-7732				ARAKAWA T, 1985, J BIOL CHEM, V260, P4435; ARAKAWA T, 1987, BIOCHEMISTRY-US, V26, P5428, DOI 10.1021/bi00391a032; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; DUDICH IV, 1992, MOL BIOL+, V26, P342; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; Gottesman ME, 2000, CURR OPIN MICROBIOL, V3, P197, DOI 10.1016/S1369-5274(00)00075-8; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8; Kendrick BS, 1998, P NATL ACAD SCI USA, V95, P14142, DOI 10.1073/pnas.95.24.14142; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; Landar A, 2000, J MOL BIOL, V299, P169, DOI 10.1006/jmbi.2000.3734; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Lee HJ, 2001, VIROLOGY, V281, P170, DOI 10.1006/viro.2000.0761; Lockridge KM, 2000, VIROLOGY, V268, P272, DOI 10.1006/viro.2000.0195; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; MULKERRIN MG, 1989, BIOCHEMISTRY-US, V28, P6556, DOI 10.1021/bi00442a005; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; Schaefer G, 2001, J IMMUNOL, V166, P5859, DOI 10.4049/jimmunol.166.10.5859; Soo C, 1999, J CELL BIOCHEM, V74, P1; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TAYSACO ML, 1992, SCIENCE, V255, P594; Tsai CJ, 1997, PROTEIN SCI, V6, P1426, DOI 10.1002/pro.5560060707; Tulman ER, 2001, J VIROL, V75, P7122, DOI 10.1128/JVI.75.15.7122-7130.2001; VANDENBROECK K, 1993, EUR J BIOCHEM, V215, P481, DOI 10.1111/j.1432-1033.1993.tb18057.x; Vandenbroeck K, 1998, EUR J BIOCHEM, V251, P181, DOI 10.1046/j.1432-1327.1998.2510181.x; Vandenbroeck K, 1998, BIOCHIMIE, V80, P729, DOI 10.1016/S0300-9084(99)80026-1; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WALTER MR, 1995, BIOCHEMISTRY-US, V34, P12118, DOI 10.1021/bi00038a004; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Xu D, 1998, PROTEIN SCI, V7, P533; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	59	13	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25668	25676		10.1074/jbc.M202984200	http://dx.doi.org/10.1074/jbc.M202984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11970958	hybrid			2022-12-27	WOS:000176747000106
J	Arai, A; Spencer, JA; Olson, EN				Arai, A; Spencer, JA; Olson, EN			STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS PLAY; GENE-EXPRESSION; FOCAL ADHESIONS; FAMILY GTPASES; MAP KINASE; ACTIN; BINDING; SKELETAL; SMOOTH; CELL	Changes in actin dynamics influence diverse cellular processes and couple the actin-based cytoskeleton to changes in gene transcription. Members of the Rho GTPase family regulate cytoskeletal organization by stimulating actin polymerization and stress fiber formation when activated by extracellular signaling. The transcriptional activity of serum response factor (SRF) is stimulated in response to changes in actin dynamics and Rho signaling, but the proteins that mediate this phenomenon have not been fully identified. We describe a novel, evolutionarily conserved actin-binding protein, called STARS (striated muscle activator of Rho signaling), that is expressed specifically in cardiac and skeletal muscle cells. STARS binds to the I-band of the sarcomere and to actin filaments in transfected cells, where it activates Rho-signaling events. STARS stimulates the transcriptional activity of SRF through a mechanism that requires actin binding and involves Rho GTPase activation. STARS provides a potential mechanism for specifically enhancing Rho-dependent transcription in muscle cells and for linking changes in actin dynamics to gene transcription.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu						Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Ehler E, 1999, J CELL SCI, V112, P1529; GODDETTE DW, 1986, J BIOL CHEM, V261, P5970; Gregorio CC, 2000, TRENDS CELL BIOL, V10, P355, DOI 10.1016/S0962-8924(00)01793-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Hubank M, 1999, METHOD ENZYMOL, V303, P325; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mack CP, 1999, CIRC RES, V84, P852; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Souchet M, 2002, J CELL SCI, V115, P629; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VAN AL, 1997, GENE DEV, V11, P2295; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wei L, 2001, FASEB J, V15, P785, DOI 10.1096/fj.00-026com; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	53	95	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24453	24459		10.1074/jbc.M202216200	http://dx.doi.org/10.1074/jbc.M202216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983702	hybrid			2022-12-27	WOS:000176611800064
J	Bifulco, G; Di Carlo, C; Caruso, M; Oriente, F; Sardo, AD; Formisano, P; Beguinot, F; Nappi, C				Bifulco, G; Di Carlo, C; Caruso, M; Oriente, F; Sardo, AD; Formisano, P; Beguinot, F; Nappi, C			Glucose regulates insulin mitogenic effect by modulating SHP-2 activation and localization in JAr cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; PROTEIN-KINASE; TYROSINE-PHOSPHATASE; DIFFERENT MECHANISMS; PANCREATIC-ISLETS; RECEPTOR; APOPTOSIS; EXPRESSION; PHOSPHORYLATION; ALPHA	The glucose effect on cell growth has been investigated in the JAr human choriocarcinoma cells. When JAr cells were cultured in the presence of 6 mm glucose (LG), proliferation and thymidine incorporation were induced by serum, epidermal growth factor, and insulin-like growth factor 1 but not by insulin. In contrast, at 25 mm glucose (HG), proliferation and thymidine incorporation were stimulated by insulin, serum, epidermal growth factor, and insulin-like growth factor 1 to a comparable extent, whereas basal levels were 25% lower than those in LG. HG culturing also enhanced insulin-stimulated insulin receptor and insulin receptor substrate 1 (IRS1) tyrosine phosphorylations while decreasing basal phosphorylations. These actions of glucose were accompanied by an increase in cellular tyrosine phosphatase activity. The activity of SHP-2 in HG-treated JAr cells was 400% of that measured in LG-treated cells. SHP-2 co-precipitation with IRS1 was also increased in HG-treated cells. SHP-2 was mainly cytosolic in LG-treated cells. However, HG culturing largely redistributed SHP-2 to the internal membrane compartment, where tyrosine-phosphorylated IRS1 predominantly localizes. Further exposure to insulin rescued SHP-2 cytosolic localization, thereby preventing its interaction with IRS1. Antisense inhibition of SHP-2 reverted the effect of HG on basal and insulin-stimulated insulin receptor and IRS1 phosphorylation as well as that on thymidine incorporation. Thus, in JAr cells, glucose modulates insulin mitogenic action by modulating SHP-2 activity and intracellular localization.	Univ Naples Federico II, Dipartimento Biol & Patol Mol & Cellulare L Calif, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Ginecol Ostetricia & Fisiopatol Ripr, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Bifulco, G (corresponding author), Via Pansini 5, I-80131 Naples, Italy.		Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526; BIFULCO, Giuseppe/0000-0001-7772-8591; Di Spiezio Sardo, Attilio/0000-0001-6485-5735	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		BAHN RS, 1980, ENDOCRINOLOGY, V107, P2121, DOI 10.1210/endo-107-6-2121; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; Boileau P, 2001, ENDOCRINOLOGY, V142, P3974, DOI 10.1210/en.142.9.3974; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; CHEN CF, 1988, J CLIN ENDOCR METAB, V71, P923; Crossey PA, 2000, DIABETES, V49, P457, DOI 10.2337/diabetes.49.3.457; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Federici M, 1999, DIABETES, V48, P2277, DOI 10.2337/diabetes.48.12.2277; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fine EL, 1999, DIABETES, V48, P2454, DOI 10.2337/diabetes.48.12.2454; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; IPATA PL, 1967, ANAL BIOCHEM, V20, P30, DOI 10.1016/0003-2697(67)90261-8; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KHUNE MR, 1993, J BIOL CHEM, V268, P11479; KIKKAWA R, 1993, DIABETOLOGIA, V36, P276, DOI 10.1007/BF00400228; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lao TT, 1997, PLACENTA, V18, P227, DOI 10.1016/S0143-4004(97)90097-7; Li RH, 1997, HUM REPROD, V12, P830, DOI 10.1093/humrep/12.4.830; MARSHALL CJ, 1995, CELL, V80, P225; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Okada Y, 1998, DIABETES RES CLIN PR, V41, P157, DOI 10.1016/S0168-8227(98)00076-X; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Pinter E, 2001, AM J PATHOL, V158, P1199, DOI 10.1016/S0002-9440(10)64069-2; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; SIMPSON ER, 1981, ANNU REV PHYSIOL, V43, P163, DOI 10.1146/annurev.ph.43.030181.001115; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Sjoholm A, 1997, DIABETES, V46, P1141, DOI 10.2337/diabetes.46.7.1141; Solow BT, 1999, MOL ENDOCRINOL, V13, P1784, DOI 10.1210/me.13.10.1784; Tsujikawa K, 2001, MOL ENDOCRINOL, V15, P271, DOI 10.1210/me.15.2.271; Weiss U, 2001, DIABETOLOGIA, V44, P209, DOI 10.1007/s001250051601; Yang TJ, 1998, BIOCHEM PHARMACOL, V55, P1633, DOI 10.1016/S0006-2952(98)00018-5; Zhang QM, 1997, J BIOL CHEM, V272, P23703, DOI 10.1074/jbc.272.38.23703	47	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24306	24314		10.1074/jbc.M202962200	http://dx.doi.org/10.1074/jbc.M202962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983706	hybrid			2022-12-27	WOS:000176611800045
J	Nguyen, TH; Liu, J; Lombroso, PJ				Nguyen, TH; Liu, J; Lombroso, PJ			Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; SRC-FAMILY KINASES; MOLECULAR CHARACTERIZATION; SUBUNIT 2B; IN-VIVO; PTP-SL; PHOSPHORYLATION; ALPHA	A family of protein tyrosine phosphatases enriched within the central nervous system called striatal enriched phosphatase (STEP) has been implicated in the regulation of the N-methyl-D-aspartate receptor. STEP61, a membrane-associated isoform. located in the postsynaptic densities (PSDs) of striatal neurons, contains two transmembrane domains, two proline-rich domains, and a kinase-interacting motif. This study demonstrates that STEP61 associates with Fyn, a member of the Src family kinases that is also enriched in PSDs. By using human embryonic kidney 293 cells for co-transfection, we determined that a substrate-trapping variant (STEP61 CS) binds to Fyn but not to other members of the Src family present in PSDs. In a complementary experiment, myc-tagged Fyn immunoprecipitates STEP61 CS. STEP., binds to Fyn through one of its proline-rich domains and the kinase-interacting motif domain, whereas Fyn binds to STEP., through its Src homology 2 domain and the unique N-terminal domain. STEP61 CS pulls down Fyn when the Tyr(420) site is phosphorylated. In vitro, wildtype STEP61 dephosphorylates Fyn at Tyr(420) but not at Tyr(531). These results suggest that STEP regulates the activity of Fyn by specifically dephosphorylating the regulatory Tyr(420) and may be one mechanism by which Fyn activity is decreased within PSDs.	Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA	Yale University	Nguyen, TH (corresponding author), 48480 Lakeview Blvd, Fremont, CA 94538 USA.	tnguyen@lumicyte.com			NIMH NIH HHS [R01 MH52711, MH18268, KO2 MH01527] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052711, K02MH001527] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; Buist A, 2000, J BIOL CHEM, V275, P20754, DOI 10.1074/jbc.M001626200; Bult A, 1996, J NEUROSCI, V16, P7821; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gurd JW, 1999, J NEUROCHEM, V73, P1990; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kojima N, 1998, LEARN MEMORY, V5, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; OYAMA T, 1995, NEUROSCIENCE, V69, P869, DOI 10.1016/0306-4522(95)00278-Q; Paul S, 2000, J NEUROSCI, V20, P5630, DOI 10.1523/JNEUROSCI.20-15-05630.2000; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	37	131	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24274	24279		10.1074/jbc.M111683200	http://dx.doi.org/10.1074/jbc.M111683200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983687	hybrid			2022-12-27	WOS:000176611800040
J	She, QB; Ma, WY; Zhong, SP; Dong, ZG				She, QB; Ma, WY; Zhong, SP; Dong, ZG			Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of bad by ultraviolet B radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; NECROSIS-FACTOR-ALPHA; DEATH AGONIST BAD; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CELL-SURVIVAL; GROWTH-FACTOR; UV-RADIATION; P53 PROTEIN; BH3 DOMAIN	The Bcl-2 family member Bad is a pro-apoptotic protein, and phosphorylation of Bad by cytokines and growth factors promotes cell survival in many cell types. Induction of apoptosis by UV radiation is well documented. However, little is known about UV activation of cell survival pathways. Here, we demonstrate that UVB induces Bad phosphorylation at serine 112 in JNK1, RSK2, and MSK1-dependent pathways. Inhibition of mitogen-activated protein (MAP) kinases including ERKs, JNXs, and p38 kinase by the use of their respective dominant negative mutant or a specific inhibitor for MEK1 or p38 kinase, PD98059 or SB202190, resulted in abrogation of UVB-induced phosphorylation of Bad at serine 112. Incubation of active MAP kinase members with Bad protein showed serine 112 phosphorylation of Bad by JNK1 only. However, activated RSK2 and MSK1, downstream kinases of ERKs and p38 kinase, respectively, also phosphorylated Bad at serine 112 in vitro. Cells from a Coffin-Lowry syndrome patient (deficient in RSK2) or expressing an N-terminal or C-terminal kinase-dead mutant of MSK1 were defective for UVB-induced serine 112 phosphorylation of Bad. Furthermore, MA,P kinase pathway-dependent serine 112 phosphorylation was shown to be required for dissociation of Bad from Bcl-X-L. These data illustrated that UVB-induced phosphorylation of Bad at serine 112 was mediated through MA,P kinase signaling pathways in which JNK1, RSK2, and MSK1 served as direct mediators.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			She, Qing-Bai/0000-0002-7207-0599	NCI NIH HHS [CA77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Scheid MP, 1999, BLOOD, V93, P217, DOI 10.1182/blood.V93.1.217.401k16_217_225; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULLRICH SE, 1995, PHOTOCHEM PHOTOBIOL, V62, P389, DOI 10.1111/j.1751-1097.1995.tb02359.x; Wan YS, 2001, INT J ONCOL, V18, P461; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	65	79	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24039	24048		10.1074/jbc.M109907200	http://dx.doi.org/10.1074/jbc.M109907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983683	hybrid			2022-12-27	WOS:000176611800011
J	Angove, HC; Cole, JA; Richardson, DJ; Butt, JN				Angove, HC; Cole, JA; Richardson, DJ; Butt, JN			Protein film voltammetry reveals distinctive fingerprints of nitrite and hydroxylamine reduction by a cytochrome c nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES; HEME-C; NRFH	The cytochrome c nitrite reductases perform a key step in the biological nitrogen cycle by catalyzing the six-electron reduction of nitrite to ammonium. Graphite electrodes painted with Escherichia coli cytochrome c nitrite reductase and placed in solutions containing nitrite (pH 7) exhibit large catalytic reduction currents during cyclic voltammetry at potentials below 0 V. These catalytic currents were not observed in the absence of cytochrome c nitrite reductase and were shown to originate from an enzyme film engaged in direct electron exchange with the electrode. The catalytic current-potential profiles observed on progression from substrate-limited to enzyme-limited nitrite reduction revealed a fingerprint of catalytic behavior distinct from that observed during hydroxylamine reduction, the latter being an alternative substrate for the enzyme that is reduced to ammonium in a two electron process. Cytochrome c nitrite reductase clearly interacts differently with these two substrates. However, similar features underlie the development of the voltammetric response with increasing nitrite or hydroxylamine concentration. These features are consistent with coordinated two-electron reduction of the active site and suggest that the mechanisms for reduction of both substrates are underpinned by common rate-defining processes.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of East Anglia; University of East Anglia; University of Birmingham	Butt, JN (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.		Butt, Julea/E-2133-2011; Richardson, David J/E-2275-2011	Butt, Julea/0000-0002-9624-5226; 				Anderson LJ, 2001, BIOCHEMISTRY-US, V40, P11294, DOI 10.1021/bi002706b; Anderson LJ, 2000, FARADAY DISCUSS, V116, P155, DOI 10.1039/b000946f; Armstrong FA, 1997, CHEM SOC REV, V26, P169, DOI 10.1039/cs9972600169; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; Butt JN, 2000, BIOPHYS J, V78, P1001, DOI 10.1016/S0006-3495(00)76658-6; Costa C, 1996, J BIOL CHEM, V271, P23191, DOI 10.1074/jbc.271.38.23191; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Einsle O., 2001, HDB METALLOPROTEINS, V1, P440; Heering HA, 1998, J PHYS CHEM B, V102, P6889, DOI 10.1021/jp981023r; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; KAJIE SI, 1986, EUR J BIOCHEM, V154, P457, DOI 10.1111/j.1432-1033.1986.tb09419.x; MORENO C, 1993, EUR J BIOCHEM, V212, P79, DOI 10.1111/j.1432-1033.1993.tb17635.x; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pereira IAC, 2000, BBA-PROTEIN STRUCT M, V1481, P119, DOI 10.1016/S0167-4838(00)00111-4; SCHARF M, 1995, BIOCHEM BIOPH RES CO, V209, P1018, DOI 10.1006/bbrc.1995.1599; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Simon J, 2001, EUR J BIOCHEM, V268, P5776, DOI 10.1046/j.0014-2956.2001.02520.x; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; SUCHETA A, 1993, BIOCHEMISTRY-US, V32, P5455, DOI 10.1021/bi00071a023	21	70	73	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23374	23381		10.1074/jbc.M200495200	http://dx.doi.org/10.1074/jbc.M200495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970951	Green Accepted, hybrid			2022-12-27	WOS:000176475700037
J	Das, S; Cho, W				Das, S; Cho, W			Roles of catalytic domain residues in interfacial binding and activation of group IV cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2 DOMAIN; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; AROMATIC RESIDUES; HIGH-AFFINITY; TRANSLOCATION; SPECIFICITY; MECHANISM; DOCKING; LIPIDS	Group TV cytosolic phospholipase A. (cPLA(2)) has been shown to play a critical role in eicosanoid biosynthesis. cPLA(2) is composed of the C2 domain that mediates the Ca2+-dependent interfacial binding of protein and the catalytic domain. To elucidate the mechanism of interfacial activation of cPLA(2), we measured the effects of mutations of selected ionic and hydrophobic residues in the catalytic domain on the enzyme activity and the membrane binding of cPLA(2). Mutations of anionic residues located on (Glu(419) and Glu(420)) or near (Asp(436), AsP438, Asp(439), and Asp(440)) the active site lid enhanced the affinity for cPLA2 for anionic membranes, implying that the electrostatic repulsion between these residues and the anionic membrane surface might trigger the opening of the active site. This notion is further supported by a biphasic dependence of cPLA(2) activity on the anionic lipid composition of the vesicles. Mutations of a cluster of cationic residues (Lys(541), Lys(543), Lys(544), and Arg(488)), while significantly enhancing the activity of enzyme, abrogated the specific activation effect by phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). These data, in conjunction with cell activity of cPLA(2) and mutants transfected into HEK293 cells, suggest that the cationic residues form a specific binding site for PtdIns(4,5)P-2 and that the specific PtdIns(4,5)P-2 binding is involved in cellular activation of cPLA(2). Also, three hydrophobic residues at the rim of the active site (Ile(399), Leu(400), and Leu(552)) were shown to partially penetrate the membrane, thereby promoting membrane binding and activation of cPLA(2). Based on these results, we propose an interfacial activation mechanism for cPLA(2) which involves the removal of the active site lid by nonspecific electrostatic repulsion, the interdomain hinge movement induced by specific PtdIns(4,5)P-2 binding, and the partial membrane penetration by catalytic domain hydrophobic residues.	Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 1999, METH MOL B, V109, P7; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Cygler M, 1997, METHOD ENZYMOL, V284, P3; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WHITE DA, 1973, PHOSPHOLIPID COMPOSI, P441; Williams SD, 2000, J LIPID RES, V41, P1585	41	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23838	23846		10.1074/jbc.M202322200	http://dx.doi.org/10.1074/jbc.M202322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956215	hybrid			2022-12-27	WOS:000176475700097
J	Gradin, K; Takasaki, C; Fujii-Kuriyama, Y; Sogawa, K				Gradin, K; Takasaki, C; Fujii-Kuriyama, Y; Sogawa, K			The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; PROLYL HYDROXYLATION; HYPOXIA; PROTEIN; RECRUITMENT; ALPHA; TRANSACTIVATION; HOMEOSTASIS; HIF-1-ALPHA; EXPRESSION	The hypoxia-inducible factor (HIF)-1alpha and the HIF-like factor (HLF) transcription factors are regulated at multiple levels including protein stabilization, nuclear import, and activation of transactivation, resulting in recruitment of coactivators such as the cAMP-response element-binding protein (CREB)-binding protein (CBP)/p300 and SRC-1. During low oxygen tension these proteins modulate a network of genes that are necessary for angiogenesis, erythropopoiesis, and glycolysis. We report here that the C-terminal transactivation domain of HLF is phosphorylated on multiple sites and that phosphorylation on threonine 844 of HLF is necessary for the transcriptional activation function of the protein independently of the hypoxia condition. Importantly, using the mammalian two-hybrid system we demonstrate that a substitution of threonine 844 to an alanine decreased the enhanced transcriptional activation function mediated by CBP/p300.	Tohoku Univ, Dept Biomol Sci, Grad Sch Life Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Japan Sci & Technol, Core Res Evolut Sci & Technol, Tokyo 1500002, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Sogawa, K (corresponding author), Tohoku Univ, Dept Biomol Sci, Grad Sch Life Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan.							Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	26	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23508	23514		10.1074/jbc.M201307200	http://dx.doi.org/10.1074/jbc.M201307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11983697	hybrid			2022-12-27	WOS:000176475700055
J	Fong, A; Sun, SC				Fong, A; Sun, SC			Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IKK-ALPHA; ACTIVATION; CANCER; KINASE; PHOSPHORYLATION; PRECURSOR; PATHWAYS; SUBUNIT; P105	Processing of the nfkappab2 gene product p100 to generate p52 is an important step in NF-kappaB regulation. This step is regulated by a nonclassical NF-kappaB signaling pathway involving the NF-kappaB-inducing kinase (NIK). NIK induces p100 processing by triggering phosphorylation of specific C-terminal serines of p100. However, the downstream molecular events leading to p100 processing remain unclear. Here we show that NIK induced the physical recruitment of beta-transducin repeat-containing protein (beta-TrCP), a component of the SCF ubiquitin ligase complex, to p100. This event required the phosphorylation sites as well as the death domain of p100. Using the RNA interference technique, we demonstrated that beta-TrCP is essential for NIK-induced p100 ubiquitination and processing. Interestingly the constitutive processing of p100 mutants was independent of beta-TrCP. These results suggest that beta-TrCP is an essential component of NIK-induced p100 processing.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NIAID NIH HHS [1R01 AI45045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Caplen NJ, 2002, TRENDS BIOTECHNOL, V20, P49, DOI 10.1016/S0167-7799(01)01900-X; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; Harborth J, 2001, J CELL SCI, V114, P4557; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	26	117	129	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22111	22114		10.1074/jbc.C200151200	http://dx.doi.org/10.1074/jbc.C200151200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11994270	hybrid			2022-12-27	WOS:000176313600002
J	Hamada, K; Miyata, T; Mayanagi, K; Hirota, J; Mikoshiba, K				Hamada, K; Miyata, T; Mayanagi, K; Hirota, J; Mikoshiba, K			Two-state conformational changes in inositol 1,4,5-trisphosphate receptor regulated by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; ENDOPLASMIC-RETICULUM; RELEASE CHANNEL; SKELETAL-MUSCLE; LIGAND-BINDING; MOUSE; PURIFICATION; DEPRESSION; MICROSCOPY; DOMAINS	Inositol 1,4,5-trisphosphate receptor (IP3R) is a highly controlled calcium (Ca2+) channel gated by inositol 1,4,5-trisphosphate (IP3). Multiple regulators modulate IP3-triggered pore opening by binding-to discrete allosteric sites within IP3R Accordingly we have postulated that these regulators structurally control ligand gating behavior; however, no structural evidence has been available. Here we show that Ca2+, the most pivotal regulator, induced marked structural changes in the tetrameric IP3R purified from mouse cerebella. Electron microscopy of the IP3R particles revealed two distinct structures with 4-fold symmetry: a windmill structure and a square structure. Ca2+ reversibly promoted a transition from the square to the windmill with relocations of four peripheral IP3-binding domains, assigned by binding to heparin-gold. Ca2+-dependent susceptibilities to limited digestion strongly support the notion that these alterations exist. Thus, Ca2+ appeared to regulate IP3 gating activity through the rearrangement of functional domains.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; BERI, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Hamada, K (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Hamada, Kozo/GXM-9371-2022; Hirota, Junji/G-1357-2019; Hirota, Junji/O-9315-2019; Mikoshiba, Katsuhiko/N-7943-2015	Hirota, Junji/0000-0002-5741-0655; Hirota, Junji/0000-0002-5741-0655; Hamada, Kozo/0000-0002-2795-802X				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Furuichi T, 1999, CALCIUM AS A CELLULAR REGULATOR, P200; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Kanaseki T, 1998, CELL STRUCT FUNCT, V23, P373, DOI 10.1247/csf.23.373; Katayama E, 1996, EMBO J, V15, P4844, DOI 10.1002/j.1460-2075.1996.tb00865.x; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Street VA, 1997, J NEUROSCI, V17, P635; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	27	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21115	21118		10.1074/jbc.C200244200	http://dx.doi.org/10.1074/jbc.C200244200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11980893	hybrid			2022-12-27	WOS:000176286000002
J	Xie, ZJ; Munson, SJ; Huang, NW; Portale, AA; Miller, WL; Bikle, DD				Xie, ZJ; Munson, SJ; Huang, NW; Portale, AA; Miller, WL; Bikle, DD			The mechanism of 1,25-dihydroxyvitamin D-3 autoregulation in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RESPONSIVE ELEMENTS; VITAMIN-D METABOLISM; MOLECULAR-CLONING; DIFFERENTIATION; 24-HYDROXYLASE; GENE; CDNA; PROMOTER; GROWTH; 1-ALPHA,25-DIHYDROXYVITAMIN-D3	The synthesis of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) from its precursor, 25-dihydroxyvitamin D-3 (25(OH)D-3), is catalyzed by the mitochondrial cytochrome P450 enzyme 25-hydroxyvitamin D-3-1alpha-hydroxylase (1alpha-hydroxylase). It has been generally assumed that 1,25(OH)(2)D-3 inhibits the activity of this enzyme by regulating its expression at the genomic level. We confirmed that 1,25(OH)(2)D-3 reduced the apparent conversion of 1,25(OH)D-3 to 1,25(OH)(2)D-3 while stimulating the conversion of 1,25(OH)(2)D-3 and 25(OH)D-3 to 1,24,25(OH)(3)D-3 and 24,25(OH)(2)D-3, respectively. However, 1,25(OH)(2)D-3 failed to reduce the abundance of its mRNA or its encoded protein in human keratinocytes. Instead, when catabolism of 1,25(OH)(2)D-3 was blocked with a specific inhibitor of the 25-hydroxyvitamin D-3-24-hydroxylase (24-hydroxylase) all apparent inhibition of la-hydroxylase activity by 1,25(OH)(2)D-3 was reversed. Thus, the apparent reduction in la-hydroxylase activity induced by 1,25(OH)(2)D-3 is due to increased catabolism of both substrate and product by the 24-hydroxylase. We believe this to be a unique mechanism for autoregulation of steroid hormone synthesis.	Univ Calif San Francisco, Endocrine Unit, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; No Calif Inst Res & Educ, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Northern California Institute for Research & Education; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Xie, ZJ (corresponding author), Univ Calif San Francisco, Endocrine Unit, Vet Affairs Med Ctr, 4150 Clement St 111N, San Francisco, CA 94121 USA.		Miller, Walter L/J-3696-2012; xie, zhongjian/K-7858-2016	xie, zhongjian/0000-0002-4328-1303				BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BIKLE DD, 1993, J INVEST DERMATOL, V101, P713, DOI 10.1111/1523-1747.ep12371681; BIKLE DD, 1986, J CLIN INVEST, V78, P557, DOI 10.1172/JCI112609; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; HENRY HL, 1974, J BIOL CHEM, V249, P7584; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Kong XF, 1999, P NATL ACAD SCI USA, V96, P6988, DOI 10.1073/pnas.96.12.6988; MATSUMOTO K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P311, DOI 10.1016/S0167-4889(97)90006-9; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; Schuessler M, 2001, STEROIDS, V66, P399, DOI 10.1016/S0039-128X(00)00229-4; Schuster I, 2001, STEROIDS, V66, P451, DOI 10.1016/S0039-128X(00)00166-5; Schuster I, 2001, STEROIDS, V66, P409, DOI 10.1016/S0039-128X(00)00159-8; SHERWOOD LM, 1987, NEW ENGL J MED, V316, P1601, DOI 10.1056/NEJM198706183162511; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Zhang MYH, 2002, ENDOCRINOLOGY, V143, P587, DOI 10.1210/en.143.2.587	26	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36987	36990		10.1074/jbc.M201404200	http://dx.doi.org/10.1074/jbc.M201404200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	11956203	hybrid			2022-12-27	WOS:000178447100012
J	Yamada, T; Zhu, DC; Saxon, A; Zhang, K				Yamada, T; Zhu, DC; Saxon, A; Zhang, K			CD45 controls interleukin-4-mediated IgE class switch recombination in human B cells through its function as a Janus kinase phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SRC-FAMILY KINASES; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; MICROGLIAL ACTIVATION; INTERFERON-GAMMA; GENE-EXPRESSION; PHOSPHORYLATION; INDUCTION; ANTIGEN	CD45 plays a critical regulatory role in receptor signaling through its protein tyrosine phosphatase and Janus kinase (JAK) phosphatase activities. To investigate whether CD45 also plays a regulatory role in Ig class switching in human B cells, we examined the effects of CD45 triggering on Ig class switching to IgE and its relationship with CD45 JAK phosphatase activity. Anti-CD45 triggering of CD45 significantly inhibited interleukin-4 + anti-CD40-induced switch recombination in a switch recombination vector assay in stably transfected Ramos 2G6 human B cells, as well as Ig E germ-line transcription and Smu-Sepsilon switch recombination in primary human B cells. These negative regulatory effects on Ig class switching were concomitant with the ability of CD45 to dephosphorylate the induced phosphorylation of JAK1, JAK3, and signal transducer and activator of transcription 6, but not on stress-activated/mitogen-activated protein kinases. We also showed that phosphorylated JAK1 and JAK3 were directly dephosphorylated by recombinant CD45 in vitro. These results indicate that CD45 is able to function as JAK phosphatase in human B cells and that this activity is directly associated with the negative regulation of the class switch recombination to IgE. CD45 may be an appropriate target drug for modulating IgE in allergic diseases.	Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy,Div Clin Immunol, Dept Med,Hart & Louis Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zhang, K (corresponding author), Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy,Div Clin Immunol, Dept Med,Hart & Louis Lab, 10833 Conte Ave, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA-16042] Funding Source: Medline; NIAID NIH HHS [AI-40551, AI-28697, AI-34567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, U19AI034567, R29AI040551, P30AI028697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; Blank N, 2001, J IMMUNOL, V166, P6034, DOI 10.4049/jimmunol.166.10.6034; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; Craxton A, 1998, J IMMUNOL, V161, P3225; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; FENGHAO X, 1995, J CLIN INVEST, V96, P907, DOI 10.1172/JCI118138; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Hartatik T, 2001, BIOCHEM BIOPH RES CO, V284, P26, DOI 10.1006/bbrc.2001.4931; HASEGAWA K, 1990, INT IMMUNOL, V2, P367, DOI 10.1093/intimm/2.4.367; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; HOOK WA, 1991, J IMMUNOL, V147, P2670; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Katagiri T, 1999, J IMMUNOL, V163, P1321; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Kinoshita K, 1998, IMMUNITY, V9, P849, DOI 10.1016/S1074-7613(00)80650-0; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Li YY, 1996, J IMMUNOL, V157, P1440; Linehan LA, 1998, J IMMUNOL, V161, P302; Losman JA, 1999, J IMMUNOL, V162, P3770; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; MASLIAH E, 1991, ACTA NEUROPATHOL, V83, P12, DOI 10.1007/BF00294425; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MITTLER RS, 1994, J IMMUNOL, V153, P84; MORIKAWA K, 1991, SCAND J IMMUNOL, V34, P273, DOI 10.1111/j.1365-3083.1991.tb01547.x; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; STEVNEZERNORDGR.J, 1986, EMBO J, V5, P95; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeuchi T, 1997, CLIN EXP IMMUNOL, V109, P20, DOI 10.1046/j.1365-2249.1997.4371334.x; Tan J, 2000, J BIOL CHEM, V275, P37224, DOI 10.1074/jbc.M002006200; Tan J, 2000, J NEUROSCI, V20, P7587; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yamada T, 2001, J IMMUNOL, V166, P538, DOI 10.4049/jimmunol.166.1.538; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; Zhang K, 2002, EUR J IMMUNOL, V32, P424, DOI 10.1002/1521-4141(200202)32:2<424::AID-IMMU424>3.0.CO;2-P; Zhong RZ, 1998, J MOL MED-JMM, V76, P572, DOI 10.1007/s001090050252	46	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28830	28835		10.1074/jbc.M201781200	http://dx.doi.org/10.1074/jbc.M201781200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11994288	hybrid			2022-12-27	WOS:000177342600064
J	New, JH; Kowalczykowski, SC				New, JH; Kowalczykowski, SC			Rad52 protein has a second stimulatory role in DNA strand exchange that complements replication protein-A function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; RECOMBINATION; MEDIATOR	Rad52 protein plays a central role in double strand break repair and homologous recombination in Saccharomyces cerevisiae. We have identified a new mechanism by which Rad52 protein stimulates Rad51 protein-promoted DNA strand exchange. This function of Rad52 protein is revealed when subsaturating amounts (relative to the single-stranded DNA concentration) of replication protein-A (RPA) are used. Under these conditions, Rad52 protein is needed for extensive DNA strand exchange. Interestingly, in this new role, Rad52 protein neither acts simply as a single strand DNA-binding protein per se nor, in contrast to its previously identified stimulatory roles, does it require physical interaction with RPA because it can be substituted by the Escherichia coli single strand DNA-binding protein. We propose that Rad52 protein acts by stabilizing the Rad51 presynaptic filament.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 258 Hutchison Hall, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062653, R01GM062653] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline; NIGMS NIH HHS [GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEBOWITZ J, 1985, THESIS J HOPKINS U B; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	22	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26171	26176		10.1074/jbc.M203670200	http://dx.doi.org/10.1074/jbc.M203670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004070	Green Submitted, hybrid			2022-12-27	WOS:000176908700046
J	Artigues, A; Iriarte, A; Martinez-Carrion, M				Artigues, A; Iriarte, A; Martinez-Carrion, M			Binding to chaperones allows import of a purified mitochondrial precursor into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROTEINS; FREE TRANSLATION SYSTEM; HEAT-SHOCK PROTEIN; ASPARTATE-AMINOTRANSFERASE; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC CHAPERONES; SUBSTRATE-SPECIFICITY; STRESS PROTEINS; DNAK CHAPERONE	Refolding of the acid-unfolded precursor to mitochondrial aspartate aminotransferase (pmAAT) is inhibited when cytosolic Hsc70 is included in the refolding reaction (Artigues, A., Iriarte, A., and Martinez-Carrion, M. (1997) J. Biol. Chem. 272, 16852-16861). At low molar excess of Hsc70 pmAAT is recovered in insoluble aggregates containing equal amounts of Hsc70. However, in the presence of a large excess of Hsc70, refolding of pmAAT is still arrested, but the enzyme remains in solution. Similar behavior was observed with two other cytosolic chaperones, bovine Hsp90 and yeast Ydj1. Co-immunoprecipitation of pmAAT using Hsc70 antibodies confirmed the formation of soluble Hsc70-pmAAT complexes at high concentrations of the chaperone. Data from analytical centrifugation, sedimentation in glycerol gradients, and partial purification of the soluble complexes indicate that multiple Hsc70 molecules bind per pmAAT polypeptide chain. The absence of catalytic activity together with the protease susceptibility of pmAAT bound to Hsc70, Hsp90, or Ydj1 suggest that these chaperones bind and maintain pmAAT in a partially unfolded state, analogous to the import-competent conformation of the protein synthesized in cell-free extracts. Remarkably, the purified pmAAT bound to Hsc70 or Ydj1, but not to Hsp90, is imported by isolated mitochondria in a reticulocyte lysate-dependent manner. Thus, both Hsc70 and Ydj1 can trap an import-competent folding intermediate of pmAAT, but productive binding and import into mitochondria require the collaboration of additional cytosolic factors from the lysate.	Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, 5007 Rockhill Rd, Kansas City, MO 64110 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Artigues A, 1998, J BIOL CHEM, V273, P33130, DOI 10.1074/jbc.273.50.33130; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BECKER K, 1992, J BIOL CHEM, V267, P5637; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; Jensen RE, 1999, CURR BIOL, V9, pR779, DOI 10.1016/S0960-9822(00)80012-3; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; LAIN B, 1994, J BIOL CHEM, V269, P15588; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Mattingly JR, 2000, ARCH BIOCHEM BIOPHYS, V382, P113, DOI 10.1006/abbi.2000.2003; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; Mattingly JR, 1998, J BIOL CHEM, V273, P23191, DOI 10.1074/jbc.273.36.23191; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Minami M, 2001, EUR J BIOCHEM, V268, P2520, DOI 10.1046/j.1432-1327.2001.02145.x; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; Nagata H, 1998, BIOCHEMISTRY-US, V37, P6924, DOI 10.1021/bi980164g; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; TERADA K, 1995, MOL CELL BIOL, V15, P3708; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	56	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25047	25055		10.1074/jbc.M203474200	http://dx.doi.org/10.1074/jbc.M203474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983713	hybrid			2022-12-27	WOS:000176747000029
J	Lelievre, E; Lionneton, F; Mattot, V; Spruyt, N; Soncin, F				Lelievre, E; Lionneton, F; Mattot, V; Spruyt, N; Soncin, F			Ets-1 regulates fli-1 expression in endothelial cells - Identification of Ets binding sites in the fli-1 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ETS-1; CHICK-EMBRYO; APOPTOSIS; PROTEINS; DIFFERENTIATION; EMBRYOGENESIS; ANGIOGENESIS; ERYTHROLEUKEMIA; SPECIFICITY; INHIBITION	To understand the role of the Ets-1 transcription factor during angiogenesis, we have overexpressed it in endothelial cells and analyzed the levels of expression of several candidate target genes involved in angiogenesis. The transcripts levels of the ETS transcription factor fli-1 are specifically up-regulated in endothelial cells, which overexpress Ets-1, but not in fibroblasts. Analysis of the promoter of the mouse fli-1 gene reveals that the 1-kb region that comprises the transcription starts and part of exon 1 is responsible for the response of the promoter to Ets-1. The -270/-41 fragment contains two known Spi-1-responding Ets binding sites (EBS), which are also necessary for the activation by Ets-1. In contrast to Spi-1, a third EBS is necessary for the full response of this promoter fragment to Ets-1. The rest of the promoter activity has been located in the -986/-505 region, where three active EBSs have been identified. Furthermore, endogenous Fli-1 was found to be bound to its own gene promoter and to be able to promote the transactivation of its gene. These results suggest that Ets-1 activates an auto-regulatory loop of expression of fli-1 in endothelial cells, a mechanism that could have significant implications for the endothelial cell fate.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Soncin, F (corresponding author), Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Barat C, 2000, BBA-GENE STRUCT EXPR, V1517, P164, DOI 10.1016/S0167-4781(00)00239-6; Barbeau B, 1999, ONCOGENE, V18, P5535, DOI 10.1038/sj.onc.1202913; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BEN DY, 1991, GENE DEV, V5, P908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Goltzene F, 2000, EXP CELL RES, V260, P233, DOI 10.1006/excr.2000.5005; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kappel A, 2000, BLOOD, V96, P3078; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Lionneton F, 2001, PROTEIN EXPRES PURIF, V21, P492, DOI 10.1006/prep.2001.1405; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Maxam A M, 1980, Methods Enzymol, V65, P499; Melet F, 1996, MOL CELL BIOL, V16, P2708; Meyer D, 1995, INT J DEV BIOL, V39, P909; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; NERLOV C, 1991, ONCOGENE, V6, P1583; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; QUEVA C, 1993, ONCOGENE, V8, P2511; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETH A, 1993, ONCOGENE, V8, P1783; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Takahashi Y, 2000, GENE DEV, V14, P804; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WERNERT N, 1992, AM J PATHOL, V140, P119; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	52	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25143	25151		10.1074/jbc.M201628200	http://dx.doi.org/10.1074/jbc.M201628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991951	hybrid			2022-12-27	WOS:000176747000040
J	Wolf, D; Rodova, M; Miska, EA; Calvet, JP; Kouzarides, T				Wolf, D; Rodova, M; Miska, EA; Calvet, JP; Kouzarides, T			Acetylation of beta-catenin by CREB-binding protein (CBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN RECEPTOR GENE; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASES; THYROID-CARCINOMA; C-MYC; EXPRESSION; WNT; PATHWAY; TARGET; DOMAIN	Acetylation controls the activity of numerous proteins involved in regulating gene transcription as well as many other cellular processes. In this report we show that the CREB-binding protein (CBP) acetyltransferase acetylates beta-catenin protein in vivo. beta-Catenin is a central component of the Wnt signaling pathway, which is of key importance in development as well as being heavily implicated in a variety of human cancers. We show that the CBP-mediated acetylation of beta-catenin occurs at a single site, lysine 49. Importantly, this lysine is frequently found mutated in cancer and is in a region of importance to the regulation of beta-catenin. We show that mutation of this site leads specifically to an increase in the ability of beta-catenin to activate the c-myc gene but not other beta-catenin-regulated genes. This suggests that acetylation of beta-catenin is involved in regulating Wnt signaling in a promoter-specific fashion.	Univ Cambridge, Wellcome CRC Canc Res Campaigne, Inst Pathol, Cambridge CB2 1QR, England; Univ Cambridge, Wellcome CRC Canc Res Campaigne, Dept Pathol, Cambridge CB2 1QR, England; Univ Kansas, Med Ctr, Kansas City, KS 66160 USA	University of Cambridge; University of Cambridge; University of Kansas; University of Kansas Medical Center	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Canc Res Campaigne, Inst Pathol, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162; Miska, Eric/0000-0002-4450-576X	NIDDK NIH HHS [DK57301, DK53763] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057301, P01DK053763] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BRABANT G, 1991, MOL CELL ENDOCRINOL, V82, pR7, DOI 10.1016/0303-7207(91)90018-N; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chan HM, 2001, J CELL SCI, V114, P2363; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HASHIMOTO T, 1990, ENDOCRINOL JAPON, V37, P247; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McManus KJ, 2001, BIOCHEM CELL BIOL, V79, P253, DOI 10.1139/bcb-79-3-253; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; ROMANO MI, 1993, HORM RES, V39, P161, DOI 10.1159/000182718; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SHI YF, 1993, CLIN ENDOCRINOL, V39, P269, DOI 10.1111/j.1365-2265.1993.tb02365.x; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WALZER L, 1998, NATURE, V395, P521; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25562	25567		10.1074/jbc.M201196200	http://dx.doi.org/10.1074/jbc.M201196200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11973335	hybrid			2022-12-27	WOS:000176747000093
J	Kanayama, A; Inoue, J; Sugita-Konishi, Y; Shimizu, M; Miyamoto, Y				Kanayama, A; Inoue, J; Sugita-Konishi, Y; Shimizu, M; Miyamoto, Y			Oxidation of I kappa B alpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; NEUTROPHIL; EXPRESSION; ACID; MYELOPEROXIDASE; INACTIVATION; PROTEOLYSIS; CELLS; BETA	A band shift of IkappaBalpha was observed in Western blots with Jurkat cells treated with I nM taurine chloramine (TauCl) for I h. TauC1 treatment inhibited tumor necrosis factor a (TNFalpha)-initiated nuclear factor kappaB (NF-kappaB) activation. TauCl did not inhibit either the upstream of IkappaB kinase (IKK) activation or IKK itself but did inhibit NF-kappaB activation induced by IKK overexpression. Deletion experiments showed that a TauCl modification site causing the band shift of IkappaBalpha is Met(45). High performance liquid chromatography and mass spectrometry analyses of a small peptide containing Met4(5) revealed that TauC1 oxidizes Met45. A mutant of IkappaBalpha whose Met(45) was converted to alanine did not generate a band shift upon TauC1 treatment and degraded in response to TNFalpha stimulation. However, a reporter assay revealed that NF-kappaB-dependent luciferase expression was not fully recovered in cells transfected with this mutant. These results indicate that Met(45) oxidation of IkappaBalpha is a molecular mechanism underlying the TauCl-induced inhibition of NF-kappaB activation. A similar band shift was observed when HL-60 cells expressing myeloperoxidase were treated with 100 muM hydrogen peroxide for 5 min. When rat neutrophils were incubated with bacteria, intracellular taurine decreased interleukin-8 production. Therefore, taurine may help suppress excessive inflammatory reaction in neutrophils.	Univ Tokyo, Dept Integrat Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Keio Univ, Dept Appl Chem, Fac Sci & Technol, Yokohama, Kanagawa 2238522, Japan; Natl Inst Infect Dis, Dept Biomed Food Res, Shinjuku Ku, Tokyo 1628640, Japan	University of Tokyo; University of Tokyo; Keio University; National Institute of Infectious Diseases (NIID)	Miyamoto, Y (corresponding author), Univ Tokyo, Dept Integrat Biosci, Grad Sch Frontier Sci, Biosci Bldg 402,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	yusei74@k.u-tokyo.ac.jp						ABRINK M, 1994, LEUKEMIA, V8, P1579; Aoki T, 1996, ONCOGENE, V12, P1159; Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chen JG, 2000, BIOPHYS J, V78, P174, DOI 10.1016/S0006-3495(00)76583-0; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Kontny E, 2000, ARTHRITIS RHEUM, V43, P2169, DOI 10.1002/1529-0131(200010)43:10<2169::AID-ANR4>3.0.CO;2-#; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcinkiewicz J, 1998, IMMUNOPHARMACOLOGY, V40, P27, DOI 10.1016/S0162-3109(98)00023-X; MCDONALD PP, 1997, FEBS LETT, V412, P538; Ogino T, 1997, J BIOL CHEM, V272, P26247, DOI 10.1074/jbc.272.42.26247; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stapleton PP, 1998, JPEN-PARENTER ENTER, V22, P42, DOI 10.1177/014860719802200142; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Xia Y, 1997, ANAL BIOCHEM, V245, P93, DOI 10.1006/abio.1996.9940; ZELIKOVIE L, 1989, NEW PROTECTIVE ROLES, P253	33	125	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24049	24056		10.1074/jbc.M110832200	http://dx.doi.org/10.1074/jbc.M110832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983684	hybrid			2022-12-27	WOS:000176611800012
J	Takashima, S; Ishida, H; Inazu, T; Ando, T; Ishida, H; Kiso, M; Tsuji, S; Tsujimoto, M				Takashima, S; Ishida, H; Inazu, T; Ando, T; Ishida, H; Kiso, M; Tsuji, S; Tsujimoto, M			Molecular cloning and expression of a sixth type of alpha 2,8-sialyltransferase (ST8Sia VI) that sialylates O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; GENOMIC STRUCTURE; SUBSTRATE-SPECIFICITY; PROMOTER ACTIVITY; SYNTHASE; GLYCOPROTEINS; RESIDUES; ALPHA-2,6-SIALYL; BIOSYNTHESIS; ORGANIZATION	A novel member of the mouse alpha2,8-sialyltransferase (ST8Sia) family, designated ST8Sia VI, was identified by BLAST analysis of expressed sequence tags. The sequence of STSSia VI encodes a protein of 398 amino acids and shows 42.0 and 38.3% amino acid sequence identities to mouse alpha2,8-sialyltransferases ST8Sia I (GD3 synthase) and STSSia V (GD1c, GT1a, GQ1b, and GT3 synthases), respectively. The recombinant soluble form of STSSia VI expressed in COS-7 cells exhibited alpha2,8-sialyltransferase activity toward both glycolipids and glycoproteins that have the NeuAcalpha2,3(6)Gal sequence at the nonreducing end of their carbohydrate groups. This enzyme formed NeuAcalpha2,8NeuAc structures, but not oligosialic or polysialic acid structures. Analysis of the fetuin sialylated by STSSia VI indicated that ST8Sia VI prefers O-glycans to N-glycans as acceptor substrates. Substrate specificities and kinetic properties also showed that ST8Sia VI prefers O-glycans to glycolipids as acceptor substrates. ST8Sia VI also exhibited activity toward oligosaccharides such as sialyllactose and sialyllactosamine, and the structure of the minimal acceptor substrate for ST8Sia VI was determined as the NeuAcalpha2,3(6)Gal sequence. The expression of the ST8Sia VI gene was ubiquitous, and the highest expression was observed in kidney, with three major transcripts of 8.2, 3.8, and 2.7 kb. This is the first report of a mammalian alpha2,8-sialyltransferase that sialylates O-glycans preferentially.	RIKEN, Lab Cellular Biochem, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Noguchi Inst, Itabashi Ku, Tokyo, Japan; Gifu Univ, Dept Appl Bioorgan Chem, Fac Agr & Life Sci, Gifu 5011193, Japan; Ochanomizu Univ, Dept Chem, Fac Sci, Bunkyo Ku, Tokyo 1128610, Japan	RIKEN; Gifu University; Ochanomizu University	Tsujimoto, M (corresponding author), RIKEN, Lab Cellular Biochem, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	tsujimot@postman.riken.go.jp	Inazu, Toshiyuki/R-1966-2019					DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; Eckhardt M, 1998, GLYCOBIOLOGY, V8, P1165, DOI 10.1093/glycob/8.12.1165; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HARDUINLEPERS A, 2001, RRD CANCER 1, V3, P111; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Ikehara Y, 1999, FEBS LETT, V463, P92, DOI 10.1016/S0014-5793(99)01605-1; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; KAMEYAMA A, 1990, CARBOHYD RES, V200, P269, DOI 10.1016/0008-6215(90)84197-3; Kitajima K, 1999, SIALOBIOLOGY OTHER N, P69; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Nara K, 1996, EUR J BIOCHEM, V238, P647, DOI 10.1111/j.1432-1033.1996.0647w.x; OHTA S, 1993, ANTICANCER RES, V13, P331; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PRABHANJAN H, 1991, CARBOHYD RES, V211, pC1, DOI 10.1016/0008-6215(91)80105-V; Saito M, 2000, BBA-GEN SUBJECTS, V1523, P230, DOI 10.1016/S0304-4165(00)00127-6; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; Suzuki M, 2000, GLYCOBIOLOGY, V10, P1113; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Takashima S, 1998, J BIOL CHEM, V273, P7675, DOI 10.1074/jbc.273.13.7675; Takashima S, 2000, J BIOCHEM-TOKYO, V128, P1033, DOI 10.1093/oxfordjournals.jbchem.a022831; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Tsuji S., 1999, SIALOBIOLOGY OTHER N, P145; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	47	54	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24030	24038		10.1074/jbc.M112367200	http://dx.doi.org/10.1074/jbc.M112367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980897	hybrid			2022-12-27	WOS:000176611800010
J	Zhang, F; Chen, Y; Kweon, DH; Kim, CS; Shin, YK				Zhang, F; Chen, Y; Kweon, DH; Kim, CS; Shin, YK			The four-helix bundle of the neuronal target membrane SNARE complex is neither disordered in the middle nor uncoiled at the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-SNARE; PROTEIN-STRUCTURE; INFLUENZA HEMAGGLUTININ; SYNAPTIC EXOCYTOSIS; CRYSTAL-STRUCTURE; SPIN-LABELS; SIDE-CHAINS; FUSION; RECEPTOR; BACTERIORHODOPSIN	Assembly of the SNARE complex is an essential step for membrane fusion and neurotransmitter release in neurons. The plasma membrane SNAREs syntaxin 1A and SNAP-25 (t-SNAREs) and the delivery-vesicle SNARE VAMP2 (or v-SNARE) contain the "SNARE regions" that essentially mediate SNARE pairing. Using site-directed spin labeling and EPR distance measurement we show that two identical copies of the SNARE region from syntaxin 1A intertwine as a coiled coil near the "ionic layer" region. The structure of the t-SNARE complex appears to be virtually identical to that of the ternary SNARE complex, except that VAMP2 is substituted to the second copy of syntaxin 1A. Furthermore, it appears that the coiled coil structure is maintained up to residue 259 of syntaxin 1A, identical to that of the ternary complex. These results are somewhat contradictory to the previous reports, suggesting that the t-SNARE complex has the disordered midsection (Xiao, W. Z., Poirier, M. A., Bennett, M. K., and Shin, Y. K. (2001) Nat. Struc. Biol. 8,308-311) and the uncoiled C-terminal region (Margittai, M., Fasshauer, D., Pabst, S., Jahn, R., and Langen, R. (2001) J. Biol. Chem. 276, 13169-13177). The newly refined structure of the t-SNARE complex provides a basis for the better understanding of the SNARE assembly process. It also provides possible structural-functional clues to the membrane fusion in the v-SNARE deleted fusion models.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.		Zhang, Fan/A-3477-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051290, R01GM051290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; GUAM K, 1991, ANAL BIOCHEM, V192, P262; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hustedt EJ, 1999, ANNU REV BIOPH BIOM, V28, P129, DOI 10.1146/annurev.biophys.28.1.129; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2000, BIO MAGN RE, V19, P185; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Russell CJ, 1999, BIOCHEMISTRY-US, V38, P337, DOI 10.1021/bi981179h; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xiao WZ, 2000, J MOL BIOL, V304, P715, DOI 10.1006/jmbi.2000.4255; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174	44	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24294	24298		10.1074/jbc.M201200200	http://dx.doi.org/10.1074/jbc.M201200200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983696	hybrid			2022-12-27	WOS:000176611800043
J	Augusto, LA; Li, J; Synguelakis, M; Johansson, J; Chaby, R				Augusto, LA; Li, J; Synguelakis, M; Johansson, J; Chaby, R			Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE SP-C; A SP-A; PULMONARY SURFACTANT; LIPID-A; BIOPHYSICAL ACTIVITY; IN-VIVO; SECONDARY STRUCTURE; EPITHELIAL-CELLS; INNATE IMMUNITY; DEFICIENT MICE	In the respiratory tract, recognition of bacterial endotoxin (lipopolysacharide, LPS) is a critical step of the innate host defense system directed against invading pathogens. Secretions of the airways contain proteins that have direct antimicrobial activity (lysozyme, lactoferrin, defensins, and cathelicidins) as well as complement factors and surfactant proteins that contribute to host defense. The hydrophobic surfactant protein C (SP-C) recognizes LPS (Augusto, L., Le Blay, K., Auger, G., Blanot, D., and Chaby, R. (2001) Am. J. Physiol. 281, L776-L785). In the present study, using synthetic analogs of SP-C, we demonstrate that the palmitoyl residues of SP-C are not required for the interaction with LPS and that both the hydrophilic and hydrophobic regions of SP-C are required for specific binding of a radiolabeled rough-type LPS. In addition, using LPS submitted to different chemical treatments as well as synthetic analogs of the lipid A moiety of LPS, we established that the terminal phosphate group at the reducing end of the lipid A disaccharide in a configuration is of crucial importance for recognition by SP-C. The N-linked fatty acyl chain on the reducing glucosamine of lipid A also takes part in the interaction. Dipalmitoyl phosphatidylcholine is not specifically required for the LPS-binding activity of SP-C, although a lipid environment significantly increases the binding. These results provide a basis for experiments on the role of SP-C in presentation of LPS to alveolar cells and for the design of drugs for the management of endotoxin-induced lung injury.	Univ Paris 11, Natl Ctr Sci Res, UMR 8619, Endotoxin Grp, F-91405 Orsay, France; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet	Chaby, R (corresponding author), Univ Paris 11, Natl Ctr Sci Res, UMR 8619, Endotoxin Grp, F-91405 Orsay, France.		Augusto, Luis/AAR-2230-2021	Johansson, Jan/0000-0002-8719-4703; Augusto, Luis Antonio/0000-0003-2070-944X				Augusto L, 2001, AM J PHYSIOL-LUNG C, V281, pL776, DOI 10.1152/ajplung.2001.281.4.L776; Beamer LJ, 1998, PROTEIN SCI, V7, P906; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Brandenburg K, 1998, EUR J BIOCHEM, V258, P686, DOI 10.1046/j.1432-1327.1998.2580686.x; CHANTRES JR, 1992, J PHARM SCI, V81, P74, DOI 10.1002/jps.2600810115; CHARON D, 1985, BIOCHEMISTRY-US, V24, P2736, DOI 10.1021/bi00332a021; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CLERCX A, 1995, EUR J BIOCHEM, V229, P465, DOI 10.1111/j.1432-1033.1995.tb20487.x; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; Dankesreiter S, 2000, J IMMUNOL, V164, P4804, DOI 10.4049/jimmunol.164.9.4804; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; Gustafsson M, 2000, BBA-BIOMEMBRANES, V1466, P169, DOI 10.1016/S0005-2736(00)00198-X; Gustafsson M, 1997, BIOCHEM J, V326, P799, DOI 10.1042/bj3260799; Gustafsson M, 2001, J MOL BIOL, V310, P937, DOI 10.1006/jmbi.2001.4810; Hallman Mikko, 2001, Biology of the Neonate, V80, P36; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; JOHANSSON J, 1995, FEBS LETT, V362, P261, DOI 10.1016/0014-5793(95)00216-V; Johansson J, 1998, BBA-MOL BASIS DIS, V1408, P161, DOI 10.1016/S0925-4439(98)00065-9; JOHANSSON J, 1995, BIOCHEM J, V307, P535, DOI 10.1042/bj3070535; KALINA M, 1995, AM J PHYSIOL-LUNG C, V268, pL144, DOI 10.1152/ajplung.1995.268.1.L144; Karibian D, 1999, RAPID COMMUN MASS SP, V13, P2252, DOI 10.1002/(SICI)1097-0231(19991130)13:22<2252::AID-RCM783>3.0.CO;2-G; KATYAL SL, 1977, LAB INVEST, V36, P585; KIRIKAE T, 1994, FEMS IMMUNOL MED MIC, V8, P13; Knirel YA, 1996, CARBOHYD RES, V283, P129, DOI 10.1016/0008-6215(95)00401-7; Korfhagen TR, 1998, BBA-MOL BASIS DIS, V1408, P296, DOI 10.1016/S0925-4439(98)00075-1; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; LeVine AM, 1997, J IMMUNOL, V158, P4336; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Lutz C, 1998, AM J RESP CRIT CARE, V158, P840, DOI 10.1164/ajrccm.158.3.9801089; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Nilsson G, 1998, EUR J BIOCHEM, V255, P116, DOI 10.1046/j.1432-1327.1998.2550116.x; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Palmblad M, 1999, BIOCHEM J, V339, P381, DOI 10.1042/0264-6021:3390381; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PHILLIPS NJ, 1993, BIOCHEMISTRY-US, V32, P2003, DOI 10.1021/bi00059a017; PISON U, 1994, EUR J CLIN INVEST, V24, P586, DOI 10.1111/j.1365-2362.1994.tb01110.x; Poelstra K, 1997, AM J PATHOL, V151, P1163; Rahman MM, 1999, GLYCOBIOLOGY, V9, P1371, DOI 10.1093/glycob/9.12.1371; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; RUBIO S, 1995, J BIOL CHEM, V270, P12162, DOI 10.1074/jbc.270.20.12162; RYAN LK, 1989, AM REV RESPIR DIS, V140, P1429, DOI 10.1164/ajrccm/140.5.1429; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; WATSON J, 1975, J IMMUNOL, V114, P1462; Yousefi-Salakdeh E, 1999, BIOCHEM J, V343, P557, DOI 10.1042/0264-6021:3430557	49	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23484	23492		10.1074/jbc.M111925200	http://dx.doi.org/10.1074/jbc.M111925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980896	hybrid			2022-12-27	WOS:000176475700052
J	Liang, CL; Chen, JL; Hsu, YPP; Ou, JT; Chang, YS				Liang, CL; Chen, JL; Hsu, YPP; Ou, JT; Chang, YS			Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYTIC SWITCH; TRANSCRIPTIONAL ACTIVATION; DIMERIZATION DOMAIN; BINDING-ELEMENT; LEUCINE ZIPPER; VIRAL-DNA; PROMOTER; IDENTIFICATION; RECEPTOR; CELLS	Induction of Epstein-Barr virus (EBV) production in an EBV-positive cell is achieved by expression of the gene BZLF1 that switches the latent state into a lytic state. The expression of the BZLF1 gene is initiated from the promoter Zp, which is normally suppressed in EBV-transformed B cells. The BZLF1 gene can be induced for expression by activating agents, such as transforming growth factor-beta (TGF-beta) and 12-O-tetradecanoylphorbol-13-acetate. The 12-O-tetradecanoylphorbol-13-acetate-responsive element located in the Zp is the AP-1 motif. The TGF-beta-responsive element, however, has not been determined. We demonstrated that the Smad4-binding element site, GTCTG, from -233 to -229, was located in the regulatory region of the Zp relative to the BZLF1 transcription initiation site and was physically associated with Smad4. This association was important for the TGF-beta induction of Zp. We also showed from the results of co-transfection experiments and electrophoretic mobility shift assays that both the AP-1 motif and Smad4-binding element site appeared to be required for the TGF-beta-induced activation of Zp. This effect was mediated through the cooperation of Smad3/Smad4 and c-Jun/c-Fos that formed a complex. TGF-beta treatment of Rael cells induced production of infectious EBV particles that was capable of infecting EBV-negative CA46 cells and transforming normal cord blood B cells, in vitro. Those data support a mechanism that TGF-beta induces the latent EBV in cells to enter the viral lytic cycle through regulation of key viral proteins by TGF-beta signal transducers. Those findings also suggest a role of TGF-beta in EBV-associated diseases.	Chang Gung Univ, Sch Med, Grad Inst Basic Med Sci, Tao Yuan, Taiwan; Chang Gung Univ, Sch Med, Dept Microbiol & Immunol, Tao Yuan, Taiwan; Natl Tsing Hua Univ, Grad Inst Life Sci, Hsinchu 300, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan	Chang Gung University; Chang Gung University; National Tsing Hua University; National Yang Ming Chiao Tung University	Chang, YS (corresponding author), Chang Gung Univ, Sch Med, Grad Inst Basic Med Sci, 259 Wen Hwa 1st Rd, Tao Yuan, Taiwan.			Chang, Yu-Sun/0000-0002-6457-3890				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; CAYROL C, 1995, J VIROL, V69, P4206, DOI 10.1128/JVI.69.7.4206-4212.1995; Chang PJ, 1998, J VIROL, V72, P5128, DOI 10.1128/JVI.72.6.5128-5136.1998; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHANG YS, 1995, INT J CANCER, V62, P673, DOI 10.1002/ijc.2910620605; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Chen HL, 1999, P NATL ACAD SCI USA, V96, P9339, DOI 10.1073/pnas.96.16.9339; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; DAIBATA M, 1994, VIROLOGY, V198, P446, DOI 10.1006/viro.1994.1056; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIRENZO L, 1994, INT J CANCER, V57, P914, DOI 10.1002/ijc.2910570623; Fahmi H, 2000, J VIROL, V74, P5810, DOI 10.1128/JVI.74.13.5810-5818.2000; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FARRELL PJ, 1983, EMBO J, V2, P1331, DOI 10.1002/j.1460-2075.1983.tb01588.x; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FLEMINGTON E, 1990, J VIROL, V64, P1217, DOI 10.1128/JVI.64.3.1217-1226.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; GROGAN E, 1987, P NATL ACAD SCI USA, V84, P1332, DOI 10.1073/pnas.84.5.1332; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KOUZARIDES T, 1991, ONCOGENE, V6, P195; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Liang CL, 2000, VIROLOGY, V277, P184, DOI 10.1006/viro.2000.0582; LIN JC, 1979, VIROLOGY, V99, P183, DOI 10.1016/0042-6822(79)90052-7; Liu SF, 1997, VIROLOGY, V228, P11, DOI 10.1006/viro.1996.8371; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; SHIMIZU N, 1993, J VIROL, V67, P3240, DOI 10.1128/JVI.67.6.3240-3245.1993; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsai CH, 1997, J BIOMED SCI, V4, P69, DOI 10.1007/BF02255596; TSAI CN, 1995, DNA CELL BIOL, V14, P767, DOI 10.1089/dna.1995.14.767; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZURHAUSEN H, 1978, NATURE, V272, P373	49	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23345	23357		10.1074/jbc.M107420200	http://dx.doi.org/10.1074/jbc.M107420200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971895	hybrid			2022-12-27	WOS:000176475700034
J	Davis, DB; Doherty, KR; Delmonte, AJ; McNally, EM				Davis, DB; Doherty, KR; Delmonte, AJ; McNally, EM			Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; PROTEIN-KINASE-C; MIYOSHI MYOPATHY; CAENORHABDITIS-ELEGANS; DYSFERLIN MUTATION; SYNAPTOTAGMIN-I; MYOBLAST FUSION; SKELETAL-MUSCLE; MEMBRANE; GENE	Mutations in dysferlin, a novel membrane protein of unknown function, lead to muscular dystrophy. Myoferlin is highly homologous to dysferlin and like dysferlin is a plasma membrane protein with six C2 domains highly expressed in muscle. C2 domains are found in a variety of membrane-associated proteins where they have been implicated in calcium, phospholipid, and protein-binding. We investigated the pattern of dysferlin and myoferlin expression in a cell culture model of muscle development and found that dysferlin is expressed in mature myotubes. In contrast, myoferlin is highly expressed in elongated "prefusion" myoblasts and is decreased in mature myotubes where dysferlin expression is greatest. We tested ferlin C2 domains for their ability to bind phospholipid in a calcium-sensitive manner. We found that C2A, the first C2 domain of dysferlin and myoferlin, bound 50% phosphatidylserine and that phospholipid binding was regulated by calcium concentration. A dysferlin point mutation responsible for muscular dystrophy was engineered into the dysferlin C2A domain and demonstrated reduced calcium-sensitive phospholipid binding. Based on these data, we propose a mechanism for muscular dystrophy in which calcium-regulated phospholipid binding is abnormal, leading to defective maintenance and repair of muscle membranes.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland,Rm G611,MC 6088, Chicago, IL 60637 USA.		Davis, Dawn/B-1624-2013; McNally, Elizabeth/W-4909-2019; Sadleir, Katherine R/N-1199-2019	Davis, Dawn/0000-0002-0239-4715; Sadleir, Katherine R/0000-0001-8310-841X; McNally, Elizabeth/0000-0002-1221-719X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007381] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007381] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Bai JH, 2002, P NATL ACAD SCI USA, V99, P1665, DOI 10.1073/pnas.032541099; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Britton S, 2000, GENOMICS, V68, P313, DOI 10.1006/geno.2000.6290; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; DAVID JD, 1981, DEV BIOL, V82, P297, DOI 10.1016/0012-1606(81)90453-X; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; Illarioshkin SN, 2000, NEUROLOGY, V55, P1931, DOI 10.1212/WNL.55.12.1931; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P12020, DOI 10.1021/bi981107q; KALDERON N, 1979, J CELL BIOL, V81, P411, DOI 10.1083/jcb.81.2.411; KNUDSEN KA, 1977, DEV BIOL, V58, P328, DOI 10.1016/0012-1606(77)90095-1; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lobo MVT, 1999, HISTOCHEM J, V31, P347, DOI 10.1023/A:1003744007153; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Matsumura T, 1999, P JPN ACAD B-PHYS, V75, P207, DOI 10.2183/pjab.75.207; McNally EM, 2000, AM J MED GENET, V91, P305, DOI 10.1002/(SICI)1096-8628(20000410)91:4<305::AID-AJMG12>3.0.CO;2-S; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; MENKE A, 1995, J CELL SCI, V108, P727; Nakagawa M, 2001, J NEUROL SCI, V184, P15, DOI 10.1016/S0022-510X(00)00484-6; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; PAPAHADJOPOULOS D, 1978, MEMBRANE FUSION, V5, P766; PAPAHADJOPOULOS D, 1979, METHODS MEMBRANE BIO, V10, P1; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Ponting CP, 1996, PROTEIN SCI, V5, P162; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Selcen D, 2001, NEUROLOGY, V56, P1472, DOI 10.1212/WNL.56.11.1472; Seri M, 1999, AM J HUM GENET, V64, P586, DOI 10.1086/302241; SESSIONS A, 1983, BIOCHIM BIOPHYS ACTA, V728, P103, DOI 10.1016/0005-2736(83)90442-X; SESSIONS A, 1981, FEBS LETT, V134, P75, DOI 10.1016/0014-5793(81)80554-6; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ueyama H, 2001, NEUROMUSCULAR DISORD, V11, P139, DOI 10.1016/S0960-8966(00)00168-1; Wang ZM, 2002, BIOPHYS J, V82, P1338, DOI 10.1016/S0006-3495(02)75489-1; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; Weiler T, 1999, HUM MOL GENET, V8, P871, DOI 10.1093/hmg/8.5.871	45	150	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22883	22888		10.1074/jbc.M201858200	http://dx.doi.org/10.1074/jbc.M201858200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959863	hybrid			2022-12-27	WOS:000176313600099
J	Wong, WK; Ou, XM; Chen, K; Shih, JC				Wong, WK; Ou, XM; Chen, K; Shih, JC			Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAO ACTIVITY; MEK KINASE; PROMOTER; TRANSCRIPTION; SP1; DISEASE; BINDING; RAF-1	Monoamine oxidases (MAO) A and B deaminate a number of biogenic amines. Aberrant expression of MAO is implicated in several psychiatric and neurogenerative disorders. In this study, we have shown that phorbol 12-myristate 13-acetate (PMA) increases human MAO B, but not MAO A, gene expression. The sequence between -246 and -225 bp consists of overlapping binding sites (Sp1/Egr-1/Sp1) that are recognized by Sp1, Sp3, and PMA-inducible Egr-1 is essential for PMA activation. PMA transiently increases egr-1 and c-jun gene expression. Mutation studies show that Egr-1 and c-Jun transactivate the MAO B promoter and increase endogenous MAO B transcripts Via the Sp1/Egr-1/Sp1 overlapping binding sites. Sp3 inhibits Sp1 and Egr-1 activation of MAO B gene expression. c-fos gene expression was increased by PATA but not involved in MAO B gene transcription. Furthermore, protein kinase C inhibitor blocks the PMA-dependent activation of MAO B. Cotransfection of the MAO B promoter with dominant negative forms of Ras, Raf-1,MEKK1, MEK1, MEK3, MEK7, ERK2, JNK1, and p38/RK inhibit the PMA-dependent activation of the MAO B promoter. These results indicate that MAO B expression is selectively induced by the activation of protein kinase C and MAPK signaling pathway and that c-Jun and Egr-1 appear to be the ultimate targets of this regulation.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90089 USA.	jcshih@usc.edu			NIMH NIH HHS [R37 MH39085, R37 MH039085-23, R37 MH039085, R01 MH37020, R01 MH037020-16] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAI Y, 1988, J NEURAL TRANSM, V72, P99, DOI 10.1007/BF01250233; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BOND PA, 1977, CLIN CHIM ACTA, V80, P317, DOI 10.1016/0009-8981(77)90039-0; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVOR EJ, 1993, AM J MED GENET, V48, P209, DOI 10.1002/ajmg.1320480407; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGASHIRA T, 1976, JPN J PHARMACOL, V26, P493, DOI 10.1254/jjp.26.493; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FOWLER CJ, 1980, J NEURAL TRANSM, V49, P1, DOI 10.1007/BF01249185; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; GRIMSBY J, 1990, J NEUROCHEM, V55, P1166, DOI 10.1111/j.1471-4159.1990.tb03121.x; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOLSCHNEIDER DP, 1998, PSYCHOPHARMOCOLOGY 4; JOSSAN SS, 1991, NEUROSCIENCE, V45, P1, DOI 10.1016/0306-4522(91)90098-9; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; MANN JJ, 1986, J NEURAL TRANSM, V65, P277, DOI 10.1007/BF01249088; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Oreland L., 1993, MONOAMINE OXIDASE BA, P219; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHNEIDER G, 1981, ARCH PSYCHIAT NERVEN, V230, P5, DOI 10.1007/BF00343762; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SHINGU T, 1994, J BIOL CHEM, V269, P32551; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; ZHU QS, 1992, J NEUROSCI, V12, P4437	41	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22222	22230		10.1074/jbc.M202844200	http://dx.doi.org/10.1074/jbc.M202844200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956220	hybrid, Green Accepted			2022-12-27	WOS:000176313600017
J	Bordone, L; Campbell, C				Bordone, L; Campbell, C			DNA ligase III is degraded by calpain during cell death induced by DNA-damaging agents.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CASPASE-MEDIATED CLEAVAGE; INDUCED APOPTOSIS; EARLY EVENT; PROTEINS; ALPHA; MECHANISM; ACTIN; IDENTIFICATION; INTERFERON	A yeast two-hybrid screen identified the regulatory subunit of the calcium-dependent protease calpain as a putative DNA ligase Ill-binding protein. Calpain binds to the N-terminal region of DNA ligase III, which contains an acidic proline, aspartate, serine, and threonine (PEST) domain frequently present in proteins cleaved by calpain. Recombinant DNA ligase III was a substrate for calpain degradation in vitro. This calpain-mediated proteolysis was calcium-dependent and was blocked by the specific calpain inhibitor calpeptin. Western blot analysis revealed that DNA ligase III was degraded in human fibrosarcoma HT1080 cells following exposure to gamma-radiation. The degradation of DNA ligase III was prevented by pretreatment with calpeptin, which protected irradiated cells from death. Calpeptin treatment also blocked 9-amino camptothecin-induced DNA ligase III proteolysis and simultaneously protected the cells from death. HT1080 clones expressing a modified DNA ligase III that lacked a recognizable PEST domain were significantly more resistant to killing by gamma-radiation or 9-amino camptothecin than were cells that overexpressed the wild-type form of DNA ligase III. These data show that calpain-mediated proteolysis of DNA ligase III plays an essential role in DNA damage-induced cell death in human cells.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Campbell, C (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St,SE, Minneapolis, MN 55455 USA.	campb034@umn.edu			NCI NIH HHS [CA61906] Funding Source: Medline; NIA NIH HHS [AG16678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA061906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEMARTINO GN, 1986, J BIOL CHEM, V261, P2047; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Elce JS, 1997, J BIOL CHEM, V272, P11268; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Huang YY, 1999, MOL CELL BIOL, V19, P2986; INOMATA M, 1988, J BIOL CHEM, V263, P19783; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KIM MY, 1991, J BIOL CHEM, V266, P484; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KULKARNI GV, 1994, J CELL SCI, V107, P1169; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; Li L, 2001, INT J RADIAT ONCOL, V49, P1157, DOI 10.1016/S0360-3016(00)01524-8; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; ROBERTSLEWIS JM, 1993, J NEUROCHEM, V61, P378, DOI 10.1111/j.1471-4159.1993.tb03583.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; Tong X, 2000, INT J RADIAT BIOL, V76, P1387, DOI 10.1080/09553000050151664; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	46	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26673	26680		10.1074/jbc.M112037200	http://dx.doi.org/10.1074/jbc.M112037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994275	hybrid			2022-12-27	WOS:000176908700109
J	Kane, R; Murtagh, J; Finlay, D; Marti, A; Jaggi, R; Blatchford, D; Wilde, C; Martin, F				Kane, R; Murtagh, J; Finlay, D; Marti, A; Jaggi, R; Blatchford, D; Wilde, C; Martin, F			Transcription factor NFIC undergoes N-glycosylation during early mammary gland involution.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; ADENOVIRUS DNA-REPLICATION; PROTEIN GENE-EXPRESSION; PROGRAMMED CELL-DEATH; EPITHELIAL-CELLS; BINDING PROTEINS; KAPPA-B; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; TRANSGENIC MICE	Expression of a 74-kDa nuclear factor I (NFI) protein is triggered in early involution in the mouse mammary gland, and its expression correlates with enhanced occupation of a twin (NFI) binding element in the clusterin promoter, a gene whose transcription is induced at this time (Furlong, E. E., Keon, N. K., Thornton, F. D., Rein, T., and Martin, F. (1996) J. BioL Chem. 271,29688-29697). We now identify this 74-kDa NFI as an NFIC isoform based on its interaction in Western analysis with two NFIC-specific antibodies. A transition from the expression of a 49-kDa NFIC in lactation to the expression of the 74-kDa NFIC in early involution is demonstrated. We show that the 74-kDa NFIC binds specifically to concanavalin A (ConA) and that this binding can be reversed by the specific ConA ligands, methyl a-D-mannopyranoside and methyl a-D-glucopyranoside. In addition, its apparent molecular size was reduced to similar to63 kDa by treatment with the peptide N-glycosidase. The 49-kDa lactation-associated NFIC did not bind ConA nor was it affected by peptide N-glycosidase. Tunicamycin, a specific inhibitor of N-glycosylation, blocked formation of the 74-kDa NFI in involuting mouse mammary gland in vivo when delivered from implanted Elvax depot pellets. Finally, the production of the ConA binding activity could be reiterated in "mammospheres" formed from primary mouse mammary epithelial cells associated with a laminin-rich extracellular matrix. Synthesis of the 74-kDa NFIC was also inhibited in this setting by tunicamycin. Thus, involution triggers the production of an NFIC isoform that is post-translationally modified by N-glycosylation. We further show, by using quantitative competitive reverse transcriptase-PCR, that there is increased expression of the major mouse mammary NFIC mRNA transcript, mNFIC2, in early involution, suggesting that the involution-associated change in NFIC expression also has a transcriptional contribution.	Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Natl Univ Ireland Univ Coll Dublin, Dept Pharmacol, Dublin 4, Ireland; Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland	University College Dublin; University College Dublin; University of Bern	Martin, F (corresponding author), Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.	finian.martin@ucd.ie						ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarkson RWE, 1999, J MAMMARY GLAND BIOL, V4, P165, DOI 10.1023/A:1018725207969; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; French LE, 1996, BIOL REPROD, V55, P1213, DOI 10.1095/biolreprod55.6.1213; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; GRONOSTAJSKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P4013, DOI 10.1073/pnas.81.13.4013; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HAY RT, 1985, J MOL BIOL, V186, P129, DOI 10.1016/0022-2836(85)90263-3; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; Imagawa M, 2000, FEBS LETT, V484, P118, DOI 10.1016/S0014-5793(00)02119-0; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOHLER PO, 1971, ACTA ENDOCRINOL-COP, P137; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, J BIOL CHEM, V269, P14235; Liu YC, 1997, J BIOL CHEM, V272, P10739; Marti A, 1999, J MAMMARY GLAND BIOL, V4, P145, DOI 10.1023/A:1018721107061; MARTI A, 1994, ONCOGENE, V9, P1213; McGarvey PB, 2000, BIOINFORMATICS, V16, P290, DOI 10.1093/bioinformatics/16.3.290; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; O'Connell FC, 2000, CELL DEATH DIFFER, V7, P360, DOI 10.1038/sj.cdd.4400647; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; ROULET E, 1995, MOL CELL BIOL, V15, P5552; Rozen S, 2000, Methods Mol Biol, V132, P365; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; STRANGE R, 1992, DEVELOPMENT, V115, P49; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; Wilson K, 2000, QUAL HEALTH RES, V10, P507, DOI 10.1177/104973200129118606	67	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25893	25903		10.1074/jbc.M202469200	http://dx.doi.org/10.1074/jbc.M202469200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11991954	hybrid			2022-12-27	WOS:000176908700012
J	Li, S; Rosen, BP; Borges-Walmsley, MI; Walmsley, AR				Li, S; Rosen, BP; Borges-Walmsley, MI; Walmsley, AR			Evidence for cooperativity between the four binding sites of dimeric ArsD, an As(III)-responsive transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; COPPER-TRANSPORTING ATPASE; SINGLE-TRYPTOPHAN MUTANTS; WILSON DISEASE GENE; MENKES DISEASE; CANDIDATE GENE; ARSENATE REDUCTASE; LACTOSE REPRESSOR; STRUCTURAL BASIS; ENCODES	ArsD is a trans-acting repressor of the arsRDABC operon that confers resistance to arsenicals and antimonials in Escherichia coli. It possesses two-pairs of vicinal cysteine residues, Cys(12)-Cys(13) and Cys(112)-Cys(113), that potentially form separate binding sites for the metalloids that trigger dissociation of ArsD from the operon. However, as a homodimer it has four vicinal cysteine pairs. Titration of the steady-state fluorescence of ArsD with metalloids revealed positive cooperativity, with a Hill coefficient of 2, between these sites. Disruption of the Cys(112)-Cys(113) site by mutagenesis of arsD, but not the Cys(12)-Cys(13) site, largely abolished this cooperativity, indicative of interactions between adjacent Cys(112)-Cys(113) sites within the dimer. The kinetics of metalloid binding were determined by stopped flow spectroscopy; the rate increased in a sigmoidal manner, with a Hill coefficient of 4, indicating that the pre-steady-state measurements reported cooperativity between all four sites of the dimer rather than just the intermolecular interactions reported by the steady-state measurements. The kinetics of Sb(III) displacement by As(III) revealed that the metalloid-binding sites behave differentially, with the rapid exchange of As(III) for Sb(III) at one site retarding the release of Sb(III) from the other sites. We propose a model involving the sequential binding and release of metalloids by the four binding sites of dimeric ArsD, with only one site releasing free metalloids.	Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of Glasgow; Wayne State University	Walmsley, AR (corresponding author), Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Level 3,Robertson Bldg,56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.			Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI45428] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Barry JK, 1997, BIOCHEMISTRY-US, V36, P15632, DOI 10.1021/bi971685r; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CHEN CM, 1986, J BIOL CHEM, V261, P5030; Chen YX, 1997, J BIOL CHEM, V272, P14257, DOI 10.1074/jbc.272.22.14257; DELNOMDEDIEU M, 1993, CHEM RES TOXICOL, V6, P598, DOI 10.1021/tx00035a002; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7287; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Kintrup M, 2000, EUR J BIOCHEM, V267, P821, DOI 10.1046/j.1432-1327.2000.01063.x; Li S, 2001, MOL MICROBIOL, V41, P687, DOI 10.1046/j.1365-2958.2001.02546.x; Liu JY, 1997, J BIOL CHEM, V272, P21084, DOI 10.1074/jbc.272.34.21084; Martin P, 2001, STRUCTURE, V9, P1071, DOI 10.1016/S0969-2126(01)00672-4; Matthews KS, 2000, NAT STRUCT BIOL, V7, P184, DOI 10.1038/73274; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Ozarowski A, 1999, BIOCHEMISTRY-US, V38, P6715, DOI 10.1021/bi990242f; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Vergani B, 2000, BIOCHEMISTRY-US, V39, P2759, DOI 10.1021/bi9912591; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427	28	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25992	26002		10.1074/jbc.M201619200	http://dx.doi.org/10.1074/jbc.M201619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11980902	hybrid, Green Accepted			2022-12-27	WOS:000176908700024
J	Lomax, RB; Camello, C; Van Coppenolle, F; Petersen, OH; Tepikin, AV				Lomax, RB; Camello, C; Van Coppenolle, F; Petersen, OH; Tepikin, AV			Basal and physiological Ca2+ leak from the endoplasmic reticulum of pancreatic acinar cells - Second messenger-activated channels and translocons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CA-2+ RELEASE; CYCLIC-ADP-RIBOSE; CALCIUM STORES; INOSITOL TRISPHOSPHATE; INTRACELLULAR STORES; MEMBRANE-VESICLES; CHOLECYSTOKININ; HEPARIN; ER; MOBILIZATION	We have studied the Ca2+ leak pathways in the endoplasmic reticulum. of pancreatic acinar cells by directly measuring Ca2+ in the endoplasmic reticulum. ([Ca2+](ER)). Cytosolic Ca2+ ([Ca2+](C)) was clamped to the resting level by a BAPTA-Ca2+ mixture. Administration of cholecystokinin within the physiological concentration range caused a graded decrease of [Ca2+](ER), and the rate of Ca2+ release generated by 10 pm cholecystokinin is at least 3x as fast as the basal Ca2+ leak revealed by inhibition of the endoplasmic reticulum Ca2+-ATPase. Acetylcholine also evokes a dose-dependent decrease of [Ca2+](ER), with an EC50 of 0.98 +/- 0.06 mum. Inhibition of receptors for inositol 1,4,5-trisphosphate (IP3) by heparin or flunarizine blocks the effect of acetylcholine but only partly blocks the effect of cholecystokinin. 8-NH2 cyclic ADP-ribose (20 mum) inhibits the action of cholecystokinin, but not of acetylcholine. The basal Ca2+ leak from the endoplasmic reticulum. is not blocked by antagonists of the IP3 receptor, the ryanodine receptor, or the receptor for nicotinic acid adenine dinucleotide phosphate. However, treatment with puromycin (0.1-1 mm) to remove nascent polypeptides from ribosomes increases Ca2+ leak from the endoplasmic reticulum by a mechanism independent of the endoplasmic reticulum Ca2+ pumps and of the receptors for IP3 or ryanodine.	Univ Liverpool, Physiol Lab, MRC, Secretory Control Res Grp, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Lomax, RB (corresponding author), Univ Liverpool, Physiol Lab, MRC, Secretory Control Res Grp, Liverpool L69 3BX, Merseyside, England.		Camello, Cristina/K-8238-2014; Petersen, Ole H/E-8708-2010	Camello, Cristina/0000-0003-0882-8497; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513				BALLINGER A, 1995, CLIN SCI, V89, P375, DOI 10.1042/cs0890375; Beecroft MD, 1998, BIOCHEM J, V334, P431, DOI 10.1042/bj3340431; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; BROMSTROM CO, 1996, J BIOL CHEM, V271, P24995; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Cancela JM, 1998, PFLUG ARCH EUR J PHY, V435, P746, DOI 10.1007/s004240050578; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FAVRE CJ, 1994, BIOCHEM J, V302, P155, DOI 10.1042/bj3020155; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Jeffery J, 2000, BIOCHEM BIOPH RES CO, V268, P711, DOI 10.1006/bbrc.2000.2194; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; Missiaen L, 1996, BIOCHEM J, V317, P849, DOI 10.1042/bj3170849; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; OVEREND CL, 1998, J PHYSL, V507, P750; PALADE P, 1989, MOL PHARMACOL, V36, P673; PALADE P, 1987, J BIOL CHEM, V262, P6135; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Pessah IN, 1997, AM J PHYSIOL-CELL PH, V272, pC601, DOI 10.1152/ajpcell.1997.272.2.C601; Pestka S, 1974, Methods Enzymol, V30, P261; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; SEILER SM, 1987, BIOCHEM PHARMACOL, V36, P3331, DOI 10.1016/0006-2952(87)90307-8; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; THOM P, 1993, CELL, V74, P661; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wetmore DR, 1996, BIOCHEMISTRY-US, V35, P6549, DOI 10.1021/bi9530752; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285	46	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26479	26485		10.1074/jbc.M201845200	http://dx.doi.org/10.1074/jbc.M201845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994289	Green Submitted, hybrid			2022-12-27	WOS:000176908700086
J	Amasaki, Y; Adachi, S; Ishida, Y; Iwata, M; Arai, N; Arai, K; Miyatake, S				Amasaki, Y; Adachi, S; Ishida, Y; Iwata, M; Arai, N; Arai, K; Miyatake, S			A constitutively nuclear form of NFATx shows efficient transactivation activity and induces differentiation of CD4(+)CD8(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; SIGNAL-TRANSDUCTION; POSITIVE SELECTION; CYCLOSPORINE-A; NEGATIVE SELECTION; KAPPA-B; NF-ATC; CALCINEURIN; ACTIVATION; THYMOCYTES	The Ca2+ signal facilitates nuclear translocation of NFAT through the dephosphorylation of clustered serine residues in the calcium regulatory domain by the Ca2+/calmodulin-dependent phosphatase calcineurin. The conformation of dephosphorylated NFAT exposes the nuclear localization signal for translocation into the nucleus and masks the nuclear export sequence to keep the protein in the nucleus. It has been reported that deletion of some serine-rich motifs masking the nuclear localization signal results in the translocation of NFAT into the nucleus, but that the nuclear export sequence located at the N terminus also needs to, be deleted for NFATx (NFAT4/NFATc3) to exert efficient transactivation function. Here, we report that deletion of the critical serine-rich motifs of NFATx leads to a conformation that efficiently exposes the nuclear localization signal and that has stronger transcription activity compared with the fully activated wild-type protein in the presence of the nuclear export sequence. This also suggests that the regulation of the transactivation domain by phosphorylation observed in NFAT1 may not contribute significantly to the transcription activity of NFATx. The expression of this constitutively nuclear form of NFATx in the CD4(+)CD8(+) T cell line facilitates differentiation into the CD4 single-positive stage upon stimulation with phorbol ester. Our data suggest that NFATx is involved in the regulation of co-receptor expression during differentiation into the CD4 single-positive stage.	Tokyo Metropolitan Inst Med Sci, Dept Immunol, Bunkyo Ku, Tokyo 1138613, Japan; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; Mitsubishi Kagaku Inst Life Sci, Life Sci Res Dept, Tokyo 1948511, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo	Miyatake, S (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Immunol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	smiya@rinshoken.or.jp						Adachi S, 2000, J BIOL CHEM, V275, P14708, DOI 10.1074/jbc.275.19.14708; Adachi S, 2001, BIOCHEM BIOPH RES CO, V288, P1188, DOI 10.1006/bbrc.2001.5912; AIFANTIS L, 2001, NAT IMMUNOL, V2, P463; Amasaki Y, 1998, J IMMUNOL, V160, P2324; ANDERSON G, 1995, J IMMUNOL, V154, P3636; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Imamura R, 1998, J IMMUNOL, V161, P3455; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Kuwata T, 1998, BIOCHEM BIOPH RES CO, V247, P242, DOI 10.1006/bbrc.1998.8767; Liu J, 1997, MOL BIOL CELL, V8, P157, DOI 10.1091/mbc.8.1.157; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Miyatake S, 1997, EUR J IMMUNOL, V27, P1816, DOI 10.1002/eji.1830270733; NAKAYAMA E, 1979, P NATL ACAD SCI USA, V76, P3486, DOI 10.1073/pnas.76.7.3486; Ochoa-Garay J, 1998, J IMMUNOL, V160, P3835; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; URDAHL KB, 1994, J IMMUNOL, V152, P2853; WANG CR, 1995, J EXP MED, V181, P927, DOI 10.1084/jem.181.3.927; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams O, 2001, EUR J IMMUNOL, V31, P1876, DOI 10.1002/1521-4141(200106)31:6<1876::AID-IMMU1876>3.0.CO;2-F; ZHAO Y, 1995, INT IMMUNOL, V7, P1387, DOI 10.1093/intimm/7.9.1387; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	43	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25640	25648		10.1074/jbc.M201860200	http://dx.doi.org/10.1074/jbc.M201860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997392	hybrid, Green Accepted			2022-12-27	WOS:000176747000103
J	Hoyos, B; Imam, A; Korichneva, I; Levi, E; Chua, R; Hammerling, U				Hoyos, B; Imam, A; Korichneva, I; Levi, E; Chua, R; Hammerling, U			Activation of c-Raf kinase by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; SIGNAL-TRANSDUCTION PATHWAYS; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; INSULIN-RECEPTOR; REVERSIBLE REGULATION; CELL-PROLIFERATION; PHOSPHATIDIC-ACID	The present study highlights retinoids as modulators of c-Raf kinase activation by UV light. Whereas a number of retinoids, including retinol, 14-hydroxyretroretinol, anhydroretinol (AR), and retinoic acid bound the c-Raf cysteine-rich domain (CRD) with equal affinity in vitro as well as in vivo, they displayed different, even opposing, effects on UV-mediated kinase activation; retinol and 14-hydroxyretroretinol augmented responses, whereas retinoic acid and AR were inhibitory. Oxidation of thiol groups of cysteines by reactive oxygen, generated during UV irradiation, was the primary event in c-Raf activation, causing the release of zinc ions and, by inference, a change in CRD structure. Retinoids modulated these oxidation events directly: retinol enhanced, whereas AR suppressed, zinc release, precisely mirroring the retinoid effects on c-Raf kinase activation. Oxidation of c-Raf was not sufficient for kinase activation, productive interaction with Ras being mandatory. Further, canonical tyrosine phosphorylation and the action of phosphatase were essential for optimal c-Raf kinase competence. Thus, retinoids bound c-Raf with high affinity, priming the molecule for UV/reactive oxygen species-mediated changes of the CRD that set off GTP-Ras interaction and, in context with an appropriate phosphorylation pattern, lead to full phosphotransferase capacity.	Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hammerling, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA T32 09149, CA89362S1, CA49933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009149, R01CA049933, R01CA089362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chan WH, 2000, J CELL BIOCHEM, V78, P73, DOI 10.1002/(SICI)1097-4644(20000701)78:1<73::AID-JCB7>3.0.CO;2-P; Chen YQ, 1997, P NATL ACAD SCI USA, V94, P10205, DOI 10.1073/pnas.94.19.10205; Chen YQ, 1999, CANCER RES, V59, P3985; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Cunnick JM, 1998, BIOCHEM MOL BIOL INT, V45, P887; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; DERGUINI F, 1995, J BIOL CHEM, V270, P18875, DOI 10.1074/jbc.270.32.18875; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Englaro W, 1998, ONCOGENE, V16, P661, DOI 10.1038/sj.onc.1201536; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Garant MJ, 1999, BIOCHEMISTRY-US, V38, P5896, DOI 10.1021/bi982844p; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; Geilen CC, 1996, J DERMATOL SCI, V12, P255, DOI 10.1016/0923-1811(95)00481-5; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Goldstone SD, 1997, BBA-MOL CELL RES, V1355, P353, DOI 10.1016/S0167-4889(96)00150-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; HUANG Y, 1994, J BIOL CHEM, V269, P31183; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hurley JH, 1997, PROTEIN SCI, V6, P477; Iantomasi T, 2001, BIOCHEM BIOPH RES CO, V280, P1279, DOI 10.1006/bbrc.2001.4274; Imam A, 2001, FASEB J, V15, P28; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Korichneva I, 1999, J CELL SCI, V112, P2521; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; MURAKAMI Y, 1988, CANCER RES, V48, P1587; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Pu MY, 1996, ONCOGENE, V13, P2615; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Sano H, 2001, J IMMUNOL, V166, P3515, DOI 10.4049/jimmunol.166.5.3515; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Tobi SE, 2000, J PHOTOCH PHOTOBIO B, V57, P102, DOI 10.1016/S1011-1344(00)00084-1; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Xia K, 1999, MOL CELL BIOL, V19, P4819; Yasui H, 2000, BIOCHEM BIOPH RES CO, V269, P131, DOI 10.1006/bbrc.2000.2254; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	87	53	55	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23949	23957		10.1074/jbc.M110750200	http://dx.doi.org/10.1074/jbc.M110750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971897	hybrid			2022-12-27	WOS:000176475700110
J	Re, F; Strominger, JL				Re, F; Strominger, JL			Monomeric recombinant MD-2 binds Toll-like receptor 4 tightly and confers lipopolysaccharide responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; RECOGNITION; EXPRESSION; CLEARANCE; ENDOTOXIN; PROTEINS; MOLECULE; CELLS; CD14; TLR4	In order to mediate cellular response to lipopolysaccharide (LPS), Toll-like receptor (TLR) 4 must interact with MD-2, a secreted protein. In this study, a biochemical assay was developed to demonstrate that recombinant MD-2 can interact with the extracellular portion of TLR4 in solution. The ability of MD-2 to multimerize was confirmed, and MD-1 was also shown to possess this ability. Through site-directed mutagenesis, more than two intermolecular disulfide bonds were found to stabilize the MD-2 multimer. MD-2's abilities to confer LPS responsiveness and to bind TLR4 were strongly associated functions. Remarkably, although the majority of recombinant MD-2 exists in multimeric form, monomeric MD-2 was found to preferentially bind TLR4 and to confer LPS responsiveness more efficiently than MD-2 multimers.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University	Re, F (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,Dana 1414, Boston, MA 02115 USA.				NCI NIH HHS [5R35-CA47554] Funding Source: Medline; NIAID NIH HHS [N01-AI45198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Miyake K, 1998, J IMMUNOL, V161, P1348; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098	17	95	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23427	23432		10.1074/jbc.M202554200	http://dx.doi.org/10.1074/jbc.M202554200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976338	hybrid			2022-12-27	WOS:000176475700044
J	Sun, Y; Liu, S; Ferguson, S; Wang, LQ; Klepcyk, P; Yun, JS; Friedman, JE				Sun, Y; Liu, S; Ferguson, S; Wang, LQ; Klepcyk, P; Yun, JS; Friedman, JE			Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-BETA; GLYCOGEN-SYNTHASE KINASE-3; GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT; GTP GENE-TRANSCRIPTION; GROWTH-HORMONE GENE; GLUCOSE-PRODUCTION; IN-VIVO; DIABETES-MELLITUS; FATTY-ACIDS; OB/OB MICE	The ability of insulin to suppress gluconeogenesis in type 11 diabetes mellitus is impaired; however, the cellular mechanisms for this insulin resistance remain poorly understood. To address this question, we generated transgenic (TG) mice overexpressing the phosphoenolpyruvate carboxykinase (PEPCK) gene under control of its own promoter. TG mice had increased basal hepatic glucose production (HGP), but normal levels of plasma free fatty acids (FFAs) and whole-body glucose disposal during a hyperinsulinemic-euglycemic clamp compared with wild-type controls. The steady-state levels of PEPCK and glucose-6-phosphatase mRNAs were elevated in livers of TG mice and were resistant to down-regulation by insulin. Conversely, GLUT2 and glucokinase mRNA levels were appropriately regulated by insulin, suggesting that insulin resistance is selective to gluconeogenic gene expression. Insulin-stimulated phosphorylation of the insulin receptor, insulin receptor substrate (IRS)-1, and associated phosphatidylinositol 3-kinase were normal in TG mice, whereas IRS-2 protein and phosphorylation were down-regulated compared with control mice. These results establish that a modest (2-fold) increase in PEPCK gene expression in vivo is sufficient to increase HGP without affecting FFA concentrations. Furthermore, these results demonstrate that PEPCK overexpression results in a metabolic pattern that increases glucose-6-phosphatase mRNA and results in a selective decrease in IRS-2 protein, decreased phosphatidylinositol 3-kinase activity, and reduced ability of insulin to suppress gluconeogenic gene expression. However, acute suppression of HGP and glycolytic gene expression remained intact, suggesting that FFA and/or IRS-1 signaling, in addition to reduced IRS-2, plays an important role in downstream insulin signal transduction pathways involved in control of gluconeogenesis and progression to type II diabetes mellitus.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Ohio Univ, Edison Anim Biotechnol Ctr, Athens, OH 45107 USA	Case Western Reserve University; University System of Ohio; Ohio University	Friedman, JE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat Biochem & Mol Genet, Mail Stop B195,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Boden G, 2001, DIABETES, V50, P810, DOI 10.2337/diabetes.50.4.810; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; FERBER S, 1994, METABOLISM, V43, P1346, DOI 10.1016/0026-0495(94)90026-4; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hornbuckle LA, 2001, AM J PHYSIOL-ENDOC M, V281, pE713, DOI 10.1152/ajpendo.2001.281.4.E713; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; PARK EA, 1993, J BIOL CHEM, V268, P613; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Roden M, 2001, RECENT PROG HORM RES, V56, P219, DOI 10.1210/rp.56.1.219; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SHAFRIR E, 1988, FRONTIERS DIABETES R, V2, P304; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Wang LQ, 2000, J BIOL CHEM, V275, P14173, DOI 10.1074/jbc.M000764200; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamashita H, 2001, ENDOCRINOLOGY, V142, P2888, DOI 10.1210/en.142.7.2888; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598	53	136	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23301	23307		10.1074/jbc.M200964200	http://dx.doi.org/10.1074/jbc.M200964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964395	hybrid			2022-12-27	WOS:000176475700028
J	Pillutla, RC; Hsiao, KC; Beasley, JR; Brandt, J; Ostergaard, S; Hansen, PH; Spetzler, JC; Danielsen, GM; Andersen, AS; Brissette, RE; Lennick, M; Fletcher, PW; Blume, AJ; Schaffer, L; Goldstein, NI				Pillutla, RC; Hsiao, KC; Beasley, JR; Brandt, J; Ostergaard, S; Hansen, PH; Spetzler, JC; Danielsen, GM; Andersen, AS; Brissette, RE; Lennick, M; Fletcher, PW; Blume, AJ; Schaffer, L; Goldstein, NI			Peptides identify the critical hotspots involved in the biological activation of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; LIGAND-BINDING; PROTEIN HORMONE; MECHANISM; DETERMINANTS; AGONIST; COMPLEX; POTENT	We used phage display to generate surrogate peptides that define the hotspots involved in protein-protein interaction between insulin and the insulin receptor. All of the peptides competed for insulin binding and had affinity constants in the high nanomolar to low micromolar range. Based on competition studies, peptides were grouped into non-overlapping Sites 1, 2, or 3. Some Site 1 peptides were able to activate the tyrosine kinase activity of the insulin receptor and act as agonists in the insulin-dependent fat cell assay, suggesting that Site 1 marks the hotspot involved in insulin-induced activation of the insulin receptor. On the other hand, Site 2 and 3 peptides were found to act as antagonists in the phosphorylation and fat cell assays. These data show that a peptide display can be used to define the molecular architecture of a receptor and to identify the critical regions required for biological activity in a site-directed manner.	DGI Technol, Dept Mol Biol, Edison, NJ 08818 USA; DGI Technol, Dept Screening Technol, Edison, NJ 08818 USA; DGI Technol, Dept Prot Technol, Edison, NJ 08818 USA; Novo Nordisk AS, Dept Insulin Res, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Dept Diabet Biol, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Goldstein, NI (corresponding author), DGI Technol, Dept Mol Biol, Edison, NJ 08818 USA.		Ostergaard, Soren/B-8123-2019	Ostergaard, Soren/0000-0002-9415-3352				Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; Blume AJ, 2000, BIOPOLYMERS, V55, P347, DOI 10.1002/1097-0282(2000)55:4<347::AID-BIP1007>3.0.CO;2-J; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; Hammond BJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE1136, DOI 10.1152/ajpendo.1997.272.6.E1136; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; Mynarcik DC, 1995, J RECEPT SIGNAL TR R, V15, P887, DOI 10.3109/10799899509049863; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Pillutla R C, 2001, BMC Biotechnol, V1, P6, DOI 10.1186/1472-6750-1-6; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHENKER E, 1988, BIOCHEM BIOPH RES CO, V157, P140, DOI 10.1016/S0006-291X(88)80024-X; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	21	65	96	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22590	22594		10.1074/jbc.M202119200	http://dx.doi.org/10.1074/jbc.M202119200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11964401	hybrid			2022-12-27	WOS:000176313600065
J	Yaekashiwa, M; Wang, LH				Yaekashiwa, M; Wang, LH			Transcriptional control of the human thromboxane synthase gene in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN LOCUS; SMALL MAF PROTEINS; LEUCINE ZIPPER PROTEIN; RNA POLYMERASE-II; FACTOR NF-E2; MOLECULAR-CLONING; MESSENGER-RNA; CHROMATIN STRUCTURE; INITIATOR ELEMENT	Thromboxane A(2), a potent mediator of vasoconstriction and platelet aggregation, is synthesized from prostaglandin H-2 by thromboxane synthase (TXAS). We report here on promoter analyses of human TXAS using in vitro transcription and in vivo transfection methods. The 39-bp core promoter, containing both TATA and initiator elements, accurately initiates transcription in an orientation-dependent manner in a cell-free transcription system. Mutation of either TATA or initiator abolished transcriptional activity, but the upstream sequence had no effect on TXAS promoter activities in vitro, suggesting that the core promoter is sufficient for transcriptional activity from a naked DNA template. In contrast, mutation of both elements drastically decreased the promoter activity in vivo. Furthermore, TXAS proximal promoter containing the nucleotides -90 to -56 relative to the transcriptional start site was necessary for promoter transactivation in vivo. Transcriptional activities from 5'-deletion mutants indicated that the effects of the nucleotides -90/-56 were more pronounced in stably transfected cells (a 150-fold difference) than in the transiently transfected cells (an 8-fold difference), reflecting the effects of TXAS transcriptional activation from replicating and nonreplicating DNA templates. Partial micrococcal nuclease digestion indicated that the sequence -90/-56, where the NF-E2 site is located, is associated with alterations of nucleosomal structure at the regions of promoter and reporter gene but not the region further downstream. Mutagenesis and forced expression studies demonstrated a critical role of p45 NF-E2 in controlling TXAS expression under native chromatin conditions. Band shifting and chromatin immunoprecipitation assays indicated that p45 NF-E2 was bound to the TXAS promoter in vitro and in vivo. Indirect end labeling and ligation-mediated PCR analyses further demonstrated that the occupation of TXAS promoter NF-E2 site was associated with disruption of nucleosomal structure. Collectively, these results indicate that binding of NF-E2 is critical both for alteration of the nucleosomal structure and for activation of the TXAS promoter, whereas the TATA and initiator elements are essential for transcription.	Univ Texas, Div Hematol, Dept Internal Med, Houston, TX 77030 USA	University of Texas System	Wang, LH (corresponding author), Univ Texas, Div Hematol, Dept Internal Med, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060625] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60625] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Carey M, 2000, TRANSCRIPTIONAL REGU; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Forsberg EC, 1999, J BIOL CHEM, V274, P26850, DOI 10.1074/jbc.274.38.26850; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gong QH, 1996, MOL CELL BIOL, V16, P6055; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lee KD, 1996, BIOCHEM J, V319, P783, DOI 10.1042/bj3190783; LEE KD, 1994, BIOCHEM BIOPH RES CO, V201, P379, DOI 10.1006/bbrc.1994.1712; LEWIS BA, 1995, J BIOL CHEM, V270, P28139; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MEHTA JL, 1988, P NATL ACAD SCI USA, V85, P4511, DOI 10.1073/pnas.85.12.4511; MIYATA A, 1994, EUR J BIOCHEM, V224, P273, DOI 10.1111/j.1432-1033.1994.00273.x; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; NEEDLEMAN P, 1977, SCIENCE, V195, P409, DOI 10.1126/science.831285; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NUSING R, 1990, EICOSANOIDS, V3, P175; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OHASHI K, 1992, J BIOL CHEM, V267, P789; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Pao CI, 1996, J BIOL CHEM, V271, P8667, DOI 10.1074/jbc.271.15.8667; REMUZZI G, 1985, J CLIN INVEST, V75, P94, DOI 10.1172/JCI111703; SALZER WL, 1990, J CLIN INVEST, V85, P1135, DOI 10.1172/JCI114545; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Schubeler D, 2000, GENE DEV, V14, P940; SHEN RF, 1994, GENE, V140, P261, DOI 10.1016/0378-1119(94)90555-X; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Tazawa R, 1996, ARCH BIOCHEM BIOPHYS, V334, P349, DOI 10.1006/abbi.1996.0464; TONE Y, 1994, FEBS LETT, V340, P241, DOI 10.1016/0014-5793(94)80146-0; ULLRICH V, 1990, STROKE, V21, P134; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WANG LH, 1991, BIOCHEM BIOPH RES CO, V177, P286, DOI 10.1016/0006-291X(91)91980-Q; WANG LH, 1994, ARCH BIOCHEM BIOPHYS, V315, P273, DOI 10.1006/abbi.1994.1500; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; Zhang LQ, 1997, GENOMICS, V45, P519, DOI 10.1006/geno.1997.4982; ZHANG LQ, 1993, BIOCHEM BIOPH RES CO, V194, P741, DOI 10.1006/bbrc.1993.1884; Zucker TP, 1998, CIRCULATION, V97, P589	67	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22497	22508		10.1074/jbc.M111058200	http://dx.doi.org/10.1074/jbc.M111058200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956185	hybrid			2022-12-27	WOS:000176313600052
J	Fruton, JS				Fruton, JS			The first years of the journal of biological chemistry.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Yale Univ, Sch Med, Hist Lab, New Haven, CT 06520 USA	Yale University	Fruton, JS (corresponding author), Yale Univ, Sch Med, Hist Lab, 333 Cedar St, New Haven, CT 06520 USA.							ABEL JJ, 1891, ARCH PHYSL, P236; AMSTERDAMSKA O, 1998, MOL BIOL MED NEW PRA, P47; CLARKE HT, 1952, J CHEM SOC, P3319, DOI 10.1039/jr9520003319; CORNER GW, 1964, HIST ROCKEFELLER I M, P554; Dakin HD, 1922, OXIDATIONS REDUCTION; DALE HH, 1939, OBITUARY NOTICES FEL, V2, P577; Edsall J T, 1985, Hist Philos Life Sci, V7, P105; EDSALL JT, 1980, J BIOL CHEM, V255, P8939; Ehrlichs P, 1904, HOPPESEYLERS Z PHYSL, V41, P379; HARTLEY P, 1952, OBIT NOT FELL ROY SO, V8, P129; Hastings A B, 1976, Biogr Mem Natl Acad Sci, V48, P309; HAWTHORNE RM, 1983, PERSPECT BIOL MED, V26, P553; HAWTHORNE RM, 1974, PERSPECT BIOL MED, V18, P24; Herter CA, 1905, J EXP MED, V7, P79, DOI 10.1084/jem.7.1.79; MURNAGHAN JH, 1967, PERSPECT BIOL MED, V10, P334; PETERS JP, 1946, QUANTITATIVE CLIN CH, V1; PETERS JP, 1943, QUANTITATIVE CLIN CH, V2; RICHARDS A N, 1956, Fed Proc, V15, P803; Schmidt C F, 1971, Biogr Mem Natl Acad Sci, V42, P271; VOEGTLIN CARL, 1939, JOUR PHARMACOL AND EXP THERAP, V67, P373; WILLIAMS OT, 1911, BIOCHEM J, V5, pR21	21	0	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20113	20116		10.1074/jbc.R200004200	http://dx.doi.org/10.1074/jbc.R200004200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11960998	hybrid			2022-12-27	WOS:000176204500001
J	Kavurma, MM; Bobryshev, Y; Khachigian, LM				Kavurma, MM; Bobryshev, Y; Khachigian, LM			RETRACTED: Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1 (Retracted Article. See vol 285, pg 21902, 2010)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							HUMAN ATHEROSCLEROTIC LESIONS; SMOOTH-MUSCLE-CELLS; T-CELLS; APOPTOSIS; ACTIVATION; EXPRESSION; PROMOTER; FAMILY; DEATH; PROTEINS	The FasL/Fas system has been implicated in smooth muscle cell apoptosis and atherosclerotic plaque instability, a process that can lead to plaque rupture, precipitating myocardial infarction and sudden death. The transcriptional mechanisms regulating FasL gene expression in vascular smooth muscle cells are poorly understood. We recently described a novel mechanism mediating inducible FasL gene expression in smooth muscle cells involving the zinc finger transcription factor Sp1 (Kavurma, M. M., Santiago, F. S., Bofocco, E., and Khachigian, L. M. (2001) J. Biol. Chem. 276, 4964-4971). We now show that FasL gene expression is governed by cooperative activation between Sp1 and the Ets family of transcription factors. The overexpression. of Ets-1 was sufficient to induce FasL promoter-dependent expression and protein synthesis. Ets-1 activation of the promoter was abrogated either by deletion or mutation of the Sp1 binding site. The overexpression of Ets-1 together with Sp1 produced cooperative activation of the Fas1, promoter. Sp1 induction of the FasL promoter was abrogated by an Ets-1 mutant lacking the activation domain. Conversely, Ets-1 activation of the promoter was blocked by an Sp1 mutant bearing the DNA-binding domain. The mutation of the (-365)GGAA(-362) element in the FasL promoter abolished Ets-1 activation and attenuated Sp1-inducible gene expression. Immunoprecipitation and supershift experiments revealed that endogenous Ets-1 and Sp1 physically interact and co-occupy this site. Thus, FasL gene expression in vascular smooth muscle cells is mediated by cooperativity between Ets-1 and Sp1.	Univ New S Wales, Ctr Thrombosis & Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia; Univ New S Wales, St Vincents Hosp, Surg Profess Unit, Sydney, NSW 2052, Australia	University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Thrombosis & Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020; Bobryshev, Yuri/J-2838-2013	Khachigian, Levon/0000-0003-3446-0323				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Bauriedel G, 1999, CARDIOVASC RES, V41, P480, DOI 10.1016/S0008-6363(98)00318-6; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Cai WJ, 1997, ATHEROSCLEROSIS, V131, P177, DOI 10.1016/S0021-9150(97)06099-1; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Geng YJ, 1998, CIRCULATION, V98, P48; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	29	55	58	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36244	36252		10.1074/jbc.M200463200	http://dx.doi.org/10.1074/jbc.M200463200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	11970950	hybrid			2022-12-27	WOS:000178275100060
J	Kovacs, M; Malnasi-Csizmadia, A; Woolley, RJ; Bagshaw, CR				Kovacs, M; Malnasi-Csizmadia, A; Woolley, RJ; Bagshaw, CR			Analysis of nucleotide binding to Dictyostelium myosin II motor domains containing a single tryptophan near the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; SMOOTH-MUSCLE MYOSIN; DISCOIDEUM MYOSIN; CONFORMATIONAL-CHANGES; RELAY LOOP; SUBFRAGMENT-1; RESIDUE; ATP; TRANSITION; RESOLUTION	Dictyostelium myosin II motor domain constructs containing a single tryptophan residue near the active sites were prepared in order to characterize the process of nucleotide binding. Tryptophan was introduced at positions 113 and 131, which correspond to those naturally present in vertebrate skeletal muscle myosin, as well as position 129 that is also close to the adenine binding site. Nucleotide (ATP and ADP) binding was accompanied by a large quench in protein fluorescence in the case of the tryptophans at 129 and 131 but a small enhancement for that at 113. None of these residues was sensitive to the subsequent open-closed transition that is coupled to hydrolysis (i.e. ADP and ATP induced similar fluorescence changes). The kinetics of the fluorescence change with the F129W mutant revealed at least a three-step nucleotide binding mechanism, together with formation of a weakly competitive off-line intermediate that may represent a nonproductive mode of nucleotide binding. Overall, we conclude that the local and global conformational changes in myosin IIs induced by nucleotide binding are similar in myosins from different species, but the sign and magnitude of the tryptophan fluorescence changes reflect nonconserved residues in the immediate vicinity of each tryptophan. The nucleotide binding process is at least three-step, involving conformational changes that are quite distinct from the open-closed transition sensed by the tryptophan Trp(501) in the relay loop.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	University of Leicester; Eotvos Lorand University	Bagshaw, CR (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	crb5@le.ac.uk	Kovacs, Mihaly/A-6841-2011; Bagshaw, Clive R./L-5484-2019; Csizmadia, András Málnási/K-7632-2018	Bagshaw, Clive R./0000-0002-5396-153X; Csizmadia, András Málnási/0000-0002-2430-8398; Kovacs, Mihaly/0000-0002-1200-4741				BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 2000, SINGLE MOL, V1, P269; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Kovacs M, 2002, BIOPHYS J, V82, p407A; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MILLAR NC, 1988, BIOCHEM J, V249, P735, DOI 10.1042/bj2490735; Onishi H, 2000, P NATL ACAD SCI USA, V97, P11203, DOI 10.1073/pnas.200362897; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sellers J. R., 1999, MYOSINS; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; WALMSLEY AR, 1989, ANAL BIOCHEM, V176, P313, DOI 10.1016/0003-2697(89)90315-1; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l	27	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28459	28467		10.1074/jbc.M202180200	http://dx.doi.org/10.1074/jbc.M202180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11971905	hybrid			2022-12-27	WOS:000177342600016
J	Doring, F; Wischmeyer, E; Kuhnlein, RP; Jackle, H; Karschin, A				Doring, F; Wischmeyer, E; Kuhnlein, RP; Jackle, H; Karschin, A			Inwardly rectifying K+ (Kir) channels in Drosophila - A crucial role of cellular milieu factors for Kir channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; EXPRESSION; GENE; ENCODES; CLONING; SUBUNITS; RECEPTOR; BARTTER; SHAKER	Three cDNAs encoding inwardly rectifying potassium (Kir) channels were isolated from Drosophila melanogaster. The protein sequences of Drosophila KirI (dKirI) and dKirII are moderately (<44%) and dKirIII sequence is weakly (<27%) identical to human Kir channel subunits. During fly development, five dKir channel transcripts derived from three genes are differentially expressed. Whole mount in situ hybridizations revealed dKirI transcripts absent from embryos, but dKirII and dKirIII are expressed in the embryonic hind gut and in Malpighian tubules, respectively, thus covering the entire osmoregulatory system of the developing fly. In the head of adult flies, predominantly dKirII transcripts were detected. When expressed in Xenopus oocytes, dKir channel activity was only observed after amino acid substitutions in their cytosolic tails (e.g. exchange of a unique valine in the NH2 terminus). In contrast, heterologous expression of wild type dKirI and dYirII in Drosophila S2 cells readily evoked typical inwardly rectifying K+ currents, which were weakly sensitive to Ba2+. Thus, the specific milieu of insect cells provides a crucial cellular environment for proper function of dKir channels.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	University of Wurzburg; Max Planck Society	Doring, F (corresponding author), Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany.	fdoering@mail.uni-wuerzburg.de		Doring, Frank/0000-0003-1017-1498				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Derst C, 1998, J BIOL CHEM, V273, P23884, DOI 10.1074/jbc.273.37.23884; Doring F, 1998, J NEUROSCI, V18, P8625; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; Forsyth SE, 1997, FEBS LETT, V409, P277, DOI 10.1016/S0014-5793(97)00514-0; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ishii M, 1997, J NEUROSCI, V17, P7725; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; Karschin C, 1996, J NEUROSCI, V16, P3559; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; Kuhnlein RP, 1996, DEVELOPMENT, V122, P2215; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; METZLER M, 2001, EUR J NEUROSCI, V13, P477; Nakamura N, 1999, BIOCHEM J, V342, P329, DOI 10.1042/0264-6021:3420329; Nasonkin I, 1999, J BIOL CHEM, V274, P29420, DOI 10.1074/jbc.274.41.29420; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; Rodriguez-Soriano J, 1998, PEDIATR NEPHROL, V12, P315, DOI 10.1007/s004670050461; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Schmidt A, 1996, MOL GEN GENET, V251, P381, DOI 10.1007/BF02172530; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; SHEPHER RM, 2000, DIABETES ANN, V13, P43; Stobbart R.H., 1974, P361; Takashima S, 2001, MECH DEVELOP, V101, P79, DOI 10.1016/S0925-4773(00)00555-4; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	41	43	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25554	25561		10.1074/jbc.M202385200	http://dx.doi.org/10.1074/jbc.M202385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964404	hybrid, Green Submitted			2022-12-27	WOS:000176747000092
J	Fusetti, F; von Moeller, H; Houston, D; Rozeboom, HJ; Dijkstra, BW; Boot, RG; Aerts, JMFG; van Aalten, DMF				Fusetti, F; von Moeller, H; Houston, D; Rozeboom, HJ; Dijkstra, BW; Boot, RG; Aerts, JMFG; van Aalten, DMF			Structure of human chitotriosidase - Implications for specific inhibitor design and function of mammalian chitinase-like lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; X-RAY STRUCTURE; SERRATIA-MARCESCENS; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; ALLOSAMIDIN; PROTEIN; RESOLUTION; FAMILY; IDENTIFICATION	Chitin hydrolases have been identified in a variety of organisms ranging from bacteria to eukaryotes. They have been proposed to be possible targets for the design of novel chemotherapeutics against human pathogens such as fungi and protozoan parasites as mammals were not thought to possess chitin-processing enzymes. Recently, a human chitotriosidase was described as a marker for Gaucher disease with plasma levels of the enzyme elevated up to 2 orders of magnitude. The chitotriosidase was shown to be active against colloidal chitin and is inhibited by the family 18 chitinase inhibitor allosamidin. Here, the crystal structure of the human chitotriosidase and complexes with a chitooligosaccharide and allosamidin are described. The structures reveal an elongated active site cleft, compatible with the binding of long chitin polymers, and explain the inactivation of the enzyme through an inherited genetic deficiency. Comparison with YM1 and HCgp-39 shows how the chitinase has evolved into these mammalian lectins by the mutation of key residues in the active site, tuning the substrate binding specificity. The soaking experiments with allosamidin and chitooligosaccharides give insight into ligand binding properties and allow the evaluation of differential binding and design of species-selective chitinase inhibitors.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Dundee; University of Amsterdam; Academic Medical Center Amsterdam	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk	Dijkstra, Bauke W./H-4308-2019; Aerts, Johannes/A-1028-2009	Dijkstra, Bauke W./0000-0001-9731-6586; Aerts, Johannes/0000-0001-8168-2565; Rozeboom, Henriette/0000-0002-1656-6477; Houston, Douglas/0000-0002-3469-1546; van Aalten, Daan/0000-0002-1499-6908; Boot, Rolf/0000-0002-7031-3390				BARRANGER JA, 1988, GLUCOSYLCERAMIDE LIP, P1677; Blattner R, 1997, PESTIC SCI, V50, P312, DOI 10.1002/(SICI)1096-9063(199708)50:4&lt;312::AID-PS594&gt;3.0.CO;2-O; Bokma E, 2000, FEBS LETT, V478, P119, DOI 10.1016/S0014-5793(00)01833-0; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Choi EH, 2001, GENES IMMUN, V2, P248, DOI 10.1038/sj.gene.6363767; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HAWTIN RE, 1995, VIROLOGY, V212, P673, DOI 10.1006/viro.1995.1525; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Izumida H, 1996, J ANTIBIOT, V49, P76, DOI 10.7164/antibiotics.49.76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIMOTO Y, 1991, J ANTIBIOT, V44, P716, DOI 10.7164/antibiotics.44.716; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; SAKUDA S, 1987, J ANTIBIOT, V40, P296, DOI 10.7164/antibiotics.40.296; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Sami L, 2001, J GEN APPL MICROBIOL, V47, P201, DOI 10.2323/jgam.47.201; Spindler-Barth M, 1998, PESTIC SCI, V52, P47, DOI 10.1002/(SICI)1096-9063(199801)52:1&lt;47::AID-PS672&gt;3.0.CO;2-Y; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	43	176	187	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25537	25544		10.1074/jbc.M201636200	http://dx.doi.org/10.1074/jbc.M201636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960986	Green Published, hybrid			2022-12-27	WOS:000176747000090
J	Marella, M; Lehmann, S; Grassi, J; Chabry, J				Marella, M; Lehmann, S; Grassi, J; Chabry, J			Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; MONOCLONAL-ANTIBODIES; CHOLERA-TOXIN; NORMAL BRAIN; SURFACE; DOMAINS; ISOFORM; CELLS; CAVEOLAE; RECEPTOR	Conversion of the normal membrane-bound prion protein (PrP-sen) to its pathological isoform (PrP-res) is a key event in the pathogenesis of transmissible spongiform encephalopathies. Although the subcellular sites of conversion are poorly characterized, several lines of evidence have suggested the involvement of membrane lipid rafts in the conversion process. Here we report that copper stimulates the endocytosis of PrP-sen via a caveolin-dependent pathway in both microglia and neuroblastoma cells. We show that the polyene antibiotic filipin both limits endocytosis of PrP-sen and dramatically reduces the amount of membrane-bound PrP-sen. This reduction results from a rapid and massive release of full matured PrP-sen into the culture medium. Finally, we demonstrate that filipin is a potent inhibitor of PrP-res formation into chronically infected neuroblastoma cells. Our results reinforce the role of rafts in PrP trafficking and raise the possibility that the release of PrP-sen from the plasma membrane decreases the amount of available substrate PrP-sen at the conversion sites.	CNRS, IPMC, Unite Mixte Rech 6097, F-06560 Valbonne, France; CNRS, Inst Genet Humaine, F-34396 Montpellier, France; CEA, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CEA; UDICE-French Research Universities; Universite Paris Saclay	Chabry, J (corresponding author), CNRS, IPMC, Unite Mixte Rech 6097, 660 Route Lucioles, F-06560 Valbonne, France.		Lehmann, Sylvain/P-1301-2017; Chabry, Joelle/O-2101-2016	Lehmann, Sylvain/0000-0001-6117-562X; 				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Demaimay R, 1997, J VIROL, V71, P9685, DOI 10.1128/JVI.71.12.9685-9689.1997; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; HOLZ RW, 1974, ANN NY ACAD SCI, V235, P469, DOI 10.1111/j.1749-6632.1974.tb43284.x; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KARDOS J, 1989, NEUROSCI LETT, V103, P139, DOI 10.1016/0304-3940(89)90565-X; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; Koo EH, 1996, J CELL SCI, V109, P991; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Lansbury PT, 1996, CURR BIOL, V6, P914, DOI 10.1016/S0960-9822(02)00624-3; Lehmann S, 1999, BIOMED PHARMACOTHER, V53, P39, DOI 10.1016/S0753-3322(99)80059-6; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mange A, 2000, J VIROL, V74, P3135, DOI 10.1128/JVI.74.7.3135-3140.2000; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; UKKONEN P, 1986, J EXP MED, V163, P952, DOI 10.1084/jem.163.4.952; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	50	118	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25457	25464		10.1074/jbc.M203248200	http://dx.doi.org/10.1074/jbc.M203248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994310	hybrid			2022-12-27	WOS:000176747000080
J	Russwurm, M; Mergia, E; Mullershausen, F; Koesling, D				Russwurm, M; Mergia, E; Mullershausen, F; Koesling, D			Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ADENYLYL-CYCLASE; HEME; ACTIVATION; COMPLEX; DISSOCIATION; MECHANISM; BINDING; ENZYME; SYSTEM	Many of the physiological effects of the signaling molecule nitric oxide are mediated by the stimulation of the NO-sensitive guanylyl cyclase. Activation of the enzyme is achieved by binding of NO to the prosthetic heme group of the enzyme and the initiation of conformational changes. So far, the rate of NO dissociation of the purified enzyme has only been determined spectrophotometrically, whereas the respective deactivation, i.e. the decline in enzymatic activity, has only been determined in cytosolic fractions and intact cells. Here, we report on the deactivation of purified NO-sensitive guanylyl cyclase determined after addition of the NO scavenger oxyhemoglobin or dilution. The deactivation rate corresponded to a half-life of the NO/guanylyl cyclase complex of similar to4 s, which is in good agreement with the spectrophotometrically measured NO dissociation rate of the enzyme. The deactivation rate of the enzyme determined in platelets yielded a much shorter half-life indicating either partial damage of the enzyme during the purification procedure or the existence of endogenous deactivation accelerating factors. YC-1, a component causing sensitization of guanylyl cyclase toward NO, inhibited deactivation of guanylyl cyclase, resulting in an extremely prolonged half-life of the NO/guanylyl cyclase complex of more than 10 min. The deactivation of an ATP-utilizing guanylyl cyclase mutant was almost unaffected by YC-1, indicating the existence of a special structure within the catalytic domain required for YC-1 binding or for the transduction of the YC-1 effect. In contrast to the wild type enzyme, YC-1 did not increase NO sensitivity of this mutant, clearly establishing inhibition of deactivation as the underlying mechanism of the NO sensitizer YC-1.	Ruhr Univ Bochum, Fak Med MA N1, D-44780 Bochum, Germany	Ruhr University Bochum	Koesling, D (corresponding author), Ruhr Univ Bochum, Fak Med MA N1, D-44780 Bochum, Germany.							BELLAMY TC, 2000, J BIOL CHEM, V9, P4287; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; Dierks EA, 1998, ARCH BIOCHEM BIOPHYS, V351, P1, DOI 10.1006/abbi.1997.0408; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1998, MOL PHARMACOL, V54, P962, DOI 10.1124/mol.54.6.962; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Margulis A, 2000, BIOCHEMISTRY-US, V39, P1034, DOI 10.1021/bi992040p; MONCADA S, 1991, P NATL ACAD SCI USA, V88, P2166, DOI 10.1073/pnas.88.6.2166; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	27	65	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24883	24888		10.1074/jbc.M110570200	http://dx.doi.org/10.1074/jbc.M110570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978784	hybrid			2022-12-27	WOS:000176747000009
J	Diakos, C; Prieschl, EE; Saemann, M; Novotny, V; Bohmig, G; Csonga, R; Baumruker, T; Zlabinger, GJ				Diakos, C; Prieschl, EE; Saemann, M; Novotny, V; Bohmig, G; Csonga, R; Baumruker, T; Zlabinger, GJ			Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPORESPONSIVENESS IN-VITRO; SIGNAL-TRANSDUCTION; SODIUM-BUTYRATE; TRANSCRIPTION FACTORS; FATTY-ACIDS; PATHWAYS; NFAT; SUPPRESSION; INHIBITION; EXPRESSION	The transcription factor nuclear factor of activated T-cells (NF-AT) plays an essential role in the activation of many early immune response genes. A dynamic equilibrium between calcineurin and cellular kinases controls its phosphorylation and thus regulates its activity by determining its subcellular localization. Here, we demonstrate that T-cell activation in the presence of the bacterial metabolite n-butyrate, which leads to inhibition of interleukin-2 transcription, is characterized by the maintenance of the activity of counter-regulatory kinases glycogen synthase kinase 3 and protein kinase A as well as persistence of intracellular cAMP levels, whereas calcium response and mitogen-activated protein kinase activation were indistinguishable from cells stimulated in the absence of n-butyrate. Nuclear binding of NF-AT was decreased but other transcription factors implicated in interleukin-2 expression such as AP1 and nuclear factor kappaB were unaffected. The effect on NF-AT binding appeared to be the result of increased nuclear export because the export inhibitor leptomycin B completely restored nuclear binding of NF-AT. We, therefore, provide first evidence for interference with NF-AT regulation alternative to the currently understood inhibition of nuclear import. This mechanism might represent a bacterial strategy to subvert host defense, which could be of particular clinical importance in the gastrointestinal tract where high amounts of n-butyrate are physiologically present.	Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Univ Vienna, Div Nephrol, Dept Internal Med 3, A-1090 Vienna, Austria; Novartis Res Inst, Dept Allerg Dis, A-1235 Vienna, Austria	University of Vienna; University of Vienna; Novartis	Zlabinger, GJ (corresponding author), Univ Vienna, Inst Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	gerhard.zlabinger@univie.ac.at		Zlabinger, Gerhard/0000-0002-7478-4173				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70, DOI 10.1177/014860719902300518; Archer S, 1998, SURGERY, V124, P248, DOI 10.1067/msy.1998.90567; AUGUST A, 1995, TISSUE ANTIGENS, V46, P155, DOI 10.1111/j.1399-0039.1995.tb03114.x; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; Berridge MJ, 1997, CRIT REV IMMUNOL, V17, P155, DOI 10.1615/CritRevImmunol.v17.i2.30; BOHMIG GA, 1995, TRANSPLANTATION, V59, P1500, DOI 10.1097/00007890-199505270-00029; Bohmig GA, 1999, TRANSPL IMMUNOL, V7, P221, DOI 10.1016/S0966-3274(99)80006-9; BOHMIG GA, 1996, TRANSPLANT INT S1, V9, P318; Brodsky FM, 1999, IMMUNOL REV, V168, P5, DOI 10.1111/j.1600-065X.1999.tb01278.x; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chapman MA, 2001, ANN ROY COLL SURG, V83, P75; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Coradini D, 2000, CELL PROLIFERAT, V33, P139, DOI 10.1046/j.1365-2184.2000.00173.x; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; FOSS FM, 1989, ONCOGENE RES, V5, P13; Gilbert KM, 2000, J PHARMACOL EXP THER, V294, P1146; GILBERT KM, 1993, J IMMUNOL, V151, P1245; HENGEL H, 1991, J IMMUNOL, V147, P1115; HERZ F, 1983, BIOCHIM BIOPHYS ACTA, V762, P289, DOI 10.1016/0167-4889(83)90083-6; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LEGROS GS, 1985, LYMPHOKINE RES, V4, P221; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; PALIOGIANNI F, 1993, J EXP MED, V178, P1813, DOI 10.1084/jem.178.5.1813; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ramstad C, 2000, CELL SIGNAL, V12, P557, DOI 10.1016/S0898-6568(00)00097-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saemann MD, 2000, TRANSPLANTATION, V70, P1215; Saemann MD, 2000, FASEB J, V14, P2380; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; SUTHANTHIRAN M, 1982, TRANSPLANTATION, V33, P534, DOI 10.1097/00007890-198205000-00014; TAMIR A, 1994, J IMMUNOL, V152, P3391; Tsuruta L, 1995, J ALLERGY CLIN IMMUN, V96, P1126, DOI 10.1016/S0091-6749(95)70197-4; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Waclavicek M, 1998, J IMMUNOL, V161, P4671; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	50	24	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24243	24251		10.1074/jbc.M200191200	http://dx.doi.org/10.1074/jbc.M200191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983691	hybrid			2022-12-27	WOS:000176611800036
J	Ebert, DH; Deussing, J; Peters, C; Dermody, TS				Ebert, DH; Deussing, J; Peters, C; Dermody, TS			Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSID PROTEIN SIGMA-3; INFECTIOUS SUBVIRION PARTICLES; VIRAL ATTACHMENT PROTEIN; DISTINCT BINDING-SITES; DOUBLE-STRANDED-RNA; MOUSE L-CELLS; PERSISTENT INFECTIONS; MAMMALIAN REOVIRUSES; CHROMIUM RELEASE; SIALIC-ACID	After attachment to receptors, reovirus virions are internalized by endocytosis and exposed to acid-dependent proteases that catalyze viral disassembly. Previous studies using the cysteine protease inhibitor E64 and a mutant cell line that does not support reovirus disassembly suggest a requirement for specific endocytic proteases in reovirus entry. This study identifies the endocytic proteases that mediate reovirus disassembly in murine fibroblast cells. Infection of both L929 cells treated with the cathepsin L inhibitor Z-Phe-Tyr(t-Bu)-diazomethyl ketone and cathepsin L-deficient mouse embryo fibroblasts resulted in inefficient proteolytic disassembly of viral outer-capsid proteins and decreased viral yields. In contrast, both L929 cells treated with the cathepsin B inhibitor CA-074Me and cathepsin B-deficient mouse embryo fibroblasts support reovirus disassembly and growth. However, removal of both cathepsin B and cathepsin L activity completely abrogates disassembly and growth of reovirus. Concordantly, cathepsin L mediates reovirus disassembly more efficiently than cathepsin B in vitro. These results demonstrate that either cathepsin L or cathepsin B is required for reovirus entry into murine fibroblasts and indicate that cathepsin L is the primary mediator of reovirus disassembly. Moreover, these findings suggest that specific endocytic proteases can determine host cell susceptibility to infection by intracellular pathogens.	Vanderbilt Univ, Elizabeth B Lamb Ctr Pediat Res, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Sch Med, Nashville, TN 37232 USA; Univ Freiburg, Inst Mol Med & Zellforsch, D-79106 Freiburg, Germany	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Freiburg	Dermody, TS (corresponding author), Vanderbilt Univ, Elizabeth B Lamb Ctr Pediat Res, Sch Med, D7235 MCN, Nashville, TN 37232 USA.	terry.dermody@mcmail.vanderbilt.edu	Deussing, Jan M/ABB-5993-2021	Deussing, Jan/0000-0002-9329-5252	NIAID NIH HHS [R01 AI32539] Funding Source: Medline; NIGMS NIH HHS [T32 GM07347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSFALGMACHLEIDT I, 1992, BIOL CHEM H-S, V373, P433, DOI 10.1515/bchm3.1992.373.2.433; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barton ES, 2001, J BIOL CHEM, V276, P2200, DOI 10.1074/jbc.M004680200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; BORSA J, 1979, J GEN VIROL, V45, P161, DOI 10.1099/0022-1317-45-1-161; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Chandran K, 1998, J VIROL, V72, P467, DOI 10.1128/JVI.72.1.467-475.1998; CHANG CT, 1971, VIROLOGY, V46, P544, DOI 10.1016/0042-6822(71)90058-4; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Coombs KM, 1998, VIROLOGY, V243, P218, DOI 10.1006/viro.1998.9061; Dean R T, 1976, Essays Biochem, V12, P1; DERMODY TS, 1993, J VIROL, V67, P2055, DOI 10.1128/JVI.67.4.2055-2063.1993; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Ebert DH, 2001, J VIROL, V75, P3197, DOI 10.1128/JVI.75.7.3197-3206.2001; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GENTSCH JR, 1985, J VIROL, V56, P356, DOI 10.1128/JVI.56.2.356-364.1985; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Hooper JW, 1996, J VIROL, V70, P672, DOI 10.1128/JVI.70.1.672-677.1996; Hooper JW, 1996, J VIROL, V70, P459, DOI 10.1128/JVI.70.1.459-467.1996; Jane-Valbuena J, 1999, J VIROL, V73, P2963; JAYASURIYA AK, 1988, VIROLOGY, V163, P591, DOI 10.1016/0042-6822(88)90300-5; KEDL R, 1995, J VIROL, V69, P552, DOI 10.1128/JVI.69.1.552-559.1995; Kothandaraman S, 1998, VIROLOGY, V251, P264, DOI 10.1006/viro.1998.9434; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PWK, 1981, VIROLOGY, V108, P134, DOI 10.1016/0042-6822(81)90533-X; Liemann S, 2002, CELL, V108, P283, DOI 10.1016/S0092-8674(02)00612-8; LUCIAJANDRIS P, 1993, J VIROL, V67, P5339, DOI 10.1128/JVI.67.9.5339-5345.1993; MILLER JE, 1992, J VIROL, V66, P5347, DOI 10.1128/JVI.66.9.5347-5356.1992; Moin K, 2000, ADV EXP MED BIOL, V477, P391; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nason EL, 2001, J VIROL, V75, P6625, DOI 10.1128/JVI.75.14.6625-6634.2001; NIBERT ML, 1995, J VIROL, V69, P5057, DOI 10.1128/JVI.69.8.5057-5067.1995; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Olland AM, 2001, EMBO J, V20, P979, DOI 10.1093/emboj/20.5.979; PACITTI AF, 1987, J VIROL, V61, P1407, DOI 10.1128/JVI.61.5.1407-1415.1987; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; ROTHE G, 1992, BIOL CHEM H-S, V373, P547, DOI 10.1515/bchm3.1992.373.2.547; RUBIN DH, 1992, MICROB PATHOGENESIS, V12, P351, DOI 10.1016/0882-4010(92)90098-9; SCHIFF LA, 1988, MOL CELL BIOL, V8, P273, DOI 10.1128/MCB.8.1.273; SELIGER LS, 1992, VIROLOGY, V187, P202, DOI 10.1016/0042-6822(92)90308-C; SHAW E, 1993, FEBS LETT, V334, P340, DOI 10.1016/0014-5793(93)80707-2; SILVERSTEIN SC, 1972, VIROLOGY, V47, P797, DOI 10.1016/0042-6822(72)90571-5; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; TOSTESON MT, 1993, P NATL ACAD SCI USA, V90, P10549, DOI 10.1073/pnas.90.22.10549; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; Wetzel JD, 1997, J VIROL, V71, P1362, DOI 10.1128/JVI.71.2.1362-1369.1997	59	202	211	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24609	24617		10.1074/jbc.M201107200	http://dx.doi.org/10.1074/jbc.M201107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986312	hybrid			2022-12-27	WOS:000176611800084
J	Liu, MM; Albanese, C; Anderson, CM; Hilty, K; Webb, P; Uht, RM; Price, RH; Pestell, RG; Kushner, PJ				Liu, MM; Albanese, C; Anderson, CM; Hilty, K; Webb, P; Uht, RM; Price, RH; Pestell, RG; Kushner, PJ			Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MAMMARY-GLAND DEVELOPMENT; PROSTATE-CANCER; ER-ALPHA; E-CDK2 ACTIVATION; KINASE-ACTIVITY; MICE; PROMOTER; TRANSCRIPTION; PROGRESSION	Induction of cyclin D1 gene transcription by estrogen receptor alpha (ERalpha) plays an important role in estrogen-mediated proliferation. There is no classical estrogen response element in the cyclin D1 promoter, and induction by ERalpha has been mapped to an alternative response element, a cyclic AMP-response element at -57, with possible participation of an activating protein-1 site at -954. The action of ERbeta at the cyclin D1 promoter is unknown, although evidence suggests that ERbeta may inhibit the proliferative action of ERalpha. We examined the response of cyclin D1 promoter constructs by luciferase assay and the response of the endogenous protein by Western blot in HeLa cells transiently expressing ERalpha, ERalphaK206A (a derivative that is superactive at alternative response elements), or ERbeta. In each case, ER activation at the cyclin D1 promoter is mediated by both the cyclic AMP-response element and the activating protein-1 site, which play partly redundant roles. The activation by ERbeta occurs only with antiestrogens. Estrogens, which activate cyclin D1 gene expression with ERa, inhibit expression with ERbeta. Strikingly, the presence of ERbeta completely inhibits cyclin D1 gene activation by estrogen and ERa or even by estrogen and the superactive ERaK206A. The observation of the opposing action and dominance of ERbeta over ERalpha in activation of cyclin D1 gene expression has implications for the postulated role of ERbeta as a modulator of the proliferative effects of estrogen.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94112 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine	Kushner, PJ (corresponding author), Univ Calif San Francisco, Dept Med, 2200 Post St,Rm C442, San Francisco, CA 94112 USA.	kushner@itsa.ucsf.edu		Anderson, Carol/0000-0002-0308-5447	NCI NIH HHS [R01 CA86072, R01 CA75503, R01 CA80210, R01 CA70896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075503, R01CA070896, R01CA086072, R01CA080210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Altucci L, 1996, ONCOGENE, V12, P2315; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; Dupont S, 2000, DEVELOPMENT, V127, P4277; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Frierson HF, 1996, MODERN PATHOL, V9, P725; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HERBER B, 1994, ONCOGENE, V9, P1295; Horvath LG, 2001, CANCER RES, V61, P5331; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Lukas J, 1996, MOL CELL BIOL, V16, P6917; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pasquali D, 2001, J CLIN ENDOCR METAB, V86, P2051, DOI 10.1210/jc.86.5.2051; Pelletier G, 2000, J CLIN ENDOCR METAB, V85, P4835, DOI 10.1210/jc.85.12.4835; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Prins GS, 2001, CANCER RES, V61, P6089; Risbridger G, 2001, DEV BIOL, V229, P432, DOI 10.1006/dbio.2000.9994; Roger P, 2001, CANCER RES, V61, P2537; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Signoretti S, 2001, AM J PATHOL, V159, P13, DOI 10.1016/S0002-9440(10)61666-5; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Sutherland RL, 1995, CIBA F SYMP, V191, P218; Tonetti DA, 1999, J MAMMARY GLAND BIOL, V4, P401, DOI 10.1023/A:1018722502034; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1998, MOL BASIS SEX HORMON, P121; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936	62	363	375	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24353	24360		10.1074/jbc.M201829200	http://dx.doi.org/10.1074/jbc.M201829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986316	hybrid			2022-12-27	WOS:000176611800051
J	Prajapati, S; Gaynor, RB				Prajapati, S; Gaynor, RB			Regulation of I kappa B kinase (IKK)gamma/NEMO function by IKK beta-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; TAX TRANSFORMING PROTEIN; DEFICIENT MICE; ACTIVATION; COMPLEX; GAMMA; SUBUNIT; ALPHA; RECRUITMENT; COMPONENT	The IkappaB kinase (IKK) complex includes the catalytic components IKKalpha and IKKbeta in addition to the scaffold protein IKKgamma/NEMO. Increases in the activity of the IKK complex result in the phosphorylation and subsequent degradation of IkappaB and the activation of the NF-kappaB pathway. Recent data indicate that the constitutive activation of the NF-kappaB pathway by the human T-cell lymphotrophic virus, type 1, Tax protein leads to enhanced phosphorylation of IKKgamma/NEMO by IKKbeta. To address further the significance of IKKbeta-mediated phosphorylation of IKKgamma/NEMO, we determined the sites in IKKgamma/NEMO that were phosphorylated by IKKbeta, and we assayed whether IKKgamma/NEMO phosphorylation was involved in modulating IKKbeta activity. IKKgamma/NEMO is rapidly phosphorylated following treatment of cells with stimuli such as tumor necrosis factor-alpha and interleukin-1 that activate the NF-kappaB pathway. By using both in vitro and in vivo assays, IKKbeta was found to phosphorylate IKKgamma/NEMO predominantly in its carboxyl terminus on serine residue 369 in addition to sites in the central region of this protein. Surprisingly, mutation of these carboxyl-terminal serine residues increased the ability of IKKgamma/NEMO to stimulate IKKbeta kinase activity. These results indicate that the differential phosphorylation of IKKgamma/NEMO by IKKbeta and perhaps other kinases may be important in regulating IKK activity.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	46	55	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24331	24339		10.1074/jbc.M201393200	http://dx.doi.org/10.1074/jbc.M201393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11971901	hybrid			2022-12-27	WOS:000176611800048
J	Tian, B; Lessan, K; Kahm, J; Kleidon, J; Henke, C				Tian, B; Lessan, K; Kahm, J; Kleidon, J; Henke, C			beta(1) integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3-kinase/Akt/protein kinase B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; GRANULATION-TISSUE; ENDOTHELIAL-CELLS; TYROSINE KINASES; LINKED KINASE; SHEAR-STRESS; APOPTOSIS; SURVIVAL	Integrins regulate cell viability through their interaction with the extracellular matrix. Integrins can sense mechanical forces arising from the matrix and convert these stimuli to chemical signals capable of modulating intracellular signal transduction. The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is a major regulator of cell survival. It is not known, however, whether integrins, acting as mechanoreceptors, regulate cell survival via the PI3K/Akt pathway. Here, we show that in response to a matrix-derived mechanical stimulus, beta(1) integrin regulated cell viability by regulating Akt activity in a PI3K-dependent fashion. To accomplish this, we employed fibroblasts cultured in collagen gels. During contraction of collagen matrices, fibroblasts underwent apoptosis. We demonstrate that ligation of beta(1) integrin with anti-beta(1) integrin antibodies protected fibroblasts from apoptosis. The nature of the survival signal activated by beta(1) integrin engagement with antibody was mediated by PI3K acting through Akt/protein kinase B. We show that Akt phosphorylation decreased during collagen contraction and that this decrease correlated precisely with the onset of fibroblast apoptosis. Fibroblasts transfected with constitutively active PI3H displayed increased Akt phosphorylation and were protected from anoikis and collagen gel contraction-induced apoptosis. Our data identify a novel role for beta(1) integrin in regulating fibroblast viability through a PI3K/Akt/protein kinase B signaling pathway in response to a matrix-derived mechanical stimulus.	Univ Minnesota, Dept Med, Div Pulm & Crit Care, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Henke, C (corresponding author), Univ Minnesota, Dept Med, Div Pulm & Crit Care, FUMC Box 276,420 Delaware St SE, Minneapolis, MN 55455 USA.	henke002@tc.umn.edu			NHLBI NIH HHS [P50 HL50152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Crouch DH, 1996, ONCOGENE, V12, P2689; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DARBY I, 1990, LAB INVEST, V63, P21; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Grinnell F, 1999, CURR TOPICS PATHOL, V93, P61; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Henke C, 1996, AM J PATHOL, V149, P1639; Henke CA, 1996, J CLIN INVEST, V97, P2541, DOI 10.1172/JCI118702; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NAKAGAWA S, 1989, J INVEST DERMATOL, V93, P792, DOI 10.1111/1523-1747.ep12284425; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; POLUNOVSKY VA, 1993, J CLIN INVEST, V92, P388, DOI 10.1172/JCI116578; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Wu CY, 1999, J CELL SCI, V112, P4485; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	46	135	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24667	24675		10.1074/jbc.M203565200	http://dx.doi.org/10.1074/jbc.M203565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986332	hybrid			2022-12-27	WOS:000176611800092
J	Wang, Z; Wilson, GF; Griffith, LC				Wang, Z; Wilson, GF; Griffith, LC			Calcium/calmodulin-dependent protein kinase II phosphorylates and regulates the Drosophila Eag potassium channel.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS; CURRENTS; MELANOGASTER; SUBUNIT; MUSCLE; FAMILY; LOCUS; GENES	Modulation of neuronal excitability is believed to be an important mechanism of plasticity in the nervous system. Calcium/calmodulin-dependent protein kinase 11 (CaMKII) has been postulated to regulate the ether et go-go (eag) potassium channel in Drosophila. Inhibition of CaMKII and mutation of the eag gene both cause hyperexcitability at the larval neuromuscular junction (NMJ) and memory formation defects in the adult. In this study, we identify a single site, threonine 787, as the major CaMKII phosphorylation site in Eag. This site can be phosphorylated by CaMKII both in a heterologous cell system and in vivo at the larval NMJ. Expression of Eag in Xenopus oocytes was used to assess the function of phosphorylation. Injection of either a specific CaMKII inhibitor peptide or lavendustin C, another CaMKII inhibitor, reduced Eag current amplitude acutely. Mutation of threonine 787 to alanine also reduced amplitude. Moreover, both CaMKII inhibition and the alanine mutation accelerated inactivation. The reduction in current amplitudes and the accelerated inactivation of dephosphorylated Eag channels would result in decreased outward potassium currents and hyperexcitability at presynaptic terminals and, thus, are consistent with the NMJ phenotype observed when CaMKII is inhibited. These results show that Eag is a substrate of CaMKII and suggest that direct modulation of potassium channels may be an important function of this kinase.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	Brandeis University; Brandeis University; University of Michigan System; University of Michigan	Griffith, LC (corresponding author), Brandeis Univ, Dept Biol, MS008,415 South St, Waltham, MA 02454 USA.	griffith@brandeis.edu		Wang, Zheng/0000-0001-7678-0072; Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062648] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54408, R01 GM054408] Funding Source: Medline; NIMH NIH HHS [MH62648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cowan T.M., 1984, Journal of Neurogenetics, V1, P333, DOI 10.3109/01677068409107095; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DRYSDALE R, 1991, GENETICS, V127, P497; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARLOW F, 1988, ANTIBODIES LAB MANUA; Jin R, 1998, J NEUROSCI, V18, P8955; KAPLAN WD, 1969, GENETICS, V61, P399; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McCulloch RI, 2001, BIOCHEMISTRY-US, V40, P7273, DOI 10.1021/bi010546d; Moore DD, 1995, GLOB MOB SURV; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PARK D, 2002, IN PRESS J NEUROBIO; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SINGH S, 1990, J EXP BIOL, V152, P59; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang Z, 1998, J NEUROCHEM, V71, P378; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wilson GF, 1998, J BIOL CHEM, V273, P6389, DOI 10.1074/jbc.273.11.6389; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	28	64	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24022	24029		10.1074/jbc.M201949200	http://dx.doi.org/10.1074/jbc.M201949200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11980904	hybrid			2022-12-27	WOS:000176611800009
J	Amir, RE; Iwai, K; Ciechanover, A				Amir, RE; Iwai, K; Ciechanover, A			The NEDD8 pathway is essential for SCF beta-TrCp-mediated ubiquitination and processing of the NF-kappa B precursor p105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-RICH REGION; COP9 SIGNALOSOME; P50 SUBUNIT; PROTEIN; LIGASE; CONJUGATION; IDENTIFICATION; DEGRADATION; E3; BINDING	The p50 subunit of NF-kappaB is generated by limited processing of the precursor p105. IkappaB kinase-mediated phosphorylation of the C-terminal domain of p105 recruits the SCFbeta-TrCP ubiquitin ligase, resulting in rapid ubiquitination and subsequent processing/degradation of p105. NEDD8 is known to activate SCF ligases following modification of their cullin component. Here we show that NEDDylation is required for conjugation and processing of p105 by SCFbeta-TrCP following phosphorylation of the molecule. In a crude extract, a dominant negative E2 enzyme, UBC12, inhibits both conjugation and processing of p105, and inhibition is alleviated by an excess of WT-UBC12. In a reconstituted cell-free system, ubiquitination of p105 was stimulated only in the presence of all three components of the NEDD8 pathway, El, E2, and NEDD8. A Cul-1 mutant that cannot be NEDDylated could not stimulate ubiquitination and processing of p105. Similar findings were observed also in cells. It should be noted that NEDDylation is required only for the stimulated but not for basal processing of p105. Although the mechanisms that underlie processing of p105 are largely obscure, it is clear that NEDDylation and the coordinated activity of SCFbeta-TrCP on both p105 and IkappaBalpha serve as an important regulatory mechanism controlling NF-kappaB activity.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Osaka Metropolitan University	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.		IWAI, KAZUHIRO/GSN-7385-2022; Ciechanover, Aaron J/C-9166-2017	Iwai, Kazuhiro/0000-0001-5620-5951				Betts JC, 1996, MOL CELL BIOL, V16, P6363; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Foo SY, 1999, TRENDS GENET, V15, P229; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; OSKA F, 1998, GENE DEV, V12, P2263; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	50	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23253	23259		10.1074/jbc.M200967200	http://dx.doi.org/10.1074/jbc.M200967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953428	hybrid			2022-12-27	WOS:000176475700022
J	Morris, MC; Gondeau, C; Tainer, JA; Divita, G				Morris, MC; Gondeau, C; Tainer, JA; Divita, G			Kinetic mechanism of activation of the Cdk2/cyclin A complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; INK4 INHIBITORS; CDK COMPLEX; SPECIFICITY	Eukaryotic cell cycle progression is controlled by the ordered action of cyclin-dependent kinases, activation of which occurs through the binding of the cyclin to the Cdk followed by phosphorylation of a conserved threonine in the T-loop of the Cdk by Cdk-activating kinase (CAK). Despite our understanding of the structural changes, which occur upon Cdk/cyclin formation and activation, little is known about the dynamics of the molecular events involved. We have characterized the mechanism of Cdk2/cyclin A complex formation and activation at the molecular and dynamic level by rapid kinetics and demonstrate here that it is a two-step process. The first step involves the rapid association between the PSTAIRE helix of Cdk2 and helices 3 and 5 of the cyclin to yield an intermediate complex in which the threonine in the T-loop is not accessible for phosphorylation. Additional contacts between the C-lobe of the Cdk and the N-terminal helix of the cyclin then induce the isomerization of the Cdk into a fully mature form by promoting the exposure of the T-loop for phosphorylation by CAK and the formation of the substrate binding site. This conformational change is selective for the cyclin partner.	The Scripps Res Inst, La Jolla, CA 92037 USA; Ctr Rech Biochim Macromol, Dept Biochem, UPR 1086 CNRS, F-34293 Montpellier, France	Scripps Research Institute; Universite de Montpellier	Divita, G (corresponding author), The Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gilles@scripps.edu	MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021; Tainer, John/GWQ-4878-2022	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728; Tainer, John/0000-0003-1659-2429				Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; ENDICOTT JA, 1994, PROTEIN ENG, V7, P243, DOI 10.1093/protein/7.2.243; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Goda T, 2001, J BIOL CHEM, V276, P15415, DOI 10.1074/jbc.M011101200; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris MC, 1998, BIOCHEMISTRY-US, V37, P14257, DOI 10.1021/bi980913u; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; PICHKAM KM, 1994, J MOL BIOL CELL, V5, P587; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0	21	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23847	23853		10.1074/jbc.M107890200	http://dx.doi.org/10.1074/jbc.M107890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959850	Green Published, hybrid			2022-12-27	WOS:000176475700098
J	Xu, WL; Gauss, P; Shen, JY; Dunn, CA; Bessman, MJ				Xu, WL; Gauss, P; Shen, JY; Dunn, CA; Bessman, MJ			The gene e.1 (nudE.1) of T4 bacteriophage designates a new member of the nudix hydrolase superfamily active on flavin adenine dinucleotide, adenosine 5 '-triphospho-5 '-adenosine, and ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUPINUS-ANGUSTIFOLIUS L; ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATASE; MUTT; PROTEINS; FAMILY; IDENTIFICATION; MECHANISM; ENZYMES; CLONING	The T4 bacteriophage gene e.1 was cloned into an expression vector and expressed in Escherichia coli, and the purified protein was identified as a Nudix hydrolase active on FAD, adenosine 5'-triphospho-5'-adenosine (Ap(3)A), and ADP-ribose. Typical of members of the Nudix hydrolases, the enzyme has an alkaline pH optimum (pH 8) and requires a divalent cation for activity that can be satisfied by Mg2+ or Mn2+. For all substrates, AMP is one of the products, and unlike most of the other enzymes active on Ap(3)A, the T4 enzyme hydrolyzes higher homologues including AP(4-6)A This is the first member of the Nudix hydrolase gene superfamily identified in bacterial viruses and the only one present in T4. Although the protein was predicted to be orthologous to E. coli MutT on the basis of a sequence homology search, the properties of the gene and of the purified protein do not support this notion because of the following. (a) The purified enzyme hydrolyzes substrates not acted upon by MutT, and it does not hydrolyze canonical MutT substrates. (b) The e.1 gene does not complement mutT1 in vivo. (c) The deletion of e.1 does not increase the spontaneous mutation frequency of T4 phage. The properties of the enzyme most closely resemble those of Orf186 of E. coli, the product of the nudE gene, and we therefore propose the mnemonic nudE.1 for the T4 phage orthologue.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, The McCollum Pratt Inst, Baltimore, MD 21218 USA; Western State Coll Colorado, Dept Biol, Gunnison, CO 81231 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM 18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; Jozwik Catherine E., 1994, P464; Kawabata T, 2000, GENE, V259, P223, DOI 10.1016/S0378-1119(00)00442-X; KUTTER E, 1994, MOL BIOL BACTERIOP T, V4, P406; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Sambrook J., 2001, MOL CLONING; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085	23	26	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23181	23185		10.1074/jbc.M203325200	http://dx.doi.org/10.1074/jbc.M203325200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976345	hybrid			2022-12-27	WOS:000176475700013
J	Wang, JX; Su, M; Fan, J; Seth, A; McCulloch, CA				Wang, JX; Su, M; Fan, J; Seth, A; McCulloch, CA			Transcriptional regulation of a contractile gene by mechanical forces applied through integrins in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-ACTIN; SERUM RESPONSE FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; C-FOS GENE; SMOOTH-MUSCLE; CARDIAC MYOCYTES; CARG ELEMENTS; IN-VITRO; PROMOTER; EXPRESSION	We examined mechanotranscriptional regulation of the contractile gene, alpha-smooth muscle actin (SMA), in osteoblastic cells. Tensile forces were applied through collagen-coated magnetite beads to ROS17/2.8 cells. These cells were desmin -, vimentin + and expressed low levels of SMA. After force application (480 piconewton/ cell), SMA protein and mRNA were increased but beta-actin was unchanged. Beads coated with bovine serum albumin or poly-L-lysine produced no change of SMA. In cells transiently transfected with plasmids containing the SMA promoter fused to beta-galactosidase or green fluorescent protein coding sequences, SMA promoter activity was increased by similar to60% after 4 h of force, whereas control (Rous sarcoma virus) promoter activity was unaffected. Transfections with beta-galactosidase or green fluorescent protein reporter constructs showed that force-loaded cells exhibited higher beta-galactosidase activity than cells without force. Cytochalasin D and latrunculin B inhibited force-induced increases of SMA promoter activity. Deletion analyses showed that SMA promoter activity was increased similar to70% after force with a minimal construct containing 155 bp upstream of the translation start site. The force effect on the SMA promoter was abrogated in cells transfected with CArG-B box mutants. Gel mobility shift analyses of nuclear extracts showed strong binding to the CArG-B motif after force. We conclude that the CArG-B box is a force-responsive element in the SMA promoter.	Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E8, Canada	University of Toronto	McCulloch, CA (corresponding author), Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Fac Dent, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E8, Canada.							AOYAGI T, 1993, J BIOL CHEM, V268, P27176; Arora PD, 1999, AM J PATHOL, V155, P2087, DOI 10.1016/S0002-9440(10)65527-7; AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Dugina V, 1998, EXP CELL RES, V238, P481, DOI 10.1006/excr.1997.3868; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; Glogauer M, 1998, PFLUG ARCH EUR J PHY, V435, P320; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GRONOWICZ GA, 1995, ENDOCRINOLOGY, V136, P598, DOI 10.1210/en.136.2.598; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; Kinner B, 2001, J ORTHOP RES, V19, P233, DOI 10.1016/S0736-0266(00)00081-4; Komuro I, 2000, JPN HEART J, V41, P117, DOI 10.1536/jhj.41.117; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; Menard C, 2000, BIOMATERIALS, V21, P1867, DOI 10.1016/S0142-9612(00)00062-4; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAKANO Y, 1991, GENE, V99, P285; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Wang J, 2001, TISSUE CELL, V33, P86, DOI 10.1054/tice.2000.0160; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776	39	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22889	22895		10.1074/jbc.M203130200	http://dx.doi.org/10.1074/jbc.M203130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953441	hybrid			2022-12-27	WOS:000176313600100
J	Wakasugi, K; Slike, BM; Hood, J; Ewalt, KL; Cheresh, DA; Schimmel, P				Wakasugi, K; Slike, BM; Hood, J; Ewalt, KL; Cheresh, DA; Schimmel, P			Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; HUMAN INTERLEUKIN-8 RECEPTOR; INDUCIBLE PROTEIN-10 IP-10; CELL LUNG-CANCER; CXC CHEMOKINES; GAMMA; BINDING; ANTAGONISTS; NEUTROPHILS; RESIDUES	The first step of protein synthesis is catalyzed by aminoacyl-tRNA synthetases. In addition, certain mammalian tRNA synthetases link protein synthesis to cytokine signaling pathways. In particular, human tyrosyl-tRNA synthetase (TyrRS) can be split by proteolysis into two fragments having distinct cytokine activities. One of the TyrRS fragments (mini TyrRS) contains features identical to those in CXC chemokines (like interleukin-8) that also act as angiogenic factors. Here mini TyrRS (but not full-length TyrRS) is shown to stimulate chemotaxis of endothelial cells in vitro and stimulate angiogenesis in each of two in vivo animal models. The angiogenic activity of mini TyrRS can be opposed by anti-angiogenic chemokines like IP-10. Thus, a biological fragment of human tyrosyl-tRNA synthetase links protein synthesis to regulation of angiogenesis.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu	Wakasugi, Keisuke/AAQ-1642-2020	Wakasugi, Keisuke/0000-0002-8408-5616	NATIONAL CANCER INSTITUTE [R01CA092577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NCI NIH HHS [CA92577] Funding Source: Medline; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Brooks PC, 1999, METH MOL B, V129, P257; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gasperini S, 1999, J IMMUNOL, V162, P4928; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Keane MP, 1997, J IMMUNOL, V159, P1437; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEE J, 1992, J BIOL CHEM, V267, P16283; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nicolaou KC, 1998, BIOORGAN MED CHEM, V6, P1185, DOI 10.1016/S0968-0896(98)00090-X; Norrby K, 1996, CELL PROLIFERAT, V29, P315, DOI 10.1111/j.1365-2184.1996.tb01583.x; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; STRIETER RM, 1992, AM J PATHOL, V141, P1279; TOLSTRUP AB, 1995, J BIOL CHEM, V270, P397, DOI 10.1074/jbc.270.1.397; Turpaev KT, 1996, EUR J BIOCHEM, V240, P732, DOI 10.1111/j.1432-1033.1996.0732h.x; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	34	103	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20124	20126		10.1074/jbc.C200126200	http://dx.doi.org/10.1074/jbc.C200126200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11956181	hybrid			2022-12-27	WOS:000176204500004
J	Sundaramoorthy, M; Meiyappan, M; Todd, P; Hudson, BG				Sundaramoorthy, M; Meiyappan, M; Todd, P; Hudson, BG			Crystal structure of NC1 domains - Structural basis for type IV collagen assembly in basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPORT SYNDROME; NONCOLLAGENOUS DOMAIN; MOLECULAR RECOGNITION; LENS CAPSULE; CHAIN; IDENTIFICATION; PROCOLLAGEN; GENE; SEQUENCE; NETWORK	Type IV collagen, which is present in all metazoan, exists as a family of six homologous alpha(IV) chains, alpha1-alpha6, in mammals. The six chains assemble into three different triple helical protomers and self-associate as three distinct networks. The network underlies all epithelia as a component of basement membranes, which play important roles in cell adhesion, growth, differentiation, tissue repair and molecular ultrafiltration. The specificity of both protomer and network assembly is governed by amino acid sequences of the C-terminal noncollagenous (NC1) domain of each chain. In this study, the structural basis for protomer and network assembly was investigated by determining the crystal structure of the ubiquitous [(alpha1)(2).alpha2](2) NC1 hexamer of bovine lens capsule basement membrane at 2.0 Angstrom resolution. The NC1 monomer folds into a novel tertiary structure. The (alpha1)(2).alpha2 trimer is organized through the unique three-dimensional domain swapping interactions. The differences in the primary sequences of the hypervariable region manifest in different secondary structures, which determine the chain specificity at the monomer-monomer interfaces. The trimer-trimer interface is stabilized by the extensive hydrophobic and hydrophilic interactions without a need for disulfide cross-linking.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Sundaramoorthy, M (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	msundar@kumc.edu		Hudson, Billy/0000-0002-5420-4100; Meiyappan, Muthuraman/0000-0001-7407-8677	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053763, R37DK018381, R01DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18381, DK 63925, DK 53763] Funding Source: Medline; ORIP NIH HHS [RI 80086] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ORIP NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; Boute N, 1996, BIOL CELL, V88, P37, DOI 10.1016/S0248-4900(97)86829-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; Dauter Z, 1999, J MOL BIOL, V289, P93, DOI 10.1006/jmbi.1999.2744; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; EXPOSITO JY, 1994, J BIOL CHEM, V269, P13167; Fowler SJ, 2000, J BIOL CHEM, V275, P39589, DOI 10.1074/jbc.M005871200; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; GUO XD, 1989, J BIOL CHEM, V264, P17574; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Iwata M, 1996, J BIOCHEM-TOKYO, V120, P133; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADLER K, 1994, PROTEIN PROFILE, V1, P519; KASHTAN CE, 1993, AM J KIDNEY DIS, V22, P627, DOI 10.1016/S0272-6386(12)80424-0; Kashtan CE, 1996, KIDNEY INT, V50, P1445, DOI 10.1038/ki.1996.459; KOIVU J, 1987, J BIOL CHEM, V262, P6159; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PECZON BD, 1982, EXP EYE RES, V35, P643, DOI 10.1016/S0014-4835(82)80076-6; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Pihlajaniemi T, 1996, CONTRIB NEPHROL, V117, P46; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROSENBLOOM J, 1976, J BIOL CHEM, V251, P2070; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; SIBLEY MH, 1994, EMBO J, V13, P3278, DOI 10.1002/j.1460-2075.1994.tb06629.x; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; STUBBS M, 1990, J MOL BIOL, V211, P683, DOI 10.1016/0022-2836(90)90066-U; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1985, ANN NY ACAD SCI, V460, P58, DOI 10.1111/j.1749-6632.1985.tb51157.x; UITTO J, 1973, BIOCHEM BIOPH RES CO, V55, P904, DOI 10.1016/0006-291X(73)91229-1; UITTO VJ, 1981, ARCH BIOCHEM BIOPHYS, V210, P445, DOI 10.1016/0003-9861(81)90208-3; WEBER M, 1992, KIDNEY INT, V41, P620, DOI 10.1038/ki.1992.95; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176; ZHOU J, 1994, J BIOL CHEM, V269, P13193	66	121	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31142	31153		10.1074/jbc.M201740200	http://dx.doi.org/10.1074/jbc.M201740200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	11970952	hybrid			2022-12-27	WOS:000177579800094
J	Penuel, E; Akita, RW; Sliwkowski, MX				Penuel, E; Akita, RW; Sliwkowski, MX			Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; HEREGULIN BINDING-SITE; ERBB SIGNALING NETWORK; TRANSMEMBRANE DOMAIN; EXTRACELLULAR DOMAINS; POINT MUTATION; BREAST-CANCER; ONCOGENE	Ligand-independent ErbB2 activation occurs principally by two distinct mechanisms: overexpression and mutation. Overexpression of ErbB2 at the plasma membrane drives receptor self-association in a concentration-dependent manner, which in turn leads to constitutive receptor activation. Subsets of human breast cancers contain a molecular alteration that leads to erbB2 gene amplification and subsequent protein overexpression. Although not recognized to occur in human cancers, mutation can also lead to increased ErbB2 association. A well characterized mutant of the rodent ortholog neu involves substitution of glutamate for valine within the transmembrane domain. In each case, a number of explanations have been proposed to explain the resulting ErbB2 activation. These include stabilization of receptor oligomers, release of negative constraints, and altered receptor conformations. Here we define a short amino acid segment comprising amino acids 966-968 in the intracellular domain that seemingly disrupts receptor-receptor association that is driven either by overexpression or mutation in the transmembrane region. Because of the hydrophobic nature of these amino acids (VVI), we propose that alteration of this segment likely results in a global conformational change in an area that has been proposed previously to be a dimerization motif for ErbB homomeric association.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Sliwkowski, MX (corresponding author), Genentech Inc, Dept Mol Oncol, Mail Stop 50,1 DNA Way, San Francisco, CA 94080 USA.							Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARTE MT, 1995, ARCH BIOCHEM BIOPHYS, V322, P378, DOI 10.1006/abbi.1995.1478; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; LASKY LA, 1984, DNA-J MOLEC CELL BIO, V3, P23, DOI 10.1089/dna.1.1984.3.23; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	48	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28468	28473		10.1074/jbc.M202510200	http://dx.doi.org/10.1074/jbc.M202510200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12000754	hybrid			2022-12-27	WOS:000177342600017
J	Lindsay, AJ; McCaffrey, MW				Lindsay, AJ; McCaffrey, MW			Rab11-FIP2 functions in transferrin recycling and associates with endosomal membranes via its COOH-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; BINDING PROTEIN RAB4; PLASMA-MEMBRANE; IDENTIFICATION; TRAFFICKING; COMPARTMENT; INTERACTS; EFFECTORS; FUSION; EEA1	Rab11-FIP2 is a recently described member of the Rip11/Rab11-FIP/Rab coupling protein family of Rab11 interacting proteins. Rab11-FIP2 interacts with both Rab11 and myosin Vb and co-localizes with Rab11 in both HeLa and Madin-Darby canine kidney cells (Hales, C. M., Griner, R., Hobdy-Henderson, K. C., Dorn, M. C., Hardy, D., Kumar, R., Navarre, J., Chan, E. K., Lapierre, L. A., and Goldenring, J. R. (2001) J. Biol. Chem. 276, 39067-390751). Here, we characterized the specificity of the interaction between Rab11-FIP2 and Rab11 and report that it does not interact with Rab4, Rab3, Rab5, Rab6, or Rab7. We demonstrate that the COOH-terminal region of Rab11-FIP2, which contains the Rab11 binding domain (11131)), is necessary and sufficient for its early endosomal membrane association. In contrast, the amino-terminal region, which contains a phospholipid binding C2-domain, by itself was insufficient for membrane binding. Expression of a deletion mutant of Rab11-FIP2, containing the RBD, caused tubulation of a transferrin receptor-positive early endosomal compartment in HeLa cells. Endogenous Pab11 was also associated with this compartment. This phenotype cannot be reversed by excess wild-type Rab11, or dominant-positive Rab11 (Rab11Q70L), suggesting that Rab11-FIP2 functions downstream of Rab11 in endosomal trafficking.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Mol Cell Biol Lab, Cork, Ireland	University College Cork	McCaffrey, MW (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Mol Cell Biol Lab, Prospect Row, Cork, Ireland.	m.mccaffrey@ucc.ie	Lindsay, Andrew J/P-9778-2017	Lindsay, Andrew J/0000-0001-9693-7022				Bielli A, 2001, BIOCHEM BIOPH RES CO, V281, P1141, DOI 10.1006/bbrc.2001.4468; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Trischler M, 1999, J CELL SCI, V112, P4773; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	37	96	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27193	27199		10.1074/jbc.M200757200	http://dx.doi.org/10.1074/jbc.M200757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994279	hybrid			2022-12-27	WOS:000177055900064
J	Cao, Y; Kang, Q; Zhao, ZF; Zolkiewska, A				Cao, Y; Kang, Q; Zhao, ZF; Zolkiewska, A			Intracellular processing of metalloprotease disintegrin ADAM12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ADAM-12 MELTRIN-ALPHA; CYSTEINE-RICH DOMAIN; ENDOPLASMIC-RETICULUM; CONVERTING-ENZYME; CELL-ADHESION; SECRETASE CLEAVAGE; MYOBLAST FUSION; QUALITY-CONTROL; GROWTH-FACTOR	ADAM12 has been implicated in cell-cell interactions in myogenesis and cancer, but the structure of the mature form of ADAM12 is not known, and its localization on the cell surface has been questioned. In this report, we show that full-length ADAM12 is N-glycosylated in the endoplasmic reticulum (ER) and proteolytically processed in the trans-Golgi network to an similar to90-kDa form. The similar to90-kDa form, which lacks the prodomain, was the predominant form present at the cell surface. Replacement of Leu(73) in the putative a-helical region in the prodomain with proline resulted in retention of ADAM12 in the ER and a complete lack of its processing. However, deletion of the entire pro- and metalloprotease domains did not affect the processing and trafficking of ADAM12. In contrast, replacement of the cytoplasmic domain of ADAM12 with that of ADAM9 or adding a c-Myc tag at the C terminus led to a significant increase in transport of the protein to the cell surface. These results suggest that the cytoplasmic domain of ADAM12 plays an important role in regulating ADAM12 exit from the ER. We conclude that properly folded mouse ADAM12, after passing a rate-limiting step of exit from the ER, is processed in the secretory pathway and reaches the cell surface, where it can mediate adhesion-mediated signaling.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewska, A (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045787] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15563] Funding Source: Medline; NIAMS NIH HHS [AR45787] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bornemann A, 2000, J MUSCLE RES CELL M, V21, P475, DOI 10.1023/A:1005657607591; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao Y, 2001, BIOCHEM J, V357, P353, DOI 10.1042/0264-6021:3570353; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kadota N, 2000, J BIOCHEM-TOKYO, V128, P941, DOI 10.1093/oxfordjournals.jbchem.a022845; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	63	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26403	26411		10.1074/jbc.M110814200	http://dx.doi.org/10.1074/jbc.M110814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000744	hybrid			2022-12-27	WOS:000176908700077
J	Weston, CJ; Venning, JD; Jackson, JB				Weston, CJ; Venning, JD; Jackson, JB			The membrane-peripheral subunits of transhydrogenase from Entamoeba histolytica are functional only when dimerized	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING TRANSHYDROGENASE; NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; ESCHERICHIA-COLI; RHODOSPIRILLUM-RUBRUM; CATALYTIC PROPERTIES; SOLUTION SCATTERING; HYDRIDE TRANSFER; MITOCHONDRIAL TRANSHYDROGENASE; BIOLOGICAL MACROMOLECULES; NADP(H)-BINDING DOMAINS	Unlike their bacterial and mammalian counterparts, the NADP(H)- and NAD(H)-binding components of proton-translocating transhydrogenase from the protozoan parasite Entamoeba histolytica (denoted ehdIII and ehdI, respectively) are tethered by a polypeptide linker. The recombinant tethered fragment, ehdIII-ehdI, was prepared without its membrane-spanning dII component. Dimers of ehdIII-ehdI catalyzed transhydrogenation, but monomers were inactive. The addition of ehdIII to ehdIII-ehdI monomers did not lead to an increase in the rate of transhydrogenation, showing that this inactivity is not the result of an unfavorable topology introduced by the linker. The addition of a bacterial dI to ehdIII-ehdI led to an increase in the rate of transhydrogenation, showing that the linker is flexible. A hybrid protein in which ehdIII is tethered to the bacterial dI (denoted ehdIII-rrdI) more readily formed active dimers. Data from small angle x-ray scattering by the hybrid dimers were fitted to models derived from the high-resolution crystal structure of the bacterial dI(2)dIII(1) complex (Cotton, N. P. J., White, S. A., Peake, S. J., McSweeney, S., and Jackson, J. B. (2001) Structure 9, 165-176). The results show that the ehdIII-rrdI dimer is asymmetric; one dIII associates with dI, as in the bacterial complex, but the other is displaced. The results provide evidence for the alternating site, binding change model for proton translocation by intact transhydrogenase.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.							ANDERSON WM, 1981, BIOCHIM BIOPHYS ACTA, V635, P194, DOI 10.1016/0005-2728(81)90018-9; Bizouarn T, 2000, BBA-BIOENERGETICS, V1457, P211, DOI 10.1016/S0005-2728(00)00103-1; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Ghosh S, 2000, INFECT IMMUN, V68, P4319, DOI 10.1128/IAI.68.7.4319-4322.2000; HOEK JB, 1988, BIOCHEM J, V254, P1; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 2002, BIOCHEMISTRY-US, V41, P4173, DOI 10.1021/bi012078d; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1411, P159, DOI 10.1016/S0005-2728(99)00013-4; PERSSON B, 1987, ARCH BIOCHEM BIOPHYS, V259, P341, DOI 10.1016/0003-9861(87)90500-5; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; PHELPS DC, 1985, BIOCHEMISTRY-US, V24, P3503, DOI 10.1021/bi00335a017; Pinheiro TJT, 2001, J BIOL CHEM, V276, P44757, DOI 10.1074/jbc.M109227200; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1999, BIOCHEM J, V341, P329, DOI 10.1042/0264-6021:3410329; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; VERMEULEN AN, 1993, FEMS MICROBIOL LETT, V110, P223, DOI 10.1111/j.1574-6968.1993.tb06324.x; Weston CJ, 2001, FEBS LETT, V488, P51, DOI 10.1016/S0014-5793(00)02386-3; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	42	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26163	26170		10.1074/jbc.M203514200	http://dx.doi.org/10.1074/jbc.M203514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004068	hybrid			2022-12-27	WOS:000176908700045
J	Bavendiek, U; Libby, P; Kilbride, M; Reynolds, R; Mackman, N; Schonbeck, U				Bavendiek, U; Libby, P; Kilbride, M; Reynolds, R; Mackman, N; Schonbeck, U			Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; ACUTE CORONARY SYNDROMES; SHEAR-STRESS INDUCTION; VASCULAR SMOOTH-MUSCLE; HUMAN MONOCYTIC CELLS; EPITHELIAL-CELLS; ARTERY DISEASE; IN-VITRO; LIPOPOLYSACCHARIDE; LIGATION	Induction of tissue factor expression in endothelial cells via ligation of CD40 probably figures prominently in the pathogenesis of prevalent inflammatory diseases, including atherosclerosis. However, the molecular mechanisms of tissue factor gene expression triggered by CD40 ligand (CD40L) in this cell type remain unknown. We demonstrate here that the tissue factor promoter region -278 bp to +121 bp contains the CD40L-responsive elements, consisting of activator protein 1 (AP-1)+/-, nuclear factor (NF) kappaB-, and Egr-1-binding sites. Mutations of either the AP-1- or NF-kappaB-binding sites markedly reduced the CD40L-dependent promoter activation. The AP-1 and NF-kappaB sites displayed constitutive and CD40L-enhanceable DNA binding activity, respectively. Of note, mutation of the Egr-1-binding sites, previously not associated with CD40 signaling, impaired activation of the tissue factor promoter. Accordingly, CD40L strongly induced Egr-1 protein expression and DNA binding activity to all three bindings sites. In contrast to CD40L, other established inducers of tissue factor in endothelial cells, interleukin-1beta or tumor necrosis factor a, did not increase the expression of Egr-1. In conclusion, induction of tissue factor gene expression in human endothelial cells by CD40L involves AP-1 and NF-kappaB as well as Egr-1, a pathway previously not implicated in CD40 signaling and distinct from that employed by certain other proinflammatory cytokines.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Leducq Ctr Cardiovasc Res,Cardiovasc Div, Boston, MA 02115 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Scripps Research Institute	Schonbeck, U (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Leducq Ctr Cardiovasc Res,Cardiovasc Div, 221 Longwood Ave,EBRC 309, Boston, MA 02115 USA.		Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056985, R37HL034636, R01HL034636] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34636, HL-56985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 1999, CIRCULATION, V100, P1215, DOI 10.1161/01.CIR.100.11.1215; Bennett BL, 1996, J BIOL CHEM, V271, P19680, DOI 10.1074/jbc.271.33.19680; Cui MZ, 1999, J BIOL CHEM, V274, P32795, DOI 10.1074/jbc.274.46.32795; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Houston P, 1999, ARTERIOSCL THROM VAS, V19, P281, DOI 10.1161/01.ATV.19.2.281; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Mach F, 1997, CIRCULATION, V96, P396; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Miller DL, 1998, J LEUKOCYTE BIOL, V63, P373, DOI 10.1002/jlb.63.3.373; Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; POTGENS AJG, 1994, THROMB HAEMOSTASIS, V71, P208; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; Schonbeck U, 2000, AM J PATHOL, V156, P7, DOI 10.1016/S0002-9440(10)64699-8; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Schonbeck U, 1999, J EXP MED, V189, P843, DOI 10.1084/jem.189.5.843; Slupsky JR, 1998, THROMB HAEMOSTASIS, V80, P1008; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Zhou L, 1998, THROMB HAEMOSTASIS, V79, P1025	34	116	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25032	25039		10.1074/jbc.M204003200	http://dx.doi.org/10.1074/jbc.M204003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978801	hybrid			2022-12-27	WOS:000176747000027
J	Dineley, KT; Bell, KA; Bui, D; Sweatt, JD				Dineley, KT; Bell, KA; Bui, D; Sweatt, JD			beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CHOLINERGIC HYPOTHESIS; LONGITUDINAL MRI; SENILE DEMENTIA; CONTEXTUAL FEAR; CHANNEL DOMAIN; IN-VITRO; MEMORY	The alpha7 nicotinic acetylcholine receptor is highly expressed in hippocampus and in cholinergic projection neurons from the basal forebrain, structures that are particularly vulnerable to the ravages of Alzheimer's disease. Previous work suggests that beta-amyloid peptide can interact with alpha7 nicotinic acetylcholine receptors, although the nature of this interaction has not been well characterized. To test whether beta-amyloid peptide can activate alpha7 nicotinic acetylcholine receptors, we expressed these receptors in Xenopus oocytes and performed two-electrode voltage clamp recordings, characterizing the response to beta-amyloid peptide 1-42 applied at concentrations ranging from I pm to 100 nM. In alpha7-expressing oocytes, beta-amyloid peptide 1-42 elicits inward currents at low concentrations (1-100 pm), whereas at higher concentrations (nM), less effective receptor activation is observed, indicative of receptor desensitization. Preincubation with the alpha7-selective agents, the antagonist methyllycaconatine, and the agonist 4-OH-GTS-21 blocked beta-amyloid peptide-induced receptor activation. beta-amyloid peptide 1-42 at low concentrations was able to activate the L250T mutant alpha7 receptor. The endogenous Ca2+-activated chloride current in Xenopus oocytes is recruited upon receptor activation since replacing Ca2+ with Ba2+ in the recording solution reduced current amplitude. Thus, when beta-amyloid peptide activation of alpha7 receptors occurs, these currents are comprised, at least in part, of Ca2+.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Dineley, KT (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.	kdineley@cns.bcm.tmc.edu		Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57014] Funding Source: Medline; NINDS NIH HHS [NS13546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Blum S, 1999, J NEUROSCI, V19, P3535; BOWEN DM, 1976, BRAIN, V99, P459, DOI 10.1093/brain/99.3.459; Brining SK, 1997, NEUROBIOL AGING, V18, P581, DOI 10.1016/S0197-4580(97)00153-X; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; DAVIES P, 1976, LANCET, V2, P1403; DEFIEBRE CM, 1995, MOL PHARMACOL, V47, P164; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Dodart JC, 2000, REV NEUROSCIENCE, V11, P75; Fox NC, 1996, BRAIN, V119, P2001, DOI 10.1093/brain/119.6.2001; Fox NC, 1996, ANN NY ACAD SCI, V777, P226, DOI 10.1111/j.1749-6632.1996.tb34423.x; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Meyer EM, 1998, J PHARMACOL EXP THER, V287, P918; PERRY EK, 1977, LANCET, V1, P189; Pettit DL, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-01-j0003.2001; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SEGUELA P, 1993, J NEUROSCI, V13, P596; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2000, J NEUROCHEM, V75, P1155, DOI 10.1046/j.1471-4159.2000.0751155.x	34	200	201	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25056	25061		10.1074/jbc.M200066200	http://dx.doi.org/10.1074/jbc.M200066200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983690	hybrid			2022-12-27	WOS:000176747000030
J	Fukuzawa, J; Nishihira, J; Hasebe, N; Haneda, T; Osaki, J; Saito, T; Nomura, T; Fujino, T; Wakamiya, N; Kikuchi, K				Fukuzawa, J; Nishihira, J; Hasebe, N; Haneda, T; Osaki, J; Saito, T; Nomura, T; Fujino, T; Wakamiya, N; Kikuchi, K			Contribution of macrophage migration inhibitory factor to extracellular signal-regulated kinase activation by oxidative stress in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIS-INDUCING FACTOR; PROTEIN-KINASE; ANGIOTENSIN-II; CRYSTAL-STRUCTURE; CARDIAC MYOCYTES; MESSENGER-RNA; CYTOKINE; MIF; EXPRESSION; MAPK	In response to oxidative stress, the pathogenesis of a number of cardiovascular events and several genes are stimulated by extracellular signal-regulated kinases (ERK1/2). Biphasic (early, 10 min; and delayed, 120 min) ERK1/2 activation by H2O2, a reactive oxygen species, was observed in cultured neonatal rat cardiomyocytes. We investigated the hypothesis that the delayed activation of ERK1/2 depends on a factor secreted by oxidative stress (FSO). The delayed activation was inhibited by calphostin C, a protein kinase C inhibitor. Conditioned medium (CM) obtained from cells stimulated with H2O2 induced rapid and monophasic ERK1/2 activation which was not inhibited by calphostin C. In contrast: calphostin C-pretreated CM did not activate ERK1/2. Macrophage migration inhibitory factor (MIF) was one of the candidate FSOs activating ERK1/2. The existence of MIF in CM, the recombinant MIF-stimulated ERK1/2 rapid activation, and anti-MIF neutralizing antibody-induced inhibition of the delayed activation implied that MIF could be the FSO. Pretreatment of cardiomyocytes with a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor did not suppress the MIF secretion, although it prevented the ERK1/2 activation by H2O2. These results indicate that MIF is secreted from cardiomyocytes as a result of oxidative stress and activates ERK1/2 through a MEK1/2-dependent mechanism, although the secretion is not regulated by ERK1/2 but by protein kinase C.	Asahikawa Med Coll, Dept Med 1, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan; Hokkaido Univ, Sch Med, Cent Res Inst, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Nemuro Municipal Hosp, Nemuro 0878686, Japan	Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical College; Hokkaido University	Fukuzawa, J (corresponding author), Asahikawa Med Coll, Dept Med 1, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	fukuzawa@asahikawa-med.ac.jp						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Booz GW, 1996, HYPERTENSION, V28, P635, DOI 10.1161/01.HYP.28.4.635; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; ERIKSON E, 1986, J BIOL CHEM, V261, P350; Fukuzawa J, 2000, HYPERTENSION, V35, P1191, DOI 10.1161/01.HYP.35.6.1191; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Hunt RA, 1999, HYPERTENSION, V34, P603, DOI 10.1161/01.HYP.34.4.603; IRONS CE, 1993, AM J PHYSIOL, V264, pH282, DOI 10.1152/ajpheart.1993.264.1.H282; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Kaye D, 1996, J CLIN INVEST, V97, P281, DOI 10.1172/JCI118414; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koong AC, 2000, CANCER RES, V60, P883; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin SG, 2000, CIRC RES, V87, P1202, DOI 10.1161/01.RES.87.12.1202; Linke MJ, 1997, AM J PHYSIOL-LUNG C, V272, pL171, DOI 10.1152/ajplung.1997.272.2.L171; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mischke R, 1998, FEBS LETT, V427, P85, DOI 10.1016/S0014-5793(98)00400-1; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; NISHIHIRA J, 1995, BBA-PROTEIN STRUCT M, V1247, P159, DOI 10.1016/0167-4838(94)00215-3; Nishio Y, 1999, BBA-MOL BASIS DIS, V1453, P74, DOI 10.1016/S0925-4439(98)00086-6; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Takahashi M, 2001, CARDIOVASC RES, V52, P438, DOI 10.1016/S0008-6363(01)00408-4; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Tanaki K, 2001, J AM COLL CARDIOL, V37, P676, DOI 10.1016/S0735-1097(00)01123-2; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TURNERS JF, 1980, BIOCHEM J, V156, P434; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yu CM, 2001, AM J CARDIOL, V88, P774, DOI 10.1016/S0002-9149(01)01850-1	47	36	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24889	24895		10.1074/jbc.M112054200	http://dx.doi.org/10.1074/jbc.M112054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978785	hybrid			2022-12-27	WOS:000176747000010
J	Vinogradov, E; Frirdich, E; MacLean, LL; Perry, MB; Petersen, BO; Duus, JO; Whitfield, C				Vinogradov, E; Frirdich, E; MacLean, LL; Perry, MB; Petersen, BO; Duus, JO; Whitfield, C			Structures of lipopolysaccharides from Klebsiella pneumoniae - Elucidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIBRIO-CHOLERAE O1; D-GALACTAN-I; CASSETTE TRANSPORT-SYSTEM; RFB GENE-CLUSTER; ESCHERICHIA-COLI; NCTC-5055 LIPOPOLYSACCHARIDE; SEROTYPE O1-K20; ANTIGEN; BIOSYNTHESIS; EXPRESSION	Deamination of LPSs from Klebsiella pneumoniae released O-chain polysaccharides together with a fragment of the core oligosaccharide. The structures of the products from serotypes 01, O2a, O2a,c, 03, 04, 05, and 012 were determined by NMR spectroscopy and chemical methods, identifying the linkage region between the 0 antigens and the core as well as novel residues at the non-reducing ends of the polysaccharides. All serotypes had an identical linkage between the 0 chain and core. [GRAPHICS] where L-glycero-D-manno-heptose is non-stoichiometric. Analysis of the LPSs from a waaL (O-polysaccharide ligase-deficient) mutant showed that the beta-GlcNAc in the linkage region is derived from the O-chain biosynthesis pathway, and the alpha-3-deoxy-D-manno-octulosonic acid represents the core residue to which the 0 chain is ligated. Consistent with the common ligation site, the WaaL proteins from these serotypes are essentially identical. Polysaccharides from serotypes 01, O2a, and O2a,c contain no special groups at the non-reducing end, whereas polysaccharides from serotypes 03,04,05, and 012 have residues at the non-reducing end that are not found in the polymer repeating units.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark	National Research Council Canada; University of Guelph	Vinogradov, E (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.		Duus, Jens Øllgaard/N-4279-2013	Duus, Jens Øllgaard/0000-0003-3625-1250; Vinogradov, Evgeny/0000-0002-5364-1376				BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; BJORNDAL H, 1972, ACTA CHEM SCAND, V26, P1269, DOI 10.3891/acta.chem.scand.26-1269; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; CURVALL M, 1973, ACTA CHEM SCAND, V27, P2645, DOI 10.3891/acta.chem.scand.27-2645; DITTA G, 1985, PLASMID, V13, P149, DOI 10.1016/0147-619X(85)90068-X; ERBING C, 1977, CARBOHYD RES, V56, P377, DOI 10.1016/S0008-6215(00)83359-5; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Guan S, 2001, J BACTERIOL, V183, P3318, DOI 10.1128/JB.183.11.3318-3327.2001; Hansen DS, 1999, J CLIN MICROBIOL, V37, P56, DOI 10.1128/JCM.37.1.56-62.1999; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; JANN K, 1979, BIOCHEM BIOPH RES CO, V86, P1185, DOI 10.1016/0006-291X(79)90242-0; JANN K, 1985, EUR J BIOCHEM, V151, P393, DOI 10.1111/j.1432-1033.1985.tb09114.x; JANN K, 1982, EUR J BIOCHEM, V127, P157, DOI 10.1111/j.1432-1033.1982.tb06850.x; JANSSON PE, 1985, CARBOHYD RES, V145, P59, DOI 10.1016/S0008-6215(00)90412-9; KELLY RF, 1995, J ENDOTOXIN RES, V0002; KELLY RF, 1993, MOL MICROBIOL, V10, P615, DOI 10.1111/j.1365-2958.1993.tb00933.x; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; Kido N, 2000, J BACTERIOL, V182, P2567, DOI 10.1128/JB.182.9.2567-2573.2000; KJAER M, 1994, METHODS ENZYMOL, V239, P288; KOL O, 1992, CARBOHYD RES, V236, P339, DOI 10.1016/0008-6215(92)85028-X; KOL O, 1991, CARBOHYD RES, V217, P117, DOI 10.1016/0008-6215(91)84122-U; LINDBERG B, 1972, ACTA CHEM SCAND, V26, P2231, DOI 10.3891/acta.chem.scand.26-2231; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; MACLEAN LL, 1993, CARBOHYD RES, V239, P325, DOI 10.1016/0008-6215(93)84231-T; MANNING PA, 1995, GENE, V158, P1, DOI 10.1016/0378-1119(95)00124-O; MCCALLUM KL, 1989, CAN J MICROBIOL, V35, P994, DOI 10.1139/m89-166; MCCALLUM KL, 1989, INFECT IMMUN, V57, P3816, DOI 10.1128/IAI.57.12.3816-3822.1989; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; MERINO S, 1992, INFECT IMMUN, V60, P2529, DOI 10.1128/IAI.60.6.2529-2535.1992; Merino S, 2000, INFECT IMMUN, V68, P2435, DOI 10.1128/IAI.68.5.2435-2440.2000; PREHM P, 1976, EUR J BIOCHEM, V67, P53, DOI 10.1111/j.1432-1033.1976.tb10631.x; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; STROEHER UH, 1992, P NATL ACAD SCI USA, V89, P2566, DOI 10.1073/pnas.89.7.2566; Sugiyama T, 1997, GENE, V198, P111, DOI 10.1016/S0378-1119(97)00300-4; Sugiyama T, 1998, J BACTERIOL, V180, P2775, DOI 10.1128/JB.180.10.2775-2778.1998; TRAUTMANN M, 1994, INFECT IMMUN, V62, P1282, DOI 10.1128/IAI.62.4.1282-1288.1994; Trautmann M, 1997, CLIN DIAGN LAB IMMUN, V4, P550, DOI 10.1128/CDLI.4.5.550-555.1997; Unger F. M., 1981, ADV CARBOHYD CHEM BI, V38, P323; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Vinogradov E, 2001, EUR J BIOCHEM, V268, P1722; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; WEISGERBER C, 1984, EUR J BIOCHEM, V140, P553, DOI 10.1111/j.1432-1033.1984.tb08137.x; WEISGERBER C, 1982, EUR J BIOCHEM, V127, P165, DOI 10.1111/j.1432-1033.1982.tb06851.x; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; WHITFIELD C, 1991, J BACTERIOL, V173, P1420, DOI 10.1128/jb.173.4.1420-1431.1991; WHITFIELD C, 1992, J BACTERIOL, V174, P4913, DOI 10.1128/JB.174.15.4913-4919.1992; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9	53	128	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25070	25081		10.1074/jbc.M202683200	http://dx.doi.org/10.1074/jbc.M202683200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11986326	hybrid			2022-12-27	WOS:000176747000032
J	Tzeng, YL; Datta, A; Strole, C; Kolli, VSK; Birck, MR; Taylor, WP; Carlson, RW; Woodard, RW; Stephens, DS				Tzeng, YL; Datta, A; Strole, C; Kolli, VSK; Birck, MR; Taylor, WP; Carlson, RW; Woodard, RW; Stephens, DS			KpsF is the arabinose-5-phosphate isomerase required for 3-deoxy-D-manno-octulosonic acid biosynthesis and for both lipooligosaccharide assembly and capsular polysaccharide expression in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; GRAM-NEGATIVE BACTERIA; POLYSIALIC ACID; SEROGROUP-B; SIALIC-ACID; GENE-CLUSTER; LIPID-A; LIPOPOLYSACCHARIDE BIOSYNTHESIS; MENINGOCOCCAL POLYSACCHARIDES; STRUCTURAL DETERMINATION	We have identified and defined the function of kpsF of Neisseria meningitidis and the homologues of kpsF in encapsulated K1 and K5 Escherichia coli. KpsF was shown to be the arabinose-5-phosphate isomerase, an enzyme not previously identified in prokaryotes, that mediates the interconversion of ribulose 5-phosphate and arabinose 5-phosphate. KpsF is required for 3-deoxy-D-manno-octulosonic acid (Kdo) biosynthesis in N. meningitidis. Mutation of kpsF or the gene encoding the CMP-Kdo synthetase (kpsU/kdsB) in N. meningitidis resulted in expression of a lipooligosaccharide (LOS) structure that contained only lipid A and reduced capsule expression in the five invasive disease-associated meningococcal serogroups (A, B, C, Y, and W-1351). The step linking meningococcal capsule and LOS biosynthesis was shown to be Kdo production as the expression of capsule was wild type in a Kdo transferase (kdtA) mutant. Thus, in addition to lipooligosaccharide assembly, Kdo is required for meningococcal capsular polysaccharide expression. Furthermore, N. meningitidis, unlike enteric Gram-negative bacteria, can survive and synthesize only unglycosylated lipid A.	Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30303 USA; Med Ctr, Dept Vet Affairs, Atlanta, GA 30033 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA	Emory University; University System of Georgia; University of Georgia; University of Michigan System; University of Michigan	Stephens, DS (corresponding author), Emory Univ, Sch Med, Div Infect Dis, Dept Med, 69 Butler St,SE, Atlanta, GA 30303 USA.		Stephens, David S/A-8788-2012	DATTA, ANUP/0000-0002-3796-6891; Woodard, Ronald/0000-0002-7472-3653	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040247, R21AI040247, R01AI033517] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40247, AI-33517] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bateman A, 1999, TRENDS BIOCHEM SCI, V24, P94, DOI 10.1016/S0968-0004(99)01357-2; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; BIGHAM EC, 1984, J MED CHEM, V27, P717, DOI 10.1021/jm00372a003; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; Christodoulides M, 2000, MOL MICROBIOL, V35, P32, DOI 10.1046/j.1365-2958.2000.01694.x; Cieslewicz M, 1997, MOL MICROBIOL, V26, P237, DOI 10.1046/j.1365-2958.1997.5651942.x; Cieslewicz M, 1996, J BACTERIOL, V178, P3212, DOI 10.1128/jb.178.11.3212-3220.1996; CIUCANO I, 1984, CARBOHYD RES, V131, P9; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DISCHE Z, 1951, J BIOL CHEM, V192, P583; EDEBRINK P, 1994, CARBOHYD RES, V257, P269, DOI 10.1016/0008-6215(94)80040-5; FINKE A, 1991, J BACTERIOL, V173, P4088, DOI 10.1128/jb.173.13.4088-4094.1991; FROSCH M, 1993, MOL MICROBIOL, V8, P483, DOI 10.1111/j.1365-2958.1993.tb01592.x; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JANIK A, 1976, J CLIN MICROBIOL, V4, P71; Kahler CM, 1998, INFECT IMMUN, V66, P5939, DOI 10.1128/IAI.66.12.5939-5947.1998; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Kahler CM, 1996, J BACTERIOL, V178, P1265, DOI 10.1128/jb.178.5.1265-1273.1996; LIU TY, 1971, J BIOL CHEM, V246, P2849; LIU TY, 1971, J BIOL CHEM, V246, P4703; MCALLISTER CF, 1993, MOL MICROBIOL, V10, P13, DOI 10.1111/j.1365-2958.1993.tb00899.x; MENARD R, 1993, J BACTERIOL, V175, P5899; Moe GR, 1999, INFECT IMMUN, V67, P5664, DOI 10.1128/IAI.67.11.5664-5675.1999; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PAZZANI C, 1993, J BACTERIOL, V175, P5978, DOI 10.1128/JB.175.18.5978-5983.1993; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; Rahman MM, 1998, CARBOHYD RES, V307, P311; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; RAU H, 1995, ARCH MICROBIOL, V164, P280, DOI 10.1007/s002030050265; ROSENOW C, 1995, FEMS MICROBIOL LETT, V125, P159, DOI 10.1016/0378-1097(94)00492-A; Shih GC, 2001, MICROBIOL-SGM, V147, P2367, DOI 10.1099/00221287-147-8-2367; Simpson DA, 1996, J BACTERIOL, V178, P6466, DOI 10.1128/jb.178.22.6466-6474.1996; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; STEPHENS DS, 1991, INFECT IMMUN, V59, P4097, DOI 10.1128/IAI.59.11.4097-4102.1991; Swartley JS, 1996, J BACTERIOL, V178, P4052, DOI 10.1128/jb.178.14.4052-4059.1996; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; Swartley JS, 1998, J BACTERIOL, V180, P1533, DOI 10.1128/JB.180.6.1533-1539.1998; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; TROY FA, 1975, J BIOL CHEM, V250, P156; Tzeng YL, 2000, MICROBES INFECT, V2, P687, DOI 10.1016/S1286-4579(00)00356-7; Tzeng YL, 2001, INFECT IMMUN, V69, P2502, DOI 10.1128/IAI.69.4.2502-2511.2001; Valverde C, 1997, BIOTECHNIQUES, V22, P230, DOI 10.2144/97222bm07; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WOOD T, 1985, PENTOSE PHOSPHATE PA; WUNDER DE, 1994, J BACTERIOL, V176, P4025, DOI 10.1128/JB.176.13.4025-4033.1994; Yamada M, 1990, DNA Seq, V1, P141, DOI 10.3109/10425179009016042; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; Zhou DG, 1996, GENE, V171, P133, DOI 10.1016/0378-1119(96)00103-5	57	51	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24103	24113		10.1074/jbc.M200931200	http://dx.doi.org/10.1074/jbc.M200931200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956197	hybrid			2022-12-27	WOS:000176611800018
J	Chen, HC; Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, M; Farese, RV; Farese, RV				Chen, HC; Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, M; Farese, RV; Farese, RV			Activation of the ERK pathway and atypical protein kinase C Isoforms in exercise- and aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR)-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; RICH TYROSINE KINASE-2; INSULIN-INDUCED ACTIVATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL REGULATION; GLUT4 TRANSLOCATION; SKELETAL-MUSCLE; PHOSPHOLIPASE-D	Exercise increases glucose transport in muscle by activating 5'-AMP-activated protein kinase (AMPK), but subsequent events are unclear. Presently, we examined the possibility that AMPK increases glucose transport through atypical protein kinase Cs (aPKCs) by activating proline-rich tyrosine kinase-2 (PYK2), ERK pathway components, and phospholipase D (PLD). In mice, treadmill exercise rapidly activated ERK and aPKCs in mouse vastus lateralis muscles. In rat extensor digitorum longus (EDL) muscles, (a) AMPK activator, 5-aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR), activated PYK2, ERK and aPKCs; (b) effects of AICAR on ERK and aPKCs were blocked by tyrosine kinase inhibitor, genistein, and MEK1 inhibitor, PD98059; and (c) effects of AICAR on aPKCs and 2-deoxyglucose (2-DOG) uptake were inhibited by genistein, PD98059, and PLD-inhibitor, 1-butanol. Similarly, in L6 myotubes, (a) AICAR activated PYK2, ERK, PLD, and aPKCs; (b) effects of AICAR on ERK were inhibited by genistein, PD98059, and expression of dominant-negative PYK2; (c) effects of AICAR on PLD were inhibited by MEK1 inhibitor UO126; (d) effects of AICAR on aPKCs were inhibited by genistein, PD98059, 1-butanol, and expression of dominant-negative forms of PYK2, GRB2, SOS, HAS, RAF, and ERK; and (e) effects of AICAR on 2DOG uptake/GLUT4 translocation were inhibited by genistein, PD98059, UO126, I-butanol, cell-permeable myristoylated PKC-zeta pseudosubstrate, and expression of kinase-inactive RAF, ERK, and PKC-zeta. AMPK activator dinitrophenol had effects on ERH, aPKCs, and 2-DOG uptake similar to those of AICAR. Our findings suggest that effects of exercise on glucose transport that are dependent on AMPK are mediated via PYK2, the ERK pathway, PLD, and aPKCs.	Univ S Florida, James A Haley Vet Hosp, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Coll Med, Tampa, FL 33612 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Farese, RV (corresponding author), Univ S Florida, James A Haley Vet Hosp, Coll Med, ACOS 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@hsc.usf.edu	Farese, Robert/B-3605-2015	Chen, Hubert/0000-0002-7599-7218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065969] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balon TW, 2001, BIOCHEM BIOPH RES CO, V282, P1008, DOI 10.1006/bbrc.2001.4677; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Bandyopadhyay G, 2001, J BIOL CHEM, V276, P35537, DOI 10.1074/jbc.M106042200; Bandyopadhyay G, 2000, J BIOL CHEM, V275, P40817, DOI 10.1074/jbc.M007920200; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; CORDERRE L, 1995, J BIOL CHEM, V270, P27584; Hayashi T, 1999, AM J PHYSIOL-CELL PH, V277, pC701, DOI 10.1152/ajpcell.1999.277.4.C701; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1996, ENDOCRINOLOGY, V137, P3014, DOI 10.1210/en.137.7.3014; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wojtaszewski JFP, 1999, AM J PHYSIOL-ENDOC M, V277, pE724, DOI 10.1152/ajpendo.1999.277.4.E724	26	162	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23554	23562		10.1074/jbc.M201152200	http://dx.doi.org/10.1074/jbc.M201152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11978788	hybrid			2022-12-27	WOS:000176475700060
J	Endo, A; Nagashima, KI; Kurose, H; Mochizuki, S; Matsuda, M; Mochizuki, N				Endo, A; Nagashima, KI; Kurose, H; Mochizuki, S; Matsuda, M; Mochizuki, N			Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; ADAPTER PROTEIN; LYSOPHOSPHATIDIC ACID; DEPENDENT ACTIVATION; KINASE INHIBITORS; SIGNALING PATHWAY; SURFACE-RECEPTOR; ANGIOTENSIN-II	Sphingosine 1-phosphate (S1P), a ligand for endothelial differentiation gene family proteins, is one of the most potent signal mediators released from activated platelets. Here, we report that S1P induces membrane ruffling of human umbilical vein endothelial cells (HUVECs) via the vascular endothelial growth factor receptor (VEGFR), Src family tyrosine kinase(s), and the CrkII adaptor protein. S1P induced prominent phosphorylation of CrkII in HUVECs, indicating that CrkII was involved in the S1P-induced signaling pathway. S1P-induced CrkII phosphorylation was blocked by pertussis toxin and overexpression of the carboxyl terminus of beta-adrenergic receptor kinase, indicating that the betagamma subunit of G(i) was required for the phosphorylation. Notably, the S1P-induced CrkII phosphorylation was also abolished by inhibitors of VEGFR or Sre family tyrosine kinases. By using Picchu, a real time monitoring protein for CrkII phosphorylation, we found that S1P induced rapid CrkII phosphorylation at membrane ruffles. Finally, we observed that expression of a dominant negative mutant of CrkII inhibited the S1P-induced membrane ruffling and cell migration. These results delineated a novel S1P signaling pathway that involves sequential activation of G(i)-coupled receptor(s), VEGFR, Sre family tyrosine kinase(s), and the CrkII adaptor protein, and which is responsible for both the induction of membrane ruffling and the increase in cell motility.	Natl Cardiovasc Ctr, Inst Res, Dept Struct Anal, Suita, Osaka 5658565, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan; Jikei Univ, Sch Med, Div Cardiol, Minato Ku, Tokyo 1058461, Japan; Osaka Univ, Dept Tumor Virol, Microbial Dis Res Inst, Osaka 5650871, Japan	National Cerebral & Cardiovascular Center - Japan; University of Tokyo; Jikei University; Osaka University	Mochizuki, N (corresponding author), Natl Cardiovasc Ctr, Inst Res, Dept Struct Anal, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.			Matsuda, Michiyuki/0000-0002-5876-9969				BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kovala AT, 2000, FASEB J, V14, P2486, DOI 10.1096/fj.00-0147com; KOVALENKO M, 1994, CANCER RES, V54, P6106; Kurokawa K, 2001, J BIOL CHEM, V276, P31305, DOI 10.1074/jbc.M104341200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Strawn LM, 1996, CANCER RES, V56, P3540; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291	60	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23747	23754		10.1074/jbc.M111794200	http://dx.doi.org/10.1074/jbc.M111794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956190	hybrid			2022-12-27	WOS:000176475700085
J	He, YW; Cress, WD				He, YW; Cress, WD			E2F-3B is a physiological target of cyclin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F-1; CELL-CYCLE; S-PHASE; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; DNA-REPLICATION; FAMILY MEMBERS; RB/E2F PATHWAY; IN-VIVO; A CDK2	The E2F family of transcription factors controls the expression of numerous genes that are required for the G(1)/S transition. Among the mechanisms that modulate the activity of the E2F proteins, cyclin A has been found to be important for the down-regulation of E2F-1, -2, and -3A activity after cells have progressed through G(1)/S. Specifically, phosphorylation of these E2F proteins by cyclin A/Cdk2 ultimately results in their necessary degradation as cells progress through S phase. E2F-3B was recently identified as an alternatively spliced form of E2F-3A that was predicted to lack a functional cyclin A binding domain. In this paper, we present considerable evidence that contradicts this prediction. First, we demonstrate binding of cyclin A to E2F-3B as bacterially expressed proteins in vitro. Second, we demonstrate binding of cyclin A to E2F-313 in mammalian cells in vivo. Third, we show that co-expression of cyclin A with E2F-3B significantly reduces E2F-3B-mediated transcriptional activity. Finally, in synchronized cells, we observe down-regulation of E2F-3B protein expression coincident with the up-regulation of cyclin A. We conclude that E2F-3B is a physiological target of cyclin A.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33620 USA; Univ S Florida, Coll Med, Dept Interdiciplinary Oncol, Tampa, FL 33620 USA; H Lee Moffitt Comprehens Canc Ctr, Tampa, FL 33612 USA; Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER; NCI NIH HHS [CA78214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Allen KE, 1997, J CELL SCI, V110, P2819; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EBLEN ST, 1995, CELL GROWTH DIFFER, V6, P915; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Jordan-Sciutto KL, 1998, BIOCHEM CELL BIOL, V76, P37; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lavia P, 1999, BIOESSAYS, V21, P221; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; LOGAN TJ, 1995, CANCER RES, V55, P2883; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Magae J, 1996, J CELL SCI, V109, P1717; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Takahashi Y, 2000, GENE DEV, V14, P804; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	52	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23493	23499		10.1074/jbc.M202629200	http://dx.doi.org/10.1074/jbc.M202629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980909	hybrid			2022-12-27	WOS:000176475700053
J	Kincer, JF; Uittenbogaard, A; Dressman, J; Guerin, TM; Febbraio, M; Guo, L; Smart, EJ				Kincer, JF; Uittenbogaard, A; Dressman, J; Guerin, TM; Febbraio, M; Guo, L; Smart, EJ			RETRACTED: Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase-mediated vascular dysfunction (Retracted article. See vol. 288, pg. 6584, 2013)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							INSULIN-RESISTANCE; CHOLESTEROL DEPLETION; SCAVENGER RECEPTOR; PLASMA-MEMBRANE; CLASS-B; FATTY-ACID; IN-VITRO; CD36; CAVEOLAE; LOCALIZATION	Numerous studies have implicated either the presence or absence of CD36 in the development of hypertension. In addition, hypercholesterolemia is associated with the loss of nitric oxide-induced vasodilation and the subsequent increase in blood pressure. In the current study, we tested the hypothesis that diet-induced hypercholesterolemia promotes the disruption of agonist-stimulated nitric oxide generation and vasodilation in a CD36-dependent manner. To test this, C57BL/6, apoE null, CD36 null, and apoE/CD36 null mice were maintained on chow or high fat diets. In contrast to apoE null mice fed a chow diet, apoE null mice fed a high fat diet did not respond to acetylcholine with a decrease in blood pressure. Caveolae isolated from in vivo vessels did not contain endothelial nitric-oxide synthase and were depleted of cholesterol. Age-matched apoE/CD36 null mice fed a chow or high fat diet responded to acetylcholine with a decrease in blood pressure. The mechanism underlying the vascular dysfunction was reversible because vessels isolated from apoE null high fat-fed mice regained responsiveness to acetylcholine when incubated with plasma obtained from chow-fed mice. Further analysis demonstrated that the plasma low density lipoprotein fraction was responsible for depleting caveolae of cholesterol, removing endothelial nitric-oxide synthase from caveolae, and preventing nitric oxide production. In addition, the pharmacological removal of caveola cholesterol with cyclodextrin mimicked the effects caused by the low density lipoprotein fraction. We conclude that the ablation of CD36 prevented the negative impact of hypercholesterolemia on agonist-stimulated nitric oxide-mediated vasodilation in apoE null mice. These studies provide a direct link between CD36 and the early events that underlie hypercholesterolemia-mediated hypertension and mechanistic linkages between CD36 function, nitric-oxide synthase activation, caveolae integrity, and blood pressure regulation.	Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA; Anim Med Ctr, Dept Med, Div Hematol Med Oncol, Weill Med Coll, New York, NY 10021 USA	University of Kentucky; Cornell University	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.	ejsmart@uky.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62844] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Aitman TJ, 2001, LANCET, V357, P651, DOI 10.1016/S0140-6736(00)04149-0; Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Collison M, 2000, DIABETES, V49, P2222, DOI 10.2337/diabetes.49.12.2222; DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Villiers WJS, 1999, J LEUKOCYTE BIOL, V66, P740, DOI 10.1002/jlb.66.5.740; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Fazio S, 2001, FRONT BIOSCI-LANDMRK, V6, pD515, DOI 10.2741/Fazio; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1999, CURR OPIN NEPHROL HY, V8, P55, DOI 10.1097/00041552-199901000-00010; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Pravenec M, 1999, J CLIN INVEST, V103, P1651, DOI 10.1172/JCI6691; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; Pravenec M, 2000, FOLIA BIOL-PRAGUE, V46, P233; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sowers JR, 2001, HYPERTENSION, V37, P1053, DOI 10.1161/01.HYP.37.4.1053; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241	53	47	47	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23525	23533		10.1074/jbc.M202465200	http://dx.doi.org/10.1074/jbc.M202465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976335	hybrid, Green Published			2022-12-27	WOS:000176475700057
J	Kitabatake, M; Ali, K; Demain, A; Sakamoto, K; Yokoyama, S; Soll, D				Kitabatake, M; Ali, K; Demain, A; Sakamoto, K; Yokoyama, S; Soll, D			Indolmycin resistance of Streptomyces coelicolor A3(2) by induced expression of one of its two tryptophanyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEVEL MUPIROCIN RESISTANCE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING; REVEALS; RECOGNITION; COMPLEX; PROTEIN; ACID; SITE	Aminoacyl-tRNA synthetases, a family of enzymes essential for protein synthesis, are promising targets of antimicrobials. Indolmycin, a secondary metabolite of Streptomyces griseus and a selective inhibitor of prokaryotic tryptophanyl-tRNA synthetase (TrpRS), was used to explore the mechanism of inhibition and to explain the resistance of a naturally occurring strain. Streptomyces coelicolor A3(2), an indolmycin-resistant strain, contains two trpS genes encoding distinct TrpRS enzymes. We show that TrpRS1 is indolmycin-resistant in vitro and in vivo, whereas TrpRS2 is sensitive. The lysine (position 9) in the enzyme tryptophan binding site is essential for making TrpRS1 indolmycin-resistant. Replacement of lysine 9 by glutamine, which at this position is conserved in most bacterial TrpRS proteins, abolished the ability of the mutant trpS gene to confer indolmycin resistance in vivo. Molecular modeling suggests that lysine 9 sterically hinders indolmycin binding to the enzyme. Tryptophan recognition (assessed by k(cat)/K-M) by TrpRS1 is 4-fold lower than that of TrpRS2. Examination of the mRNA for the two enzymes revealed that only TrpRS2 mRNA is constitutively expressed, whereas mRNA for the indolmycin-resistant TrpRS1 enzyme is induced when the cells are exposed to indolmycin.	RIKEN, Genomic Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Tokyo, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; MIT, Dept Biol, Cambridge, MA 02139 USA	RIKEN; Yale University; University of Tokyo; Massachusetts Institute of Technology (MIT)	Yokoyama, S (corresponding author), RIKEN, Genomic Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp; dieter.soll@yale.edu	Yokoyama, Shigeyuki/N-6911-2015; Sakamoto, Kensaku/N-7496-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Sakamoto, Kensaku/0000-0003-2866-5031	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022854, R01GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnez JG, 1998, COLD SPRING HARBOR M, P465; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BRYANT R, 1982, THESIS YALE U; Bunjun S, 2000, P NATL ACAD SCI USA, V97, P12997, DOI 10.1073/pnas.230444397; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HODGSON JE, 1994, ANTIMICROB AGENTS CH, V38, P1205, DOI 10.1128/AAC.38.5.1205; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 1999, P NATL ACAD SCI USA, V96, P418, DOI 10.1073/pnas.96.2.418; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; Kanamaru T, 2001, ANTIMICROB AGENTS CH, V45, P2455, DOI 10.1128/AAC.45.9.2455-2459.2001; KHORANA HG, 1968, BIOCHEM J, V109, P709, DOI 10.1042/bj1090709c; Kieser T., 2001, PRACTICAL STREPTOMYC; KISSELEV LL, 1993, BIOCHIMIE, V75, P1027, DOI 10.1016/0300-9084(93)90002-A; MARSH W. S., 1960, ANTIBIOT AND CHEMOTHER, V10, P316; Onaka H, 1997, MOL MICROBIOL, V24, P991, DOI 10.1046/j.1365-2958.1997.4081772.x; Praetorius-Ibba M, 2000, BIOCHEMISTRY-US, V39, P13136; PREOBRAZHENSKAYA MN, 1968, TETRAHEDRON, V24, P6131, DOI 10.1016/S0040-4020(01)96345-8; RAHMAN M, 1990, J MED MICROBIOL, V33, P97, DOI 10.1099/00222615-33-2-97; RAO KOPPAKA V., 1960, ANTIBIOT AND CHEMOTHER, V10, P312; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; SIPPONEN P, 1993, SCAND J GASTROENTERO, V28, P3, DOI 10.3109/00365529309098333; Sugiura I, 2000, STRUCTURE, V8, P197, DOI 10.1016/S0969-2126(00)00095-2; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Watanabe H, 2001, J HOSP INFECT, V47, P294, DOI 10.1053/jhin.2000.0931; WERNER RG, 1976, EUR J BIOCHEM, V68, P1, DOI 10.1111/j.1432-1033.1976.tb10758.x; WERNER RG, 1981, J ANTIBIOT, V34, P551, DOI 10.7164/antibiotics.34.551; Witty DR, 1996, BIOORG MED CHEM LETT, V6, P1375, DOI 10.1016/0960-894X(96)00237-5; Witty DR, 1996, TETRAHEDRON LETT, V37, P3067, DOI 10.1016/0040-4039(96)00471-6; Wolf YI, 1999, GENOME RES, V9, P689; ZARGAROVA T A, 1990, Biokhimiya, V55, P1328	40	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23882	23887		10.1074/jbc.M202639200	http://dx.doi.org/10.1074/jbc.M202639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970956	hybrid			2022-12-27	WOS:000176475700102
J	Malfait, AM; Liu, RQ; Ijiri, K; Komiya, S; Tortorella, MD				Malfait, AM; Liu, RQ; Ijiri, K; Komiya, S; Tortorella, MD			Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL COLLAGENASE MMP-8; HUMAN SYNOVIAL-FLUID; MATRIX-METALLOPROTEINASE; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; CLEAVAGE-SITE; KNEE CARTILAGE; PROTEOGLYCAN; CATABOLISM; FRAGMENTS	Osteoarthritis is a degenerative joint disorder characterized by breakdown of articular cartilage. Degradation of aggrecan, which together with type 11 collagen provides cartilage with its unique characteristics of compressibility and elasticity, is an early and sustained feature of osteoarthritis. The present work was set up to identify the enzyme(s) responsible for aggrecan breakdown in osteoarthritis. We found that the two cartilage aggrecanases, ADAM-TS4 and ADAM-TS5, are present in osteoarthritic cartilage and that they are responsible for aggrecan degradation without the participation of matrix metalloproteinases. This is based on 1) neoepitopes found on aggrecan fragments in osteoarthritis (OA) cartilage explants in vitro, 2) aggrecan fragments detected in synovial fluid of OA patients, 3) the observation that an aggrecanase inhibitor, BB-16, blocked aggrecan degradation in OA cartilage in vitro, whereas the matrix metalloproteinase inhibitor XS309 did not, and 4) the presence of mRNA and protein for ADAM-TS4 and ADAM-TS5 in OA cartilage. These results suggest that ADAM-TS4 and ADAM-TS5 represent a potential target for the treatment of osteoarthritis.	DuPont Pharmaceut Co, Wilmington, DE 19880 USA; Imperial Coll Sch Med, London W6 8LH, England; Kagoshima Univ, Fac Med, Kagoshima 8908520, Japan	DuPont; Imperial College London; Kagoshima University	Malfait, AM (corresponding author), Pharmacia Corp, Skikie Discovery Biol, 4901 Searle Pky, Skokie, IL 60077 USA.	anne-marie.malfait@pharmacia.com		Malfait, Anne-Marie/0000-0003-1428-0384				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P553, DOI 10.1053/joca.2001.0425; BENDELE AM, 1988, ARTHRITIS RHEUM, V31, P561, DOI 10.1002/art.1780310416; Billinghurst RC, 2000, ARTHRITIS RHEUM, V43, P664, DOI 10.1002/1529-0131(200003)43:3<664::AID-ANR24>3.0.CO;2-D; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Burton-Wurster N, 1993, JOINT CARTILAGE DEGR, P347; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; DUNHAM J, 1989, AGENTS ACTIONS, V28, P93, DOI 10.1007/BF02022987; Elliott S, 2001, DRUG AGING, V18, P87, DOI 10.2165/00002512-200118020-00002; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Greenwald RA, 1999, ANN NY ACAD SCI, V878, P413, DOI 10.1111/j.1749-6632.1999.tb07699.x; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kaushal GP, 2000, J CLIN INVEST, V105, P1335, DOI 10.1172/JCI10078; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MOSKOWITZ RW, 1979, ARTHRITIS RHEUM, V22, P155, DOI 10.1002/art.1780220208; PALMOSKI M, 1979, ARTHRITIS RHEUM, V22, P508, DOI 10.1002/art.1780220511; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 2000, BIOCHEM J, V351, P161, DOI 10.1042/0264-6021:3510161; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Shaw T, 2000, EXPERT OPIN INV DRUG, V9, P1469, DOI 10.1517/13543784.9.7.1469; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Yao WQ, 2001, J MED CHEM, V44, P3347, DOI 10.1021/jm015533c	46	245	267	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22201	22208		10.1074/jbc.M200431200	http://dx.doi.org/10.1074/jbc.M200431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956193	hybrid			2022-12-27	WOS:000176313600014
J	Sarno, S; Ghisellini, P; Pinna, LA				Sarno, S; Ghisellini, P; Pinna, LA			Unique activation mechanism of protein kinase CK2 - The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; BETA-SUBUNIT; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; ZEA-MAYS; II-ALPHA; PROLIFERATION; MUTANTS; PROVIDES; COMPLEX	CK2 is an essential, ubiquitous, and highly pleiotropic protein kinase whose catalytic subunits (alpha and alpha') and holoenzyme (composed by two catalytic and two regulatory beta-subunits) are both constitutively active, a property that is suspected to contribute to its pathogenic potential. Extensive interactions between the N-terminal segment and the activation loop are suspected to underlie the high constitutive activity of the isolated catalytic subunit. Here we show that a number of point mutations (Tyr(26) --> Phe, Glu(180) --> Ala, Tyr(182) --> Phe) and deletions (Delta2-6, Delta2-12, Delta2-18, Delta2-24, Delta2-30) expected to affect these interactions are more or less detrimental to catalytic activity of the a-subunit of human CK2, the deleted mutants Delta2-24 and Delta2-30 being nearly inactive under normal assay conditions. Kinetic analyses showed that impaired catalytic activity of mutants Delta2-12, Delta2-18, Delta2-24, and Y182F is mainly accounted for by dramatic increases in the K-m values for ATP, whereas a drop in K-cat with K-m values almost unchanged was found with mutants Y26F and E180A. Holoenzyme reconstitution restored the activity of mutants Delta2-12, Delta2-18, Y26F, E180A, and Y182F to wild type level and also conferred catalytic activity to the intrinsically inactive mutants, Delta2-24 and Delta2-30. These data demonstrate that specific interactions between the N-terminal segment and the activation loop are essential to provide a fully active conformation to the catalytic subunits of CK2; they also show that these interactions become dispensable upon formation of the holoenzyme, whose constitutive activity is conferred by the beta-subunit through a different mechanism.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Venetian Inst Mol Med, Padua, Italy; Univ Genoa, Dept Biophys M&O Sci & Technol, I-16132 Genoa, Italy	University of Padua; Veneto Institute Molecular Medicine; University of Genoa	Pinna, LA (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	lorenzo.pinna@unipd.it						Ahmed K, 2000, J CELL BIOCHEM, P130; Battistutta R, 2000, EUR J BIOCHEM, V267, P5184, DOI 10.1046/j.1432-1327.2000.01587.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Marin O, 1999, J BIOL CHEM, V274, P29260, DOI 10.1074/jbc.274.41.29260; Marks Friedrich, 1996, P1, DOI 10.1002/9783527615032.ch1; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; RUZZENE M, 1999, PROTEIN PHOSPHORYLAT, P221; Sarno S, 2000, BIOCHEMISTRY-US, V39, P12324, DOI 10.1021/bi0011431; Sarno S, 1998, FEBS LETT, V441, P29, DOI 10.1016/S0014-5793(98)01516-6; Sarno S, 1996, J BIOL CHEM, V271, P10595, DOI 10.1074/jbc.271.18.10595; Sarno S, 2001, MOL CELL BIOCHEM, V227, P13, DOI 10.1023/A:1013136117395; Sarno S, 1997, BIOCHEMISTRY-US, V36, P11717, DOI 10.1021/bi9705772; SARNO S, 2001, IN PRESS PHARM THER; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SEMPLICI F, 2002, IN PRESS ONCOGENE	37	69	69	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22509	22514		10.1074/jbc.M200486200	http://dx.doi.org/10.1074/jbc.M200486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956194	hybrid			2022-12-27	WOS:000176313600053
J	Bracher, A; Kadlec, J; Betz, H; Weissenhorn, W				Bracher, A; Kadlec, J; Betz, H; Weissenhorn, W			X-ray structure of a neuronal complexin-SNARE complex from squid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; SYNAPTIC EXOCYTOSIS; KINETIC COMPONENTS; CRYSTAL-STRUCTURE; PROTEIN; VESICLE; CALCIUM; CORE; SNAP-25	Nerve terminals release neurotransmitters from vesicles into the synaptic cleft upon transient increases in intracellular Ca2+. This exocytotic process requires the formation of trans SNARE complexes and is regulated by accessory proteins including the complexins. Here we report the crystal structure of a squid core complexin-SNARE complex at 2.95-Angstrom resolution. A helical segment of complexin binds in anti-parallel fashion to the four-helix bundle of the core SNARE complex and interacts at its C terminus with syntaxin and synaptobrevin around the ionic zero layer of the SNARE complex. We propose that this structure is part of a multiprotein fusion machinery that regulates vesicle fusion at a late pre-fusion stage. Accordingly, Ca2+ may initiate membrane fusion by acting directly or indirectly on complexin, thus allowing the conformational transitions of the trans SNARE complex that are thought to drive membrane fusion.	European Mol Biol Lab, F-38042 Grenoble, France; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Weissenhorn, W (corresponding author), European Mol Biol Lab, 6 Rue Jules Horowitz, F-38042 Grenoble, France.	weissen@embl-grenoble.fr	Kadlec, Jan/G-3235-2014	Kadlec, Jan/0000-0002-4853-6918				Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Eastwood SL, 2001, NEUROSCIENCE, V105, P219, DOI 10.1016/S0306-4522(01)00141-5; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Finley MFA, 2002, J NEUROSCI, V22, P1266, DOI 10.1523/JNEUROSCI.22-04-01266.2002; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Graham ME, 2001, J CELL SCI, V114, P4397; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Lonart G, 2000, J BIOL CHEM, V275, P27703; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; Misura KMS, 2000, CURR OPIN STRUC BIOL, V10, P662, DOI 10.1016/S0959-440X(00)00151-2; Morton AJ, 2001, J NEUROCHEM, V76, P166, DOI 10.1046/j.1471-4159.2001.00059.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	60	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26517	26523		10.1074/jbc.M203460200	http://dx.doi.org/10.1074/jbc.M203460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004067	hybrid			2022-12-27	WOS:000176908700091
J	Filling, C; Berndt, KD; Benach, J; Knapp, S; Prozorovski, T; Nordling, E; Ladenstein, R; Jornvall, H; Oppermann, U				Filling, C; Berndt, KD; Benach, J; Knapp, S; Prozorovski, T; Nordling, E; Ladenstein, R; Jornvall, H; Oppermann, U			Critical residues for structure and catalysis in short-chain dehydrogenases/reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURE; TERNARY COMPLEX; ACTIVE-SITE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; CARBONYL REDUCTASE; ALCOHOL; SPECIFICITY; RESOLUTION	Short-chain dehydrogenases/reductases form a large, evolutionarily old family of NAD(P)(H)-dependent enzymes with over 60 genes found in the human genome. Despite low levels of sequence identity (often 10-30%), the three-dimensional structures display a highly similar alpha/beta folding pattern. We have analyzed the role of several conserved residues regarding folding, stability, steady-state kinetics, and coenzyme binding using bacterial 3beta/17beta-hydroxysteroid dehydrogenase and selected mutants. Structure determination of the wildtype enzyme at 1.2-Angstrom resolution by x-ray crystallography and docking analysis was used to interpret the biochemical data. Enzyme kinetic data from mutagenetic replacements emphasize the critical role of residues Thr-12, Asp-60, Asn-86, Asn-87, and Ala-88 in coenzyme binding and catalysis. The data also demonstrate essential interactions of Asn-111 with active site residues. A general role of its side chain interactions for maintenance of the active site configuration to build up a proton relay system is proposed. This extends the previously recognized catalytic triad of Ser-Tyr-Lys residues to form a tetrad of Asn-Ser-Tyr-Lys in the majority of characterized short-chain dehydrogenases/reductase enzymes.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Novum, Ctr Struct Biochem, SE-14157 Huddinge, Sweden; Sodertorns Hogskola, Dept Nat Sci, SE-14104 Huddinge, Sweden; Karolinska Inst, Stockholm Bioinformat Ctr, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Sodertorn University; Karolinska Institutet	Oppermann, U (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	Udo.Oppermann@mbb.ki.se	Berndt, Kurt/J-8574-2015; Knapp, Stefan/AAG-2347-2019	Berndt, Kurt/0000-0002-3049-967X; Knapp, Stefan/0000-0001-5995-6494; Nordling, Erik/0000-0001-9310-7947				Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Benach J, 1996, EUR J BIOCHEM, V236, P144, DOI 10.1111/j.1432-1033.1996.t01-1-00144.x; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; Filling C, 2001, BIOCHEM BIOPH RES CO, V289, P712, DOI 10.1006/bbrc.2001.6032; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Ghosh D, 2001, CHEM-BIOL INTERACT, V130, P637, DOI 10.1016/S0009-2797(00)00255-6; Ghosh D, 2001, J BIOL CHEM, V276, P18457, DOI 10.1074/jbc.M100538200; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Liao DI, 2001, BIOCHEMISTRY-US, V40, P8696, DOI 10.1021/bi0107243; Obeyesekere VR, 1998, BIOCHEM BIOPH RES CO, V250, P469, DOI 10.1006/bbrc.1998.9313; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; Oppermann UCT, 1997, ADV EXP MED BIOL, V414, P403; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Zhou HP, 1999, BIOCHEM BIOPH RES CO, V257, P414, DOI 10.1006/bbrc.1999.0356	26	446	461	5	108	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25677	25684		10.1074/jbc.M202160200	http://dx.doi.org/10.1074/jbc.M202160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976334	hybrid			2022-12-27	WOS:000176747000107
J	Hedayati, MA; Steffen, SE; Bryant, FR				Hedayati, MA; Steffen, SE; Bryant, FR			Effect of the Streptococcus pneumoniae MmsA protein on the RecA protein-promoted three-strand exchange reaction - Implications for the mechanism of transformational recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; ESCHERICHIA-COLI; BRANCH MIGRATION; 3-STRAND RECOMBINATION; PURIFICATION; RESISTANCE; SEQUENCE; LOCUS	Streptococcus pneumoniae is a naturally transformable bacterium that is able to incorporate DNA from its environment into its own chromosome. This process, known as transformational recombination, is dependent in part on the mmsA gene, which encodes a protein having a sequence that is 40% identical to that of the Escherichia coli RecG protein, a junction-specific DNA helicase believed to be involved in the branch migration of recombinational intermediates. We have developed an expression system for the MmsA protein and have purified the MmsA protein to more than 99% homogeneity. The MmsA protein has DNA-dependent ATP hydrolysis and DNA junction-helicase activities that are similar to those of the E. coli RecG protein. The effect of the MmsA protein on the S. pneumoniae RecA protein-promoted three-strand exchange reaction was also investigated. In the standard direction (circular single-stranded (ss) DNA + linear double-stranded (ds) DNA --> linear ssDNA + nicked circular dsDNA), the MmsA protein appears to promote the branch migration of partially exchanged intermediates in a direction opposite of the RecA protein, resulting in a nearly complete inhibition of the overall strand exchange reaction. In the reverse direction (linear ssDNA + nicked circular dsDNA --> circular ssDNA + linear dsDNA), however, the MmsA protein appears to facilitate the conversion of partially exchanged intermediates into fully exchanged products, leading to a pronounced stimulation of the overall reaction. These results are discussed in terms of the molecular mechanism of transformational recombination.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bryant, FR (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM 36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Claverys JP, 2000, MOL MICROBIOL, V35, P251, DOI 10.1046/j.1365-2958.2000.01718.x; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Dowson Christopher G., 1994, Trends in Microbiology, V2, P361, DOI 10.1016/0966-842X(94)90612-2; Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hakenbeck R, 1999, MOL MICROBIOL, V33, P673, DOI 10.1046/j.1365-2958.1999.01521.x; LACKS S, 1962, J MOL BIOL, V5, P119, DOI 10.1016/S0022-2836(62)80067-9; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARTIN B, 1992, NUCLEIC ACIDS RES, V20, P6412, DOI 10.1093/nar/20.23.6412; Martin B, 1996, MOL MICROBIOL, V19, P1035, DOI 10.1046/j.1365-2958.1996.445975.x; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; Mortier-Barriere I, 1998, MOL MICROBIOL, V27, P159, DOI 10.1046/j.1365-2958.1998.00668.x; MortierBarrere I, 1997, MICROB DRUG RESIST, V3, P233, DOI 10.1089/mdr.1997.3.233; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; Steffen SE, 2000, ARCH BIOCHEM BIOPHYS, V382, P303, DOI 10.1006/abbi.2000.2029; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729	25	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24863	24869		10.1074/jbc.M202041200	http://dx.doi.org/10.1074/jbc.M202041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960988	hybrid			2022-12-27	WOS:000176747000006
J	Etheridge, KT; Banik, SSR; Armbruster, BN; Zhu, YS; Terns, RM; Terns, MP; Counter, CM				Etheridge, KT; Banik, SSR; Armbruster, BN; Zhu, YS; Terns, RM; Terns, MP; Counter, CM			The nucleolar localization domain of the catalytic subunit of human telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; TERMINAL DOMAINS; YEAST TELOMERASE; RNA COMPONENT; HUMAN-CELLS; EXPRESSION; PROTEIN; GENE	Telomerase is the enzyme essential to complete the replication of the terminal DNA of most eukaryotic chromosomes. In humans, this enzyme is composed of the telomerase reverse transcriptase (hTERT) and telomerase RNA (hTR) subunits. hTR has been found in the nucleolus, a site of assembly of ribosomes as well as other ribonucleoproteins (RNPs). We therefore tested whether the hTERT component is also found in the nucleolus, where it could complex with the hTR RNA to form a functional enzyme. We report here that hTERT does indeed localize to the nucleolus, and we mapped the domain responsible for this localization to the hTR-binding region of the protein by deletion analysis. Substitution mutations in two of the three conserved hTR-binding domains in this nucleolar localization domain (NoLD) abolished nucleolar localization. However, another mutation that impeded hTR binding did not alter this subcellular localization. Additionally, wild type hTERT was detected in the nucleolus of cells that failed to express hTR. Taken together, we propose that the nucleolar localization of hTERT involves more than just the association with the hTR subunit. Furthermore, the coincidental targeting of both the hTR and hTERT subunits to the nucleolus supports the premise that the assembly of telomerase occurs in the nucleolus.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Duke University; Duke University; Duke University; University System of Georgia; University of Georgia	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3813, Durham, NC 27710 USA.		Terns, Michael/N-6435-2016	Counter, Christopher M/0000-0003-0748-3079; Zhu, Yusheng/0000-0002-0666-7127	NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Chapon C, 1997, RNA, V3, P1337; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GARCIABLANCO MA, 1995, J CELL BIOL, V128, P15, DOI 10.1083/jcb.128.1.15; GOU C, 2001, J UROLOGY, V166, P694; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Guo W, 2001, INT J MOL MED, V8, P73; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kuramoto M, 2001, GENE, V277, P101, DOI 10.1016/S0378-1119(01)00684-9; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lukowiak AA, 2001, RNA, V7, P1833; Malik HS, 2000, GENE, V251, P101, DOI 10.1016/S0378-1119(00)00207-9; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Takenaka Y, 2001, GENE, V264, P153, DOI 10.1016/S0378-1119(01)00337-7; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000	49	112	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24764	24770		10.1074/jbc.M201227200	http://dx.doi.org/10.1074/jbc.M201227200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956201	hybrid			2022-12-27	WOS:000176611800103
J	Mamluk, R; Gechtman, Z; Kutcher, ME; Gasiunas, N; Gallagher, J; Klagsbrun, M				Mamluk, R; Gechtman, Z; Kutcher, ME; Gasiunas, N; Gallagher, J; Klagsbrun, M			Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; CELL-SURFACE; TUMOR-CELLS; SEMAPHORIN-III; NERVOUS-SYSTEM; PROTEIN; IDENTIFICATION; EXPRESSION; SULFATE; MOLECULES	Neuroplin-1 (NRP1), a receptor for vascular endothelial growth factor (VEGF) family members, has three distinct extracellular domains, a1a2, b1b2, and c. To determine the VEGF(165) and placenta growth factor 2 (PIGF-2) -binding sites of NRP1, recombinant NRP1 domains were expressed in mammalian cells as Myc-tagged, soluble proteins, and used in co-precipitation experiments with I-125-VEGF(165) and I-125-PIGF-2. Anti-Myc antibodies immunoprecipitated I-125-VEGF(165) and I-125-PIGF-2 in the presence of the b1b2 but not of the a1a2 and c domains. Neither b1 nor b2 alone was capable of binding I-125-VEGF(165). In competition experiments, VEGF(165) competed PIGF-2 binding to the NRP1 b1b2 domain, suggesting that the binding sites of VEGF(165) and PIGF-2 overlap. The presence of the a1a2 domain greatly enhanced VEGF(165), but not PIGF-2 binding to b1b2. Heparin enhanced the binding of both I-125-VEGF(165) and I-125-PIGF-2 to the b1b2 domain by 20- and 4-fold, respectively. A heparin chain of at least 20-24 monosaccharides was necessary for binding. In addition, the b1b2 domain of NRP1 could bind heparin directly, requiring heparin oligomers of at least 8 monosaccharide units. It was concluded that an intact b1b2 domain serves as the VEGF(165)-, PIGF-2-, and heparin-binding sites in NRP1, and that heparin is a critical component for regulating VEGF(165) and PIGF-2 interactions with NRP1 by physically interacting with both receptor and ligands.	Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA.			Kutcher, Matthew/0000-0003-4566-5359				Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Fuh G, 2000, J BIOL CHEM, V275, P26690; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; MAGLIONE D, 1993, ONCOGENE, V8, P925; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; OLSON ST, 1992, ADV EXP MED BIOL, V313, P155; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	37	196	202	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24818	24825		10.1074/jbc.M200730200	http://dx.doi.org/10.1074/jbc.M200730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986311	hybrid			2022-12-27	WOS:000176611800109
J	Salter, JP; Choe, Y; Albrecht, H; Franklin, C; Lim, KC; Craik, CS; McKerrow, JH				Salter, JP; Choe, Y; Albrecht, H; Franklin, C; Lim, KC; Craik, CS; McKerrow, JH			Cercarial elastase is encoded by a functionally conserved gene family across multiple species of schistosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PROTEASE INHIBITORS; MANSONI ELASTASE; SERINE-PROTEASE; INVASION; CLONING; PROTEINASE; PARASITES; SEQUENCE; SKIN	Water borne cercaria(ae) of the trematode genus Schistosoma rapidly penetrate host skin. A single serine protease activity, cercarial elastase, is deposited in advance of the invading parasite by holocytosis of vesicles from ten large acetabular gland cells. Cercarial elastase activity is a composite of multiple isoforms. Genes coding for the isoforms can be divided into two classes by amino acid and promoter sequence homology. Two of the five genes identified in Schistosoma mansoni account for over 90% of the activity and protein released. The remaining genes produce little protein or are silent. Positional scanning synthetic combinatorial substrate libraries demonstrate that the two major isoforms have similar substrate specificities and are, therefore, isoenzymes. The closely related Schistosoma hematobium and the distantly related Schistosomatium douthitti also contain multiple orthologous cercarial elastase genes suggesting that gene duplication may have occurred after speciation in Schistosoma evolution and that this duplication has been conserved.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Program Biomed Sci, San Francisco, CA 94143 USA; Discovery Partners Int AG, Discovery Biol Div, CH-4123 Allschwil, Switzerland	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	McKerrow, JH (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus,POB 0511, San Francisco, CA 94143 USA.		Albrecht, Hugo/F-9569-2011	Albrecht, Hugo/0000-0002-3951-1866				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CHARRIERFERRARA S, 1992, MOL BIOCHEM PARASIT, V56, P339, DOI 10.1016/0166-6851(92)90184-L; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; DORSEY CH, 1971, EXP PARASITOL, V30, P199, DOI 10.1016/0014-4894(71)90084-1; Dresden H.L, 1977, Journal Parasit, V63, P163; FELSENSTEIN J, 1993, PHYLIP SOFTWARE PACK; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Lim KC, 1999, AM J TROP MED HYG, V60, P487, DOI 10.4269/ajtmh.1999.60.487; MCKERROW JH, 1985, J BIOL CHEM, V260, P3703; NEWPORT GR, 1988, J BIOL CHEM, V263, P13179; Pierrot C, 1996, PARASITOLOGY, V113, P519, DOI 10.1017/S0031182000067561; Pierrot C, 1995, MOL BIOCHEM PARASIT, V75, P113, DOI 10.1016/0166-6851(95)02502-2; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; Salter JP, 2000, J BIOL CHEM, V275, P38667, DOI 10.1074/jbc.M006997200; STIREWALT MA, 1973, EXP PARASITOL, V33, P56, DOI 10.1016/0014-4894(73)90009-X; WAINE GJ, 1993, INFECT IMMUN, V61, P4716, DOI 10.1128/IAI.61.11.4716-4723.1993	17	78	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24618	24624		10.1074/jbc.M202364200	http://dx.doi.org/10.1074/jbc.M202364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986325	hybrid			2022-12-27	WOS:000176611800085
J	Simbulan-Rosenthal, CM; Velena, A; Veldman, T; Schlegel, R; Rosenthal, DS				Simbulan-Rosenthal, CM; Velena, A; Veldman, T; Schlegel, R; Rosenthal, DS			HPV-16 E6/7 immortalization sensitizes human keratinocytes to ultraviolet B by altering the pathway from caspase-8 to caspase-9-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; NORMAL HUMAN SKIN; TERMINAL DIFFERENTIATION; EPITHELIAL-CELLS; LIGAND CD95L; GENE; ACTIVATION; EXPRESSION; MUTATIONS; P53	UVB from solar radiation is both an initiating and promoting agent for skin cancer. We have found that primary human keratinocytes undergo an apoptotic response to UVB. To determine whether these responses are altered during the course of immortalization, we examined markers of apoptosis in primary human foreskin keratinocytes (HFK) transduced with either a retroviral vector expressing the E6 and E7 genes of HPV-16 or with empty vector alone (LXSN-HFK). Whereas LXSN-HFK as well as early passage keratinocytes expressing HPV-16 E6 and E7 (p7 E6/7-HFK) were both moderately responsive to UVB irradiation, late passage-immortalized keratinocytes (p27 E6/7-HFK) were exquisitely sensitive to UVB-induced apoptosis. After exposure to UVB, enhanced annexin V-positivity and internucleosomal DNA fragmentation were observed in p27 E6/7-HFK compared with either LXSN- or p7 E6/7-HFK. Caspase-3 fluorometric activity assays as well as immunoblot analysis with antibodies to caspase-3 and poly(ADP-ribose) polymerase revealed elevated caspase-3 activity and processing at lower UVB doses in p27 E6/7-HFK compared with LXSN- or p7 E6/7-HFK. In addition, the caspase inhibitor DEVD-CHO reduced the apoptotic response and increased survival of all three HFK types. Immunoblot analysis revealed that caspase-8 was activated in all three cell types, but caspase-9 was only activated in p27 E6/7-HFK. Cell cycle analysis further showed that only p27 E6/7-HFK exhibit G(2)/M accumulation that is enhanced by UVB treatment. This accumulation was associated with a rapid down-regulation of Bcl-2 in these cells. The immortalization process subsequent to the expression of HPV E6 and E7 may therefore determine UVB sensitivity by switching the mode of apoptosis from a caspase-8 to a Bcl-2-caspase-9-mediated pathway of apoptosis.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, 3900 Reservoir Rd,NW, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342; Rosenthal, Dean/0000-0002-7624-0209				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bavinck JNB, 2000, BRIT J DERMATOL, V142, P103, DOI 10.1046/j.1365-2133.2000.03248.x; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FADOK VA, 1992, J IMMUNOL, V148, P2207; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Poignee M, 2001, CANCER RES, V61, P7118; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; VINDELOV LL, 1983, CYTOMETRY, V3, P332, DOI 10.1002/cyto.990030505; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; Zhuang LH, 1999, J IMMUNOL, V162, P1440; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; zur Hausen H, 1996, BIOCHIM BIOPHYS ACTA, V1288, P55	36	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24709	24716		10.1074/jbc.M200281200	http://dx.doi.org/10.1074/jbc.M200281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976323	hybrid			2022-12-27	WOS:000176611800097
J	Wu, WD; Graves, LM; Gill, GN; Parsons, SJ; Samet, JM				Wu, WD; Graves, LM; Gill, GN; Parsons, SJ; Samet, JM			Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FACTOR EGF RECEPTOR; C-SRC; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; BREAST-CANCER; MITOGENIC RESPONSIVENESS; INTRACELLULAR CA2+; SH3 DOMAINS; KINASE	Previous studies have shown that exposure of cells to Zn2+ ions induces Ras and MAPK activation through the EGF receptor (EGFR). To further determine the role of EGFR in Zn2+-induced signaling, mouse B82L fibroblasts expressing no detectable EGFR protein (B82L-par), wild type EGFR (B82L-wt), kinase-deficient EGFR (B82L-K721M), or COOH-truncated EGFR (B82L-c'958) were tested. Exposure to Zn2+ induced Ras activity in B82L-wt, B82L-K721M, and B82L-c'958 but not in B82L-par cells, indicating that the tyrosine kinase domain and the auto-phosphorylation sites of the EGFR were not required for Zn2+-induced Ras activation. Zn2+ induced Src activation in all B82L cell lines, including B82L-par, indicating that Src activation is independent of the presence of the EGFR. A Src kinase inhibitor blocked Zn2+-induced Ras activation in all the B82L cell lines capable of this response, suggesting the involvement of Src kinase in Zn2+-induced Ras activation via the EGFR. Zn2+ induced the association of the EGFR with Src and specifically increased the phosphorylation of EGFR at tyrosine 845 (Tyr-845), a known Src phosphorylation site. Stably transfected B82L cells with a point mutation of the EGFR at Tyr-845 (B82L-Y845F) exhibited only basal Ras activity following exposure to Zn2+. These data demonstrate that Src-dependent phosphorylation of the EGFR at Tyr-845 is required for EGFR transactivation and Zn2+-induced Ras activation.	US EPA, Human Studies Div, Natl Hlth & Environm Effect Res Lab ORD MD58A, Off Res & Dev, Res Triangle Pk, NC 27711 USA; Univ Virginia, Ctr Hlth, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Hlth, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA	United States Environmental Protection Agency; University of Virginia; University of Virginia; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Samet, JM (corresponding author), US EPA, Human Studies Div, Natl Hlth & Environm Effect Res Lab ORD MD58A, Off Res & Dev, Res Triangle Pk, NC 27711 USA.		Graves, Lee/AAG-5470-2021					Adamson IYR, 2000, TOXICOL APPL PHARM, V166, P111, DOI 10.1006/taap.2000.8955; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P279, DOI 10.1081/CLT-100102426; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kuschner WG, 1997, ENVIRON RES, V75, P7, DOI 10.1006/enrs.1997.3765; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598; Maret W, 2001, P NATL ACAD SCI USA, V98, P12325, DOI 10.1073/pnas.231481398; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Martin CJ, 1999, AM J IND MED, V35, P574, DOI 10.1002/(SICI)1097-0274(199906)35:6<574::AID-AJIM4>3.0.CO;2-L; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; NOGUCHI M, 1993, CANCER RES, V53, P2035; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WELSH JB, 1994, MOL BIOL CELL, V5, P539, DOI 10.1091/mbc.5.5.539; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wong L, 1999, J BIOL CHEM, V274, P8900, DOI 10.1074/jbc.274.13.8900; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924; Wu WD, 2001, AM J PHYSIOL-LUNG C, V281, pL483, DOI 10.1152/ajplung.2001.281.2.L483	66	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24252	24257		10.1074/jbc.M200437200	http://dx.doi.org/10.1074/jbc.M200437200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983694	hybrid, Green Published			2022-12-27	WOS:000176611800037
J	Brosh, RM; Waheed, J; Sommers, JA				Brosh, RM; Waheed, J; Sommers, JA			Biochemical characterization of the DNA substrate specificity of Werner syndrome helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALLED REPLICATION FORKS; SINGLE-STRANDED-DNA; SYNDROME PROTEIN; SYNDROME CELLS; SYNDROME GENE; FLAP ENDONUCLEASE-1; POLYMERASE-DELTA; REPEAT SEQUENCE; HOLLIDAY JUNCTIONS; S-PHASE	Werner syndrome is a hereditary premature aging disorder characterized by genome instability. The product of the gene defective in WS, WRN, is a helicase/exonuclease that presumably functions in DNA metabolism. To understand the DNA structures WRN acts upon in vivo, we examined its substrate preferences for unwinding. WRN unwound a 3'-single-stranded (ss)DNA-tailed duplex substrate with streptavidin bound to the end of the 3'-ssDNA tail, suggesting that WRN does not require a free DNA end to unwind the duplex; however, WRN was completely blocked by streptavidin bound to the 3'-ssDNA tail 6 nucleotides upstream of the single-stranded/double-stranded DNA junction. WRN efficiently unwound the forked duplex with streptavidin bound just upstream of the junction, suggesting that WRN recognizes elements of the fork structure to initiate unwinding. WRN unwound two important intermediates of replication/repair, a 5'-ssDNA flap substrate and a synthetic replication fork. WRN was able to translocate on the lagging strand of the synthetic replication fork to unwind duplex ahead of the fork. For the 5'-flap structure, WRN specifically displaced the 5'-flap oligonucleotide, suggesting a role of WRN in Okazaki fragment processing. The ability of WRN to target DNA replication/repair intermediates may be relevant to its role in genome stability maintenance.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.							Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Pichierri P, 2000, MUTAT RES-FUND MOL M, V456, P45, DOI 10.1016/S0027-5107(00)00109-3; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	51	109	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23236	23245		10.1074/jbc.M111446200	http://dx.doi.org/10.1074/jbc.M111446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956187	hybrid			2022-12-27	WOS:000176475700020
J	Lu, SM; Hodges, RS				Lu, SM; Hodges, RS			A de novo designed template for generating conformation-specific antibodies that recognize alpha-helices in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; HERPES-SIMPLEX VIRUS; GCN4 LEUCINE-ZIPPER; COILED-COILS; OLIGOMERIZATION STATE; HYDROPHOBIC CORE; PRION PROTEIN; CIRCULAR-DICHROISM; BUNDLE PROTEIN; STABILITY	The generation of antibodies directed toward the surface-exposed regions of a protein using synthetic peptides as immunogens representing surface loops and turns has been widely successful. However, peptides representing a-helical regions are typically unstructured in solution and unable to produce antibodies that recognize a-helices in native proteins. We describe a de novo designed parallel two-stranded a-helical coiled-coil template for immunization to prepare antibodies that recognize a-helical protein sequences in the native protein. This template was designed for maximum stability through an IIe/Leu hydrophobic core and an interchain disulfide bridge. Surface-exposed helical residues are inserted into the template and used for immunization to generate polyclonal antibodies. To demonstrate the feasibility of this approach, 15 residues of the yeast transcription factor GCN4 were inserted into this template, and the resultant antibodies were screened for conformational specificity. Peptide antigens that contain the same surface-exposed residues but differ in structure were used as competitors in a competition assay. Direct competition between the capture peptide immobilized on a biosensor chip, the peptide antigens, and the antibodies generated by the template demonstrated that the antibodies were specific for helical structure in the native coiled-coil (synthetic GCN4 residues 250-280). These antibodies were unable to recognize the same inserted sequence in an unstructured analog. The helix-specific antibodies were also able to identify native GCN4 (31.3 kDa) from yeast whole cell extracts.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA.	robert.hodges@uchsc.edu						Aslam M., 1998, BIOCONJUGATION PROTE; Barthe P, 2000, PROTEIN SCI, V9, P942, DOI 10.1110/ps.9.5.942; Benjamin David C., 1996, Methods (Orlando), V9, P508, DOI 10.1006/meth.1996.0058; Berger C, 1999, FEBS LETT, V450, P149, DOI 10.1016/S0014-5793(99)00458-5; BETZ S, 1995, PHILOS T ROY SOC B, V348, P81, DOI 10.1098/rstb.1995.0048; Bosshard HR, 2001, NEWS PHYSIOL SCI, V16, P171; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cooper JA, 1997, MOL IMMUNOL, V34, P433, DOI 10.1016/S0161-5890(97)00056-4; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DYSON HJ, 1995, FASEB J, V9, P37, DOI 10.1096/fasebj.9.1.7821757; Foster TF, 2001, VIROLOGY, V287, P18, DOI 10.1006/viro.2001.1004; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hay FC., 2001, EPITOPE MAPPING PRAC; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Houston M E Jr, 1995, J Pept Sci, V1, P274; Irving MB, 2001, CURR OPIN CHEM BIOL, V5, P314, DOI 10.1016/S1367-5931(00)00208-8; JIN L, 1996, STRUCTURE ANTIGENS, V3, P21; Kohn WD, 1998, TRENDS BIOTECHNOL, V16, P379, DOI 10.1016/S0167-7799(98)01212-8; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Lee DL, 2001, J MOL BIOL, V306, P539, DOI 10.1006/jmbi.2000.4351; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Miceli R, 1996, Drug Des Discov, V13, P95; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; NEWMAN MA, 1992, J IMMUNOL, V149, P3260; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PARKER JMR, 1984, J PROTEIN CHEM, V3, P465, DOI 10.1007/BF01025065; PARKER JMR, 1984, J PROTEIN CHEM, V3, P479, DOI 10.1007/BF01025066; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8; Rabanal F, 1996, TETRAHEDRON LETT, V37, P1347, DOI 10.1016/0040-4039(96)00019-6; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; STANFIELD RL, 1994, TRENDS BIOTECHNOL, V12, P275, DOI 10.1016/0167-7799(94)90139-2; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Starovasnik MA, 1997, P NATL ACAD SCI USA, V94, P10080, DOI 10.1073/pnas.94.19.10080; STRYNADKA NCJ, 1988, J VIROL, V62, P3474, DOI 10.1128/JVI.62.9.3474-3483.1988; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; TSANG P, 1992, BIOCHEMISTRY-US, V31, P3862, DOI 10.1021/bi00130a018; Van Regenmortel M H, 1995, Biomed Pept Proteins Nucleic Acids, V1, P109; Van Regenmortel MHV, 1998, J MOL RECOGNIT, V11, P163; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Walsh STR, 1999, P NATL ACAD SCI USA, V96, P5486, DOI 10.1073/pnas.96.10.5486; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114; ZHU BY, 1993, PROTEIN SCI, V2, P383	54	26	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23515	23524		10.1074/jbc.M201981200	http://dx.doi.org/10.1074/jbc.M201981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971904	hybrid			2022-12-27	WOS:000176475700056
J	Barendt, WM; Wright, SH				Barendt, WM; Wright, SH			The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; CONTRALUMINAL TRANSPORT; FUNCTIONAL EXPRESSION; CLONING; ANIONS; SYSTEMS; TUBULE; OCT1; PH	The organic cation transporter, OCT2, plays a role in renal secretion of a broad array of weak bases. To determine whether the degree of ionization of these compounds plays a role in their interaction with OCT2, we examined the influence of external pH values on the activity of the human ortholog of OCT2, as expressed in Chinese hamster ovary-K1 cells. Importantly, changing the pH value from 7.0 to 8.0 had no effect on the rate of transport of the fixed cations, tetraethylammonium and 1-methyl-4-phenylpyridinium, i.e. the pH value did not have an effect upon the transporter itself. Cimetidine (pK(a) 6.92), a competitive inhibitor of hOCT2, displayed a 3.5-fold increase in IC50 as pH values increased from 7 to S. hOCT2-mediated cimetidine transport decreased over this pH range, the consequence of an increase in K-t and decrease in J(max) at the higher pH value. The weak bases trimethoprim and 4-phenylpyridine showed a similar pattern of pH-sensitive interaction with hOCT2. The non-ionizable sterol, corticosterone, also inhibited hOCT2 activity, although it was neither competitive in nature nor was it sensitive to pH in the manner observed with weak bases. We conclude that the degree of ionization plays a critical role in binding of substrate to organic cation transporters.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA	University of Arizona	Wright, SH (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL07249] Funding Source: Medline; NIDDK NIH HHS [DK58251] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058251, R01DK058251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Budiman T, 2000, J BIOL CHEM, V275, P29413, DOI 10.1074/jbc.M004645200; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Dresser MJ, 2000, J PHARMACOL EXP THER, V292, P1146; Dzekunov SM, 1998, J MEMBRANE BIOL, V166, P9, DOI 10.1007/s002329900443; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Koepsell H, 1998, ANNU REV PHYSIOL, V60, P243, DOI 10.1146/annurev.physiol.60.1.243; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; MOTOHASHI H, 2002, J AM SOC NEPHROL, V13; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RENNICK BR, 1981, AM J PHYSIOL, V240, pF83, DOI 10.1152/ajprenal.1981.240.2.F83; ROCHRAMEL F, 1992, HDB PHYSL, V2; Segel I.H., 1975, ENZYME KINETICS; Segel IH, 1976, BIOCH CALCULATIONS; SOMOGYI A, 1983, CLIN PHARMACOKINET, V8, P463, DOI 10.2165/00003088-198308060-00001; ULLRICH KJ, 1992, PFLUG ARCH EUR J PHY, V421, P286, DOI 10.1007/BF00374841; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P300, DOI 10.1007/BF00374180; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	24	63	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22491	22496		10.1074/jbc.M203114200	http://dx.doi.org/10.1074/jbc.M203114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953440	hybrid			2022-12-27	WOS:000176313600051
J	Corsi, B; Cozzi, A; Arosio, P; Drysdale, J; Santambrogio, P; Campanella, A; Biasiotto, G; Albertini, A; Levi, S				Corsi, B; Cozzi, A; Arosio, P; Drysdale, J; Santambrogio, P; Campanella, A; Biasiotto, G; Albertini, A; Levi, S			Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN H-FERRITIN; ERYTHROID-CELLS; OXIDATIVE STRESS; SKELETAL-MUSCLE; MESSENGER-RNA; L-CHAIN; GENE; OVEREXPRESSION; MUTATION; HYPERFERRITINEMIA	Mitochondrial ferritin (MtF) is a newly identified ferritin encoded by an intronless gene on chromosome 5q23.1. The mature recombinant MtF has a ferroxidase center and binds iron in vitro similarly to H-ferritin. To explore the structural and functional aspects of MtF, we expressed the following forms in HeLa cells: the MtF precursor (similar to28 kDa), a mutant MtF precursor with a mutated ferroxidase center, a truncated MtF lacking the similar to6-kDa mitochondrial leader sequence, and a chimeric H-ferritin with this leader sequence. The experiments show that all constructs with the leader sequence were processed into similar to22-kDa subunits that assembled into multimeric shells electrophoretically distinct from the cytosolic ferritins. Mature MtF was found in the matrix of mitochondria, where it is a homopolymer. The wild type MtF and the mitochondrially targeted H-ferritin both incorporated the Fe-55 label in vivo. The mutant MtF with an inactivated ferroxidase center did not take up iron, nor did the truncated MtF expressed transiently in cytoplasm. Increased levels of MtF both in transient and in stable transfectants resulted in a greater retention of iron as MtF in mitochondria, a decrease in the levels of cytosolic ferritins, and up-regulation of transferrin receptor. Neither effect occurred with the mutant MtF with the inactivated ferroxidase center. Our results indicate that exogenous iron is as available to mitochondrial ferritin as it is to cytosolic ferritins and that the level of MtF expression may have profound consequences for cellular iron homeostasis.	Hosp San Raffaele, IRCCS, Prot Engn Unit, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Brescia, Fac Med, Sect Chem, I-25100 Brescia, Italy; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Brescia; Tufts University	Levi, S (corresponding author), Hosp San Raffaele, IRCCS, Prot Engn Unit, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Campanella, Alessandro/N-8315-2015; arosio, paolo/S-3272-2019; Biasiotto, Giorgio/Z-3660-2019; arosio, paolo/E-6817-2010; levi, sonia/A-3161-2015; Santambrogio, Paolo/AAN-3837-2020; Cozzi, Anna/AAN-3821-2020	Campanella, Alessandro/0000-0002-3463-1199; arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; Biasiotto, Giorgio/0000-0001-7495-7807; albertini, alberto/0000-0002-7989-649X	Telethon [GP0075Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBAS A, 1993, J BIOL CHEM, V268, P8541; Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1071; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; COZZI A, 1989, CLIN CHIM ACTA, V184, P197, DOI 10.1016/0009-8981(89)90052-1; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Curtis ARJ, 2001, NAT GENET, V28, P350, DOI 10.1038/ng571; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Ferreira GC, 1999, INT J BIOCHEM CELL B, V31, P995, DOI 10.1016/S1357-2725(99)00066-7; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200; Levi S, 1998, BLOOD, V91, P4180, DOI 10.1182/blood.V91.11.4180.411k38_4180_4187; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1987, GENE, V51, P267; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Ponka P, 1997, BLOOD, V89, P1; RADEMAKERS LHPM, 1993, EUR J CLIN INVEST, V23, P130, DOI 10.1111/j.1365-2362.1993.tb00752.x; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; Tan G, 2001, HUM MOL GENET, V10, P2099, DOI 10.1093/hmg/10.19.2099; THOMPSON CH, 1993, J INTERN MED, V234, P149, DOI 10.1111/j.1365-2796.1993.tb00724.x; VILLA A, 1993, EXP CELL RES, V209, P140, DOI 10.1006/excr.1993.1294; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	35	125	132	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22430	22437		10.1074/jbc.M105372200	http://dx.doi.org/10.1074/jbc.M105372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953424	hybrid			2022-12-27	WOS:000176313600043
J	Trivier, E; Ganesan, TS				Trivier, E; Ganesan, TS			RYK, a catalytically inactive receptor tyrosine kinase, associates with EphB2 and EphB3 but does not interact with AF-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL OVARIAN-CANCER; H-RYK; POSTTRANSLATIONAL MODIFICATION; EXTRACELLULAR DOMAINS; ECTODOMAIN CLEAVAGE; DOWN-REGULATION; CDNA SEQUENCE; IN-VITRO; PROTEIN; DROSOPHILA	RYK is an atypical orphan receptor tyrosine kinase that lacks detectable kinase activity. Nevertheless, using a chimeric receptor approach, we previously found that RYK can signal via the mitogen-activated protein kinase pathway. Recently, it has been shown that murine Ryk can bind to and be phosphorylated by the ephrin receptors EphB2 and EphB3. In this study, we show that human RYK associates with EphB2 and EphB3 but is not phosphorylated by them. This association requires both the extracellular and cytoplasmic domains of RYK and is not dependent on activation of the Eph receptors. It was also previously shown that AF-6 (afadin), a PDZ domain-containing protein, associates with murine Ryk. We show here that AF-6 does not bind to human RYK in vitro or in vivo. This suggests that there are significant functional differences between human and murine RYK. Further studies are required to determine whether RYK modulates the signaling of EphB2 and EphB3.	John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Mol Oncol Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Ganesan, TS (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Mol Oncol Labs, Oxford OX3 9DS, England.		GANESAN, Trivadi Sundaram/AAU-1499-2020	GANESAN, Trivadi Sundaram/0000-0002-4671-8099				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bonkowsky JL, 1999, MECH DEVELOP, V82, P181, DOI 10.1016/S0925-4773(99)00007-6; Bonkowsky JL, 1999, NATURE, V402, P540, DOI 10.1038/990122; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Feng GP, 2000, NEURON, V25, P295, DOI 10.1016/S0896-6273(00)80895-8; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Halford MM, 1999, J BIOL CHEM, V274, P7379, DOI 10.1074/jbc.274.11.7379; Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Jardine LJ, 1999, ONCOGENE, V18, P7602, DOI 10.1038/sj.onc.1203137; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Katso RMT, 1999, CANCER RES, V59, P2265; Katso RMT, 2000, CLIN CANCER RES, V6, P3271; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; McCarthy MJ, 1999, LAB INVEST, V79, P889; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Patthy L, 2000, TRENDS BIOCHEM SCI, V25, P12, DOI 10.1016/S0968-0004(99)01504-2; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991	49	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23037	23043		10.1074/jbc.M202486200	http://dx.doi.org/10.1074/jbc.M202486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956217	hybrid			2022-12-27	WOS:000176313600119
J	Brinkmann, V; Davis, MD; Heise, CE; Albert, R; Cottens, S; Hof, R; Bruns, C; Prieschl, E; Baumruker, T; Hiestand, P; Foster, CA; Zollinger, M; Lynch, KR				Brinkmann, V; Davis, MD; Heise, CE; Albert, R; Cottens, S; Hof, R; Bruns, C; Prieschl, E; Baumruker, T; Hiestand, P; Foster, CA; Zollinger, M; Lynch, KR			The immune modulator FTY720 targets sphingosine 1-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATING MATURE LYMPHOCYTES; PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; IMMUNOSUPPRESSIVE ACTIVITY; SPHINGOSINE-1-PHOSPHATE; KINASE; LYSOPHOSPHOLIPIDS; SEQUESTRATION; ACCELERATION	Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis. In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation. FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms. Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compound is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis. Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.	Novartis Pharma AG, Dept Transplantat, CH-4002 Basel, Switzerland; Novartis Pharma AG, Dept Arthrit & Bone Metab, CH-4002 Basel, Switzerland; Novartis Pharma AG, Dept Preclin Safety, CH-4002 Basel, Switzerland; Novartis Res Inst, Dept Dermatol & Immunopathol, A-1235 Vienna, Austria; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Novartis; Novartis; Novartis; Novartis; University of Virginia; University of Virginia	Lynch, KR (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, Box 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	krl2z@virginia.edu			NCI NIH HHS [R01 CA88994] Funding Source: Medline; NIGMS NIH HHS [F31 GM64101, R01 GM52722] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722, F31GM064101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Beer MS, 2000, ANN NY ACAD SCI, V905, P118; BOLTON C, 1982, J NEUROL SCI, V56, P147, DOI 10.1016/0022-510X(82)90138-1; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chiba K, 1998, J IMMUNOL, V160, P5037; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Henning G, 2001, J EXP MED, V194, P1875, DOI 10.1084/jem.194.12.1875; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; HOBSON JP, 2001, NATURE, V291, P1800; Im DS, 2001, BIOCHEMISTRY-US, V40, P14053, DOI 10.1021/bi011606i; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kanazawa I, 2001, TRENDS MOL MED, V7, P339, DOI 10.1016/S1471-4914(01)02017-2; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Matsuda S, 1999, J IMMUNOL, V162, P3321; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Miyamoto T, 2001, J AM COLL CARDIOL, V37, P1713, DOI 10.1016/S0735-1097(01)01204-9; Nikolova Z, 2001, TRANSPLANTATION, V72, P168, DOI 10.1097/00007890-200107150-00033; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; PALIK JH, 2001, J BIOL CHEM, V276, P11830; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Steinman L, 1999, NEURON, V24, P511, DOI 10.1016/S0896-6273(00)81107-1; TEDESCO T, 2001, AM J TRANSPLANT, V1, pS243; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	36	1229	1311	2	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21453	21457		10.1074/jbc.C200176200	http://dx.doi.org/10.1074/jbc.C200176200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11967257	hybrid			2022-12-27	WOS:000176286000044
J	Horiuchi, T; Taoka, M; Isobe, T; Komano, T; Inouye, S				Horiuchi, T; Taoka, M; Isobe, T; Komano, T; Inouye, S			Role of fruA and csgA genes in gene expression during development of Myxococcus xanthus - Analysis by two-dimensional gel electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUITING BODY MORPHOGENESIS; C-FACTOR; GUANOSINE PENTAPHOSPHATE; SIGNALING PROTEIN; CELL-INTERACTIONS; ESCHERICHIA-COLI; REGULATED GENES; TETRAPHOSPHATE; LOCUS; MYXOBACTERIA	Two genes, fruA and csgA, encoding a putative transcription factor and C-factor, respectively, are essential for fruiting body formation of Myxococcus xanthus. To investigate the role of fruA and csgA genes in developmental gene expression, developing cells as well as vegetative cells of M. xanthus wild-type, fruA::Tc, and csgA731 strains were pulse-labeled with [S-35]methionine, and the whole cell proteins were analyzed using two-dimensional immobilized pH gradient/SDS-PAGE. Differences in protein synthesis patterns among more than 700 protein spots were detected during development of the three strains. Fourteen proteins showing distinctly different expression patterns in mutant cells were analyzed in more detail. Five of the 14 proteins were identified as elongation factor Tu (EF-Tu), Dru, DofA, FruA, and protein S by immunoblot analysis and mass spectroscopy. A gene encoding DofA was cloned and sequenced. Although both fruA and csgA genes regulate early development of M. xanthus, they were found to differently regulate expression of several developmental genes. The production of six proteins, including DofA and protein S, was dependent on fruA, whereas the production of two proteins was dependent on csgA, and one protein was dependent on both fruA and csgA. To explain the present findings, a new model was presented in which different levels of FruA phosphorylation may distinctively regulate the expression of two groups of developmental genes.	Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Dept Chem, Hachioji, Tokyo 1920397, Japan; Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Tokyo Metropolitan University; Tokyo Metropolitan University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Komano, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo 1920397, Japan.		Inouye, Sharon/R-7216-2019; Isobe, Toshiaki/Q-9279-2017	Taoka, Masato/0000-0001-5554-4951				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKER ME, 1994, BIOCHEM J, V301, P311, DOI 10.1042/bj3010311; BRETSCHER AP, 1978, P NATL ACAD SCI USA, V75, P2746; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Crawford EW, 2000, GENE DEV, V14, P483; Davis JM, 1995, MOL MICROBIOL, V18, P943, DOI 10.1111/j.1365-2958.1995.18050943.x; DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; Ellehauge E, 1998, MOL MICROBIOL, V30, P807, DOI 10.1046/j.1365-2958.1998.01113.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GOLLOP R, 1991, J BACTERIOL, V173, P3597, DOI 10.1128/jb.173.11.3597-3600.1991; Gorski L, 2000, J BACTERIOL, V182, P2438, DOI 10.1128/JB.182.9.2438-2444.2000; HAGEN DC, 1978, DEV BIOL, V64, P284, DOI 10.1016/0012-1606(78)90079-9; Harris BZ, 1998, GENE DEV, V12, P1022, DOI 10.1101/gad.12.7.1022; INOUYE M, 1979, DEV BIOL, V68, P579, DOI 10.1016/0012-1606(79)90228-8; INOUYE S, 1983, P NATL ACAD SCI-BIOL, V80, P6829, DOI 10.1073/pnas.80.22.6829; KAISER D, 1993, MYXOBACTERIA, V2, P257; KIM SK, 1991, J BACTERIOL, V173, P1722, DOI 10.1128/jb.173.5.1722-1728.1991; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; KIM SK, 1990, GENE DEV, V4, P896, DOI 10.1101/gad.4.6.896; KROOS L, 1987, GENE DEV, V1, P840, DOI 10.1101/gad.1.8.840; KROOS L, 1986, DEV BIOL, V117, P252, DOI 10.1016/0012-1606(86)90368-4; Kruse T, 2001, MOL MICROBIOL, V40, P156, DOI 10.1046/j.1365-2958.2001.02365.x; LEE BU, 1995, GENE DEV, V9, P2964, DOI 10.1101/gad.9.23.2964; LI SF, 1992, GENE DEV, V6, P401, DOI 10.1101/gad.6.3.401; MANOIL C, 1980, J BACTERIOL, V141, P305, DOI 10.1128/JB.141.1.305-315.1980; MANOIL C, 1980, J BACTERIOL, V141, P297, DOI 10.1128/JB.141.1.297-304.1980; Ogawa M, 1996, MOL MICROBIOL, V22, P757, DOI 10.1046/j.1365-2958.1996.d01-1725.x; Otani M, 2001, J BACTERIOL, V183, P6282, DOI 10.1128/JB.183.21.6282-6287.2001; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMKETS LJ, 1982, J BACTERIOL, V152, P451; SHIMKETS LJ, 1988, MOL GEN GENET, V211, P63, DOI 10.1007/BF00338394; SHIMKETS LJ, 1990, J BACTERIOL, V172, P5299, DOI 10.1128/jb.172.9.5299-5306.1990; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SHIMKETS LJ, 1983, P NATL ACAD SCI-BIOL, V80, P1406, DOI 10.1073/pnas.80.5.1406; SINGER M, 1995, GENE DEV, V9, P1633, DOI 10.1101/gad.9.13.1633; SogaardAndersen L, 1996, GENE DEV, V10, P740, DOI 10.1101/gad.10.6.740; Taoka M, 2000, ELECTROPHORESIS, V21, P1872, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1872::AID-ELPS1872>3.0.CO;2-#	39	32	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26753	26760		10.1074/jbc.M111214200	http://dx.doi.org/10.1074/jbc.M111214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11997385	hybrid			2022-12-27	WOS:000177055900008
J	Wang, HX; Hays, JB				Wang, HX; Hays, JB			Mismatch repair in human nuclear extracts - Quantitative analyses of excision of nicked circular mismatched DNA substrates, constructed by a new technique employing synthetic oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTS-ALPHA; TUMOR-CELLS; IN-VITRO; CISPLATIN; ADDUCTS; DAMAGE; HETERODIMER; RESISTANCE; TOLERANT; LESIONS	Mammalian mismatch repair (MMR) systems respond to broad ranges of DNA mismatches and lesions. Kinetic analyses of MMR processing in vitro have focused on base mismatches in a few sequence contexts, because of a lack of general and quantitative MMR assays and because of the difficulty of constructing a multiplicity of MMR substrates, particularly those with DNA lesions. We describe here simple and efficient construction of 11 different MMR substrates, by ligating synthetic oligomers into gapped plasmids generated using sequence-specific N.BstNBI nicking endonuclease, then using sequence-specific nicking endonuclease N.AlwI to introduce single nicks for initiation of 3' to 5' or 5' to 3' excision. To quantitatively assay MMR excision gaps in base-mispaired substrates, generated in human nuclear extracts lacking exogenous dNTPs, we used position- and strand-specific oligomer probes. Mispair-provoked excision along the shorter path from the pre-existing nick toward the mismatch, either 3' to 5' or 5' to T, predominated over longer path excision by roughly 10:1 to 20:1. MMR excision was complete within 7 min, was highly specific (90:1) for the nicked strand, and was strongly mispair-dependent (at least 40:1). Nonspecific (mismatch-independent) 5' to 3' excision was considerably greater than nonspecific 3' to 5' excision, especially at pre-existing gaps, but was not processive. These techniques can be used to construct and analyze MMR substrates with DNA mismatches or lesions in any sequence context.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, ALS 1007, Corvallis, OR 97331 USA.				NIEHS NIH HHS [ES09848] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009848] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fink D, 1997, CANCER RES, V57, P1841; Fritzell JA, 1997, CANCER RES, V57, P5143; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HELIG JS, 1998, CURRENT PROTOCOL MOL; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; JONES M, 1987, GENETICS, V115, P605; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu HB, 2000, GENETICS, V154, P503; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nara K, 2001, CANCER RES, V61, P50; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wang HX, 2000, MOL BIOTECHNOL, V15, P97, DOI 10.1385/MB:15:2:97; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; Wang HX, 2002, J BIOL CHEM, V277, P26143, DOI 10.1074/jbc.M200358200; Wang HX, 2001, MOL BIOTECHNOL, V19, P133, DOI 10.1385/MB:19:2:133; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Xu Y, 2001, P NATL ACAD SCI USA, V98, P12990, DOI 10.1073/pnas.241215698	33	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26136	26142		10.1074/jbc.M200357200	http://dx.doi.org/10.1074/jbc.M200357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006560	hybrid			2022-12-27	WOS:000176908700041
J	Wang, Z; Frederick, J; Garabedian, MJ				Wang, Z; Frederick, J; Garabedian, MJ			Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; PROTEIN; ACTIVATION; TRANSCRIPTION; COMPLEXES; SITES; ACID	The glucocorticoid receptor (GR) is phosphorylated at multiple serine residues in a hormone-dependent manner, yet progress on elucidating the function of GR phosphorylation has been hindered by the lack of a simple assay to detect receptor phosphorylation in vivo. We have produced antibodies that specifically recognize phosphorylation sites within human GR at Ser(203) and Ser(211). In the absence of hormone, the level of GR phosphorylation at Ser(211) was low compared with phosphorylation at Ser(203). Phosphorylation of both residues increased upon treatment with the GR agonist dexamethasone. Using a battery of agonists and antagonists, we found that the transcriptional activity of GR correlated with the amount of phosphorylation at Ser(211), suggesting that Ser(211) phosphorylation is a biomarker for activated GR in vivo. Mechanistically, the kinetics of Ser(203) and Ser(211) phosphorylation in response to hormone differed, with Ser(211) displaying a more robust and sustained phosphorylation relative to Ser(203). Analysis of GR immunoprecipitates with phospho-GR-specific antibodies indicated that the receptor was phosphorylated heterogeneously at Ser(203) in the absence of hormone, whereas in the presence of hormone, a subpopulation of receptors was phosphorylated at both Ser(203) and Ser(211). Interestingly, biochemical fractionation studies following hormone treatment indicated that the Ser(203)-phosphorylated form of the receptor was predominantly cytoplasmic, whereas Ser(211)-phosphorylated GR was found in the nucleus. Likewise, by immunofluorescence, Ser(203)-phosphorylated GR was located in the cytoplasm and perinuclear regions of the cell, but not in the nucleoplasm, whereas strong phospho-Ser(211) staining was evident in the nucleoplasm of hormone-treated cells. Our results suggest that differentially phosphorylated receptor species are located in unique subcellular compartments, likely modulating distinct aspects of receptor function.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	garabm01@med.nyu.edu			NCI NIH HHS [P30 CA16087] Funding Source: Medline; NIDDK NIH HHS [R01 DK54836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; BODWELL JE, 1993, J STEROID BIOCHEM, V47, P31, DOI 10.1016/0960-0760(93)90054-Z; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Garabedian Michael J., 1998, P237; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MARIDOR G, 1993, J CELL SCI, V106, P535; MASON SA, 1993, J BIOL CHEM, V268, P21501; ORTI E, 1993, J BIOL CHEM, V268, P7779; Pocuca N, 1998, J STEROID BIOCHEM, V66, P303, DOI 10.1016/S0960-0760(98)00057-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Reichardt HM, 2000, Z RHEUMATOL, V59, P1; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; Webster JC, 1997, J BIOL CHEM, V272, P9287; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	32	227	234	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26573	26580		10.1074/jbc.M110530200	http://dx.doi.org/10.1074/jbc.M110530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000743	hybrid			2022-12-27	WOS:000176908700098
J	Dickinson, LA; Edgar, AJ; Ehley, J; Gottesfeld, JM				Dickinson, LA; Edgar, AJ; Ehley, J; Gottesfeld, JM			Cyclin L is an RS domain protein involved in pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CDK-ACTIVATING KINASE; C-TERMINAL DOMAIN; MESSENGER-RNA; DEPENDENT KINASES; SR PROTEINS; IN-VIVO; P-TEFB; TRANSCRIPTION; CTD	We report the cDNA cloning and functional characterization of human cyclin L, a novel cyclin related to the C-type cyclins that are involved in regulation of RNA polymerase II (pol II) transcription. Cyclin L also contains a COOH-terminal dipeptide repeat of alternating arginines and serines, a hallmark of the SR family of splicing factors. We show that recombinant cyclin L interacts with p110 PITSLRE kinase, and that cyclin L antibody co-immunoprecipitates a kinase activity from HeLa nuclear extracts that phosphorylates the carboxyl-terminal domain (CTD) of pol II and splicing factor SC35, and is inhibited by the cdk inhibitor p21. Cyclin L antibody inhibits the second step of RNA splicing in vitro, and recombinant cyclin L protein stimulates splicing under suboptimal conditions. Significantly, the lC(50) for splicing inhibition by p21 is similar to the lC(50) for inhibition of the cyclin L-associated kinase activity. Cyclin L and its associated kinase are thus new members of the pre-mRNA processing machinery.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Chelsea & Westminster Hosp, Imperial Coll Sch Med, Div Invest Sci, Tissue Engn Ctr, London SW10 9NH, England	Scripps Research Institute; Imperial College London	Gottesfeld, JM (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.			Gottesfeld, Joel/0000-0002-4643-5777				Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Boucher L, 2001, RNA, V7, P1693; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; FU XD, 1995, RNA, V1, P663; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8126; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Reichert V, 2000, NUCLEIC ACIDS RES, V28, P416, DOI 10.1093/nar/28.2.416; Rickert P, 1996, ONCOGENE, V12, P2631; Riedl T, 2000, GENE EXPRESSION, V9, P3; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SOLOVYEV V, 1997, P 5 INT C INT SYST M, P294; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	43	87	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25465	25473		10.1074/jbc.M202266200	http://dx.doi.org/10.1074/jbc.M202266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980906	hybrid			2022-12-27	WOS:000176747000081
J	Lim, S; Jin, K; Friedman, E				Lim, S; Jin, K; Friedman, E			Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1; DOWN-SYNDROME; COLON-CANCER; CELLS; SPECIFICITY; MINIBRAIN; DIFFERENTIATION; SUBSTRATE; COFACTOR; DYRK1A	Mirk/Dyrk1B is an arginine-directed serine/threonine protein kinase that is expressed at low levels in most normal tissues but at elevated levels in many tumor cell lines and in normal skeletal muscle. Colon carcinoma cell lines stably overexpressing Mirk proliferated in serum-free medium, but the mechanism of Mirk action is unknown. DCoHm (dimerization cofactor of hepatocyte nuclear factor 1alpha (HNF1alpha) from muscle), a novel gene of the DCoH family with 78% amino acid identity to DCoH, was identified as a Mirk-binding protein by yeast two-hybrid analysis and cloned. Mirk co-immunoprecipitated with DCoHm and bound to DCoHm in glutathione S-transferase pull-down assays. DCoH stabilizes HNF1alpha as a dimer and enhances its transcriptional activity on the beta-fibrinogen promoter reporter, and DCoHm had similar activity. Mirk enhanced HNF1alpha transcriptional activity in a dose-dependent manner, whereas two kinase-inactive Mirk mutants and a Mirk N-terminal deletion mutant did not. Mirk, DCoHm, and HNF1alpha formed a complex. Mirk bound to a specific region within the CREB-binding protein-binding region of HNF1alpha and phosphorylated HNF1alpha at a site adjacent to the Mirk-binding region. Conversely, the HNF1alpha binding domain was located within the first five conserved kinase subdomains of Mirk. Mirk co-immunoprecipitated with the MAPK kinase MKK3, an upstream activator of p38. MKK3 enhanced Mirk kinase activity and the transcriptional activation of HNF1alpha by Mirk, suggesting that Mirk, like p38, is activated by certain environmental stress agents. The Mirk-binding protein DCoH has been shown to be selectively expressed in colon carcinomas but not in normal tissue. Mirk may function as an HNF1alpha transcriptional activator in response to an MKK3-mediated stress signal, and the selective expression of DCoH could restrict the Mirk response to carcinoma cells.	Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.			Lim, Seunghwan/0000-0001-8920-0890	NCI NIH HHS [R01 CA67405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Bonham K, 2000, J BIOL CHEM, V275, P37604, DOI 10.1074/jbc.M004882200; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Erickson RH, 2000, BIOCHEM BIOPH RES CO, V270, P235, DOI 10.1006/bbrc.2000.2420; Eskinazi R, 1999, AM J PATHOL, V155, P1105, DOI 10.1016/S0002-9440(10)65213-3; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Johnen G, 1997, P NATL ACAD SCI USA, V94, P13469, DOI 10.1073/pnas.94.25.13469; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee K, 2000, CANCER RES, V60, P3631; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; NOLTEN LA, 1995, MOL ENDOCRINOL, V9, P1488, DOI 10.1210/me.9.11.1488; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	28	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25040	25046		10.1074/jbc.M203257200	http://dx.doi.org/10.1074/jbc.M203257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980910	hybrid			2022-12-27	WOS:000176747000028
J	Reed, RC; Zheng, TL; Nicchitta, CV				Reed, RC; Zheng, TL; Nicchitta, CV			GRP94-associated enzymatic activities - Resolution by chromatographic fractionation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; RETICULUM CHAPERONE GRP94; TUMOR REJECTION ANTIGENS; ENDOPLASMIC-RETICULUM; CLASS-I; MAJOR HISTOCOMPATIBILITY; DENDRITIC CELLS; CASEIN KINASE; PEPTIDES; GP96	GRP94 (gp96), which performs established functions as a molecular chaperone and immune system modulator, has been reported to display a number of intrinsic enzymatic activities, including ATP hydrolysis, protein phosphorylation, and aminopeptidase. In observing that GRP94 co-purified with bacterial beta-galactosidase through multiple chromatographic steps, we have examined the hypothesis that the reported enzymatic activities of GRP94 may reflect co-purification of contaminant enzymes, rather than intrinsic catalytic functions. In subjecting GRP94 to increasingly stringent chromatographic purification, we report that a GRP94 carboxyl-terminal directed protein kinase activity could be separated from GRP94 by heparin affinity chromatography. Analysis of the kinase substrate specificity indicates that this kinase is distinct from casein kinase II, which is known to co-purify with GRP94. Electrophoretically pure GRP94 displayed low, but significant levels of aminopeptidase activity. Further purification of GRP94 by anion exchange and heparin affinity chromatography yielded resolution of GRP94 from the aminopeptidase activity. Furthermore, exhaustive trypsinolysis of GRP94 preparations displaying aminopeptidase activity yielded complete proteolysis of GRP94 but did not affect aminopeptidase activity. These results are discussed with respect to current models for GRP94 function and the role of such co-purifying (poly)peptides in the generation of GRP94-dependent cellular immune responses.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	c.nicchitta@cellbio.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Berwin B, 2001, J BIOL CHEM, V276, P21083, DOI 10.1074/jbc.M101836200; Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; CALA SE, 1994, J BIOL CHEM, V269, P5926; Cala SE, 2000, BBA-MOL CELL RES, V1496, P296, DOI 10.1016/S0167-4889(00)00028-8; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Fruci D, 2001, IMMUNITY, V15, P467, DOI 10.1016/S1074-7613(01)00203-5; GRAHAM LD, 1994, BIOCHEM J, V301, P917, DOI 10.1042/bj3010917; Ishiguro S, 2002, EMBO J, V21, P898, DOI 10.1093/emboj/21.5.898; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; KORNBERG A, 1990, METHOD ENZYMOL, V182, P1; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Lobigs M, 2000, EUR J IMMUNOL, V30, P1496, DOI 10.1002/(SICI)1521-4141(200005)30:5<1496::AID-IMMU1496>3.0.CO;2-6; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; MELNICK J, 1992, J BIOL CHEM, V267, P21303; Menoret A, 2001, J BIOL CHEM, V276, P33313, DOI 10.1074/jbc.M103383200; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Riera M, 1999, MOL CELL BIOCHEM, V191, P97, DOI 10.1023/A:1006810311743; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, BIOCHEM J, V301, P919, DOI 10.1042/bj3010919; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Srivastava PK, 1997, METHODS, V12, P165, DOI 10.1006/meth.1997.0464; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; UDONO H, 1994, J IMMUNOL, V152, P5398; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152	39	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25082	25089		10.1074/jbc.M203195200	http://dx.doi.org/10.1074/jbc.M203195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983709	hybrid			2022-12-27	WOS:000176747000033
J	Samuni, U; Dantsker, D; Khan, I; Friedman, AJ; Peterson, E; Friedman, JM				Samuni, U; Dantsker, D; Khan, I; Friedman, AJ; Peterson, E; Friedman, JM			Spectroscopically and kinetically distinct conformational populations of sol-gel-encapsulated carbonmonoxy myoglobin - A comparison with hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RESONANCE RAMAN-SPECTROSCOPY; HISTIDINE STRETCHING MODE; CYTOCHROME-C PEROXIDASE; ABSORPTION-BAND-III; T-STATE HEMOGLOBIN; LIGAND-BINDING; STRUCTURAL DYNAMICS; HEME-PROTEINS; SOLVENT VISCOSITY; QUATERNARY STRUCTURES	We have used sol-gel encapsulation protocols to trap kinetically and spectroscopically distinct conformational populations of native horse carbonmonoxy myoglobin. The method allows for direct comparison of functional and spectroscopic properties of equilibrium and non-equilibrium populations under the same temperature and viscosity conditions. The results implicate tertiary structure changes that include the proximal heme environment in the mechanism for population-specific differences in the observed rebinding kinetics. Differences in the resonance Raman frequency of nu(Fe-His), the iron-proximal histidine stretching mode, are attributed to differences in the positioning of the F helix. For myoglobin, the degree of separation between the F helix and the heme is assigned as the conformational coordinate that modulates both this frequency and the innermost barrier controlling CO rebinding. A comparison with the behavior of encapsulated derivatives of human adult hemoglobin indicates that these CO binding-induced conformational changes are qualitatively similar to the tertiary changes that occur within both the R and T quaternary states. Protein-specific differences in the time scale for the proposed F helix relaxation are attributed to variations in the intra-helical hydrogen bonding patterns that help stabilize the position of the F helix.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Friedman, Adam/0000-0001-8925-1620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065188, R01HL058247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058890] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL65188, R01 HL58247] Funding Source: Medline; NIGMS NIH HHS [P01 GM58890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGMON N, 1991, P E WARB S WORLD SCI, P333; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; AVNIR D, 1994, CHEM MATER, V6, P1605, DOI 10.1021/cm00046a008; BALASUBRAMANIAN S, 1993, BIOCHEMISTRY-US, V32, P2202, DOI 10.1021/bi00060a011; BANGCHAROENPAURPONG O, 1984, J AM CHEM SOC, V106, P5688, DOI 10.1021/ja00331a045; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; Bitler A, 1999, BIOPHYS J, V77, P2764, DOI 10.1016/S0006-3495(99)77109-2; Bjorling SC, 1996, BIOCHEMISTRY-US, V35, P8619, DOI 10.1021/bi952247s; BRAUN S, 1992, J NON-CRYST SOLIDS, V147, P739, DOI 10.1016/S0022-3093(05)80708-2; Bruno S, 2001, PROTEIN SCI, V10, P2401, DOI 10.1110/ps.20501; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2001, EMBO REP, V2, P674, DOI 10.1093/embo-reports/kve159; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Brunori M, 2000, BIOPHYS CHEM, V86, P221, DOI 10.1016/S0301-4622(00)00142-3; CAMPBELL BF, 1987, J BIOL CHEM, V262, P14885; Causgrove TP, 1996, J PHYS CHEM-US, V100, P3273, DOI 10.1021/jp952483c; Christian JF, 1997, BIOCHEMISTRY-US, V36, P11198, DOI 10.1021/bi9710075; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; DANTSKER D, 2001, J MOL BIOL, V315, P257; Das TK, 1998, J AM CHEM SOC, V120, P10268, DOI 10.1021/ja982127i; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; Dave BC, 1997, J SOL-GEL SCI TECHN, V8, P629, DOI 10.1007/BF02436913; Dick LA, 1999, BIOCHEMISTRY-US, V38, P6406, DOI 10.1021/bi981760d; Doster W., 1993, PROTEIN SOLVENT INTE, P375; Eggers DK, 2001, PROTEIN SCI, V10, P250, DOI 10.1110/ps.36201; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; Esquerra RM, 1998, BIOCHEMISTRY-US, V37, P17527, DOI 10.1021/bi9814437; FINDSEN EW, 1988, BIOCHEMISTRY-US, V27, P8719, DOI 10.1021/bi00424a005; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; Galkin O, 1997, BIOPHYS J, V73, P2752, DOI 10.1016/S0006-3495(97)78304-8; GILCH H, 1993, BIOPHYS J, V65, P1470, DOI 10.1016/S0006-3495(93)81216-5; GILCH H, 1995, BIOPHYS J, V69, P214, DOI 10.1016/S0006-3495(95)79893-9; Gill I, 2000, TRENDS BIOTECHNOL, V18, P282, DOI 10.1016/S0167-7799(00)01457-8; Goldbeck RA, 2001, BIOPHYS J, V81, P2919, DOI 10.1016/S0006-3495(01)75932-2; Goldbeck RA, 1996, BIOCHEMISTRY-US, V35, P8628, DOI 10.1021/bi952248k; Gottfried DS, 1996, J PHYS CHEM-US, V100, P12034, DOI 10.1021/jp9609489; Hagen SJ, 1996, J CHEM PHYS, V104, P3395, DOI 10.1063/1.471044; Hagen SJ, 1996, J PHYS CHEM-US, V100, P12008, DOI 10.1021/jp960219t; Hu XH, 1999, BIOCHEMISTRY-US, V38, P3462, DOI 10.1021/bi982513c; Huang J, 1997, BIOCHEMISTRY-US, V36, P14353, DOI 10.1021/bi9700274; Huang J, 1999, BIOCHEMISTRY-US, V38, P4514, DOI 10.1021/bi982724h; IIZUKA T, 1974, BIOCHIM BIOPHYS ACTA, V371, P126, DOI 10.1016/0005-2795(74)90161-5; JAYARAMAN V, 1995, SCIENCE, V269, P1843, DOI 10.1126/science.7569921; Juszczak LJ, 1999, J BIOL CHEM, V274, P30357, DOI 10.1074/jbc.274.43.30357; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Khan I, 2001, BIOCHEMISTRY-US, V40, P7581, DOI 10.1021/bi010051o; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; KIGER L, 1995, EUR J BIOCHEM, V228, P665, DOI 10.1111/j.1432-1033.1995.tb20307.x; KITAGAWA T, 1992, PROG BIOPHYS MOL BIO, V58, P1, DOI 10.1016/0079-6107(92)90009-U; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kleinert T, 1998, BIOCHEMISTRY-US, V37, P717, DOI 10.1021/bi971508q; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIDDINGTON R, 1994, METHOD ENZYMOL, V232, P15; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; LUISI B, 1989, J MOL BIOL, V206, P723, DOI 10.1016/0022-2836(89)90579-2; LYONS KB, 1978, NATURE, V275, P565, DOI 10.1038/275565a0; Mizutani Y, 2001, J PHYS CHEM B, V105, P10992, DOI 10.1021/jp010923w; Mueser TC, 2000, BIOCHEMISTRY-US, V39, P15353, DOI 10.1021/bi0012944; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; ONDRIAS MR, 1982, J BIOL CHEM, V257, P8766; ONDRIAS MR, 1982, BIOCHEMISTRY-US, V21, P3428, DOI 10.1021/bi00257a028; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SAGE JT, 1995, J PHYS CHEM-US, V99, P3394, DOI 10.1021/j100010a059; Samuni U, 2000, J PHYS CHEM B, V104, P10802, DOI 10.1021/jp000802g; SASSAROLI M, 1986, J BIOL CHEM, V261, P3704; SASSAROLI M, 1987, BIOCHEMISTRY-US, V26, P3092, DOI 10.1021/bi00385a022; Sastry GM, 1997, BIOCHEMISTRY-US, V36, P7097, DOI 10.1021/bi9626057; Schlichting I, 2000, CURR OPIN STRUC BIOL, V10, P744, DOI 10.1016/S0959-440X(00)00158-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; Shibayama N, 1999, J MOL BIOL, V285, P1383, DOI 10.1006/jmbi.1998.2407; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shreve AP, 1999, J PHYS CHEM B, V103, P7969, DOI 10.1021/jp991163g; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; SPIRO TG, 1995, METHODS ENZYMOL, V246, P416; SPIRO TG, 1990, BIOCHEMISTRY-US, V29, P4497, DOI 10.1021/bi00471a001; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; Stavrov SS, 2001, CHEM PHYS, V271, P145, DOI 10.1016/S0301-0104(01)00412-8; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; SZABO A, 1973, P NATL ACAD SCI USA, V70, P673, DOI 10.1073/pnas.70.3.673; SZABO A, 1978, P NATL ACAD SCI USA, V75, P2108, DOI 10.1073/pnas.75.5.2108; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Wang DJ, 1998, BIOCHEMISTRY-US, V37, P9940, DOI 10.1021/bi980295h; WELLS AV, 1991, J AM CHEM SOC, V113, P9655, DOI 10.1021/ja00025a034	116	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25783	25790		10.1074/jbc.M200301200	http://dx.doi.org/10.1074/jbc.M200301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976324	hybrid			2022-12-27	WOS:000176747000121
J	Yang, Y; Li, LX; Wong, GW; Krilis, SA; Madhusudhan, MS; Sali, A; Stevens, RL				Yang, Y; Li, LX; Wong, GW; Krilis, SA; Madhusudhan, MS; Sali, A; Stevens, RL			RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs - Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE SPLICE VARIANTS; PROTOONCOGENE C-KIT; EXCHANGE FACTOR; PERIPHERAL-BLOOD; PLASMA-MEMBRANE; MOUSE; LINE; ACTIVATION; MICE; EXPRESSION	A cDNA was isolated from interleukin 3-developed, mouse bone marrow-derived mast cells (MCs) that contained an insert (designated mRasGRP4) that had not been identified in any species at the gene, mRNA, or protein level. By using a homology-based cloning approach, the similar to2.6-kb hRasGRP4 transcript was also isolated from the mononuclear progenitors; residing in the peripheral blood of normal individuals. This transcript information was then used to locate the RasGRP4 gene in the mouse and human genomes, to deduce its exon/intron organization, and then to identify 10 single nucleotide polymorphisms in the human gene that result in 5 amino acid differences. The > 15-kb hRasGRP4 gene consists of 18 exons and resides on a regdon of chromosome 19q13.1 that had not been sequenced by the Human Genome Project. Human and mouse MCs and their progenitors selectively express RasGRP4, and this new intracellular protein contains all of the domains present in the RasGRP family of guanine nucleotide exchange factors even though it is <50% identical to its closest homolog. Recombinant RasGRP4 can activate H-Ras in a cation-dependent manner. Transfection experiments also suggest that RasGRP4 is a diacylglycerollphorbol ester receptor. Transcript analysis of an asthma patient, a mastocytosis patient, and the HMC-1 cell line derived from a MC leukemia patient revealed the presence of substantial amounts of non-functional forms of hRasGRP4 due to an inability to remove intron 5 in the precursor transcript. Because only abnormal forms of hRasGRP4 were identified in the HMC-1 cell line, this immature MC progenitor was used to address the function of RasGRP4 in MCs. HMC-1 leukemia cells differentiated and underwent granule maturation when induced to express a normal form of RasGRP4. Thus, RasGRP4 plays an important role in the final stages of MC development.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Univ New S Wales, Dept Med, Kogarah, NSW 2217, Australia; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Lab Mol Biophys, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of New South Wales Sydney; St George Hospital; Rockefeller University	Stevens, RL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506	NHLBI NIH HHS [HL-63284, HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063284, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, R29GM054762] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamas SP, 1997, LIFE SCI, V61, P1105, DOI 10.1016/S0024-3205(97)00243-9; Atamas SP, 1996, J IMMUNOL, V156, P435; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bottorff D, 1999, MAMM GENOME, V10, P358, DOI 10.1007/s003359901001; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORDON JR, 1990, BLOOD, V75, P1637; Graham TE, 1998, J IMMUNOL, V161, P6733; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KLEIN SC, 1995, IMMUNOGENETICS, V41, P57, DOI 10.1007/BF00188440; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lorenzo PS, 2001, CANCER RES, V61, P943; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marone G, 2001, J ALLERGY CLIN IMMUN, V107, P22, DOI 10.1067/mai.2001.111589; Marsh DG, 1997, NAT GENET, V15, P389; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; OBERHAUSER AF, 1994, FEBS LETT, V339, P171, DOI 10.1016/0014-5793(94)80409-5; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Rashidi Hooman H., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P175; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1984, J IMMUNOL, V132, P1479; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; Song JS, 1999, J IMMUNOL, V163, P802; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; SWANN PG, 1999, SIGNAL TRANSDUCTION, P152; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Tsytsikov VN, 1996, J BIOL CHEM, V271, P23055, DOI 10.1074/jbc.271.38.23055; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; Tuvim MJ, 1999, AM J RESP CELL MOL, V20, P79, DOI 10.1165/ajrcmb.20.1.3279; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	68	83	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25756	25774		10.1074/jbc.M202575200	http://dx.doi.org/10.1074/jbc.M202575200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11956218	hybrid			2022-12-27	WOS:000176747000119
J	Zeng, QH; Chen, SQ; You, ZB; Yang, F; Carey, TE; Saims, D; Wang, CY				Zeng, QH; Chen, SQ; You, ZB; Yang, F; Carey, TE; Saims, D; Wang, CY			Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SCATTER FACTOR; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; ONCOGENIC RAS; ORAL-CANCER; MAP KINASE; C-MET; EXPRESSION	Hepatocyte growth factor (HGF), also known as a scatter factor, regulates a variety of biological activities including cell proliferation, survival, migration, and angiogenesis. Importantly, HGF and its receptor c-Met have been found to be associated with metastasis of human head and neck squamous cell carcinoma (HNSCC). Because anoikis resistance plays an important role in tumor progression and metastasis, here we examined whether HGF suppressed suspension-induced apoptosis (anoikis) in HNSCC cells, and if so, we assessed downstream signaling pathways mediated by HGF. We found that HNSCC cells underwent anoikis upon loss of matrix contact, whereas HGF provided protection against it. HGF-induced anoikis resistance was found to be dependent on both ERK and Akt signaling pathways. The inhibition of either ERK or Akt activation abolished HGF-mediated survival. Furthermore, we found that HGF did not activate NFkappaB transcription in HNSCC cells and that HGF-mediated anoikis resistance was independent of NFkappaB. Taken together, our results suggest that anoikis resistance induced by HGF may also play an important role in the progression and metastasis of HNSCC.	Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signalling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Oral Pathol Oral Med & Oral Oncol, Ann Arbor, MI 48109 USA; NE Normal Univ, Sch Life Sci, Inst Cytol & Genet, Changchun 130021, Peoples R China	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Northeast Normal University - China	Wang, CY (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signalling & Apoptosis, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.			Carey, Thomas/0000-0002-5202-7518	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013848, R01DE013788] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE13788, R01-DE13848] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Dong G, 2001, CANCER RES, V61, P5911; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kang MK, 2001, CRIT REV ORAL BIOL M, V12, P38, DOI 10.1177/10454411010120010301; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kuechle MK, 2000, CELL DEATH DIFFER, V7, P566, DOI 10.1038/sj.cdd.4400687; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Qian CN, 2002, CANCER RES, V62, P589; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Shillitoe EJ, 2000, ORAL ONCOL, V36, P1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	56	123	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25203	25208		10.1074/jbc.M201598200	http://dx.doi.org/10.1074/jbc.M201598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994287	hybrid			2022-12-27	WOS:000176747000047
J	Barchowsky, A; Soucy, NV; O'Hara, KA; Hwa, J; Noreault, TL; Andrew, AS				Barchowsky, A; Soucy, NV; O'Hara, KA; Hwa, J; Noreault, TL; Andrew, AS			A novel pathway for nickel-induced interleukin-8 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; FACTOR-KAPPA-B; IDIOPATHIC PULMONARY FIBROSIS; INDUCIBLE FACTOR 1-ALPHA; AIRWAY EPITHELIAL-CELLS; GENE-EXPRESSION; BINDING-PROTEIN; FACTOR-I; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL EXPRESSION	Inhalation of particulate nickel subsulfide (Ni3S2) causes chronic active inflammation and fibrosis of the lungs. However, the mechanisms for these effects are not well understood. Therefore, cell culture experiments with BEAS-2B human airway epithelial cells were conducted to test the hypothesis that exposure to noncytotoxic levels of Ni3S2 induces expression of inflammatory cytokines such as interleukin-8 (IL-8). Exposure to Ni3S2 for 48 h was required to significantly increase IL-8 protein levels. Transcriptional stimulation of IL-8 mRNA levels preceded the increase in protein. Transient exposure to soluble nickel sulfate failed to increase IL-8 mRNA. Transfection with truncated IL-8 promoter constructs linked to the luciferase gene demonstrated that nickel-induced IL-8 transcription required -272 bp of the promoter relative to the transcriptional start site. A -133-bp construct, containing cytokine and hypoxia-sensitive AP-1, NF-IL6, and NF-kappaB sites, was insufficient for induction by nickel. Transfection with a dominant negative AP-1 construct or mutation of the AP-1, GATA, or C/EBP sites in the -272-bp IL-8 promoter construct blocked induction by nickel. Inhibiting ERK, phosphatidylinositol 3-kinase, but not p38 kinase, diacylglycerol kinase, or hypoxia-inducible factor-1alpha, attenuated nickel induction of IL-8. These studies indicate that nickel induced IL-8 transcription through a novel pathway that requires both AP-1 and non-traditional transcription factors.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Barchowsky, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NIEHS NIH HHS [ES07373] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007373] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM T, 1992, J BIOL CHEM, V267, P5021; Andrew A, 2000, TOXICOL APPL PHARM, V168, P50, DOI 10.1006/taap.2000.9009; Andrew AS, 2001, AM J PHYSIOL-LUNG C, V281, pL607, DOI 10.1152/ajplung.2001.281.3.L607; Andrew AS, 2001, AM J PHYSIOL-LUNG C, V281, pL616, DOI 10.1152/ajplung.2001.281.3.L616; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; English AM, 2001, MET IONS BIOL SYST, V38, P313; Entingh AJ, 2001, ENDOCRINOLOGY, V142, P221, DOI 10.1210/en.142.1.221; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Haber LT, 2000, REGUL TOXICOL PHARM, V31, P210, DOI 10.1006/rtph.2000.1377; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hetland RB, 2000, J TOXICOL ENV HEAL A, V60, P47, DOI 10.1080/009841000156583; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Kayyali US, 2001, J BIOL CHEM, V276, P14359, DOI 10.1074/jbc.M010100200; Keane MP, 1997, J IMMUNOL, V159, P1437; Kelleher P, 2000, ENVIRON HEALTH PERSP, V108, P685, DOI 10.2307/3454405; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Mori N, 1998, CANCER RES, V58, P3993; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; Ogushi Fumitaka, 1997, Journal of Medical Investigation, V44, P53; Oller AR, 1997, TOXICOL APPL PHARM, V143, P152, DOI 10.1006/taap.1996.8075; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; ROSENTHAL GI, 1994, J IMMUNOL, V153, P3237; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Schmalz G, 2000, EUR J ORAL SCI, V108, P442, DOI 10.1034/j.1600-0722.2000.108005442.x; Shumilla JA, 1999, TOXICOL APPL PHARM, V158, P288, DOI 10.1006/taap.1999.8704; Shumilla JA, 1999, J BIOL CHEM, V274, P36207, DOI 10.1074/jbc.274.51.36207; Sodhi A, 2000, CANCER RES, V60, P4873; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Terunuma A, 2001, J DERMATOL SCI, V26, P85, DOI 10.1016/S0923-1811(00)00165-1; White ES, 2001, J IMMUNOL, V166, P7549, DOI 10.4049/jimmunol.166.12.7549; Wu GD, 1997, J BIOL CHEM, V272, P2396; Xu L, 1999, CANCER RES, V59, P5822; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Ziegenhagen MW, 1998, J INVEST MED, V46, P223	46	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24225	24231		10.1074/jbc.M202941200	http://dx.doi.org/10.1074/jbc.M202941200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978798	hybrid			2022-12-27	WOS:000176611800034
J	Berkowitz, B; Huang, DB; Chen-Park, FE; Sigler, PB; Ghosh, G				Berkowitz, B; Huang, DB; Chen-Park, FE; Sigler, PB; Ghosh, G			The x-ray crystal structure of the NF-kappa B p50 center dot p65 heterodimer bound to the interferon beta-kappa B site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN HMG-I(Y); TRANSCRIPTION FACTORS; DNA-BINDING; P50/P65 HETERODIMER; VIRUS INDUCTION; HMG I(Y); IN-VITRO; HOMODIMER; ENHANCEOSOME; EXPRESSION	We have determined the x-ray crystal structure of the transcription factor NF-kappaB p50-p65 heterodimer complexed to kappaB DNA from the cytokine interferon beta enhancer (IFNbeta-kappaB). To better understand how the binding modes of NF-kappaB on its two best studied DNA targets might contribute to promoter-specific transcription, this structure is compared with the previously determined complex crystal structure containing NF-kappaB bound to the Ig kappa light chain gene enhancer as well as to a second NF-kappaB-Ig kappa light chain gene enhancer complex also reported in this paper. The global binding modes of all NF-kappaB.DNA complex structures are similar, although crystal-packing interactions lead to differences between identical complexes of the same crystallographic asymmetric unit. An extensive network of stacked amino acid side chains that contribute to base-specific DNA contacts is conserved among the three complexes. Consistent with earlier reports, however, the IFNbeta-kappaB DNA is bent significantly less by NF-kappaB than is the Ig K light chain gene enhancer. This and other small structural changes may play a role in explaining why NF-kappaB-directed transcription is sensitive to the context of specific promoters. The precise molecular mechanism behind the involvement of the high mobility group protein I(Y) in interferon beta enhanceosome formation remains elusive.	Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Biol, San Diego, CA 92103 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Yale University	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,9500 Gilman Dr, San Diego, CA 92103 USA.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; BRUNGER AT, 1998, ACTA CRYSTALLOGR D, V10, P25; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Chen-Park FE, 2002, J BIOL CHEM, V277, P24701, DOI 10.1074/jbc.M200007200; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074	37	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24694	24700		10.1074/jbc.M200006200	http://dx.doi.org/10.1074/jbc.M200006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11970948	hybrid			2022-12-27	WOS:000176611800095
J	Koistinen, P; Heino, J				Koistinen, P; Heino, J			The selective regulation of alpha(v)beta(1) integrin expression is based on the hierarchical formation of alpha(v)-containing heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-ADHESION DOMAIN; ALPHA-V-INTEGRINS; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; GENE-EXPRESSION; ALPHA-V-BETA-1; MIGRATION; COLLAGEN	The integrin beta(1) subunit can form a heterodimer with 12 different alpha subunits. According to the present model, the expression level of any alphabeta complex is regulated by the availability of the specific alpha subunit, whereas beta(1) subunit is constantly present in a large excess. The expression of several heterodimers containing the alpha(V) subunit seems to be regulated by an identical mechanism. The fact that many cells express alpha(V)beta(1) heterodimer, and that this fibronectin/vitronectin receptor may be selectively regulated, compromises the present model of the regulation of beta(1) and alpha(V) integrins. We have tried to solve this problem by assuming that distinct alphabeta heterodimers are formed with different tendency. To test the hypothesis, we analyzed WM-266-4 melanoma cells transfected with a cDNA construct coding for an intracellular single-chain anti-alpha(V) integrin antibody. We could see 70-80% reduction in the cell surface expression of alpha(V) subunit. However, the only one of the alpha(V) integrins reduced on the cell surface was alpha(V)beta(1). This suggests that the cell surface expression level of alpha(V)beta(1) is dependent on the number of alpha(V) subunits available after the formation of other alpha(V)-containing heterodimers. Thus, there seems to be a hierarchy in the complex formation between alpha(V) and its different beta-partners. These observations explain how alpha(V)beta(1) can be specifically regulated without concomitant changes in the expression of other alpha(V) or beta(1) integrins.	Univ Jyvaskyla, Dept Biol, FIN-40351 Jyvaskyla, Finland; Turku Univ, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Turku Univ, MediC Res Lab, FIN-20520 Turku, Finland; Turku Univ, Dept Biochem Med, FIN-20520 Turku, Finland	University of Jyvaskyla; University of Turku; University of Turku; University of Turku	Heino, J (corresponding author), Univ Jyvaskyla, Dept Biol & Envrionm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.							AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BODARY SC, 1990, J BIOL CHEM, V265, P5938; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Dahm LM, 1998, J CELL SCI, V111, P1175; DELANNET M, 1994, DEVELOPMENT, V120, P2687; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gailit J, 1996, J INVEST DERMATOL, V106, P102, DOI 10.1111/1523-1747.ep12328177; GOLDBERG HA, 1986, CONNECT TISSUE RES, V15, P209, DOI 10.3109/03008208609001980; Gouon V, 1996, INT J CANCER, V68, P650; HEINO J, 1989, J BIOL CHEM, V264, P380; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Jackson T, 2002, J VIROL, V76, P935, DOI 10.1128/JVI.76.3.935-941.2002; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; Koivisto L, 2000, EXP CELL RES, V255, P10, DOI 10.1006/excr.1999.4769; Li E, 2001, J VIROL, V75, P5405, DOI 10.1128/JVI.75.11.5405-5409.2001; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MARASCO WA, 1992, J CLIN INVEST, V90, P1467, DOI 10.1172/JCI116014; Milner R, 1996, J NEUROSCI, V16, P7240; MILNER R, 1994, DEVELOPMENT, V120, P3497; Milner R, 2001, MOL CELL NEUROSCI, V18, P108, DOI 10.1006/mcne.2001.1003; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; PISCHEL KD, 1987, J IMMUNOL, V138, P226; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856-5862.2000; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	35	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24835	24841		10.1074/jbc.M203149200	http://dx.doi.org/10.1074/jbc.M203149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11997396	hybrid			2022-12-27	WOS:000176611800111
J	Le Ferrec, E; Lagadic-Gossmann, D; Rauch, C; Bardiau, C; Maheo, K; Massiere, F; Le Vee, M; Guillouzo, A; Morel, F				Le Ferrec, E; Lagadic-Gossmann, D; Rauch, C; Bardiau, C; Maheo, K; Massiere, F; Le Vee, M; Guillouzo, A; Morel, F			Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; ANTIOXIDANT RESPONSE ELEMENT; PROTEIN-DNA INTERACTIONS; REPUBLIC-OF-CHINA; DIOXIN RECEPTOR; 5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOL-3-THIONE OLTIPRAZ; GLUTATHIONE TRANSFERASES; PHENOBARBITAL INDUCTION; INDUCIBLE EXPRESSION; INTRACELLULAR CA2+	Oltipraz, a synthetic derivative of the cruciferous vegetable product 1,2-dithiole-3-thione, is considered as one of the most potent chemoprotectants. It modulates both cytochrome P-450 (CYP) and glutathione S-transferase expression and activities in rat tissues. Its effects, however, are variable according to the enzyme, tissue, and species. We show here that, as previously found in rat lung and kidney, CYP1A1 is inducible by oltipraz in both rat intestine and Caco-2 cells, a cell line originated from a human colon adenocarcinoma. In these cells, a 50 pm oltipraz treatment increased CYP1A1 mRNA (similar to30-fold), protein and activity. mRNA level was augmented as early as 2 h after the beginning of treatment, suggesting a transcriptional activation, and was maximal between 8 and 12 h. Transient transfection of Caco-2 cells with constructs containing different sizes of the 5'-flanking region of the CYP1A1 gene upstream of the luciferase reporter gene showed an increase in luciferase activity in oltipraz-treated cells, which correlates with the presence of the xenobiotic responsive element (XRE). Furthermore we demonstrated that resveratrol, an antagonist of the aryl hydrocarbon (Ah) receptor, inhibited the induction of both CYP1A1 promoter activity and mRNA by oltipraz, supporting the involvement of the Ah receptor in this induction. In an attempt to further characterize the mechanism of CYP1A1 induction, we showed a rapid increase in intracellular calcium concentration upon treatment of Caco-2 cells with oltipraz. Moreover, the effect of this compound on CY-P1A1 was strongly abolished in the presence of BAPTA-AM, a well known chelator of intracellular calcium, and 2-aminoethyl diphenylborate, an inhibitor of store-operated calcium channels. These results bring the first demonstration that oltipraz activates transcription of the CYP1A1 gene through the Ah receptor-XRE pathway in Caco-2 cells and that CYP1A1 induction relies upon an increase of intracellular calcium concentration.	Univ Rennes 1, INSERM, U456, F-35043 Rennes, France; Biopred, F-35000 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Morel, F (corresponding author), Univ Rennes 1, INSERM, U456, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.		LAGADIC-GOSSMANN, Dominique/I-5079-2015; Le FERREC, Eric/K-1374-2015; GUILLOUZO, Andre/Z-2373-2019; Maheo, Karine/AAC-3259-2022; Le Vee, Marc/U-8843-2019; LE VÉE, Marc/AAP-6961-2020	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Le FERREC, Eric/0000-0002-2015-2779; 				ANSHER SS, 1986, FOOD CHEM TOXICOL, V24, P405, DOI 10.1016/0278-6915(86)90205-X; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOONE CW, 1990, CANCER RES, V50, P2; BOULENC X, 1992, J PHARMACOL EXP THER, V263, P1471; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243; Casper RF, 1999, MOL PHARMACOL, V56, P784; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciolino HP, 1998, CANCER RES, V58, P5707; Corchero J, 2001, PHARMACOGENETICS, V11, P1, DOI 10.1097/00008571-200102000-00001; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Corcos L, 1998, FEBS LETT, V425, P293, DOI 10.1016/S0014-5793(98)00246-4; Daujat M, 1996, EUR J BIOCHEM, V237, P642, DOI 10.1111/j.1432-1033.1996.0642p.x; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DEWAZIERS I, 1990, J PHARMACOL EXP THER, V253, P387; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Guigal N, 2000, BIOCHEM BIOPH RES CO, V267, P572, DOI 10.1006/bbrc.1999.1959; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; Heist EK, 1998, CELL CALCIUM, V23, P103; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Kensler T W, 1995, J Cell Biochem Suppl, V22, P101; LANGOUET S, 1995, CANCER RES, V55, P5574; Langouet S, 1997, CARCINOGENESIS, V18, P1343, DOI 10.1093/carcin/18.7.1343; Le Ferrec E, 2001, CARCINOGENESIS, V22, P49, DOI 10.1093/carcin/22.1.49; LESCA P, 1995, BIOCHEM BIOPH RES CO, V209, P474, DOI 10.1006/bbrc.1995.1526; LIU YL, 1988, TOXICOL APPL PHARM, V93, P442, DOI 10.1016/0041-008X(88)90047-6; Long WP, 1999, J BIOL CHEM, V274, P12391, DOI 10.1074/jbc.274.18.12391; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Maheo K, 1998, HEPATOLOGY, V28, P1655, DOI 10.1002/hep.510280627; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; Primiano T, 1997, Adv Pharmacol, V38, P293; Putney JW, 2001, J CELL SCI, V114, P2223; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; RAO CV, 1993, CANCER RES, V53, P2502; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sadar MD, 1996, J BIOL CHEM, V271, P17635, DOI 10.1074/jbc.271.30.17635; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Tannheimer SL, 1999, MOL CARCINOGEN, V25, P48, DOI 10.1002/(SICI)1098-2744(199905)25:1<48::AID-MC6>3.0.CO;2-6; Tannheimer SL, 1997, CARCINOGENESIS, V18, P1177, DOI 10.1093/carcin/18.6.1177; Vargas M, 1998, DRUG METAB DISPOS, V26, P91; Wang JS, 1996, CANCER EPIDEM BIOMAR, V5, P253; WATTENBERG LW, 1986, CARCINOGENESIS, V7, P1379, DOI 10.1093/carcin/7.8.1379; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	51	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24780	24787		10.1074/jbc.M111319200	http://dx.doi.org/10.1074/jbc.M111319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959854	hybrid			2022-12-27	WOS:000176611800105
J	Chen, YY; Cross, KJ; Paolini, RA; Fielding, JE; Slakeski, N; Reynolds, EC				Chen, YY; Cross, KJ; Paolini, RA; Fielding, JE; Slakeski, N; Reynolds, EC			CPG70 is a novel basic metallocarboxypeptidase with C-terminal polycystic kidney disease domains from Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LESION MODEL; CYSTEINE PROTEINASES; PERIODONTAL-DISEASE; CRYSTAL-STRUCTURE; VIRULENCE; BACTERIAL; GENE; RGPA; W50; KGP	In a search for a basic carboxypeptidase that might work in concert with the major virulence factors, the Arg- and Lys-specific cysteine endoproteinases of Porphyromonas gingivalis, a novel 69.8-kDa metallocarboxypeptidase CPG70 was purified to apparent homogeneity from the culture fluid of P. gingivalis HG66. Carboxypeptidase activity was measured by matrix-assisted laser desorption ionization-mass spectrometry using peptide substrates derived from a tryptic digest of hemoglobin. CPG70 exhibited activity with peptides containing C-terminal Lys and Arg residues. The k(cat)/K-m values for the hydrolysis of the synthetic dipeptides FA-Ala-Lys and FA-Ala-Arg by CPG70 were 99 and 56 mM(-1)s(-1), respectively. The enzyme activity was strongly inhibited by the Arg analog (2-guanidinoethylmercapto)-succinic acid and 1,10-phenanthroline. High resolution inductively coupled plasma-mass spectrometry demonstrated that I mol of CPG70 was associated with 0.6 mol of zinc, 0.2 mol of nickel, and 0.2 mol of copper. A search of the P. gingivalis W83 genomic data base (TIGR) with the N-terminal amino acid sequence determined for CPG70 revealed that the enzyme is an N- and C-terminally truncated form of a predicted 91.5-kDa protein (PG0232). Analysis of the deduced amino acid sequence of the full-length protein revealed an N-terminal signal sequence followed by a pro-segment, a metallocarboxypeptidase catalytic domain, three tandem polycystic kidney disease domains, and an 88-residue C-terminal segment. The catalytic domain exhibited the highest sequence identity with the duck metallocarboxypeptidase D domain II. Insertional inactivation of the gene encoding CPG70 resulted in a P. gingivalis isogenic mutant that was avirulent in the murine lesion model under the conditions tested.	Univ Melbourne, Sch Dent Sci, Melbourne, Vic 3000, Australia	University of Melbourne	Reynolds, EC (corresponding author), Univ Melbourne, Sch Dent Sci, 711 Elizabeth St, Melbourne, Vic 3000, Australia.		Cross, Keith/F-4566-2012; Cross, Keith J/N-4602-2013	Cross, Keith/0000-0002-4079-2132; Slakeski, Nada/0000-0001-9776-6018; Fielding, James/0000-0003-2995-9576; Reynolds, Eric/0000-0002-6618-4856; Paolini, Rita/0000-0002-2170-4723				Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; [Anonymous], 1993, SPSS WINDOWS BASE SY; AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; Banbula A, 2001, J BIOL CHEM, V276, P6299, DOI 10.1074/jbc.M008789200; Bhogal PS, 1997, MICROBIOL-SGM, V143, P2485, DOI 10.1099/00221287-143-7-2485; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Canaff L, 1999, MOL CELL ENDOCRINOL, V156, P1, DOI 10.1016/S0303-7207(99)00129-X; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; FLETCHER HM, 1995, INFECT IMMUN, V63, P1521, DOI 10.1128/IAI.63.4.1521-1528.1995; Fox C H, 1992, Curr Opin Dent, V2, P5; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; MALEY J, 1992, FEMS MICROBIOL LETT, V15, P75; MCKEE AS, 1986, INFECT IMMUN, V52, P349, DOI 10.1128/IAI.52.2.349-355.1986; Mikolajczyk-Pawlinska J, 1998, BIOL CHEM, V379, P205, DOI 10.1515/bchm.1998.379.2.205; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; O'Brien-Simpson NM, 2001, INFECT IMMUN, V69, P7527, DOI 10.1128/IAI.69.12.7527-7534.2001; O'Brien-Simpson NM, 2000, INFECT IMMUN, V68, P4055, DOI 10.1128/IAI.68.7.4055-4063.2000; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Shi Y, 1999, J BIOL CHEM, V274, P17955, DOI 10.1074/jbc.274.25.17955; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; Slakeski N, 1998, MICROBIOL-UK, V144, P1583, DOI 10.1099/00221287-144-6-1583; SOCRANSKY SS, 1992, J PERIODONTOL, V63, P322, DOI 10.1902/jop.1992.63.4s.322; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Travis J, 2000, ADV EXP MED BIOL, V477, P455; Urban S, 2000, EMBO J, V19, P1217, DOI 10.1093/emboj/19.6.1217; van Adelsberg J, 1999, DEV GENET, V24, P299, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<299::AID-DVG13>3.0.CO;2-J; Veith PD, 2002, BIOCHEM J, V363, P105, DOI 10.1042/0264-6021:3630105; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0	35	49	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23433	23440		10.1074/jbc.M200811200	http://dx.doi.org/10.1074/jbc.M200811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976326	hybrid			2022-12-27	WOS:000176475700045
J	Mogensen, JE; Wimmer, R; Larsen, JN; Spangfort, MD; Otzen, DE				Mogensen, JE; Wimmer, R; Larsen, JN; Spangfort, MD; Otzen, DE			The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; POLLEN-TUBE GROWTH; BINDING-PROTEIN; CHERRY ALLERGEN; RIBONUCLEASE-ACTIVITY; NMR-SPECTROSCOPY; PR-10 PROTEIN; CDNA CLONING; FATTY-ACIDS; GENE FAMILY	Bet v 1 is a 17-kDa protein abundantly present in the pollen of the White birch tree and is the primary cause of birch pollen allergy in humans. Its three-dimensional structure is remarkable in that a solvent-accessible cavity traverses the core of the molecule. The biological function of Bet v 1 is unknown, although it is homologous to a family of pathogenesis-related proteins in plants. In this study we first show that Bet v 1 in the native state is able to bind the fluorescent probe 8-anilino-1-naphthalenesulfonic acid (ANS). ANS binds to Bet v 1 with 1:1 stoichiometry, and NMR data indicate that binding takes place in the cavity. Using an ANS displacement assay, we then identify a range of physiologically relevant ligands, including fatty acids, flavonoids, and cytokinins, which generally bind with low micromolar affinity. The ability of these ligands to displace ANS suggests that they also bind in the cavity, although the exact binding sites seem to vary among different ligands. The cytokinins, for example, seem to bind at a separate site close to ANS, because they increase the fluorescence of the ANS.Bet v 1 complex. Also, the fluorescent sterol dehydroergosterol binds to Bet v 1 as demonstrated by direct titrations. This study provides the first qualitative and quantitative data on the ligand binding properties of this important pollen allergen. Our findings indicate that ligand binding is important for the biological function of Bet v 1.	Univ Aalborg, Dept Biotechnol, Inst Life Sci, DK-9000 Aalborg, Denmark; ALK Abello AS, Biochem Allergy Res, DK-2970 Horsholm, Denmark	Aalborg University; ALK-Abello AS	Otzen, DE (corresponding author), Univ Aalborg, Dept Biotechnol, Inst Life Sci, Sohngaardsholmsvej 49, DK-9000 Aalborg, Denmark.		Larsen, Jørgen Nedergaard/AAI-3423-2020; Wimmer, Reinhard/M-2346-2019; Wimmer, Reinhard/A-7901-2012	Wimmer, Reinhard/0000-0001-6942-5056; Otzen, Daniel/0000-0002-2918-8989				Bantignies B, 2000, PLANT MOL BIOL, V42, P871, DOI 10.1023/A:1006475303115; Billeter M, 1995, J BIOMOL NMR, V5, P1; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; Franklin-Tong VE, 1999, PLANT CELL, V11, P727, DOI 10.1105/tpc.11.4.727; Fujimoto Y, 1998, EUR J BIOCHEM, V258, P794, DOI 10.1046/j.1432-1327.1998.2580794.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P115, DOI 10.1159/000024367; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; Iyer LM, 2001, PROTEINS, V43, P134, DOI 10.1002/1097-0134(20010501)43:2<134::AID-PROT1025>3.3.CO;2-9; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kobayashi K, 2000, PLANT CELL PHYSIOL, V41, P148, DOI 10.1093/pcp/41.2.148; KRESBECH GC, 1975, SURFACTANTS WATER CO, P95; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LARSEN JN, 1995, ACI NEWS, V7, P141; Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245, DOI 10.1007/BF02668748; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MO YY, 1992, P NATL ACAD SCI USA, V89, P7213, DOI 10.1073/pnas.89.15.7213; Moiseyev GP, 1997, FEBS LETT, V407, P207, DOI 10.1016/S0014-5793(97)00337-2; NESSLER CL, 1990, PLANTA, V180, P487, DOI 10.1007/BF02411445; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Osman H, 2001, FEBS LETT, V489, P55, DOI 10.1016/S0014-5793(01)02078-6; Osmark P, 1998, PLANT MOL BIOL, V38, P1243, DOI 10.1023/A:1006060224012; OSMARK P, 1996, THESIS U COPENHAGEN; OSSIPOV V, 1995, BIOCHEM SYST ECOL, V23, P213, DOI 10.1016/0305-1978(94)00092-U; Peters T. J., 1995, ALBUMIN BIOCH GENETI; Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poupard P, 2001, AUST J PLANT PHYSIOL, V28, P57; POZUETAROMERO J, 1995, PLANT MOL BIOL, V28, P1011, DOI 10.1007/BF00032663; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Richieri GV, 1996, J BIOL CHEM, V271, P31068, DOI 10.1074/jbc.271.49.31068; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1990, LIPIDS, V25, P669, DOI 10.1007/BF02544032; Schweimer K, 1999, APPL MAGN RESON, V17, P449, DOI 10.1007/BF03162177; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; Spangfort MD, 1996, PROTEIN EXPRES PURIF, V8, P365, DOI 10.1006/prep.1996.0112; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SWOBODA I, 1994, BBA-GENE STRUCT EXPR, V1219, P457, DOI 10.1016/0167-4781(94)90072-8; SWOBODA I, 1995, PLANT CELL ENVIRON, V18, P865, DOI 10.1111/j.1365-3040.1995.tb00595.x; Swoboda I, 1996, PHYSIOL PLANTARUM, V96, P433, DOI 10.1111/j.1399-3054.1996.tb00455.x; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Utriainen M, 1998, PLANT CELL ENVIRON, V21, P821, DOI 10.1046/j.1365-3040.1998.00326.x; Van Damme EJM, 2000, PLANT PHYSIOL, V122, P433, DOI 10.1104/pp.122.2.433; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Vanderheeren G, 1998, BIOPHYS J, V75, P2195, DOI 10.1016/S0006-3495(98)77663-5; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Wilhelmi LK, 1999, CURR OPIN PLANT BIOL, V2, P18, DOI 10.1016/S1369-5266(99)80004-1; Wimmer R, 1997, J BIOMOL NMR, V9, P101, DOI 10.1023/A:1018631903764; Wolters-Arts M, 1998, NATURE, V392, P818, DOI 10.1038/33929	71	199	213	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23684	23692		10.1074/jbc.M202065200	http://dx.doi.org/10.1074/jbc.M202065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953433	hybrid			2022-12-27	WOS:000176475700077
J	Ribeiro, CS; Carneiro, K; Ross, CA; Menezes, JRL; Engelender, S				Ribeiro, CS; Carneiro, K; Ross, CA; Menezes, JRL; Engelender, S			Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; LEWY BODIES; PRESYNAPTIC PROTEIN; HIPPOCAMPAL-NEURONS; PRECURSOR PROTEIN; BODY FORMATION; BRAIN; MUTATION; GENE	a-Synuclein is the major component of Lewy bodies in patients with Parkinson's disease, and mutations in the a-synuclein gene are responsible for some familial forms of the disease. a-Synuclein is enriched in the presynapse, but its synaptic targets are unknown. Synphilin-1 associates in vivo with a-synuclein promoting the formation of intracellular inclusions. Additionally synphilin-1 has been found to be an intrinsic component of Lewy bodies in patients with Parkinson's disease. To understand the role of synphilin-1 in Parkinson's disease, we sought to define its localization and function in the brain. We now report that, like a-synuclein, synphilin-1 was enriched in neurons. In young rats, synphilin-1 was prominent in neuronal cell bodies but gradually migrated to neuropil during development. Immunoelectron microscopy of adult rat cerebral cortex demonstrated that synphilin-1 was highly enriched in presynaptic nerve terminals. Synphilin-1 co-immunoprecipitated with synaptic vesicles, indicating a strong association with these structures. In vitro binding experiments demonstrated that the N terminus of synphilin-1 robustly associated with synaptic vesicles and that this association was resistant to high salt washing but was abolished by inclusion of a-synuclein in the incubation medium. Our data indicated that synphilin-1 is a synaptic partner of a-synuclein, and it may mediate synaptic roles attributed to a-synuclein.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Johns Hopkins Univ, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Univ Fed Rio de Janeiro, Dept Anat, BR-21941590 Rio De Janeiro, Brazil	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Johns Hopkins University; Johns Hopkins University; Universidade Federal do Rio de Janeiro	Engelender, S (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, POB 4696, IL-31096 Haifa, Israel.		Carneiro, Katia/AAQ-3415-2020; Menezes, João R. L./D-5668-2012; Ross, Christopher A/H-8395-2013; Carneiro, Katia/I-6014-2015	Carneiro, Katia/0000-0001-5915-5486; Engelender, Simone/0000-0001-7401-6855	NINDS NIH HHS [NS38377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Engelender S, 2000, MAMM GENOME, V11, P763, DOI 10.1007/s003350010123; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hsu LJ, 1998, J NEUROCHEM, V71, P338; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; LEE G, 2001, SOC NEUR ABSTR, V27; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nagano Y, 2001, NEUROSCI LETT, V316, P103, DOI 10.1016/S0304-3940(01)02330-8; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2000, BRAIN PATHOL, V10, P520; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6	32	88	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23927	23933		10.1074/jbc.M201115200	http://dx.doi.org/10.1074/jbc.M201115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956199	hybrid			2022-12-27	WOS:000176475700107
J	Sugiura, M; Kono, K; Liu, H; Shimizugawa, T; Minekura, H; Spiegel, S; Kohama, T				Sugiura, M; Kono, K; Liu, H; Shimizugawa, T; Minekura, H; Spiegel, S; Kohama, T			Ceramide kinase, a novel lipid kinase - Molecular cloning and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN-COUPLED RECEPTOR; LEUKEMIA HL-60 CELLS; MARINE BACTERIUM; SPHINGOSINE; SPHINGOSINE-1-PHOSPHATE; APOPTOSIS; 1-PHOSPHATE; BINDING; EDG-1	Ceramide-1-phosphate is a sphingolipid metabolite that has been implicated in membrane fusion of brain synaptic vesicles and neutrophil phagolysosome formation. Ceramide-l-phosphate can be produced by ATP-dependent ceramide kinase activity, although little is known of this enzyme because it has not yet been highly purified or cloned. Based on sequence homology to sphingosine kinase type 1, we have now cloned a related lipid kinase, human ceramide kinase (hCERK). hCERK encodes a protein of 537 amino acids that has a catalytic region with a high degree of similarity to the diacylglycerol kinase catalytic domain. hCERK also has a putative N-myristoylation site on its NH2 terminus followed by a pleckstrin homology domain. Membrane but not cytosolic fractions from HEK293 cells transiently transfected with a hCERK expression vector readily phosphorylated ceramide but not sphingosine or other sphingoid bases, diacylglycerol. or phosphatidylinositol. This activity was clearly distinguished from those of bacterial or human diacylglycerol. kinases. With natural ceramide as a substrate, the enzyme had a pH optimum of 6.0-7.5 and showed Michaelis-Menten kinetics, with K-m values of 187 and 32 muM for ceramide and ATP, respectively. Northern blot analysis revealed that hCERK mRNA expression was high in the brain, heart, skeletal muscle, kidney, and liver. A BLAST search analysis using the hCERK sequence revealed that putative ceramide kinases (CERKs) exist widely in diverse multicellular organisms including plants, nematodes, insects, and vertebrates. Phylogenetic analysis revealed that CERKs are a new class of lipid kinases that are clearly distinct from sphingosine and diacylglycerol kinases. Cloning of CERK should provide new molecular tools to investigate the physiological functions of ceramide-1-phosphate.	Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	Daiichi Sankyo Company Limited; Virginia Commonwealth University	Kohama, T (corresponding author), Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.	kohama@shina.sankyo.co.jp		Kohama, Takafumi/0000-0002-6822-8170				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bajjalieh S, 2000, METHOD ENZYMOL, V311, P207; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; Kono K, 2000, J ANTIBIOT, V53, P753, DOI 10.7164/antibiotics.53.753; Kono K, 2000, J ANTIBIOT, V53, P459, DOI 10.7164/antibiotics.53.459; Kono K, 2000, J ANTIBIOT, V53, P759, DOI 10.7164/antibiotics.53.759; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; LIU H, 2002, IN PRESS PROG NUC RE; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	46	236	249	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23294	23300		10.1074/jbc.M201535200	http://dx.doi.org/10.1074/jbc.M201535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956206	hybrid			2022-12-27	WOS:000176475700027
J	Takei, Y; Kadomatsu, K; Itoh, H; Sato, W; Nakazawa, K; Kubota, S; Muramatsu, T				Takei, Y; Kadomatsu, K; Itoh, H; Sato, W; Nakazawa, K; Kubota, S; Muramatsu, T			5 '-,3 '-Inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; PROTEIN-KINASE; GROWTH-FACTOR; WILMS-TUMOR; ISIS 2302; EXPRESSION; INHIBITION; DNA; CELLS	Oligodeoxynucleotides modified at both 5'- and 3'-ends with inverted thymidine (5'-,3'-inverted T) were introduced as new reagents for antisense strategies. These modifications were performed to make the oligodeoxynucleotides resistant to nucleases. The effectiveness of these oligodeoxynucleotides was evaluated in terms of inhibition of synthesis of midkine (MK), a heparin-binding growth factor, and consequent inhibition of growth of CMT-93 mouse rectal carcinoma cells. 5'-,3'-Inverted T antisense AM suppressed synthesis of MK by CMT-93 cells and their growth in culture. Furthermore, 5'-,3'-inverted T oligodeoxynucleotides exhibited less cytotoxicity and better stability than phosphorothioate oligodeoxynucleotides. When 5'-,3'-inverted T antisense MK was mixed with atelocollagen, and injected into CMT-93 tumors pregrown in nude mice, tumor growth was markedly suppressed as compared with tumors injected with sense controls. The suppressive effect of 5'-,3'-inverted T antisense MK on tumor growth was stronger than that of phosphorothioate antisense MK. These findings indicated the usefulness of inverted thymidine-modified antisense oligodeoxynucleotides as a new reagent instead of phosphorothioate-modified oligodeoxynucleotides.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Koken Biosci Inst, Shinjuku Ku, Tokyo 1690072, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Tokyo 1130033, Japan	Nagoya University; University of Tokyo	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai cho, Nagoya, Aichi 4668550, Japan.	tmurama@med.nagoya-u.ac.jp	Kadomatsu, Kenji/G-8083-2012; TAKEI, Yoshifumi/I-7260-2014					AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; Flaherty KT, 2001, CURR OPIN ONCOL, V13, P499, DOI 10.1097/00001622-200111000-00013; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P473, DOI 10.1089/oli.1.1997.7.473; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Henry SP, 1997, TOXICOLOGY, V116, P77, DOI 10.1016/S0300-483X(96)03532-9; Henry SP, 1997, TOXICOLOGY, V120, P145, DOI 10.1016/S0300-483X(97)03661-5; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P395; HORNER MJ, 1996, FUNDAM APPL TOXICO S, V36, P147; IDZIAK I, 1993, TETRAHEDRON LETT, V34, P5417, DOI 10.1016/S0040-4039(00)73923-2; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kandimalla ER, 1997, NUCLEIC ACIDS RES, V25, P370, DOI 10.1093/nar/25.2.370; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; Monteith DK, 1999, TOXICOL PATHOL, V27, P8, DOI 10.1177/019262339902700103; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; OBrien T, 1996, CANCER RES, V56, P2515; Ochiya T, 1999, NAT MED, V5, P707, DOI 10.1038/9560; Owada K, 1999, J NEUROCHEM, V73, P2084; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Robins MJ, 2000, NUCLEOS NUCLEOT NUCL, V19, P69, DOI 10.1080/15257770008032997; Roth CM, 1999, ANNU REV BIOMED ENG, V1, P265, DOI 10.1146/annurev.bioeng.1.1.265; SANDS H, 1994, MOL PHARMACOL, V45, P932; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; SARIN PS, 1988, P NATL ACAD SCI USA, V85, P7448, DOI 10.1073/pnas.85.20.7448; SARMIENTO UM, 1994, ANTISENSE RES DEV, V4, P99, DOI 10.1089/ard.1994.4.99; Sioud M, 2000, J MOL BIOL, V296, P937, DOI 10.1006/jmbi.2000.3491; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; SPROAT BS, 1995, J BIOTECHNOL, V41, P221, DOI 10.1016/0168-1656(95)00012-F; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Takei Y, 2001, CANCER RES, V61, P8486; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Tari AM, 2000, METHOD ENZYMOL, V313, P372; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TSUTSUI J, 1993, CANCER RES, V53, P1281; Uhlmann E, 1998, ANGEW CHEM INT EDIT, V37, P2797; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZHANG RW, 1995, BIOCHEM PHARMACOL, V49, P929, DOI 10.1016/0006-2952(95)00010-W	51	44	56	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23800	23806		10.1074/jbc.M112100200	http://dx.doi.org/10.1074/jbc.M112100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959856	hybrid			2022-12-27	WOS:000176475700092
J	Vanoye, CG; MacGregor, GG; Dong, K; Tang, LQ; Buschmann, AS; Hall, AE; Lu, M; Giebisch, G; Hebert, SC				Vanoye, CG; MacGregor, GG; Dong, K; Tang, LQ; Buschmann, AS; Hall, AE; Lu, M; Giebisch, G; Hebert, SC			The carboxyl termini of K-ATP channels bind nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; ADENOSINE-TRIPHOSPHATE; CONFORMATIONAL-CHANGES; SULFONYLUREA RECEPTOR; GASTRIC H+,K+-ATPASE; CYTOPLASMIC DOMAIN; ESCHERICHIA-COLI; KIR6.2 SUBUNIT; INHIBITION; SITE	ATP-sensitive potassium (K-ATP) channels are expressed in many excitable, as well as epithelial, cells and couple metabolic changes to modulation of cell activity. ATP regulation of K-ATP channel activity may involve direct binding of this nucleotide to the pore-forming inward rectifier (Kir) subunit despite the lack of known nucleotide-binding motifs. To examine this possibility, we assessed the binding of the fluorescent ATP analogue, 2',3'-O-(2,4,6-trinitrophenylcyclo-hexadienylidene)adenosine 5'triphosphate (TNP-ATP) to maltose-binding fusion proteins of the NH2- and COOH-terminal cytosolic regions of the three known K-ATP channels (Kirl.1, Kir6.1, and Kir6.2) as well as to the COOH-terminal region of an ATP-insensitive inward rectifier K+ channel (Kir2.1). We show direct binding of TNP-ATP to the COOH termini of all three known K-ATP channels but not to the COOH terminus of the ATP-insensitive channel, Kir2.1. TNP-ATP binding was specific for the COOH termini of K-ATP channels because this nucleotide did not bind to the NH2 termini of Kirl.1 or Kir6.1. The affinities for TNP-ATP binding to K-ATP COOH termini of Kirl.1, Kir6.1, and Kir6.2 were similar. Binding was abolished by denaturing with 4 m urea or SDS and enhanced by reduction in pH. TNP-ATP to protein stoichiometries were similar for all KATp COOH-terminal proteins with 1 mol of TNP-ATP binding/ mole of protein. Competition of TNP-ATP binding to the Kirl.1 COOH terminus by MgATP was complex with both Mg2+ and MgATP effects. Glutaraldehyde cross-linking demonstrated the multimerization potential of these COOH termini, suggesting that these cytosolic segments may directly interact in intact tetrameric channels. Thus, the COOH termini of K-ATP tetrameric channels contain the nucleotide-binding pockets of these metabolically regulated channels with four potential nucleotide-binding sites/channel tetramer.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Vanderbilt Univ, Sch Med, Div Genet Med, Dept Med, Nashville, TN 37232 USA	Yale University; Vanderbilt University	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St,SHM B147,POB 208026, New Haven, CT 06520 USA.				NIDDK NIH HHS [DK54999, DK54998] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054998, R01DK054999] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Collins A, 1996, J NEUROSCI, V16, P1; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; DIVITA G, 1993, J BIOL CHEM, V268, P13178; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HILGEMANN DW, 2001, SCI STKE; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; KLINGENBERG M, 1984, BIOCHEMISTRY-US, V23, P2442, DOI 10.1021/bi00306a019; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; Lee SF, 2000, J BIOL CHEM, V275, P15809, DOI 10.1074/jbc.M000601200; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; Markworth E, 2000, DIABETES, V49, P1413, DOI 10.2337/diabetes.49.9.1413; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Misler S, 1992, Curr Opin Nephrol Hypertens, V1, P21, DOI 10.1097/00041552-199210000-00005; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanemoto M, 2000, AM J PHYSIOL-RENAL, V278, pF659, DOI 10.1152/ajprenal.2000.278.4.F659; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Yokoshiki H, 1998, AM J PHYSIOL-CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	59	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23260	23270		10.1074/jbc.M112004200	http://dx.doi.org/10.1074/jbc.M112004200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956191	hybrid			2022-12-27	WOS:000176475700023
J	Vilar, M; Sauri, A; Monne, M; Marcos, JF; von Heijne, G; Perez-Paya, E; Mingarro, I				Vilar, M; Sauri, A; Monne, M; Marcos, JF; von Heijne, G; Perez-Paya, E; Mingarro, I			Insertion and topology of a plant viral movement protein in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO MOSAIC-VIRUS; RNA-BINDING DOMAIN; CELL-TO-CELL; AMINO-ACIDS; CYTOSKELETON; PLASMODESMATA; TRAFFICKING; TRANSPORT; INFECTION; TOMBUSVIRIDAE	Virus-encoded movement proteins (MPs) mediate cell-to-cell spread of viral RNA through plant membranous intercellular connections, the plasmodesmata. The molecular pathway by which MPs interact with viral genomes and target plasmodesmata channels is largely unknown. The 9-kDa MP from carnation mottle carmovirus (CarMV) contains two potential transmembrane domains. To explore the possibility that this protein is in fact an intrinsic membrane protein, we have investigated its insertion into the endoplasmic reticulum membrane. By using in vitro translation in the presence of dog pancreas microsomes, we demonstrate that CarMV p9 inserts into the endoplasmic reticulum without the aid of any additional viral or plant host components. We further show that the membrane topology of CarMV p9 is N-cyt-C-cyt (N and C termini of the protein facing the cytoplasm) by in vitro translation of a series of truncated and full-length constructs with engineered glycosylation sites. Based on these results, we propose a topological model in which CarMV p9 is anchored in the membrane with its N- and C-terminal tail segments interacting with its soluble, RNA-bound partner CarMV p7, to accomplish the viral cell-to-cell movement function.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; CSIC, Inst Agroquim & Tecnol Alimentos, Dept Ciencia Alimentos, E-46100 Burjassot, Spain	University of Valencia; Stockholm University; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Mingarro, I (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain.	Ismael.Mingarro@uv.es	von Heijne, Gunnar/F-5576-2011; Marcos, Jose F./A-7121-2011; Monné, Magnus/D-5642-2012; Mingarro, Ismael/B-4745-2014; Vilar, Marçal/B-4581-2016; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Marcos, Jose F./0000-0003-3339-2584; Monné, Magnus/0000-0003-2344-3878; Mingarro, Ismael/0000-0002-1910-1229; Vilar, Marçal/0000-0002-9376-6544; 				Aaziz R, 2001, TRENDS PLANT SCI, V6, P326, DOI 10.1016/S1360-1385(01)01981-1; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Brill LM, 2000, P NATL ACAD SCI USA, V97, P7112, DOI 10.1073/pnas.130187897; Canizares MC, 2001, ARCH VIROL, V146, P2039, DOI 10.1007/s007050170051; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; Chen MH, 2000, EMBO J, V19, P913, DOI 10.1093/emboj/19.5.913; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; DEOM CM, 1991, VIROLOGY, V180, P251, DOI 10.1016/0042-6822(91)90029-B; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Ghoshroy S, 1997, ANNU REV PLANT PHYS, V48, P25; Grieco F, 1999, J GEN VIROL, V80, P1103, DOI 10.1099/0022-1317-80-5-1103; HACKER DL, 1992, VIROLOGY, V186, P1, DOI 10.1016/0042-6822(92)90055-T; Heinlein M, 1998, PLANT CELL, V10, P1107, DOI 10.1105/tpc.10.7.1107; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; KOONIN EV, 1991, J GEN VIROL, V72, P2895, DOI 10.1099/0022-1317-72-12-2895; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lazarowitz SG, 1999, PLANT CELL, V11, P535, DOI 10.1105/tpc.11.4.535; Li VZ, 1998, VIROLOGY, V244, P405, DOI 10.1006/viro.1998.9125; Marcos JF, 1999, VIROLOGY, V255, P354, DOI 10.1006/viro.1998.9596; Mas P, 1999, J CELL BIOL, V147, P945, DOI 10.1083/jcb.147.5.945; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; Melcher U, 2000, J GEN VIROL, V81, P257, DOI 10.1099/0022-1317-81-1-257; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Oparka KJ, 1997, PLANT J, V12, P781, DOI 10.1046/j.1365-313X.1997.12040781.x; Oparka KJ, 1999, CELL, V97, P743, DOI 10.1016/S0092-8674(00)80786-2; Pickard BG, 1999, CELL, V98, P5, DOI 10.1016/S0092-8674(00)80600-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Qu F, 1999, ENCY VIROLOGY, P243; Reichel C, 1998, P NATL ACAD SCI USA, V95, P11169, DOI 10.1073/pnas.95.19.11169; Reichel C, 1999, TRENDS PLANT SCI, V4, P458, DOI 10.1016/S1360-1385(99)01490-9; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; RUSSO M, 1994, ADV VIRUS RES, V44, P381, DOI 10.1016/S0065-3527(08)60334-6; Solovyev AG, 2000, VIROLOGY, V269, P113, DOI 10.1006/viro.2000.0200; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Tzfira T, 2000, ANNU REV MICROBIOL, V54, P187, DOI 10.1146/annurev.micro.54.1.187; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; Vilar M, 2001, J BIOL CHEM, V276, P18122, DOI 10.1074/jbc.M100706200; Ward BM, 1997, J VIROL, V71, P3726, DOI 10.1128/JVI.71.5.3726-3733.1997; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; YANG JT, 1986, METHOD ENZYMOL, V130, P208	44	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23447	23452		10.1074/jbc.M202935200	http://dx.doi.org/10.1074/jbc.M202935200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976343	Green Published, hybrid			2022-12-27	WOS:000176475700047
J	Wang, XL; Gjernes, E; Prydz, H				Wang, XL; Gjernes, E; Prydz, H			Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in a human keratinocyte line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; MESSENGER-RNA DEGRADATION; FACTOR EXPRESSION; BLOOD-COAGULATION; GENE-EXPRESSION; MELANOMA-CELLS; SIGNAL-TRANSDUCTION; BINDING; METASTASIS	Tissue factor (TF), a transmembrane receptor for the serine protease coagulation factor VII(a) (FVIIa), is the main initiator of the coagulation cascade. Through incompletely elucidated mechanisms, TF serves additional functions in tumor-associated angiogenesis and metastasis. We have studied interleukin-8 (IL-8) as a possible link between TF-FYIIa complex formation and subsequent processes. Recombinant human FVIIa induced the up-regulation of both IL-8 mRNA and protein in a FYIIa dose- and time-dependent fashion. A neutralizing antibody to TF reduced this induction by 93 +/- 5%. Active site-inhibited FYIIa had no stimulatory effect and completely blocked that of FVIIa. This confirms that the increased IL-8 production was dependent on the formation of TF-FYIIa complexes and the proteolytic activity of FYIIa. The IL-8 promoter contains DNA binding sites for nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1). In response to FVIIa, the DNA binding activity of both NF-kappaB and AP-1 was enhanced in an electrophoretic mobility shift assay. In addition, the IL-8 promoter was transcriptionally activated both in a luciferase reporter system and a nuclear run-off assay. Moreover, IL-8 mRNA stability was significantly enhanced by FVIIa-induced activation of the mitogen-activated protein kinases ERK1/2 and p38. Taken together, TF-FVIIa signaling induced increased transcription as well as mRNA stabilization leading to the significant up-regulation of IL-8 protein synthesis.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Gaustadalleen 21, N-0349 Oslo, Norway.							Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; BARTALENA L, 1992, MOL ENDOCRINOL, V6, P935, DOI 10.1210/me.6.6.935; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; CARSON SD, 1987, BLOOD, V70, P490; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Dunwiddie Christopher T., 1993, Methods in Enzymology, V223, P291; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Inoue K, 2000, CANCER RES, V60, P2290; Kakkar AK, 1999, BRIT J SURG, V86, P890, DOI 10.1046/j.1365-2168.1999.01153.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Koomagi R, 1998, INT J CANCER, V79, P19, DOI 10.1002/(SICI)1097-0215(19980220)79:1<19::AID-IJC4>3.3.CO;2-9; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Martin DMA, 1998, THROMB RES, V90, P1, DOI 10.1016/S0049-3848(98)00015-2; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Ollivier V, 2000, ARTERIOSCL THROM VAS, V20, P1374, DOI 10.1161/01.ATV.20.5.1374; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Ruf W, 1996, Curr Opin Hematol, V3, P379; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shoji M, 1998, AM J PATHOL, V152, P399; SICA A, 1990, IMMUNOLOGY, V69, P548; SINGH RK, 1994, CANCER RES, V54, P3242; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STRIETER RM, 1992, AM J PATHOL, V141, P1279; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Ueno T, 2000, BRIT J CANCER, V83, P164; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; Yatsunami J, 1997, CANCER LETT, V120, P101, DOI 10.1016/S0304-3835(97)00296-6; Zandi E, 1999, MOL CELL BIOL, V19, P4547	55	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23620	23626		10.1074/jbc.M202242200	http://dx.doi.org/10.1074/jbc.M202242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973337	hybrid			2022-12-27	WOS:000176475700068
J	Back, SH; Shin, SJ; Jang, SK				Back, SH; Shin, SJ; Jang, SK			Polypyrimidine tract-binding proteins are cleaved by caspase-3 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-ENTRY-SITE; INITIATION-FACTOR 4G; MOUTH-DISEASE VIRUS; CAP-INDEPENDENT TRANSLATION; 5' NONTRANSLATED REGION; PROGRAMMED CELL-DEATH; MESSENGER-RNA; INTERNAL INITIATION; FUNCTIONAL REQUIREMENT; MEDIATED TRANSLATION	The polypyrimidine tract-binding protein (PTB), an RNA-binding protein, is required for efficient translation of some mRNAs containing internal ribosomal entry sites (IRESs). Here we provide evidence that the addition of apoptosis-inducing agents to cells results in the cleavage of PTB isoforms 1, 2, and 4 by caspase-3. This cleavage of PTB separated the N-terminal region, containing NLS-RRM1, from the C-terminal region, containing RRM2-3-4. Our data indicate that there are three noncanonical caspase-3 target sites in PTBs, namely Ile-Val-Pro-Asp(7) down arrow Ile, Leu-Tyr-Thr-Asp(139) down arrow Ser, and Ala-Ala-Val-Asp(172) down arrow Ala. The C-terminal PTB fragments localized to the cytoplasm, as opposed to the nucleus where most intact PTBs are found. Moreover, these G terminal PTB fragments inhibited translation of polio-viral mRNA, which contains an IRES element requiring PTB for its activation. This suggests that translation of some IRES-containing mRNAs is regulated by proteolytic cleavage of PTB during apoptosis.	Pohang Univ Sci & Technol, Div Mol Life Sci, Dept Life Sci, Natl Creat Res Ctr Biomol Interact, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Natl Res Lab, Pohang 790784, Kyungbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Jang, SK (corresponding author), Pohang Univ Sci & Technol, Div Mol Life Sci, Dept Life Sci, Natl Creat Res Ctr Biomol Interact, San31, Pohang 790784, Kyungbuk, South Korea.	sungkey@postech.ac.kr	Jang, Sung K/P-1230-2017					Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Back SH, 2002, J VIROL, V76, P2529, DOI 10.1128/JVI.76.5.2529-2542.2002; Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; Belsham GJ, 2000, TRENDS MICROBIOL, V8, P330, DOI 10.1016/S0966-842X(00)01788-1; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Buendia B, 1999, J CELL SCI, V112, P1743; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; CHANG KH, 1993, J VIROL, V67, P6716, DOI 10.1128/JVI.67.11.6716-6725.1993; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Flygare J, 2000, EUR J BIOCHEM, V267, P5977, DOI 10.1046/j.1432-1327.2000.01675.x; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; Giraud S, 2001, J BIOL CHEM, V276, P5668, DOI 10.1074/jbc.M005928200; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Hermann Ralph, 2001, Human Antibodies, V10, P83; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; Hunt SL, 1999, RNA, V5, P344, DOI 10.1017/S1355838299981414; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; Kaminski A, 1995, RNA, V1, P924; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kim YK, 2000, J MOL BIOL, V304, P119, DOI 10.1006/jmbi.2000.4179; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LIN CH, 1995, RNA, V1, P234; LUZ N, 1991, J VIROL, V65, P6486, DOI 10.1128/JVI.65.12.6486-6494.1991; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARTIN SJ, 1993, SCIENCE, V262, P1355; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; Niepmann M, 1996, FEBS LETT, V388, P39, DOI 10.1016/0014-5793(96)00509-1; Oh YL, 1998, BIOCHEM J, V331, P169, DOI 10.1042/bj3310169; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Romanelli MG, 1997, EXP CELL RES, V235, P300, DOI 10.1006/excr.1997.3677; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Sella O, 1999, MOL CELL BIOL, V19, P5429; Shav-Tal Y, 2000, EXP HEMATOL, V28, P1029, DOI 10.1016/S0301-472X(00)00510-5; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000	85	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27200	27209		10.1074/jbc.M203887200	http://dx.doi.org/10.1074/jbc.M203887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004072	hybrid			2022-12-27	WOS:000177055900065
J	Langer, MR; Fry, CJ; Peterson, CL; Denu, JM				Langer, MR; Fry, CJ; Peterson, CL; Denu, JM			Modulating acetyl-CoA binding in the GCN5 family of histone acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; YEAST HO GENE; P300/CBP-ASSOCIATED FACTOR; KINETIC MECHANISM; CRYSTAL-STRUCTURE; COENZYME-A; IN-VIVO; CHROMATIN; TRANSCRIPTION; PROTEIN	The histone acetyltransferase (HAT) GCN5 is the founding member for a family of chromatin remodeling enzymes. GCN5 is the catalytic subunit of a large multi-subunit complex that functions in the regulation of gene activation via acetylation of lysine residues within the N-terminal tails of core histone proteins. Using acetylCoA as a co-substrate, the high affinity binding of acetylCoA is a critical first step in the reaction. Here, we examine the biochemical and biological importance of a conserved hydroxyl-bearing residue in signature motif A. Interestingly, one major exception is the Saccharomyces cerevisiae GCN5, where an alanine (Ala(190)) is located in the corresponding position. In related GCN5 family structures, a hydroxyl-containing side chain residue is hydrogen-bonded to the alpha-phosphate oxygen of CoA. We demonstrate that this key hydrogen bond contributes similar to10-fold to the binding affinity of GCN5 HATs for acetylCoA. Human p300/CBP-associating factor, human GCN5, and tetrahymena GCN5 displayed dissociation constants (K-d) for acetyl-CoA of 0.64 +/- 0.12, 0.56 +/- 0.15, and 0.62 +/- 0.17 muM, respectively. In contrast, S. cerevisiae GCN5 displayed a Kd of 8.5 mum. When Ala(190) was replaced with threonine, the A190T derivative yielded a K-d value of 0.56 +/- 0.1 muM for acetyl-CoA, completely restoring the higher affinity binding seen with the GCN5 homologs that naturally harbor a threonine at this position. Detailed kinetic analyses revealed that the A190T derivative was otherwise catalytically indistinguishable from wild type GCN5. We also demonstrate that the A190T allele rescued the slow growth phenotype and the defect in HO transcription caused by a deletion of GCN5. Furthermore, the A190T allele supported wild type levels of transcriptionally targeted and global histone H3 acetylation. In each case, the A190T derivative behaved similarly to wild type GCN5, suggesting that the efficacy of HAT activity by GCN5 is not limited by the availability of nuclear acetyl-CoA pools.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Oregon Health & Science University; University of Massachusetts System; University of Massachusetts Worcester	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785, R01GM049650, R37GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59785, R01 GM049650, R37 GM049650, GM 49650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Kim Y, 2000, ANAL BIOCHEM, V280, P308, DOI 10.1006/abio.2000.4546; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1974, J BIOL CHEM, V249, P5163; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	43	33	33	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27337	27344		10.1074/jbc.M203251200	http://dx.doi.org/10.1074/jbc.M203251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994311	hybrid			2022-12-27	WOS:000177055900082
J	Hansen, JB; Petersen, RK; Jorgensen, C; Kristiansen, K				Hansen, JB; Petersen, RK; Jorgensen, C; Kristiansen, K			Deregulated MAPK activity prevents adipocyte differentiation of fibroblasts lacking the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; 3T3-L1 ADIPOGENESIS; KINASE ACTIVATION; GENE-EXPRESSION; C/EBP-ALPHA; PPAR-GAMMA; CELL-CYCLE; RAS; BINDING; PHOSPHORYLATION	A functional retinoblastoma protein (pRB) is required for adipose conversion of preadipocyte cell lines and primary mouse embryo fibroblasts (MEFs) in response to treatment with standard adipogenic inducers. Interestingly, lack of functional pRB in AMFs was recently linked to elevated Ras activity. Ras-dependent signaling plays a significant, although incompletely understood, role in adipocyte differentiation, because activated Ras has been reported to either promote or inhibit adipogenesis depending on the cellular context. In various cell types activation of Ras leads to activation of the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase 1/2 (ERK1/2), and protein kinase B (PKB)/Akt, which exert opposing effects on adipogenesis, with ERK1/2 inhibiting and PKB/Akt promoting terminal differentiation. Here we report that the levels of activated ERK1/2 and PKB/Akt are significantly increased in pRB-deficient MEFs both before and after the addition of adipogenic inducers. Consistently, we detected higher levels of activated Ras in AMFs lacking pRB. Suppression of ERKI/2 activation by the MEK inhibitor UO126 restored the ability of pRB-deficient MEFs to undergo adipocyte differentiation, as manifested by expression of adipocyte marker genes and lipid accumulation. Furthermore and reflecting the elevated levels of activated PKB/Akt in the pRB-deficient MEFs, differentiation proceeded in an insulin-independent manner. In conclusion, we suggest that pRB plays a pivotal role in adipogenesis by suppressing MAPK activity.	Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Rheosci AS, DK-2610 Rodovre, Denmark	University of Southern Denmark	Kristiansen, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.		Kristiansen, Karsten/J-5148-2014; Hansen, Jacob B/F-3775-2010	Kristiansen, Karsten/0000-0002-6024-0917; Hansen, Jacob B/0000-0001-5249-2586; Jorgensen, Claus/0000-0002-7841-943X				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee KY, 1999, MOL CELL BIOL, V19, P7724; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Page BD, 2001, MOL CELL, V7, P451, DOI 10.1016/S1097-2765(01)00193-9; PORRAS A, 1992, J BIOL CHEM, V267, P21124; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Raptis L, 1997, CELL GROWTH DIFFER, V8, P11; Raptis L, 1997, EXP CELL RES, V235, P188, DOI 10.1006/excr.1997.3646; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Rosen ED, 2000, GENE DEV, V14, P1293; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEARS R, 2000, GENE DEV, V14, P2105; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	41	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26335	26339		10.1074/jbc.M203870200	http://dx.doi.org/10.1074/jbc.M203870200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000769	hybrid			2022-12-27	WOS:000176908700068
J	Biemel, KM; Friedl, DA; Lederer, MO				Biemel, KM; Friedl, DA; Lederer, MO			Identification and quantification of major Maillard cross-links in human serum albumin and lens protein - Evidence for glucosepane as the dominant compound	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLGLYOXAL; LYSINE; GLYOXAL; MECHANISM; GLYCATION; SENESCENCE; INCREASE; PENTOSES	Glycation reactions leading to protein modifications (advanced glycation end products) contribute to various pathologies associated with the general aging process and long term complications of diabetes. However, only few relevant compounds have so far been detected in vivo. We now report on the first unequivocal identification of the lysine-arginine cross-links glucosepane 5, DOGDIC 6, MODIC 7, and GODIC 8 in human material. For their accurate quantification by coupled liquid chromatography-electrospray ionization mass spectrometry, C-13-labeled reference compounds were synthesized independently. Compounds 5-8 are formed via the a-dicarbonyl compounds N-6-(2,3-dihydroxy-5,6-dioxohexyl)-L-lysinate (1a,b), 3-deoxyglucosone (2), methylglyoxal (3), and glyoxal (4), respectively. The protein-bound dideoxyosone la,b seems to be of prime significance for cross-linking because it presumably is not detoxified by mammalian enzymes as readily as 2-4. Hence, the follow-up product glucosepane 5 was found to be the dominant compound. Up to 42.3 pmol of 5/mg of protein was identified in human serum albumin of diabetics; the level of 5 correlates markedly with the glycated hemoglobin HbA(1c). In the water-insoluble fraction of lens proteins from normoglycemics, concentration of 5 ranges between 132.3 and 241.7 pmol/mg. The advanced glycoxidation end product GODIC 8 is elevated significantly in brunescent lenses, indicating enhanced oxidative stress in this material. Compounds 5-8 thus appear predestined as markers for pathophysiological processes.	Univ Hohenheim, Inst Lebensmittelchem 170, D-70593 Stuttgart, Germany; Burger Hosp, ZIM, Klinikum Stuttgart, Med Klin 3, D-70191 Stuttgart, Germany	University Hohenheim; Klinikum Stuttgart	Lederer, MO (corresponding author), Univ Hohenheim, Inst Lebensmittelchem 170, Garbenstr 28, D-70593 Stuttgart, Germany.	ledererm@uni-hohenheim.de						Beisswenger PJ, 2001, DIABETES CARE, V24, P726, DOI 10.2337/diacare.24.4.726; Biemel KM, 2002, ANGEW CHEM INT EDIT, V41, P801, DOI 10.1002/1521-3773(20020301)41:5<801::AID-ANIE801>3.0.CO;2-I; Biemel KM, 2001, J BIOL CHEM, V276, P23405, DOI 10.1074/jbc.M102035200; BRINKMANN E, 1995, J CHEM SOC PERK T 1, P2817, DOI 10.1039/p19950002817; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291; EBLE AS, 1983, J BIOL CHEM, V258, P9406; FEATHER MS, 1995, BBA-GEN SUBJECTS, V1244, P10, DOI 10.1016/0304-4165(94)00156-R; Friedman M, 1996, J AGR FOOD CHEM, V44, P631, DOI 10.1021/jf950394r; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200; HAYASE F, 1991, Amino Acids (Vienna), V1, P307, DOI 10.1007/BF00814000; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LO TWC, 1994, J BIOL CHEM, V269, P32299; LOIDLSTAHLHOFEN A, 1994, BBA-LIPID LIPID MET, V1211, P156, DOI 10.1016/0005-2760(94)90264-X; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NAKAMURA K, 1992, J CHEM SOC CHEM COMM, P992, DOI 10.1039/c39920000992; Obayashi H, 1996, BIOCHEM BIOPH RES CO, V226, P37, DOI 10.1006/bbrc.1996.1308; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; Odani H, 1999, BIOCHEM BIOPH RES CO, V256, P89, DOI 10.1006/bbrc.1999.0221; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RAY M, 1987, J BIOL CHEM, V262, P5974; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; Reiser KM, 1998, P SOC EXP BIOL MED, V218, P23; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; Sachs L, 1993, STAT METHODEN PLANUN; SACHS L, 1978, ANGEWANDTE STAT STAT; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shamsi FA, 1999, CURR EYE RES, V19, P276, DOI 10.1076/ceyr.19.3.276.5315; Skovsted IC, 1998, CELL MOL BIOL, V44, P1159; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; WALTER HF, 1991, RUCKSTANDSANALYTIK P, P1; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; Yamaguchi M, 1998, DIABETIC MED, V15, P458, DOI 10.1002/(SICI)1096-9136(199806)15:6<458::AID-DIA601>3.0.CO;2-Q	39	173	183	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24907	24915		10.1074/jbc.M202681200	http://dx.doi.org/10.1074/jbc.M202681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978796	hybrid			2022-12-27	WOS:000176747000012
J	Chang, YJ; Wu, HL; Hamaguchi, N; Hsu, YC; Lin, SW				Chang, YJ; Wu, HL; Hamaguchi, N; Hsu, YC; Lin, SW			Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis - Residues Asn(89)-Gly(93) are critical for binding factor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-IX; SOLUBLE TISSUE FACTOR; BLOOD-COAGULATION; HEMOPHILIA-B; FACTOR-X; ENZYME-ACTIVITY; LIGHT-CHAIN; PROTEIN-C; ACTIVATION; COFACTOR	This paper describes the consequences of alanine-scanning mutagenesis on 28 positions of the second epidermal growth factor (EGF-2) domain of factor IX. We identified four positions of Gln(97), Phe(98), Tyr(115), and Leu(117) that are critical for secretion of factor IX. Of the remaining mutations, 4 mutants (V86A, E113A, K122A, and S123A) are as active as wild-type factor IX (lXwt); 16 (D85A, K100A, N101A, D104A, N105X R116A, E119A, T87A, 190A, K91A, R94A, E96A, S102A, K106A, T112A, and N120A) retain reduced but detectable activity, and 4 (N89A, N92A, G93A, and V107A) are nearly inert in the clotting assay. Both factor XIa and the factor VIIa-tissue factor complex effectively catalyzed the activation of these mutants except N89A. The mutant V107A failed to form the factor tenase complex with factor VIIIa because of a 35-fold increase in K,. The mutants N89A and N92A did not compete with factor lXwt for factor VIIIa binding, and G93A exhibited a 6-fold increase in K-i values in the competitive binding assay. It appears that mutations at these positions have significantly affected the interaction between factor IX and factor VIIIa, although other mutations had little effect on the binding of factor IX to factor VIIIa. Mutations in two regions, Thr(87)-Gly(93) and Asn(101)-Val(107), significantly increased the K-m value of factor IXa (2-10-fold) in cleavage of factor X in the absence of factor VIIIa. In the presence of factor VIIIa, the catalytic efficiency of each mutant toward factor X paralleled its clotting activity. Briefly, we propose two relatively distinctive functions of factor IX for two adjacent regions in the EGF-2 domain; the first loop region (residues 89-94) is involved with the binding of its cofactor, factor VIIIa, and the third loop with connected 13-sheets (residues 102-108) is involved in the proper binding to the substrate, factor X.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Brandeis Univ, Rosensteil Basic Med Res Ctr, Waltham, MA 02119 USA; Natl Taiwan Univ Hosp, Grad Inst Med Technol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan	National Cheng Kung University; Brandeis University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lin, SW (corresponding author), Natl Taiwan Univ, Grad Inst Med Technol, Sch Med, Taipei, Taiwan.			LIN, SHU-WHA/0000-0001-6748-5581; Chang, Yu-Jia/0000-0003-3978-3244				AHMAD SS, 1995, BIOCHEM J, V310, P427, DOI 10.1042/bj3100427; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Benham AM, 2000, CRIT REV BIOCHEM MOL, V35, P433, DOI 10.1080/10409230091169258; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Celie PHN, 2000, J BIOL CHEM, V275, P229, DOI 10.1074/jbc.275.1.229; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; Chang YJ, 1999, BIOCHEMISTRY-US, V38, P10940, DOI 10.1021/bi990055h; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; Himber J, 2001, THROMB HAEMOSTASIS, V85, P475; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Hsu YC, 2001, BIOCHEMISTRY-US, V40, P11261, DOI 10.1021/bi010262t; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Kolkman JA, 1999, J BIOL CHEM, V274, P29087, DOI 10.1074/jbc.274.41.29087; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; Larson PJ, 1996, J BIOL CHEM, V271, P3869; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LIN SW, 1990, J BIOL CHEM, V265, P144; LIN SW, 1994, BLOOD, V84, P1866; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MANN KG, 1990, BLOOD, V76, P1; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; Wong MY, 1999, BIOCHEMISTRY-US, V38, P8948, DOI 10.1021/bi982835g; Wu DH, 2001, J BIOL CHEM, V276, P15025, DOI 10.1074/jbc.M005935200; Wu PC, 2000, THROMB HAEMOSTASIS, V84, P626, DOI 10.1055/s-0037-1614078; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	42	32	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25393	25399		10.1074/jbc.M105432200	http://dx.doi.org/10.1074/jbc.M105432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960977	hybrid			2022-12-27	WOS:000176747000072
J	Conti, LR; Radeke, CM; Vandenberg, CA				Conti, LR; Radeke, CM; Vandenberg, CA			Membrane targeting of ATP-sensitive potassium channel - Effects of glycosylation on surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; INSULIN-SECRETING CELLS; SULFONYLUREA RECEPTOR; K+ CHANNELS; FAMILIAL HYPERINSULINISM; ENDOPLASMIC-RETICULUM; SUBUNIT STOICHIOMETRY; PLASMA-MEMBRANE; P-GLYCOPROTEIN; TRAFFICKING	Oligosaccharides play significant roles in trafficking, folding, and sorting of membrane proteins. Sulfonylurea receptors (SURx), members of the ATP binding cassette family of proteins, associate with the inward rectifier Kir6.x to form ATP-sensitive potassium channels (K-ATP). These channels are found on the plasma membrane in many tissues and play a pivotal role in synchronizing electrical excitability with cell metabolic state. Trafficking defects resulting from three independent SUR1 mutations involved in the disease persistent hyperinsulinemic hypoglycemia of infancy have been described. Two of these mutations displayed notable decreases in glycosylation. Here we have investigated the relationship between the two N-linked glycosylation sites (Asn(10) and Asn(1050)) and SUR1 trafficking. Using patch clamp analysis, surface biotinylation, and immunofluorescence microscopy, we demonstrate a significant decrease in surface expression of SUR1 single or double glycosylation site mutants (N10Q,N1050Q) when co-expressed with Kir6.2. Additionally, we show prominent retention within the ER of the SUR1 double glycosylation mutant under the same conditions. Further investigation revealed that mutation of the ER retention signal was able to partially restore surface expression of the SUR1 double glycosylation mutant. These studies suggest that SUR1 glycosylation is a key element for the proper trafficking and surface expression of K-ATP channels.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041656, R29HL041656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; ASHCROFT SJH, 1993, ADV EXP MED BIOL, V334, P47; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Makhina EN, 1998, J BIOL CHEM, V273, P3369, DOI 10.1074/jbc.273.6.3369; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; OConnor SE, 1996, CHEM BIOL, V3, P803, DOI 10.1016/S1074-5521(96)90064-2; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; Pabon A, 2000, J BIOL CHEM, V275, P30677, DOI 10.1074/jbc.M005338200; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	38	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25416	25422		10.1074/jbc.M203109200	http://dx.doi.org/10.1074/jbc.M203109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994306	hybrid			2022-12-27	WOS:000176747000075
J	McCarthy, RA; Barth, JL; Chintalapudi, MR; Knaak, C; Argraves, WS				McCarthy, RA; Barth, JL; Chintalapudi, MR; Knaak, C; Argraves, WS			Megalin functions as an endocytic sonic hedgehog receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PROXIMAL TUBULE CELLS; MICE LACKING; ALPHA-2-MACROGLOBULIN RECEPTOR; CRANIOFACIAL MORPHOGENESIS; MEDIATES ENDOCYTOSIS; ANIMAL DEVELOPMENT; LIGAND-BINDING; PROTEIN	Embryos deficient in the morphogen Sonic hedgehog (Shh) or the endocytic receptor megalin exhibit common neurodevelopmental abnormalities. Therefore, we have investigated the possibility that a functional relationship exists between the two proteins. During embryonic development, megalin was found to be expressed along the apical surfaces of neuroepithelial cells and was co-expressed with Shh in the ventral floor plate of the neural tube. Using enzyme-linked immunosorbent assay, homologous ligand displacement, and surface plasmon resonance techniques, it was found that the amino-terminal fragment of Shh (N-Shh) bound to megalin with high affinity. Megalin-expressing cells internalized NShh through a mechanism that was inhibited by antagonists of megalin, viz. anti-receptor-associated protein and anti-megalin antibodies. Heparin also inhibited NShh endocytosis, implicating proteoglyeans in the internalization process, as has been described for other megalin ligands. Use of chloroquine to inhibit lysosomal proteinase activity showed that N-Shh endocytosed via megalin was not efficiently targeted to the lysosomes for degradation. The ability of megalin-internalized N-Shh to bypass lysosomes may relate to the finding that the interaction between N-Shh and megalin was resistant to dissociation with low pH. Together, these findings show that megalin is an efficient endocytic receptor for NShh. Furthermore, they implicate megalin as a new regulatory component of the Shh signaling pathway.	Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Argraves, WS (corresponding author), Med Univ S Carolina, Dept Cell Biol, 171 Ashley Ave, Charleston, SC 29425 USA.	argraves@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061873] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61873, R01 HL061873] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwala S, 2001, SCIENCE, V291, P2147, DOI 10.1126/science.1058624; Ahlgren SC, 1999, CURR BIOL, V9, P1304, DOI 10.1016/S0960-9822(00)80052-4; Argraves WS, 2001, FRONT BIOSCI, V6, pD406, DOI 10.2741/Argraves; Balinsky, 1975, INTRO EMBRYOLOGY; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Charrier JB, 2001, DEVELOPMENT, V128, P4011; Chen WB, 2001, DEVELOPMENT, V128, P2385; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Gritli-Linde A, 2001, DEV BIOL, V236, P364, DOI 10.1006/dbio.2001.0336; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Helms JA, 1997, DEV BIOL, V187, P25, DOI 10.1006/dbio.1997.8589; Hu D, 1999, DEVELOPMENT, V126, P4873; Hynes M, 2000, NAT NEUROSCI, V3, P41, DOI 10.1038/71114; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; Lewis KE, 1999, DEV BIOL, V208, P14, DOI 10.1006/dbio.1998.9169; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Marino M, 2001, J AM SOC NEPHROL, V12, P637, DOI 10.1681/ASN.V124637; Marino M, 2000, THYROID, V10, P461, DOI 10.1089/thy.2000.10.461; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Miller LAD, 2001, J HISTOCHEM CYTOCHEM, V49, P1593, DOI 10.1177/002215540104901213; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Nielsen R, 2001, J AM SOC NEPHROL, V12, P1099, DOI 10.1681/ASN.V1261099; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Schneider RA, 2001, DEVELOPMENT, V128, P2755; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Varga ZM, 2001, DEVELOPMENT, V128, P3497; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Williams KP, 1999, J CELL SCI, V112, P4405; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1998, BIOL CHEM, V379, P1025; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Ying LT, 2000, DEV DYNAM, V219, P143, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1050>3.3.CO;2-H; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zhang XM, 2001, DEV BIOL, V233, P271, DOI 10.1006/dbio.2000.0195	54	149	158	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25660	25667		10.1074/jbc.M201933200	http://dx.doi.org/10.1074/jbc.M201933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964399	hybrid			2022-12-27	WOS:000176747000105
J	Solecki, DJ; Gromeier, M; Mueller, S; Bernhardt, G; Wimmer, E				Solecki, DJ; Gromeier, M; Mueller, S; Bernhardt, G; Wimmer, E			Expression of the human poliovirus Receptor/CD155 gene is activated by sonic-hedgehog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; RESPIRATORY FACTOR-I; HUMAN HOMOLOG; CHROMOSOMAL LOCALIZATION; ADHESION MOLECULE; CORE PROMOTER; NTERA-2 CELLS; MOUSE HOMOLOG	The human poliovirus receptor/CD155 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. The ectodomain of CD155 mediates cell attachment to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1. CD155 is a primate-restricted gene that is expressed during development in mesenchymal tissues and ventrally derived structures within the CNS. Its function in adults is as yet unknown, but significantly, CD155 is aberrantly expressed in neuroectodermal tumors. We show that the expression of CD155 mRNA is up-regulated when human Ntera2 cells are treated with purified Sonic hedgehog (Shh) protein. Reporter gene expression driven by the CD155 core promoter is activated by Shh in transient co-transfection assays. Analysis of the CD155 core promoter indicates that an intact GLI binding site is required for Shh activation. In addition, overexpression of Gli1 or Gli3 potently activates reporter gene expression driven by the CD155 core promoter. These data identify the CD155 gene as a transcriptional target of Shh, a finding that has significance for the normal function of CD155 during development and the expression of CD155 in neuroectodermal tumors.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Solecki, DJ (corresponding author), Rockefeller Univ, Dev Neurobiol Lab, 1230 York Ave, New York, NY 10021 USA.	soleckd@mail.rockefeller.edu	Solecki, David/N-8080-2018; Bernhardt, Günter/F-6946-2012; Mueller, Steffen/HGE-0738-2022	Bernhardt, Günter/0000-0002-0510-2853; Mueller, Steffen/0000-0003-2660-258X	NIAID NIH HHS [AI39485] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI039485, R01AI039485] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; Becker TS, 1998, DEVELOPMENT, V125, P4369; BERNHARDT G, 1994, VIROLOGY, V199, P105, DOI 10.1006/viro.1994.1102; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Gromeier M, 2000, VIROLOGY, V273, P248, DOI 10.1006/viro.2000.0418; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jensen AM, 1997, DEVELOPMENT, V124, P363; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1994, ARCH VIROL, V139, P351, DOI 10.1007/BF01310797; Lange R, 2001, VIROLOGY, V285, P218, DOI 10.1006/viro.2001.0943; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Martinez-Morales JR, 1997, DEVELOPMENT, V124, P5139; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Miller LAD, 2001, J HISTOCHEM CYTOCHEM, V49, P1593, DOI 10.1177/002215540104901213; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Pons S, 2000, DEVELOPMENT, V127, P333; Raffel C, 1997, CANCER RES, V57, P842; REIFENBERGER G, 1995, CANCER RES, V55, P731; Reifenberger J, 1998, CANCER RES, V58, P1798; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Schaefer L, 2000, MAMM GENOME, V11, P104, DOI 10.1007/s003350010021; SEIFFERT D, 1995, DEV DYNAM, V203, P71, DOI 10.1002/aja.1002030108; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Solecki D, 1999, J BIOL CHEM, V274, P1791, DOI 10.1074/jbc.274.3.1791; Solecki D, 2000, J BIOL CHEM, V275, P12453, DOI 10.1074/jbc.275.17.12453; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; van Tuyl M, 2000, Respir Res, V1, P30, DOI 10.1186/rr9; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WIMMER E, 1994, COLD SPRING HARBOR M, P101; Wolter M, 1997, CANCER RES, V57, P2581; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang XM, 2001, DEVELOPMENT, V128, P943	62	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25697	25702		10.1074/jbc.M201378200	http://dx.doi.org/10.1074/jbc.M201378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983699	hybrid			2022-12-27	WOS:000176747000110
J	Carrozza, MJ; John, S; Sil, AK; Hopper, JE; Workman, JL				Carrozza, MJ; John, S; Sil, AK; Hopper, JE; Workman, JL			Gal80 confers specificity on HAT complex interactions with activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; RNA-POLYMERASE-II; CHROMATIN-REMODELING COMPLEXES; SACCHAROMYCES-CEREVISIAE; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; REGULATORY PROTEINS; YEAST; PROMOTER; GENE	Several yeast transcription activators have been shown to interact with and recruit histone acetyltransferase complexes to promoters in chromatin. The promiscuity of activator/RAT interactions suggests that additional factors temporally regulate these interactions in response to signaling pathways. In this study, we demonstrate that the negative regulator, Gal80, blocks interactions between the SAGA and NuA4 HAT complexes and the Gal4 activator. By contrast, Gal80 did not inhibit SAGA and NuA4 interaction with another activator Gcn4. The function of Gal80 prevented Gal4 targeting of SAGA and displaced SAGA targeted by Gal4 to a promoter within a nucleosome array. In the same set of experiments, targeting of SAGA by Gcn4 was unaffected by Gal80. These studies demonstrate that the specificity of HAT/activator interactions can be dictated by cofactors that modulate activation domain function in response to cellular signals.	Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.				NIGMS NIH HHS [GM027925, GM047867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047867, R37GM047867, R01GM027925] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Ansari AZ, 1998, P NATL ACAD SCI USA, V95, P13543, DOI 10.1073/pnas.95.23.13543; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhat PJ, 2001, MOL MICROBIOL, V40, P1059, DOI 10.1046/j.1365-2958.2001.02421.x; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DICKSON RC, 1990, NUCLEIC ACIDS RES, V18, P5213, DOI 10.1093/nar/18.17.5213; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; Ikeda K, 1999, MOL CELL BIOL, V19, P855; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Owen-Hughes T, 1999, METH MOL B, V119, P319; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; Peng G, 2000, MOL CELL BIOL, V20, P5140, DOI 10.1128/MCB.20.14.5140-5148.2000; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Roberts SM, 1997, GENETICS, V147, P451; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SALMERON JM, 1990, GENETICS, V125, P21; Sil AK, 1999, MOL CELL BIOL, V19, P7828; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Steger DJ, 1999, METHODS, V19, P410, DOI 10.1006/meth.1999.0877; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; YUN SJ, 1991, J BIOL CHEM, V266, P693	59	30	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24648	24652		10.1074/jbc.M201965200	http://dx.doi.org/10.1074/jbc.M201965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986320	hybrid			2022-12-27	WOS:000176611800089
J	Kakonen, SM; Selander, KS; Chirgwin, JM; Yin, JJ; Burns, S; Rankin, WA; Grubbs, BG; Dallas, M; Cui, Y; Guise, TA				Kakonen, SM; Selander, KS; Chirgwin, JM; Yin, JJ; Burns, S; Rankin, WA; Grubbs, BG; Dallas, M; Cui, Y; Guise, TA			Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENE; TGF-BETA; EXPRESSION; RECEPTOR; INHIBITION; INDUCTION; INVASION; MATRIX; RAS	Transforming growth factor (TGF)-beta promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-beta, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-beta type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibody-treated mice. TGF-beta can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-beta-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-beta-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-beta-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-beta-stimulated PTHrP production. Furthermore, TGF-beta treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-beta and may provide a new molecular target for anti-osteolytic therapy.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Drug Dev,Canc Therapy & Res Ctr, San Antonio, TX 78245 USA; Vet Adm Res Serv, San Antonio, TX 78245 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Guise, TA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Drug Dev,Canc Therapy & Res Ctr, 14960 Omicron Dr, San Antonio, TX 78245 USA.	guise@uthscsa.edu	Selander, Katri/GWM-8685-2022	Kakonen, Sanna-Maria/0000-0001-9393-6235; Rankin, Wayne/0000-0002-4427-9547	NCI NIH HHS [CA69158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069158, R29CA069158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benitez-Verguizas J, 1999, LIFE SCI, V65, P1807, DOI 10.1016/S0024-3205(99)00437-3; BUNDRED NJ, 1991, BRIT MED J, V303, P1506, DOI 10.1136/bmj.303.6816.1506; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fink SP, 2001, CANCER RES, V61, P256; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Hunt KK, 1998, CANCER RES, V58, P5656; Iddon J, 2000, J PATHOL, V191, P170; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; MERRYMAN JI, 1994, ENDOCRINOLOGY, V134, P2424, DOI 10.1210/en.134.6.2424; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; POWELL GJ, 1991, CANCER RES, V51, P3059; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Southby J, 1996, ENDOCRINOLOGY, V137, P1349, DOI 10.1210/en.137.4.1349; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Usui T, 1998, INVEST OPHTH VIS SCI, V39, P1981; Verschueren K, 1999, CYTOKINE GROWTH F R, V10, P187, DOI 10.1016/S1359-6101(99)00012-X; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Werkmeister JR, 1998, ENDOCRINE, V8, P291, DOI 10.1385/ENDO:8:3:291; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	65	208	216	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24571	24578		10.1074/jbc.M202561200	http://dx.doi.org/10.1074/jbc.M202561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964407	hybrid			2022-12-27	WOS:000176611800079
J	Yu, LG; Andrews, N; Weldon, M; Gerasimenko, OV; Cambpell, BJ; Sing, R; Grierson, I; Petersen, OH; Rhodes, JM				Yu, LG; Andrews, N; Weldon, M; Gerasimenko, OV; Cambpell, BJ; Sing, R; Grierson, I; Petersen, OH; Rhodes, JM			An N-terminal truncated form of Orp150 is a cytoplasmic ligand for the anti-proliferative mushroom Agaricus bisporus lectin and is required for nuclear localization sequence-dependent nuclear protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-REGULATED PROTEIN; ENDOPLASMIC-RETICULUM; STRESS-PROTEIN; IN-VITRO; TRANSPORT; BINDING; EXPRESSION; RAN; GLYCOSYLATION; INHIBITION	Nuclear localization sequence-dependent nuclear protein import is essential for maintaining cell function and can be selectively blocked in epithelial cells by mushroom (Agaricus bisporus) lectin. Here we report that a major intracellular ligand for this lectin is an N-terminally truncated form of oxygen-regulated protein 150 (Orp150), which lacks the endoplasmic reticulum translocation signal peptide of full-length Orp150. This cytoplasmic form of Orp150 expresses the lectin carbohydrate ligand (sialyl-2,3-galactosyl-,61,3-N-acetyl-galactosamine-alpha) and is shown to be essential for nuclear localization sequence-dependent nuclear protein import.	Univ Liverpool, Henry Wellcome Lab Mol & Cellular Gastroenterol, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Henry Wellcome Lab Mol & Cellular Gastroenterol, Dept Physiol, Liverpool L69 3GA, Merseyside, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Liverpool; University of Liverpool; University of Cambridge	Rhodes, JM (corresponding author), Univ Liverpool, Henry Wellcome Lab Mol & Cellular Gastroenterol, Dept Med, Liverpool L69 3GA, Merseyside, England.	rhodesjm@liv.ac.uk	Petersen, Ole H/E-8708-2010; Rhodes, Jonathan M/C-2496-2009; Gerasimenko, Oleg/A-6622-2010	Gerasimenko, Oleg/0000-0003-2573-8258				Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Bando Y, 2000, AM J PHYSIOL-CELL PH, V278, pC1172, DOI 10.1152/ajpcell.2000.278.6.C1172; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Chen X, 1996, FEBS LETT, V380, P68, DOI 10.1016/0014-5793(96)00011-7; CHEN YX, 1995, GLYCOCONJUGATE J, V12, P55, DOI 10.1007/BF00731869; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; DUVERGER E, 1993, EXP CELL RES, V207, P197, DOI 10.1006/excr.1993.1181; Duverger E, 1996, GLYCOBIOLOGY, V6, P381, DOI 10.1093/glycob/6.4.381; DUVERGER E, 1995, J CELL SCI, V108, P1325; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HART GW, 1999, ESSENTIALS GLYCOBIOL, P171; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kaneda S, 2000, J BIOCHEM-TOKYO, V128, P529, DOI 10.1093/oxfordjournals.jbchem.a022783; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MILLER MW, 1994, J BIOL CHEM, V269, P9289; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; PRESANT CA, 1972, J BIOL CHEM, V247, P6937; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Saphire ACS, 2000, J BIOL CHEM, V275, P4298, DOI 10.1074/jbc.275.6.4298; Saris N, 1997, J CELL BIOL, V137, P813, DOI 10.1083/jcb.137.4.813; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; SUEYOSHI S, 1988, CARBOHYD RES, V178, P213, DOI 10.1016/0008-6215(88)80113-7; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tsukamoto Y, 1998, LAB INVEST, V78, P699; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YU LG, 1993, CANCER RES, V53, P4627; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890	53	28	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24538	24545		10.1074/jbc.M203550200	http://dx.doi.org/10.1074/jbc.M203550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11960996	hybrid			2022-12-27	WOS:000176611800075
J	Pope, MA; Porello, SL; David, SS				Pope, MA; Porello, SL; David, SS			Escherichia coli apurinic-apyrimidinic endonucleases enhance the turnover of the adenine glycosylase MutY with G : A substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; DNA-POLYMERASE-BETA; C-TERMINAL DOMAIN; STRUCTURAL GENE APN1; HUMAN HOMOLOG; EXONUCLEASE-III; ABASIC SITES; MAJOR HUMAN; IN-VITRO; APURINIC/APYRIMIDINIC ENDONUCLEASES	The DNA repair enzyme MutY plays an important role in the prevention of DNA mutations resulting from the presence of the oxidatively damaged lesion 7,8-dihydro8-oxo-2'-deoxyguanosine (OG). MutY is a base excision repair (BER) glycosylase that removes misincorporated adenine residues from OG:A mispairs, as well as G:A and C:A mispairs. We have previously shown that, under conditions of low MutY concentrations relative to an OG:A or G:A substrate, the time course of the adenine glycosylase reaction exhibits biphasic kinetic behavior due to slow release of the DNA product by MutY. The dissociation of MutY from its product may require the recruitment of other proteins from the BER pathway, such as an apurinic-apyrimidinic (AP) endonuclease, as turnover-enhancing cofactors. The effect of the AP endonucleases endonuclease IV (Endo M, exonuclease III (Exo III), and Ape1 on the reaction kinetics of MutY with G:A- and OG:A.containing substrates was investigated. The effect of the glycosylases UDG and MutM and the DNA polymerase pol I was also characterized. Endo IV and Exo III, unlike Ape1, UDG, and pol I, greatly enhance the rate of product release with a G:A substrate, whereas the rate constant for the adenine removal step remains unchanged. Furthermore, the turnover rate with a truncated form of MutY, Stop 225, which lacks 125 amino acids of the C terminus, is unaffected by the presence of Endo IV or Exo III. These results constitute the first evidence of an interaction between the MutY-product DNA complex and Endo IV or Exo III. Furthermore they suggest a role for the C-terminal domain of MutY in mediating this interaction.	Univ Utah, Dept Chem, Salt Lake City, UT 84103 USA	Utah System of Higher Education; University of Utah	David, SS (corresponding author), Univ Utah, Dept Chem, Salt Lake City, UT 84103 USA.	david@chemistry.chem.utah.edu			NCI NIH HHS [CA 67985] Funding Source: Medline; NIGMS NIH HHS [GM08537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067985, R29CA067985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Chepanoske CL, 2000, ARCH BIOCHEM BIOPHYS, V380, P11, DOI 10.1006/abbi.2000.1890; Chepanoske CL, 1999, NUCLEIC ACIDS RES, V27, P3197, DOI 10.1093/nar/27.15.3197; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Demple B, 1999, NATO ADV SCI I A-LIF, V302, P59; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOESTCH PW, 1990, MUTAT RES, V236, P173; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haas BJ, 1999, J BACTERIOL, V181, P2834, DOI 10.1128/JB.181.9.2834-2839.1999; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; Masson JY, 1996, GENE, V179, P291, DOI 10.1016/S0378-1119(96)00375-7; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NASH HM, 1996, CURR BIOL, V6, P1230; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Porello SL, 1996, J AM CHEM SOC, V118, P10684, DOI 10.1021/ja9602206; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Ramotar D, 1998, BBA-GENE STRUCT EXPR, V1396, P15, DOI 10.1016/S0167-4781(97)00160-7; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sambrook J., 2002, MOL CLONING LAB MANU; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Sung JS, 2001, J BIOL CHEM, V276, P2276, DOI 10.1074/jbc.M008147200; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Williams SD, 2000, BIOCHEMISTRY-US, V39, P10098, DOI 10.1021/bi0004652; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743	76	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22605	22615		10.1074/jbc.M203037200	http://dx.doi.org/10.1074/jbc.M203037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960995	hybrid			2022-12-27	WOS:000176313600067
J	Boehm, JE; Singh, U; Combs, C; Antonyak, MA; Cerione, RA				Boehm, JE; Singh, U; Combs, C; Antonyak, MA; Cerione, RA			Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RETINOIC-ACID; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; DIFFERENTIATION; CYCLE; IDENTIFICATION; ACTIVATION	Tissue transglutaminase (TGase) is involved in the regulation of several biological events including cellular differentiation and apoptosis. The expression and activation of TGase are up-regulated in response to retinoic acid (RA), leading to the protection of several cell lines against N-(4-hydroxyphenyl)retinamide (HPR)-induced apoptosis. The anti-apoptotic mechanisms of TGase are poorly understood at this time. We examined the interaction of TGase with the retinoblastoma (Rb) protein, a substrate of TGase that is also implicated in cell survival functions. In cells undergoing HPR-induced apoptosis, Rb is degraded. This degradation is blocked when cells are pretreated with RA, an important regulator of TGase. In vitro studies revealed that TGase protects Rb from caspase-induced degradation in a transamidation-dependent manner. Experiments performed with fibroblasts from Rb-/- mice further demonstrated that the presence of Rb was required for TGase to exhibit antiapoptotic activity in response to RA treatment. Microinjection of Rb-/- cells with a transamidation-defective TGase mutant and Rb afforded no protection from HPR-induced apoptosis. Taken together, these findings suggest that the ability of TGase to modify Rb via transamidation underlies the ability of TGase to provide protection against apoptotic insults and to ensure that cells remain viable during differentiation.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Texas A&M Univ, Vet Affairs Hosp, Cardiovasc Res Inst, Dept Mol Cardiol, Temple, TX 76504 USA	Cornell University; Cornell University; Texas A&M University System	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061762, F32GM063320] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61762, GM63320] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Facchiano F, 2001, EXP CELL RES, V271, P118, DOI 10.1006/excr.2001.5356; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FINK ML, 1980, P NATL ACAD SCI-BIOL, V77, P4564, DOI 10.1073/pnas.77.8.4564; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hebert SS, 2000, J BIOL CHEM, V275, P32482, DOI 10.1074/jbc.M006528200; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PIACENTINI M, 1988, BIOCHEM J, V253, P33, DOI 10.1042/bj2530033; Singh US, 1998, J BIOL CHEM, V273, P1946, DOI 10.1074/jbc.273.4.1946; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; SPORN MB, 1983, CANCER RES, V43, P3034; SUEDHOFF T, 1990, CANCER RES, V50, P7830; Szegezdi E, 2000, CELL DEATH DIFFER, V7, P1225, DOI 10.1038/sj.cdd.4400751; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	34	98	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20127	20130		10.1074/jbc.C200147200	http://dx.doi.org/10.1074/jbc.C200147200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11956182	hybrid			2022-12-27	WOS:000176204500005
J	den Dekker, E; Gorter, G; Heemskerk, JWM; Akkerman, JWN				den Dekker, E; Gorter, G; Heemskerk, JWM; Akkerman, JWN			Development of platelet inhibition by cAMP during megakaryocytopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CELL-LINE; IN-VITRO; SIGNAL-TRANSDUCTION; ANCHORING PROTEIN; CATALYTIC SUBUNIT; INTACT-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; PROSTACYCLIN RECEPTOR; REGULATORY SUBUNITS	Prostacyclin is a potent inhibitor of agonist-induced Ca2+ increases in platelets, but in the megakaryocytic cell line MEG-01 this inhibition is absent. Using human megakaryocytic cell lines representing different stages in megakaryocyte (Mk) maturation as well as stem cells and immature and mature megakaryocytes, we show that the inhibition by prostacyclin develops at a late maturation stage shortly before platelets are formed. This late appearance is not caused by insufficient cAMP formation or absent protein kinase A (PKA) activity in immature cells. Instead, the appearance of Ca2+ inhibition by prostacyclin is accompanied by a sharp increase in the expression of the catalytic subunit of PKA (PKA-C) but not by changes in the expression of the PKA-regulatory subunits Ialpha/beta, IIalpha, and IIbeta. Overexpression of PKA-C in the megakaryocytic cell line CHRF-288-11 potentiates the Ca2+ inhibition by prostacyclin. Thus, up-regulation of PKA-C appears to be a key step in the development of Ca2+ inhibition by prostacyclin in platelets.	Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3508 GA Utrecht, Netherlands; Maastricht Univ, Dept Biochem & Human Biol, NL-6200 MD Maastricht, Netherlands	Utrecht University; Utrecht University; Maastricht University	Akkerman, JWN (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, POB 85500, NL-3508 GA Utrecht, Netherlands.		Heemskerk, Johan/AAM-8323-2021	Heemskerk, Johan/0000-0002-2848-5121				BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; den Dekker E, 2002, ARTERIOSCL THROM VAS, V22, P179, DOI 10.1161/hq0102.101515; den Dekker E, 2001, BBA-MOL CELL RES, V1539, P243, DOI 10.1016/S0167-4889(01)00112-4; den Dekker E, 2001, THROMB HAEMOSTASIS, V86, P1106; Dodge KL, 1999, ENDOCRINOLOGY, V140, P5165, DOI 10.1210/en.140.11.5165; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; FOSS KB, 1994, EUR J BIOCHEM, V220, P217, DOI 10.1111/j.1432-1033.1994.tb18617.x; FUGMAN DA, 1990, BLOOD, V75, P1252; GREENBERG SM, 1988, BLOOD, V72, P1968; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; HOWARD P, 1991, J BIOL CHEM, V266, P10189; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Kahn NN, 1997, P NATL ACAD SCI USA, V94, P8779, DOI 10.1073/pnas.94.16.8779; KAHN NN, 1990, CIRC RES, V66, P932, DOI 10.1161/01.RES.66.4.932; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Kim SN, 1997, BIOCHEM BIOPH RES CO, V232, P469, DOI 10.1006/bbrc.1997.6313; Lacabaratz-Porret C, 2000, BIOCHEM J, V350, P723, DOI 10.1042/0264-6021:3500723; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; OGURA M, 1985, BLOOD, V66, P1384; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Sasaki Y, 1997, BLOOD, V90, P1039, DOI 10.1182/blood.V90.3.1039.1039_1039_1046; SCHWANER I, 1992, BIOCHEM J, V281, P301, DOI 10.1042/bj2810301; SERNERI GGN, 1984, LANCET, V2, P838; Siddiqua A, 1999, THROMB HAEMOSTASIS, P635; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SUGIYAMA H, 1992, J BIOL CHEM, V267, P25256; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; UHLER MD, 1987, J BIOL CHEM, V262, P15202; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023; Zauli G, 1998, BLOOD, V92, P472, DOI 10.1182/blood.V92.2.472.414k30_472_480	46	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29321	29329		10.1074/jbc.M111390200	http://dx.doi.org/10.1074/jbc.M111390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11997386	hybrid, Green Published			2022-12-27	WOS:000177342600122
J	Collet, JF; Riemer, J; Bader, MW; Bardwell, JCA				Collet, JF; Riemer, J; Bader, MW; Bardwell, JCA			Reconstitution of a disulfide isomerization system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; ESCHERICHIA-COLI; PROTEIN DSBD; ISOMERASE; MEMBRANE; IDENTIFICATION; ELECTRONS; RESIDUES	Isomerization of disulfide bonds is vital for the proper folding of proteins that possess multiple disulfides. In prokaryotes, the catalytic pathway responsible for disulfide isomerization involves thioredoxin, thioredoxin reductase, and the DsbC, DsbG, and DsbD proteins. To be active as isomerases, DsbC and DsbG must be kept reduced. This task is performed by the cytoplasmic membrane protein DsbD. DsbD in turn is reduced by the cytoplasmic thioredoxin and is composed of three domains. The beta domain is membrane-embedded, whereas the a and gamma domains are localized to the periplasm. It had been proposed that electrons are transferred within DsbD by a succession of disulfide exchange reactions between the three domains. To test this model using biochemical methods, we purified to homogeneity different polypeptides corresponding to the alpha, beta, gamma, and betagamma domains. Using these domains, we could reconstitute a DsbD activity and, for the first time, reconstitute in vitro the electron transport pathway from NADPH and thioredoxin to DsbC and DsbG. We showed that electrons are transferred from thioredoxin to the beta domain then successively to the gamma domain, the alpha domain, and finally on to DsbC or DsbG. We also determined the redox potential of the gamma domain to be -241 mV, and that of the a domain was found to be -229 mV. This shows that the direction of electron flow within DsbD is thermodynamically driven.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Catholique Louvain, Chim Physiol Lab, B-1200 Brussels, Belgium	University of Michigan System; University of Michigan; Universite Catholique Louvain	Bader, MW (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.		Collet, Jean Francois/F-2105-2010; Riemer, Jan/B-3340-2012; Riemer, Jan/AAC-1072-2021	Riemer, Jan/0000-0002-7574-8457; Collet, Jean-Francois/0000-0001-8069-7036				Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Goldstone D, 2001, P NATL ACAD SCI USA, V98, P9551, DOI 10.1073/pnas.171315498; Gordon EHJ, 2000, MOL MICROBIOL, V35, P1360, DOI 10.1046/j.1365-2958.2000.01796.x; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Krupp R, 2001, J BIOL CHEM, V276, P3696, DOI 10.1074/jbc.M009500200; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	17	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26886	26892		10.1074/jbc.M203028200	http://dx.doi.org/10.1074/jbc.M203028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004064	hybrid			2022-12-27	WOS:000177055900026
J	Ma, YL; Taylor, S				Ma, YL; Taylor, S			A 15-residue bifunctional element in D-AKAP1 is required for both endoplasmic reticulum and mitochondrial targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SITE-DIRECTED MUTAGENESIS; GREEN FLUORESCENT PROTEIN; REGULATORY SUBUNITS; ANCHOR PROTEIN; CYCLIC-AMP; GERM-CELLS; IDENTIFICATION; DIFFERENTIATION; HEXOKINASE-1	The cAMP-dependent protein kinase anchoring protein, D-AKAP1, has two N-terminal splice variants. The shorter forms (NO, D-AKAP1a, and -1c) target to mitochondria, and the longer forms (N1, D-AKAP1b, and -1d) with 33 additional residues N-terminal to NO target to the endoplasmic reticulum (ER) (Huang, L. J., Wang, L., Ma, Y., Durick, K., Perkins, G., Deerinck, T. J., Ellisman, M. H., and Taylor, S. S. (1999) J. Cell Biol. 145, 951-959). In D-AKAP1a, translation may initiate from both Met-34 or Met-49 producing two molecules both targeted to mitochondria. The shorter molecule contains the 15-residue targeting motif, homologous to the N-terminal mitochondrial targeting motif of hexokinase I. Extensive mutagenesis showed that one hydrophobic surface of the 15-residue hexokinase-homologous segment contained the key elements for mitochondrial targeting. The same 15 residues are also part of the ER-targeting signal, but for ER targeting multiple hydrophobic residues are required that encompass both surfaces of the helix. The different involvement of the same helical motif for targeting to the two organelles appears to reflect different modes of interaction with the two organelles. This is the first example of a bifunctional helical element that is required for both ER and mitochondrion targeting.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, S (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr,MC 0658, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; Kehrer-Sawatzki H, 1999, GENE, V235, P1, DOI 10.1016/S0378-1119(99)00222-X; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Ma Y, 1999, CANCER RES, V59, P5341; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scott JD, 2000, ADV PHARMACOL, V47, P175; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Steen RL, 2001, J CELL BIOL, V153, P621, DOI 10.1083/jcb.153.3.621; Steenaart NAE, 1996, BIOCHEMISTRY-US, V35, P3764, DOI 10.1021/bi9528053; Sui DX, 1997, ARCH BIOCHEM BIOPHYS, V345, P111, DOI 10.1006/abbi.1997.0241; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; XIE GC, 1988, ARCH BIOCHEM BIOPHYS, V267, P803, DOI 10.1016/0003-9861(88)90090-2; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	47	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27328	27336		10.1074/jbc.M201421200	http://dx.doi.org/10.1074/jbc.M201421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11994283	hybrid			2022-12-27	WOS:000177055900081
J	Xu, Y; Keene, DR; Bujnicki, JM; Hook, M; Lukomski, S				Xu, Y; Keene, DR; Bujnicki, JM; Hook, M; Lukomski, S			Streptococcal Scl1 and Scl2 proteins form collagen-like triple helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; GROUP-A STREPTOCOCCUS; CIRCULAR-DICHROISM; ELECTRON-MICROSCOPY; SECONDARY STRUCTURE; SUBCOMPONENT C1Q; SURFACE PROTEIN; SEQUENCE; BINDING; COMPLEMENT	The collagens are a family of animal proteins containing segments of repeated Gly-Xaa-Yaa (GXY) motifs that form a characteristic triple-helical structure. Genes encoding proteins with repeated GXY motifs have also been reported in bacteria and phages; however, it is unclear whether these prokaryotic proteins can form a collagen-like triple-helical structure. Here we used two recently identified streptococcal proteins, Sell and Scl2, containing extended GXY sequence repeats as model proteins. First we observed that prior to heat denaturation recombinant Sel proteins migrated as homotrimers in gel electrophoresis with and without SDS. We next showed that the collagen-like domain of Scl is resistant to proteolysis by trypsin. We further showed that circular dichroism spectra of the Sel proteins contained features characteristic of collagen triple helices, including a positive maximum of ellipticity at 220 nm. Furthermore the triple helices of Scl1 and Scl2 showed a temperature-dependent unfolding with melting temperatures of 36.4 and 37.6degreesC, respectively, which resembles those seen for collagens. We finally demonstrated by electron microscopy that the Scl proteins are organized into "lollipop-like" structures, similar to those seen in human proteins with collagenous domains. This implies that the repeated GXY tripeptide motif is a structural indicator of collagen-like triple helices in proteins from such phylogenetically distant sources as bacteria and humans.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Shriners Hosp Children, Portland, OR 97201 USA; Int Inst Mol & Cellular Biol, Bioinformat Lab, PL-02109 Warsaw, Poland	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Lukomski, S (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 50666] Funding Source: Medline; NIAMS NIH HHS [AR 44415] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACTON S, 1993, J BIOL CHEM, V268, P3530; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; BAMFORD DH, 1990, NATURE, V344, P497, DOI 10.1038/344497b0; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BROWN FR, 1972, J MOL BIOL, V63, P101, DOI 10.1016/0022-2836(72)90524-4; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; CHARALAMBOUS BM, 1988, EMBO J, V7, P2903, DOI 10.1002/j.1460-2075.1988.tb03148.x; Cremer MA, 1998, J MOL MED, V76, P275, DOI 10.1007/s001090050217; DRICKAMER K, 1987, KIDNEY INT, V32, P167; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Gibofsky A, 1998, RHEUM DIS CLIN N AM, V24, P237, DOI 10.1016/S0889-857X(05)70007-7; GIOUD M, 1982, COLLAGEN REL RES, V2, P557; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAAS C, 1991, EUR J BIOCHEM, V197, P799; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; LU J, 1990, J IMMUNOL, V144, P2287; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; MARCIEL AM, 1997, MICROB PATHOG, V22, P202; Ohashi T, 1998, ARCH BIOCHEM BIOPHYS, V360, P223, DOI 10.1006/abbi.1998.0957; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Persikov AV, 2000, BIOPOLYMERS, V55, P436, DOI 10.1002/1097-0282(2000)55:6<436::AID-BIP1019>3.0.CO;2-D; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; REID KBM, 1993, BIOCHEM SOC T, V21, P464, DOI 10.1042/bst0210464; Ruggiero F, 2000, FEBS LETT, V469, P132, DOI 10.1016/S0014-5793(00)01259-X; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Smith MCM, 1998, SCIENCE, V279, P1834; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stevens DL., 2000, STREPTOCOCCAL INFECT; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	53	148	156	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27312	27318		10.1074/jbc.M201163200	http://dx.doi.org/10.1074/jbc.M201163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11976327	hybrid			2022-12-27	WOS:000177055900079
J	Babinski, KJ; Ribeiro, AA; Raetz, CRH				Babinski, KJ; Ribeiro, AA; Raetz, CRH			The Escherichia coli gene encoding the UDP-2,3-diacylglucosamine pyrophosphatase of lipid A biosynthesis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; CDP-DIGLYCERIDE HYDROLASE; UDP-N-ACETYLGLUCOSAMINE; GENOME SEQUENCE; A BIOSYNTHESIS; ANTIBACTERIAL AGENTS; 1ST STEP; IDENTIFICATION; MEMBRANE; ACYLTRANSFERASE	UDP-2,3-diacylglucosamine hydrolase is believed to catalyze the fourth step of lipid A biosynthesis in Escherichia coli. This reaction involves pyrophosphate bond hydrolysis of the precursor LTDP-2,3-diacylglucosamine to yield 2,3-diacylglucosamine 1-phosphate and UMP. To identify the gene encoding this hydrolase, E. coli lysates generated with individual A clones of the ordered Kohara library were assayed for overexpression of the enzyme. The sequence of A clone 157[6E7], promoting overproduction of hydrolase activity, was examined for genes encoding hypothetical proteins of unknown function. The amino acid sequence of one such open reading frame, ybbF, is 50.5% identical to a Haemophilus influenzae hypothetical protein and is also conserved in most other Gram-negative organisms, but is absent in Gram-positives. Cell extracts prepared from cells overexpressing ybbF behind the T7lac promoter have similar to540 times more hydrolase activity than cells with vector alone. YbbF was purified to -60% homogeneity, and its catalytic properties were examined. Enzymatic activity is maximal at pH 8 and is inhibited by 0.01% (or more) Triton X-100. The apparent K. for UDP-2,3-diacylglucosamine is 62 gm. YbbF requires a diacylated substrate and does not cleave CDP-diacylglycerol. P-31 NMR studies of the UMP product generated from UDP-2,3-diacylglucosamine in the presence of 40% H(2)(18)0 show that the enzyme attacks the alpha-phosphate group of the UDP moiety. Because ybbF encodes the specific UDP-2,3-diacylglucosamine hydrolase involved in lipid A biosynthesis, it is now designated lpxH.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, NMR Spect Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Ausubel FM, 1988, MOL REPROD DEV; Babinski KJ, 2002, J BIOL CHEM, V277, P25947, DOI 10.1074/jbc.M204068200; Babinski KJ, 1998, FASEB J, V12, pA1288; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, V2, P1715; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H., 1999, ENDOTOXIN HLTH DIS; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BULAWA CE, 1983, J BIOL CHEM, V258, P4974; BULAWA CE, 1984, J BIOL CHEM, V259, P1257; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COHN M, 1982, ANNU REV BIOPHYS BIO, V11, P23, DOI 10.1146/annurev.bb.11.060182.000323; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; ICHO T, 1985, J BIOL CHEM, V260, P2092; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; Kaneko T, 1996, DNA Res, V3, P109; KAWAHARA K, 1979, BIOCHIM BIOPHYS ACTA, V572, P1; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1972, J BIOL CHEM, V247, P2245; RAETZ CRH, 1976, J BACTERIOL, V125, P855, DOI 10.1128/JB.125.3.855-863.1976; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER EG, 1976, BIOCHIM BIOPHYS ACTA, V441, P294, DOI 10.1016/0005-2760(76)90172-7; Small D.M., 1986, ALKANES PHOSPHOLIPID; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	65	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25937	25946		10.1074/jbc.M204067200	http://dx.doi.org/10.1074/jbc.M204067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000770	hybrid			2022-12-27	WOS:000176908700017
J	van Alebeek, GJWM; Christensen, TMIE; Schols, HA; Mikkelsen, JD; Voragen, AGJ				van Alebeek, GJWM; Christensen, TMIE; Schols, HA; Mikkelsen, JD; Voragen, AGJ			Mode of action of pectin lyase A of Aspergillus niger on differently C(6)-substituted oligogalacturonides.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-ESTERIFIED OLIGOGALACTURONIDES; FLIGHT MASS-SPECTROMETRY; ENZYMES; PURIFICATION	A thorough investigation of the mode of action of Aspergillus niger (4M-147) pectin lyase A (PIA) on differently C(6)-substituted oligogalacturonides is described. PLA appeared to be very specific for fully methyl-esterified oligogalacturonides: removal of the methyl-ester or changing the type of ester (ethyl esterification) or transamidation resulted in (almost) complete loss of conversion. The PLA activity increased with increasing length of the substrate up to a degree of polymerization (DP) of 8 indicating the presence of at least eight subsites on the enzyme. Product analysis demonstrated the formation of several Delta4,5 unsaturated products and their saturated counterparts. The Delta4,5 unsaturated trimer was the main product up to DP 8. For DP 9 and 10 Delta4,5 unsaturated tetramer was the major product. Based upon the bond cleavage frequencies, a provisional subsite map was calculated, which supports the presence of eight subsites. By limited alkaline de-esterification of fully methyl-esterified pentamer and hexamer two sets of partially methyl-esterified pentamers (x and y methyl groups) and hexamers (a and b methyl groups) were prepared. Matrix-assisted laser desorption/ionization time of flight mass spectroscopy (MALDI-TOF MS) analysis demonstrated that the methyl-ester distribution was fully random. Using these partially methyl-esterified oligogalacturonides as substrates for PLA a 10-fold decrease in reaction rate was recorded compared with the fully methyl-esterified counterparts. Analysis of the methyl-ester distribution of the products showed that PIA tolerates carboxyl groups in the substrate binding cleft. At either subsite +2, +4, or -1 to -4 a free carboxyl group could be tolerated, whereas methyl-esters were obligatory at subsite +1 and +3. So PLA is capable to cleave the bond between a methyl-esterified and a non-esterified galacturonic acid residue, where the newly formed Delta4,5 unsaturated non-reducing end residue always contains a methyl-ester.	Univ Wageningen & Res Ctr, Food Chem Lab, Dept Agrotechnol & Food Sci, NL-6703 HD Wageningen, Netherlands; Danisco Biotechnol, DK-1001 Copenhagen K, Denmark	Wageningen University & Research	Voragen, AGJ (corresponding author), Univ Wageningen & Res Ctr, Food Chem Lab, Dept Agrotechnol & Food Sci, Bomenweg 2, NL-6703 HD Wageningen, Netherlands.	fons.voragen@chem.fdsci.wag-ur.nl	Schols, Henk A/A-1742-2009					Benen JAE, 1999, EUR J BIOCHEM, V259, P577, DOI 10.1046/j.1432-1327.1999.00080.x; Benen JAE, 2000, BIOCHEMISTRY-US, V39, P15563, DOI 10.1021/bi000693w; Coutinho PM, 1999, ROY SOC CH, P3; Daas PJH, 1998, ANAL BIOCHEM, V257, P195, DOI 10.1006/abio.1997.2554; EDSTROM RD, 1964, J BIOL CHEM, V239, P2403; HERI W, 1961, HELV CHIM ACTA, V44, P1945, DOI 10.1002/hlca.19610440716; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; KESTER HCM, 1994, FEMS MICROBIOL LETT, V120, P63, DOI 10.1016/0378-1097(94)00176-6; Korner R, 1998, J MASS SPECTROM, V33, P836; Korner R, 1999, ANAL CHEM, V71, P1421, DOI 10.1021/ac981240o; KUSTERSVANSOMEREN M, 1992, MOL GEN GENET, V234, P113, DOI 10.1007/BF00272352; Limberg G, 2000, CARBOHYD RES, V327, P293, DOI 10.1016/S0008-6215(00)00067-7; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; ONeill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI [DOI 10.1016/B978-0-12-461012-5.50018-5, 10.1016/b978-0-12-461012-5.50018-5]; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Schols HA, 1996, PROGR BIOTECHNOL, V14, P3, DOI 10.1016/S0921-0423(96)80242-5; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; van Alebeek GJWM, 2000, J MASS SPECTROM, V35, P831, DOI 10.1002/1096-9888(200007)35:7<831::AID-JMS7>3.0.CO;2-4; van Alebeek GJWM, 2000, CARBOHYD POLYM, V43, P39, DOI 10.1016/S0144-8617(99)00207-6; van Alebeek GJWM, 2001, CARBOHYD POLYM, V46, P311, DOI 10.1016/S0144-8617(00)00330-1; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; Voragen A. G. J., 1995, V67, P287; VORAGEN AGJ, 1972, THESIS WAGENINGEN	24	38	39	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25929	25936		10.1074/jbc.M202250200	http://dx.doi.org/10.1074/jbc.M202250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000753	hybrid			2022-12-27	WOS:000176908700016
J	Kong, XD; Li, ZQ; Gou, XJ; Zhu, SZ; Zhang, HY; Wang, XP; Zhang, J				Kong, XD; Li, ZQ; Gou, XJ; Zhu, SZ; Zhang, HY; Wang, XP; Zhang, J			A monomeric L-aspartase obtained by in vitro selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN EVOLUTION; ESCHERICHIA-COLI; MOLECULAR EVOLUTION; AMMONIA-LYASE; SPECIFICITY; STABILIZATION; INTERMEDIATE; MUTAGENESIS; ENHANCEMENT; EXPRESSION	By mimicking the partial spatial structure of the dimer of the L-aspartase subunit, the central ten-helix bundle, and an "active site" between the cleft of domain 1 (D1) and domain 3 (D3) from different subunits, we designed L-aspartase variants, in which D1D2 and D2D3 were ligated with a random hexapeptide loop. As expected, we obtained the variant with the highest activity (relative activity is 21.3% of the native enzyme, named as drAsp017) by in vitro selection. The molecular weight of this variant, obtained from size-exclusion column chromatography, is about 81 kDa, which indicates that it is indeed a monomer, whereas native L-aspartase is a tetramer. The activity-reversibility of drAsp017 (10(-7) m) was 80% after incubation for 30 min at 50degreesC, while native enzyme only retained about 17% under the same conditions. Reactivation of drAsp017 denatured in 4 m guanidine HCl was independent of protein concentration at up to 20 x 10(-8) m at 25 degreesC, whereas the protein concentration of native enzyme strongly affected its reactivation under the above conditions. The sensitivity of drAsp017 (10-7 M) to effective factors in the fumarateamination reaction compared with native enzyme was also determined. Half-saturating concentrations of the activator L-aspartate and Mg2+ for drAsp017 (0.8 and 0.5 mm, respectively) are much higher than that of the native enzyme (0.10 and 0.15 mm, respectively). The data show that a monomeric L-aspartase is obtained by in vitro selection. Thus, the conversion of oligomeric proteins into their functional monomers could have important applications.	Jilin Univ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China; Jilin Univ, Minist Educ, Changchun 130023, Peoples R China	Jilin University; Jilin University	Zhang, J (corresponding author), Jilin Univ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China.							Beck C, 2001, BIOCHEMISTRY-US, V40, P10956, DOI 10.1021/bi0155450; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; Chirumamilla RR, 2001, MOL CELL BIOCHEM, V224, P159, DOI 10.1023/A:1011904405002; Collinet B, 2001, EUR J BIOCHEM, V268, P5107, DOI 10.1046/j.0014-2956.2001.02439.x; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gershenson A, 2000, Genet Eng (N Y), V22, P55; Gonzalez-Blasco G, 2000, J BIOL CHEM, V275, P13708, DOI 10.1074/jbc.275.18.13708; IMAISHI H, 1989, PHYSIOL CHEM PHYS ME, V21, P221; Jayasekera MMK, 1997, BIOCHEMISTRY-US, V36, P9145, DOI 10.1021/bi970452x; KARSTEN WE, 1991, ARCH BIOCHEM BIOPHYS, V287, P60, DOI 10.1016/0003-9861(91)90388-Y; Kolkman JA, 2001, NAT BIOTECHNOL, V19, P423, DOI 10.1038/88084; Kong XD, 2001, BIOCHEM BIOPH RES CO, V289, P137, DOI 10.1006/bbrc.2001.5937; Kurtzman AL, 2001, CURR OPIN BIOTECH, V12, P361, DOI 10.1016/S0958-1669(00)00228-7; Lehmann M, 2001, CURR OPIN BIOTECH, V12, P371, DOI 10.1016/S0958-1669(00)00229-9; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; Meyer A, 2002, J BIOL CHEM, V277, P5575, DOI 10.1074/jbc.M110018200; Morawski B, 2001, BIOTECHNOL BIOENG, V76, P99, DOI 10.1002/bit.1149; MURASE S, 1993, J BIOCHEM, V114, P393, DOI 10.1093/oxfordjournals.jbchem.a124187; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; Saab-Rincon G, 2001, PROTEIN ENG, V14, P149, DOI 10.1093/protein/14.3.149; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; Shi WX, 1997, BIOCHEMISTRY-US, V36, P9136, DOI 10.1021/bi9704515; Suenaga H, 2001, J BACTERIOL, V183, P5441, DOI 10.1128/JB.183.18.5441-5444.2001; Sun LH, 2001, PROTEIN ENG, V14, P699, DOI 10.1093/protein/14.9.699; Viola RE, 2000, ADV ENZYMOL RAMB, V74, P295; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; Wang CW, 2001, J BIOL CHEM, V276, P41161, DOI 10.1074/jbc.M105786200; Wang LJ, 2000, BIOCHEM BIOPH RES CO, V276, P346, DOI 10.1006/bbrc.2000.3472; Wiseman A, 2001, TRENDS BIOTECHNOL, V19, P382, DOI 10.1016/S0167-7799(01)01736-X; ZHANG HY, 1993, BIOCHEM BIOPH RES CO, V192, P15, DOI 10.1006/bbrc.1993.1375	31	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24289	24293		10.1074/jbc.M200370200	http://dx.doi.org/10.1074/jbc.M200370200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983692	hybrid			2022-12-27	WOS:000176611800042
J	Palackal, NT; Lee, SH; Harvey, RG; Blair, IA; Penning, TM				Palackal, NT; Lee, SH; Harvey, RG; Blair, IA; Penning, TM			Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHO-QUINONES; DEHYDROGENASE ISOFORMS; DIOL EPOXIDES; FJORD-REGION; DNA-ADDUCTS; METABOLITES; OXIDATION; BENZO<A>PYRENE-7,8-DIONE; BENZO<G>CHRYSENE; REACTIVITY	Polycyclic aromatic hydrocarbons (PAH) are environmental pollutants and suspected human lung carcinogens. In patients with non-small cell lung carcinoma, differential display shows that aldo-keto reductase (AKR1C) transcripts are dramatically overexpressed. However, whether AKR1C isoforms contribute to the carcinogenic process and oxidize potent PAH trans-dihydrodiols (proximate carcinogens) to reactive and redox active o-quinones is unknown; nor is it known whether these reactions occur in human lungs. We now show that four homogeneous human recombinant aldo-keto reductases (AKR1C1-AKR1C4) are regioselective and oxidize only the relevant non-K region trans-dihydrodiols. However, these enzymes are not stereo-selective, since they oxidized 100%, of these racemic substrates. The highest utilization ratios (V-max/K-m) were observed for some of the most potent proximate carcinogens known (e.g. 7,12-dimethylbenz[a]anthracene-3,4-diol (DMBA-3,4-diol) and benzo[g]chrysene-11,12-diol). In vitro, DMBA-3,4-diol was oxidized by AKR1C4 to the highly reactive 7,12-dimethylbenz[a]anthracene-3,4-dione (DMBA-3,4-dione), which was trapped in situ as its mono- and bis-thioether conjugates, which arise from the sequential 1,6- and 1,4-Michael addition of thiol nucleophiles. Human multiple tissue expression array analysis showed that AKR1C isoform. transcripts were highly expressed in the human lung carcinoma cell line A549. Isoform-specific reverse transcriptase-PCR showed that AKR1C1, AKR1C2, and AKR1C3 transcripts were all expressed. Western blot analysis and functional assays confirmed high expression of AKR1C protein and enzyme activity in these lung cells. A549 cell lysates were found to convert DMBA-3,4-diol to the corresponding o-quinone. In trapping experiments, LC/MS analysis identified peaks in the cell lysates that corresponded to the synthetically prepared mono- and bis-thioether conjugates of DMBA-3,4-dione. This quinone is one of the most electrophilic and redox-active o-quinones produced by AKRs. Its unique ability to form bis-thioether conjugates parallels the formation of bis- and tris-glutathionyl conjugates of hydroquinone, which display end organ toxicity. The ability to measure DMBA-3,4-dione formation in A549 cells implicates the AKR pathway in the metabolic activation of PAH in human lung.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Pennsylvania; University of Pennsylvania; University of Chicago	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Blair, Ian A/B-3320-2010	Lee, Seon Hwa/0000-0003-1095-5516; Penning, Trevor/0000-0002-3937-1066	NATIONAL CANCER INSTITUTE [R01CA039504] Funding Source: NIH RePORTER; NCI NIH HHS [CA39504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN S, 1995, CARCINOGENESIS, V16, P2813, DOI 10.1093/carcin/16.11.2813; Amin S, 1996, POLYCYCL AROMAT COMP, V11, P365, DOI 10.1080/10406639608544688; Burczynski ME, 1998, BIOCHEMISTRY-US, V37, P6781, DOI 10.1021/bi972725u; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; Burczynski ME, 1999, CANCER RES, V59, P607; BUSHMAN DR, 1989, J ORG CHEM, V54, P3533, DOI 10.1021/jo00276a009; CAVALIERI EL, 1995, XENOBIOTICA, V25, P677, DOI 10.3109/00498259509061885; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; CIACCIO PJ, 1994, J BIOL CHEM, V269, P15558; CROISYDELCEY M, 1979, TETRAHEDRON LETT, P2849; FlowersGeary L, 1996, CHEM-BIOL INTERACT, V99, P55, DOI 10.1016/0009-2797(95)03660-1; FLOWERSGEARY L, 1992, BIOCH LIFE SCI ADV, V11, P49; FRENKEL K, 1995, FREE RADICAL BIO MED, V19, P373, DOI 10.1016/0891-5849(95)00046-Z; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; FU PP, 1979, J ORG CHEM, V44, P3778, DOI 10.1021/jo01336a008; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GLAZE ER, 2001, P AM ASSOC CANC RES, V42, P2540; HARVEY RG, 1975, J AM CHEM SOC, V97, P3468, DOI 10.1021/ja00845a032; HARVEY RG, 1977, TETRAHEDRON LETT, P2387; Hsu NY, 2001, CANCER RES, V61, P2727; Hukkanen J, 2000, AM J RESP CELL MOL, V22, P360, DOI 10.1165/ajrcmb.22.3.3845; ISLAM NB, 1990, J AM CHEM SOC, V112, P6363, DOI 10.1021/ja00173a026; KHANNA M, 1995, J BIOL CHEM, V270, P20162, DOI 10.1074/jbc.270.34.20162; Lang DS, 1998, CELL BIOL TOXICOL, V14, P23, DOI 10.1023/A:1007412404180; LEE H, 1986, J ORG CHEM, V51, P3502, DOI 10.1021/jo00368a021; LEE HM, 1979, J ORG CHEM, V44, P4948, DOI 10.1021/jo00394a043; MANAM S, 1992, MOL CARCINOGEN, V6, P68, DOI 10.1002/mc.2940060111; McCoull KD, 1999, CHEM RES TOXICOL, V12, P237, DOI 10.1021/tx980182z; Monks TJ, 1997, CHEM RES TOXICOL, V10, P1296, DOI 10.1021/tx9700937; MURTY VS, 1992, CHEM-BIOL INTERACT, V84, P169, DOI 10.1016/0009-2797(92)90077-X; Nair J, 2000, CHEM RES TOXICOL, V13, P703, DOI 10.1021/tx000045d; PATAKI J, 1983, CARCINOGENESIS, V4, P399, DOI 10.1093/carcin/4.4.399; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; Penning TM, 1996, CHEM RES TOXICOL, V9, P84, DOI 10.1021/tx950055s; PLATT KL, 1983, J ORG CHEM, V48, P265, DOI 10.1021/jo00150a027; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SHOU M, 1993, CARCINOGENESIS, V14, P475, DOI 10.1093/carcin/14.3.475; SMITHGALL TE, 1988, BIOCHEM J, V254, P715, DOI 10.1042/bj2540715; SMITHGALL TE, 1988, CANCER RES, V48, P1227; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SMITHGALL TE, 1988, J BIOL CHEM, V263, P1814; SUKUMARAN KB, 1979, J AM CHEM SOC, V101, P1353, DOI 10.1021/ja00499a086; SUKUMARAN KB, 1980, J ORG CHEM, V45, P4407, DOI 10.1021/jo01310a029; Todorovic R, 1997, CHEM RES TOXICOL, V10, P941, DOI 10.1021/tx970003y; YU D, 2002, IN PRESS CHEM RES TO, V15; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717	46	179	191	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24799	24808		10.1074/jbc.M112424200	http://dx.doi.org/10.1074/jbc.M112424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978787	hybrid			2022-12-27	WOS:000176611800107
J	Wommer, S; Rival, S; Heinz, U; Galleni, M; Frere, JM; Franceschini, N; Amicosante, G; Rasmussen, B; Bauer, R; Adolph, HW				Wommer, S; Rival, S; Heinz, U; Galleni, M; Frere, JM; Franceschini, N; Amicosante, G; Rasmussen, B; Bauer, R; Adolph, HW			Substrate-activated zinc binding of metallo-beta-lactamases - Physiological importance of the mononuclear enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-HYDROPHILA AE036; STENOTROPHOMONAS-MALTOPHILIA; MECHANISM; THIONEIN; L1	We have investigated the influence of substrate binding on the zinc ion affinity of representatives from the three metallo-g-lactamase subclasses, B1 (BcII from Bacillus cereus and BlaB from Chryseobacterium meningosepticum), B2 (CphA from Aeromonas hydrophila), and B3 (L1 from Stenotrophomonas maltophilia). By competition experiments with metal-free apoenzymes and chromophoric zinc chelators or EDTA, we determined the dissociation constants in the absence and presence of substrates. For the formation of the monozine enzymes we determined constants of 1.8, 5.1, 0.007, and 2.6 nm in the absence and 13.6, 1.8, 1.2, and 5.7 pm in the presence of substrates for Bell, BlaB, CphA, and L1, respectively. A second zinc ion binds in the absence (presence) of substrates with considerably higher dissociation constants, namely 1.8 (0.8), 0.007 (0.025), 50 (1.9), and 0.006 (0.12) mum for BcII, BlaB, CphA, and L1, respectively. We have concluded that the apo form might be the prevailing state of most of the metallo-beta-lactamases under physiological conditions in the absence of substrates. Substrate availability induces a spontaneous self-activation due to a drastic decrease of the dissociation constants, resulting in the formation of active mononuclear enzymes already at picomolar free zinc ion concentrations. In the presence of substrates, the binuclear state of the enzymes only exists at unphysiologic high zinc concentrations and might be of no biological relevance. From the competition experiments with EDTA it is further concluded that the reactivation rate does not depend on the pool of free zinc ions but proceeds via the EDTA-Zn(II)-enzyme ternary complexes.	Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany; Univ Saarland, Dept Biochem, D-66041 Saarbrucken, Germany; Univ Liege, Ctr Ingn Prot, B-4000 Liege, Belgium; Univ Aquila, Dipartimento Sci & Technol Biomed & Biometria, I-67100 Laquila, Italy; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Royal Vet & Agr Univ, Dept Math & Phys, DK-1871 Frederiksberg, Denmark; Max Planck Inst Informat, D-66123 Saarbrucken, Germany	Saarland University; Saarland University; University of Liege; University of L'Aquila; University of Copenhagen; University of Copenhagen; Max Planck Society	Adolph, HW (corresponding author), Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany.		Adolph, Hans W/A-2104-2008	FRANCESCHINI, Nicola/0000-0003-2237-0355; amicosante, gianfranco/0000-0002-6813-2101				Boschi L, 2000, ANTIMICROB AGENTS CH, V44, P1538, DOI 10.1128/AAC.44.6.1538-1543.2000; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; BRUNETTI AP, 1969, J AM CHEM SOC, V91, P4680, DOI 10.1021/ja01045a014; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DYE JL, 1960, J AM CHEM SOC, V82, P314, DOI 10.1021/ja01487a016; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Rhazi N, 1999, BIOCHEM J, V341, P409, DOI 10.1042/0264-6021:3410409; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; SKOCHDOPOLE R, 1959, J INORG NUCL CHEM, V11, P222, DOI 10.1016/0022-1902(59)80248-7; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; VALLADARES MH, 1996, MICROB DRUG RESIST, V2, P253; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Yang Y, 2001, P NATL ACAD SCI USA, V98, P5556, DOI 10.1073/pnas.101123298	25	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24142	24147		10.1074/jbc.M202467200	http://dx.doi.org/10.1074/jbc.M202467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967267	hybrid			2022-12-27	WOS:000176611800023
J	Gigoux, V; L'Hoste, S; Raynaud, F; Camonis, J; Garbay, C				Gigoux, V; L'Hoste, S; Raynaud, F; Camonis, J; Garbay, C			Identification of Aurora kinases as RasGAP Src homology 3 domain-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SH3 DOMAIN; GAP; PHOSPHORYLATION; APOPTOSIS; GENE; INHIBITION; INDUCTION; SURVIVIN	The GTPase-activating protein RasGAP functions as both a negative regulator and an effector of Ras proteins. In tumor cells, RasGAP is no longer able to deactivate oncogenic Ras proteins, and its effector function becomes predominant. As RasGAP itself has no obvious enzymatic function that may explain this effector function, we looked for downstream RasGAP effectors that could fulfill this role. We looked for the existence of RasGAP Src homology 3 (SH3) domain partners as this domain is involved in the regulation of cell proliferation and has an anti-apoptotic effect. We report here the identification of a new RasGAP SH3 domain-binding protein, named Aurora. This Drosophila melanogaster Ser/Thr kinase has three human orthologs called Aurora/Ipl1-related kinase or HsAIRK-1, -2, and -3. Coimmunoprecipitation experiments in COS cells confirmed that HsAIRK-1 and HsAIRK-2 both interact with RasGAP. RasGAP pull-down experiments showed that it interacts with HsAIRK-1 in G(2)/M HeLa cells. We also demonstrated that RasGAP binds to the kinase domain of Aurora and that this interaction inhibits the kinase activity of HsAIRK-1 and HsAIRK-2. Finally we showed that RasGAP forms a ternary complex with HsAIRK and survivin. This complex may be involved in the regulation of the balance between cell division and apoptosis.	Inst Curie, INSERM U528, Lab Transduct Signal & Oncogenese, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Garbay, C (corresponding author), CNRS, Lab Pharmacochim Mol & Struct, FRE2463, INSERM U266,UFR Sci Pharmaceut & Biol, 4 Ave Observ, F-75270 Paris 06, France.	garbay@pharmacie.univ-paris5.fr	Gigoux, Véronique/AAE-6090-2020	Gigoux, Véronique/0000-0003-1408-5335				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; Giet R, 1999, J CELL SCI, V112, P3591; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; YANG YS, 1994, EMBO J, V13, P1270, DOI 10.1002/j.1460-2075.1994.tb06379.x	30	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23742	23746		10.1074/jbc.C200121200	http://dx.doi.org/10.1074/jbc.C200121200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976319	hybrid			2022-12-27	WOS:000176475700084
J	van Dooren, GG; Su, V; D'Ombrain, C; McFadden, GI				van Dooren, GG; Su, V; D'Ombrain, C; McFadden, GI			Processing of an apicoplast leader sequence in Plasmodium falciparum and the identification of a putative leader cleavage enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; SMALL-SUBUNIT; SUBCELLULAR-LOCALIZATION; MALARIAL PARASITE; TRANSIT PEPTIDE; SITE SELECTION; COMMON ORIGIN; BLOOD STAGES; ACTIVE-SITE; PROTEIN	The plastid (apicoplast) of the malaria-causing parasite Plasmodium falciparum was derived via a secondary endosymbiotic process. As in other secondary endosymbionts, numerous genes for apicoplast proteins are located in the nucleus, and the encoded proteins are targeted to the organelle courtesy of a bipartite N-terminal extension. The first part of this leader sequence is a signal peptide that targets proteins to the secretory pathway. The second, so-called transit peptide region is required to direct proteins from the secretory pathway across the multiple membranes surrounding the apicoplast. In this paper we perform a pulse-chase experiment and N-terminal sequencing to show that the transit peptide of an apicoplast-targeted protein is cleaved, presumably upon import of the protein into the apicoplast. We identify a gene whose product likely performs this cleavage reaction, namely a stromal-processing peptidase (SPP) homologue. In plants SPP cleaves the transit peptides of plastid-targeted proteins. The P. falciparum SPP homologue contains a bipartite N-terminal apicoplast-targeting leader. Interestingly, it shares this leader sequence with a A-aminolevulinic acid dehydratase homologue via an alternative splicing event.	Univ Melbourne, Plant Cell Biol Res Ctr, Sch Bot, Melbourne, Vic 3010, Australia	University of Melbourne	McFadden, GI (corresponding author), Univ Melbourne, Plant Cell Biol Res Ctr, Sch Bot, Melbourne, Vic 3010, Australia.	gim@unimelb.edu.au	McFadden, Geoffrey McFadden I/F-7667-2014; van Dooren, Giel G/A-8896-2012	McFadden, Geoffrey McFadden I/0000-0002-5351-1627; van Dooren, Giel G/0000-0003-2455-9821				BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; Bonday ZQ, 2000, NAT MED, V6, P898, DOI 10.1038/78659; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Cheresh P, 2002, J BIOL CHEM, V277, P16265, DOI 10.1074/jbc.M109331200; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Deane JA, 2000, PROTIST, V151, P239, DOI 10.1078/1434-4610-00022; DeRocher A, 2000, J CELL SCI, V113, P3969; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; Figueroa P, 2000, BIOCHEM BIOPH RES CO, V271, P380, DOI 10.1006/bbrc.2000.2644; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Glaser E, 1996, BBA-BIOENERGETICS, V1275, P33, DOI 10.1016/0005-2728(96)00046-1; Henze K, 2001, TRENDS GENET, V17, P383, DOI 10.1016/S0168-9525(01)02312-5; Hopkins J, 1999, PROTIST, V150, P283, DOI 10.1016/S1434-4610(99)70030-1; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Koussevitzky S, 1998, J BIOL CHEM, V273, P27064, DOI 10.1074/jbc.273.42.27064; Kubo N, 1999, P NATL ACAD SCI USA, V96, P9207, DOI 10.1073/pnas.96.16.9207; Kumar AM, 1996, TRENDS PLANT SCI, V1, P371, DOI 10.1016/S1360-1385(96)80311-6; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang M, 1998, J BIOL CHEM, V273, P30973, DOI 10.1074/jbc.273.47.30973; Liaud MF, 1997, J MOL EVOL, V44, pS28, DOI 10.1007/PL00000050; Lingelbach K, 1998, J CELL SCI, V111, P1467; McFadden GI, 1999, J EUKARYOT MICROBIOL, V46, P339, DOI 10.1111/j.1550-7408.1999.tb04613.x; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205; Reumann S, 1999, TRENDS PLANT SCI, V4, P302, DOI 10.1016/S1360-1385(99)01449-1; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; ROJAS MO, 1995, J BIOCHEM, V118, P1118, DOI 10.1093/oxfordjournals.jbchem.a124996; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; Sato S, 2000, INT J PARASITOL, V30, P427, DOI 10.1016/S0020-7519(99)00185-X; Sato S, 2002, CURR GENET, V40, P391, DOI 10.1007/s00294-002-0273-3; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SCHMIDT RJ, 1985, MOL CELL BIOL, V5, P1093, DOI 10.1128/MCB.5.5.1093; SMITH AG, 1988, BIOCHEM J, V249, P423, DOI 10.1042/bj2490423; SMITH SM, 1979, NATURE, V278, P662, DOI 10.1038/278662a0; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Srivastava P, 1998, EXP PARASITOL, V88, P60, DOI 10.1006/expr.1998.4193; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Sulli C, 1996, PLANT CELL, V8, P43; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; van Dooren GG, 2001, BBA-MOL CELL RES, V1541, P34, DOI 10.1016/S0167-4889(01)00154-9; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WHO, 1999, WORLD HLTH REP 1999, P49; Wilson CM, 1996, MOL BIOCHEM PARASIT, V79, P135, DOI 10.1016/0166-6851(96)02690-4; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; YAMAUCHI K, 1980, J BIOL CHEM, V255, P1746; Yung S, 2001, MOL BIOCHEM PARASIT, V118, P11, DOI 10.1016/S0166-6851(01)00359-0; Zhang ZD, 2000, J MOL EVOL, V51, P26, DOI 10.1007/s002390010064; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zuegge J, 2001, GENE, V280, P19, DOI 10.1016/S0378-1119(01)00776-4	64	135	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23612	23619		10.1074/jbc.M201748200	http://dx.doi.org/10.1074/jbc.M201748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976331	hybrid			2022-12-27	WOS:000176475700067
J	Ma, XR; Hu, JB; Lindner, DJ; Kalvakolanu, DV				Ma, XR; Hu, JB; Lindner, DJ; Kalvakolanu, DV			Mutational analysis of human thioredoxin reductase 1 - Effects on p53-mediated gene expression and interferon and retinoic acid-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; REDOX REGULATION; GROWTH ARREST; DNA-BINDING; SCHIZOSACCHAROMYCES-POMBE; CYSTEINE-SELENOCYSTEINE; TARGETED DISRUPTION; SUPPRESSES GROWTH; HUMAN LEUKEMIA; FISSION YEAST	The interferon (IFN-)-beta and all-trans-retinoic acid combination suppresses tumor growth by inducing apoptosis in several tumor cell lines. A genetic technique permitted the isolation of human thioredoxin reductase (TR) as a critical regulator of IFN/all-trans-retinoic acid-induced cell death. Our recent studies have shown that TR1:thioredoxin 1-regulated cell death is effected in part through the activation of p53-dependent responses. To understand its death regulatory function, we have performed a mutational analysis of TR. Human TR1 has three major structural domains, the FAD binding domain, the NADPH binding domain, and an interface domain (ID). Here, we show that the deletion of the C-terminal interface domain results in a constitutive activation of TR-dependent death responses and promotes p53-dependent gene expression. TR mutant without the ID still retains its dependence on thioredoxin for promoting these responses. Thus, our data suggest that TR-ID acts as a regulatory domain.	Univ Maryland, Sch Med, Greenebaum Canc Ctr,Dept Microbiol & Immunol, Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA	University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr,Dept Microbiol & Immunol, Mol & Cellular Biol Program, 665 W Baltimore St,BRB 9th Floor, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 78282, CA 71401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chen YQ, 1999, CANCER RES, V59, P3985; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; Dai SD, 1996, J MOL BIOL, V264, P1044, DOI 10.1006/jmbi.1996.0695; Dal-Pizzol F, 2001, FREE RADICAL RES, V34, P395, DOI 10.1080/10715760100300331; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DiPaolo RS, 1999, J CLIN ONCOL, V17, P2213, DOI 10.1200/JCO.1999.17.7.2213; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FAN SJ, 1995, CANCER RES, V55, P1649; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fujiwara N, 2001, J BIOCHEM-TOKYO, V129, P803, DOI 10.1093/oxfordjournals.jbchem.a002923; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAINAUT P, 1993, CANCER RES, V53, P4469; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kalvakolanu DV, 2001, MOL BASIS CANC, P503; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KEM SE, 1992, SCIENCE, V256, P827; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000; Lindner Daniel J., 1997, Seminars in Oncology, V24, P99; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Merrill GF, 1999, CANCER RES, V59, P3175; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; MIYASHITA T, 1995, CELL, V80, P293; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; Wen Y, 2001, CANCER RES, V61, P7142; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	81	14	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22460	22468		10.1074/jbc.M202286200	http://dx.doi.org/10.1074/jbc.M202286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953436	hybrid			2022-12-27	WOS:000176313600047
J	Tu, HM; Sasaki, T; Snellman, A; Gohring, W; Pirila, P; Timpl, R; Pihlajaniemi, T				Tu, HM; Sasaki, T; Snellman, A; Gohring, W; Pirila, P; Timpl, R; Pihlajaniemi, T			The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; ELECTRON-MICROSCOPY; BASEMENT-MEMBRANES; ALPHA(2)BETA(1) INTEGRINS; PROLYL 4-HYDROXYLASE; CALCIUM-BINDING; HUMAN-PLACENTA; CELL-ADHESION; DOMAINS; EXPRESSION	Type XIII collagen consists of a short N-terminal intracellular domain, a transmembrane domain, and a collagenous ectodomain, and it is found at many sites of cell adhesion. We report on the characterization of recombinant type XIII collagen. The shed ectodomain was purified from insect cell culture medium and shown to form 240-kDa trimers with a T-m of 42 degreesC. Correct chain association into a triple-helical conformation was confirmed by limited pepsin digestion and CD spectroscopy. Rotary shadowing electron microscopy of the ectodomain revealed it to be a 150-nm rod with two flexible hinges separating 31-, 52-, and 68-nm portions. The rods represent the collagenous domains 1-3, and the hinges coincide with the non-collagenous domains 2 and 3. By using surface plasmon resonance analysis, the ectodomain showed interaction with immobilized fibronectin, nidogen-2, and perlecan with K-D values in the nanomolar range. The binding sites of type XIII collagen for fibronectin were localized to the collagenous domains, whereas the binding activities for nidogen-2 and perlecan resided in the pepsin-sensitive portions of the ectodomain. Furthermore, the ectodomain bound significantly to heparin, which also inhibited shedding of the ectodomain in insect cell cultures. The results reveal that type XIII collagen is notably distinct in its structure compared with other cell-surface proteins, and the in vitro binding with fibronectin, heparin, and two basement membrane components is indicative of multiple cell-matrix interactions in which this ubiquitously expressed protein participates.	Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90220 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; Max Planck Society	Pihlajaniemi, T (corresponding author), Univ Oulu, Bioctr, Collagen Res Unit, Aapistie 7, FIN-90220 Oulu, Finland.	Taina.Pihlajaniemi@oulu.fi		Pihlajaniemi, Taina/0000-0002-1664-9045				AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hynes RO, 1990, FIBRONECTINS; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kielty Cay M., 1993, P103; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lander A D, 1994, Chem Biol, V1, P73, DOI 10.1016/1074-5521(94)90043-4; Mansson B, 2001, J BIOL CHEM, V276, P32883, DOI 10.1074/jbc.M101680200; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; Nokelainen M, 2001, YEAST, V18, P797, DOI 10.1002/yea.730; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; Sandborn WJ, 2000, INFLAMM BOWEL DIS, V6, P70, DOI 10.1097/00054725-200002000-00019; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; Sund M, 2001, EMBO J, V20, P5153, DOI 10.1093/emboj/20.18.5153; Sund M, 2001, MATRIX BIOL, V20, P215, DOI 10.1016/S0945-053X(01)00134-2; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	49	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23092	23099		10.1074/jbc.M107583200	http://dx.doi.org/10.1074/jbc.M107583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956183	hybrid			2022-12-27	WOS:000176313600125
J	Moody, JE; Millen, L; Binns, D; Hunt, JF; Thomas, PJ				Moody, JE; Millen, L; Binns, D; Hunt, JF; Thomas, PJ			Cooperative, ATP-dependent association of the nucleotide binding cassettes during the catalytic cycle of ATP-binding cassette transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ABC TRANSPORTER; HISTIDINE PERMEASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACTIVE-SITE; SUBUNIT; CONSEQUENCES; PURIFICATION; HYDROLYSIS	ATP-binding cassette (ABC) tran porters harvest the energy present in cellular ATP to drive the translocation of a structurally diverse set of solutes across the membrane barriers of eubacteria, archaebacteria, and eukaryotes. The positively cooperative ATPase activity (Hill coefficient, 1.7) of a model soluble cassette of known structure, MJ0796, from Methanococcus jannaschii indicates that at least two binding sites participate in the catalytic reaction. Mutation of the catalytic base in MJ0796, E171Q, produced a cassette that can bind but not efficiently hydrolyze ATP. The equivalent mutation (E179Q) in a homologous cassette, MJ1267, had an identical effect. Both mutant cassettes formed dimers in the presence of ATP but not ADP, indicating that the energy of ATP binding is first coupled to the tran port cycle through a domain association reaction. The non-hydrolyzable nucleotides adenosine 5'-(beta,gamma-imino)triphosphate and adenosine 5'-3-O-(thio)triphosphate were poor analogues of ATP in terms of their ability to promote dimerization. Moreover, inclusion of MgCl2, substitution of KCl for NaCl, or alterations in the polarity of the side chain at the catalytic base all weakened the ATP-dependent dimer, suggesting that electrostatic interactions are critical for the association reaction. Thus, upon hydrolysis of bound ATP and the release of product, both electrostatic and conformational changes drive the cassettes apart, providing a second opportunity to couple free energy changes to the transport reaction.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75290 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75290 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University	Thomas, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75290 USA.	philip.thomas@utsouthwestern.edu	Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [R01 DK049835, R37 DK049835, DK49835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R37DK049835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bliss JM, 1996, GLYCOBIOLOGY, V6, P445, DOI 10.1093/glycob/6.4.445; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Dean M, 2001, J LIPID RES, V42, P1007; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Goldsmith EJ, 1996, FASEB J, V10, P702, DOI 10.1096/fasebj.10.7.8635687; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; MINTON AP, 1990, ANAL BIOCHEM, V190, P1, DOI 10.1016/0003-2697(90)90125-S; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSING J, 1975, BIOCHIM BIOPHYS ACTA, V376, P13, DOI 10.1016/0005-2728(75)90201-7; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Thomas PJ, 2001, NAT STRUCT BIOL, V8, P920, DOI 10.1038/nsb1101-920; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	29	274	279	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21111	21114		10.1074/jbc.C200228200	http://dx.doi.org/10.1074/jbc.C200228200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11964392	hybrid, Green Accepted			2022-12-27	WOS:000176286000001
J	Baillie, GS; Huston, E; Scotland, G; Hodgkin, M; Gall, I; Peden, AH; MacKenzie, C; Houslay, ES; Currie, R; Pettitt, TR; Walmsley, AR; Wakelam, MJO; Warwicker, J; Houslay, MD				Baillie, GS; Huston, E; Scotland, G; Hodgkin, M; Gall, I; Peden, AH; MacKenzie, C; Houslay, ES; Currie, R; Pettitt, TR; Walmsley, AR; Wakelam, MJO; Warwicker, J; Houslay, MD			TAPAS-1, a novel microdomaln within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PHOSPHOLIPASE-D; PROTEIN-KINASE; MOLECULAR TARGETS; COS7 CELLS; BINDING; DOMAIN; ACTIVATION; RD1	Here we identify an 11-residue helical module in the unique N-terminal region of the cyclic AMP-specific phosphodiesterase PDE4A1 that determines association with phospholipid bilayers and shows a profound selectivity for interaction with phosphatidic acid (PA). This module contains a core bilayer insertion unit that is formed by two tryptophan residues, Trp(19) and Trp(20), whose orientation is optimized for bilayer insertion by the Leu(16):Val(17) pairing. Ca2+, at submicromolar levels, interacts with Asp(21) in this module and serves to gate bilayer insertion, which is completed within 10 ms. Selectivity for interaction with PA is suggested to be achieved primarily through the formation of a charge network of the form (Asp(21-):Ca2+:PA(2-):Lys(24+)) with overall neutrality at the bilayer surface. This novel phospholipid-binding domain, which we call TAPAS-1 (tryptophan anchoring phosphatidic acid selective-binding domain 1), is here identified as being responsible for membrane association of the PDE4A1 cAMP-specific phosphodiesterase. TAPAS-1 may not only serve as a paradigm for other PA-binding domains but also aid in detecting related phospholipid-binding domains and in generating simple chimeras for conferring membrane association and intracellular targeting on defined proteins.	Univ Glasgow, IBLS, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Birmingham, Sch Med, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Glasgow, IBLS, Div Infect & Immunol, Glasgow G12 8QQ, Lanark, Scotland; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Glasgow; University of Manchester; University of Birmingham; University of Glasgow; University of Dundee	Houslay, MD (corresponding author), Univ Glasgow, IBLS, Div Biochem & Mol Biol, Mol Pharmacol Grp, Wolfson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	M.Houslay@bio.gla.ac.uk	Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020; Currie, Richard/N-6074-2017	Warwicker, Jim/0000-0002-1302-0815; Wakelam, Michael/0000-0003-4059-9276; Houslay, Miles/0000-0002-3826-8091; Baillie, George/0000-0003-2469-6316; Currie, Richard/0000-0002-6528-3326				Beard MB, 1999, FEBS LETT, V460, P173, DOI 10.1016/S0014-5793(99)01335-6; Beard MB, 2002, CELL SIGNAL, V14, P453, DOI 10.1016/S0898-6568(01)00264-9; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bolger GB, 1997, BIOCHEM J, V328, P539; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Grange Muriel, 1998, Cell Biochemistry and Biophysics, V29, P1, DOI 10.1007/BF02737825; HITCHCOCK PB, 1974, P NATL ACAD SCI USA, V71, P3036, DOI 10.1073/pnas.71.8.3036; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Huston E, 2000, J BIOL CHEM, V275, P28063; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kimber MS, 2000, MOL CELL, V5, P1043, DOI 10.1016/S1097-2765(00)80269-5; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pettitt TR, 2001, BIOCHEM J, V360, P707, DOI 10.1042/0264-6021:3600707; Pooley L, 1997, BIOCHEM J, V321, P177, DOI 10.1042/bj3210177; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Savany A, 1996, CELL SIGNAL, V8, P511, DOI 10.1016/S0898-6568(96)00107-6; Scotland G, 1998, METH MOL B, V88, P141; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; Spina D, 1998, ADV PHARMACOL, V44, P33, DOI 10.1016/S1054-3589(08)60125-8; Sullivan M, 1998, BIOCHEM J, V333, P693, DOI 10.1042/bj3330693; SZABO AG, 2000, SPECTROPHOTOMETRY SP, V2, P33; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Vasudevan C, 1998, J CELL SCI, V111, P1277; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Walmsley AR, 2000, PRACT APPROACH SER, P167; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458; Wolfe C, 1998, MOL MEMBR BIOL, V15, P221, DOI 10.3109/09687689709044324; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	71	127	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28298	28309		10.1074/jbc.M108353200	http://dx.doi.org/10.1074/jbc.M108353200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11994273	hybrid			2022-12-27	WOS:000177189800089
J	Jedrzejas, MJ; Mello, LV; de Groot, BL; Li, SL				Jedrzejas, MJ; Mello, LV; de Groot, BL; Li, SL			Mechanism of hyaluronan degradation by Streptococcus pneumoniae hyaluronate lyase - Structures of complexes with the substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; ACTIVE-SITE; BINDING; ENZYME; PURIFICATION; PNEUMOLYSIN; REFINEMENT	Hyaluronate lyase enzymes degrade hyaluronan, the main polysaccharide component of the host connective tissues, predominantly into unsaturated disaccharide units, thereby destroying the normal connective tissue structure and exposing the tissue cells to various endo-and exogenous factors, including bacterial toxins. The crystal structures of Streptococcus pneumoniae hyaluronate lyase with tetra- and hexasaccharide hyaluronan substrates bound in the active site were determined at 1.52- and 2.0-Angstrom resolution, respectively. Hexasaccharide is the longest substrate segment that binds entirely within the active site of these enzymes. The enzyme residues responsible for substrate binding, positioning, catalysis, and product release were thereby identified and their specific roles characterized. The involvement of three residues in catalysis, Asn(349), His(399), and Tyro(408), is confirmed, and the details of proton acceptance and donation within the catalytic machinery are described. The mechanism of processivity of the enzyme is analyzed. The flexibility (allosteric) behavior of the enzyme may be understood in terms of the results of flexibility analysis of this protein, which identified two modes of motion that are also proposed to be involved in the hyaluronan degradation process. The first motion describes an opening and closing of the catalytic cleft located between the alpha- and beta-domains. The second motion demonstrates the mobility of a binding cleft, which may facilitate the binding of the negatively charged hyaluronan to the enzyme.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Natl Ctr Genet Resources & Biotechnol, BR-70770900 Brasilia, DF, Brazil; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Alabama System; University of Alabama Birmingham; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Max Planck Society	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Baker JR, 2000, BIOCHEM J, V348, P465, DOI 10.1042/0264-6021:3480465; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COURTISS EH, 1995, PLAST RECONSTR SURG, V95, P876, DOI 10.1097/00006534-199595050-00017; DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; de Groot BL, 1999, J MOL BIOL, V286, P1241, DOI 10.1006/jmbi.1998.2568; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; Ducruix A., 1992, CRYSTALLIZATION NUCL; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GREILING H, 1975, CONNECT TISSUE RES, V3, P135, DOI 10.3109/03008207509152171; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Kleinjung J, 2000, FEBS LETT, V470, P257, DOI 10.1016/S0014-5793(00)01295-3; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P15125, DOI 10.1074/jbc.M011102200; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LOCK RA, 1988, MICROB PATHOGENESIS, V5, P461, DOI 10.1016/0882-4010(88)90007-1; McCourt PAG, 1999, MATRIX BIOL, V18, P427, DOI 10.1016/S0945-053X(99)00045-1; MCDANIEL LS, 1991, INFECT IMMUN, V59, P222, DOI 10.1128/IAI.59.1.222-228.1991; McPherson A., 1999, CRYSTALLIZATION BIOL; Mello LV, 1997, PROTEIN ENG, V10, P381, DOI 10.1093/protein/10.4.381; Mello LV, 1998, BIOCHEMISTRY-US, V37, P3137, DOI 10.1021/bi971402v; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; MUFSON MA, 1990, PRINCIPLES PRACTICE; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; PATON JC, 1986, INFECT IMMUN, V54, P50, DOI 10.1128/IAI.54.1.50-55.1986; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; PRITCHARD DG, 1994, ARCH BIOCHEM BIOPHYS, V315, P431, DOI 10.1006/abbi.1994.1521; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P1015, DOI 10.1093/oxfordjournals.jbchem.a133052; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, P11; TOOLE BP, 1984, ROLE EXTRACELLULAR M; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	55	99	102	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28287	28297		10.1074/jbc.M112009200	http://dx.doi.org/10.1074/jbc.M112009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11991948	Green Submitted, hybrid			2022-12-27	WOS:000177189800088
J	Fu, LH; Wang, XF; Eyal, Y; She, YM; Donald, LJ; Standing, KG; Ben-Hayyim, G				Fu, LH; Wang, XF; Eyal, Y; She, YM; Donald, LJ; Standing, KG; Ben-Hayyim, G			A selenoprotein in the plant kingdom. Mass spectrometry confirms that an opal codon (UGA) encodes selenocysteine in Chlamydomonas reinhardtii glutathione peroxidase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION-SEQUENCE SECIS; MAMMALIAN-CELLS; TRANSFER-RNAS; SELENIUM; EXPRESSION; PROTEIN; ACID; GENE; IDENTIFICATION; PURIFICATION	Selenoproteins that contain the rare amino acid selenocysteine in their primary structure have been identified in diverse organisms such as viruses, bacteria, archea, and mammals, but so far not in yeast or plants. Among the most thoroughly investigated families of selenoenzymes are the animal glutathione peroxidases (GPXs). In the last few years, genes encoding GPX-like homologues from Chlamydomonas and higher plants have been isolated, but, unlike the animal ones, all of them have cysteine (rather than selenocysteine) residues in their catalytic site. In all organisms investigated that contain selenoproteins, selenocysteine is encoded by a UGA opal codon, which is usually a stop codon. We report here that, in Chlamydomonas reinhardtii, the cDNA-cloned sequence of a GPX homologue contains an internal TGA codon in frame to the ATG. Specific mRNA expression, protein production, and enzyme activity are selenium-dependent. Sequence analysis of the peptides produced by proteolytic digestion, performed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), confirmed the presence of a selenocysteine residue at the predicted site and suggest its location in the mitochondria. Thus, our data present the first direct proof that a UGA opal codon is decoded in the plant kingdom to incorporate selenocysteine.	Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, IL-50250 Bet Dagan, Israel; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Manitoba, Dept Phys & Astron, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba; University of Manitoba	Ben-Hayyim, G (corresponding author), Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, IL-50250 Bet Dagan, Israel.	vhgozal@agri.gov.il	Standing, Kenneth/E-2416-2011	She, Yi-Min/0000-0002-0571-4630; Eyal, Yoram/0000-0003-4332-1616				Aho EL, 1995, DNA SEQUENCE, V6, P55, DOI 10.3109/10425179509074701; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; Avsian-Kretchmer O, 1999, PLANTA, V209, P469, DOI 10.1007/s004250050750; BARTLING D, 1993, EUR J BIOCHEM, V216, P579, DOI 10.1111/j.1432-1033.1993.tb18177.x; BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Chernushevich IV, 1999, ANAL CHEM, V71, p452A, DOI 10.1021/ac990524l; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU FF, 1993, J BIOL CHEM, V268, P2571; COOKSON E, 1992, P NATL ACAD SCI USA, V89, P5837, DOI 10.1073/pnas.89.13.5837; Engelberg-Kulka H, 2001, BIOFACTORS, V14, P61, DOI 10.1002/biof.5520140109; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; Eyal Y, 1999, BIOTECHNIQUES, V27, P656, DOI 10.2144/99274bm04; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Flohe L., 1982, LIPID PEROXIDES BIOL, P149; Gamain B, 1996, MOL BIOCHEM PARASIT, V78, P237, DOI 10.1016/S0166-6851(96)02632-1; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; Hazebrouck S, 2000, J BIOL CHEM, V275, P28715, DOI 10.1074/jbc.M004985200; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; HUANG KX, 1994, BIOL TRACE ELEM RES, V46, P173, DOI 10.1007/BF02790077; Kohrer C, 2001, P NATL ACAD SCI USA, V98, P14310, DOI 10.1073/pnas.251438898; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; LAUCHLI A, 1993, BOT ACTA, V106, P455; Leisinger U, 1999, PLANT SCI, V149, P139, DOI 10.1016/S0168-9452(99)00151-X; LI WJ, 2000, BIOCHIM BIOPHYS ACTA, V1943, P225; Liu ZS, 1998, NUCLEIC ACIDS RES, V26, P896, DOI 10.1093/nar/26.4.896; Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Ma SG, 2002, J BIOL CHEM, V277, P12749, DOI 10.1074/jbc.M111462200; Miyasaka H, 2000, WORLD J MICROB BIOT, V16, P23, DOI 10.1023/A:1008982332139; Mullineaux PM, 1998, PLANT J, V13, P375, DOI 10.1046/j.1365-313X.1998.00052.x; OVERBAUGH JM, 1985, PLANT PHYSIOL, V77, P437, DOI 10.1104/pp.77.2.437; PRICE NM, 1988, PLANT PHYSIOL, V86, P192, DOI 10.1104/pp.86.1.192; ROCHE C, 1994, GENE, V138, P149, DOI 10.1016/0378-1119(94)90798-6; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SABEH F, 1993, ENZYME PROTEIN, V47, P92, DOI 10.1159/000468662; Sachdev SW, 2001, BIOCHEM J, V357, P851; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEN QC, 1993, J BIOL CHEM, V268, P11463; SHIGEOKA S, 1991, BIOCHEM J, V275, P623, DOI 10.1042/bj2750623; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; SUNDE RA, 1993, BIOCHEM BIOPH RES CO, V193, P905, DOI 10.1006/bbrc.1993.1711; TAKEDA T, 1993, PLANT SCI, V94, P81, DOI 10.1016/0168-9452(93)90009-O; Terry N, 2000, ANNU REV PLANT PHYS, V51, P401, DOI 10.1146/annurev.arplant.51.1.401; TOYODA H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P213, DOI 10.1016/0167-4781(90)90042-Z; URSINI F, 1995, METHOD ENZYMOL, V252, P38; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; VERENTCHIKOV AN, 1994, ANAL CHEM, V66, P126, DOI 10.1021/ac00073a022; Vernet P, 1996, BIOCHEM CELL BIOL, V74, P125, DOI 10.1139/o96-014; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; YOKOTA A, 1988, PLANT PHYSIOL, V86, P649, DOI 10.1104/pp.86.3.649; Zhang W, 1999, BIOL TRACE ELEM RES, V70, P97, DOI 10.1007/BF02783852	58	123	135	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25983	25991		10.1074/jbc.M202912200	http://dx.doi.org/10.1074/jbc.M202912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11973339	hybrid			2022-12-27	WOS:000176908700023
J	Graichen, R; Liu, DX; Sun, Y; Lee, KO; Lobie, PE				Graichen, R; Liu, DX; Sun, Y; Lee, KO; Lobie, PE			Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; D1 PROMOTER; TUMOR-CELLS; MORPHOGENETIC PROTEIN; HEMATOPOIETIC-CELLS; DNA-DAMAGE; FACTOR-I; EXPRESSION; P53; PROLIFERATION	Multiple cellular effects of human growth hormone (hGH) are mediated by an indirect mechanism requiring transcriptional activation of genes encoding protein effector molecules such as insulin-like growth factor-1. Such protein effector molecules then act directly to mediate the cellular functions of hGH. We report here that autocrine hGH production by mammary carcinoma cells specifically results in the transcriptional repression of the p53-regulated placental transforming growth factor-beta (PTGF-beta) gene. Transcriptional repression of the PTGF-beta gene does not require the p53-binding sites in the PTGF-beta promoter, and autocrine hGH also desensitized the response of the PTGF-beta promoter to p53 overexpression. Transcriptional repression of the PTGF-beta gene is accompanied by consequent decreases in its protein product, Smad-mediated transcription, and its cellular effects that include cell cycle arrest and apoptosis. PTGF-beta specifically inhibited the autocrine hGH-stimulated expression of cyclin D1 required for autocrine hGH-stimulated mammary carcinoma cell cycle progression. Thus, one mechanism by which autocrine hGH promotes an increase in mammary carcinoma cell number is by transcriptional repression of protein effector molecules that promote cell cycle arrest and apoptosis. Such transcriptional repression of negative regulatory factors, such as PTGF-beta, may also be requisite for direct stimulation of mammary carcinoma cell mitogenesis by hGH.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Med, Singapore 119074, Singapore; Pfizer Global Res & Dev, Ann Arbor Labs, Canc Mol Sci, Ann Arbor, MI 48105 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Pfizer	Lobie, PE (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Lee, Kok-Onn/E-9874-2011	Lee, Kok-Onn/0000-0002-3040-1185				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carlsson C, 1997, ENDOCRINOLOGY, V138, P3940, DOI 10.1210/en.138.9.3940; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Del Bino G, 1999, CELL PROLIFERAT, V32, P25, DOI 10.1046/j.1365-2184.1999.00130.x; EKBERG S, 1992, J ENDOCRINOL, V135, P59, DOI 10.1677/joe.0.1350059; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Fawcett TW, 1997, CELL STRESS CHAPERON, V2, P104, DOI 10.1379/1466-1268(1997)002<0104:POHSIH>2.3.CO;2; Friedrichsen BN, 2001, MOL ENDOCRINOL, V15, P136, DOI 10.1210/me.15.1.136; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; IZUMI T, 1995, MOL CELL ENDOCRINOL, V112, P95, DOI 10.1016/0303-7207(95)03591-T; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jeay S, 2001, ENDOCRINOLOGY, V142, P147, DOI 10.1210/en.142.1.147; Kato Y, 1996, ENDOCR J, V43, P177, DOI 10.1507/endocrj.43.177; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; KLAPPER DG, 1983, ENDOCRINOLOGY, V112, P2215, DOI 10.1210/endo-112-6-2215; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Li H, 1998, ENDOCRINOLOGY, V139, P3855, DOI 10.1210/en.139.9.3855; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Liu ND, 1997, EXP CELL RES, V237, P196, DOI 10.1006/excr.1997.3789; Liu XP, 2001, CANCER LETT, V170, P183, DOI 10.1016/S0304-3835(01)00589-4; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; ROGERS SA, 1994, AM J PHYSIOL, V267, pF208, DOI 10.1152/ajprenal.1994.267.2.F208; Salatino M, 2001, EXP CELL RES, V265, P152, DOI 10.1006/excr.2001.5175; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Swolin D, 1996, J CLIN ENDOCR METAB, V81, P4329, DOI 10.1210/jc.81.12.4329; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	58	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26662	26672		10.1074/jbc.M109931200	http://dx.doi.org/10.1074/jbc.M109931200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994274	hybrid			2022-12-27	WOS:000176908700108
J	Koh, SS; Li, HW; Lee, YH; Widelitz, RB; Chuong, CM; Stallcup, MR				Koh, SS; Li, HW; Lee, YH; Widelitz, RB; Chuong, CM; Stallcup, MR			Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; PATHWAY; TARGET; WNT; ACETYLTRANSFERASES; METHYLATION; SPECIFICITY; EXPRESSION; CHROMATIN; CBP/P300	The androgen receptor (AR) binds to and activates transcription of specific genes in response to its cognate steroid hormone, dihydrotestosterone. Transcriptional activation by the DNA-bound AR is accomplished with the help of a variety of coactivator proteins. For example, the p160 coactivators bind directly to AR and recruit additional coactivators such as the histone acetyltransferase p300 and the histone methyltransferase CARM1. The current study tested whether CARM1 can cooperate with other types of coactivator proteins. Recently it was shown that beta-catenin can also bind directly to and serve as a coactivator for AR. Here it is shown that CARM1 binds to beta-catenin and can function in synergy with beta-catenin and p300 as coactivators for AR. The methyltransferase activity of CARM1 is important for its synergistic coactivator function with beta-catenin. The synergistic coactivator function of beta-catenin and CARM1 is not restricted to steroid receptors because these two coactivators can also act synergistically with another type of DNA binding transcriptional activator, LEF-1/TCF-4.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Lee, Young-Ho/G-2361-2014	Lee, Young-Ho/0000-0001-6415-4912	NCI NIH HHS [CA83716, R01 CA083716] Funding Source: Medline; NIAMS NIH HHS [R01 AR042177-06S1, R01 AR042177-06, R01 AR042177, R01 AR042177-05, AR42177, R01 AR042177-07, R01 AR042177-07S1] Funding Source: Medline; NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [R01 DK043093, DK43093] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker N, 2000, BIOESSAYS, V22, P961; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chuong CM, 2000, CURR OPIN GENET DEV, V10, P449, DOI 10.1016/S0959-437X(00)00111-8; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Lu JF, 1997, GENE, V196, P201, DOI 10.1016/S0378-1119(97)00228-X; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Truica CI, 2000, CANCER RES, V60, P4709; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2	33	105	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26031	26035		10.1074/jbc.M110865200	http://dx.doi.org/10.1074/jbc.M110865200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11983685	Green Accepted, hybrid			2022-12-27	WOS:000176908700028
J	Chou, CF; Lai, CL; Chang, YC; Duester, G; Yin, SJ				Chou, CF; Lai, CL; Chang, YC; Duester, G; Yin, SJ			Kinetic mechanism of human class IV alcohol dehydrogenase functioning as retinol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STOMACH ALCOHOL; OMEGA-HYDROXYFATTY ACIDS; FIRST-PASS METABOLISM; SUBSTRATE-SPECIFICITY; EXPRESSION PATTERNS; STRUCTURAL BASIS; LIGAND SYNTHESIS; MOLECULAR-BASIS; MOUSE EMBRYOS; ETHANOL	Molecular genetic studies have indicated that alcohol dehydrogenase may be involved in the synthesis of retinoic acid, a hormonal molecule regulating diverse cellular functions at the transcriptional level. Class IV alcohol dehydrogenase (ADH) has been reported to be the most efficient enzyme catalyzing oxidation of retinol in human ADH family. Initial velocity, product inhibition, and dead-end inhibition experiments were performed with the recombinant human class IV ADH to elucidate kinetic mechanism with all-trans-retinol and all-trans-retinal as natural substrates. Fluorescence quenching was titrated in formation of the binary and abortive ternary enzyme complexes. The minimal mechanism deduced from steady-state kinetic and equilibrium binding studies is best described as an asymmetric rapid equilibrium random mechanism with two dead-end ternary complexes for retinol oxidation and a rapid equilibrium ordered mechanism with one dead-end ternary complex for retinal reduction, a unique mechanistic form for zinc-containing ADHs in the medium chain dehydrogenase/reductase superfamily. Dissociation constants for the binary complexes as well as the productive and abortive ternary complexes determined from different experimental approaches are in reasonable agreement. Kinetic isotope effect studies suggest rate-limiting isomerization of the central ternary complexes in both reaction directions. The potential interference of retinol metabolism by ethanol through the ADH pathway may play a significant role in the pathogenesis of fetal alcohol syndrome and alcohol-related upper digestive tract cancer.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Natl Def Med Ctr, Dept Biochem, Taipei 114, Taiwan; Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	National Defense Medical Center; National Defense Medical Center; Sanford Burnham Prebys Medical Discovery Institute	Yin, SJ (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.			Lai, Ching-Long/0000-0001-7401-362X; Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adolph HW, 2000, BIOCHEMISTRY-US, V39, P12885, DOI 10.1021/bi001376s; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AllaliHassani A, 1997, FEBS LETT, V405, P26, DOI 10.1016/S0014-5793(97)00151-8; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Ang HL, 1997, DEV DYNAM, V208, P536; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHA S, 1968, J BIOL CHEM, V243, P820; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cleland W W, 1979, Methods Enzymol, V63, P103; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; DALZIEL K, 1962, BIOCHEM J, V84, P240, DOI 10.1042/bj0840240; DALZIEL K, 1963, J BIOL CHEM, V238, P2850; DALZIEL K, 1966, BIOCHEM J, V100, P36; De Luca LM, 1997, J NUTR BIOCHEM, V8, P426, DOI 10.1016/S0955-2863(97)00063-6; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1997, BIOL REPROD, V56, P102, DOI 10.1095/biolreprod56.1.102; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Edenberg HJ, 2000, PROG NUCLEIC ACID RE, V64, P295, DOI 10.1016/S0079-6603(00)64008-4; EFTINK MR, 1986, BIOCHEMISTRY-US, V25, P6631, DOI 10.1021/bi00369a045; EFTINK MR, 1982, BIOCHEMISTRY-US, V21, P117, DOI 10.1021/bi00530a021; Estonius M, 1996, FEBS LETT, V397, P338, DOI 10.1016/S0014-5793(96)01204-5; Foglio MH, 1999, BBA-PROTEIN STRUCT M, V1432, P239, DOI 10.1016/S0167-4838(99)00104-1; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; HANES CS, 1972, CAN J BIOCHEM CELL B, V50, P1385, DOI 10.1139/o72-182; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1998, ALCOHOL CLIN EXP RES, V22, P1607, DOI 10.1111/j.1530-0277.1998.tb03955.x; Haselbeck RJ, 1997, DEV DYNAM, V208, P447, DOI 10.1002/(SICI)1097-0177(199704)208:4<447::AID-AJA1>3.0.CO;2-I; HOOG JO, 1995, ADV EXP MED BIOL, V372, P355; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JORNVALL H, 1970, EUR J BIOCHEM, V16, P41, DOI 10.1111/j.1432-1033.1970.tb01050.x; Jornvall H, 2000, PHARMACOLOGY, V61, P184, DOI 10.1159/000028399; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kedishvili NY, 1997, J BIOL CHEM, V272, P7494, DOI 10.1074/jbc.272.11.7494; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Peralba JM, 1999, J BIOL CHEM, V274, P26021, DOI 10.1074/jbc.274.37.26021; Plapp BV, 2001, CHEM-BIOL INTERACT, V130, P445, DOI 10.1016/S0009-2797(00)00284-2; POCKER Y, 1993, ADV EXP MED BIOL, V328, P411; SCHIMERLIK MI, 1973, J BIOL CHEM, V248, P8418; Segel I. H., 1975, ENZYME KINETICS, P273; SEKHAR VC, 1990, BIOCHEMISTRY-US, V29, P4289, DOI 10.1021/bi00470a005; SILVERSTEIN E, 1964, J BIOL CHEM, V239, P3908; Sund H., 1963, ENZYMES, V7, P25; Szalai G, 2002, EUR J BIOCHEM, V269, P224, DOI 10.1046/j.0014-2956.2001.02642.x; THEORELL H, 1951, ACTA CHEM SCAND, V5, P1127, DOI 10.3891/acta.chem.scand.05-1127; THEORELL H, 1971, ARCH BIOCHEM BIOPHYS, V142, P69, DOI 10.1016/0003-9861(71)90260-8; Ulven SM, 2000, DEV BIOL, V220, P379, DOI 10.1006/dbio.2000.9634; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; Yin SJ, 1997, GASTROENTEROLOGY, V112, P766, DOI 10.1053/gast.1997.v112.pm9041238; Yin SJ, 1997, ADV EXP MED BIOL, V414, P347; Yin SJ, 1999, ADV EXP MED BIOL, V463, P265; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZHENG YW, 1993, J BIOL CHEM, V268, P24933	63	36	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25209	25216		10.1074/jbc.M201947200	http://dx.doi.org/10.1074/jbc.M201947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997393	hybrid			2022-12-27	WOS:000176747000048
J	Deregibus, MC; Cantaluppi, V; Doublier, S; Brizzi, MF; Deambrosis, I; Albini, A; Camussi, G				Deregibus, MC; Cantaluppi, V; Doublier, S; Brizzi, MF; Deambrosis, I; Albini, A; Camussi, G			HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; TAT PROTEIN; ENDOTHELIAL-CELLS; HIV-TAT; COUPLED RECEPTOR; TRANSGENIC MICE; KINASE-B; IN-VIVO; APOPTOSIS; LESIONS	In this study we found that Tat protected vincristine-treated Kaposi's sarcoma cells from apoptosis and from down-regulation of several anti-apoptotic genes such as AKT-1, AKT-2, BCL2, BCL-XL, and insulin-like growth factor I and induced the de novo expression of the interleukin-3 gene. Moreover, we found that Tat enhanced phosphorylation of AKT and BAD proteins. The inhibition of phosphatidylinositol 3-kinase with two unrelated pharmacological inhibitors, wortmannin and LY294002, abrogated both the anti-apoptotic effect and the phosphorylation of AKT induced by Tat. After treatment with Tat, the AKT enzymatic activity showed a biphasic increase: an early activation (15 min), independent from protein synthesis; and a delayed activation (24 h), which was significantly decreased upon blockage of protein synthesis. Experiments with a function blocking anti-vascular endothelial cell growth factor receptor-2 antibody suggested that both the early and delayed AKT activation and the protection from apoptosis were triggered by the interaction of Tat with vascular endothelial cell growth factor receptor-2. Moreover, experiments with function-blocking antibodies directed against insulin-like growth factor I/insulin-like growth factor I receptor or interleukin-3 indicated their involvement in the delayed activation of AKT and their contribution to the anti-apoptotic effect of Tat on vincristine-treated Kaposi's sarcoma cells.	Univ Turin, Dipartimento Med Interna, Cattedra Nefrol, CeRMS, I-10126 Turin, Italy; Ist Nazl Ric Canc, I-16100 Genoa, Italy	University of Turin; University of Genoa; IRCCS AOU San Martino IST	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.		Cantaluppi, Vincenzo/K-8531-2016; Camussi, Giovanni/J-7624-2016; Brizzi, Maria Felice/J-7882-2016	Cantaluppi, Vincenzo/0000-0002-4120-3555; Camussi, Giovanni/0000-0003-2795-232X; Albini, Adriana/0000-0002-9624-5103				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CANTALUPPI V, 2001, AIDS, V10, P965; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chokunonga E, 2000, INT J CANCER, V85, P54, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;54::AID-IJC10&gt;3.0.CO;2-D; CORALLINI A, 1993, CANCER RES, V53, P5569; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1991, ADV EXP MED BIOL, V303, P27; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Lee FC, 1996, HEMATOL ONCOL CLIN N, V10, P1051, DOI 10.1016/S0889-8588(05)70384-1; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Mitsuyasu RT, 2000, CURR OPIN ONCOL, V12, P174, DOI 10.1097/00001622-200003000-00013; Montaner S, 2001, CANCER RES, V61, P2641; Mori S, 1996, CANCER RES, V56, P1874; Morini M, 2000, BIOCHEM BIOPH RES CO, V273, P267, DOI 10.1006/bbrc.2000.2941; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Samaniego F, 1997, J IMMUNOL, V158, P1887; St Croix B, 2000, SCIENCE, V289, P1197; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEIHUA W, 2000, J BIOL CHEM, V275, P40113; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; ZAULI G, 1993, CANCER RES, V53, P4481; Zauli G, 2001, FASEB J, V15, P483, DOI 10.1096/fj.00-0354com; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	53	84	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25195	25202		10.1074/jbc.M200921200	http://dx.doi.org/10.1074/jbc.M200921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994280	hybrid			2022-12-27	WOS:000176747000046
J	Gonzalez-Perrett, S; Batelli, M; Kim, K; Essafi, M; Timpanaro, G; Moltabetti, N; Reisin, IL; Arnaout, MA; Cantiello, HF				Gonzalez-Perrett, S; Batelli, M; Kim, K; Essafi, M; Timpanaro, G; Moltabetti, N; Reisin, IL; Arnaout, MA; Cantiello, HF			Voltage dependence and pH regulation of human polycystin-2-mediated cation channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; CALCIUM CHANNELS; PERMEANT IONS; PROTEIN; PROTONS; PKD2; GENE	Polycystin-2, the product of the human PKD2 gene, whose mutations cause autosomal dominant polycystic kidney disease, is a large conductance, Ca2+-permeable non-selective cation channel. Polycystin-2 is functionally expressed in the apical membrane of the human syncytiotrophoblast, where it may play a role in the control of fetal electrolyte homeostasis. Little is known, however, about the mechanisms that regulate polycystin-2 channel function. In this study, the role of pH in the regulation of polycystin-2 was assessed by ion channel reconstitution of both apical membranes of human syncytiotrophoblast and the purified FIAG-tagged protein from in vitro transcribed/translated material. A kinetic analysis of single channel currents, including dwell time histograms, confirmed two open and two close states for spontaneous channel behavior and a strong voltage dependence of the open probability of the channel (P-o). A reduction of cis pH (pH(cis)) decreased P-o and shifted the voltage dependence of channel function but had no effect on the single channel conductance. An increase in pH(cis), in contrast, increased NPo (channel number times P-o). Elimination of the H+ chemical gradient did not reverse the low pH(cis) inhibition of polycystin-2. Similar findings confirmed the pH effect on the in vitro translated, FLAG-tagged purified polycystin-2. The data indicate the presence of an H+ ion regulatory site in the channel protein, which is accessible from the cytoplasmic side of the protein. This protonation site controls polycystin-2 cation-selective channel activity.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Fac Farm & Bioquim, Dept Fisicoquim & Quim Analit, Lab Canales Ion, RA-1113 Buenos Aires, DF, Argentina; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Fac Med, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina	University of Buenos Aires; Harvard University; Harvard Medical School	Cantiello, HF (corresponding author), Massachusetts Gen Hosp E, Renal Unit, 149 13th St, Charlestown, MA 02129 USA.		Essafi, Makram/V-8411-2019; Montalbetti, Nicolas/T-4212-2019	Montalbetti, Nicolas/0000-0003-2897-9540	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez O., 1986, ION CHANNEL RECONSTI, P115; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; Eyring H., 1963, MODERN CHEM KINETICS; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grosman C, 1997, J MEMBRANE BIOL, V157, P83, DOI 10.1007/s002329900218; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HANKE W, ION CHANNEL RECONSTI, P141; HESS P, 1989, ANN NY ACAD SCI, V560, P80, DOI 10.1111/j.1749-6632.1989.tb24082.x; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; PATLAK JB, 1988, J GEN PHYSIOL, V92, P413, DOI 10.1085/jgp.92.4.413; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; SNEDECOR GW, 1973, STATISTICAL METHODS, P59; Stulc J, 1997, PHYSIOL REV, V77, P805, DOI 10.1152/physrev.1997.77.3.805; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	19	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24959	24966		10.1074/jbc.M105084200	http://dx.doi.org/10.1074/jbc.M105084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991947	hybrid			2022-12-27	WOS:000176747000017
J	Liu, S; Carrillo, JJ; Pediani, JD; Milligan, G				Liu, S; Carrillo, JJ; Pediani, JD; Milligan, G			Effective information transfer from the alpha(1b)-adrenoceptor to G alpha(11) requires both beta/gamma interactions and an aromatic group four amino acids from the C terminus of the G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; ALPHA-SUBUNITS; ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; PHOSPHOLIPASE-C; CHO CELLS; ACTIVATION; AGONIST	Co-expression of the alpha(1b)-adrenoreceptor and Galpha(11) in cells derived from a Galpha(q)/Galpha(11) knock-out mouse allows agonist-mediated elevation of intracellular Ca2+ levels that is transduced by beta/gamma released from the G protein a subunit. Mutation of Tyr(356) of Galpha(11) to Phe, within a receptor contact domain, had little effect on function but this was reduced greatly by alteration to Ser and virtually eliminated by conversion to Asp. This pattern was replicated following incorporation of each form of Ga-11 into fusion proteins with the alpha(1b)-adrenoreceptor. Following a [S-35] guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) binding assay, immunoprecipitation of the wild type alpha(1b)-adrenoreceptor-Galpha(11) fusion protein indicated that the agonist phenylephrine stimulated guanine nucleotide exchange on Galpha(11) more than 30-fold. Information transfer by agonist was controlled in residue 356 Galpha(11) mutants with rank order Tyr > Phe > Trp > Ile > Ala = Gln = Arg > Ser > Asp, although these alterations did not alter the binding affinity of either phenylephrine or an antagonist ligand. Mutation of a beta/gamma contact interface in the alpha(1b)-adrenoreceptor-Tyr(356) Gat, fusion protein did not alter ligand binding affinity but did reduce greatly beta/gamma binding and phenylephrine stimulation of [S-35]GTPgammas binding. It also prevented agonist elevation of intracellular Ca2+ levels, as did a mutation in Galpha(11) that prevents G protein subunit dissociation. These results indicate that a bulky aromatic group is required four amino acids from the C terminus of Galpha(11) to maximize information transfer from an agonist-occupied receptor and disprove the hypothesis that tyrosine phosphorylation of this residue is required for G protein activation (Umemori, H., Inoue, T., Kume, S., Seldyama, N., Nagao, M, Itoh, H., Nakanishi, S., Mikoshiba, K, and Yamamoto, T. (1997) Science 276,1878-1881). This is distinct from Galpha(i1) where hydrophobicity of the amino acid is the key determinant at this location. They also further demonstrate a key role for the IVY complex in enhancing receptor to G protein a subunit information transfer.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Milligan, Graeme/F-9426-2011; Pediani, John/F-2708-2019	Milligan, Graeme/0000-0002-6946-3519; Pediani, John/0000-0001-6615-537X				Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CARRILLO JJ, 2002, IN PRESS J PHARM EXP; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; DeLapp NW, 1999, J PHARMACOL EXP THER, V289, P946; Dupuis DS, 2001, NEUROPHARMACOLOGY, V40, P36, DOI 10.1016/S0028-3908(00)00098-8; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; KIM GD, 1994, J BIOL CHEM, V269, P19933; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Milligan G, 1999, TRENDS PHARMACOL SCI, V20, P118, DOI 10.1016/S0165-6147(99)01320-6; MILLIGAN G, 1998, BIOCHEM J, V255, P1; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; Stevens PA, 2000, MOL PHARMACOL, V58, P438, DOI 10.1124/mol.58.2.438; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WIELAND T, 1994, METHOD ENZYMOL, V237, P1; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745	40	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25707	25714		10.1074/jbc.M201015200	http://dx.doi.org/10.1074/jbc.M201015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994281	hybrid			2022-12-27	WOS:000176747000112
J	Beinke, S; Belich, MP; Ley, SC				Beinke, S; Belich, MP; Ley, SC			The death domain of NF-kappa B1 p105 is essential for signal-induced p105 proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCINE-RICH REGION; DIFFERENTIAL REGULATION; PRECURSOR P105; KINASE COMPLEX; PROTEINS; PHOSPHORYLATION; BETA; P50; UBIQUITINATION	Stimulation of cells with tumor necrosis factor a (TNFalpha) triggers NF-kappaB1 p105 proteolysis, releasing associated Rel subunits to translocate into the nucleus and modulate target gene expression. Phosphorylation of serine 927 within the p105 PEST region by the IkappaB kinase (IKK) complex is required to promote p105 proteolysis in response to TNFalpha stimulation. In this study, the role of the p105 death domain (DD) in signal-induced p105 proteolysis is investigated. Endogenous p105 is shown to interact with the IKK complex in HeLa cells, and transient transfection experiments in 293 cells indicate that each of the catalytic components of the IKK complex, IKK1 and IKK2, can bind to p105. Interaction of p105 with both IKK1 and IKK2 is substantially reduced by deletion of the p105 DD or introduction of a specific point mutation (L841A) into the p105 DD homologous to the lpr mutation in Fas. Phosphorylation of immunoprecipitated p105 on serine 927 by purified recombinant IKK1 or IKK2 protein in vitro is dramatically reduced in both DD mutants relative to wild type. Furthermore, both of the DD mutations significantly impair the ability of low concentrations of IKK2 to induce p 105 serine 927 phosphorylation and proteolysis in transiently transfected 3T3 cells. However, high levels of transiently expressed IKK2 bypass the requirement for the p105 DD to induce p105 serine 927 phosphorylation. Finally, p105 serine 927 phosphorylation by the endogenous IKK complex after TNFalpha stimulation and subsequent p105 proteolysis is blocked in both p105 DD mutants when stably expressed in HeLa cells. Thus, the p105 DD acts as a docking site for IKK, increasing its local concentration in the vicinity of the p105 PEST region and facilitating efficient serine 927 phosphorylation.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Ley, SC (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Mill Hill, London NW7 1AA, England.	sley@nimr.mrc.ac.uk						ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Syrovets T, 2001, BLOOD, V97, P3941, DOI 10.1182/blood.V97.12.3941; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24162	24168		10.1074/jbc.M201576200	http://dx.doi.org/10.1074/jbc.M201576200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976329	hybrid			2022-12-27	WOS:000176611800026
J	Bottini, N; Stefanini, L; Williams, S; Alonso, A; Jascur, T; Abraham, RT; Couture, C; Mustelin, T				Bottini, N; Stefanini, L; Williams, S; Alonso, A; Jascur, T; Abraham, RT; Couture, C; Mustelin, T			Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE-COMMON ANTIGEN; T-CELLS; SIGNAL-TRANSDUCTION; ACID-PHOSPHATASE; KINASE PP56LCK; GROWTH-FACTOR; PHOSPHORYLATION; CD45	The ZAP-70 protein-tyrosine kinase plays a central role in signaling from the T cell antigen receptor. Recruitment and activation of ZAP-70 are transient and are terminated by phosphorylation of negative regulatory tyrosine residues and dephosphorylation of positively acting sites. We report that the low molecular weight protein-tyrosine phosphatase (LMPTP) specifically dephosphorylates the negative regulatory Tyr-292 of ZAP-70, thereby counteracting inactivation of ZAP-70. Expression of low levels of LMPTP resulted in increased ZAP-70 phosphorylation, presumably at the activating Tyr-493 and other sites, increased kinase activity, and augmented downstream signaling to the mitogen-activated protein kinase pathway. The ZAP-70 Y292F mutant was not affected by LMPTP. Our results indicate that LMPTP, like CD45, dephosphorylates a negative regulatory tyrosine site in a protein-tyrosine kinase and thereby strengthens T cell receptor signaling.	Burnham Inst, Program Signal Transduct, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), Burnham Inst, Program Signal Transduct, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Alonso, Andrés/L-7523-2014; Ingegnoli, Francesca/B-6226-2017	Alonso, Andrés/0000-0001-8674-9378; Ingegnoli, Francesca/0000-0002-6727-1273; Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI40552, AI48032, AI35603] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603, R01AI040552, R01AI048032, R21AI040552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; DISSING J, 1987, BIOCHEM GENET, V25, P901, DOI 10.1007/BF00502609; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Gibson S, 1996, J IMMUNOL, V156, P2716; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Han SL, 2000, EUR J IMMUNOL, V30, P1318, DOI 10.1002/(SICI)1521-4141(200005)30:5<1318::AID-IMMU1318>3.0.CO;2-G; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD85, DOI 10.2741/mustelin; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; TURKA LA, 1992, EUR J IMMUNOL, V22, P551, DOI 10.1002/eji.1830220238; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WO YYP, 1992, J BIOL CHEM, V267, P10856; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	49	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24220	24224		10.1074/jbc.M202885200	http://dx.doi.org/10.1074/jbc.M202885200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976341	hybrid			2022-12-27	WOS:000176611800033
J	Chen-Park, FE; Huang, DB; Noro, B; Thanos, D; Ghosh, G				Chen-Park, FE; Huang, DB; Noro, B; Thanos, D; Ghosh, G			The kappa B DNA sequence from the HIV long terminal repeat functions as an allosteric regulator of HIV transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; P50/P65 HETERODIMER; BETA ENHANCEOSOME; ACTIVATION; BINDING; HOMODIMER; MECHANISM; RECEPTOR; CBP/P300; PROMOTER	NF-kappaB is an inducible transcription factor involved in the immune response, inflammation, and viral transcription. To address how the two NF-kappaB and three Sp1 binding sites of the human immunodeficiency virus (HIV) long terminal repeat (LTR) control multiple activator assembly and transcription, we first observed and compared unique conformations between the crystallographic structure of the NF-kappaB p50-p65 heterodimer bound to the uPA-kappaB target site to that of the p50-p65-HIV-kappaB complex. Next, cooperativity between two NF-kappaB molecules bound to tandem HIV-kappaB sequences was measured as well as that of NF-kappaB and transcription factor Sp1 when bound to adjacent sites. The cooperativity of hybrid HIV-LTR enhancers was measured with the 3' kappaB site converted to uPA-kappaB or to interferon beta gene enhancer kappaB. The hybrids were defective in transcriptional activator assembly and less active transcriptionally. These functional differences correlate with observed conformational differences and demonstrate that distinct kappaB DNA sequences function as allosteric regulators in a gene-specific manner.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Columbia University	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,9500 Gilman Dr, La Jolla, CA 92093 USA.		Thanos, Dimitris/AAE-5720-2019					BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1998, ACTA CRYSTALLOGR D, V10, P25; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; Holmbeck SMA, 1998, J MOL BIOL, V284, P533, DOI 10.1006/jmbi.1998.2207; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P219; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; Roebuck KA, 1999, INT J MOL MED, V4, P223; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Tisne C, 1999, J MOL BIOL, V293, P139, DOI 10.1006/jmbi.1999.3157; Tisne C, 1998, J MOL BIOL, V279, P127, DOI 10.1006/jmbi.1998.1757; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	41	73	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24701	24708		10.1074/jbc.M200007200	http://dx.doi.org/10.1074/jbc.M200007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11970949	hybrid			2022-12-27	WOS:000176611800096
J	Donelan, MJ; Morfini, G; Julyan, R; Sommers, S; Hays, L; Kajio, H; Briaud, I; Easom, RA; Molkentin, JD; Brady, ST; Rhodes, CJ				Donelan, MJ; Morfini, G; Julyan, R; Sommers, S; Hays, L; Kajio, H; Briaud, I; Easom, RA; Molkentin, JD; Brady, ST; Rhodes, CJ			Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells - Implications for regulated beta-granule transport and insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGHT-CHAIN; IN-VIVO; PHOSPHORYLATION; SECRETION; GLUCOSE; ISLETS; RAT; CALCINEURIN; INHIBITION	The specific biochemical steps required for glucose-regulated insulin exocytosis from beta-cells are not well defined. Elevation of glucose leads to increases in cytosolic [Ca2+](i) and biphasic release of insulin from both a readily releasable and a storage pool of beta-granules. The effect of elevated [Ca2+](i) on phosphorylation of isolated beta-granule membrane proteins was evaluated, and the phosphorylation of four proteins was found to be altered by [Ca2+](i). One (a 18/20-kDa doublet) was a Ca2+-dependent increase in phosphorylation, and, surprisingly, three others (138, 42, and 36 kDa) were Ca2+-dependent dephosphorylations. The 138-kDa beta-granule phosphoprotein was found to be kinesin heavy chain (KHC). At low levels of [Ca2+](i) KHC was phosphorylated by casein kinase 2, but KHC was rapidly dephosphorylated by protein phosphatase 2B beta (PP2Bbeta) as [Ca2+](i) increased. Inhibitors of PP2B specifically reduced the second, microtubule-dependent, phase of insulin secretion, suggesting that dephosphorylation of KHC was required for transport of beta-granules from the storage pool to replenish the readily releasable pool of beta-granules. This is distinct from synaptic vesicle exocytosis, because neurotransmitter release from synaptosomes did not require a Ca2+-dependent KHC dephosphorylation. These results suggest a novel mechanism for regulating KHC function and beta-granule transport in beta-cells that is mediated by casein kinase 2 and PP2B. They also implicate a novel regulatory role for PP2B/calcineurin in the control of insulin secretion downstream of a rise in [Ca2+](i).	Pacific NW Res Inst, Seattle, WA 98112 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98112 USA	Cincinnati Children's Hospital Medical Center; University of North Texas System; University of North Texas Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98112 USA.	cjr@pnri.org	Morfini, Gerardo/AAP-8070-2021	Morfini, Gerardo/0000-0001-6059-5518; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041170, R56NS023868, R01NS023868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG012646] Funding Source: NIH RePORTER; NIA NIH HHS [AG12646] Funding Source: Medline; NIDDK NIH HHS [DK47919] Funding Source: Medline; NINDS NIH HHS [NS41170, NS23868] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ALARCON C, 1995, J CLIN INVEST, V95, P1032, DOI 10.1172/JCI117748; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; BALCZON R, 1992, ENDOCRINOLOGY, V131, P331, DOI 10.1210/en.131.1.331; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BOYD AE, 1982, J CELL BIOL, V92, P425, DOI 10.1083/jcb.92.2.425; BRADY ST, 1995, TRENDS CELL BIOL, V5, P159, DOI 10.1016/S0962-8924(00)88980-1; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEROLD KC, 1993, TRANSPLANTATION, V55, P186, DOI 10.1097/00007890-199301000-00035; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; Kajio H, 2001, DIABETES, V50, P2029, DOI 10.2337/diabetes.50.9.2029; Kenyon NS, 1998, DIABETES METAB REV, V14, P303, DOI 10.1002/(SICI)1099-0895(199812)14:4<303::AID-DMR243>3.0.CO;2-E; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Meng YX, 1997, ENDOCRINOLOGY, V138, P1979, DOI 10.1210/en.138.5.1979; MONTAGUE W, 1975, BIOCHEM J, V148, P237, DOI 10.1042/bj1480237; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; OLSZEWSKI S, 1994, J BIOL CHEM, V269, P27987; PENN EJ, 1982, FEBS LETT, V139, P4, DOI 10.1016/0014-5793(82)80474-2; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Seiler S, 2000, NAT CELL BIOL, V2, P333, DOI 10.1038/35014022; Sistiaga A, 2000, NEUROPHARMACOLOGY, V39, P1544, DOI 10.1016/S0028-3908(00)00034-4; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Thaler C D, 1996, Int Rev Cytol, V164, P269; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Woehlke G, 2000, NAT REV MOL CELL BIO, V1, P50, DOI 10.1038/35036069; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	57	80	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24232	24242		10.1074/jbc.M203345200	http://dx.doi.org/10.1074/jbc.M203345200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978799	hybrid			2022-12-27	WOS:000176611800035
J	Sekine, K; Hase, T; Sato, N				Sekine, K; Hase, T; Sato, N			Reversible DNA compaction by sulfite reductase regulates transcriptional activity of chloroplast nucleoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTIANA-TABACUM-L; DEPENDENT RNA-POLYMERASE; PROPLASTID-NUCLEI; CULTURED-CELLS; MOLECULAR CHARACTERIZATION; ENVELOPE MEMBRANE; PLASTID NUCLEOIDS; ESCHERICHIA-COLI; BINDING PROTEIN; PEND PROTEIN	The transcriptional activity of nucleoids changes during plastid development, presumably due to the morphological and molecular differences of the nucleoids. Pea chloroplast nucleoids have an abundant 70-kDa protein identified as sulfite reductase (SiR) that can compact DNA. Using an in vitro transcription assay, we show here that heparin increased the transcriptional activity of chloroplast nucleoids with concomitant release of SiR. Using a fluorometric method we developed for analyzing DNA compaction, we found that the fluorescence intensity of chloroplast DNA stained with 4',6-diamidino-2-phenylindole was decreased by the addition of SiR and increased by the subsequent addition of heparin. Addition of exogenous SiR increased the compaction of isolated nucleoids, and the addition of heparin relaxed it. SiR effectively repressed the in vitro transcription activity of nucleoids and counteracted the activation by heparin. These results suggest that SiR regulates the transcriptional activity of chloroplast nucleoids through changes in DNA compaction.	Saitama Univ, Fac Sci, Dept Mol Biol, Saitama, Saitama 3388570, Japan; Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Saitama University; Osaka University	Sato, N (corresponding author), Saitama Univ, Fac Sci, Dept Mol Biol, 255 Shimo Ohkubo, Saitama, Saitama 3388570, Japan.	naokisat@molbiol.saitama-u.ac.jp	Hase, Toshiharu/H-9271-2013	Sato, Naoki/0000-0001-6230-0410				Allison LA, 2000, BIOCHIMIE, V82, P537, DOI 10.1016/S0300-9084(00)00611-8; Baba K, 2001, PLANT PHYSIOL, V125, P595, DOI 10.1104/pp.125.2.595; BLINGLY M, 2000, EMBO J, V19, P1851; BRIAT JF, 1980, EUR J BIOCHEM, V111, P503, DOI 10.1111/j.1432-1033.1980.tb04966.x; Cannon GC, 1999, PLANT MOL BIOL, V39, P835, DOI 10.1023/A:1006135615924; Frenkiel-Krispin D, 2001, EMBO J, V20, P1184, DOI 10.1093/emboj/20.5.1184; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Ideguchi T, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P713; KADESCH TR, 1980, J MOL BIOL, V136, P79, DOI 10.1016/0022-2836(80)90367-8; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; KUROIWA T, 1991, INT REV CYTOL, V128, P1; MADON J, 1983, EUR J BIOCHEM, V135, P279, DOI 10.1111/j.1432-1033.1983.tb07649.x; MARRISON JL, 1992, PLANT J, V2, P783, DOI 10.1111/j.1365-313X.1992.tb00147.x; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; McLeod SM, 2001, CURR OPIN MICROBIOL, V4, P152, DOI 10.1016/S1369-5274(00)00181-8; Murakami S, 2000, FEBS LETT, V468, P15, DOI 10.1016/S0014-5793(00)01186-8; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; NEMOTO Y, 1990, PLANT CELL PHYSIOL, V31, P767; NEMOTO Y, 1989, PLANT CELL PHYSIOL, V30, P445; NEMOTO Y, 1988, PLANT CELL PHYSIOL, V29, P167; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Ringrose L, 2001, NATURE, V412, P493, DOI 10.1038/35087692; Sakai A, 1998, PLANT CELL PHYSIOL, V39, P928, DOI 10.1093/oxfordjournals.pcp.a029456; SAKAI A, 1991, PLANT CELL PHYSIOL, V32, P835; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Sato N, 1999, BIOCHIMIE, V81, P619, DOI 10.1016/S0300-9084(99)80119-9; Sato N, 2001, NUCLEIC ACIDS RES, V29, P2244, DOI 10.1093/nar/29.11.2244; Sato N, 2001, TRENDS PLANT SCI, V6, P151, DOI 10.1016/S1360-1385(01)01888-X; Sato N, 1998, PLANT CELL, V10, P859, DOI 10.1105/tpc.10.5.859; SATO N, 1993, EMBO J, V12, P555, DOI 10.1002/j.1460-2075.1993.tb05687.x; Sato N, 1997, PROTOPLASMA, V200, P163, DOI 10.1007/BF01283292; Sato N, 2001, FEBS LETT, V487, P347, DOI 10.1016/S0014-5793(00)02342-5; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; Wolffe AP, 2001, CELL, V104, P631, DOI 10.1016/S0092-8674(02)01453-8; Yonekura-Sakakibara K, 1998, J BIOCHEM, V124, P615, DOI 10.1093/oxfordjournals.jbchem.a022156; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010	38	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24399	24404		10.1074/jbc.M201714200	http://dx.doi.org/10.1074/jbc.M201714200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11997391	hybrid			2022-12-27	WOS:000176611800057
J	Virumae, K; Saarma, U; Horowitz, J; Remme, J				Virumae, K; Saarma, U; Horowitz, J; Remme, J			Functional importance of the 3 '-terminal adenosine of tRNA in ribosomal translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA BINDING; UNMODIFIED TRANSFER-RNA; ELONGATION-FACTOR TU; A-SITE; 3'-CCA END; P-SITE; TRANSLOCATION; NUCLEOTIDES; 3'-END	The, universally conserved T-terminal CCA sequence of tRNA interacts with large ribosomal subunit RNA during translation. The functional importance of the interaction between the T-terminal nucleotide of tRNA and the ribosome was studied in vitro using mutant in vitro transcribed tRNA(Val) A76G. Val-tRNA(CCG)., does not support polypeptide synthesis on poly(GUA) as a message. However, in a co-translation system, where Val-tRNA(CCG), represented only a small fraction of total Val-tRNA(CCG) the mutant tRNA is able to transfer valine into a polypeptide chain, albeit at a reduced level. The A76G mutation does not affect binding of Val- or NAcVal-tRNA(CCG) to the A- or P-sites as shown by efficient peptide bond formation, although the donor activity of the mutant NAcVal-tRNA(CCG) in the peptidyl transfer reaction is slightly reduced compared with wild-type NAeVal-tRNA. Translocation of 3'-CCG-tRNA from the P-to the E-site is not significantly influenced. However, the A76G mutation drastically inhibits translocation of peptidyl-tRNA G 76 from the ribosomal A-site to the P-site, which apparently explains its failure to support cell-free protein synthesis. Our results indicate that the identity of the T-terminal nucleotide of tRNA is critical for tRNA movement in the ribosome.	Univ Tartu, Inst Mol & Cell Biol, EE-51010 Tartu, Estonia; Estonian Bioctr, EE-51010 Tartu, Estonia; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	University of Tartu; Estonian Biocentre; Iowa State University	Remme, J (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Riia 23, EE-51010 Tartu, Estonia.		Remme, Jaanus/A-4614-2011; Saarma, Urmas/AAC-9813-2019; Remme, Jaanus/L-1830-2019; Saarma, Urmas/J-6448-2015	Remme, Jaanus/0000-0002-4011-6580; Saarma, Urmas/0000-0002-3222-571X; Remme, Jaanus/0000-0002-4011-6580; Saarma, Urmas/0000-0002-3222-571X	FIC NIH HHS [TW00870] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; Bocchetta M, 2001, RNA, V7, P54, DOI 10.1017/S1355838201001650; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; BOURD SB, 1983, EUR J BIOCHEM, V135, P465, DOI 10.1111/j.1432-1033.1983.tb07674.x; CHLADEK S, 1985, ANGEW CHEM INT EDIT, V24, P371, DOI 10.1002/anie.198503711; CHU WC, 1989, NUCLEIC ACIDS RES, V17, P7241, DOI 10.1093/nar/17.18.7241; CLAESSON C, 1990, FEBS LETT, V273, P173, DOI 10.1016/0014-5793(90)81077-2; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Feinberg JS, 2001, P NATL ACAD SCI USA, V98, P11120, DOI 10.1073/pnas.211184098; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAENNI AL, 1966, BIOCHIM BIOPHYS ACTA, V114, P135, DOI 10.1016/0005-2787(66)90261-9; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; Khaitovich P, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P229; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; Leder P, 1973, Adv Protein Chem, V27, P213, DOI 10.1016/S0065-3233(08)60448-9; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Liu JCH, 1998, RNA, V4, P639, DOI 10.1017/S1355838298980013; LIU MS, 1994, P NATL ACAD SCI USA, V91, P10389, DOI 10.1073/pnas.91.22.10389; LIU MS, 1993, BIOTECHNIQUES, V15, P264; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; NAZARENKO IA, 1994, EMBO J, V13, P2464, DOI 10.1002/j.1460-2075.1994.tb06531.x; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SAMUELSSON T, 1988, J BIOL CHEM, V263, P13692; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; Spahn CMT, 1996, J BIOL CHEM, V271, P32849, DOI 10.1074/jbc.271.51.32849; STRELTSOV S, 1979, FEBS LETT, V104, P279, DOI 10.1016/0014-5793(79)80832-7; TAMURA K, 1994, FEBS LETT, V353, P173, DOI 10.1016/0014-5793(94)01038-2; TAMURA K, 1994, J BIOL CHEM, V269, P22173; TEZUKA M, 1990, BIOCHEMISTRY-US, V29, P667, DOI 10.1021/bi00455a011; WAGNER T, 1983, BIOCHEMISTRY-US, V22, P94, DOI 10.1021/bi00270a013; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; Wower J, 2000, J BIOL CHEM, V275, P37887, DOI 10.1074/jbc.M005031200; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	43	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24128	24134		10.1074/jbc.M200393200	http://dx.doi.org/10.1074/jbc.M200393200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967262	hybrid			2022-12-27	WOS:000176611800021
J	Desmyter, A; Spinelli, S; Payan, F; Lauwereys, M; Wyns, L; Muyldermans, S; Cambillau, C				Desmyter, A; Spinelli, S; Payan, F; Lauwereys, M; Wyns, L; Muyldermans, S; Cambillau, C			Three Camelid VHH domains in complex with porcine pancreatic alpha-amylase - Inhibition and versatility of binding topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANTIBODY FRAGMENT; LOOP STRUCTURES; RECOGNITION; ENZYME; IMMUNOGLOBULINS; CONFORMATIONS	Camelids produce functional antibodies devoid of light chains and CH1 domains. The antigen-binding fragment of such heavy chain antibodies is therefore comprised in one single domain, the camelid heavy chain antibody VH (VHH). Here we report on the structures of three dromedary VHH domains in complex with porcine pancreatic a-amylase. Two VHHs bound outside the catalytic site and did not inhibit or inhibited only partially the amylase activity. The third one, AMD9, interacted with the active site crevice and was a strong amylase inhibitor (K-i = 10 nM). In contrast with complexes of other proteinaceous amylase inhibitors, amylase kept its native structure. The water-accessible surface areas of VHHs covered by amylase ranged between 850 and 1150 Angstrom(2), values similar to or even larger than those observed in the complexes between proteins and classical antibodies. These values could certainly be reached because a surprisingly high extent of framework residues are involved in the interactions of VHHs with amylase. The framework residues that participate in the antigen recognition represented 25-40% of the buried surface. The inhibitory interaction of AMD9 involved mainly its complementarity-determining region (CDR) 2 loop, whereas the CDR3 loop was small and certainly did not protrude as it does in cAb-Lys3, a VHH-inhibiting lysozyme. AMD9 inhibited amylase, although it was outside the direct reach of the catalytic residues; therefore it is to be expected that inhibiting VHHs might also be elicited against proteases. These results illustrate the versatility and efficiency of VHH domains as protein binders and enzyme inhibitors and are arguments in favor of their use as drugs against diabetes.	Free Univ Brussels VIB, B-1640 Rhode St Genese, Belgium; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CNRS, UMR 60998, Architecture & Fonct Macromol Biol, F-13402 Marseille 20, France	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Muyldermans, S (corresponding author), Free Univ Brussels VIB, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	svmuylde@vub.ac.be; cambillau@afmb.cnrs-mrs.fr	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1998, SPOCK CTR MACROMOLEC; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Decanniere K, 2000, J MOL BIOL, V300, P83, DOI 10.1006/jmbi.2000.3839; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Kabat EA, 1991, US PUBLIC HLTH SERVI; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MINXIE Q, 1993, J MOL BIO, V231, P785; MINXIE Q, 1994, BIOCHEMISTRY-US, V33, P6284; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nguyen VK, 1999, MOL IMMUNOL, V36, P515, DOI 10.1016/S0161-5890(99)00067-X; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V81, P77; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Spinelli S, 2000, BIOCHEMISTRY-US, V39, P1217, DOI 10.1021/bi991830w; Spinelli S, 2001, J MOL BIOL, V311, P123, DOI 10.1006/jmbi.2001.4856; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; Woolven BP, 1999, IMMUNOGENETICS, V50, P98, DOI 10.1007/s002510050694	33	138	153	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23645	23650		10.1074/jbc.M202327200	http://dx.doi.org/10.1074/jbc.M202327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960990	hybrid			2022-12-27	WOS:000176475700071
J	Drachman, JG; Miyakawa, Y; Luthi, JN; Dahlen, DD; Raney, A; Geddis, AE; Kaushansky, K				Drachman, JG; Miyakawa, Y; Luthi, JN; Dahlen, DD; Raney, A; Geddis, AE; Kaushansky, K			Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; THROMBOPOIETIN SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; KINASE ACTIVATION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; FUNCTIONAL-ANALYSIS; C-MYC; ERYTHROPOIETIN RECEPTOR; SHC PHOSPHORYLATION	The thrombopoietin (TPO) receptor c-Mpl, like other members of the cytokine receptor superfamily, requires the association and activation of Janus kinases (JAKs) for normal signal transduction. The membrane-proximal portion of the signaling domain, containing conserved box1 and box2 motifs, is sufficient to support the proliferation of cytokine-dependent cell lines and basal megakaryocytopoiesis in vivo. We hypothesized that activation of the JAK2 kinase alone might be sufficient for proliferative signaling. To test this premise, we constructed chimeric receptors in which the extracellular and transmembrane portions of Mpl were fused to the pseudokinase and kinase domains of murine JAK2 kinase. When expressed in the interleukin-3-dependent cell line Ba/F3, the chimeric receptors were appropriately expressed on the cell surface and were able to initiate tyrosine kinase activity upon exposure to TPO. However, chimeric receptors lacking an intact box2 domain of Mpl were unable to support proliferation at any concentration of TPO. Only chimeric receptors containing both JAK2 kinase activity and the box2 region initiated proliferative signaling. Within the box2 motif, we determined that the sequence Glu(56)-Ile(57)-Leu(58) of the Mpl cytoplasmic domain is critical for proliferation of the chimeric receptors. Furthermore, TPO-dependent induction of c-myc transcription is also dependent on this motif. These results indicate that JAK2 activation alone is not sufficient for TPO-induced proliferation and that one or more essential signaling pathways must arise from the cytoplasmic domain of Mpl that includes box2. Although the nature of the signal transduction pathway is not yet known, this second proliferative event is likely to regulate c-myc expression.	Puget Sound Blood Ctr, Seattle, WA 98104 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Puget Sound Blood Center; University of Washington; University of Washington Seattle	Drachman, JG (corresponding author), Puget Sound Blood Ctr, 921 Terry Ave, Seattle, WA 98104 USA.				NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003498, R01HL065498] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA31615] Funding Source: Medline; NHLBI NIH HHS [R01 HL65498, K08 HL03498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BENIT L, 1994, J VIROL, V68, P5270; Bondurant MC, 1996, J CELL PHYSIOL, V168, P255, DOI 10.1002/(SICI)1097-4652(199608)168:2<255::AID-JCP4>3.0.CO;2-O; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Dahlen DD, 2000, BLOOD, V96, p571A; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Kaushansky K, 1999, BIOESSAYS, V21, P353, DOI 10.1002/(SICI)1521-1878(199904)21:4<353::AID-BIES12>3.0.CO;2-P; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Porteu F, 1996, MOL CELL BIOL, V16, P2473; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sayeski PP, 1999, CIRC RES, V84, P1332, DOI 10.1161/01.RES.84.11.1332; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; Thompson A, 1996, J BIOL CHEM, V271, P22976, DOI 10.1074/jbc.271.38.22976; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	45	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23544	23553		10.1074/jbc.M201120200	http://dx.doi.org/10.1074/jbc.M201120200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980901	hybrid			2022-12-27	WOS:000176475700059
J	Fujitani, N; Kawabata, S; Osaki, T; Kumaki, Y; Demura, M; Nitta, K; Kawano, K				Fujitani, N; Kawabata, S; Osaki, T; Kumaki, Y; Demura, M; Nitta, K; Kawano, K			Structure of the antimicrobial peptide tachystatin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAB TACHYPLEUS-TRIDENTATUS; 3-DIMENSIONAL SOLUTION STRUCTURE; CELLULOSE-BINDING DOMAIN; BOVINE NEUTROPHILS; CLOTTING FACTORS; BETA-DEFENSINS; HEMOCYTES; PROTEINS; SPECTROSCOPY; MOTIF	The solution structure of antimicrobial peptide tachystatin A from the Japanese horseshoe crab (Tachypleus tridentatus) was determined by two-dimensional nuclear magnetic resonance measurements and distance-restrained simulated annealing calculations. The correct pairs of disulfide bonds were also confirmed in this study. The obtained structure has a cysteine-stabilized triple-stranded beta-sheet as a dominant secondary structure and shows an amphiphilic folding observed in many membrane-interactive peptides. Interestingly, tachystatin A shares structural similarities with the calcium channel antagonist omega-agatoxin IVA isolated from spider toxin and mammalian defensins, and we predicted that omega-agatoxin IVA also have the antifungal activity. These structural comparisons and functional correspondences suggest that tachystatin A and omega-agatoxin IVA may exert the antimicrobial activity in a manner similar to defensins, and we have confirmed such activity using fungal culture assays. Furthermore, tachystatin A is a chitin-binding peptide, and omega-agatoxin IVA also showed chitin-binding activities in this study. Tachystatin A and omega-agatoxin IVA showed no structural homology with well known chitin-binding motifs, suggesting that their structures belong to a novel family of chitin-binding peptides. Comparison of their structures with those of cellulose-binding proteins indicated that Phe(9) of tachystatin A might be an essential residue for binding to chitin.	Hokkaido Univ, Div Biol Sci, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan; Kyushu Univ, Dept Mol Biol, Grad Sch Med Sci, Fukuoka 8128582, Japan; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1010062, Japan	Hokkaido University; Kyushu University; Kyushu University; University of Toyama; Japan Science & Technology Agency (JST)	Nitta, K (corresponding author), Hokkaido Univ, Div Biol Sci, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan.		Demura, Makoto/F-5272-2011; Kawano, Keiichi/F-5265-2011; Fujitani, Naoki/A-4072-2012	Demura, Makoto/0000-0003-0912-9284; Osaki, Tsukasa/0000-0002-9487-3253; Fujitani, Naoki/0000-0002-4035-7317				ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; Billeter M, 1995, J BIOMOL NMR, V5, P1; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; GRIESINGER C, 1985, J AM CHEM SOC, V107, P6394, DOI 10.1021/ja00308a042; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; Iwanaga S, 1998, J BIOCHEM, V123, P1; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KIM JI, 1995, J MOL BIOL, V250, P659, DOI 10.1006/jmbi.1995.0406; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRISHNAN A, 1994, J BIOL CHEM, V269, P20971; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; Nagy T, 1998, FEBS LETT, V429, P312, DOI 10.1016/S0014-5793(98)00625-5; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Osaki T, 1999, J BIOL CHEM, V274, P26172, DOI 10.1074/jbc.274.37.26172; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGAN LJ, 1991, J NEUROSCI, V11, P2259; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	47	38	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23651	23657		10.1074/jbc.M111120200	http://dx.doi.org/10.1074/jbc.M111120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959852	hybrid			2022-12-27	WOS:000176475700072
J	Woulfe, D; Jiang, H; Mortensen, R; Yang, J; Brass, LF				Woulfe, D; Jiang, H; Mortensen, R; Yang, J; Brass, LF			Activation of Rap1B by G(i) family members in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE; G-PROTEIN; RECEPTOR; IDENTIFICATION; ADP; THROMBOEMBOLISM; INTEGRIN; SIGNAL; AGGREGATION; RESISTANCE	It has become increasingly appreciated that receptors coupled to Galpha(i) family members can stimulate platelet aggregation, but the mechanism for this has remained unclear. One possible mediator is the small GTPase, Rap1, which has been shown to contribute to integrin activation in several cell lines and to be activated by a calcium-dependent mechanism in platelets. Here, we demonstrate that Rap1 is also activated by Gai family members in platelets. First, we show that platelets from mice lacking the Gai family member Galpha(z) (which couples to the alpha(2A) adrenergic receptor) are deficient in epinephrine-stimulated Rap1 activation. We also show that platelets from mice lacking Galpha(i2), which couples to the ADP receptor, P2Y12, exhibit reduced Rap1 activation in response to ADP. In contrast, platelets from mice that lack Galpha(q) show no decrease in the ability to activate Rap1 in response to epinephrine but show a partial reduction in ADP-stimulated Rap1 activation. This result, combined with studies of human platelets treated with ADP` receptor-selective inhibitors, indicates that ADP-stimulated Rap1 activation in human platelets is dependent on both the Galpha(i)-coupled P2Y12 receptor and the Galpha(q)-coupled P2Y1 receptor. Galpha(i)-dependent activation of Rap1 in platelets does not appear to be mediated by enhanced intracellular calcium release because no increase in intracellular calcium concentration was detected in response to epinephrine and because the calcium response to ADP` was not diminished in platelets from the Galpha(12)-/- mouse. Finally, using human platelets treated with selective inhibitors of phosphatidylinositol 3-kinase (PI3K) and mouse platelets selectively lacking the Goy-activated form of his enzyme (PI3Kgamma), we show that G(i)-mediated Rap1 activation is PI3K-dependent. In summary, activation of Rap1 can be stimulated by G(q)- and PI3K-dependent mechanisms in platelets and by G(q)- and Ca2+-dependent mechanisms, both of which may play a role in promoting platelet activation.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Michigan, Dept Physiol & Med Endocrine, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan	Brass, LF (corresponding author), Univ Penn, Dept Med, Rm 913 BRB-II,421 Curie Blvd, Philadelphia, PA 19104 USA.	Brass@mail.med.upenn.edu			NHLBI NIH HHS [HL-45181, HL-40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL045181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTONI A, 2002, IN PRESS J BIOL CHEM, V277; Brass LF, 1999, J CLIN INVEST, V104, P1663, DOI 10.1172/JCI8944; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Daniel JL, 1999, THROMB HAEMOSTASIS, V82, P1322; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gabbeta J, 1997, P NATL ACAD SCI USA, V94, P8750, DOI 10.1073/pnas.94.16.8750; GAGNON AW, 1991, BLOOD, V78, P1247; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kauffenstein G, 2001, FEBS LETT, V505, P281, DOI 10.1016/S0014-5793(01)02824-1; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Koziak K, 2001, BRIT J HAEMATOL, V114, P134, DOI 10.1046/j.1365-2141.2001.02894.x; Larson MK, 2001, BLOOD, V98, p751A; Leon C, 2001, CIRCULATION, V103, P718; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; MARTI KB, 1992, P NATL ACAD SCI USA, V89, P2784, DOI 10.1073/pnas.89.7.2784; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Nagano T, 2000, J NEUROCHEM, V75, P1, DOI 10.1046/j.1471-4159.2000.0750001.x; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; WILLIAMS AG, 1990, BLOOD, V76, P721; Woulfe D, 2001, J CLIN INVEST, V107, P1503, DOI 10.1172/JCI13361; WOULFE D, 2002, IN PRESS PLATELETS; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	36	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23382	23390		10.1074/jbc.M202212200	http://dx.doi.org/10.1074/jbc.M202212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970953	hybrid			2022-12-27	WOS:000176475700038
J	Kiely, PA; Sant, A; O'Connor, R				Kiely, PA; Sant, A; O'Connor, R			RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; MOTIF-CONTAINING PROTEIN; KINASE-C; TYROSINE-PHOSPHATASE; BETA-SUBUNIT; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; RESISTANCE; APOPTOSIS; SRC	The insulin receptor and insulin-like growth factor 1 receptor UGF-1R), activated by their ligands, control metabolism, cell survival, and proliferation. Although the signaling pathways activated by these receptors are well characterized, regulation of their activity is poorly understood. To identify regulatory proteins we undertook a two-hybrid screen using the IGF-1R beta-chain as bait. This screen identified Receptor for Activated C Kinases (RACK1) as an IGF-1R-interacting protein. RACK1 also interacted with the IGF-1R in fibroblasts and MCF-7 cells and with endogenous insulin receptor in COS cells. Interaction with the IGF-1R did not require tyrosine kinase activity or receptor autophosphorylation but did require serine 1248 in the C terminus. Overexpression of RACK1 in either R+ fibroblasts or MCF-7 cells inhibited IGF-1-induced phosphorylation of Akt, whereas it enhanced phosphorylation of Erks and Jnks. Src, the p85 subunit of phosphatidylinositol 3-kinase, and SHP-2 were all associated with RACK1 in these cells. Interestingly, the proliferation of MCF-7 cells was enhanced by overexpression of RACK1, whereas IGF-1-mediated protection from etoposide killing was greatly reduced. Altogether the data indicate that RACK1 is an IGF-1R-interacting protein that can modulate receptor signaling and suggest that RACK1 has a particular role in regulating Akt activation and cell survival.	Natl Univ Ireland, Dept Biochem, Cell Biol Lab, Lee Maltings Cork, Ireland; Natl Univ Ireland, Inst Biosci, Lee Maltings Cork, Ireland; ImmunoGen Inc, Cambridge, MA 02139 USA	ImmunoGen, Inc.	O'Connor, R (corresponding author), Natl Univ Ireland, Dept Biochem, Cell Biol Lab, Lee Maltings Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Booth RA, 2002, J BIOL CHEM, V277, P6719, DOI 10.1074/jbc.M108033200; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hongo A, 1996, ONCOGENE, V12, P1231; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; Ligensa T, 2001, J BIOL CHEM, V276, P33419, DOI 10.1074/jbc.M104509200; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Liu YM, 1998, CANCER RES, V58, P570; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Morrione A, 1996, CANCER RES, V56, P3165; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; O'Connor Rosemary, 1998, V62, P137; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Resnicoff M, 1998, INT J MOL MED, V1, P883; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Siddle K, 2001, BIOCHEM SOC T, V29, P513, DOI 10.1042/BST0290513; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Urso B, 1999, FEBS LETT, V460, P423, DOI 10.1016/S0014-5793(99)01388-5; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Venkatesan AM, 2001, RECENT PROG HORM RES, V56, P295, DOI 10.1210/rp.56.1.295; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Zabolotny JM, 2001, P NATL ACAD SCI USA, V98, P5187, DOI 10.1073/pnas.071050398; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	60	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22581	22589		10.1074/jbc.M201758200	http://dx.doi.org/10.1074/jbc.M201758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11964397	hybrid			2022-12-27	WOS:000176313600064
J	Lin, AP; McAlister-Henn, L				Lin, AP; McAlister-Henn, L			Isocitrate binding at two functionally distinct sites in yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BRANCH POINT; MOLECULAR-CLONING; SUBUNIT STRUCTURE; KINETIC-ANALYSIS; PHOSPHORYLATION; ENZYME; EXPRESSION	Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an octamer containing two types of homologous subunits. Ligand-binding analyses were conducted to examine effects of residue changes in putative catalytic and regulatory isocitrate-binding sites respectively contained in IDH2 and IDH1 subunits. Replacement of homologous serine residues in either subunit site, S98A in IDH2 or S92A in IDH1, was found to reduce by half the total number of holoenzyme isocitrate-binding sites, confirming a correlation between detrimental effects on isocitrate binding and respective kinetic defects in catalysis and allosteric activation by AMP. Replacement of both serine residues eliminates isocitrate binding and measurable catalytic activity. The putative isocitrate-binding sites of IDH1 and IDH2 contain five identical and four nonidentical residues. Reciprocal replacement of the four nonidentical residues in either or both subunits (A108R, F136Y, T241D, and N245D in IDH1 and/or R114A, Y142F, D248T, and D252N in IDH2) was found to be permissive for isocitrate binding. This provides further evidence for two types of binding sites in IDH, although the authentic residues have been shown to be necessary for normal kinetic contributions. Finally, the mutant enzymes with residue replacements in the IDH1 site were found to be unable to bind AMP, suggesting that allosteric activation is dependent both upon binding of isocitrate at the IDH1 site and upon the changes in the enzyme normally elicited by this binding.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; BURKE WF, 1974, BIOCHIM BIOPHYS ACTA, V351, P333, DOI 10.1016/0005-2795(74)90196-2; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; Huh TL, 1997, FASEB J, V11, pA892; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; ILLINGWORTH JA, 1972, BIOCHEM J, V129, P1119, DOI 10.1042/bj1291119; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; NICHOLS BJ, 1995, BIOCHEM J, V310, P917, DOI 10.1042/bj3100917; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Panisko E.A., 2000, THESIS U TEXAS SAN A; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; RABIN BR, 1967, BIOCHEM J, V102, pC22, DOI 10.1042/bj1020022C; REEVES HC, 1972, BIOCHIM BIOPHYS ACTA, V258, P27, DOI 10.1016/0005-2744(72)90964-3; RICARD J, 1974, EUR J BIOCHEM, V49, P195, DOI 10.1111/j.1432-1033.1974.tb03825.x; Rice DW, 1997, J MOL BIOL, V267, P1026, DOI 10.1006/jmbi.1997.0924; ROST B, 1995, 3 INT C INT SYST MOL, P314; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; WALSH K, 1984, J BIOL CHEM, V259, P9646; WALSH K, 1985, J BIOL CHEM, V260, P8430; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811	39	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22475	22483		10.1074/jbc.M202534200	http://dx.doi.org/10.1074/jbc.M202534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953438	hybrid			2022-12-27	WOS:000176313600049
J	Agellon, LB; Drover, VAB; Cheema, SK; Gbaguidi, GF; Walsh, A				Agellon, LB; Drover, VAB; Cheema, SK; Gbaguidi, GF; Walsh, A			Dietary cholesterol fails to stimulate the human cholesterol 7 alpha-hydroxylase gene (CYP7A1) in transgenic mice.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; RECEPTOR LXR-ALPHA; BILE-ACID BIOSYNTHESIS; THYROID-HORMONE; HYPOPHYSECTOMIZED RATS; NUCLEAR RECEPTORS; PATHWAY; EXPRESSION; LIVER; MOUSE	Dietary cholesterol has been shown to have a stimulatory effect on the murine cholesterol 7alpha-hydroxylase gene (Cyp7a1), but its effect on human cholesterol 7alpha-hydroxylase gene (CYP7A1) expression in vivo is not known. A transgenic mouse strain harboring the human CYP7A1 gene and homozygous for the disrupted murine Cyp7a1 gene was created. Cholesterol feeding increased the expression of the endogenous modified Cyp7a1 allele but failed to stimulate the human CYP7A1 transgene. In transfected hepatoma cells, 25-hydroxycholesterol increased murine Cyp7a1 gene promoter activity, whereas the human CYP7A1 gene promoter was unresponsive. Electrophoretic mobility shift assays demonstrated the interaction of the liver X receptor alpha (LXRalpha): retinoid X receptor (RXR) heterodimer, a transcription factor complex that is activated by oxysterols, with the murine Cyp7a1 gene promoter, whereas no binding to the human CYP7A1 gene promoter was detected. The results demonstrate that the human CYP7A1 gene is not stimulated by dietary cholesterol in the intact animal, and this is attributable to the inability of the CYP7A1 gene promoter to interact with LXRalpha:RXR.	Univ Alberta, Heritage Med Res Ctr 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	University of Alberta; University of Alberta; Rockefeller University	Agellon, LB (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada.							Agellon LB, 1997, BIOCHEM CELL BIOL, V75, P255, DOI 10.1139/bcb-75-3-255; Agellon LB, 2000, BBA-MOL CELL BIOL L, V1486, P198, DOI 10.1016/S1388-1981(00)00057-3; Cheema SK, 2000, J BIOL CHEM, V275, P12530, DOI 10.1074/jbc.275.17.12530; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Drover VAB, 2002, MOL ENDOCRINOL, V16, P14, DOI 10.1210/me.16.1.14; Goodart SA, 1999, BIOCHEM BIOPH RES CO, V266, P454, DOI 10.1006/bbrc.1999.1799; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; NESS GC, 1994, BBA-LIPID LIPID MET, V1214, P229, DOI 10.1016/0005-2760(94)90068-X; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Qiu Y, 2001, GENOMICS, V73, P66, DOI 10.1006/geno.2000.6467; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 2001, J LIPID RES, V42, P1594; Torchia EC, 1996, BIOCHEM BIOPH RES CO, V225, P128, DOI 10.1006/bbrc.1996.1141; WOOD TG, 1984, P NATL ACAD SCI USA, V24, P7817	24	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20131	20134		10.1074/jbc.C200105200	http://dx.doi.org/10.1074/jbc.C200105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11967256	hybrid			2022-12-27	WOS:000176204500006
J	Tasumi, S; Ohira, T; Kawazoe, I; Suetake, H; Suzuki, Y; Aida, K				Tasumi, S; Ohira, T; Kawazoe, I; Suetake, H; Suzuki, Y; Aida, K			Primary structure and characteristics of a lectin from skin mucus of the Japanese eel Anguilla japonica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION DOMAIN; AMINO-ACID-SEQUENCE; C-TYPE LECTINS; CONGER-MYRIASTER; ANIMAL LECTINS; SERINE-PROTEASE; PURIFICATION; COMPLEMENT; GALECTINS	Two types of lactose-binding lectins, AJL-1 and AJL-2, were purified from the skin mucus extract of the Japanese eel Anguilla japonica by lactose,affinity chromatography and subsequent gel filtration. The molecular masses of AJL-1 and AJL-2 were 16,091 and 31,743 Da, respectively. Intact AJL-1 was comprised of two identical 16-kDa subunits having blocked N termini and no disulfide bonds. AJL-2 was a homodimer with, disulfide bonds. Based on the N-terminal amino acid sequence of the AJL-2 monomer, the nucleotide sequence of cDNA encoding this lectin was determined by 3'- and 5'-rapid amplification of cDNA ends. The deduced amino acid sequence showed similar to30% homology with C-type lectins, which bind to carbohydrates in a Ca2+-dependent manner. In addition, AJL-2 exhibited highly conserved consensus amino acid residues of the C-type carbohydrate recognition domain, although this lectin showed Ca2+ independent activity. Gene expression of AJL-2 was detected only in the skin by Northern blot analysis, and this lectin localization was demonstrated in the club cells by immunohistochemistry. These results indicate that AJL-2 is secreted on the body surface and function as a component of skin mucus. AJL-2 agglutinated Escherichia coli and suppressed its growth, suggesting that this lectin is involved in host defense.	Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan; Univ Tokyo, Grad Sch Agr & Agr Life Sci, Dept Aquat Biosci, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Suzuki, Y (corresponding author), Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan.			Tasumi, Satoshi/0000-0003-3047-6942				ALHASSAN JM, 1986, COMP BIOCHEM PHYS B, V85, P31, DOI 10.1016/0305-0491(86)90217-8; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; GIGA Y, 1987, J BIOL CHEM, V262, P6197; GOTONANCE R, 1995, FISHERIES SCI, V61, P137, DOI 10.2331/fishsci.61.137; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P2320; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; JI YH, 1993, J IMMUNOL, V150, P571; KAMIYA H, 1988, DEV COMP IMMUNOL, V12, P309, DOI 10.1016/0145-305X(88)90007-9; KAMIYA H, 1980, BIOCHIM BIOPHYS ACTA, V622, P171, DOI 10.1016/0005-2795(80)90028-8; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIM BL, 1994, J BIOL CHEM, V269, P11820; MALHOTRA R, 1990, BIOCHEM SOC T, V18, P1145, DOI 10.1042/bst0181145; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Muramoto K, 1999, COMP BIOCHEM PHYS B, V123, P33, DOI 10.1016/S0305-0491(99)00037-1; MURAMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1116, P129, DOI 10.1016/0304-4165(92)90109-8; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SASTRY K, 1991, J IMMUNOL, V147, P692; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; SHIOMI K, 1990, NIPPON SUISAN GAKK, V56, P119; SHIOMI K, 1989, COMP BIOCHEM PHYS B, V92, P255, DOI 10.1016/0305-0491(89)90275-7; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; SUZUKI Y, 1985, Nippon Suisan Gakkaishi, V51, P2083; SUZUKI Y, 1986, DEV COMP IMMUNOL, V10, P509, DOI 10.1016/0145-305X(86)90172-2; TAKAMATSU N, 1993, GENE, V128, P251; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; TIFFOCHE C, 1993, EUR J BIOCHEM, V213, P901, DOI 10.1111/j.1432-1033.1993.tb17834.x; Toda M, 1996, FISHERIES SCI, V62, P138, DOI 10.2331/fishsci.62.138; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Yuasa HJ, 1998, COMP BIOCHEM PHYS B, V119, P479, DOI 10.1016/S0305-0491(98)00008-X	45	131	140	5	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27305	27311		10.1074/jbc.M202648200	http://dx.doi.org/10.1074/jbc.M202648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11959866	hybrid			2022-12-27	WOS:000177055900078
J	Gelebart, P; Kovacs, T; Brouland, JP; van Gorp, R; Grossmann, J; Rivard, N; Panis, Y; Martin, V; Bredoux, R; Enouf, J; Papp, B				Gelebart, P; Kovacs, T; Brouland, JP; van Gorp, R; Grossmann, J; Rivard, N; Panis, Y; Martin, V; Bredoux, R; Enouf, J; Papp, B			Expression of endomembrane calcium pumps in colon and gastric cancer cells - Induction of SERCA3 expression during differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; HISTONE DEACETYLASE INHIBITORS; RETICULUM CA2+-ATPASE-3 GENE; MESSENGER-RNA LEVELS; LARGE-BOWEL CANCER; CHAIN FATTY-ACIDS; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; DIETARY FIBER	Calcium mobilization from the endoplasmic reticulum (ER) into the cytosol is a key component of several signaling networks controlling tumor cell growth, differentiation, or apoptosis. Sarco/endoplasmic reticulum calcium transport ATPases (SERCA-type calcium pumps), enzymes that accumulate calcium in the ER, play an important role in these phenomena. We report that SERCA3 expression is significantly reduced or lost in colon carcinomas when compared with normal colonic epithelial cells, which express this enzyme at a high level. To study the involvement of SERCA enzymes in differentiation, in this work differentiation of colon and gastric cancer cell lines was initiated, and the change in the expression of SERCA isoenzymes as well as intracellular calcium levels were investigated. Treatment of the tumor cells with butyrate or other established differentiation inducing agents resulted in a marked and specific induction of the expression of SERCA3, whereas the expression of the ubiquitous SERCA2 enzymes did not change significantly or was reduced. A similar marked increase in SERCA3 expression was found during spontaneous differentiation of post-confluent Caco-2 cells, and this closely correlated with the induction of other known markers of differentiation. Analysis of the expression of the SERCA3 alternative splice isoforms revealed induction of all three known iso-SERCA3 variants (3a, 3b, and 3c). Butyrate treatment of the KATO-III gastric cancer cells led to higher resting cytosolic calcium concentrations and, in accordance with the lower calcium affinity of SERCA3, to diminished ER calcium content. These data taken together indicate a defect in SERCA3 expression in colon cancers as compared with normal colonic epithelium, show that the calcium homeostasis of the endoplasmic reticulum may be remodeled during cellular differentiation, and indicate that SERCA3 constitutes an interesting new differentiation marker that may prove useful for the analysis of the phenotype of gastrointestinal adenocarcinomas.	Hop Lariboisiere, U348 INSERM, IFR 6, F-75010 Paris, France; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hop Lariboisiere, Serv Anat Pathol, F-75010 Paris, France; Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany; Univ Sherbrooke, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Hop Lariboisiere, Serv Chirurg Gen & Digest, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Regensburg; University of Sherbrooke; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Papp, B (corresponding author), Hop Lariboisiere, U348 INSERM, IFR 6, 8 Rue Guy Patin, F-75010 Paris, France.	bela.papp@inserm.lrb.ap-hop-paris.fr	Gelebart, Pascal/AAI-1439-2020; Kovács, Tünde/O-6020-2017	Gelebart, Pascal/0000-0003-2434-8987; Kovács, Tünde/0000-0003-1064-2616; Papp, Bela/0000-0002-5025-3087; Brouland, Jean Philippe/0000-0003-3475-0101				ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; AVIRAM A, 1994, INT J CANCER, V56, P906, DOI 10.1002/ijc.2910560625; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Carroll RE, 2000, CELL GROWTH DIFFER, V11, P385; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Choe Gheeyong, 1997, Journal of Korean Medical Science, V12, P433; Conley BA, 1998, CLIN CANCER RES, V4, P629; Cooper GR, 1997, BIOCHEM J, V325, P601, DOI 10.1042/bj3250601; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gilon P, 1999, J BIOL CHEM, V274, P20197, DOI 10.1074/jbc.274.29.20197; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Golovina VK, 2000, GLIA, V31, P15, DOI 10.1002/(SICI)1098-1136(200007)31:1<15::AID-GLIA20>3.0.CO;2-H; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230; HAUCK W, 1991, CANCER RES, V51, P3526; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HEERDT BG, 1994, CANCER RES, V54, P3288; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; INESI G, 1994, J MEMBRANE BIOL, V141, P1; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kovacs T, 2001, BIOCHEM J, V358, P559, DOI 10.1042/0264-6021:3580559; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; KWANDUN W, 1995, AM J PHYSIOL, V269, pC775; Lacabaratz-Porret C, 2000, BIOCHEM J, V350, P723, DOI 10.1042/0264-6021:3500723; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; Launay S, 1997, J BIOL CHEM, V272, P10746; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Litvak DA, 2000, ANTICANCER RES, V20, P779; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Maier S, 2000, INT J CANCER, V88, P245; Mariadason JM, 2000, CANCER RES, V60, P4561; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; McConkey DJ, 2001, METHOD CELL BIOL, V66, P229; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Musashi M, 2000, INT J HEMATOL, V72, P12; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; PINTO M, 1983, BIOL CELL, V47, P323; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REPHAELI A, 1991, INT J CANCER, V49, P66, DOI 10.1002/ijc.2910490113; Sakai A, 2001, CANCER LETT, V168, P183, DOI 10.1016/S0304-3835(01)00531-6; SCHAEFER A, 1994, J BIOL CHEM, V269, P8786; Shack S, 1996, CLIN CANCER RES, V2, P865; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Wang YX, 2001, INT J ONCOL, V18, P617; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; Wu JT, 2001, AM J PHYSIOL-GASTR L, V280, pG482, DOI 10.1152/ajpgi.2001.280.3.G482; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; Zippel R, 2000, EXP CELL RES, V258, P403, DOI 10.1006/excr.2000.4937	87	108	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26310	26320		10.1074/jbc.M201747200	http://dx.doi.org/10.1074/jbc.M201747200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11986315	hybrid			2022-12-27	WOS:000176908700065
J	Puig, S; Lee, J; Lau, M; Thiele, DJ				Puig, S; Lee, J; Lau, M; Thiele, DJ			Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; MENKES-DISEASE PROTEIN; SACCHAROMYCES-CEREVISIAE; WILSON-DISEASE; MOLECULAR CHARACTERIZATION; SCHIZOSACCHAROMYCES-POMBE; IRON TRANSPORT; BINDING DOMAIN; EXPRESSION; CHAPERONE	The redox active metal copper is an essential cofactor in critical biological processes such as respiration, iron transport, oxidative stress protection, hormone production, and pigmentation. A widely conserved family of high affinity copper transport proteins (Ctr proteins) mediates copper uptake at the plasma membrane. However, little is known about Ctr protein topology, structure, and the mechanisms by which this class of transporters mediates high affinity copper uptake. In this report, we elucidate the topological orientation of the yeast Ctr1 copper transport protein. We show that a series of clustered methionine residues in the hydrophilic extracellular domain and an MXXXM motif in the second transmembrane domain are important for copper uptake but not for protein sorting and delivery to the cell surface. The conversion of these methionine residues to cysteine, by site-directed mutagenesis, strongly suggests that they coordinate to copper during the process of metal transport. Genetic evidence supports an essential role for cooperativity between monomers for the formation of an active Ctr transport complex. Together, these results support a fundamentally conserved mechanism for high affinity copper uptake through the Ctr proteins in yeast and humans.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	dthiele@umich.edu	Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NCI NIH HHS [1R24CA 86307] Funding Source: Medline; NIGMS NIH HHS [GM41840, GM62555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555, R01GM041840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Harrison MD, 1999, J BIOCHEM MOL TOXIC, V13, P93, DOI 10.1002/(SICI)1099-0461(1999)13:2<93::AID-JBT5>3.0.CO;2-3; HARTTER DE, 1988, SYNAPSE, V2, P412, DOI 10.1002/syn.890020408; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Peterson CW, 1996, FEBS LETT, V379, P85, DOI 10.1016/0014-5793(95)01492-6; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	56	304	314	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26021	26030		10.1074/jbc.M202547200	http://dx.doi.org/10.1074/jbc.M202547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11983704	hybrid			2022-12-27	WOS:000176908700027
J	Yieh, L; Hatzis, H; Kassavetis, G; Sandmeyer, SB				Yieh, L; Hatzis, H; Kassavetis, G; Sandmeyer, SB			Mutational analysis of the transcription factor IIIB-DNA target of Ty3 retroelement integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; POSITION-SPECIFIC INTEGRATION; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; PROMOTER ELEMENT; MULTIPLE ROLES; FACTOR-TFIIIB; U6 GENE; YEAST	The Ty3 retrovirus-like element inserts preferentially at the transcription initiation sites of genes transcribed by RNA polymerase 111. The requirements for transcription factor (TF) IIIC and TFIIIB in Ty3 integration into the two initiation sites of the U6 gene carried on pU6LboxB were previously examined. Ty3 integrates at low but detectable frequencies in the presence of TFIIIB subunits Brf1 and TATA-binding protein. Integration increases in the presence of the third subunit, Bdp1. TFIIIC is not essential, but the presence of TFIIIC specifies an orientation of TFIIIB for transcriptional initiation and directs integration to the U6 gene-proximal initiation site. In the current study, recombinant wild-type TATA-binding protein, wild type and mutant Brf1, and Bdp1 proteins and highly purified TFIIIC were used to investigate the roles of specific protein domains in Ty3 integration. The amino-terminal half of Brf1, which contains a TFIIB-like repeat, contributed more strongly than the carboxyl-terminal half of Brf1 to Ty3 targeting. Each half of Bdp1 split at amino acid 352 enhanced integration. In the presence of TFIIIB and TFIIIC, the pattern of integration extended downstream by several base pairs compared with the pattern observed in vitro in the absence of TFIIIC and in vivo, suggesting that TFIIIC may not be present on genes targeted by Ty3 in vivo. Mutations in Bdp1 that affect its interaction with TFIIIC resulted in TFIIIC-independent patterns of Ty3 integration. Brf1 zinc ribbon and Bdp1 internal deletion mutants that are competent for polymerase III recruitment but defective in promoter opening were competent for Ty3 integration irrespective of the state of DNA supercoiling. These results extend the similarities between the TFIIIB domains required for transcription and Ty3 integration and also reveal requirements that are specific to transcription.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego; University of California System; University of California San Diego	Sandmeyer, SB (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	sbsandme@uci.edu			NIGMS NIH HHS [GM18386, GM33281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033281, R37GM018386, R01GM018386] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Ausubel F., 1999, CURRENT PROTOCOLS MO; Aye M, 2001, MOL CELL BIOL, V21, P7839, DOI 10.1128/MCB.21.22.7839-7851.2001; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Connolly CM, 1997, FEBS LETT, V405, P305, DOI 10.1016/S0014-5793(97)00200-7; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Grove A, 2002, EMBO J, V21, P704, DOI 10.1093/emboj/21.4.704; Hahn S, 2000, GENE DEV, V14, P719; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KAISER MW, 1995, J BIOL CHEM, V270, P11398, DOI 10.1074/jbc.270.19.11398; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; Sandmeyer SB, 1996, CURR TOP MICROBIOL, V214, P261; SANDMEYER SB, 1982, P NATL ACAD SCI-BIOL, V79, P7674, DOI 10.1073/pnas.79.24.7674; SANDMEYER SB, 1988, NUCLEIC ACIDS RES, V16, P1499, DOI 10.1093/nar/16.4.1499; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Yieh L, 2000, J BIOL CHEM, V275, P29800, DOI 10.1074/jbc.M003149200	54	31	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25920	25928		10.1074/jbc.M202729200	http://dx.doi.org/10.1074/jbc.M202729200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994300	Green Published, hybrid			2022-12-27	WOS:000176908700015
J	Caohuy, H; Pollard, HB				Caohuy, H; Pollard, HB			Protein kinase C and guanosine triphosphate combine to potentiate calcium-dependent membrane fusion driven by annexin 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; GTP-GAMMA-S; PERMEABILIZED PC12 CELLS; RAT MAST-CELLS; GUANINE-NUCLEOTIDES; CATECHOLAMINE SECRETION; INSULIN-SECRETION; NEUROTRANSMITTER RELEASE; EXOCYTOTIC SECRETION; HUMAN-NEUTROPHILS	Exocytotic secretion is promoted by the concerted action of calcium, guanine nucleotide, and protein kinase C. We now show that the calcium-dependent membrane fusion activity of annexin 7 in vitro is further potentiated by the combined addition of guanine nucleotide and protein kinase C. The observed increment involves the simultaneous activation of annexin 7 by these two effectors. Guanosine triphosphate (GTP) and its non-hydrolyzable analogues optimally enhance the phosphorylation of annexin 7 by protein kinase C in vitro. Reciprocally, phosphorylation by protein kinase C significantly potentiates the binding and hydrolysis of GTP by annexin 7. Only protein kinase C-dependent phosphorylation has a significant positive effect on annexin 7 GTPase, although other protein kinases, including cAMP-dependent protein kinase, cGMP-dependent protein kinase, and pp60(c-src), have been shown to label the protein with high efficiency. In vivo, the ratio of bound GDP/GTP and phosphorylation of annexin 7 change in direct proportion to the extent of catecholamine release from chromaffin cells in response to stimulation by carbachol, or to inhibition by various protein kinase C inhibitors. These results thus lead us to hypothesize that annexin 7 may serve as a common site of action for calcium, guanine nucleotide, and protein kinase C in the exocytotic membrane fusion process in chromaffin cells.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Pollard, HB (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	hpollard@usuhs.mil						AHNERTHILGER G, 1992, BIOCHEM J, V284, P321, DOI 10.1042/bj2840321; AHNERTHILGER G, 1987, BIOCHEMISTRY-US, V26, P7842, DOI 10.1021/bi00398a046; BADER MF, 1989, J BIOL CHEM, V264, P16426; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BROCKLEHURST KW, 1985, BIOCHEM J, V228, P35, DOI 10.1042/bj2280035; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; BURNS AL, 1990, BIOCHEM SOC T, V18, P1118, DOI 10.1042/bst0181118; CAOHUY H, 2002, IN PRESS ANN NY ACAD; CARLIER MF, 1982, BIOCHEMISTRY-US, V21, P1215, DOI 10.1021/bi00535a017; CARROLL AG, 1990, J NEUROCHEM, V55, P930, DOI 10.1111/j.1471-4159.1990.tb04580.x; CHEEK TR, 1987, J BIOL CHEM, V262, P11663; CHINALI G, 1980, J BIOL CHEM, V255, P7455; CHURCHER Y, 1990, CELL REGUL, V1, P523, DOI 10.1091/mbc.1.7.523; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COORSSEN JR, 1990, CELL REGUL, V1, P1027, DOI 10.1091/mbc.1.13.1027; CREUTZ CE, 1982, J CELL BIOCHEM, V18, P87, DOI 10.1002/jcb.1982.240180108; DOLLY JO, 1994, SEMIN NEUROSCI, V6, P149; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FASANO O, 1982, J BIOL CHEM, V257, P3145; FUNG BKK, 1983, J BIOL CHEM, V258, P495; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HONG K, 1982, P NATL ACAD SCI-BIOL, V79, P4642, DOI 10.1073/pnas.79.15.4642; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; Hung CH, 1996, P NATL ACAD SCI USA, V93, P10797, DOI 10.1073/pnas.93.20.10797; Hung CH, 2001, J BIOL CHEM, V276, P12813, DOI 10.1074/jbc.M008482200; KNIGHT DE, 1985, FEBS LETT, V189, P345, DOI 10.1016/0014-5793(85)81053-X; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; Kumai T, 1998, JPN J PHARMACOL, V77, P205, DOI 10.1254/jjp.77.205; LILLIE TH, 1991, PHILOS T R SOC LOND, V336, P877; LILLIE THW, 1993, CIBA F SYMP, V176, P164; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NIR S, 1987, BIOCHIM BIOPHYS ACTA, V903, P309, DOI 10.1016/0005-2736(87)90221-5; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OETTING M, 1986, FEBS LETT, V208, P99, DOI 10.1016/0014-5793(86)81540-X; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; POLLARD HB, 1992, PROG BRAIN RES, V92, P247, DOI 10.1016/S0079-6123(08)61180-2; Proks P, 1996, J PHYSIOL-LONDON, V496, P255, DOI 10.1113/jphysiol.1996.sp021682; RAFFANIELLO RD, 1993, J BIOL CHEM, V268, P8491; REEVES J, 1968, J CELL PHYSL, V78, P49; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; Shono M, 1997, J CARDIOVASC PHARM, V30, P419, DOI 10.1097/00005344-199710000-00003; Sloan DC, 1997, BIOCHEM J, V328, P13; SMOLEN JE, 1989, CELL SIGNAL, V1, P471, DOI 10.1016/0898-6568(89)90032-6; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; SONTAG JM, 1992, EUR J NEUROSCI, V4, P98, DOI 10.1111/j.1460-9568.1992.tb00112.x; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; YANAGIHARA N, 1979, FEBS LETT, V105, P296, DOI 10.1016/0014-5793(79)80633-X	65	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25217	25225		10.1074/jbc.M202452200	http://dx.doi.org/10.1074/jbc.M202452200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994295	hybrid			2022-12-27	WOS:000176747000049
J	Drocourt, L; Ourlin, JC; Pascussi, JM; Maurel, P; Vilarem, MJ				Drocourt, L; Ourlin, JC; Pascussi, JM; Maurel, P; Vilarem, MJ			Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; RESPONSIVE ENHANCER MODULE; CYCLOSPORINE-A OXIDASE; CYTOCHROME-P450 GENES; 5'-FLANKING REGION; SIGNALING PATHWAY; DRUG-INTERACTIONS; PRIMARY CULTURES; INDUCTION	The fully active dihydroxylated metabolite of vitamin D-3 induces the expression of CYP3A4 and, to a lesser extent, CYP2B6 and CYP2C9 genes in normal differentiated primary human hepatocytes. Electrophoretic mobility shift assays and cotransfection in HepG2 cells using wild-type and mutated oligonucleotides revealed that the vitamin D receptor (VDR) binds and transactivates those xenobiotic-responsive elements (ER6, DR3, and DR4) previously identified in CYP3A4, CYP2B6, and CYP2C9 promoters and shown to be targeted by the pregnane X receptor (PXR) and/or the constitutive androstane receptor (CAR). Full VDR response of various CYP3A4 heterologous/homologous promoter-reporter constructs requires both the proximal ER6 and the distal DR3 motifs, as observed previously with rifampicin-activated PXR. Cotransfection of a CYP3A4 homologous promoter-reporter construct (including distal and proximal PXR-binding motifs) and of PXR or CAR expression vectors in HepG2 cells revealed the ability of these receptors to compete with VDR for transcriptional regulation of CYP3A4. In conclusion, this work suggests that VDR, PXR, and CAR control the basal and inducible expression of several CYP genes through competitive interaction with the same battery of responsive elements.	Inst Federatif Rech 24, INSERM, U128, CNRS, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vilarem, MJ (corresponding author), Inst Federatif Rech 24, INSERM, U128, CNRS, 1919 Route Mende, F-34293 Montpellier 05, France.	vilarem@falbala.erbm.cnrs-mop.fr	pascussi, jean marc/F-9311-2013	pascussi, jean marc/0000-0002-5168-5383				Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Auwerx J, 1999, CELL, V97, P161; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BRODIE MJ, 1982, CLIN PHARMACOL THER, V32, P525, DOI 10.1038/clpt.1982.197; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; BURGOSTRINIDAD M, 1986, BIOCHEMISTRY-US, V25, P2692, DOI 10.1021/bi00357a061; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P10; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P82; Carlberg C., 1997, P 10 INT VIT D WORKS, P268; D'Erasmo Emilio, 1998, Recenti Progressi in Medicina, V89, P529; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Freedman LP, 1999, J NUTR, V129, p581S, DOI 10.1093/jn/129.2.581S; Fujisawa K, 2000, J BIOCHEM-TOKYO, V127, P373, DOI 10.1093/oxfordjournals.jbchem.a022618; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P468; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; OHNUMA N, 1980, ARCH BIOCHEM BIOPHYS, V204, P387, DOI 10.1016/0003-9861(80)90047-8; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pascussi JM, 2001, EUR J BIOCHEM, V268, P6346, DOI 10.1046/j.0014-2956.2001.02540.x; Pascussi JM, 1999, BIOCHEM BIOPH RES CO, V260, P377, DOI 10.1006/bbrc.1999.0745; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; PICHARD L, 1992, MOL PHARMACOL, V41, P1047; SchmiedlinRen P, 1997, MOL PHARMACOL, V51, P741, DOI 10.1124/mol.51.5.741; Segura C, 1999, HISTOCHEM CELL BIOL, V112, P163, DOI 10.1007/s004180050403; Shany S, 2001, STEROIDS, V66, P319, DOI 10.1016/S0039-128X(00)00154-9; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557; Zhou ZF, 1997, J BIOL CHEM, V272, P8227, DOI 10.1074/jbc.272.13.8227	53	290	309	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25125	25132		10.1074/jbc.M201323200	http://dx.doi.org/10.1074/jbc.M201323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991950	hybrid			2022-12-27	WOS:000176747000038
J	Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC				Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC			The location of plastocyanin in vascular plant photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; FLASH ABSORPTION-SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; SYNECHOCYSTIS SP PCC-6803; PSI-H SUBUNIT; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; ELECTRON-TRANSFER; SYNECHOCOCCUS-ELONGATUS; CYTOCHROME C(6)	We have studied the binding sites of the electron donor and acceptor proteins of vascular plant photosystem I by electron microscopy/crystallography. Previously, we identified the binding site for the electron acceptor (ferredoxin). In this paper we complete these studies with the characterization of the electron donor (plastocyanin) binding site. After cross-linking, plastocyanin is detected using Fourier difference analysis of two dimensionally ordered arrays of photosystem I located at the periphery of chloroplast grana. Plastocyanin binds in a small cavity on the lumenal surface of photosystem 1, close to the center and with a slight bias toward the PsaL subunit of the complex. The recent release of the full coordinates for the cyanobacterial photosystem I reaction center has allowed a detailed comparison between the structures of the eukaryotic and prokaryotic systems. This reveals a very close homology, which is particularly striking for the lumenal side of photosystem I.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Exeter, Sch Biol Sci, Exeter EX4 4PS, Devon, England; Texas A&M Univ, Dept Biochem & Biophys, Microscopy & Imaging Ctr, College Stn, TX 77843 USA	University of Manchester; University of Exeter; Texas A&M University System; Texas A&M University College Station	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.			Ford, Robert/0000-0002-0958-1505				AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bottin H, 2001, BIOCHEM BIOPH RES CO, V287, P833, DOI 10.1006/bbrc.2001.5658; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; DelaCerda B, 1997, BIOCHEMISTRY-US, V36, P10125, DOI 10.1021/bi9708601; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; HARRIS JR, 1995, J STRUCT BIOL, V115, P102, DOI 10.1006/jsbi.1995.1034; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1996, ARCH BIOCHEM BIOPHYS, V330, P414, DOI 10.1006/abbi.1996.0270; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V36, P275; Inoue T, 1999, BIOCHEMISTRY-US, V38, P6063, DOI 10.1021/bi9824442; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kitmitto A, 1998, J BIOL CHEM, V273, P29592, DOI 10.1074/jbc.273.45.29592; Kitmitto A, 1997, J BIOL CHEM, V272, P19497, DOI 10.1074/jbc.272.31.19497; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Lagoutte B, 2001, PLANT PHYSIOL, V126, P307, DOI 10.1104/pp.126.1.307; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Mamedov MD, 2001, FEBS LETT, V500, P172, DOI 10.1016/S0014-5793(01)02615-1; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Olesen K, 1999, BIOCHEMISTRY-US, V38, P16695, DOI 10.1021/bi991242i; Ruffle SV, 2000, J BIOL CHEM, V275, P36250, DOI 10.1074/jbc.M006549200; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Setif P, 2001, BBA-BIOENERGETICS, V1507, P161, DOI 10.1016/S0005-2728(01)00205-5; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; Young S, 1997, BBA-BIOENERGETICS, V1322, P106, DOI 10.1016/S0005-2728(97)00064-9; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	39	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25692	25696		10.1074/jbc.M202670200	http://dx.doi.org/10.1074/jbc.M202670200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976339	hybrid			2022-12-27	WOS:000176747000109
J	D'Alonzo, RC; Kowalski, AJ; Denhardt, DT; Nickols, GA; Partridge, NC				D'Alonzo, RC; Kowalski, AJ; Denhardt, DT; Nickols, GA; Partridge, NC			Regulation of collagenase-3 and osteocalcin gene expression by collagen and osteopontin in differentiating MC3T3-E1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST PHENOTYPE; PARATHYROID-HORMONE; BONE-RESORPTION; IN-VITRO; INTERSTITIAL COLLAGENASE; MESSENGER-RNA; PROGRESSIVE DEVELOPMENT; INTEGRIN EXPRESSION; ACTIVATOR PROTEIN-1; MATRIX PROTEINS	Both collagenase-3 and osteocalcin mRNAs are expressed maximally during the later stages of osteoblast differentiation. Here, we demonstrate that collagenase-3 mRNA expression in differentiating MC3T3-E1 cells is dependent upon the presence of ascorbic acid, is inhibited in the presence of the collagen synthesis inhibitor, 3,4-dehydroproline, and is stimulated by growth on collagen in the absence of ascorbic acid. Transient transfection studies show that collagenase-3 promoter activity increases during cell differentiation and requires the presence of ascorbic acid. Additionally, we show that, in differentiating MC3T3-E1 cells, collagenase-3 gene expression increases in the presence of an anti-osteopontin monoclonal antibody that binds near the RGD motif of this protein, whereas osteocalcin expression is inhibited. Furthermore, an RGD peptidomimetic compound, designed to block interaction of ligands to the alpha(v) integrin subunit, increases osteocalcin expression and inhibits collagenase-3 expression, suggesting that the RGD peptidomimetic initiates certain alpha(v) integrin signaling in osteoblastic cells. Overall, these studies demonstrate that stimulation of collagenase-3 expression during osteoblast differentiation requires synthesis of a collagenous matrix and that osteopontin and alpha(v) integrins exert divergent regulation of collagenase-3 and osteocalcin expression during osteoblast differentiation.	Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Pharmacia Co, Dept Arthrit & Inflammat Pharmacol, St Louis, MO 63198 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Pfizer	Partridge, NC (corresponding author), Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu		Partridge, Nicola/0000-0002-5406-4814	NIAMS NIH HHS [AR44439] Funding Source: Medline; NIDDK NIH HHS [DK47420, DK48109, R01 DK047420] Funding Source: Medline; NIEHS NIH HHS [ESO6897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047420, R01DK047420, R01DK048109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006897] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; Carron CP, 2000, J ENDOCRINOL, V165, P587, DOI 10.1677/joe.0.1650587; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; CLOVER J, 1992, J CELL SCI, V103, P267; Crippes BA, 1996, ENDOCRINOLOGY, V137, P918, DOI 10.1210/en.137.3.918; Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756-3282(99)00106-4; Davis BA, 1998, CALCIFIED TISSUE INT, V63, P416, DOI 10.1007/s002239900550; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEDA K, 1993, J CELL PHYSIOL, V156, P130, DOI 10.1002/jcp.1041560118; Ivaska J, 2000, CELL MOL LIFE SCI, V57, P16, DOI 10.1007/s000180050496; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; KIRK MD, 1995, J BONE MINER RES, V10, P1203; KleinNulend J, 1997, J CELL PHYSIOL, V170, P174, DOI 10.1002/(SICI)1097-4652(199702)170:2<174::AID-JCP9>3.0.CO;2-L; KUBOTA T, 1993, ARCH ORAL BIOL, V38, P23, DOI 10.1016/0003-9969(93)90150-K; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005; MASI L, 1992, CALCIFIED TISSUE INT, V51, P202, DOI 10.1007/BF00334548; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Miles RR, 1998, J CELL BIOCHEM, V68, P355, DOI 10.1002/(SICI)1097-4644(19980301)68:3<355::AID-JCB6>3.0.CO;2-T; Moursi AM, 1997, J CELL SCI, V110, P2187; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nanci A, 1999, J STRUCT BIOL, V126, P256, DOI 10.1006/jsbi.1999.4137; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PARTRIDGE NC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P269; Partridge NC, 1996, CRIT REV EUKAR GENE, V6, P15, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.20; Partridge Nicola C., 1996, P207; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Pistone M, 1996, CELL BIOL INT, V20, P471, DOI 10.1006/cbir.1996.0062; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; QUARLES LD, 1992, J BONE MINER RES, V7, P683; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Shapses SA, 2000, J BONE MINER RES, V15, pS474; Shi ST, 1996, J BONE MINER RES, V11, P1139, DOI 10.1002/jbmr.5650110813; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749-6632.1995.tb44633.x; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097-4652(199912)181:3<479::AID-JCP12>3.0.CO;2-D; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WONG GL, 1980, ARTHRITIS RHEUM, V23, P1081, DOI 10.1002/art.1780231003; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Yamada S, 1999, REV HETEROATOM CHEM, V19, P203; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	84	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24788	24798		10.1074/jbc.M202604200	http://dx.doi.org/10.1074/jbc.M202604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964409	hybrid			2022-12-27	WOS:000176611800106
J	Linseman, DA; McClure, ML; Bouchard, R; Laessig, TA; Ahmadi, FA; Heidenreich, KA				Linseman, DA; McClure, ML; Bouchard, R; Laessig, TA; Ahmadi, FA; Heidenreich, KA			Suppression of death receptor signaling in cerebellar Purkinje neurons protects neighboring granule neurons from apoptosis via an insulin-like growth factor I-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; CELL-DEATH; IGF-I; GENE-EXPRESSION; RAT CEREBELLUM; NERVOUS-SYSTEM; FAS LIGAND; SURVIVAL; BCL-2	Neuronal apoptosis contributes to the progression of neurodegenerative disease. Primary cerebellar granule neurons are an established in vitro model for investigating neuronal death. After removal of serum and depolarizing potassium, granule neurons undergo apoptosis via a mechanism that requires intrinsic (mitochondrial) death signals; however, the role of extrinsic (death receptor-mediated) signals is presently unclear. Here, we investigate involvement of death receptor signaling in granule neuron apoptosis by expressing adenoviral, AU1-tagged, dominant-negative Fas-associated death domain (Ad-AU1-DeltaFADD). Ad-AU1-DeltaFADD decreased apoptosis of granule neurons from 65 +/- 5 to 27 +/- 2% (n = 7, p < 0.01). Unexpectedly, immunocytochemical staining for AU1 revealed that <5% of granule neurons expressed DeltaFADD. In contrast, DeltaFADD was expressed in >95% of calbindin-positive Purkinje neurons (similar to2% of the cerebellar culture). Granule neurons in proximity to DeltaFADD-expressing Purkinje cells demonstrated markedly increased survival. Both granule and Purkinje neurons expressed insulin-like growth factor-I (IGF-I) receptors, and DeltaFADD-mediated survival of granule neurons was inhibited by an IGF-I receptor blocking antibody. These results demonstrate that the selective suppression of death receptor signaling in Purkinje neurons is sufficient to rescue neighboring granule neurons that depend on Purkinje cell-derived IGF-I. Thus, the extrinsic death pathway has a profound but indirect effect on the survival of cerebellar granule neurons.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80220 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Heidenreich, KA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, 4200 E Ninth Ave, Denver, CO 80262 USA.		Linseman, Daniel/L-3846-2019		NINDS NIH HHS [NS38619-01A1] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON IK, 1988, ACTA PHYSIOL SCAND, V132, P167, DOI 10.1111/j.1748-1716.1988.tb08314.x; Baker NL, 1999, DEV BRAIN RES, V118, P109, DOI 10.1016/S0165-3806(99)00136-4; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BONDY CA, 1991, J NEUROSCI, V11, P3442; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; Clarkson ED, 2001, EXP NEUROL, V168, P183, DOI 10.1006/exnr.2000.7593; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Doughty ML, 2000, J NEUROSCI, V20, P3687; Fan HB, 2001, J COMP NEUROL, V436, P82; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; GALLI C, 1995, J NEUROSCI, V15, P1172; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Ghoumari AM, 2000, EUR J NEUROSCI, V12, P2935, DOI 10.1046/j.1460-9568.2000.00186.x; Gleichmann M, 2000, NEUROSCI LETT, V282, P69, DOI 10.1016/S0304-3940(00)00857-0; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; HOCKBERGER PE, 1994, NEUROIMAGE, V1, P276, DOI 10.1006/nimg.1994.1012; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lin X, 1997, DEV BRAIN RES, V99, P234, DOI 10.1016/S0165-3806(97)00015-1; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Selimi F, 2000, J NEUROSCI, V20, P992, DOI 10.1523/JNEUROSCI.20-03-00992.2000; Selimi F, 2000, J NEUROSCI, V20, P5339, DOI 10.1523/JNEUROSCI.20-14-05339.2000; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; VOGEL MW, 1995, J NEUROBIOL, V26, P537, DOI 10.1002/neu.480260407; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zanjani HS, 1996, J COMP NEUROL, V374, P332, DOI 10.1002/(SICI)1096-9861(19961021)374:3<332::AID-CNE2>3.0.CO;2-2; Zawada WM, 2001, BRAIN RES, V891, P185; Zhang W, 1997, DEV BRAIN RES, V98, P164, DOI 10.1016/S0165-3806(96)00168-X; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	52	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24546	24553		10.1074/jbc.M201098200	http://dx.doi.org/10.1074/jbc.M201098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964396	hybrid			2022-12-27	WOS:000176611800076
J	Koipally, J; Georgopoulos, K				Koipally, J; Georgopoulos, K			Ikaros-CtIP interactions do not require C-terminal binding protein and participate in a deacetylase-independent mode of repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; CTBP; BRCA1; GENE; COREPRESSOR; MECHANISM; FAMILY; EXPRESSION; COMPLEXES	Ikaros and Aiolos are Kruppel zinc finger proteins that play key roles in hemo-lymphoid development and homeostasis. We have previously shown that they can repress transcription through the recruitment of histone deacetylases (HDACs). Here, we provide the first functional evidence that these proteins can also repress gene function in a manner that does not require deacetylase activity. This functionality can be attributed in part to Ikaros interactions with the HDAC-independent corepressor, C-terminal binding protein (CtBP). However, mutations that block Ikaros-CtBP interactions do not abolish Ikaros's repression activity, implicating the involvement of additional corepressors. Consistent with this expectation, we show that Ikaros can interact with a CtBP-interacting protein (CUP), which has also been linked to a deacetylase-independent strategy of repression. Despite being a CtBP interactor, CUP's association with Ikaros does not require CtBP but instead relies upon its Rb interaction domain. Significantly, Ikaros can interact with Rb, which itself can repress gene function in a deacetylase-independent manner. A mutation in Ikaros that abrogates CUP interactions significantly reduces repression, and a double mutation that prevents interaction with both CtIP and CtBP even further alleviates repression. Finally, we show that CtIP and CtBP can interact with the general transcription factors, TATA binding protein and transcription factor IIB, which suggests a possible mechanism for their deacetylase-independent mode of repression.	Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Med Sch, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Georgopoulos, K (corresponding author), Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	katia.georgopoulos@cbrc2.mgh.harvard.edu			NIAID NIH HHS [R01-AI380342] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Courey AJ, 2001, GENE DEV, V15, P2786; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhang QH, 2002, SCIENCE, V295, P1895; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	42	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23143	23149		10.1074/jbc.M202079200	http://dx.doi.org/10.1074/jbc.M202079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959865	hybrid			2022-12-27	WOS:000176475700008
J	Llano, E; Adam, G; Pendas, AM; Quesada, V; Sanchez, LM; Santamaria, I; Noselli, S; Lopez-Otin, C				Llano, E; Adam, G; Pendas, AM; Quesada, V; Sanchez, LM; Santamaria, I; Noselli, S; Lopez-Otin, C			Structural and enzymatic characterization of Drosophila Dm2-MMP, a membrane-bound matrix metalloproteinase with tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; COLLAGENASE; ACTIVATION; DOMAIN; GENE; MATRILYSIN; NOTCH; IDENTIFICATION	We report the isolation and characterization of a cDNA encoding Dm2-MMP, the second matrix metalloproteinase (MMP) identified in the Drosophila melanogaster genome. The cloned cDNA codes for a polypeptide of 758 residues that displays a domain organization similar to that of other MMPs, including signal peptide, propeptide, catalytic, and hemopexin domains. However, the structure of Dm2-MMP is unique because of the presence of an insertion of 214 amino acids between the catalytic and hemopexin domains that is not present in any of the previously described MMPs. Dm2-MMP also contains a C-terminal extension predicted to form a cleavable glycosylphosphatidylinositol anchor site. Western blot and immunofluorescence analysis of S2 cells transfected with the isolated cDNA confirmed that Dm2-MMP is localized at the cell surface. Production of the catalytic domain of Dm2-MMP in Escherichia coli and analysis of its enzymatic activity revealed that this proteinase cleaves several synthetic peptides used for analysis of vertebrate MMPs. This proteolytic activity was abolished by MMP inhibitors such as BB-94, confirming that the isolated cDNA codes for an enzymatically active metalloproteinase. Reverse transcription-PCR analysis showed that Dm2-MMP is expressed at low levels in all of the developmental stages of Drosophila as well as in adult flies. However, detailed in situ hybridization at the larval stage revealed a strong tissue-specific expression in discrete regions of the brain and eye imaginal discs. According to these results, we propose that Dm2-MMP plays both general proteolytic functions during Drosophila development and in adult tissues and specific roles in eye development and neural tissues through the degradation and remodeling of the extracellular matrix.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain; CNRS, UMR 6543, Ctr Biochim, Inst Rech Signalisat Dev & Canc, F-06108 Nice 2, France	University of Oviedo; Instituto Universitario de Oncologia de Asturias; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	Llano, Elena/K-1723-2014; López-Otín, Carlos/AAB-2106-2020; Quesada, Víctor/B-6557-2014; Pendas, Alberto M/L-1017-2014; Santamaria, Inigo/H-6727-2015; Llano, Elena/AAS-5517-2021	Llano, Elena/0000-0002-2626-5723; López-Otín, Carlos/0000-0001-6964-1904; Quesada, Víctor/0000-0002-8398-3457; Santamaria, Inigo/0000-0001-8718-5359; Llano, Elena/0000-0002-2626-5723; Pendas, Alberto M/0000-0001-9264-3721; Noselli, stephane/0000-0002-7296-324X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Coates D, 2000, BIOCHEM SOC T, V28, P464, DOI 10.1042/0300-5127:0280464; Couet J, 1996, J BIOL CHEM, V271, P4545; Delorme VGR, 2000, PLANT PHYSIOL, V123, P917, DOI 10.1104/pp.123.3.917; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Leontovich AA, 2000, DEVELOPMENT, V127, P907; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; Llano E, 1999, CANCER RES, V59, P2570; Llano E, 2000, J BIOL CHEM, V275, P35978, DOI 10.1074/jbc.M006045200; Lohi J, 2001, J BIOL CHEM, V276, P10134, DOI 10.1074/jbc.M001599200; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; Maidment JM, 1999, J BIOL CHEM, V274, P34706, DOI 10.1074/jbc.274.49.34706; Marchenko GN, 2001, GENE, V265, P87, DOI 10.1016/S0378-1119(01)00360-2; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Montell DJ, 1999, DEVELOPMENT, V126, P3035; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Oh LYS, 1999, J NEUROSCI, V19, P8464; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Puente XS, 1996, CANCER RES, V56, P944; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SAMBROOK J, 2000, MOL CLONING LAB MANU; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sotillos S, 1997, DEVELOPMENT, V124, P4769; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uria JA, 2000, CANCER RES, V60, P4745; Velasco G, 2000, CANCER RES, V60, P877; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Woolley K, 2000, BIOESSAYS, V22, P911; Yu Q, 2000, GENE DEV, V14, P163; Zuo J, 1998, J NEUROSCI, V18, P5203, DOI 10.1523/JNEUROSCI.18-14-05203.1998	61	78	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23321	23329		10.1074/jbc.M200121200	http://dx.doi.org/10.1074/jbc.M200121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967260	hybrid			2022-12-27	WOS:000176475700031
J	Amieux, PS; Howe, DG; Knickerbocker, H; Lee, DC; Su, T; Laszlo, GS; Idzerda, RL; McKnight, GS				Amieux, PS; Howe, DG; Knickerbocker, H; Lee, DC; Su, T; Laszlo, GS; Idzerda, RL; McKnight, GS			Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RI-BETA SUBUNIT; TYROSINE-PHOSPHATASE SHP-2; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; P21-ACTIVATED KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CARNEY COMPLEX	A targeted disruption of the RIalpha isoform of protein kinase A (PKA) was created by using homologous recombination in embryonic stem cells. Unlike the other regulatory and catalytic subunits of PKA, RIalpha is the only isoform that is essential for early embryonic development. RIalpha homozygous mutant embryos fail to develop a functional heart tube at E8.5 and are resorbed at approximately E10.5. Mutant embryos show significant growth retardation and developmental delay compared with wild type littermates from E7.5 to E10.5. The anterior-posterior axis of RIalpha mutants is well developed, with a prominent head structure but a reduced trunk. PKA activity measurements reveal an increased basal PKA activity in these embryos. Brachyury mRNA expression in the primitive streak of RIalpha mutants is significantly reduced, consistent with later deficits in axial, paraxial, and lateral plate mesodermal derivatives. This defect in the production and migration of mesoderm can be completely rescued by crossing RIa mutants to mice carrying a targeted disruption in the Ca catalytic subunit, demonstrating that unregulated PKA activity rather than a specific loss of RIalpha is responsible for the phenotype. Primary embryonic fibroblasts from RIalpha mutant embryos display an abnormal cytoskeleton and an altered ability to migrate in cell culture. Our results demonstrate that unregulated PKA activity negatively affects growth factor-mediated mesoderm formation during early mouse development.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill	McKnight, GS (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.		Amieux, Paul/AAG-4102-2021	Howe, Douglas/0000-0001-5831-7439	NICHD NIH HHS [U54 HD 12629] Funding Source: Medline; NIGMS NIH HHS [GM 32875] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIEUX PS, 2002, ENCY MOL MED, V4, P2637; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BRANDON EP, 1995, RECENT PROG HORM RES, V50, P403; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Casey M, 2000, J CLIN INVEST, V106, pR31, DOI 10.1172/JCI10841; Catala M, 1996, DEVELOPMENT, V122, P2599; CLEGG CH, 1994, MOL CELL NEUROSCI, V5, P153, DOI 10.1006/mcne.1994.1017; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Clegg CH, 1996, J BIOL CHEM, V271, P1638, DOI 10.1074/jbc.271.3.1638; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; Concordet JP, 1996, DEVELOPMENT, V122, P2835; FURUTA Y, 1995, ONCOGENE, V11, P1989; GeorgesLabouesse EN, 1996, DEV DYNAM, V207, P145, DOI 10.1002/(SICI)1097-0177(199610)207:2<145::AID-AJA3>3.0.CO;2-H; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Hammerschmidt M, 1998, DEV BIOL, V194, P166, DOI 10.1006/dbio.1997.8796; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; Hogan B, 1994, MANIPULATING MOUSE E; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe AK, 2001, J BIOL CHEM, V276, P14541, DOI 10.1074/jbc.C000797200; Huang YZ, 2002, J BIOL CHEM, V277, P19889, DOI 10.1074/jbc.M111412200; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Joore J, 1998, MECH DEVELOP, V79, P5, DOI 10.1016/S0925-4773(98)00152-X; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lin TH, 1997, J BIOL CHEM, V272, P8849; Manes S, 1999, MOL CELL BIOL, V19, P3125; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; POUEYMIROU WT, 1989, DEV BIOL, V133, P588, DOI 10.1016/0012-1606(89)90061-4; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RABINOVITCH PS, 1994, METHOD CELL BIOL, V41, P263; Rocchi S, 2000, BIOCHEM J, V352, P483, DOI 10.1042/0264-6021:3520483; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SCHWARTZ DA, 1992, MOL REPROD DEV, V32, P209, DOI 10.1002/mrd.1080320305; Skalhegg BS, 2002, MOL ENDOCRINOL, V16, P630, DOI 10.1210/me.16.3.630; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; Tam PPL, 1997, DEVELOPMENT, V124, P1631; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEILER K, 1989, HOUSE MOUSE ATLAS EM, P40; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang HB, 1996, DEVELOPMENT, V122, P2977	58	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27294	27304		10.1074/jbc.M200302200	http://dx.doi.org/10.1074/jbc.M200302200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004056	hybrid, Green Published			2022-12-27	WOS:000177055900077
J	Hussain, S; Assender, JW; Bond, M; Wong, LF; Murphy, D; Newby, AC				Hussain, S; Assender, JW; Bond, M; Wong, LF; Murphy, D; Newby, AC			Activation of protein kinase C zeta is essential for cytokine-induced metalloproteinase-1,-3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MATRIX METALLOPROTEINASES; TRANSGENE EXPRESSION; SUBSPECIES BLOCKS; UP-REGULATION; GELATINASE-B; GENE; MIGRATION; REQUIREMENT; INVOLVEMENT	Several matrix metalloproteinases (MMPs), including MMP-1, -3, and -9, mediate matrix destruction during chronic inflammatory diseases such as arthritis and atherosclerosis. AMP up-regulation by inflammatory cytokines involves interactions between several transcription factors, including activator protein-1 and nuclear factor kappaB (NF-kappaB). The upstream regulatory pathways are less well understood. We investigated the role of isoforms of protein kinase C (PKC) in basic fibroblast growth factor- and interleukin-1alpha-mediated MMP production from cultured rabbit aortic smooth muscle cells. A synthetic PKC inhibitor, RO318220, inhibited MMP-1, -3, and -9 production by 89 +/- 3, 75 +/- 18, and 89 +/- 9%, respectively. However, down-regulation of conventional and novel isoforms did not inhibit but rather increased MMP-9 production by 48 +/- 16%, implicating an atypical PKC isoform. Consistent with this, PKC protein levels and activity were stimulated 3.3- and 13-fold, respectively, by basic fibroblast growth factor plus interleukin-la and antisense oligonucleotides to PKCzeta significantly decreased MMP-9 formation by 62 +/- 18% compared with scrambled sequences. Moreover, adenovirus-mediated overexpression of a dominant-negative (DN) PKCzeta reduced MMP-1, -3, and -9 production by 78 +/- 9, 76 +/- 8, and 76 +/- 5%, respectively. DN-PKCzeta inhibited NF-kappaB DNA binding but did not affect ERK1/2 activation or AP-1 binding. Antisense PKC oligonucleotides and DN-PKCzeta stimulated cell proliferation by 89 +/- 14% (n = 4) and 305 +/- 74% (n = 3), respectively (both p < 0.05). Our results show that PKCzeta is essential for cytokine-induced up-regulation of MMP-1, -3, and -9, most likely by activating NF-kappaB Selective inhibition of PKCzeta is therefore a possible strategy to inhibit NIMP production in inflammatory diseases such as atherosclerosis.	Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Univ Bristol, Bristol Royal Infirm, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England; Cardiff Univ, Sch Bio Sci, Cardiff CF10 3XQ, S Glam, Wales	Bristol Royal Infirmary; University of Bristol; Bristol Royal Infirmary; University of Bristol; Cardiff University	Newby, AC (corresponding author), Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.	a.newby@bris.ac.uk	Murphy, David/C-3967-2012; assender, jean/AAK-2210-2021; Bond, Mark/AAG-9293-2019	Murphy, David/0000-0003-2946-0353; assender, jean/0000-0003-2003-4630; Bond, Mark/0000-0003-2788-278X				ASSENDER JW, 1994, FEBS LETT, V342, P76, DOI 10.1016/0014-5793(94)80588-1; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; Carlin S, 2000, AM J RESP CELL MOL, V23, P555, DOI 10.1165/ajrcmb.23.4.4197; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; FINI ME, 1994, J BIOL CHEM, V269, P28620; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Harding TC, 1997, J NEUROCHEM, V69, P2620; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KARIYA K, 1989, BIOCHEM BIOPH RES CO, V161, P1020, DOI 10.1016/0006-291X(89)91345-4; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leng L, 1996, ARTERY, V22, P140; Leszczynski D, 1996, LIFE SCI, V58, P599, DOI 10.1016/0024-3205(95)02329-1; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Morgan KG, 1998, ACTA PHYSIOL SCAND, V164, P495; NEWBY AC, 1995, BRIT J PHARMACOL, V114, P1652, DOI 10.1111/j.1476-5381.1995.tb14953.x; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; SANZ L, 1994, J BIOL CHEM, V269, P10044; SATO H, 1993, ONCOGENE, V8, P395; SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021-9150(90)90150-H; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Woessner JF, 1998, BIOL EXTRAC, P1; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; YU LP, 1991, J RHEUMATOL, V18, P1450; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28	45	54	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27345	27352		10.1074/jbc.M111890200	http://dx.doi.org/10.1074/jbc.M111890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12000746	hybrid			2022-12-27	WOS:000177055900083
J	Hresko, RC; Mueckler, M				Hresko, RC; Mueckler, M			Identification of pp68 as the tyrosine-phosphorylated form of SYNCRIP/NSAP1 - A cytoplasmic RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOPROTEIN-K PROTEIN; MESSENGER-RNA; POLY(A) TAIL; MAMMALIAN-CELLS; INSULIN ACTION; INITIATION; KINASE; TRANSLATION; ADIPOCYTES; STABILITY	Recently we reported that osmotic shock increased the insulin-stimulated tyrosine phosphorylation of a 68-kDa RNA-binding protein in 3T3-L1 adipocytes (Hresko, R. C., and Mueckler, M. (2000) J. BioL Chem. 275,1811418120). In this present study we have identified, by MALDI mass spectrometry, pp68 as the tyrosine-phosphorylated form of synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP)/NSAP1, a newly discovered cytoplasmic RNA-binding protein. Both SYNCRIP and pp68 were enriched in free polysomes found in low density microsomes isolated from 3T3-L1 adipocytes. In vitro phosphorylation studies revealed that SYNCRIP, once extracted from low density microsomes, can be tyrosine phosphorylated using purified insulin receptor. Binding of RNA to SYNCRIP specifically inhibited its in vitro phosphorylation but had no effect on receptor autophosphorylation or on the ability of the receptor to phosphorylate a model substrate, RCM-lysozyme. These results raise the possibility that regulation of mRNA translation or stability by insulin may involve the phosphorylation of SYNCRIP.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARDELLI J, 1976, J CELL BIOL, V70, P47, DOI 10.1083/jcb.70.1.47; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Harris CE, 1999, J VIROL, V73, P72, DOI 10.1128/JVI.73.1.72-80.1999; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; KELLER SR, 1991, J BIOL CHEM, V266, P12817; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; OBRIEN RM, 1996, PHYSIOL REV, V76, P1110; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PIPER RC, 1991, AM J PHYSIOL, V260, P570; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; WENGLER G, 1972, EUR J BIOCHEM, V27, P162, DOI 10.1111/j.1432-1033.1972.tb01822.x; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	35	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25233	25238		10.1074/jbc.M202556200	http://dx.doi.org/10.1074/jbc.M202556200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994298	hybrid			2022-12-27	WOS:000176747000051
J	Joubert, L; Claeysen, S; Sebben, M; Bessis, AS; Clark, RD; Martin, RS; Bockaert, J; Dumuis, A				Joubert, L; Claeysen, S; Sebben, M; Bessis, AS; Clark, RD; Martin, RS; Bockaert, J; Dumuis, A			A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; STRUCTURAL INSTABILITY; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; 3-DIMENSIONAL MODELS; LIGHT ACTIVATION; RHODOPSIN; BINDING; MUTATION	Activation of G protein-coupled receptors is thought to involve disruption of intramolecular interactions that stabilize their inactive conformation. Such disruptions are induced by agonists or by constitutively active mutations. In the present study, novel potent inverse agonists are described to inhibit the constitutive activity of 5-HT4 receptors. Using these compounds and specific receptor mutations, we investigated the mechanisms by which inverse agonists may reverse the disruption of intramolecular interactions that causes constitutive activation. Two mutations (D100(3.32)A in transmembrane domain (TMD)-III and F275(6.51)A in TMD-VI) were found to completely block inverse agonist effects without impairing their binding properties nor the molecular activation switches induced by agonists. Based on the rhodopsin model, we propose that these mutated receptors are in equilibrium between two states R and R* but are unable to reach a third "silent" state stabilized by inverse agonists. We also found another mutation in TMD-VI (W272(6.48)A) that stabilized this silent state. This mutant remained fully activated by agonists. Molecular modeling indicated that Asp-100, Phe-275, and Trp-272 might constitute a network required for stabilization of the silent state by the described inverse agonists. However, this network is not necessary for agonist activity.	CNRS, UPR 9023, F-34094 Montpellier 05, France; Roche Biosci, Neurobiol Unit, Palo Alto, CA 94304 USA	Centre National de la Recherche Scientifique (CNRS); Roche Holding	Bockaert, J (corresponding author), CNRS, UPR 9023, 141 Rue Cardonile, F-34094 Montpellier 05, France.		Claeysen, Sylvie/C-8599-2014	Claeysen, Sylvie/0000-0002-0576-5518				Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ansanay H, 1996, EUR J PHARMACOL, V298, P165, DOI 10.1016/0014-2999(95)00786-5; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Claeysen S, 2000, MOL PHARMACOL, V58, P136, DOI 10.1124/mol.58.1.136; Claeysen S, 2001, EMBO REP, V2, P61, DOI 10.1093/embo-reports/kve003; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; EBREY T, 1980, FEBS LETT, V116, P217, DOI 10.1016/0014-5793(80)80647-8; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; HIBERT MF, 1993, M S-MED SCI, V9, P31, DOI 10.4267/10608/2784; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Onaran HO, 1997, ANN NY ACAD SCI, V812, P98, DOI 10.1111/j.1749-6632.1997.tb48150.x; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scearce-Levie K, 2001, TRENDS PHARMACOL SCI, V22, P414, DOI 10.1016/S0165-6147(00)01743-0; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Surya A, 1998, TRENDS PHARMACOL SCI, V19, P243; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25502	25511		10.1074/jbc.M202539200	http://dx.doi.org/10.1074/jbc.M202539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11976337	Green Published, hybrid			2022-12-27	WOS:000176747000086
J	Strom, M; Hume, AN; Tarafder, AK; Barkagianni, E; Seabra, MC				Strom, M; Hume, AN; Tarafder, AK; Barkagianni, E; Seabra, MC			A family of Rab27-binding proteins - Melanophilin links Rab27a and myosin Va function in melanosome transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASES; GERANYLGERANYLATION; MUTATIONS; COMPLEX; GENE; IDENTIFICATION; EXOCYTOSIS; DYNAMICS; RECEPTOR; PRODUCT	The Rab27a GTPase regulates diverse processes involving lysosome-related organelles, including melanosome motility in melanocytes, and lytic granule release in cytotoxic T lymphocytes. Toward an understanding of Rab27a function, we searched for proteins that interact with Rab27a(GTP) using the yeast two-hybrid system and identified JFCI/Slp1, a protein of unknown function. JFC1/Slp1 and related proteins, including melanophilin, contain a conserved amino-terminal domain similar to the Rab3a-binding domain of Rabphilin-3. We used several methods to demonstrate that this conserved amino-terminal domain is a Rab27-binding domain. We show that this domain interacts directly, and in a GTP-dependent manner with Rab27a. Furthermore, overexpression of this domain in melanocytes results in perinuclear clustering of melanosomes, suggesting that this region is sufficient for interaction with, and perturbation of function of, Rab27a in a physiological context. Thus, we identified a novel family of Rab27-binding proteins. We also show that melanophilin associates with Rab27a and myosin Va on melanosomes in melanocytes, and present evidence that a domain within the carboxylterminal region of melanophilin interacts with the carboxyl-terminal tail of the melanocyte-specific splice isoform of myosin Va. Thus, melanophilin can associate simultaneously with activated Rab27a and myosin Va via distinct regions, and serve as a linker between these proteins.	Univ London Imperial Coll Sci & Technol, Cell & Mol Biol Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Fac Med, Div Biomed Sci, Dept Cell & Mol Biol, London SW7 2AZ, England	Imperial College London; Imperial College London	Seabra, MC (corresponding author), Univ London Imperial Coll Sci & Technol, Cell & Mol Biol Sect, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	m.seabra@ic.ac.uk	Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; Hume, Alistair/0000-0001-9443-1087; Tarafder, Abul/0000-0002-0368-6111				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HERZ J, 1990, J BIOL CHEM, V265, P21355; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; James P, 1996, GENETICS, V144, P1425; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOORE KJ, 1988, GENETICS, V119, P933; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Ramalho JS, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-2; Rose MD., 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Shen F, 1996, J BIOL CHEM, V271, P3692; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	241	251	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25423	25430		10.1074/jbc.M202574200	http://dx.doi.org/10.1074/jbc.M202574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980908	hybrid			2022-12-27	WOS:000176747000076
J	Cai, SJ; Inouye, M				Cai, SJ; Inouye, M			EnvZ-OmpR interaction and osmoregulation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE KINASE ENVZ; DNA-BINDING DOMAIN; SIGNAL-TRANSDUCTION; TRANSCRIPTION ACTIVATOR; SALMONELLA-TYPHIMURIUM; PHOSPHATASE-ACTIVITIES; BACTERIAL CHEMOTAXIS; POSITIVE REGULATOR; GENETIC-ANALYSIS; OSMOSENSOR ENVZ	EnvZ, a histidine kinase/phosphatase in Escherichia coli, responds to the osmolarity changes in the medium by regulating the phosphorylation state of the transcription factor OmpR, which controls the expression levels of outer membrane porin proteins OmpF and OmpC. Although both ompR and envZ genes are located on the ompB locus under the control of the ompB promoter and transcribed as a single polycistronic mRNA, the expression of envZ is known to be significantly less than ompR. However, to date no accurate estimation for the amounts of EnvZ and OmpR in the cell has been carried out. Here we examined the levels of EnvZ and OmpR in the wild-type strain MC4100 by quantitative Western blot analysis using anti-OmpR and anti-EnvZc (cytoplasmic domain of EnvZ) antisera. It was observed that during exponential growth in L-broth medium there were similar to3500 and 100 molecules per cell of OmpR and EnvZ, respectively. The levels of OmpR and EnvZ in MC4100 cells grown in a high osmolarity medium (nutrient broth with 20% sucrose) were about the same as those grown in L-broth, whereas they were 1.7-fold higher than those in a low osmolarity medium (nutrient broth). With His(10)-OmpR, we also determined that the K-d value for the EnvZc-OmpR complex formation is 1.20 +/- 0.17 mum. On the basis of these results, the molecular mechanism of osmoregulation of ompF and ompC is discussed.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; Bergstrom LC, 1998, GENES CELLS, V3, P777, DOI 10.1046/j.1365-2443.1998.00228.x; BERMAN ML, 1984, J BACTERIOL, V159, P750, DOI 10.1128/JB.159.2.750-756.1984; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Harrison-McMonagle P, 1999, J MOL BIOL, V285, P555, DOI 10.1006/jmbi.1998.2375; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Huang KJ, 1996, J MOL BIOL, V262, P615, DOI 10.1006/jmbi.1996.0540; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KATO M, 1989, FEBS LETT, V249, P168, DOI 10.1016/0014-5793(89)80617-9; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; Kondo H, 1997, NAT STRUCT BIOL, V4, P28, DOI 10.1038/nsb0197-28; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LILJESTROM P, 1988, J MOL BIOL, V201, P663, DOI 10.1016/0022-2836(88)90465-2; Mao WM, 1998, MOL MICROBIOL, V27, P415, DOI 10.1046/j.1365-2958.1998.00690.x; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mattison K, 2002, J BIOL CHEM, V277, P11143, DOI 10.1074/jbc.M111128200; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; Qin L, 2000, MOL MICROBIOL, V36, P24, DOI 10.1046/j.1365-2958.2000.01837.x; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; SHIN S, 1995, J BACTERIOL, V177, P4696, DOI 10.1128/jb.177.16.4696-4702.1995; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VERHOEF C, 1979, MOL GEN GENET, V169, P137, DOI 10.1007/BF00271664; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WANNER BL, 1996, ESCHERICHIA COLI SAL, V1, P1359; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808	48	211	226	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24155	24161		10.1074/jbc.M110715200	http://dx.doi.org/10.1074/jbc.M110715200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11973328	hybrid			2022-12-27	WOS:000176611800025
J	Dai, YS; Cserjesi, P; Markham, BE; Molkentin, JD				Dai, YS; Cserjesi, P; Markham, BE; Molkentin, JD			The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; SERUM RESPONSE FACTOR; TROPONIN-I GENE; ATRIAL-NATRIURETIC-FACTOR; HEART TUBE FORMATION; NEURAL-CREST; VENTRAL MORPHOGENESIS; P300; MUSCLE; COMPLEX	An intricate array of heterogeneous transcription factors participate in programming tissue-specific gene expression through combinatorial interactions that are unique to a given cell-type. The zinc finger-containing transcription factor GATA4, which is widely expressed in mesodermal and endodermal derived tissues, is thought to regulate cardiac myocyte-specific gene expression through combinatorial interactions with other semi-restricted transcription factors such as myocyte enhancer factor 2, nuclear factor of activated T-cells, serum response factor, and Nkx2.5. Here we determined that GATA4 also interacts with the cardiac-expressed basic helix-loop-helix transcription factor dHAND (also known as HAND2). GATA4 and dHAND synergistically activated expression of cardiac-specific promoters from the atrial natriuretic factor gene, the b-type natriuretic peptide gene, and the a-myosin heavy chain gene. Using artificial reporter constructs this functional synergy was shown to be GATA site-dependent, but E-box site-independent. A mechanism for the transcriptional synergy was suggested by the observation that the bHLH domain of dHAND physically interacted with the C-terminal zinc finger domain of GATA4 forming a higher order complex. This transcriptional synergy observed between GATA4 and dHAND was associated with p300 recruitment, but not with alterations in DNA binding activity of either factor. Moreover, the bHLH domain of dHAND directly interacted with the CH3 domain of p300 suggesting the existence of a higher order complex between GATA4, dHAND, and p300. Taken together with previous observations, these results suggest the existence of an enhanceosome complex comprised of p300 and multiple semi-restricted transcription factors that together specify tissue-specific gene expression in the heart.	Pfizer Global Res & Dev, Dept Mol Sci, Ann Arbor, MI 48105 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, New Orleans, LA 70112 USA	Pfizer; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Markham, BE (corresponding author), Pfizer Global Res & Dev, Dept Mol Sci, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Dai, Yanshan/B-8577-2009	Molkentin, Jeffery/0000-0002-3558-6529; Dai, Yanshan/0000-0001-5048-7417				Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; BISHOPRIC NH, 1997, J BIOL CHEM, V272, P20585; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Charite J, 2000, DEVELOPMENT, V127, P2461; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Goodman RH, 2000, GENE DEV, V14, P1553; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Howard M, 1999, DEV BIOL, V215, P62, DOI 10.1006/dbio.1999.9450; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Kuo HC, 1999, DEVELOPMENT, V126, P4223; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; McFadden DG, 2000, DEVELOPMENT, V127, P5331; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Murphy AM, 1997, BIOCHEM J, V322, P393, DOI 10.1042/bj3220393; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; NIHCOLAS SB, 1999, AM J PHYSIOL, V277, pH324; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; Rosoff ML, 1998, J BIOL CHEM, V273, P9124, DOI 10.1074/jbc.273.15.9124; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Srivastava D, 1999, TRENDS CARDIOVAS MED, V9, P11, DOI 10.1016/S1050-1738(98)00033-4; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thomas T, 1998, DEVELOPMENT, V125, P3005; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Yamagishi H, 2000, J CLIN INVEST, V105, P261, DOI 10.1172/JCI8856; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	63	146	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24390	24398		10.1074/jbc.M202490200	http://dx.doi.org/10.1074/jbc.M202490200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11994297	hybrid			2022-12-27	WOS:000176611800056
J	Martin, V; Bredoux, R; Corvazier, E; van Gorp, R; Kovacs, T; Gelebart, P; Enouf, J				Martin, V; Bredoux, R; Corvazier, E; van Gorp, R; Kovacs, T; Gelebart, P; Enouf, J			Three novel sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms - Expression, regulation, and function of the members of the SERCA3 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP EXPRESSION; MEMBRANE CA2+ PUMP; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; SARCOPLASMIC-RETICULUM; CALCINEURIN CONTROLS; DIFFERENTIAL MODULATION; DEPENDENT RELAXATION; TISSUE DISTRIBUTION; LYMPHOID-CELLS	Sarco/endoplasmic reticulum Ca2+-ATPases (SERCAs) pump Ca2+ into the endoplasmic reticulum. Recently, three human SERCA3 (h3a-c) proteins and a previously unknown rat SERCA3 (r3b/c) mRNA have been described. Here, we (i) document two novel human SERCA3 splice variants h3d and h3e, (ii) provide data for the expression and mechanisms regulating the expression of all known SERCA3 variants (r3a, r3b/c, and h3a-e), and (iii) show functional characteristics of the SERCA3 isoforms. h3d and h3e are issued from the insertion of an additional penultimate exon 22 resulting in different carboxyl termini for these variants. Distinct distribution patterns of the SERCA3 gene products were observed in a series of cell lines of hematopoietic, epithelial, embryonic origin, and several cancerous types, as well as in panels of rat and human tissues. Hypertension and protein kinase C, calcineurin, or retinoic acid receptor signaling pathways were found to differently control rat and human splice variant expression, respectively. Stable overexpression of each variant was performed in human embryonic kidney 293 cells, and the SERCA3 isoforms were fully characterized. All SERCA3 isoforms were found to pump Ca-2+ with similar affinities. However, they modulated the cytosolic Ca2+ concentration ([Ca2+](c)) and the endoplasmic reticulum Ca2+ content ([Ca2+ ](er)) in different manners. A newly generated polyclonal antibody and a pan-SERCA3 antibody proved the endogenous expression of the three novel SERCA3 proteins, h3d, h3e, and r3b/c. All these data suggest that the SERCA3 gene products have a more widespread role in cellular Ca2+ signaling than previously appreciated.	Hop Lariboisiere, Circulat Lariboisiere IFR6, INSERM, U348, F-75475 Paris 10, France; Natl Med Ctr, Inst Haematol & Immunol, H-1113 Budapest, Hungary	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Enouf, J (corresponding author), Hop Lariboisiere, Circulat Lariboisiere IFR6, INSERM, U348, 8 Rue Guy Patin, F-75475 Paris 10, France.	jocelyne.enouf@inserm.lrb.ap-hop-paris.fr	Gelebart, Pascal/AAI-1439-2020; Kovács, Tünde/O-6020-2017	Gelebart, Pascal/0000-0003-2434-8987; Kovács, Tünde/0000-0003-1064-2616				BabaAissa F, 1996, MOL BRAIN RES, V41, P169, DOI 10.1016/0169-328X(96)00088-5; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BOBE R, 1994, J BIOL CHEM, V269, P1417; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guerini D, 2000, J BIOL CHEM, V275, P3706, DOI 10.1074/jbc.275.5.3706; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; KOVACS T, 1994, J BIOL CHEM, V269, P6177; Kovacs T, 2001, BIOCHEM J, V358, P559, DOI 10.1042/0264-6021:3580559; Lacabaratz-Porret C, 2000, BIOCHEM J, V350, P723, DOI 10.1042/0264-6021:3500723; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; Launay S, 1997, J BIOL CHEM, V272, P10746; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; Liu LH, 2001, J BIOL CHEM, V276, P26737, DOI 10.1074/jbc.C100275200; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Ozog A, 1998, FEBS LETT, V427, P349, DOI 10.1016/S0014-5793(98)00464-5; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200	49	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24442	24452		10.1074/jbc.M202011200	http://dx.doi.org/10.1074/jbc.M202011200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956212	hybrid			2022-12-27	WOS:000176611800063
J	Sarkar, SN; Miyagi, M; Crabb, JW; Sen, GC				Sarkar, SN; Miyagi, M; Crabb, JW; Sen, GC			Identification of the substrate-binding sites of 2 '-5 '-oligoadenylate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2',5'-OLIGOADENYLATE SYNTHETASE; ENZYMATIC-ACTIVITY; PROTEIN; DOMAIN; ATP; PURIFICATION; INTERFERONS; POLYMERASE; MUTATIONS; ISOZYME	2'-5'-Oligoadenylate synthetases are interferon-induced enzymes that upon activation by double-stranded RNA polymerize ATP to 2'-5'-linked oligoadenylates. In our continuing effort to understand the mechanism of catalysis by these enzymes, we used photo affinity cross-linking and peptide mapping to identify the substrate-binding sites of the P69 isozyme of human 2'-5'-oligoadenylate synthetases. Radiolabeled azido 2'-5'-oligoadenylate dimers were enzymatically synthesized and used as ligands for cross-linking to the P69 protein by exposure to ultraviolet light. The radiolabeled protein was digested with trypsin, and two ligand-cross-linked peptides were purified by immobilized aluminum affinity chromatography followed by reverse phase high pressure liquid chromatography. The peptides were identified by mass spectrometry and peptide sequencing and were found to correspond to residues 420-425 and 539-547 of P69. To examine the functional importance of the cross-linking sites, specific residues in the two peptides were mutated. When residues in the two sites were mutated individually, ligand cross-linking was selectively eliminated at the mutated site, and the enzyme activity was lost almost completely. Using substrates that can serve either as a donor or as an acceptor but not both, we could identify one of the sites as the acceptor and the other as the donor site.	Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NCI NIH HHS [CA68782, CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068782, P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bandyopadhyay S, 1998, BIOCHEMISTRY-US, V37, P3824, DOI 10.1021/bi972848e; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Ghosh A, 1997, J BIOL CHEM, V272, P33220, DOI 10.1074/jbc.272.52.33220; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; Marie I, 1997, EUR J BIOCHEM, V248, P558, DOI 10.1111/j.1432-1033.1997.t01-1-00558.x; Martin G, 1999, PROTEIN SCI, V8, P2380; Martin G, 2000, EMBO J, V19, P4193, DOI 10.1093/emboj/19.16.4193; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; Rebouillat D, 1999, J BIOL CHEM, V274, P1557, DOI 10.1074/jbc.274.3.1557; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; RUSH J, 1990, J BIOL CHEM, V265, P4821; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Sarkar SN, 1999, J BIOL CHEM, V274, P1848, DOI 10.1074/jbc.274.3.1848; Sarkar SN, 1998, METHODS, V15, P233, DOI 10.1006/meth.1998.0627; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SILVERMAN RH, 1997, MRNA METABOLISM POST, P295; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yamamoto Y, 2000, J INTERF CYTOK RES, V20, P337, DOI 10.1089/107999000312496	23	14	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24321	24330		10.1074/jbc.M110202200	http://dx.doi.org/10.1074/jbc.M110202200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986302	hybrid			2022-12-27	WOS:000176611800047
J	Ouyang, YB; Crawley, JTB; Aston, CE; Moore, KL				Ouyang, YB; Crawley, JTB; Aston, CE; Moore, KL			Reduced body weight and increased postimplantation fetal death in tyrosylprotein sulfotransferase-1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE O-SULFATION; MOLECULAR-CLONING; CHOLECYSTOKININ; PROTEIN; RECEPTORS; GENES	Tyrosine sulfation is mediated by one of two Golgi isoenzymes, called tyrosylprotein sulfotransferases (TPST-1 and TPST-2). A relatively small number of proteins are known to undergo tyrosine sulfation, including certain adhesion molecules, G-protein-coupled receptors, coagulation factors, serpins, extracellular matrix proteins, and hormones. As one approach to explore the role of these enzymes in vivo and how they might interact in biological systems, we have generated TPST-1-deficient mice by targeted disruption of the Tpst1 gene. Tpst1(+/-) mice appear normal and, when interbred, yield litters of normal size with a Mendelian genetic distribution and an equal sex distribution. Tpst1(-/-) mice appear healthy but have approximate to5% lower average body weight than Tpst1(+/+) controls. In addition, we show that although fertility of Tpst1(-/-) males and females per se is normal, Tpst1(-/-) females have significantly smaller litters because of fetal death between 8.5 and 15.5 days postcoitum. These findings suggest that there are proteins involved in regulation of body weight and reproductive physiology, which require tyrosine sulfation for optimal function that are yet to be described. Our findings also strongly support the conclusion that TPST-1 and TPST-2 have distinct biological roles that may reflect differences in their macromolecular substrate specificity.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Moore, KL (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St,Mailstop 45, Oklahoma City, OK 73104 USA.	kevin-moore@omrf.ouhse.edu	Crawley, James TB/A-9290-2008	Crawley, James TB/0000-0002-6723-7841	NHLBI NIH HHS [HL63152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Hansen CP, 2000, AM J PHYSIOL-GASTR L, V279, pG903, DOI 10.1152/ajpgi.2000.279.5.G903; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Lacourse KA, 1999, AM J PHYSIOL-GASTR L, V276, pG1302, DOI 10.1152/ajpgi.1999.276.5.G1302; MOORE KL, 2001, WILEY ENCY MOL MED; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; Nicholas HB, 1999, ENDOCRINE, V11, P285, DOI 10.1385/ENDO:11:3:285; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; Rehfeld JF, 1998, PHYSIOL REV, V78, P1087, DOI 10.1152/physrev.1998.78.4.1087; RENSDOMIANO S, 1989, J BIOL CHEM, V264, P899; STEIGERWALT RW, 1981, ENDOCRINOLOGY, V109, P1746, DOI 10.1210/endo-109-5-1746; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yoshinari K, 2001, J BIOCHEM MOL TOXIC, V15, P67, DOI 10.1002/jbt.1	23	60	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23781	23787		10.1074/jbc.M202420200	http://dx.doi.org/10.1074/jbc.M202420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964405	hybrid			2022-12-27	WOS:000176475700089
J	Parkin, SE; Baer, M; Copeland, TD; Schwartz, RC; Johnson, PF				Parkin, SE; Baer, M; Copeland, TD; Schwartz, RC; Johnson, PF			Regulation of CCAAT/enhancer-binding protein (C/EBP) activator proteins by heterodimerization with C/EBP gamma (Ig/EBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; ACUTE-PHASE RESPONSE; DNA-BINDING; TRANSCRIPTION FACTORS; LEUCINE ZIPPER; HEPATOCYTE PROLIFERATION; CELL-PROLIFERATION; MESSENGER-RNA; IN-VITRO; BETA	The CCAAT/enhancer-binding proteins (C/EBPs) are basic leucine zipper transcription factors that play important roles in regulating cell growth and differentiation. C/EBP proteins form leucine zipper-mediated homodimers but are also capable of heterodimerizing with other C/EBPs in vitro. Here we show that C/EBPbeta occurs predominantly as a heterodimer that displays rapid mobility in gel shift assays. Biochemical fractionation and antibody supershift assays demonstrate that the C/EBPbeta heterodimeric partner is C/EBPgamma (Ig/EBP), a C/EBP protein that has been implicated as an inhibitor of other family members. Although most cell types express C/EBPbeta.C/EBPgamma heterodimers, macrophages contain a C/EBPbeta partner that is serologically distinct from C/EBPgamma. We found that C/EBPgamma blocked the ability of C/EBPbeta and C/EBPgamma to activate a reporter gene in L cell fibroblasts but did not inhibit a chimeric C/EBPbeta protein containing the GCN4 leucine zipper. Repression by C/EBPgamma occurs at the level of transactivation and requires heterodimerization with the C/EBP partner. C/EBPgamma was an ineffective repressor in HepG2 hepatoma cells despite forming C/EBP heterodimers, and C/EBPalpha was not effectively inhibited in either L or HepG2 cells. Our findings demonstrate that C/EBPgamma modulates C/EBP activity in a cell- and isoform-specific manner.	NCI Frederick, Basic Res Lab, Regulat Cell Growth Lab, Frederick, MD 21702 USA; NCI Frederick, Basic Res Lab, Eukaryot Transcript Regulat Sect, Frederick, MD 21702 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Michigan State University	Johnson, PF (corresponding author), NCI Frederick, Basic Res Lab, Regulat Cell Growth Lab, Frederick, MD 21702 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; An MR, 1996, MOL CELL BIOL, V16, P2295; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COOPER C, 1992, J IMMUNOL, V149, P3225; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEVELLIS J, 1973, INDUCTION ENZYMES GL; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Hu HM, 1998, J IMMUNOL, V160, P2334; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kaisho T, 1999, J EXP MED, V190, P1573, DOI 10.1084/jem.190.11.1573; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE KAW, 1992, J CELL SCI, V103, P9; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V6, P771; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POLL V, 1990, CELL, V63, P643; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WALKER WS, 1975, J IMMUNOL, V114, P765; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zafarana G, 2000, EMBO J, V19, P5856, DOI 10.1093/emboj/19.21.5856; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	51	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23563	23572		10.1074/jbc.M202184200	http://dx.doi.org/10.1074/jbc.M202184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11980905	hybrid			2022-12-27	WOS:000176475700061
J	Robichaud, GA; Barbeau, B; Fortin, JF; Rothstein, DM; Tremblay, MJ				Robichaud, GA; Barbeau, B; Fortin, JF; Rothstein, DM; Tremblay, MJ			Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; HUMAN LYMPHOCYTES-T; GENE-EXPRESSION; INTERLEUKIN-2 PRODUCTION; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTORS; VIRAL REPLICATION	Human immunodeficiency virus type-1 (HIV-1) preferentially replicates in CD4-expressing T cells bearing a "memory" (CD45RO+) rather than a "naive" (CD45RA+/CD62L+) phenotype. Yet the basis for the higher susceptibility of these cells to HIV-1 infection remains unclear. Because the nature of the CD45 isoform itself can affect biochemical events in T cells, we set out to determine whether these isoforms could differently modulate HIV-1 long terminal repeat (LTR) activity and thereby replication. Through the use of CD4+ Jurkat T cells specifically expressing distinct CD45 isoforms (i.e. CD45RABC or CD45RO), we demonstrated that a difference in CD45 isoform expression conferred preferential replication of HIV-1 to CD45RO-expressing T cell clones following a physiological CD3/CD28 stimulation. Closer analysis indicated that higher HIV-1 LTR activation levels were consistently observed in CD45RO-positive cells, which was paralleled by more pronounced nuclear factor of activated T cells (NFAT) activation in these same cells. Specific involvement of NFAT1 was revealed in studied Jurkat clones by mobility shift analyses. In addition, preferential activation of the LTR and viral replication in CD45RO T cells was FK506- and cyclosporin A-sensitive. These results underscore the importance of NFAT in HIV-1 regulation and for the first time identify the role of the CD45 isoform in limiting productive HIV-1 replication to the human CD4 memory T cell subset.	CHU Quebec, CHU Laual, Lab Immunoretorvirol Humaine, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, St Foy, PQ G1V 4G2, Canada; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA	Laval University; Laval University; Stanford University; Yale University	Tremblay, MJ (corresponding author), CHU Quebec, CHU Laual, Lab Immunoretorvirol Humaine, Ctr Rech Infectiol, RC709,2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.		Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045485, R01AI036317] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36317, AI45485] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGEMATSU K, 1995, J IMMUNOL, V154, P3627; ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Barbeau B, 2001, J IMMUNOL, V167, P2700, DOI 10.4049/jimmunol.167.5.2700; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Cayota A, 1996, CLIN EXP IMMUNOL, V104, P11, DOI 10.1046/j.1365-2249.1996.d01-652.x; CAYOTA A, 1990, LANCET, V336, P941, DOI 10.1016/0140-6736(90)92311-5; CAYOTA A, 1993, CLIN EXP IMMUNOL, V91, P241; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; Dornan S, 2002, J BIOL CHEM, V277, P1912, DOI 10.1074/jbc.M108386200; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; FORTIN JF, 1999, CAN J INFECT DIS, V10, pC25; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hall SR, 1999, EUR J IMMUNOL, V29, P2098, DOI 10.1002/(SICI)1521-4141(199907)29:07<2098::AID-IMMU2098>3.3.CO;2-2; Helbert MR, 1997, CLIN EXP IMMUNOL, V107, P300, DOI 10.1111/j.1365-2249.1997.280-ce1170.x; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; Jacque JM, 1996, J VIROL, V70, P2930; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24249; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; PICKER LJ, 1993, J IMMUNOL, V150, P1105; PULIDO R, 1994, J EXP MED, V179, P1035, DOI 10.1084/jem.179.3.1035; Roederer M, 1997, J CLIN INVEST, V99, P1555, DOI 10.1172/JCI119318; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; TEDDER TF, 1985, J IMMUNOL, V134, P2983; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Tsunetsugu-Yokota Y, 2000, J LEUKOCYTE BIOL, V67, P432, DOI 10.1002/jlb.67.3.432; Wang Y, 2000, J IMMUNOL, V164, P2557, DOI 10.4049/jimmunol.164.5.2557; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641	62	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23733	23741		10.1074/jbc.M201563200	http://dx.doi.org/10.1074/jbc.M201563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956207	hybrid			2022-12-27	WOS:000176475700083
J	Sasakura, Y; Hirata, S; Sugiyama, S; Suzuki, S; Taguchi, S; Watanabe, M; Matsui, T; Sagami, I; Shimizu, T				Sasakura, Y; Hirata, S; Sugiyama, S; Suzuki, S; Taguchi, S; Watanabe, M; Matsui, T; Sagami, I; Shimizu, T			Characterization of a direct oxygen sensor heme protein from Escherichia coli - Effects of the heme redox states and mutations at the heme-binding site on catalysis and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PHOSPHODIESTERASE; REGULATOR; BACTERIA; MELILOTI; ARCHAEA; SUBUNIT; FIXL; COOA	A protein containing a heme-binding PAS (PAS is from the protein names in which imperfect repeat sequences were first recognized: (P) under bar ER, (A) under bar RNT, and (S) under bar IM) domain from Escherichia coli has been implied a direct oxygen sensor (Ec DOS) enzyme. In the present study, we isolated cDNA for the Ec DOS full-length protein, expressed it in E. coli, and examined its structure-function relationships for the first time. Ec DOS was found to be tetrameric and was obtained as a 6-coordinate low spin ferric heme complex. Its a-helix content was calculated as 53% by CD spectroscopy. The redox potential of the heme was found to be +67 mV versus SHE. Mutation of His-77 of the isolated PAS domain abolished heme binding, whereas mutation of His-83 did not, suggesting that His-77 is one of the heme axial ligands. Ferrous, but not ferric, Ec DOS had phosphodiesterase (PDE) activity of nearly 0.15 min(-1) with cAMP, which was optimal at pH 8.5 in the presence of Mg2+ and was strongly inhibited by CO, NO, and etazolate, a selective cAMP PDE inhibitor. Absorption spectral changes indicated tight CO and NO bindings to the ferrous heme. Therefore, the present study unequivocally indicates for the first time that Ec DOS exhibits PDE activity with cAMP and that this is regulated by the heme redox state.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp	Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Fasman G.D., 1996, CIRCULAR DICHROISM C; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P5500, DOI 10.1021/bi00475a013; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; HIRATSUKA T, 1982, J BIOL CHEM, V257, P13354; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Imamura R, 1996, J BIOL CHEM, V271, P25423, DOI 10.1074/jbc.271.41.25423; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lahiri S, 2000, OXYGEN SENSING MOL M; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Mukai M, 2000, BIOCHEMISTRY-US, V39, P13810, DOI 10.1021/bi001184x; MYER YP, 1978, BIOCHEMISTRY-US, V17, P3723, DOI 10.1021/bi00611a008; Nakajima H, 2001, J BIOL CHEM, V276, P37895; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; ROGERS KR, 1999, CURR OPIN CHEM BIOL, V3, P158; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Tuckerman JR, 2001, J MOL BIOL, V308, P449, DOI 10.1006/jmbi.2001.4591; Tuominen EKJ, 2001, J BIOL CHEM, V276, P19356, DOI 10.1074/jbc.M100853200; VanDyke BR, 1996, J AM CHEM SOC, V118, P3490, DOI 10.1021/ja954181u; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200	34	100	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23821	23827		10.1074/jbc.M202738200	http://dx.doi.org/10.1074/jbc.M202738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11970957	hybrid			2022-12-27	WOS:000176475700095
J	Valentini, G; Chiarelli, LR; Fortin, R; Dolzan, M; Galizzi, A; Abraham, DJ; Wang, CQ; Bianchi, P; Zanella, A; Mattevi, A				Valentini, G; Chiarelli, LR; Fortin, R; Dolzan, M; Galizzi, A; Abraham, DJ; Wang, CQ; Bianchi, P; Zanella, A; Mattevi, A			Structure and function of human erythrocyte pyruvate kinase - Molecular basis of nonspherocytic hemolytic anemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC REGULATION; RABBIT MUSCLE; POINT MUTATIONS; ENZYME; GENE; SITE; SUBSTITUTION; DEFICIENCY; INTERFACES; RESOLUTION	Deficiency of human erythrocyte isozyme (RPK) is, together with glucose-6-phosphate dehydrogenase deficiency, the most common cause of the nonspherocytic hemolytic anemia. To provide a molecular framework to the disease, we have solved the 2.7 Angstrom resolution crystal structure of human RPK in complex with fructose 1,6-bisphosphate, the allosteric activator, and phosphoglycolate, a substrate analogue, and we have functionally and structurally characterized eight mutants (G332S, G364D, T384M, D390N, R479H, R486W, R504L, and R532W) found in RPK-deficient patients. The mutations target distinct regions of RPK structure, including domain interfaces and catalytic and allosteric sites. The mutations affect to a different extent thermostability, catalytic efficiency, and regulatory properties. These studies are the first to correlate the clinical symptoms with the molecular properties of the mutant enzymes. Mutations greatly impairing thermostability and/or activity are associated with severe anemia. Some mutant proteins exhibit moderate changes in the kinetic parameters, which are sufficient to cause mild to severe anemia, underlining the crucial role of RPK for erythrocyte metabolism. Prediction of the effects of mutations is difficult because there is no relation between the nature and location of the replaced amino acid and the type of molecular perturbation. Characterization of mutant proteins may serve as a valuable tool to assist with diagnosis and genetic counseling.	Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Travers, I-27100 Pavia, Italy; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA; Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy; Osped Maggiore, Div Ematol, IRCCS, I-20122 Milan, Italy	University of Pavia; Virginia Commonwealth University; University of Pavia; IRCCS Ca Granda Ospedale Maggiore Policlinico	Mattevi, A (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Travers, Abbiategrasso 207, I-27100 Pavia, Italy.	mattevi@ipvgen.unipv.it	mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019; Bianchi, Paola/L-2531-2016; Chiarelli, Laurent Roberto/J-8368-2016	mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; Bianchi, Paola/0000-0001-5976-5233; Chiarelli, Laurent Roberto/0000-0003-0348-9764				Allen SC, 1996, ACTA CRYSTALLOGR D, V52, P499, DOI 10.1107/S0907444995016040; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beutler E., 1984, GLUTATHIONE RED CELL; Bianchi P, 2000, BLOOD CELL MOL DIS, V26, P47, DOI 10.1006/bcmd.2000.0276; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Demina A, 1998, BLOOD, V92, P647, DOI 10.1182/blood.V92.2.647.414k13_647_652; Fenton AW, 2002, ARCH BIOCHEM BIOPHYS, V397, P28, DOI 10.1006/abbi.2001.2634; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; Friesen RHE, 1998, J BIOL CHEM, V273, P14772, DOI 10.1074/jbc.273.24.14772; GUPTA RK, 1976, BIOCHEMISTRY-US, V15, P2881, DOI 10.1021/bi00658a028; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KANNO H, 1994, BLOOD, V84, P3505; KANNO H, 1994, BLOOD, V83, P2311; KANNO H, 1991, P NATL ACAD SCI USA, V88, P8218, DOI 10.1073/pnas.88.18.8218; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKOMEK M, 1994, ANN HEMATOL, V69, P253, DOI 10.1007/BF01700280; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Larsen TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P199, DOI 10.1006/abbi.1997.0257; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LENZNER C, 1994, BLOOD, V83, P2817, DOI 10.1182/blood.V83.10.2817.2817; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6792, DOI 10.1021/bi962869t; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEUBAUER B, 1991, BLOOD, V77, P1871; Nickoloff J A, 1996, Methods Mol Biol, V58, P455; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; Valentin G, 2000, J BIOL CHEM, V275, P18145, DOI 10.1074/jbc.M001870200; vanSolinge WW, 1997, BLOOD, V90, P4987, DOI 10.1182/blood.V90.12.4987.4987_4987_4995; Wang CQ, 2001, BLOOD, V98, P3113, DOI 10.1182/blood.V98.10.3113; Wooll JO, 2001, J MOL BIOL, V312, P525, DOI 10.1006/jmbi.2001.4978; Zanella A, 1997, BLOOD, V89, P3847, DOI 10.1182/blood.V89.10.3847.3847_3847_3852; Zanella A, 2000, BEST PRACT RES CL HA, V13, P57, DOI 10.1053/beha.1999.0057	38	102	105	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23807	23814		10.1074/jbc.M202107200	http://dx.doi.org/10.1074/jbc.M202107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960989	hybrid			2022-12-27	WOS:000176475700093
J	Wang, WL; Campos, AH; Prince, CZ; Mou, YS; Pollman, MJ				Wang, WL; Campos, AH; Prince, CZ; Mou, YS; Pollman, MJ			Coordinate Notch3-hairy-related transcription factor pathway regulation in response to arterial injury - Mediator role of platelet-derived growth factor and ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL FATE; NOTCH3 MUTATIONS; ACTIVATION; INHIBITION; CADASIL; GRIDLOCK; EXPRESSION; ANTIBODY; MEMBERS; KINASE	The Notch family of receptors and downstream effectors plays a critical role in cell fate determination during vascular ontogeny. Moreover, the human cerebral autosomal dominant artriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) syndrome of premature stroke and dementia is a heritable arteriopathy with alterations in vascular smooth muscle cells (VSMCs) resulting from mutations within Notch3. However, the expression and regulation of the Notch and hairy-related transcription factor (HRT) pathway in adult VSMCs in vitro and in vivo remain poorly characterized. The present study documents that the well-described modulation of VSMC fate in response to vascular injury and growth factor activation involves a coordinate regulation of the Notch and HRT pathways. Furthermore, platelet-derived growth factor promotes a similar coordinate down-regulation of the Notch receptors and HRT genes in cultured VSMCs via an ERK-dependent signaling pathway. Moreover, we established that HRT1 and HRT2 are direct downstream target genes of Notch3 signaling in VSMCs and determined that the activity of the nuclear protein RBP-Jk is essential for their regulation. These findings provide initial insight into the context- and cell type-dependent coordinate regulation of Notch3 and downstream HRT transcriptional pathway effector genes in VSMCs in vitro and in vivo that may have important implications for understanding the role of Notch signaling in human health and vascular disease.	Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA	Morehouse School of Medicine	Pollman, MJ (corresponding author), Morehouse Sch Med, Cardiovasc Res Inst, 720 Westview Dr,SW,Res Wing, Atlanta, GA 30310 USA.	mpollman@msm.edu	Campos, Alexandre/E-8258-2010					Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Beatus P, 1999, DEVELOPMENT, V126, P3925; Campos AH, 2001, CIRCULATION, V104, P275; Chandrasekar B, 2000, J AM COLL CARDIOL, V35, P555, DOI 10.1016/S0735-1097(99)00596-3; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; CHITNIS AB, 1995, MOL CELL NEUROSCI, V6, P311, DOI 10.1006/mcne.1995.1024; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; CONLON RA, 1995, DEVELOPMENT, V121, P1533; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Joutel A, 2000, ANN NEUROL, V47, P388, DOI 10.1002/1531-8249(200003)47:3<388::AID-ANA19>3.3.CO;2-H; Joutel A, 1997, ANN NY ACAD SCI, V826, P213, DOI 10.1111/j.1749-6632.1997.tb48472.x; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 2001, LANCET, V358, P2049, DOI 10.1016/S0140-6736(01)07142-2; Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5; KANZAKI T, 1994, EUR J CLIN INVEST, V24, P377, DOI 10.1111/j.1365-2362.1994.tb02179.x; Krebs LT, 2000, GENE DEV, V14, P1343; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; McLaughlin KA, 2000, DEV BIOL, V227, P567, DOI 10.1006/dbio.2000.9913; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Mitani Y, 2000, FASEB J, V14, P805, DOI 10.1096/fasebj.14.5.805; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Pfeifer M, 1998, RESP PHYSIOL, V111, P201, DOI 10.1016/S0034-5687(97)00102-3; Pyles JM, 1997, CIRC RES, V81, P904; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rubin P, 1998, INT J RADIAT ONCOL, V40, P929, DOI 10.1016/S0360-3016(97)00937-1; Shuster CB, 1998, MICROCIRCULATION, V5, P239; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	43	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23165	23171		10.1074/jbc.M201409200	http://dx.doi.org/10.1074/jbc.M201409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971902	hybrid			2022-12-27	WOS:000176475700011
J	Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M				Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M			Scaffold role of a mitogen-activated protein kinase phosphatase, SKRP1, for the JNK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; NECROSIS-FACTOR RECEPTOR; JUN NH2-TERMINAL KINASE; MAP-KINASE; C-JUN; TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; CELL-LINES; SELECTIVELY DEPHOSPHORYLATES; TRANSDUCTION PATHWAY	Stress-activated protein kinase (SAPK) pathway-regulating phosphatase 1 (SKRP1) has been identified as a member of the mitogen-activated protein kinase (MAPK) phosphatase (MKP) family that interacts physically with the MAPK kinase (MAPKK) MKK7, a c-Jun N-terminal kinase (JNH) activator, and inactivates the MAPK JNK pathway. Although these findings indicated that SKRP1 contributes to the precise regulation of JNK signaling, it remains to be elucidated how SKRP1 is integrated into this pathway. We report that SKRP1 also plays a scaffold role for the JNK signaling, judged by the following observations. SKRP1 selectively formed the stable complexes with MKK7 but not with MKK4 and biphasically regulated the MKK7 activity and MKK7-induced gene transcription in vivo. Co-precipitation analysis between SKRP1 and MKK7-activating MAPKK kinases (MAPKKKs) revealed that SKRP1 also interacted with the MAPKKK, apoptosis signal-regulating kinase 1 (ASK1), but not with MAP kinase kinase kinase 1 (MEKK1). Consistent with these findings, SKRP1 expression increased the ASK1-MKK7 complexes in a dose-dependent manner and specifically enhanced the activation of MKK7 by ASK1. Thus, our findings are, to our knowledge, the first evidence to show that an MKP also functions as a scaffold protein for the particular MAPK signaling.	Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan	Tokyo Medical & Dental University (TMDU); Keio University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Dowd S, 1998, J CELL SCI, V111, P3389; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200	92	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23919	23926		10.1074/jbc.M200838200	http://dx.doi.org/10.1074/jbc.M200838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959862	Green Submitted, hybrid			2022-12-27	WOS:000176475700106
J	Belogurov, GA; Turkina, MV; Penttinen, A; Huopalahti, S; Baykov, AA; Lahti, R				Belogurov, GA; Turkina, MV; Penttinen, A; Huopalahti, S; Baykov, AA; Lahti, R			H+-Pyrophosphatase of Rhodospirillum rubrum - High yield expression in Escherichia coli and identification of the Cys residues responsible for inactivation by mersalyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING PYROPHOSPHATASE; SUBSTRATE-BINDING SUBUNIT; INORGANIC PYROPHOSPHATE; PUMPING PYROPHOSPHATASE; ORTHO-PHOSPHATE; INHIBITION; PROTEINS; SYNTHASE; ATP; K+	H+-translocating pyrophosphatase (H+-PPase) of the photosynthetic bacterium Rhodospirillum rubrum was expressed in Escherichia coli C43(DE3) cells. Recombinant H+-PPase was observed in inner membrane vesicles, where it catalyzed both PPi hydrolysis coupled with H+ transport into the vesicles and PPi synthesis. The hydrolytic activity of H+-PPase in E. coli vesicles was eight times greater than that in R. rubrum chromatophores but exhibited similar sensitivity to the H+-PPase inhibitor, aminomethylenediphosphonate, and insensitivity to the soluble PPase inhibitor, fluoride. Using this expression system, we showed that substitution of Cys(185), Cys(222), or Cys(573) with aliphatic residues had no effect on the activity of H+-PPase but decreased its sensitivity to the sulfhydryl modifying reagent, mersalyl. H+-PPase lacking all three Cys residues was completely resistant to the effects of mersalyl. Mg2+ and MgPPi protected Cys(185) and Cys(573) from modification by this agent but not Cys(222) Phylogenetic analyses of 23 nonredundant H+-PPase sequences led to classification into two subfamilies. One subfamily invariably contains Cys(222) and includes all known K+-independent H+-PPases, whereas the other incorporates a conserved Cys(573) but lacks Cys(222) and includes all known K+-dependent H+-PPases. These data suggest a specific link between the incidence of Cys at positions 222 and 573 and the K+ dependence of H+-PPase.	Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Turku; Lomonosov Moscow State University	Baykov, AA (corresponding author), Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland.	baykov@genebee.msu.su; reijo.lahti@utu.fi	Baykov, Alexander/AAH-5301-2021; Baykov, Alexander A/C-7981-2012	Baykov, Alexander/0000-0002-2495-8200; Belogurov, Georgiy/0000-0002-3070-6843; Kauko, Anni/0000-0003-1131-3865				BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; BALTSCHEFFSKY H, 1986, CHEM SCRIPTA, V26B, P259; Baltscheffsky M, 1995, PHOTOSYNTH RES, V46, P87, DOI 10.1007/BF00020419; BALTSCHEFFSKY M, 1967, NATURE, V216, P241, DOI 10.1038/216241a0; Baltscheffsky M, 1999, FEBS LETT, V452, P121, DOI 10.1016/S0014-5793(99)00617-1; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; BAYKOV AA, 1992, EUR J BIOCHEM, V206, P463, DOI 10.1111/j.1432-1033.1992.tb16947.x; Baykov AA, 1996, EUR J BIOCHEM, V236, P121, DOI 10.1111/j.1432-1033.1996.00121.x; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; DALEY LA, 1986, ANAL BIOCHEM, V157, P385, DOI 10.1016/0003-2697(86)90642-1; DAVIES JM, 1992, P NATL ACAD SCI USA, V89, P11701, DOI 10.1073/pnas.89.24.11701; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Drozdowicz YM, 2000, PLANT PHYSIOL, V123, P353, DOI 10.1104/pp.123.1.353; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Guillory R J, 1972, Biochem J, V129, P571; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mitsuda N, 2001, FEBS LETT, V488, P29, DOI 10.1016/S0014-5793(00)02400-5; MOYLE J, 1972, FEBS LETT, V23, P233, DOI 10.1016/0014-5793(72)80349-1; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; NYREN P, 1985, ANAL BIOCHEM, V151, P504, DOI 10.1016/0003-2697(85)90211-8; NYREN P, 1986, BIOCHIM BIOPHYS ACTA, V851, P276, DOI 10.1016/0005-2728(86)90135-0; NYREN P, 1991, FEMS MICROBIOL LETT, V77, P265, DOI 10.1016/0378-1097(91)90563-P; Perez-Castineira JR, 2001, FEBS LETT, V496, P6, DOI 10.1016/S0014-5793(01)02390-0; RANDAHL H, 1979, EUR J BIOCHEM, V102, P251, DOI 10.1111/j.1432-1033.1979.tb06287.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; ROS R, 1995, J BIOL CHEM, V270, P4368, DOI 10.1074/jbc.270.9.4368; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO MH, 1994, J BIOL CHEM, V269, P6725; SATO MH, 1991, FEBS LETT, V290, P177, DOI 10.1016/0014-5793(91)81254-6; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; STRID A, 1987, ACTA CHEM SCAND B, V41, P116, DOI 10.3891/acta.chem.scand.41b-0116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU JJ, 1991, FEBS LETT, V283, P57, DOI 10.1016/0014-5793(91)80552-E; ZHEN RG, 1994, J BIOL CHEM, V269, P23342; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	55	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22209	22214		10.1074/jbc.M202951200	http://dx.doi.org/10.1074/jbc.M202951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956221	hybrid			2022-12-27	WOS:000176313600015
J	Thoden, JB; Holden, HM; Zhuang, ZH; Dunaway-Mariano, D				Thoden, JB; Holden, HM; Zhuang, ZH; Dunaway-Mariano, D			X-ray crystallographic analyses of inhibitor and substrate complexes of wild-type and mutant 4-hydroxybenzoyl-CoA thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTACONATE COA-TRANSFERASE; SARCOPLASMIC-RETICULUM; ACIDAMINOCOCCUS FERMENTANS; MACROMOLECULAR STRUCTURES; CRYSTAL-STRUCTURE; ACTIVE-SITE; BINDING; ATPASE; PHOSPHATE; PATHWAY	The metabolic pathway by which 4-chlorobenzoate is degraded to 4-hydroxybenzoate in the soil-dwelling microbe Pseudomonas sp. strain CBS-3 consists of three enzymes including 4-hydroxybenzoyl-CoA thioesterase. The structure of the unbound form of this thioesterase has been shown to contain the so-called "hot dog" fold with a large helix packed against a five-stranded anti-parallel beta-sheet. To address the manner in which the enzyme accommodates the substrate within the active site, two inhibitors have been synthesized, namely 4-hydroxyphenacyl-CoA and 4-hydroxybenzyl-CoA. Here we describe the structural analyses of the enzyme complexed with these two inhibitors determined and refined to 1.5 and 1.8 Angstrom resolution, respectively. These studies indicate that only one protein side chain, Ser(91), participates directly in ligand binding. All of the other interactions between the protein and the inhibitors are mediated through backbone peptidic NH groups, carbonyl oxygens, and/or solvents. The structures of the enzyme-inhibitor complexes suggest that both a hydrogen bond and the positive end of a helix dipole moment serve to polarize the electrons away from the carbonyl carbon of the acyl group, thereby making it more susceptible to nucleophilic attack. Additionally, these studies demonstrate that the carboxylate group of Asp(17) is similar to3.2 Angstrom from the carbonyl carbon of the acyl group. To address the role of Asp(17), the structure of the site-directed mutant protein D17N with bound substrate has also been determined. Taken together, these investigations suggest that the reaction mechanism may proceed through an acyl enzyme intermediate.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of Wisconsin System; University of Wisconsin Madison; University of New Mexico	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu; dd39@unm.edu	Hu, Ruogu/B-2203-2008		NIGMS NIH HHS [GM 55513] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P1604, DOI 10.1021/bi00405a032; Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P5606; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Jacob U, 1997, STRUCTURE, V5, P415, DOI 10.1016/S0969-2126(97)00198-6; KLAGES U, 1981, J BACTERIOL, V146, P64, DOI 10.1128/JB.146.1.64-68.1981; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Li J, 2000, NAT STRUCT BIOL, V7, P555; Lightstone FC, 1996, J AM CHEM SOC, V118, P2595, DOI 10.1021/ja952589l; Luo LS, 2001, BIOCHEMISTRY-US, V40, P15684, DOI 10.1021/bi011536f; Mack M, 1997, FEBS LETT, V405, P209, DOI 10.1016/S0014-5793(97)00187-7; MISSIAEN L, 1988, BIOCHEM J, V253, P827, DOI 10.1042/bj2530827; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICK U, 1982, J BIOL CHEM, V257, P6111; ROCHET JC, 1994, PROTEIN SCI, V3, P975; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SOLOMON F, 1969, J BIOL CHEM, V244, P1079; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROULLIER A, 1992, J BIOL CHEM, V267, P22821	24	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27468	27476		10.1074/jbc.M203904200	http://dx.doi.org/10.1074/jbc.M203904200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11997398	hybrid			2022-12-27	WOS:000177055900096
J	D'Souza, I; Schellenberg, GD				D'Souza, I; Schellenberg, GD			Tau exon 10 expression involves a bipartite intron 10 regulatory sequence and weak 5 ' and 3 ' splice sites.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FAMILIAL FRONTOTEMPORAL DEMENTIA; MICROTUBULE-ASSOCIATED PROTEINS; FTDP-17 MUTATIONS; NEURODEGENERATIVE DISORDERS; U1 SNRNP; GENE; CHROMOSOME-17; PARKINSONISM; PHOSPHORYLATION	tau mutations that deregulate alternative exon 10 (E10) splicing cause frontotemporal dementia with parkinsonism chromosome 17-type by several mechanisms. Previously we showed that E10 splicing involved exon splicing enhancer sequences at the Wand 3' ends of E10, an exon splicing silencer, a weak 5' splice site, and an intron splicing silencer (ISS) within intron 10 (I10). Here, we identify additional regulatory sequences in I10 using both non-neuronal and neuronal cells. The ISS sequence extends from I10 nucleotides 11-18, which is sufficient to inhibit use of a weakened 5' splice site of a heterologous exon. Furthermore, ISS function is location-independent but requires proximity to a weak 5' splice site. Thus, the ISS functions as a linear sequence. A new cis-acting element, the intron splicing modulator (ISM), was identified immediately downstream of the ISS at I10 positions 19-26. The ISM and ISS form a bipartite regulatory element, within which the ISM functions when the ISS is present, mitigating E10 repression by the ISS. Additionally, the 3' splice site of E10 is weak and requires exon splicing enhancer elements for efficient E10 inclusion. Thus far, tau FTDP-17 splicing mutations affect six predicted cis-regulatory sequences.	Univ Washington, Div Gerontol, Dept Med, Seattle, WA 98195 USA; Univ Washington, Div Geriatr Med, Dept Med, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Schellenberg, GD (corresponding author), Univ Washington, Div Gerontol, Dept Med, Seattle, WA 98195 USA.				NATIONAL INSTITUTE ON AGING [R01AG011762] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11762] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CHIUCHAN G, 1998, J NEUROSCI, V18, P5322; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CRISPINO JD, 1995, GENE DEV, V9, P2314, DOI 10.1101/gad.9.18.2314; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Hwang DY, 1996, GENE DEV, V10, P338, DOI 10.1101/gad.10.3.338; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6235; Pastor P, 2001, ANN NEUROL, V49, P263, DOI 10.1002/1531-8249(20010201)49:2<263::AID-ANA50>3.0.CO;2-K; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Poorkaj P, 2001, MAMM GENOME, V12, P700, DOI 10.1007/s00335-001-2044-8; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; Shepard J, 2002, MOL CELL BIOL, V22, P221, DOI 10.1128/MCB.22.1.221-230.2002; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 2000, ANN NEUROL, V48, P939; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yasuda M, 2000, ANN NEUROL, V47, P422, DOI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G; Yean SL, 2000, NATURE, V408, P881, DOI 10.1038/35048617; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581	48	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26587	26599		10.1074/jbc.M203794200	http://dx.doi.org/10.1074/jbc.M203794200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000767	hybrid			2022-12-27	WOS:000176908700100
J	Qiao, JB; Mei, FC; Popov, VL; Vergara, LA; Cheng, XD				Qiao, JB; Mei, FC; Popov, VL; Vergara, LA; Cheng, XD			Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ANCHOR PROTEIN; ADENYLATE-CYCLASE; BINDING PROTEINS; MAP KINASE; RAS; AMP; PATHWAY; FAMILY; PHOSPHORYLATION; INHIBITION	Epac belongs to a new family of proteins that can directly mediate the action of the intracellular second messenger cAMP by activating a downstream small GTPase Rap1. The Epac/Rap1 pathway represents a novel cAMP-signaling cascade that is independent of the cAMP-dependent protein kinase (PKA). In this study, we have used fluorescence microscopy to probe the intracellular targeting of Epac during different stages of the cell division cycle and the structural features that are important for Epac localization. Our results suggest Epac, endogenous or expressed as a green fluorescent protein fusion protein, is mainly localized to the nuclear membrane and mitochondria during interphase in COS-7 cells. Deletion mutagenesis analysis reveals that whereas the DEP domain is responsible for membrane association, the mitochondrial-targeting sequence is located at the N terminus. Although Epac predominantly exhibits perinuclear localization in interphase, the subcellular localization of Epac is cell cycle-dependent. Epac disassociates from the nuclear membrane and localizes to the mitotic spindle and centrosomes in metaphase. At the end of the cell cycle, Epac is observed to reassociate with the nuclear envelope and concentrate around the contractile ring. Furthermore, overexpression of Epac in COS-7 cells leads to an increase in multinuclear cell populations. These results suggest that Epac may play an important role in mitosis.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, World Hlth Org Collaborating Ctr Trop Dis, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Sch Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; World Health Organization; University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Struct Biol, Galveston, TX 77555 USA.	xcheng@utmb.edu	Cheng, Xiaodong/O-8176-2019	Cheng, Xiaodong/0000-0002-3479-1694	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURGER MM, 1972, NATURE-NEW BIOL, V239, P161, DOI 10.1038/newbio239161a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIMINO MJ, 1981, J BIOL CHEM, V256, P876; FINE AS, 1982, J HISTOCHEM CYTOCHEM, V30, P1171, DOI 10.1177/30.11.6292286; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HARTL FU, 1974, SCIENCE, V41, P345; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; INABA T, 1985, ENDOCRINOLOGY, V117, P315, DOI 10.1210/endo-117-1-315; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KULINSKII V I, 1985, Biokhimiya, V50, P1546; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PRIZON V, 1998, ONCOGENE, V3, P201; RALL TW, 1958, J BIOL CHEM, V232, P1065; Roger PP, 1999, EXP CELL RES, V252, P492, DOI 10.1006/excr.1999.4646; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X; SULIMOVICI S, 1974, FEBS LETT, V41, P345, DOI 10.1016/0014-5793(74)81245-7; Thomson M, 1998, BBA-MOL CELL RES, V1403, P211, DOI 10.1016/S0167-4889(98)00069-X; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	44	148	156	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26581	26586		10.1074/jbc.M203571200	http://dx.doi.org/10.1074/jbc.M203571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000763	hybrid			2022-12-27	WOS:000176908700099
J	Temel, RE; Walzem, RL; Banka, CL; Williams, DL				Temel, RE; Walzem, RL; Banka, CL; Williams, DL			Apolipoprotein A-I is necessary for the in vivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; HDL RECEPTOR; TRANSGENIC MICE; APOA-I; CELLULAR-DISTRIBUTION; STEROIDOGENIC CELLS; RICH LIPOPROTEINS; TARGETED MUTATION; HEART-DISEASE; ADRENAL-CELLS	The severe depletion of cholesteryl ester (CE) in steroidogenic cells of apoA-I-/- mice suggests that apolipoprotein (apo) A-I plays a specific role in the high density lipoprotein (HDL) CE-selective uptake process mediated by scavenger receptor BI (SR-BI) in vivo. The nature of this role, however, is unclear because a variety of apolipoproteins bind to SR-BI expressed in transfected cells. In this study the role of apoA-I-/- in SR-BI-mediated HDL CE-selective uptake was tested via analyses of the biochemical properties of apoA-I-/- HDL and its interaction with SR-BI on adrenocortical cells, hepatoma cells, and cells expressing a transfected SR-BI. apoA-I-/- HDL are large heterogeneous particles with a core consisting predominantly of CE and a surface enriched in phospholipid, free cholesterol, apoA-II, and apoE. Functional analysis showed apoA-I-/- HDL to bind to SR-BI with the same or higher affinity as compared with apoA-I+/+ HDL, but apoA-I-/- HDL showed a 2-3-fold decrease in the V-max for CE transfer from the HDL particle to adrenal cells. These results indicate that the absence of apoA-I results in HDL particles with a reduced capacity for SR-BI-mediated CE-selective uptake. The reduced V-max illustrates that HDL properties necessary for binding to SR-BI are distinct from those properties necessary for the transfer of HDL CE from the core of the HDL particle to the plasma membrane. The reduced V-max for HDL CE-selective uptake likely contributes to the severe reduction in CE accumulation in steroidogenic cells of apoA-I-/- mice.	SUNY Stony Brook, Dept Pharmacol Sci, Med Ctr, Stony Brook, NY 11794 USA; La Jolla Inst Mol Med, Div Vasc Biol, San Diego, CA 92121 USA; Texas A&M Univ, Dept Poultry Sci, College Stn, TX 77843 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Texas A&M University System; Texas A&M University College Station	Williams, DL (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Med Ctr, Stony Brook, NY 11794 USA.		Eckhardt, Erik/G-1567-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058012, R01HL060844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60844, HL 58012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; de Beer MC, 2001, J LIPID RES, V42, P309; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GLOMSET JA, 1968, J LIPID RES, V9, P155; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LIU AC, 1994, J LIPID RES, V35, P2263; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; PARKS JS, 1995, J LIPID RES, V36, P349; PARKS JS, 1985, J BIOL CHEM, V260, P3155; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1997, J LIPID RES, V38, P1033; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; REAVEN E, 1989, J LIPID RES, V30, P1551; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RICHARD BM, 1993, J LIPID RES, V34, P571; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; RUBEN EM, 1991, NATURE, V353, P265; SATA T, 1972, J LIPID RES, V13, P757; SCHIMMER BP, 1981, FUNCTIONALLY DIFFERE, P61; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WALZEM RL, 1994, J LIPID RES, V35, P1354; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; Xu SZ, 1997, J LIPID RES, V38, P1289	64	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26565	26572		10.1074/jbc.M203014200	http://dx.doi.org/10.1074/jbc.M203014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000760	hybrid			2022-12-27	WOS:000176908700097
J	Boffa, MB; Hamill, JD; Bastajian, N; Dillon, R; Nesheim, ME; Koschinsky, ML				Boffa, MB; Hamill, JD; Bastajian, N; Dillon, R; Nesheim, ME; Koschinsky, ML			A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROCARBOXYPEPTIDASE-B; NF-KAPPA-B; PRO-CARBOXYPEPTIDASE-R; ACUTE-PHASE RESPONSE; FACTOR-IX PROMOTER; TRANSCRIPTION FACTOR; C/EBP-ALPHA; TAFI LEVELS; GLUCOCORTICOID RECEPTOR; FIBRINOGEN PROMOTER	Thrombin-activable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase B-like zymogen that upon activation by thrombin, thrombin-thrombomodulin, or plasmin attenuates fibrin clot lysis by inhibiting positive feedback in the fibrinolytic cascade. The concentration of TAFI in plasma varies in the human population and thus may constitute a risk factor for thrombotic disorders. In addition, TAFI has been reported to be a positive acute phase reactant in mice. We have initiated molecular analysis of the human TAFI promoter to understand the mechanisms underlying regulation of TAFI gene expression. We identified a putative C/EBP-binding site between -53 and -40 of the promoter. Mutations in this site that abolish C/EBP binding decrease TAFI promoter activity in human hepatoma (HepG2) cells by similar to80%. Get mobility shift analyses indicated that C/EBP-beta present in HepG2 nuclear extracts and C/EBP-a and -beta present in adult rat liver nuclear extracts bind to the C/EBP site. C/EBP-alpha, -beta, and -delta isoforms are all capable of binding to the C/EBP site and activating the TAFI promoter. The identification of a functional C/EBP-binding site in the human TAFI promoter may have important implications for the regulation of expression of this gene during development and in response to inflammatory stimuli.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Rm A208 Botterell Hall, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; An MR, 1996, MOL CELL BIOL, V16, P2295; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAZAAR L, 1995, J BIOL CHEM, V270, P14477; Boccia LM, 1996, MOL CELL BIOL, V16, P1929; Boffa M. B., 2001, Current Drug Targets - Cardiovascular and Haematological Disorders, V1, P59, DOI 10.2174/1568006013337999; Boffa MB, 1999, BIOCHEMISTRY-US, V38, P6547, DOI 10.1021/bi990229v; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Brouwers GJ, 2001, BLOOD, V98, P1992, DOI 10.1182/blood.V98.6.1992; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; Chabloz P, 2001, BRIT J HAEMATOL, V115, P150, DOI 10.1046/j.1365-2141.2001.03082.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chetaille P, 2000, THROMB HAEMOSTASIS, V83, P902, DOI 10.1055/s-0037-1613941; Christoffels VM, 1998, MOL CELL BIOL, V18, P6305, DOI 10.1128/MCB.18.11.6305; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; EATON DL, 1991, J BIOL CHEM, V266, P21833; Franco RF, 2001, HAEMATOLOGICA, V86, P510; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Hendriks D, 1992, Agents Actions Suppl, V38 ( Pt 1), P407; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; Henry M, 2001, BLOOD, V97, P2053, DOI 10.1182/blood.V97.7.2053; HU CH, 1995, J BIOL CHEM, V270, P28342; Juhan-Vague I, 2000, ARTERIOSCL THROM VAS, V20, P2156, DOI 10.1161/01.ATV.20.9.2156; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lisman T, 2001, GASTROENTEROLOGY, V121, P131, DOI 10.1053/gast.2001.25481; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MARI SS, 1999, J BIOL CHEM, V274, P35046; McGlynn LK, 1996, MOL CELL BIOL, V16, P1936; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Nagashima M, 2002, J CLIN INVEST, V109, P101, DOI 10.1172/JCI12119; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ong K, 2000, THROMB HAEMOSTASIS, V84, P1023; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Sato T, 2000, J IMMUNOL, V165, P1053, DOI 10.4049/jimmunol.165.2.1053; Schatteman KA, 1999, CLIN CHEM, V45, P807; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Silveira A, 2000, THROMB HAEMOSTASIS, V84, P364; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Tsay W, 1997, DNA CELL BIOL, V16, P569, DOI 10.1089/dna.1997.16.569; Van Thiel DH, 2001, THROMB HAEMOSTASIS, V85, P667; van Tilburg NH, 2000, BLOOD, V95, P2855, DOI 10.1182/blood.V95.9.2855.009k02_2855_2859; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WHITE JA, 1994, DEVELOPMENT, V120, P1861; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	61	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25329	25336		10.1074/jbc.M203688200	http://dx.doi.org/10.1074/jbc.M203688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12000765	hybrid			2022-12-27	WOS:000176747000064
J	Shetzline, MA; Walker, JKL; Valenzano, KJ; Premont, RT				Shetzline, MA; Walker, JKL; Valenzano, KJ; Premont, RT			Vasoactive intestinal polypeptide type-1 receptor regulation - Desensitization, phosphorylation, and sequestration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; SECRETIN RECEPTOR; KINASES; INTERNALIZATION; FAMILY; VIP; IDENTIFICATION; RESPONSIVENESS	The vasoactive intestinal polypeptide type-1 (VPAC(1)) receptor is a class II G protein-coupled receptor, distinct from the adrenergic receptor superfamily. The mechanisms involved in the regulation of the VPAC(1) receptor are largely unknown. We examined agonist-dependent VPAC(1) receptor signaling, phosphorylation, desensitization, and sequestration in human embryonic kidney 293 cells. Agonist stimulation of cells overexpressing this receptor led to a dose-dependent increase in cAMP that peaked within 5-10 min and was completely desensitized after 20 min. Cells cotransfected with the V-PAC(1) receptor (V-PAC(1)R) and G protein-coupled receptor kinases (GRKs) 2, 3, 5, and 6 exhibited enhanced desensitization that was not evident with GRK 4. Immunoprecipitation of the epitope-tagged VPAC(1) receptor revealed dose-dependent phosphorylation that was increased with cotransfection of any GRK. Agonist-stimulated internalization of the VPAC(1)R peaked in 10 min, and neither overexpressed beta-arrestin nor its dominant-negative mutant altered internalization. However, a dynamin-dominant negative mutant did inhibit VPAC(1) receptor internalization. Interestingly, VPAC(1)R specificity in desensitization was not evident by study of the overexpressed receptor; however, we determined that human embryonic kidney 293 cells express an endogenous VPAC(1)R that did demonstrate dose-dependent GRK specificity. Therefore, VPAC(1) receptor regulation involves agonist-stimulated, GRK-mediated phosphorylation, beta-arrestin translocation, and dynamin-dependent receptor internalization. Moreover, study of endogenously expressed receptors may provide information not evident in overexpressed systems.	Duke Univ, Med Ctr, Dept Cell Biol, Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA	Duke University; Duke University	Shetzline, MA (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Div Gastroenterol, Durham, NC 27710 USA.	shetz001@mc.duke.edu	Walker, Julia/R-7585-2017	Premont, Richard/0000-0002-8053-5026	NIDDK NIH HHS [DK02544, 5T32DK07568] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007568, K08DK002544] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DOCKRAY GJ, 1994, VASOACTIVE INTENSTIN; FABRE C, 1993, PEPTIDES, V14, P483, DOI 10.1016/0196-9781(93)90136-5; FAROUK M, 1992, GASTROENTEROLOGY, V102, P963, DOI 10.1016/0016-5085(92)90183-Y; Ferguson S S, 1998, Adv Pharmacol, V42, P420; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McDonald TP, 1998, ANN NY ACAD SCI, V865, P64, DOI 10.1111/j.1749-6632.1998.tb11164.x; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Said S I, 1970, Nature, V225, P863, DOI 10.1038/225863a0; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Shetzline MA, 1998, J BIOL CHEM, V273, P6756, DOI 10.1074/jbc.273.12.6756; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	33	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25519	25526		10.1074/jbc.M201815200	http://dx.doi.org/10.1074/jbc.M201815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978791	hybrid			2022-12-27	WOS:000176747000088
J	Borman, MA; MacDonald, JA; Muranyi, A; Hartshorne, DJ; Haystead, TAJ				Borman, MA; MacDonald, JA; Muranyi, A; Hartshorne, DJ; Haystead, TAJ			Smooth muscle myosin phosphatase-associated kinase induces Ca2+ sensitization via myosin phosphatase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; SIGNAL-TRANSDUCTION; RHO-KINASE; CHICKEN GIZZARD; BINDING SUBUNIT; ZIP KINASE; PHOSPHORYLATION; PROTEIN; CPI-17; CONTRACTION	Smooth muscle calcium sensitization reflects an inhibition of myosin light chain phosphatase (SMPP-1M) activity; however, the underlying mechanisms are not well understood. SMPP-1M activity can be modulated through phosphorylation of the myosin targeting subunit (MYPT1) by the endogenous myosin phosphatase-associated kinase, MYPT1 kinase (MacDonald, J.A., Borman, M. A., Muranyi, A., Somlyo, A. V., Hartshorne, D. J., and Haystead, T. A. (2001) Proc. Natl Acad. Sci. U. S. A 98, 2419-2424). Recombinant chicken gizzard MYPT1 (M130) was phosphorylated in vitro by a recombinant MYPT1 kinase, and the sites of phosphorylation were identified as Thr(654), Ser(808), and Thr(675). Introduction of recombinant MYPT1 kinase elicited a calcium-independent contraction in beta-escin-permeabilized rabbit ileal smooth muscle. Using an antibody that specifically recognizes MYPT1 phosphorylated at Thr(654) (M130 numbering), we determined that this calcium-independent contraction was correlated with an increase in MYPT1 phosphorylation. These results indicate that SMPP-1M phosphorylation by MYPT1 kinase is a mechanism of smooth muscle calcium sensitization.	Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Duke University; University of Virginia; University of Arizona	Haystead, TAJ (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Box 3813, Durham, NC 27710 USA.			MacDonald, Justin/0000-0002-9238-8473	NHLBI NIH HHS [HL23615, HL19242-24] Funding Source: Medline; NIDDK NIH HHS [DK52378-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL023615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HOAR PE, 1979, SCIENCE, V204, P503, DOI 10.1126/science.432654; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Ikebe M, 1996, BIOCHEM BIOPH RES CO, V225, P370, DOI 10.1006/bbrc.1996.1182; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P97; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x	33	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23441	23446		10.1074/jbc.M201597200	http://dx.doi.org/10.1074/jbc.M201597200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976330	hybrid			2022-12-27	WOS:000176475700046
J	Dubois, E; Scherens, B; Vierendeels, F; Ho, MMW; Messenguy, F; Shears, SB				Dubois, E; Scherens, B; Vierendeels, F; Ho, MMW; Messenguy, F; Shears, SB			In Saccharomyces cerevisiae, the inositol polyphosphate kinase activity of Kcs1p is required for resistance to salt stress, cell wall integrity, and vacuolar morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METABOLISM; PHOSPHOLIPASE-C; LEUCINE-ZIPPER; YEAST; ARGRIII; FAMILY; GROWTH; IDENTIFICATION; BIOGENESIS; COATOMER	A problem for inositol signaling is to understand the significance of the kinases that convert inositol hexakisphosphate to diphosphoinositol polyphosphates. This kinase activity is catalyzed by Kcs1p in the yeast Saccharomyces cerevisiae. A kcs1Delta yeast strain that was transformed with a specifically "kinase-dead" kcs1p mutant did not synthesize diphosphoinositol polyphosphates, and the cells contained a fragmented vacuolar compartment. Biogenesis of the yeast vacuole also required another functional domain in Kcs1p, which contains two leucine heptad repeats. The kinase activity of Kcs1p was also found to sustain cell growth and integrity of the cell wall and to promote adaptive responses to salt stress. Thus, the synthesis of diphosphoinositol polyphosphates has wide ranging physiological significance. Furthermore, we showed that these phenotypic responses to Kcs1p deletion also arise when synthesis of precursor material for the diphosphoinositol polyphosphates is blocked in arg82Delta cells. This metabolic block was partially bypassed, and the phenotype was partially rescued, when Kcs1p was overexpressed in the arg82Delta cells. This was due, in part, to the ability of Kcs1p to phosphorylate a wider range of substrates than previously appreciated. Our results show that diphosphoinositol polyphosphate synthase activity is essential for biogenesis of the yeast vacuole and the cell's responses to certain environmental stresses.	Free Univ Brussels, Inst Rech Microbiol Jean Marie Wiame, B-1070 Brussels, Belgium; NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dubois, E (corresponding author), Free Univ Brussels, Inst Rech Microbiol Jean Marie Wiame, 808 Route Lennik, B-1070 Brussels, Belgium.	fanarg@ulb.ac.be	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Alonso-Monge R, 2001, MOL MICROBIOL, V41, P717, DOI 10.1046/j.1365-2958.2001.02549.x; Amar N, 2000, MOL CELL BIOL, V20, P2087, DOI 10.1128/MCB.20.6.2087-2097.2000; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Brachmann CB, 1998, YEAST, V14, P115; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; Dubois E, 2000, FEBS LETT, V486, P300, DOI 10.1016/S0014-5793(00)02318-8; El Bakkoury M, 2000, MOL MICROBIOL, V35, P15, DOI 10.1046/j.1365-2958.2000.01665.x; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; HUANG KN, 1995, GENETICS, V141, P1275; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MESSENGUY F, 1971, EUR J BIOCHEM, V22, P277, DOI 10.1111/j.1432-1033.1971.tb01542.x; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; NASS R, 2001, MICROBIOLOGY, V145, P3221; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; QIU HF, 1990, MOL GEN GENET, V222, P192, DOI 10.1007/BF00633817; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Shaw JD, 2001, EXP CELL RES, V271, P1, DOI 10.1006/excr.2001.5373; Shears SB, 2000, BIOESSAYS, V22, P786, DOI 10.1002/1521-1878(200009)22:9<786::AID-BIES3>3.3.CO;2-S; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; Stolz LE, 1998, GENETICS, V148, P1715; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	43	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23755	23763		10.1074/jbc.M202206200	http://dx.doi.org/10.1074/jbc.M202206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956213	hybrid			2022-12-27	WOS:000176475700086
J	Kridel, SJ; Sawai, H; Ratnikov, BI; Chen, EI; Li, WZ; Godzik, A; Strongin, AY; Smith, JW				Kridel, SJ; Sawai, H; Ratnikov, BI; Chen, EI; Li, WZ; Godzik, A; Strongin, AY; Smith, JW			A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; PROGELATINASE-A; EXTRACELLULAR-MATRIX; CELL-SURFACE; PLASMINOGEN-ACTIVATOR; RAPID IDENTIFICATION; TUMOR-CELLS; SPECIFICITY; DISPLAY	In our study, we characterized the substrate recognition properties of membrane type-1 matrix metalloproteinase (MT1-MMP; also known as MMP-14), a key enzyme in tumor cell invasion and metastasis. A panel of optimal peptide substrates for MT1-MMP was identified using substrate phage display. The substrates can be segregated into four groups based on their degree of selectivity for MT1-MMP. Substrates with poor selectivity for MT1-MMP are comprised predominately of the Pro-X-X- down arrow -X-HY motif that is recognized by a number of MMP's. Highly selective substrates lack the characteristic Pro at the P-3 position; instead they contain an Arg at the P-4 position. This P-4 Arg is essential for efficient hydrolysis and for selectivity for MT1-MMP. Molecular modeling indicates that the selective substrates adopt a linear conformation that extends along the entire catalytic pocket of MT1-MMP, whereas non-selective substrates are kinked at the conserved P-3 Pro residue. Importantly, the selective substrates can be made nonselective by insertion of a proline kink at P-3, without significantly reducing overall k(cat)/K-m values. Altogether the study provides a structural basis for selective and non-selective substrate recognition by MT1-MMP. The findings in this report are likely to explain several aspects of MT1-MMP biology.	Burnham Inst, Program Cell Adhes, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Program Cell Adhes, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jsmith@burnham.org	Li, Weizhong/A-9735-2008; Godzik, Adam/A-7279-2009; Strongin, Alex/R-6609-2019; Godzik, Adam/AAW-1467-2020	Li, Weizhong/0000-0003-1804-9403; Godzik, Adam/0000-0002-2425-852X; Strongin, Alex/0000-0003-3765-3016; Godzik, Adam/0000-0002-2425-852X	NCI NIH HHS [CA69306, CA82713, CA77471, CA83017] Funding Source: Medline; NIAMS NIH HHS [AR42750, AR08505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069306, R01CA083017, R29CA077471, P01CA082713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1192; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; DERYUGINA EI, 2001, J BIOL CHEM, V263, P209; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Imai K, 1996, CANCER RES, V56, P2707; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KNIGHT CG, 1995, METHOD ENZYMOL, P248; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kridel SJ, 2001, ANAL BIOCHEM, V294, P176, DOI 10.1006/abio.2001.5167; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, GENE, V128, P1, DOI 10.1016/0378-1119(93)90145-S; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STOCKER W, 1995, PROTEIN SCI, V4, P823; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	52	80	85	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23788	23793		10.1074/jbc.M111574200	http://dx.doi.org/10.1074/jbc.M111574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959855	hybrid			2022-12-27	WOS:000176475700090
J	Pinakoulaki, E; Gemeinhardt, S; Saraste, M; Varotsis, C				Pinakoulaki, E; Gemeinhardt, S; Saraste, M; Varotsis, C			Nitric-oxide reductase - Structure and properties of the catalytic site from resonance Raman scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-PROTEINS; ACTIVE-SITE; IRON CENTER; SPECTROSCOPY; BINDING; NO; VIBRATIONS; MYOGLOBIN; DIOXYGEN; ADDUCTS	We have applied resonance Raman spectroscopy to investigate the properties of the dinuclear center of oxidized, reduced, and NO-bound nitric-oxide reductase from Paracoccus denitrificans. The spectra of the oxidized enzyme show two distinct nu(as)(Fe-O-Fe) modes at 815 and 833 cm(-1) of the heme/non-heme diiron center. The splitting of the Fe-O-Fe mode suggests that two different conformations (open and closed) are present in the catalytic site of the enzyme. We find evidence from deuterium exchange experiments that in the dominant conformation (833 cm-1 mode, closed), the Fe-O-Fe unit is hydrogen-bonded to distal residue(s). The ferric nitrosyl complex of nitric-oxide reductase exhibits the nu(Fe3+-NO) and nu(N-O) at 594 and 1904 cm(-1), respectively. The nitrosyl species we detect is photolabile and can be photolyzed to generate a new form of oxidized enzyme in which the proximal histidine is ligated to heme b(3), in contrast to the resting form. Photodissociation of the NO ligand yields a five-coordinate high-spin heme b(3). Based on the findings reported here, the structure and properties of the dinuclear center of nitricoxide reductase in the oxidized, reduced, and NO-bound form as well as its photoproduct can be described with certainty.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; European Mol Biol Lab, D-69012 Heidelberg, Germany	University of Crete; European Molecular Biology Laboratory (EMBL)	Varotsis, C (corresponding author), Univ Crete, Dept Chem, L Knossou 300,POB 1470, Iraklion 71409, Crete, Greece.			Pinakoulaki, Eftychia/0000-0003-3320-6112; Varotsis, Constantinos/0000-0003-2771-8891				BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; Hendriks J, 1998, J BIOENERG BIOMEMBR, V30, P15, DOI 10.1023/A:1020547225398; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; HU SZ, 1993, J BIOL CHEM, V268, P6189; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; KIM EK, 1991, J AM CHEM SOC, V113, P4962, DOI 10.1021/ja00013a036; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Laane J, 1980, PROG INORG CHEM, V27, P465, DOI 10.1002/9780470166284.ch6; MACKIN HC, 1983, FEBS LETT, V158, P199, DOI 10.1016/0014-5793(83)80577-8; MARICQ MM, 1989, J CHEM PHYS, V90, P3136, DOI 10.1063/1.455915; Miller LM, 1997, BIOCHEMISTRY-US, V36, P12199, DOI 10.1021/bi962744o; Moenne-Loccoz P, 2000, J AM CHEM SOC, V122, P9344, DOI 10.1021/ja0016295; Moenne-Loccoz P, 1998, J AM CHEM SOC, V120, P5147, DOI 10.1021/ja973671e; NAKAMOTO K, 1990, COORDIN CHEM REV, V100, P363, DOI 10.1016/0010-8545(90)85015-K; Noguchi T, 1996, BIOCHEMISTRY-US, V35, P16777, DOI 10.1021/bi961562r; Obayashi E, 1997, J AM CHEM SOC, V119, P7807, DOI 10.1021/ja9637816; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; ROUSSEAU DL, 1988, J BIOL CHEM, V263, P5681; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; Tomita T, 2001, J AM CHEM SOC, V123, P2666, DOI 10.1021/ja001431k; VAROTSIS C, 1995, J PHYS CHEM-US, V99, P16817, DOI 10.1021/j100046a004; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; ZUMFT WG, 1997, MICROBIOL MOL BIOL R, V61, P553	27	80	80	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23407	23413		10.1074/jbc.M201913200	http://dx.doi.org/10.1074/jbc.M201913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11971903	hybrid			2022-12-27	WOS:000176475700041
J	Potter, MD; Nicchitta, CV				Potter, MD; Nicchitta, CV			Endoplasmic reticulum-bound ribosomes reside in stable association with the translocon following termination of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL SEQUENCE RECOGNITION; MICROSOMAL-MEMBRANES; ER MEMBRANE; NASCENT POLYPEPTIDES; CONDUCTING CHANNEL; SECRETORY PROTEIN; SEC61P COMPLEX; BINDING; CHAIN; SITE	In current views, translation-coupled ribosome binding to the endoplasmic reticulum (ER) membrane is transient, with association occurring via the signal recognition particle pathway and dissociation occurring upon the termination of protein synthesis. Recent studies indicate, however, that ribosomal subunits remain membrane-bound following the termination of protein synthesis. To define the mechanism of post-termination ribosome association with the ER membrane, membrane-bound ribosomes were detergent-solubilized from tissue culture cells at different stages of the protein synthesis cycle, and the composition of the ribosome-associated membrane protein fraction was determined. We report that ribosomes reside in stable association with the Sec61alpha-translocon following the termination stage of protein synthesis. Additionally, in vitro experiments revealed that solubilized, gradient-purified ribosome-translocon complexes were able to initiate the translation of secretory and cytosolic proteins and were functional in assays of signal sequence recognition. Using this experimental system, synthesis of signal sequence-bearing polypeptides yielded a tight ribosome-translocon junction; synthesis of nascent polypeptides lacking a signal sequence resulted in a disruption of this junction. On the basis of these data, we propose that in situ, ribosomes reside in association with the translocon throughout the cycle of protein synthesis, with membrane release occurring upon translation of proteins lacking topogenic signals.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47897] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bastisch I, 2000, CLIN EXP IMMUNOL, V122, P49, DOI 10.1046/j.1365-2249.2000.01350.x; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1967, J MOL BIOL, V26, P279, DOI 10.1016/0022-2836(67)90297-5; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G, 2000, BIOSCIENCE REP, V20, P303, DOI 10.1023/A:1010318832604; Chevet E, 1999, EMBO J, V18, P3655, DOI 10.1093/emboj/18.13.3655; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Gruss OJ, 1999, EUR J BIOCHEM, V260, P785, DOI 10.1046/j.1432-1327.1999.00215.x; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; HIGH S, 1993, J BIOL CHEM, V268, P26745; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; MARTIN TE, 1969, J MOL BIOL, V43, P135, DOI 10.1016/0022-2836(69)90084-9; MECHLER B, 1975, J CELL BIOL, V67, P25, DOI 10.1083/jcb.67.1.25; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; Potter MD, 2000, J BIOL CHEM, V275, P2037, DOI 10.1074/jbc.275.3.2037; Potter MD, 2001, TRENDS CELL BIOL, V11, P112, DOI 10.1016/S0962-8924(00)01905-X; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	40	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23314	23320		10.1074/jbc.M202559200	http://dx.doi.org/10.1074/jbc.M202559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964406	hybrid			2022-12-27	WOS:000176475700030
J	Wehage, E; Eisfeld, J; Heiner, I; Jungling, E; Zitt, C; Luckhoff, A				Wehage, E; Eisfeld, J; Heiner, I; Jungling, E; Zitt, C; Luckhoff, A			Activation of the cation channel long transient receptor potential channel 2 (LTRPC2) by hydrogen peroxide - A splice variant reveals a mode of activation independent of ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CA2+ RELEASE; NEUTROPHIL GRANULOCYTES; RYANODINE RECEPTOR; PC12 CELLS; PROTEIN; HYDROLYSIS; INHIBITION; KINASES; INFLUX	LTRPC2 is a cation channel recently reported to be activated by adenosine diphosphate-ribose (ADP-ribose) and NAD. Since ADP-ribose can be formed from NAD and NAD is elevated during oxidative stress, we studied whole cell currents and increases in the intercellular free calcium concentration ([Ca2+](i)) in long transient receptor potential channel 2 (LTRPC2)-transfected HEK 293 cells after stimulation with hydrogen peroxide (H2O2). Cation currents carried by monovalent cations and Ca2+ were induced by H2O2 (5 mm in the bath solution) as well as by intracellular ADP-ribose (0.3 mm in the pipette solution) but not by NAD (1 mm). H2O2-induced currents developed slowly after a characteristic delay of 3-6 min and receded after wash-out of H2O2. [Ca2+](i) was rapidly increased by H2O2 in LTRPC2-transfected cells as well as in control cells; however, in LTRPC2-transfected cells, H2O2 evoked a second delayed rise in [Ca2+](i). A splice variant of LTRPC2 with a deletion in the C terminus (amino acids 1292-1325) was identified in neutrophil granulocytes. This variant was stimulated by H2O2 as the wild type. However, it did not respond to ADP-ribose. We conclude that activation of LTRPC2 by H2O2 is independent of ADP-ribose and that LTRPC2 may mediate the influx of Na+ and Ca2+ during oxidative stress, such as the respiratory burst in granulocytes.	Rhein Westfal TH Aachen, Med Fak, Inst Physiol, D-52057 Aachen, Germany	RWTH Aachen University	Luckhoff, A (corresponding author), Rhein Westfal TH Aachen, Med Fak, Inst Physiol, Paulwelsstr 30, D-52057 Aachen, Germany.							Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; COHEN MS, 1994, CLIN INFECT DIS   S2, V18, P170; COLLINS SJ, 1987, BLOOD, V70, P1233; Conrad PW, 2000, ADV EXP MED BIOL, V475, P293; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Herson PS, 1997, J PHYSIOL-LONDON, V501, P59, DOI 10.1111/j.1469-7793.1997.059bo.x; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Ito Y, 1997, J NEUROCHEM, V69, P729; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAUSE KH, 1993, BLOOD CELLS, V19, P165; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schorr W, 1999, EUR J IMMUNOL, V29, P897, DOI 10.1002/(SICI)1521-4141(199903)29:03<897::AID-IMMU897>3.3.CO;2-X; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	34	279	291	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23150	23156		10.1074/jbc.M112096200	http://dx.doi.org/10.1074/jbc.M112096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960981	hybrid			2022-12-27	WOS:000176475700009
J	Chai, WG; Beeson, JG; Lawson, AM				Chai, WG; Beeson, JG; Lawson, AM			The structural motif in chondroitin sulfate for adhesion of Plasmodium falciparum-infected erythrocytes comprises disaccharide units of 4-O-sulfated and non-sulfated N-acetylgalactosamine linked to glucuronic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; MEMBRANE PROTEIN-1 PFEMP1; HUMAN-PLACENTA; HYALURONIC-ACID; MALARIA; ADHERENCE; THROMBOMODULIN; RECEPTOR; IDENTIFICATION; PROTEOGLYCANS	An important characteristic of malaria parasite Plasmodium falciparum-infected red blood cells (IRBCs) is their ability to adhere to host endothelial cells and accumulate in various organs. Sequestration of IRBCs in the placenta, associated with excess perinatal and maternal mortality, is mediated in part by adhesion of parasites to the glycosaminoglyean chondroitin sulfate A (CSA) present on sncytiotrophoblasts lining the placental blood spaces. To define key structural features for parasite interactions, we isolated from CSA oligosaccharide fractions and established by electrospray mass spectrometry and high performance liquid chromatography disaccharide composition analysis their differing chain length, sulfate content, and sulfation pattern. Testing these defined oligosaccharide fragments for their ability to inhibit IRBC adhesion to immobilized CSA revealed the importance of non-sulfated disaccharide units in combination with 4-O-sulfated disaccharides for interaction with IRBCs. Selective removal of 6-O-sulfates from oligo- and polysaccharides to increase the proportion of non-sulfated disaccharides enhanced activity, indicating that 6-O-sulfation interferes with the interaction of CSA with IRBCs. Dodecasaccharides with four or five 4-O-sulfated and two or one non-sulfated disaccharide units, respectively, comprise the minimum chain length for effective interaction with IRBCs. Comparison of the activities of CSA and CSB oligo- and polysaccharides with a similar sulfation pattern and content achieved from partial desulfation demonstrated that glucuronic acid rather than iduronic acid residues are important for IRBC binding.	Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, MRC, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia	Imperial College London; Royal Melbourne Hospital; University of Melbourne	Chai, WG (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, MRC, Glycosci Lab, Harrow HA1 3UJ, Middx, England.	w.chai@ic.ac.uk						Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; Barragan A, 2000, BLOOD, V95, P3594, DOI 10.1182/blood.V95.11.3594.011k21_3594_3599; Beeson JG, 2002, CELL MOL LIFE SCI, V59, P258, DOI 10.1007/s00018-002-8421-y; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Chai WG, 1996, ANAL BIOCHEM, V237, P88, DOI 10.1006/abio.1996.0205; Chai WG, 1998, EUR J BIOCHEM, V251, P114, DOI 10.1046/j.1432-1327.1998.2510114.x; Chai WG, 2001, INFECT IMMUN, V69, P420, DOI 10.1128/IAI.69.1.420-425.2001; Chai WG, 1998, ANAL CHEM, V70, P2060, DOI 10.1021/ac9712761; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7; JUVANI M, 1975, BIOCHIM BIOPHYS ACTA, V411, P1, DOI 10.1016/0304-4165(75)90279-2; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; Maubert B, 2000, PARASITE IMMUNOL, V22, P191, DOI 10.1046/j.1365-3024.2000.00292.x; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; RODEN L, 1989, CIBA F SYMP, V143, P60; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; TOIDA T, 1992, ANAL SCI, V8, P799, DOI 10.2116/analsci.8.799; ZHANG WJ, 1992, TETRAHEDRON LETT, V33, P1177, DOI 10.1016/S0040-4039(00)91889-6	35	60	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22438	22446		10.1074/jbc.M111401200	http://dx.doi.org/10.1074/jbc.M111401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956186	hybrid			2022-12-27	WOS:000176313600044
J	Cronan, JE				Cronan, JE			Interchangeable enzyme modules - Functional replacement of the essential linker of the biotinylated, subunit of acetyl-CoA carboxylase with a linker from the lipoylated subunit of pyruvate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; FATTY-ACID SYNTHESIS; ESCHERICHIA-COLI; MULTIENZYME COMPLEX; POSTTRANSLATIONAL MODIFICATION; CARRIER PROTEIN; 3-DIMENSIONAL STRUCTURE; POLYPEPTIDE-CHAIN; EXCEPTIONAL SPECIFICITY	Biotin carboxbiotinylated subunit of Escherichia coli acetyl-CoA carboxylase, the enzyme that catalyzes the first committed step of fatty acid synthesis. E. coli BCCP is a member of a large family of protein domains modified by covalent attachment of biotin. In most biotinylated proteins, the biotin moiety is attached to a lysine residue located about 35 residues from the carboxyl terminus of the protein, which lies in the center of a strongly conserved sequence that forms a tightly folded anti-parallel beta-barrel structure. Located upstream of the conserved biotinoyl domain sequence are proline/alanine-rich sequences of varying lengths, which have been proposed to act as flexible linkers. In E. coli BCCP, this putative linker extends for about 42 residues with over half of the residues being proline or alanine. I report that deletion of the 30 linker residues located adjacent to the biotinoyl domain resulted in a BCCP species that was defective in function in vivo, although it was efficiently biotinylated. Expression of this BCCP species failed to restore normal growth and fatty acid synthesis to a temperature-sensitive E. coli strain that lacks BCCP when grown at nonpermissive temperatures. In contrast, replacement of the deleted BCCP linker with a linker derived from E. coli pyruvate dehydrogenase gave a chimeric BCCP species that had normal in vivo function. Expression of BCCPs having deletions of various segments of the linker region of the chimeric protein showed that some deletions of up to 24 residues had significant or full biological activity, whereas others had very weak or no activity. The inactive deletion proteins all lacked an APAAAAA sequence located adjacent to the tightly folded biotinyl domain, whereas deletions that removed only upstream linker sequences remained active. Deletions within the linker of the wild type BCCP protein also showed that the residues adjacent to the tightly folded domain play an essential role in protein function, although in this case some proteins with deletions within this region retained activity. Retention of activity was due to fusion of the domain to upstream sequences. These data provide new evidence for the functional and structural similarities of biotinylated and lipoylated proteins and strongly support a common evolutionary origin of these enzyme subunits.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, ENZYMES, V6, P37; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; BEST EA, 1993, J BACTERIOL, V175, P6881, DOI 10.1128/jb.175.21.6881-6889.1993; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Cronan JE, 2001, J BIOL CHEM, V276, P37355, DOI 10.1074/jbc.M106353200; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Dennis JJ, 1998, APPL ENVIRON MICROB, V64, P2710; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HASAN N, 1989, GENE, V82, P305, DOI 10.1016/0378-1119(89)90055-3; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; MARINI P, 1995, J BACTERIOL, V177, P7003, DOI 10.1128/jb.177.23.7003-7006.1995; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MILES JS, 1987, BIOCHIM BIOPHYS ACTA, V913, P117, DOI 10.1016/0167-4838(87)90319-0; MORRIS TW, 1994, THESIS U ILLINOIS UR; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; Ohlrogge J, 2000, BIOCHEM SOC T, V28, P567, DOI 10.1042/BST0280567; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PERHAM RN, 1981, NATURE, V292, P474, DOI 10.1038/292474a0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RADFORD SE, 1987, BIOCHEM J, V247, P641, DOI 10.1042/bj2470641; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; Reed LJ, 1998, PROTEIN SCI, V7, P220, DOI 10.1002/pro.5560070125; Ricaud PM, 1996, J MOL BIOL, V264, P179, DOI 10.1006/jmbi.1996.0632; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; TURNER SL, 1993, PROTEIN ENG, V6, P101, DOI 10.1093/protein/6.1.101; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; Yao X, 1999, PROTEIN SCI, V8, P307	43	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22520	22527		10.1074/jbc.M201249200	http://dx.doi.org/10.1074/jbc.M201249200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956202	hybrid			2022-12-27	WOS:000176313600055
J	Sasaki, A; Masuda, Y; Iwai, K; Ikeda, K; Watanabe, K				Sasaki, A; Masuda, Y; Iwai, K; Ikeda, K; Watanabe, K			A RING finger protein praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Needin family protein, Dlxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SUPPRESSOR NECDIN; PRADER-WILLI-SYNDROME; MAGE GENE FAMILY; P53; MDM2; IDENTIFICATION; COMPLEX; LYMPHOCYTES; DISRUPTION; EXPRESSION	Msx2 and Dlx5 are homeodomain proteins that play an important role in osteoblast differentiation and whose expression is induced by bone morphogenetic proteins. Recently we have identified a novel protein, Dlxin-1, that associates with these homeodomain proteins and regulates Dlx5-dependent transcriptional function (Masuda, Y., Sasaki, A., Shibuya, H., Ueno, N., Ikeda, K., and Watanabe, K. (2001) J. Biol. Chem. 276, 5331-5338). In an attempt to elucidate the molecular function of Dlxin-1, two closely related RING finger proteins, Prajal and Neurodap-1, were isolated by yeast two-hybrid screening using the C-terminal necdin homology domain of Dlxin-1 as bait. Glutathione S-transferase pull-down and immunoprecipitation/Western blotting assays following co-transfection of Dlxin-1 and Prajal revealed that Prajal binds to the C-terminal necdin homology domain of Dlxin-1 in vitro and in vivo, respectively. Overexpression of Prajal caused a decrease in Dlxin-1 protein level, which was reversed when a proteasome inhibitor was added. Overexpression of Prajal with a mutation in the RING finger inhibited the decrease in Dlxin-1 protein, pointing to the importance of ubiquitin-protein isopeptide ligase (E3) activity associated with RING finger. Wild-type Prajal, but not its RING finger mutant, promoted ubiquitination of Dlxin-1 in vivo. Finally, expression of Prajal down-regulated Dlx5-dependent transcriptional activity in a GAL4-dependent assay. These results suggest that Prajal regulates the transcription function of the homeodomain protein Dlx5 by controlling the stability of Dlxin-1 via an ubiquitin-dependent degradation pathway.	NILS, Dept Geriatr Res, Aichi 4748522, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University	Watanabe, K (corresponding author), NILS, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.		Watanabe, Ken/I-3960-2013; IWAI, KAZUHIRO/GSN-7385-2022	Watanabe, Ken/0000-0003-0664-3915; Iwai, Kazuhiro/0000-0001-5620-5951				Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chomez P, 2001, CANCER RES, V61, P5544; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Hennuy B, 2000, ENDOCRINOLOGY, V141, P3821, DOI 10.1210/en.141.10.3821; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lucas S, 1999, CANCER RES, V59, P4100; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Muscatelli F, 2000, HUM MOL GENET, V9, P3101, DOI 10.1093/hmg/9.20.3101; NAKAYAMA M, 1995, J NEUROSCI, V15, P5238; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	35	82	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22541	22546		10.1074/jbc.M109728200	http://dx.doi.org/10.1074/jbc.M109728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959851	hybrid			2022-12-27	WOS:000176313600058
J	Sawa, C; Yoshikawa, T; Matsuda-Suzuki, F; Delehouzee, S; Goto, M; Watanabe, H; Sawada, J; Kataoka, K; Handa, H				Sawa, C; Yoshikawa, T; Matsuda-Suzuki, F; Delehouzee, S; Goto, M; Watanabe, H; Sawada, J; Kataoka, K; Handa, H			YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GA-BINDING-PROTEIN; UTROPHIN PROMOTER; POLYCOMB COMPLEX; E4TF1 SUBUNITS; RB GENE; ETS; ACTIVATION; EXPRESSION; INTERACTS; SITE	The transcription factor hGABP/E4TF1 is a heterotetrameric complex composed of two DNA-binding subunits (hGABPalpha/E4TF1-60) and two transactivating subunits (hGABPbeta/E4TF1-53). In order to understand the molecular mechanism of transcriptional regulation by hGABP, we searched for proteins that interact with the non-DNA-binding subunit, hGABPbeta, using yeast two-hybrid screening. We identified a human cDNA encoding a protein related to YAF-2 (YY1-associated factor 2), which was previously isolated as an interacting partner of the Ying-Yang-1 (YY1) transcription factor. Reflecting this similarity, both YAF-2 and this novel protein (named YEAF1 for YY1- and E4TF1/hGABP-associated factor-1) interacted with hGABPbeta and YY1 in vitro and in vivo, indicating that YEAF1 and YAF-2 constitute a cofactor family for these two structurally distinct transcription factors. By using yeast three-hybrid assay, we demonstrated that hGABPbeta and YY1 formed a complex only in the presence of YEAF1, indicating that YEAF1 is a bridging factor of these two transcription factors. These cofactors are functionally different in that YAF-2 positively regulates the transcriptional activity of hGABP but YEAF1 negatively regulates this activity. Also, YAF-2 mRNA is highly expressed in skeletal muscle, whereas YEAF1 mRNA is highly expressed in placenta. We speculate that the transcriptional activity of hGABP is in part regulated by the expression levels of these tissue-specific cofactors. These results provide a novel mechanism of transcriptional regulation by functionally distinct cofactor family members.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Okazaki Natl Res Inst, Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Handa, H (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hajime/S-8957-2019; WATANABE, Hajime/AAJ-8904-2021	Watanabe, Hajime/0000-0001-9657-6554				Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Genuario R. Robert, 1993, Gene Expression, V3, P279; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Morii E, 2001, BLOOD, V97, P3032, DOI 10.1182/blood.V97.10.3032; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sowa Y, 1997, CANCER RES, V57, P3145; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Vassias I, 1998, J BIOL CHEM, V273, P8287, DOI 10.1074/jbc.273.14.8287; Villena JA, 1998, BIOCHEM J, V331, P121, DOI 10.1042/bj3310121; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	34	44	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22484	22490		10.1074/jbc.M203060200	http://dx.doi.org/10.1074/jbc.M203060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953439	hybrid			2022-12-27	WOS:000176313600050
J	Lee, DK; Suh, D; Edenberg, HJ; Hur, MW				Lee, DK; Suh, D; Edenberg, HJ; Hur, MW			POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTION MOTIF; ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; FORMALDEHYDE DEHYDROGENASE; BTB/POZ DOMAIN; HUMAN-LIVER; CHI-ADH; COMPLEX	The POZ domain is a protein-protein interaction motif that is found in many transcription factors, which are important for development, oncogenesis, apoptosis, and transcription repression. We cloned the POZ domain transcription factor, FBI-1, that recognizes the cis-element (bp -38 to -22) located just upstream of the core Sp1 binding sites (bp -22 to +22) of the ADH5/FDH minimal promoter (bp -38 to +61) in vitro and in vivo, as revealed by electrophoretic mobility shift assay and chromatin immunoprecipitation assay. The ADH5/FDH minimal promoter is potently repressed by the FBI-1. Glutathione S-transferase fusion protein pull-down showed that the POZ domains of FBI-1, Plzf, and Bel-6 directly interact with the zinc finger DNA binding domain of Sp1. DNase I footprinting assays showed that the interaction prevents binding of Spl to the GC boxes of the ADH5/FDH promoter. Gal4-POZ domain fusions targeted proximal to the GC boxes repress transcription of the Gal4 upstream activator sequence-Sp1-adenovirus major late promoter. Our data suggest that POZ domain represses transcription by interacting with Sp1 zinc fingers and by interfering with the DNA binding activity of Sp1.	Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Project Med Sci BK21,Inst Genet Sci,SeoDaeMoon Ku, Seoul 120752, South Korea; PoChon CHA Univ, Coll Med, Dept Biochem, Boondang Ku, Songnam 463836, Kyungki Do, South Korea; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Yonsei University; Pochon Cha University; Indiana University System; Indiana University-Purdue University Indianapolis	Hur, MW (corresponding author), Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Project Med Sci BK21,Inst Genet Sci,SeoDaeMoon Ku, 134 Shinchon Dong, Seoul 120752, South Korea.	mwhur2@yumc.yonsei.ac.kr		Edenberg, Howard/0000-0003-0344-9690				ADINOLFI A, 1984, ANN HUM GENET, V48, P1, DOI 10.1111/j.1469-1809.1984.tb00828.x; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DULEY JA, 1985, ALCOHOL CLIN EXP RES, V9, P263, DOI 10.1111/j.1530-0277.1985.tb05747.x; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HUR MW, 1995, J BIOL CHEM, V270, P9002, DOI 10.1074/jbc.270.15.9002; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; Huynh KD, 2000, GENE DEV, V14, P1810; JORNVALL H, 1995, ADV EXP MED BIOL, V372, P281; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Kwon HS, 2001, ARCH BIOCHEM BIOPHYS, V386, P163, DOI 10.1006/abbi.2000.2205; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; UOTILA L, 1974, J BIOL CHEM, V249, P7653; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAGNER FW, 1984, BIOCHEMISTRY-US, V23, P2193, DOI 10.1021/bi00305a014; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334	46	85	92	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26761	26768		10.1074/jbc.M202078200	http://dx.doi.org/10.1074/jbc.M202078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004059	hybrid			2022-12-27	WOS:000177055900009
J	Ahn, T; Oh, DB; Kim, H; Park, C				Ahn, T; Oh, DB; Kim, H; Park, C			The phase provertv of membrane phosholipids is affected by the functionality of signal peptides from the Escherichia coli ribose-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL MEMBRANES; WILD-TYPE; NONBILAYER LIPIDS; PLASMA-MEMBRANE; SEQUENCE; EXPORT; PHOSPHATIDYLSERINE; PHOSPHATIDYLETHANOLAMINE; CONFORMATION; PENETRATION	We examined the effects of synthetic signal peptides from the wild-type, export-defective mutant and its revertant species of ribose-binding protein on the phase properties of lipid bilayers. The lateral segregation of phosphatidylglycerol. (PG) in the lipid bilayer was detected through quenching between NBD-PGs upon the reconstitution of signal peptide into the liposome made with the Escherichia coli inner membrane composition. The tendency of lipid segregation was highly dependent on the export competency of signal peptides in vivo, with a decreasing order of wild-type, revertant, and mutant species. The colocalizations of pyrene-PG with BODIPY-PG were also induced by the signal peptides, confirming the phase separation of the acidic phospholipid. The wildtype and revertant signal peptides predominantly formed a-helical conformations with the presence of acidic phospholipid as determined by circular dichroism spectroscopy. In addition, they restricted the motion of lipid acyl chains as monitored by fluorescence anisotropy of DPH, suggesting a deep penetration of signal peptide into the lipid bilayer. However, the alpha-helical content of mutant signal peptide was only about half that of the wild-type or revertant peptide with a significantly smaller degree of penetration into the bilayer. An association of the defective signal peptides into the membrane was affected by salt extraction, whereas the functional ones were not. The aforementioned results indicate that the functionality of signal peptide is accomplished through its topologies in the membrane and also by its ability to induce lateral segregation of acidic phospholipid. We propose that the clustering of acidic phospholipid by the functional signal peptide is responsible for the formation of non-bilayer membrane structure, thereby promoting an efficient translocation of secretory proteins.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Behav Genet, Dept Biol Sci, Taejon 305701, South Korea; Pai Chai Univ, Res Inst Nat Sci, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Pai Chai University	Park, C (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Behav Genet, Dept Biol Sci, Taejon 305701, South Korea.			Oh, Doo-Byoung/0000-0002-4432-0941				Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; Ahn T, 2000, BIOCHEMISTRY-US, V39, P10147, DOI 10.1021/bi0000622; Ahn T, 1996, J BIOL CHEM, V271, P12372, DOI 10.1074/jbc.271.21.12372; AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; Chi SW, 1995, BIOPHYS J, V69, P2703, DOI 10.1016/S0006-3495(95)80141-4; CHUPIN V, 1995, BIOCHEMISTRY-US, V34, P11617, DOI 10.1021/bi00036a038; FARREN SB, 1980, BIOCHEM BIOPH RES CO, V97, P182, DOI 10.1016/S0006-291X(80)80152-5; GRAHAM I, 1985, BIOCHEMISTRY-US, V24, P7123, DOI 10.1021/bi00346a016; HOEKSTRA D, 1982, BIOCHEMISTRY-US, V21, P1055, DOI 10.1021/bi00534a036; HOYT DW, 1991, J BIOL CHEM, V266, P14406; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; IZARD JW, 1995, BIOCHEMISTRY-US, V34, P9904, DOI 10.1021/bi00031a012; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; LUIRINK J, 1994, MOL MICROBIOL, V11, P9, DOI 10.1111/j.1365-2958.1994.tb00284.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MITTLERNEHER S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P259, DOI 10.1016/0005-2736(93)90257-Z; NAGARAJ R, 1987, BIOCHIM BIOPHYS ACTA, V903, P465, DOI 10.1016/0005-2736(87)90053-8; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; SANKARAM MB, 1994, J BIOL CHEM, V269, P23477; SONG T, 1995, J MOL BIOL, V253, P304, DOI 10.1006/jmbi.1995.0554; TESCHKE CM, 1991, J BIOL CHEM, V266, P11789; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TILCOCK CPS, 1984, BIOCHEMISTRY-US, V23, P2696, DOI 10.1021/bi00307a025; TILCOCK CPS, 1988, BIOCHEMISTRY-US, V27, P1415, DOI 10.1021/bi00405a004; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; VANVENETIE R, 1981, BIOCHIM BIOPHYS ACTA, V645, P262, DOI 10.1016/0005-2736(81)90197-8; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YI GS, 1994, BIOPHYS J, V66, P1604, DOI 10.1016/S0006-3495(94)80952-X; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X	42	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26157	26162		10.1074/jbc.M203445200	http://dx.doi.org/10.1074/jbc.M203445200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004066	hybrid			2022-12-27	WOS:000176908700044
J	Bartoov-Shifman, R; Hertz, R; Wang, HY; Wollheim, CB; Bar-Tana, J; Walker, MD				Bartoov-Shifman, R; Hertz, R; Wang, HY; Wollheim, CB; Bar-Tana, J; Walker, MD			Activation of the insulin gene promoter through a direct effect of hepatocyte nuclear factor 4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; FACTOR-1-ALPHA GENE; FACTOR-4-ALPHA GENE; MISSENSE MUTATION; MAMMALIAN-CELLS; HOMEOBOX FACTOR; MODY1 GENE; EXPRESSION	Maturity onset diabetes of the young, subtype 1 (MODY1), is associated with defective glucose-dependent insulin secretion from pancreatic beta cells. MODY1 is caused by mutation in the transcription factor hepatocyte nuclear factor 4alpha (HNF4alpha). To understand better the MODY1 phenotype, we tested whether HNF4alpha was able to modulate directly the insulin gene promoter. Transfection of cultured 293T cells with an HNF4alpha expression vector led to 10-fold activation of a cotransfected reporter plasmid containing the rat insulin I gene promoter. Computer analysis revealed a potential HNF4alpha-binding site between nucleotides -57 and -69 of the promoter; mutation of this sequence led to reduced ability of HNF4alpha to activate the promoter. The ability of HNF4alpha to bind this sequence was confirmed using gel shift analysis. In transfected INS-1 beta cells, mutation of either the HNF1alpha site or the HNF4alpha site in the insulin gene promoter led to 50-75% reduction in reporter gene activity; expression of dominant negative HNF4alpha led to significant reduction in the activity of wild type and both mutated promoters. Thus, in addition to the previously described indirect action of HNF4alpha on insulin gene expression mediated through elevated HNF1alpha levels, HNF4alpha also activates the insulin gene directly, through a previously unrecognized cis element.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland; Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; University of Geneva; Hebrew University of Jerusalem	Walker, MD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; Bulman MP, 1997, DIABETOLOGIA, V40, P859, DOI 10.1007/s001250050760; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Furuta H, 1997, DIABETES, V46, P1652, DOI 10.2337/diabetes.46.10.1652; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; HERMAN WH, 1994, DIABETES, V43, P40, DOI 10.2337/diabetes.43.1.40; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEFF T, 1989, J BIOL CHEM, V264, P16132; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lindner T, 1997, J CLIN INVEST, V100, P1400, DOI 10.1172/JCI119660; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; Malecki MT, 1999, DIABETIC MED, V16, P193, DOI 10.1046/j.1464-5491.1999.00073.x; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moller AM, 1997, DIABETOLOGIA, V40, P980, DOI 10.1007/s001250050778; Moller AM, 1999, J CLIN ENDOCR METAB, V84, P367, DOI 10.1210/jc.84.1.367; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Shih DQ, 2001, P NATL ACAD SCI USA, V98, P14189, DOI 10.1073/pnas.251558998; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	45	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25914	25919		10.1074/jbc.M201582200	http://dx.doi.org/10.1074/jbc.M201582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994285	hybrid			2022-12-27	WOS:000176908700014
J	Melman, YF; Krumerman, A; McDonald, TV				Melman, YF; Krumerman, A; McDonald, TV			A single transmembrane site in the KCNE-encoded proteins controls the specificity of KvLQT1 channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; CARDIAC POTASSIUM CURRENT; LANGE-NIELSEN-SYNDROME; I-KS CHANNELS; CAUSE JERVELL; MINK; MUTATIONS; SUBUNITS; COMPLEX; ISK	KCNEs are a family of genes encoding small integral membrane proteins whose role in governing voltage-gated potassium channel gating is emerging. Whether each member of this homologous family interacts with channel proteins in the same manner is unknown; however, it is clear that the functional effect of each KCNE on channel gating is different. The specificity of KCNE1 (minK) and KCNE3 control of activation of the potassium channel KvLQT1 maps to a triplet of amino acids within the KCNE transmembrane domain by chimera analysis. We now define the structural determinants of functional specificity within this triplet. The central amino acid of the triplet (Thr-58 of minK and Val-72 of KCNE3) is essential for the specific control of voltage-dependent channel activation characteristics of both minK and KCNE3. Using site-directed mutations that substitute minK and KCNE3 residues, we determined that a hydroxylated central amino acid is necessary for the slow sigmoidal activation produced by minK. The precise spacing of the hydroxyl group was required for minK-like activation. Am aliphatic amino acid substituted at position 58 of minK is capable of reproducing KCNE3-like kinetics and voltage-independent constitutive current activation. The bulk of the central residue is another critical parameter, indicating precise positioning of this portion of the KCNE proteins within the channel complex. An intermediate phenotype produced by several smaller aliphatic-substituted mutants yields conditional voltage independence that is distinct from the voltage-dependent gating process, suggesting that KCNE3 traps the channel in a stable open state. From these results, we propose a model of KCNE-potassium channel interaction where the functional consequence depends on the precise contact at a single amino acid.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Sect Mol Cardiol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	McDonald, TV (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NHLBI NIH HHS [R01 HL57388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 2000, TRENDS PHARMACOL SCI, V21, P199, DOI 10.1016/S0165-6147(00)01475-9; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1989, FASEB J, V5, P331; Tapper AR, 2000, J GEN PHYSIOL, V116, P379, DOI 10.1085/jgp.116.3.379; Tapper AR, 2001, J BIOL CHEM, V276, P38249; TAYLOR RE, 1960, BIOPHYS J, V1, P161, DOI 10.1016/S0006-3495(60)86882-8; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Tzounopoulos T, 1998, BIOPHYS J, V74, P2299, DOI 10.1016/S0006-3495(98)77939-1; VARNUM MD, 1995, NEURON, V14, P407, DOI 10.1016/0896-6273(95)90296-1; Wang HS, 2000, MOL PHARMACOL, V57, P1218; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; Wang WY, 1998, J BIOL CHEM, V273, P34069, DOI 10.1074/jbc.273.51.34069; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	33	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25187	25194		10.1074/jbc.M200564200	http://dx.doi.org/10.1074/jbc.M200564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994278	hybrid			2022-12-27	WOS:000176747000045
J	Saur, D; Seidler, B; Paehge, H; Schusdziarra, V; Allescher, HD				Saur, D; Seidler, B; Paehge, H; Schusdziarra, V; Allescher, HD			Complex regulation of human neuronal nitric-oxide synthase Exon 1c gene transcription - Essential role of Sp and ZNF family members of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; ZINC-FINGER PROTEIN; RNA-POLYMERASE-III; REPRESS TRANSCRIPTION; PYLORIC-STENOSIS; MINIMAL PROMOTER; CIS-ELEMENTS; ACTIVATION; EXPRESSION; DOMAINS	Neuronal nitric-oxide synthase (nNOS) is expressed in a variety of human tissues and shows a complex transcriptional regulation with the presence of nine alternative first exons (1a-1i) resulting in nNOS transcripts with differing 5'-untranslated regions. We previously demonstrated that nNOS exon 1c, one of the predominant transcripts in the human gastrointestinal tract, is driven by a separate promoter (Saur, D., Paehge, H., Schusdziarra, V., and Allescher, H. D. (2000) Gastroenterology 118, 849-858). The present study focused on the quantitative expression of nNOS first exon variants in different human tissues and the characterization of the basal nNOS exon le promoter. In human brain, skeletal muscle, colon, and TGW-nu-I neuroblastoma cells, first exon expression patterns were analyzed by quantitative real-time reverse transcription-PCR. In these tissues/cells exon 1c was one of the most abundant first exons of nNOS. By transient transfections of TGW-nu-I and HeLa cells with reporter plasmids containing a series of 5' and 3' deletions in the exon 1c regulatory region, the minimal TATA-less promoter was localized within 44 base pairs. Gel mobility shift assays of this cis-regulatory region revealed a high complexity of the basal promoter with a cooperative binding of several transcription factors, like Sp and ZNF family members. When the Sp binding site of the minimal promoter construct was mutated, promoter activity was completely abolished in both cell lines, whereas mutation Of the common binding site of ZNF76 and ZNF143 resulted in a decrease of 53% in TGW-nu-I and 37% in HeLa cells. In Drosophila Schneider cells expression of Sp1, the long Sp3 isoform, ZNF76 and ZNF143 potently transactivated the nNOS exon le promoter. These results identify the critical regulatory region for the nNOS exon 1c basal promoter and stress the functional importance of multiple protein complexes involving Sp and ZNF families of transcription factors in regulating nNOS exon le transcription.	Tech Univ Munich, Med Klin & Poliklin 2, Dept Internal Med 2, D-81675 Munich, Germany	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf	Saur, D (corresponding author), Tech Univ Munich, Med Klin & Poliklin 2, Dept Internal Med 2, Ismaninger Str 22, D-81675 Munich, Germany.		Saur, Dieter/O-8355-2015; Saur, Dieter/G-4629-2011	Saur, Dieter/0000-0001-5874-0210; 				Allescher HD, 1996, AM J PHYSIOL-GASTR L, V271, pG568, DOI 10.1152/ajpgi.1996.271.4.G568; AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bakovic M, 2000, J LIPID RES, V41, P583; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chung E, 1996, AM J HUM GENET, V58, P363; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Deans Z, 1996, J BIOL CHEM, V271, P32153, DOI 10.1074/jbc.271.50.32153; Forstermann U, 1998, FASEB J, V12, P773; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HROMAS R, 1991, J BIOL CHEM, V266, P14183; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG1146, DOI 10.1152/ajpgi.1998.275.5.G1146; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mashimo H, 2000, GASTROENTEROLOGY, V119, P766, DOI 10.1053/gast.2000.16509; MEARIN F, 1993, EUR J CLIN INVEST, V23, P724, DOI 10.1111/j.1365-2362.1993.tb01292.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Ogura T, 1996, NEUROSCI LETT, V204, P89, DOI 10.1016/0304-3940(96)12324-7; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Parks CL, 1996, J BIOL CHEM, V271, P4417; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Sivarao DV, 2001, GASTROENTEROLOGY, V121, P34, DOI 10.1053/gast.2001.25541; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P511, DOI 10.1056/NEJM199208203270802; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Watkins CC, 2000, J CLIN INVEST, V106, P373, DOI 10.1172/JCI8273; Weber JRM, 1997, J NEUROSCI, V17, P7583; WERNERFELMAYER G, 1993, BIOCHEM J, V289, P357, DOI 10.1042/bj2890357; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	60	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25798	25814		10.1074/jbc.M109802200	http://dx.doi.org/10.1074/jbc.M109802200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960979	hybrid			2022-12-27	WOS:000176747000123
J	Sontag, TJ; Parker, RS				Sontag, TJ; Parker, RS			Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism - Novel mechanism of regulation of vitamin E status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-TOCOPHEROL; ALPHA-TOCOPHEROL; HUMAN LIVER; LIPID-PEROXIDATION; TRANSFER PROTEIN; HEPG2 CELLS; HUMAN URINE; METABOLISM; ACID; EXPRESSION	Postabsorptive elimination of the various forms of vitamin E appears to play a key role in regulation of tissue tocopherol concentrations, but mechanisms of tocopherol metabolism have not been elucidated. Here we describe a pathway involving cytochrome P450-mediated omega-hydroxylation of the tocopherol phytyl side chain followed by stepwise removal of two- or three-carbon moieties, ultimately yielding the X-carboxychromanol metabolite that is excreted in urine. All key intermediates of gamma-tocopherol metabolism via this pathway were identified in hepatocyte cultures using gas chromatographymass spectrometry. NADPH-dependent synthesis of the initial gamma- and alpha-tocopherol 13'-hydroxy and -carboxy metabolites was demonstrated in rat and human liver microsomes. Functional analysis of several recombinant human liver P450 enzymes revealed that tocopherol-cohydroxylase activity was associated only with CYP4F2, which also catalyzes omega-hydroxylation of leukotriene B-4 and arachidonic acid. Tocopherol-omega-hydroxylase exhibited similar binding affinities but markedly higher catalytic activities for gamma-tocopherol than alpha-tocopherol, suggesting a role for this pathway in the preferential physiological retention of alpha-tocopherol and elimination of gamma-tocopherol. Sesamin potently inhibited tocopherol-omega-hydroxylase activity exhibited by CYP4F2 and rat or human liver microsomes. Since dietary sesamin also results in elevated tocopherol levels in vivo, this pathway appears to represent a functionally significant means of regulating vitamin E status.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Parker, RS (corresponding author), Cornell Univ, Div Nutr Sci, 113 Savage Hall, Ithaca, NY 14853 USA.	rsp3@cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07158-25] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRENS WA, 1986, J AM COLL NUTR, V5, P91; BIERI JG, 1974, J NUTR, V104, P850, DOI 10.1093/jn/104.7.850; BIERI JG, 1974, AM J CLIN NUTR, V27, P980, DOI 10.1093/ajcn/27.8.980; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; CHIKU S, 1984, J LIPID RES, V25, P40; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Cooney RV, 2001, NUTR CANCER, V39, P66, DOI 10.1207/S15327914nc391_9; Hosomi A, 1997, FEBS LETT, V409, P105, DOI 10.1016/S0014-5793(97)00499-7; HUGHES L, 1990, J LABELLED COMPD RAD, V28, P1049, DOI 10.1002/jlcr.2580280909; Jiang Q, 2001, AM J CLIN NUTR, V74, P714; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; Jin RY, 1998, ARCH BIOCHEM BIOPHYS, V359, P89, DOI 10.1006/abbi.1998.0880; Kamal-Eldin A, 2000, LIPIDS, V35, P427, DOI 10.1007/s11745-000-541-y; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 1999, ARCH BIOCHEM BIOPHYS, V369, P193, DOI 10.1006/abbi.1999.1271; KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Lin HL, 1998, CARCINOGENESIS, V19, P321, DOI 10.1093/carcin/19.2.321; Parker RS, 2000, BIOCHEM BIOPH RES CO, V277, P531, DOI 10.1006/bbrc.2000.3706; Parker RS, 2000, BIOCHEM BIOPH RES CO, V269, P580, DOI 10.1006/bbrc.2000.2319; Pelkonen O, 1998, XENOBIOTICA, V28, P1203, DOI 10.1080/004982598238886; Powell PK, 1996, ARCH BIOCHEM BIOPHYS, V335, P219, DOI 10.1006/abbi.1996.0501; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; Sai Y, 2000, XENOBIOTICA, V30, P327, DOI 10.1080/004982500237541; SCHONFELD A, 1993, NAHRUNG, V37, P498; SHAK S, 1987, METHOD ENZYMOL, V141, P355; Stahl W, 1999, ANAL BIOCHEM, V275, P254, DOI 10.1006/abio.1999.4312; Swanson JE, 1999, J LIPID RES, V40, P665; TAYLOR SL, 1976, LIPIDS, V11, P530, DOI 10.1007/BF02532898; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Traber MG, 1999, ANNU REV NUTR, V19, P343, DOI 10.1146/annurev.nutr.19.1.343; TRABER MG, 1992, J LIPID RES, V33, P1171; VATASSERY GT, 1983, J AM COLL NUTR, V2, P369; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Wechter WJ, 1996, P NATL ACAD SCI USA, V93, P6002, DOI 10.1073/pnas.93.12.6002; YAMASHITA K, 1995, LIPIDS, V30, P1019, DOI 10.1007/BF02536287	39	376	398	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25290	25296		10.1074/jbc.M201466200	http://dx.doi.org/10.1074/jbc.M201466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11997390	hybrid, Green Submitted			2022-12-27	WOS:000176747000059
J	Picault, N; Palmieri, L; Pisano, I; Hodges, M; Palmieri, F				Picault, N; Palmieri, L; Pisano, I; Hodges, M; Palmieri, F			Identification of a novel transporter for dicarboxylates and tricarboxylates in plant mitochondria - Bacterial expression, reconstitution, functional characterization, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANICUM-MILIACEUM; CARRIER; PROTEIN; CDNA; PURIFICATION; TRANSLOCATOR; CITRATE; YEAST; OXALOACETATE; MECHANISM	A cDNA from Arabidopsis thaliana and four related cDNAs from Nicotiana tabacum that we have isolated encode hitherto unidentified members of the mitochondrial carrier family. These proteins have been overexpressed in bacteria and reconstituted into phospholipid vesicles. Their transport properties demonstrate that they are orthologs/isoforms of a novel mitochondrial carrier capable of transporting both dicarboxylates (such as malate, oxaloacetate, oxoglutarate, and maleate) and tricarboxylates (such as citrate, isocitrate, cisaconitate, and trans-aconitate). The newly identified dicarboxylate-tricarboxylate carrier accepts only the single protonated form of citrate (H-citrate(2-)) and the unprotonated form of malate (malate(2-)) and catalyzes obligatory, electroneutral exchanges. Oxoglutarate, citrate, and malate are mutually competitive inhibitors, showing K-i close to the respective K-m. The carrier is expressed in all plant tissues examined and is largely spread in the plant kingdom. Furthermore, nitrate supply to nitrogen-starved tobacco plants leads to an increase in its mRNA in roots and leaves. The dicarboxylate-tricarboxylate carrier may play a role in important plant metabolic functions requiring organic acid flux to or from the mitochondria, such as nitrogen assimilation, export of reducing equivalents from the mitochondria, and fatty acid elongation.	Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; Univ Paris 11, CNRS UMR8618, Inst Biotechnol Plantes, F-91405 Orsay, France	Universita degli Studi di Bari Aldo Moro; UDICE-French Research Universities; Universite Paris Saclay	Palmieri, F (corresponding author), Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Via Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	PICAULT, Nathalie/ABB-1755-2021; PISANO, ISABELLA/AAK-5039-2021; Hodges, Michael/A-8883-2008; PICAULT, Nathalie N/M-1476-2015	PICAULT, Nathalie/0000-0003-2770-9688; PICAULT, Nathalie N/0000-0003-2770-9688; PISANO, Isabella/0000-0003-0728-2226				BAKER A, 1985, NUCLEIC ACIDS RES, V13, P5857, DOI 10.1093/nar/13.16.5857; BISACCIA F, 1993, BIOCHIM BIOPHYS ACTA, V1142, P139, DOI 10.1016/0005-2728(93)90095-W; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; Borecky J, 2001, FEBS LETT, V505, P240, DOI 10.1016/S0014-5793(01)02835-6; DAY DA, 1981, ARCH BIOCHEM BIOPHYS, V211, P100, DOI 10.1016/0003-9861(81)90434-3; DOLCE V, 1994, DNA SEQUENCE, V5, P103, DOI 10.3109/10425179409039711; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Galvez S, 1999, TRENDS PLANT SCI, V4, P484, DOI 10.1016/S1360-1385(99)01500-9; Galvez S, 1996, PLANT MOL BIOL, V30, P307, DOI 10.1007/BF00020116; Genchi C, 1999, PLANT PHYSIOL, V120, P841, DOI 10.1104/pp.120.3.841; GENCHI G, 1991, PLANT PHYSIOL, V96, P1003, DOI 10.1104/pp.96.4.1003; Hanning I, 1999, PLANT PHYSIOL, V119, P1025, DOI 10.1104/pp.119.3.1025; Iacobazzi V, 1992, DNA Seq, V3, P79, DOI 10.3109/10425179209034000; JUNG DW, 1979, PLANT PHYSIOL, V63, P591, DOI 10.1104/pp.63.4.591; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Kiiskinen M, 1997, PLANT MOL BIOL, V35, P271, DOI 10.1023/A:1005868715571; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Laloi M, 1999, CELL MOL LIFE SCI, V56, P918, DOI 10.1007/s000180050484; Lancien M, 1999, PLANT PHYSIOL, V120, P717, DOI 10.1104/pp.120.3.717; MCINTOSH CA, 1992, PLANT PHYSIOL, V100, P2030, DOI 10.1104/pp.100.4.2030; OLIVER DJ, 1984, PLANT PHYSIOL, V76, P409, DOI 10.1104/pp.76.2.409; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1971, EUR J BIOCHEM, V22, P66, DOI 10.1111/j.1432-1033.1971.tb01515.x; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 1999, J BIOL CHEM, V274, P22184, DOI 10.1074/jbc.274.32.22184; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PASZKOWSKI J, 1984, EMBO J, V3, P2717, DOI 10.1002/j.1460-2075.1984.tb02201.x; REMY R, 1987, ELECTROPHORESIS, V8, P528, DOI 10.1002/elps.1150081107; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Takabatake R, 1999, PLANT MOL BIOL, V40, P479, DOI 10.1023/A:1006285009435; Taniguchi M, 1996, PLANT MOL BIOL, V30, P51, DOI 10.1007/BF00017802; Taniguchi M, 1997, PLANT PHYSIOL, V114, P285, DOI 10.1104/pp.114.1.285; VANDERREST ME, 1991, EUR J BIOCHEM, V195, P71; VIVEKANANDA J, 1988, J BIOL CHEM, V263, P4782; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WISKICH JT, 1977, ANNU REV PLANT PHYS, V28, P45, DOI 10.1146/annurev.pp.28.060177.000401; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	43	120	126	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24204	24211		10.1074/jbc.M202702200	http://dx.doi.org/10.1074/jbc.M202702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11978797	hybrid			2022-12-27	WOS:000176611800031
J	Sigoillot, FD; Evans, DR; Guy, HI				Sigoillot, FD; Evans, DR; Guy, HI			Autophosphorylation of the mammalian multifunctional protein that initiates de novo pyrimidine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; HAMSTER-CELLS; ASPARTATE-TRANSCARBAMYLASE; CREATINE-KINASE; MAP KINASE; CAD; MECHANISM; IDENTIFICATION; DOMAINS	CAD, a large multifunctional protein that carries carbamoyl phosphate synthetase (CPSase), aspartate transcarbamoylase, and dihydroorotase activities, catalyzes the first three steps of de novo pyrimidine biosynthesis in mammalian cells. The CPSase component, which catalyzes the initial, rate-limiting step, exhibits complex regulatory mechanisms involving allosteric effectors and phosphorylation that control the flux of metabolites through the pathway. Incubation of CAD with ATP in the absence of exogenous kinases resulted in the incorporation of 1 mol of P-i/mol of CAD monomer. Mass spectrometry analysis of tryptic digests showed that Thr(1037) located within the CAD CPS.B subdomain was specifically modified. The reaction is specific for MgATP, ADP was a competitive inhibitor, and the native tertiary structure of the protein was required. Phosphorylation occurred after denaturation, further purification of CAD by SDS gel electrophoresis, and renaturation on a nitrocellulose membrane, strongly suggesting that phosphate incorporation resulted from an intrinsic kinase activity and was not the result of contaminating kinases. Chemical modification with the ATP analog, 5'-p-fluorosulfonylbenzoyladenosine, showed that one or both of the active sites that catalyze the ATP-dependent partial reactions are also involved in autophosphorylation. The rate of phosphorylation was dependent on the concentration of CAD, indicating that the reaction was, at least in part, intermolecular. Autophosphorylation resulted in a 2-fold increase in CPSase activity, an increased sensitivity to the feedback inhibitor UTP, and decreased allosteric activation by 5-phosphoribosyl-1-pyrophosphate, functional changes that were distinctly different from those resulting from phosphorylation by either the protein kinase A or mitogen-activated protein kinase cascades.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Guy, HI (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	hguy@cmb.biosci.wayne.edu		Sigoillot, Frederic/0000-0002-8695-4838	NIGMS NIH HHS [GM/CA47399, R01 GM060371, GM/CA60371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399, R01GM060371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; BRAXTON BL, 1992, BIOCHEMISTRY-US, V31, P2309, DOI 10.1021/bi00123a015; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHEN JJ, 1979, J BIOL CHEM, V254, P2697; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; David SSM, 1999, BIOCHEMISTRY-US, V38, P8492, DOI 10.1021/bi990041b; FERNANDEZ R, 1988, J GEN MICROBIOL, V134, P2493; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P23808; GUY HI, 1994, ADV EXP MED BIOL, V370, P729; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; HEMMER W, 1995, BBA-PROTEIN STRUCT M, V1251, P81, DOI 10.1016/0167-4838(95)00083-7; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; KEMLING N, 1994, THESIS WAYNE STATE U; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU X, 1994, J BIOL CHEM, V269, P27747; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; POST LE, 1990, J BIOL CHEM, V265, P7742; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; Sigoillot FD, 2002, J BIOL CHEM, V277, P15745, DOI 10.1074/jbc.M201112200; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TATIBANA M, 1972, BIOCHEM BIOPH RES CO, V46, P491, DOI 10.1016/S0006-291X(72)80165-7; WAHL GM, 1979, J BIOL CHEM, V254, P8679	45	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24809	24817		10.1074/jbc.M203512200	http://dx.doi.org/10.1074/jbc.M203512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986331	hybrid			2022-12-27	WOS:000176611800108
J	Boukhvalova, M; VanBruggen, R; Stewart, RC				Boukhvalova, M; VanBruggen, R; Stewart, RC			CheA kinase and chemoreceptor interaction surfaces on CheW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; ASPARTATE RECEPTOR; COVALENT MODIFICATION; THERMOTOGA-MARITIMA; CYTOPLASMIC DOMAIN; COMPLEX; SYSTEM	Chemotactic responses of Escherichia coli to aspartic acid are initiated by a ternary protein complex composed of Tar (chemoreceptor), CheA (kinase), and CheW (a coupling protein that binds to both Tar and CheA and links their activities). We used a genetic selection based on the yeast two-hybrid assay to identify nine cheW point mutations that specifically disrupted CheW interaction with CheA but not with Tar. We sequenced these single point mutants and purified four of the mutant CheW proteins for detailed biochemical characterizations that demonstrated the weakened affinity of the mutant CheW proteins for CheA, but not for Tar. In the three-dimensional structure of CheW, the positions affected by these mutations cluster on one face of the protein, defining a potential binding interface for interaction of CheW with CheA. We used a similar two-hybrid approach to identify four mutation sites that disrupted CheW binding to Tar. Mapping of these "Tar-sensitive" mutation sites and those from previous suppressor analysis onto the structure of CheW defined an extended surface on a face of the protein that is adjacent to the CheA-binding surface and that may serve as an interface for CheW binding to Tar.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Univ Maryland, Grad Program Mol & Cellular Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Stewart, RC (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052853] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52853] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOUKHVALOVA M, 2002, J BIOL CHEM, V10; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Griswold IJ, 2002, NAT STRUCT BIOL, V9, P121, DOI 10.1038/nsb753; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hirschman A, 2001, BIOCHEMISTRY-US, V40, P13876, DOI 10.1021/bi0113622; Inouye C, 1997, GENETICS, V147, P479; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Leung DW, 1989, TECHNIQUE, V1, P11; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUBYPHELPS K, 1994, CURR OPIN CELL BIOL, V6, P3, DOI 10.1016/0955-0674(94)90109-0; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MADDOCK JR, 1993, SCIENCE, V259, P1717; Manson MD, 1998, J BACTERIOL, V180, P1009, DOI 10.1128/JB.180.5.1009-1022.1998; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; Osborn M J, 1974, Methods Enzymol, V31, P642; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; RUSSELL I, 1987, BIOL RES IND YEASTS, V1, P1; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Skidmore JM, 2000, J BACTERIOL, V182, P967, DOI 10.1128/JB.182.4.967-973.2000; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Swanson RV, 1996, J BACTERIOL, V178, P484, DOI 10.1128/jb.178.2.484-489.1996; Usher KC, 1998, PROTEIN SCI, V7, P403; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649	61	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23596	23603		10.1074/jbc.M202288200	http://dx.doi.org/10.1074/jbc.M202288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964403	hybrid			2022-12-27	WOS:000176475700065
J	David, G; Neptune, MA; DePinho, RA				David, G; Neptune, MA; DePinho, RA			SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; REPRESS TRANSCRIPTION; PROTEIN; COMPLEX; P53; GROWTH; CANCER; DIFFERENTIATION; CONJUGATION; ACTIVATION	Histone deacetylation plays a central role in the regulation of genes linked to virtually all biological processes. This modification reaction is dependent on a family of related histone deacetylases (HDACs), which function as key components of large multiprotein complexes involved in the development of normal and neoplastic cells. The mechanisms regulating HDACs and their roles in such processes are not understood, and these form the major focus for the current study. Here, in the course of assessing possible post-translational modifications of HDAC1, we demonstrated that HDAC1 is a substrate for SUMO-1 (small ubiquitin-related modifier) modification in vitro and in vivo. The HDAC1 lysines targeted for modification were identified as C-terminal Lys-444 and Lys-476, which are also present in mammalian HDAC2 and lower vertebrate HDAC1/2 orthologs yet absent from other HDAC family members, pointing to a means of differential regulation among HDAC proteins. Mutation of these target residues (lysine to arginine substitution) profoundly reduced HDAC1-mediated transcriptional repression in reporter assays without affecting HDAC1 ability to associate with mSin3A and eliminated HDAC1-induced cell cycle and apoptotic responses upon overexpression. Together, the results demonstrate that HDAC1 is modified by SUMO-1, and this modification can dramatically affect HDAC1 activity in a number of surrogate biological assays.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhou Q, 2000, J BIOL CHEM, V275, P35256, DOI 10.1074/jbc.M003106200; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	36	181	187	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23658	23663		10.1074/jbc.M203690200	http://dx.doi.org/10.1074/jbc.M203690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960997	hybrid			2022-12-27	WOS:000176475700073
J	Hofmann, S; Rothbauer, U; Muhlenbein, N; Neupert, W; Gerbitz, KD; Brunner, M; Bauer, MF				Hofmann, S; Rothbauer, U; Muhlenbein, N; Neupert, W; Gerbitz, KD; Brunner, M; Bauer, MF			The C66W mutation in the deafness dystonia peptide 1 (DDP1) affects the formation of functional DDP1 center dot TIM13 complexes in the mitochondrial intermembrane space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; PREPROTEIN TRANSLOCASE; MENTAL DEFICIENCY; CARRIER PROTEINS; TIM COMPLEXES; IMPORT; TRANSPORT; BIOGENESIS; BLINDNESS; MACHINERY	Mohr-Tranebjaerg syndrome is a progressive, neurodegenerative disorder caused by loss-of-function mutations in the DDP1/TIMM8A gene. DDP1 belongs to a family of evolutionary conserved proteins that are organized in hetero-oligomeric complexes in the mitochondrial intermembrane space. They mediate the import and insertion of hydrophobic membrane proteins into the mitochondrial inner membrane. All of them share a conserved Cys(4) metal binding site proposed to be required for the formation of zinc fingers. So far, the only missense mutation known to cause a full-blown clinical phenotype is a C66W exchange directly affecting this Cys(4) motif. Here, we show that the mutant human protein is efficiently imported into mitochondria and sorted into the intermembrane space. In contrast to wild-type DDP1, it does not complement the function of its yeast homologue Tim8. The C66W mutation impairs binding of Zn2+ ions via the Cys4 motif. As a consequence, the mutated DDP1 is incorrectly folded and loses its ability to assemble into a hetero-hexameric 70-kDa complex with its cognate partner protein human Tim13. Thus, an assembly defect of DDP1 is the molecular basis of Mohr-Tranebjaerg syndrome in patients carrying the C66W mutation.	Akad Lehrkrankenhaus Munchen Schwabing, Inst Diabetesforsch & Metab Dis Ctr, Inst Klin Chem Mol Diagnost & Mitochondriale Gene, D-80804 Munich, Germany; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Univ Heidelberg, Biochem Zentrum, D-69120 Heidelberg, Germany	University of Munich; Ruprecht Karls University Heidelberg	Bauer, MF (corresponding author), Akad Lehrkrankenhaus Munchen Schwabing, Inst Diabetesforsch & Metab Dis Ctr, Inst Klin Chem Mol Diagnost & Mitochondriale Gene, Koelner Pl 1, D-80804 Munich, Germany.		Rothbauer, Ulrich/C-7712-2018	Rothbauer, Ulrich/0000-0001-5923-8986				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Leon O, 2000, BIOL RES, V33, P21; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; Tranebjaerg L, 2000, EUR J HUM GENET, V8, P464, DOI 10.1038/sj.ejhg.5200483	31	70	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23287	23293		10.1074/jbc.M201154200	http://dx.doi.org/10.1074/jbc.M201154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956200	hybrid			2022-12-27	WOS:000176475700026
J	Nehrke, K; Arreola, J; Nguyen, HV; Pilato, J; Richardson, L; Okunade, G; Baggs, R; Shull, GE; Melvin, JE				Nehrke, K; Arreola, J; Nguyen, HV; Pilato, J; Richardson, L; Okunade, G; Baggs, R; Shull, GE; Melvin, JE			Loss of hyperpolarization-activated Cl- current in salivary acinar cells from Clcn2 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLC-2 CHLORIDE CHANNEL; SENSITIVE NA+ CURRENT; GRANULAR DUCT CELLS; EPITHELIAL-CELLS; SPLICE VARIANTS; FETAL LUNG; RAT; VOLUME; CALCIUM; SECRETION	ClC-2 is localized to the apical membranes of secretory epithelia where it has been hypothesized to play a role in fluid secretion. Although ClC-2 is clearly the inwardly rectifying anion channel in several tissues, the molecular identity of the hyperpolarization-activated Cl- current in other organs, including the salivary gland, is currently unknown. To determine the nature of the hyperpolarization-activated. Cl- current and to examine the role of ClC-2 in salivary gland function, a mouse line containing a targeted disruption of the Clcn2 gene was generated. The resulting homozygous Clcn2(-/-) mice lacked detectable hyperpolarization-activated chloride currents in parotid acinar cells and, as described previously, displayed postnatal degeneration of the retina and testis. The magnitude and biophysical characteristics of the volume- and calcium-activated chloride currents in these cells were unaffected by the absence of ClC-2. Although ClC-2 appears to contribute to fluid secretion in some cell types, both the initial and sustained salivary flow rates were normal in Clcn2(-/-) mice following in vivo stimulation with pilocarpine, a cholinergic agonist. In addition, the electrolytes and protein contents of the mature secretions were normal. Because ClC-2 has been postulated to contribute to cell volume control, we also examined regulatory volume decrease following cell swelling. However, parotid acinar cells from Clcn2(-/-) mice recovered volume with similar efficiency to wild-type littermates. These data demonstrate that ClC-2 is the hyperpolarization-activated Cl- channel in salivary acinar cells but is not essential for maximum chloride flux during stimulated secretion of saliva or acinar cell volume regulation.	Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Lab Anim Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol & Psysiol, Rochester, NY 14642 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University System of Ohio; University of Cincinnati	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.	james_melvin@urmc.rochester.edu	ARREOLA, JORGE/HGE-4524-2022; Arreola, Jorge/B-1042-2009	ARREOLA, JORGE/0000-0002-5354-3709; Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692, P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13539, DE09692] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arreola J, 1996, J PHYSIOL-LONDON, V490, P351, DOI 10.1113/jphysiol.1996.sp021149; Arreola J, 2002, J PHYSIOL-LONDON, V541, P103, DOI 10.1113/jphysiol.2002.016485; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; ARREOLA J, 1995, J PHYSIOL-LONDON, V484, P677, DOI 10.1113/jphysiol.1995.sp020695; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Brooks HL, 2001, J PHYSIOL-LONDON, V530, P359, DOI 10.1111/j.1469-7793.2001.0359k.x; Chu SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL614, DOI 10.1152/ajplung.1999.276.4.L614; Chu SJ, 1997, NUCLEIC ACIDS RES, V25, P4153, DOI 10.1093/nar/25.20.4153; Cid LP, 2000, AM J PHYSIOL-CELL PH, V279, pC1198, DOI 10.1152/ajpcell.2000.279.4.C1198; Clark S, 1998, J PHYSIOL-LONDON, V506, P665, DOI 10.1111/j.1469-7793.1998.665bv.x; DINUDOM A, 1995, J PHYSIOL-LONDON, V487, P549, DOI 10.1113/jphysiol.1995.sp020899; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DOUGLAS WW, 1963, J PHYSIOL-LONDON, V165, P528, DOI 10.1113/jphysiol.1963.sp007076; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; Fritsch J, 1997, AM J PHYSIOL-CELL PH, V272, pC778, DOI 10.1152/ajpcell.1997.272.3.C778; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kibble JD, 1996, J PHYSIOL-LONDON, V496, P69, DOI 10.1113/jphysiol.1996.sp021666; KOMWATANA P, 1994, PFLUG ARCH EUR J PHY, V428, P641, DOI 10.1007/BF00374588; Komwatana P, 1996, J MEMBRANE BIOL, V150, P133, DOI 10.1007/s002329900038; Komwatana P, 1998, J MEMBRANE BIOL, V162, P225, DOI 10.1007/s002329900360; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; MARTINEZ JR, 1972, EXPERIENTIA, V28, P167, DOI 10.1007/BF01935735; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; Mohammad-Panah R, 2001, J BIOL CHEM, V276, P8306, DOI 10.1074/jbc.M006764200; Murray CB, 1996, AM J PHYSIOL-LUNG C, V271, pL829, DOI 10.1152/ajplung.1996.271.5.L829; MURRAY CB, 1995, AM J RESP CELL MOL, V12, P597, DOI 10.1165/ajrcmb.12.6.7766424; NISHIYAMA A, 1974, J PHYSIOL-LONDON, V242, P173, DOI 10.1113/jphysiol.1974.sp010700; Park K, 2001, J MEMBRANE BIOL, V182, P31, DOI 10.1007/s00232-001-0026-0; Park K, 1998, J MEMBRANE BIOL, V163, P87, DOI 10.1007/s002329900373; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roman RM, 2001, AM J PHYSIOL-GASTR L, V280, pG344, DOI 10.1152/ajpgi.2001.280.3.G344; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; SASAKI T, 1990, FEBS LETT, V264, P130, DOI 10.1016/0014-5793(90)80782-E; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Speake T, 2002, J PHYSIOL-LONDON, V539, P385, DOI 10.1113/jphysiol.2001.014548; Tewari KP, 2000, AM J PHYSIOL-CELL PH, V279, pC40, DOI 10.1152/ajpcell.2000.279.1.C40; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442	53	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23604	23611		10.1074/jbc.M202900200	http://dx.doi.org/10.1074/jbc.M202900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11976342	hybrid			2022-12-27	WOS:000176475700066
J	Thoden, JB; Firestine, SM; Benkovic, SJ; Holden, HM				Thoden, JB; Firestine, SM; Benkovic, SJ; Holden, HM			PurT-encoded glycinamide ribonueleotide transformylase - Accommodation of adenosine nucleotide analoges within the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; MYOSIN MOTOR DOMAIN; X-RAY STRUCTURES; CRYSTAL-STRUCTURE; ATP-BINDING; B-DOMAIN; P-LOOP; PROTEINS; MGADP; SUPERFAMILY	PurT-encoded glycinamide ribonucleotide transformylase, or PurT transformylase, functions in purine biosynthesis by catalyzing the formylation of glycinamide ribonucleotide through a catalytic mechanism requiring Mg(2+)ATP and formate. From previous x-ray diffraction analyses, it has been demonstrated that PurT transformylase from Escherichia coli belongs to the ATP-grasp superfamily of enzymes, which are characterized by three structural motifs referred to as the A-, B-, and C-domains. In all of the ATP-grasp enzymes studied to date, the adenosine nucleotide ligands are invariably wedged between the B- and C-domains, and in some cases, such as biotin carboxylase and carbamoyl phosphate synthetase, the B-domains move significantly upon nucleotide binding. Here we present a systematic and high-resolution structural investigation of PurT transformylase complexed with various adenosine nucleotides or nucleotide analogs including Mg(2+)ATP, Mg2+-5'-adenylylimidodiphosphate, Mg2+-beta,gamma-methyleneadenosine 5'-triphosphate, Mg(2+)ATPgammaS, or Mg(2+)ADP. Taken together, these studies indicate that the conformation of the so-called "T-loop," delineated by Lys-155 to Gln-165, is highly sensitive to the chemical identity of the nucleotide situated in the binding pocket. This sensitivity to nucleotide identity is in sharp contrast to that observed for the "P-loop"-containing enzymes, in which the conformation of the binding motif is virtually unchanged in the presence or absence of nucleotides.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Duquesne Univ, Mylan Sch Pharm, Pittsburgh, PA 15282 USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Duquesne University	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [GM55513, GM24129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024129, R01GM024129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Fan C, 1997, BIOCHEMISTRY-US, V36, P2531, DOI 10.1021/bi962431t; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HARA T, 1996, BIOCHEMISTRY-US, V35, P11963; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Marolewski AE, 1997, BIOCHEMISTRY-US, V36, P6709, DOI 10.1021/bi962961p; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	22	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23898	23908		10.1074/jbc.M202251200	http://dx.doi.org/10.1074/jbc.M202251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953435	hybrid			2022-12-27	WOS:000176475700104
J	Mizel, SB; Snipes, JA				Mizel, SB; Snipes, JA			Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; TUMOR-NECROSIS-FACTOR; CUTTING EDGE; ENDOTOXIN TOLERANCE; BACTERIAL FLAGELLIN; SIGNAL-TRANSDUCTION; DOWN-REGULATION; LIPOPOLYSACCHARIDE; GENE; MACROPHAGES	Flagellin from a number of Gram-negative bacteria induces cytokine and nitric oxide production by inflammatory cell types. In view of the evidence that flagellin responsiveness is subject to modulation, we explored the possibilities that a prior exposure to flagellin might result in a state of reduced flagellin responsiveness or tolerance and that lipopolysaccharide (LPS) and flagellin may induce a state of cross-tolerance to each other. Our results demonstrate that a prior exposure to flagellin results in a subsequent state of flagellin tolerance in human monocytes, THP1 cells, Jurkat cells, and COS-1 cells. Tolerance occurs within 2 h after addition of flagellin and does not require protein synthesis. Flagellin did not induce tolerance to LPS in monocytes and THP1 cells; however, LPS treatment of monocytes and THP1 cells resulted in a state of flagellin cross-tolerance. Flagellin-induced self-tolerance is not the result of a decrease in the steady-state level of toll-like receptor 5 (TLR5) or interleukin-1 receptor associated kinase (IRAK), but it is associated with a block in the release of IRAK from the TLR5 complex in flagellin-tolerant cells. Release is essential for IRAK activity because the TLR5-associated IRAK lacks kinase activity. LPS-induced cross-tolerance to flagellin is also associated with a block in IRAK release from TLR5. These results provide evidence for a novel mechanism of TLR signaling control.	Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Mizel, SB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	smizel@wfubmc.edu			NIAID NIH HHS [AI-51319, AI-38670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038670, R01AI051319, R01AI038670] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Ciacci-Wooline F, 1999, INFECT IMMUN, V67, P5176, DOI 10.1128/IAI.67.10.5176-5185.1999; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; GREISMAN SE, 1969, J IMMUNOL, V103, P1223; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Riedel DD, 2000, MICROBES INFECT, V2, P463, DOI 10.1016/S1286-4579(00)00319-1; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; Tominaga K, 1999, BBA-MOL CELL RES, V1450, P130, DOI 10.1016/S0167-4889(99)00037-3; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wilson CS, 1997, J SURG RES, V69, P101, DOI 10.1006/jsre.1997.5040; Wyant TL, 1999, INFECT IMMUN, V67, P1338, DOI 10.1128/IAI.67.3.1338-1346.1999; YAMIN TT, 1997, J EXP MED, V187, P2073; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang RB, 1999, J IMMUNOL, V163, P639; Yoza B, 1998, PROG CLIN BIOL RES, V397, P209	41	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22414	22420		10.1074/jbc.M201762200	http://dx.doi.org/10.1074/jbc.M201762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953430	hybrid			2022-12-27	WOS:000176313600040
J	Xie, JX; Adams, LM; Zhao, JY; Gerken, TA; Davis, PB; Ma, JJ				Xie, JX; Adams, LM; Zhao, JY; Gerken, TA; Davis, PB; Ma, JJ			A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CL-CHANNEL; PHOSPHORYLATION; ACTIVATION; PROTEINS; BINDING; STATES	The regulatory (R) domain of the cystic fibrosis transmembrane conductance regulator (CFTR) contains con. sensus phosphorylation sites for cAMP-dependent protein kinase (PKA) that are the basis for physiological regulation of the CFTR chloride channel. A short peptide segment in the R domain with a net negative charge of B9 (amino acids 817-838, NEG2) and predicted helical tendency is shown to play a critical role in CFTR chloride channel function. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of channel activity. Exogenous NEG2 peptide interacts with CFTR to exert both stimulatory and inhibitory effects on the channel function. The NEG2 peptide with sequence scrambled to remove helical tendencies also inhibits channel function, but does not stimulate. Similar results are found for a NEG2 peptide whose helical structure is disrupted by a proline residue. When six of the negatively charged carboxylic acid residues are replaced by their cognate amides, reducing net negative charge to B3, but increasing helical propensity as assessed by circular dichroism, the peptide stimulates CFTR channel function, but does not inhibit. We speculate that the NEG2 region interacts with other cytosolic domains of CFTR to control opening and closing transitions of the chloride channel.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maj2@umdnj.edu			NHLBI NIH HHS [T32 HL07415, R01 HL/DK 49003] Funding Source: Medline; NIDDK NIH HHS [R01 DK51770, P30 DK27651] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007415, R01HL049003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK051770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; Baldursson O, 2001, J BIOL CHEM, V276, P1904, DOI 10.1074/jbc.M006934200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; Fu J, 2001, J PHYSIOL-LONDON, V536, P459, DOI 10.1111/j.1469-7793.2001.0459c.xd; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Iakoucheva LM, 2001, PROTEIN SCI, V10, P1353, DOI 10.1110/ps.40101; IKUMA M, 1999, PEDIATR PULM, V19, P176; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; King SA, 2000, BIOCHEMISTRY-US, V39, P9868, DOI 10.1021/bi992807d; Ma JJ, 2000, NEWS PHYSIOL SCI, V15, P154; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Ma JJ, 1998, CLIN CHEST MED, V19, P459, DOI 10.1016/S0272-5231(05)70093-9; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; PERCZELL A, 1992, PROTEIN-STRUCT FUNCT, V13, P7; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; Tasch JE, 1999, FEBS LETT, V445, P63, DOI 10.1016/S0014-5793(99)00086-1; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1997, AM J PHYSIOL-LUNG C, V273, pL127, DOI 10.1152/ajplung.1997.273.1.L127; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; XIE JX, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	41	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23019	23027		10.1074/jbc.M201661200	http://dx.doi.org/10.1074/jbc.M201661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950844	hybrid			2022-12-27	WOS:000176313600117
J	Cui, J; Heard, TS; Yu, JH; Lo, JL; Huang, L; Li, Y; Schaeffer, JM; Wright, SD				Cui, J; Heard, TS; Yu, JH; Lo, JL; Huang, L; Li, Y; Schaeffer, JM; Wright, SD			The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLASE GENE CYP7A; NUCLEAR RECEPTOR; BILE-ACIDS; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION DOMAIN; HORMONE-RECEPTOR; LIGAND-BINDING; PROTEIN GENE; CHOLESTEROL; IDENTIFICATION	The critical steps in bile acid metabolism have remarkable differences between humans and mice. It is known that human cholesterol 7alpha-hydroxylase, the enzyme catalyzing the rate-limiting step of bile acid synthesis, is more sensitive to bile acid suppression. In addition, hepatic bile acid export in humans is more dependent on the bile salt export pump (BSEP). To explore the molecular basis for these species differences, we analyzed the function of the ligand-binding domain (LBD) of human and murine farnesoid X receptor (FXR), a nuclear receptor for bile acids. We observed a strong interspecies difference in bile acid-mediated FXR function; in the coactivator association assay, chenodeoxycholate (CDCA) activated human FXR-LBD with 10-fold higher affinity and 3-fold higher maximum response than murine FXR-LBD. Consistently, in HepG2 cells human FXR-LBD increased reporter expression more robustly in the presence of CDCA. The basis for these differences was investigated by preparing chimeric receptors and by site-directed mutagenesis. Remarkably, the double replacements of LyS(366) and Val(384) in murine FXR (corresponding to Asn(354) and Ile(372) in human FXR) with Asn(366) and Ile(384) explained the difference in both potency and maximum activation; compared with the wild-type murine FXR-LBD, the double mutant gained 8-fold affinity and more than 250% maximum response to CDCA in vitro. This mutant also increased reporter expression to an extent comparable with that of human FXR-LBD in HepG2 cells. These results demonstrate that Asn(354) and Ile(372) are critically important for FXR function and that murine FXR can be "humanized" by substituting with the two corresponding residues of human FXR. Consistent with the difference in FXR-LBD transactivation, CDCA induced endogenous expression of human BSEP by 10-12-fold and murine BSEP by 2-3-fold in primary hepatocytes. This study not only provides the identification of critical residues for FXR function but may also explain the species difference in bile acids/cholesterol metabolism.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA	Merck & Company	Cui, J (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000, Rahway, NJ 07065 USA.	jisong_cui@merck.com						Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; DeFabiani E, 1996, BIOCHEM BIOPH RES CO, V226, P663, DOI 10.1006/bbrc.1996.1412; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Greene M. E., 1995, Gene Expression, V4, P281; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Hofmann AF, 2001, HEPATOLOGY, V34, P848, DOI 10.1053/jhep.2001.28197; Jansen PLM, 1999, GASTROENTEROLOGY, V117, P1370, DOI 10.1016/S0016-5085(99)70287-8; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Lobaccaro JMA, 2001, ANN ENDOCRINOL-PARIS, V62, P239; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; POLLARD JW, 1992, METHODS MOL BIOL SER, V75, P145; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; TONE Y, 1994, J BIOL CHEM, V269, P31157; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang DP, 1996, J LIPID RES, V37, P1831; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	42	30	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25963	25969		10.1074/jbc.M200824200	http://dx.doi.org/10.1074/jbc.M200824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004058	hybrid			2022-12-27	WOS:000176908700020
J	Endo, H; Takenaga, K; Kanno, T; Satoh, H; Mori, S				Endo, H; Takenaga, K; Kanno, T; Satoh, H; Mori, S			Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S10OA4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; ANGIOGENESIS INHIBITOR TNP-470; 67-KDA POLYPEPTIDE P67; ENDOTHELIAL-CELLS; S100 PROTEINS; PEL98 PROTEIN; E-CADHERIN; IN-VITRO; GENE; EXPRESSION	S100A4 is an EF-hand type calcium-binding protein that regulates tumor metastasis and a variety of cellular processes via interaction with different target proteins. Here we report that S100A4 physically interacts with methionine aminopeptidase 2 (MetAP2), the primary target for potent angiogenesis inhibitors, fumagillin and ovalicin. Using a yeast two-hybrid screen, S100A4 was found to interact with the N-terminal half of MetAP2. In vitro pull-down assays showed that S100A4 associates with MetAP2 in a calcium-dependent manner. In addition, the binding site of S100A4 was found located within the region between amino acid residues 170 and 229 of MetAP2. In vivo interaction of S100A4 with MetAP2 was verified by co-immunoprecipitation analysis. Immunofluorescent staining revealed that S100A4 and MetAP2 were co-localized in both quiescent and basic fibroblast growth factor-treated murine endothelial MSS31 cells, in the latter of which a significant change of intracellular distribution of both proteins was observed. Although the binding of S100A4 did not affect the in vitro methionine aminopeptidase activity of MetAP2, the cytochemical observation suggests a possible involvement of S100A4 in the regulation of MetAP2 activity through changing its localization, thereby modulating the N-terminal methionine processing of nascent substrates. These results may offer an essential clue for understanding the functional role of S100A4 in regulating endothelial cell growth and tumor metastasis.	Univ Tokyo, Div Pathol, Dept Canc Biol, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Chaba Canc Ctr Res Inst, Div Chemotherapy, Chuoh Ku, Chiba 2608717, Japan	University of Tokyo	Endo, H (corresponding author), Univ Tokyo, Div Pathol, Dept Canc Biol, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	endoh@ims.u-tokyo.ac.jp						ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bjornland K, 1999, CANCER RES, V59, P4702; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COX JV, 1983, CELL, V35, P331, DOI 10.1016/0092-8674(83)90236-2; Cutforth T, 1999, MECH DEVELOP, V82, P23, DOI 10.1016/S0925-4773(99)00006-4; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Datta B, 1999, EXP CELL RES, V250, P223, DOI 10.1006/excr.1999.4508; DATTA B, 1989, J BIOL CHEM, V264, P20620; DAVIES BR, 1993, ONCOGENE, V8, P999; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; Keirsebilck A, 1998, CANCER RES, V58, P4587; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; PARKER C, 1994, DNA CELL BIOL, V13, P1021, DOI 10.1089/dna.1994.13.1021; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; Rudland PS, 2000, CANCER RES, V60, P1595; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tanaka K, 1999, JPN J CANCER RES, V90, P647, DOI 10.1111/j.1349-7006.1999.tb00796.x; Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074-5521(99)80129-X; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; YANASE T, 1993, CANCER RES, V53, P2566; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	48	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26396	26402		10.1074/jbc.M202244200	http://dx.doi.org/10.1074/jbc.M202244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994292	hybrid			2022-12-27	WOS:000176908700076
J	Grimm, M; Spiecker, M; De Caterina, R; Shin, WS; Liao, JK				Grimm, M; Spiecker, M; De Caterina, R; Shin, WS; Liao, JK			Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; DNA-BINDING ACTIVITY; SMOOTH-MUSCLE CELLS; DR-ALPHA GENE; KAPPA-B-ALPHA; OXIDATIVE STRESS; CCAAT-BINDING; NF-Y; PROINFLAMMATORY CYTOKINES; SALMONELLA-TYPHIMURIUM	Interferon (IFN)-gamma facilitates cellular immune response, in part, by inducing the expression of major histocompatibility complex class II (MHC-II) molecules. We demonstrate that IFN-gamma induces the expression of HLA-DRA in vascular endothelial cells via mechanisms involving reactive oxygen species. IFN-gamma-induced HLA-DRA expression was inhibited by nitric oxide (NO) and antioxidants such as superoxide dismutase, catalase, pyrrolidine dithiocarbamate, and N-acetylcysteine. Nuclear run-on assays demonstrated that NO and antioxidants inhibited IFN-gamma-induced HLA-DRA gene transcription. Transient transfection studies using a fully functional HLA-DRA promoter construct ([-300]DRalpha.CAT) showed that inhibition of endogenous NO synthase activity by N-omega-monomethyl-L-arginine or addition of exogenous hydrogen peroxide (11202) augmented basal and IFN-gamma-stimulated [-300]DRalpha.CAT activity. However, H2O2 and N-omega-monomethyl-L-arginine could introduce HLA-DRA expression suggesting that H2O2 is a necessary but not a sufficient mediator of IFN-gamma-induced HLA-DRA expression. Electrophoretic mobility shift assay and Western blotting demonstrated that NO and antioxidants had little or no effect on IFN-gamma-induced IRF-1 activation or MHC-II transactivator (CIITA) expression but did inhibit IFN-gamma-induced activation of STAT1alpha (p91) and Y box transcription factors, NF-Y-A and NF-Y-B. These results indicate that NO and antioxidants may attenuate vascular inflammation by antagonizing the effects of intracellular reactive oxygen species generation by IFN-gamma, which is necessary for MHC-II gene transcription.	Brigham & Womens Hosp, Vasc Med Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, Vasc Med Unit, 221 Longwood Ave,LMRC-322, Boston, MA 02115 USA.		De Caterina, Raffaele/K-3857-2016	De Caterina, Raffaele/0000-0003-1637-574X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233, HL-48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DE CR, 1995, J CLIN INVEST, V96, P60; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GROENEWEGEN G, 1985, NATURE, V316, P361, DOI 10.1038/316361a0; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; Hobart M, 1997, J IMMUNOL, V158, P4260; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; Kielar ML, 2000, INFLAMMATION, V24, P431, DOI 10.1023/A:1007012128392; Labarrere CA, 1997, JAMA-J AM MED ASSOC, V278, P1169, DOI 10.1001/jama.278.14.1169; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LIBBY P, 1994, CLIN TRANSPLANT, V8, P313; Llovera M, 2001, BRIT J PHARMACOL, V132, P419, DOI 10.1038/sj.bjp.0703838; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MARAI N, 1993, J CLIN INVEST, V92, P1866; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PERSSON MG, 1990, BRIT J PHARMACOL, V100, P463, DOI 10.1111/j.1476-5381.1990.tb15829.x; POBER JS, 1983, NATURE, V305, P726, DOI 10.1038/305726a0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; VANDERWAL AC, 1992, AM J PATHOL, V141, P1427; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; Zhang JL, 1997, RES COMMUN MOL PATH, V96, P71	56	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26460	26467		10.1074/jbc.M110538200	http://dx.doi.org/10.1074/jbc.M110538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006557	hybrid			2022-12-27	WOS:000176908700084
J	Malhotra, JD; Koopmann, MC; Kazen-Gillespie, KA; Fettman, N; Hortsch, M; Isom, LL				Malhotra, JD; Koopmann, MC; Kazen-Gillespie, KA; Fettman, N; Hortsch, M; Isom, LL			Structural requirements for interaction of sodium channel beta 1 subunits with ankyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; FEBRILE SEIZURES PLUS; NA+-CHANNEL; CYTOPLASMIC DOMAIN; GENERALIZED EPILEPSY; MESSENGER-RNA; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; ALPHA-SUBUNITS; TENASCIN-R	Sodium channel beta subunits modulate channel kinetic properties and cell surface expression levels and function as cell adhesion molecules. beta1 and beta2 participate in homophilic cell adhesion resulting in ankyrin recruitment to cell contact sites. We hypothesized that a tyrosine residue in the cytoplasmic domain of beta1 may be important for ankyrin recruitment and tested our hypothesis using beta1 mutants replacing Tyr(181) with alanine (beta1Y181A), phenylalanine (beta1Y181F), or glutamate (beta1Y181E), or a truncated construct deleting all residues beyond Tyr(181) (beta1L182(STOP)). Ankyrin recruitment was observed in beta1L182(STOP), showing that residues Ile(166)-Tyr(181) contain the major ankyrin recruiting activity of beta1. Ankyrin recruitment was abolished in beta1Y181E, suggesting that tyrosine phosphorylation of beta1 may inhibit beta1-ankyrin interactions. Ankyrin(G) and beta1 associate in rat brain membranes and in transfected cells expressing beta1 and ankyrin(G) in the absence of sodium channel alpha subunits. beta1 subunits are recognized by anti-phosphotyrosine antibodies following treatment of these cell lines with fibroblast growth factor. beta1 and ankryin(G) association is not detectable in cells following treatment with fibroblast growth factor. Ankyrin(G) and beta1Y181E do not associate even in the absence of fibroblast growth factor treatment. beta1 subunit-mediated cell adhesion and ankyrin recruitment may contribute to sodium channel placement at nodes of Ranvier. The phosphorylation state of beta1Y181 may be a critical regulatory step in these developmental processes.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1150 W Med Dr,1301 MSRB 3, Ann Arbor, MI 48109 USA.			Hortsch, Michael/0000-0002-3750-737X; Isom, Lori/0000-0002-9479-6729	NICHD NIH HHS [R01HD29388] Funding Source: Medline; NIMH NIH HHS [R01MH59980] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; BIEBER AJ, 1994, METHOD CELL BIOL, V44, P683, DOI 10.1016/S0091-679X(08)60938-3; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DibHajj SD, 1996, FEBS LETT, V384, P78, DOI 10.1016/0014-5793(96)00273-6; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; Escayg A, 2001, AM J HUM GENET, V68, P866, DOI 10.1086/319524; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; JOE EH, 1993, J NEUROSCI, V13, P2993; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; Lustig M, 2001, CURR BIOL, V11, P1864, DOI 10.1016/S0960-9822(01)00586-3; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 1998, J BIOL CHEM, V273, P33354, DOI 10.1074/jbc.273.50.33354; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Needham LK, 2001, J NEUROSCI, V21, P1490, DOI 10.1523/JNEUROSCI.21-05-01490.2001; Oh Y, 1997, NEUROSCI LETT, V234, P107, DOI 10.1016/S0304-3940(97)00694-0; OH YS, 1994, P NATL ACAD SCI USA, V91, P9985, DOI 10.1073/pnas.91.21.9985; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; Wallace RH, 2001, AM J HUM GENET, V68, P859, DOI 10.1086/319516; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; Wong EV, 1995, NEUROSCI LETT, V200, P155, DOI 10.1016/0304-3940(95)12100-I; WONG MH, 1994, J CELL BIOL, V126, P1089, DOI 10.1083/jcb.126.4.1089; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	40	119	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26681	26688		10.1074/jbc.M202354200	http://dx.doi.org/10.1074/jbc.M202354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11997395	hybrid			2022-12-27	WOS:000176908700110
J	Wang, HX; Hays, JB				Wang, HX; Hays, JB			Mismatch repair in human nuclear extracts - Time courses and ATP requirements for kinetically distinguishable steps leading to tightly controlled 5 ' to 3 ' and aphidicolin-sensitive 3 ' to 5 ' mispair-provoked excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; SACCHAROMYCES-CEREVISIAE; HMUTS-ALPHA; TRANSLOCATION MECHANISM; MOLECULAR SWITCH; YEAST MSH2-MSH6; SLIDING CLAMP; IN-VITRO; COMPLEX; HETERODUPLEX	Mismatch repair (MMR) systems enhance genomic stability by correcting DNA replication errors. The events in mammalian MMR pathways remain poorly understood. Using HeLa cell nuclear extracts, we analyzed correction of mispairs in circular DNA substrates with single defined nicks and measured excision in the absence of exogenous dNTPs by annealing specific oligonucleotide probes. In reactions initiated by concomitant temperature shift and addition of ATP or Mg2+ to otherwise complete mixtures on ice, ATP-initiated excision and final error correction lagged behind Mg2+-initiated reactions, suggesting a very early requirement for ATP but not its hydrolysis. Subsequent stable commitment (resistance to added excess competitor substrate) began within 30 s, required hydrolyzable ATP, and plateaued after 60-70 s. This may reflect formation of hydrolysis-dependent translocating and/or pre-excision complexes. Excision along shorter nick-mispair paths began 15 s later than commitment. Both 3' to 5' and 5' to 3' excision gaps appeared at rates of similar to0.0055 of final yields per second, respectively, 30 or 2.5 times the nonspecific excision rates. The lag between 3' to 5' excision gaps at two different positions yielded an excision progress rate of 5.2 nucleotides/s. In both substrates, corrected products appeared at fractional rates of 0.0027 of final yield per second. Aphidicolin, known to inhibit both the DNA synthesis and 3' to 5' exonuclease activities of polymerases a and E, reduced appearance of 3' to 5' excision tracts roughly 4-fold at 90 mum but had no effect on 5' to 3' excision.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, ALS 1007, Corvallis, OR 97331 USA.							Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FANG WH, 1993, J BIOL CHEM, V268, P11838; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 2002, J BIOL CHEM, V277, P3673, DOI 10.1074/jbc.M106120200; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Wang HX, 2000, MOL BIOTECHNOL, V15, P97, DOI 10.1385/MB:15:2:97; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200	34	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26143	26148		10.1074/jbc.M200358200	http://dx.doi.org/10.1074/jbc.M200358200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12006561	hybrid			2022-12-27	WOS:000176908700042
J	Cervoni, N; Detich, N; Seo, SB; Chakravarti, D; Szyf, M				Cervoni, N; Detich, N; Seo, SB; Chakravarti, D; Szyf, M			The oncoprotein Set/TAF-1 beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; ACETYLATION; NEUROSPORA	Histone hypoacetylation and DNA hypermethylation are hallmarks of gene silencing. Although a role for DNA methylation in regulating histone acetylation has been established, it is not clear how and whether epigenetic histone markings influence DNA modifications in transcriptional silencing. We have previously shown that induction of histone acetylation by trichostatin A promotes demethylation of ectopically methylated DNA (Cervoni, N., and Szyf, M. (2001) J. Biol. Chem. 276, 40778-40787). The oncoprotein Set/TAF-Ibeta is a subunit of the recently identified inhibitor of acetyltransferases complex that inhibits histone acetylation by binding to and masking histone acetyltransferase targets (Seo, S. B., McNamara, P., Heo, S., Turner, A., Lane, W. S., and Chakravarti, D. (2001) Cell 104, 119-130). We show here that the overexpression of Set/TAF-Ibeta, whose expression is up-regulated in multiple tumor tissues, inhibits demethylation of ectopically methylated DNA resulting in gene silencing. Overexpression of a mutant Set/TAF-Ibeta that does not inhibit histone acetylation is defective in inhibiting DNA demethylation. Taken together, these results are consistent with a novel regulatory role for Set/TAF-Ibeta, integrating epigenetic states of histones and DNA in gene regulation and provide a new mechanism that can explain how hypermethylation of specific regions might come about by inhibition of demethylation in cancer cells.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	McGill University; University of Pennsylvania	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.			Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK57079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RAZIN A, 1977, P NATL ACAD SCI USA, V74, P2725, DOI 10.1073/pnas.74.7.2725; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; SZYF M, 1985, J BIOL CHEM, V260, P8653; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508	17	146	160	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25026	25031		10.1074/jbc.M202256200	http://dx.doi.org/10.1074/jbc.M202256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11978794	hybrid			2022-12-27	WOS:000176747000026
J	Foster, JD; Pananusorn, B; Vaughan, RA				Foster, JD; Pananusorn, B; Vaughan, RA			Dopamine transporters are phosphorylated on N-terminal serines in rat striatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VESICULAR ACETYLCHOLINE TRANSPORTER; LIGAND-BINDING DOMAINS; SEROTONIN TRANSPORTERS; FUNCTIONAL REGULATION; SYNTAXIN 1A; SUBCELLULAR REDISTRIBUTION; GABA TRANSPORTER; XENOPUS-OOCYTES; PHORBOL ESTERS	Dopamine transporters (DATs) are neuronal phospho-proteins that clear dopamine from the synaptic cleft. Activation of protein kinase C (PKC) and inhibition of protein phosphatases by okadaic acid (OA) increase phosphorylation of DAT and lead to concomitant reduction in DAT activity and cell surface expression. Numerous potential sites for phosphorylation are present on DAT, but the sites utilized and their relationship to transport regulation are currently unknown. We used peptide mapping and epitope-specific immunoprecipitation to identify the region of DAT that undergoes phosphorylation in rat striatal tissue. Phosphoamino acid analysis revealed that basal and stimulated samples were phosphorylated primarily on serine. Digestion of (PO4)-P-32-labeled DAT with trypsin and immunoprecipitation with N- or C-terminal specific antisera failed to isolate phosphopeptide fragments corresponding to photoaffinity-labeled fragments that contain all internal interhelical loops. However, digestion of (PO4)-P-32-labeled DAT with endoproteinase asp-N and immunoprecipitation with an N-terminal antiserum extracted two phosphopeptide fragments from both basal and PKC/OA-stimulated samples, demonstrating that the N-terminal cytoplasmic tail is a major site of phosphorylation. Aminopeptidase treatment of PKC- and/or OA-stimulated DAT cleaved essentially all (PO4)-P-32 label without proteolysis extending past transmembrane domains 1 and 2, providing further evidence that most phosphorylation sites are near the N terminus and not in intracellular loops or C-terminal domains. In situ proteolysis of the N-terminal tail indicates that the majority of stimulated phosphorylation sites are N-terminal to an antibody epitope at residues 42-59. Two-dimensional analysis of purified protein produced three tryptic phosphopeptides that may result from phosphorylation of multiple sites, but the fragments did not co-migrate with synthetic tryptic peptides phosphorylated at serines 2 and 4. These results indicate that most or all of the basal and stimulated phosphorylation of DAT in striatal tissue occurs on one or more residues in a group of six serines clustered near the distal end of the cytoplasmic N terminus.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA	University of North Dakota Grand Forks	Vaughan, RA (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 501 N Columbia Rd, Grand Forks, ND 58203 USA.	rvaughan@medicine.nodak.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013147] Funding Source: NIH RePORTER; NIDA NIH HHS [DA13147] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beckman ML, 1998, J NEUROSCI, V18, P6103; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Cho GW, 2000, J BIOL CHEM, V275, P19942, DOI 10.1074/jbc.M902174199; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FONTANA A, 1986, PRACTICAL PROTEIN CH, P68; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Huff RA, 1997, J NEUROCHEM, V68, P225; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Melikian HE, 1999, J NEUROSCI, V19, P7699; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; SATO K, 1995, J NEUROCHEM, V65, P1967; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuldiner S, 1997, J EXP BIOL, V200, P335; Simon JR, 1997, NEUROSCI LETT, V224, P201, DOI 10.1016/S0304-3940(97)13479-6; Thompson AC, 2000, J NEUROSCI, V20, P9333; Vaughan RA, 1996, J BIOL CHEM, V271, P21672, DOI 10.1074/jbc.271.35.21672; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; Vaughan RA, 2000, CONT NEUROS, P375; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; VAUGHAN RA, 2001, SOC NEUR ABSTR, V27, P1865	40	115	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25178	25186		10.1074/jbc.M200294200	http://dx.doi.org/10.1074/jbc.M200294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994276	hybrid			2022-12-27	WOS:000176747000044
J	Mertens, PR; Steinmann, K; Alfonso-Jaume, MA; En-Nia, A; Sun, Y; Lovett, DH				Mertens, PR; Steinmann, K; Alfonso-Jaume, MA; En-Nia, A; Sun, Y; Lovett, DH			Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE 2; AP-2 TRANSCRIPTION FACTORS; IV COLLAGENASE MMP-2; GROWTH; GENE; TRANSACTIVATION; PROGELATINASE; RADIOTHERAPY; ANGIOGENESIS; INHIBITOR	Gelatinase A, also denoted matrix metalloproteinase 2, plays multiple critical roles in the neoplastic process, including facilitation of neoangiogenesis and formation of distal metastases. The transcriptional regulation of the gelatinase A gene is under the control of strong, evolutionarily conserved cis-acting enhancer elements, designated the r2 (human) or RE-1 (rat), that harbor contiguous binding motifs for the transcription factors activating protein-2 (AP2), p53, and YB-1. Using recombinant transcription factors, complex patterns of RE-1 binding were observed by electrophoretic mobility shift assay. Increased complex formation was detected with the AP2/YB-1 and AP2/p53 combinations, while YB-1 competed with p53 for binding. The combination of AP2, p53, and YB-1 yielded novel ternary complexes, particularly when binding to single-stranded RE-1 probes. Transient transfection of hepatocellular carcinoma cell lines with a series of gelatinase A luciferase reporter constructs were in accordance with the binding patterns determined by electrophoretic mobility shift assay. Combined AP2 and p53 increased gelatinase A luciferase reporter activity significantly, and the inclusion of YB-1 yielded further increase in both reporter activity and secreted levels of gelatinase A protein. YB-1 and p53 expression are increased following multiple genotoxic stresses, including irradiation, and the synergistic interactions of these induced transcription factors with the widely expressed AP2 protein provide a probable pathophysiologic mechanism for the enhanced tumor cell synthesis of gelatinase A induced by radiation.	Rhein Westfal TH Aachen, Dept Nephrol & Immunol, Med Clin 2, D-52057 Aachen, Germany; Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94143 USA; Pfizer Global Res & Dev, Canc Mol Sci, Ann Arbor, MI 48105 USA	RWTH Aachen University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer	Mertens, PR (corresponding author), Rhein Westfal TH Aachen, Dept Nephrol & Immunol, Med Clin 2, Pauwelsstr 30, D-52057 Aachen, Germany.	Pmertens@ukaachen.de	Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araya J, 2001, AM J PHYSIOL-LUNG C, V280, pL30, DOI 10.1152/ajplung.2001.280.1.L30; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Benyon RC, 2000, GUT, V46, P443, DOI 10.1136/gut.46.4.443; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Boulikas T, 1996, ANTICANCER RES, V16, P225; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Furuya M, 2001, HUM PATHOL, V32, P163, DOI 10.1053/hupa.2001.21558; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRIGIONI WF, 1994, DIAGN MOL PATHOL, V3, P163, DOI 10.1097/00019606-199409000-00005; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Itoh T, 1998, CANCER RES, V58, P1048; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Kossakowska AE, 1999, ANN NY ACAD SCI, V878, P578, DOI 10.1111/j.1749-6632.1999.tb07732.x; Kumar A, 2000, BRIT J CANCER, V82, P960, DOI 10.1054/bjoc.1999.1025; LOVETT DH, 1992, AM J PATHOL, V141, P85; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Menke AL, 1997, CANCER RES, V57, P1353; Mertens PR, 1998, HYPERTENSION, V32, P945, DOI 10.1161/01.HYP.32.5.945; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; POULSOM R, 1992, AM J PATHOL, V141, P389; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Sun Y, 1999, MOL CARCINOGEN, V24, P25, DOI 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.3.CO;2-J; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Turck J, 1997, KIDNEY INT, V51, P1397, DOI 10.1038/ki.1997.191; Turner BC, 1998, CANCER RES, V58, P5466; Wang JL, 2000, MOL CARCINOGEN, V27, P252, DOI 10.1002/(SICI)1098-2744(200004)27:4<252::AID-MC2>3.0.CO;2-3; Wild-Bode C, 2001, CANCER RES, V61, P2744; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; Zahner G, 1997, KIDNEY INT, V51, P1116, DOI 10.1038/ki.1997.154	52	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24875	24882		10.1074/jbc.M200445200	http://dx.doi.org/10.1074/jbc.M200445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11973333	hybrid			2022-12-27	WOS:000176747000008
J	Wu, M; Xu, LG; Li, XY; Zhai, ZH; Shu, HB				Wu, M; Xu, LG; Li, XY; Zhai, ZH; Shu, HB			AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PATHWAYS; ACTIVATION; FADD; IDENTIFICATION; LETHALITY; NECROSIS; CASPER; APAF1; BRAIN	Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein that triggers caspase-independent apoptosis. We describe here the cloning and characterization of a novel AIF-homologous molecule designated AMID (AIF-homologous mitochondrion-associated inducer of death). AMID lacks a mitochondrial localization sequence but shares significant homology with AIF and NADH oxidoreductases from bacteria to mammalian species. Immunofluoreseent staining and biochemical experiments indicated that AMID was co-localized with mitochondria. Overexpression of AMID induced cell death with characteristic apoptotic morphology. Furthermore, AMID-induced apoptosis was independent of caspase activation and p53 and was not inhibited by Bcl-2. These findings suggest that AMID induces a novel caspase-independent apoptotic pathway.	Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Univ Colorado, Ctr Canc, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University; University of Colorado System; University of Colorado Denver	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, K516C,1400 Jackson St, Denver, CO 80206 USA.		Wu, Min/AAE-5066-2021	Wu, Min/0000-0003-1372-4764; Xu, Liangguo/0000-0003-1991-2889				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; LIU X, 1996, CELL, V12, P147; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sambrook J., 2002, MOL CLONING LAB MANU; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	31	143	154	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25617	25623		10.1074/jbc.M202285200	http://dx.doi.org/10.1074/jbc.M202285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11980907	hybrid			2022-12-27	WOS:000176747000100
J	Fujiyama, S; Yanagida, M; Hayano, T; Miura, Y; Isobe, T; Takahashi, N				Fujiyama, S; Yanagida, M; Hayano, T; Miura, Y; Isobe, T; Takahashi, N			Isolation and proteomic characterization of human parvulin-associating preribosomal ribonucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL CIS/TRANS ISOMERASES; FORKHEAD-ASSOCIATED DOMAIN; NUCLEOLAR PROTEIN; BINDING-PROTEIN; KI-67 ANTIGEN; GENE; CYCLOPHILIN; SEQUENCE; ESS1; MUTATIONS	Human parvulin (hParvulin; Par14/EPVH) belongs to the third family of peptidylprolyl cis-trans isomerases that exhibit an enzymatic activity of interconverting the cis-trans conformation of the prolyl peptide bond, and shows sequence similarity to the regulator enzyme for cell cycle transitions, human Pin1. However, the cellular function of hParvulin is entirely unknown. Here, we demonstrate that hParvulin associates with the preribosomal ribonucleoprotein (pre-rRNP) complexes, which contain preribosomal RNAs, at least 26 ribosomal proteins, and 26 trans-acting factors involved in rRNA processing and assembly at an early stage of ribosome biogenesis. Since an amino-terminal domain of hParvulin, which is proposed to be a putative DNA-binding domain, was alone sufficient to associate in principle with the pre-rRNP complexes, the association is probably through protein-RNA interaction. In addition, hParvulin co-precipitated at least 10 proteins not previously known to be involved in ribosome biogenesis. Coincidentally, most of these proteins are implicated in regulation of microtubule assembly or nucleolar reformation during the mitotic phase of the cell. Thus, these results, coupled with the preferential nuclear localization of hParvulin, suggest that hParvulin may be involved in ribosome biogenesis and/or nucleolar re-assembly of mammalian cells.	Tokyo Univ Agr & Technol, Dept Biotechnol, Fuchu, Tokyo 1838509, Japan; Minist Educ Culture Sports Sci & Technol Japan, Integrated Proteom Syst Project, Hachioji, Tokyo, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Biochem Lab, Hachioji, Tokyo, Japan	Tokyo University of Agriculture & Technology; Tokyo Metropolitan University	Takahashi, N (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	ntakahas@cc.tuat.ac.jp	Miura, Yutaka/C-5457-2013; TAKAHASHI, Nobuhiro/G-1129-2013; Isobe, Toshiaki/Q-9279-2017	Uchida, Takafumi/0000-0003-3665-4906				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; BABLER J, 2001, MOL CELL, V8, P517; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dousset T, 2000, MOL BIOL CELL, V11, P2705, DOI 10.1091/mbc.11.8.2705; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HIGHTOWER MJ, 1980, J CELL PHYSIOL, V105, P93, DOI 10.1002/jcp.1041050112; Hill KL, 2000, J BIOL CHEM, V275, P39369, DOI 10.1074/jbc.M006907200; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; Kops O, 1998, J BIOL CHEM, V273, P31971, DOI 10.1074/jbc.273.48.31971; Kressler D, 1999, MOL CELL BIOL, V19, P7897; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Loyer P, 1998, J CELL SCI, V111, P1495; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1997, GENE, V203, P89, DOI 10.1016/S0378-1119(97)00522-2; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; McCornack MA, 1997, FEBS LETT, V414, P84, DOI 10.1016/S0014-5793(97)00974-5; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pennisi E, 1996, SCIENCE, V274, P1613, DOI 10.1126/science.274.5293.1613; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; Rulten S, 1999, BIOCHEM BIOPH RES CO, V259, P557, DOI 10.1006/bbrc.1999.0828; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Sekerina E, 2000, J MOL BIOL, V301, P1003, DOI 10.1006/jmbi.2000.4013; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Streblow DN, 1998, VIROLOGY, V245, P197, DOI 10.1006/viro.1998.9155; Sueishi M, 2000, J BIOL CHEM, V275, P28888, DOI 10.1074/jbc.M003879200; Takagi M, 2001, J BIOL CHEM, V276, P25386, DOI 10.1074/jbc.M102227200; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKAHASHI N, 2002, IN PRESS MACROLIDE A; TANIDA I, 1991, TRANSPL P, V23, P2856; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Terada T, 2001, J MOL BIOL, V305, P917, DOI 10.1006/jmbi.2000.4293; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Uchida T, 1999, FEBS LETT, V446, P278, DOI 10.1016/S0014-5793(99)00239-2; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; XIANG JL, 1994, BIOCHEM BIOPH RES CO, V199, P1167, DOI 10.1006/bbrc.1994.1353; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yanagida M, 2000, ELECTROPHORESIS, V21, P1890; ZARDI L, 1979, CELL, V18, P649, DOI 10.1016/0092-8674(79)90120-X	62	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23773	23780		10.1074/jbc.M201181200	http://dx.doi.org/10.1074/jbc.M201181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960984	hybrid			2022-12-27	WOS:000176475700088
J	Kozak, KR; Gupta, RA; Moody, JS; Ji, C; Boeglin, WE; DuBois, RN; Brash, AR; Marnett, LJ				Kozak, KR; Gupta, RA; Moody, JS; Ji, C; Boeglin, WE; DuBois, RN; Brash, AR; Marnett, LJ			15-lipoxygenase metabolism of 2-arachidonylglycerol - Generation of a peroxisome proliferator-activated receptor alpha agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ARACHIDONIC-ACID; ARACHIDONYLETHANOLAMIDE ANANDAMIDE; KERATINOCYTE DIFFERENTIATION; MAMMALIAN LIPOXYGENASES; EPIDERMAL-KERATINOCYTES; PPAR-ALPHA; OXYGENATION; ENDOCANNABINOIDS; 2-ARACHIDONOYLGLYCEROL	The recent demonstrations that cyclooxygenase-2 and leukocyte-type 12-lipoxygenase (LOX) efficiently oxygenate 2-arachidonylglycerol (2-AG) prompted an investigation into related oxygenases capable of metabolizing this endogenous cannabinoid receptor ligand. We evaluated the ability of six LOXs to catalyze the hydroperoxidation of 2-AG. Soybean 15-LOX, rabbit reticulocyte 15-LOX, human 15-LOX-1, and human 15-LOX-2 oxygenate 2-AG, providing 15(S)-hydroperoxyeicosatetraenoic acid glyceryl ester. In contrast, potato and human 5-LOXs do not efficiently metabolize this endocannabinoid. Among a series of structurally related arachidonyl esters, arachidonylglycerols serve as the preferred substrates for 15-LOXs. Steady-state kinetic analysis demonstrates that both 15-LOX-1 and 15-LOX-2 oxygenate 2-AG comparably or preferably to arachidonic acid. Furthermore, 2-AG treatment of COS-7 cells transiently transfected with human 15-LOX expression vectors or normal human epidermal keratinocytes results in the production and extracellular release of 15-hydroxyeicosatetraenoic acid glyceryl ester (15-HETE-G), establishing that lipoxygenase metabolism of 2-AG occurs I. in an eukaryotic cellular environment. Investigations into the potential biological actions of 15-HETE-G indicate that this lipid, in contrast to its free-acid counterpart, acts as a peroxisome proliferator-activated receptor a agonist. The results demonstrate that 15-LOXs are capable of acting on 2-AG to provide 15-HETE-G and elucidate a potential role for endocannabinoid oxygenation in the generation of peroxisome proliferator-activated receptor a agonists.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med & Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		NATIONAL CANCER INSTITUTE [P01CA068484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431, R01GM053638, T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA68484] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347, GM53638, GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brash AR, 1999, ADV EXP MED BIOL, V447, P29; BRYANT RW, 1985, J BIOL CHEM, V260, P3548; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Edgemond WS, 1998, MOL PHARMACOL, V54, P180, DOI 10.1124/mol.54.1.180; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gaffney BJ, 1996, ANNU REV BIOPH BIOM, V25, P431, DOI 10.1146/annurev.bb.25.060196.002243; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; HAMPSON AJ, 1995, BBA-LIPID LIPID MET, V1259, P173, DOI 10.1016/0005-2760(95)00157-8; Hanley K, 2000, J BIOL CHEM, V275, P11484, DOI 10.1074/jbc.275.15.11484; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; HENNEICKEVONZEPELIN HH, 1991, J INVEST DERMATOL, V97, P291; Hillard CJ, 2000, J PHARMACOL EXP THER, V294, P27; Hillard CJ, 2000, PROSTAG OTH LIPID M, V61, P3, DOI 10.1016/S0090-6980(00)00051-4; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2001, J BIOL CHEM, V276, P30072, DOI 10.1074/jbc.M104467200; Krieg P, 2001, GENOMICS, V73, P323, DOI 10.1006/geno.2001.6519; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Moody JS, 2001, BIOCHEMISTRY-US, V40, P861, DOI 10.1021/bi002303b; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; Schewe T, 1981, Methods Enzymol, V71 Pt C, P430; Schmid PC, 2000, CHEM PHYS LIPIDS, V104, P185, DOI 10.1016/S0009-3084(99)00124-3; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Shappell SB, 2001, CANCER RES, V61, P497; Sjursen W, 2000, CYTOKINE, V12, P1189, DOI 10.1006/cyto.1999.0727; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Thuillier P, 2000, MOL CARCINOGEN, V29, P134, DOI 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F; Tijet N, 2000, LIPIDS, V35, P709, DOI 10.1007/s11745-000-0577-z; UEDA N, 1995, ADV PROSTAG THROMB L, V23, P163; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; van Zadelhoff G, 1998, BIOCHEM BIOPH RES CO, V248, P33, DOI 10.1006/bbrc.1998.8910; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	53	150	151	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23278	23286		10.1074/jbc.M201084200	http://dx.doi.org/10.1074/jbc.M201084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956198	hybrid			2022-12-27	WOS:000176475700025
J	Mougin, A; Torterotot, F; Branlant, C; Jacobson, MR; Huang, Q; Pederson, T				Mougin, A; Torterotot, F; Branlant, C; Jacobson, MR; Huang, Q; Pederson, T			A 3 '-terminal minihelix in the precursor of human spliceosomal U2 small nuclear RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; POLYMERASE-III; HELA-CELLS; RIBONUCLEOPROTEIN ORGANIZATION; EUKARYOTIC RNA; END FORMATION; U5 RNAS; U1; CYTOPLASM; RAT	U2 RNA is one of five small nuclear RNAs that participate in the majority of mRNA splicing. In addition to its role in mRNA splicing, the biosynthesis of U2 RNA and three of the other spliceosomal RNAs is itself an intriguing process involving nuclear export followed by 5'-cap hypermethylation, assembly with specific proteins, 3' end processing, and then nuclear import. Previous work has identified sequences near the 3' end of pre-U2 RNA that are required for accurate and efficient processing. In this study, we have investigated the structural basis of U2 RNA 3' end processing by chemical and enzymatic probing methods. Our results demonstrate that the 3' end of pre-U2 RNA is a minihelix with an estimated stabilization free energy of -6.9 kcal/mol. Parallel RNA structure mapping experiments with mutant pre-U2 RNAs revealed that the presence of this 3' minihelix is itself not required for in vitro 3'-processing of pre-U2 RNA, in support of earlier studies implicating internal regions of pre-U2 RNA. Other considerations raise the possibility that this distinctive structural motif at the 3' end of pre-U2 RNA plays a role in the cleavage of the precursor from its longer primary transcript or in its nucleocytoplasmic traffic.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; Univ H Poincare Nancy 1, CNRS, UMR 7567, F-54506 Vandoeuvre Les Nancy, France	University of Massachusetts System; University of Massachusetts Worcester; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu	Immel, Françoise/N-7079-2019; Immel, Françoise/GNP-4167-2022	Immel, Françoise/0000-0002-2028-902X; Branlant, Christiane/0000-0003-4728-5499	NIGMS NIH HHS [GM-21595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BRANLANT C, 1983, NUCLEIC ACIDS RES, V11, P8359, DOI 10.1093/nar/11.23.8359; BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; CALVET JP, 1987, J MOL BIOL, V197, P543, DOI 10.1016/0022-2836(87)90563-8; Cuello P, 1999, EMBO J, V18, P2867, DOI 10.1093/emboj/18.10.2867; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ELICEIRI GL, 1974, CELL, V3, P11, DOI 10.1016/0092-8674(74)90031-2; ELICEIRI GL, 1976, BIOCHEM BIOPH RES CO, V72, P507, DOI 10.1016/S0006-291X(76)80070-8; GURNEY T, 1980, J CELL BIOL, V87, P398, DOI 10.1083/jcb.87.2.398; Gwizdek C, 2001, J BIOL CHEM, V276, P25910, DOI 10.1074/jbc.M100493200; Huang Q, 1999, NUCLEIC ACIDS RES, V27, P1025, DOI 10.1093/nar/27.4.1025; Huang Q, 1997, MOL CELL BIOL, V17, P7178, DOI 10.1128/MCB.17.12.7178; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; KELLER EB, 1985, NUCLEIC ACIDS RES, V13, P4971, DOI 10.1093/nar/13.13.4971; KLEINSCHMIDT AM, 1990, P NATL ACAD SCI USA, V87, P1283, DOI 10.1073/pnas.87.4.1283; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; KONINGS DAM, 1987, EXP CELL RES, V172, P329, DOI 10.1016/0014-4827(87)90391-0; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; KROL A, 1981, NUCLEIC ACIDS RES, V9, P2699, DOI 10.1093/nar/9.12.2699; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; Kuwabara T, 2001, NUCLEIC ACIDS RES, V29, P2780, DOI 10.1093/nar/29.13.2780; LIN WL, 1984, J MOL BIOL, V180, P947, DOI 10.1016/0022-2836(84)90265-1; LIU MH, 1984, NUCLEIC ACIDS RES, V12, P1529, DOI 10.1093/nar/12.3.1529; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; MADORE SJ, 1984, J CELL BIOL, V98, P188, DOI 10.1083/jcb.98.1.188; MADORE SJ, 1984, J CELL BIOL, V99, P1140, DOI 10.1083/jcb.99.3.1140; MYSLINSKI E, 1984, J MOL BIOL, V180, P927, DOI 10.1016/0022-2836(84)90264-X; REDDY R, 1987, J BIOL CHEM, V262, P75; TANI T, 1983, J MOL BIOL, V168, P579, DOI 10.1016/S0022-2836(83)80303-9; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; WIEBEN ED, 1985, J MOL BIOL, V183, P69, DOI 10.1016/0022-2836(85)90281-5; YUO CY, 1985, CELL, V42, P193, DOI 10.1016/S0092-8674(85)80115-X; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZIEVE GW, 1988, J MOL BIOL, V199, P259, DOI 10.1016/0022-2836(88)90312-9; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	39	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23137	23142		10.1074/jbc.M202258200	http://dx.doi.org/10.1074/jbc.M202258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956214	hybrid			2022-12-27	WOS:000176475700007
J	Ribbe, MW; Hu, YL; Guo, ML; Schmid, B; Burgess, BK				Ribbe, MW; Hu, YL; Guo, ML; Schmid, B; Burgess, BK			The FeMoco-deficient MoFe protein produced by a nifH deletion strain of Azotobacter vinelandii shows unusual P-cluster features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; ELECTRON-PARAMAGNETIC-RESONANCE; FERROUS FE4S4 CLUSTER; FE-PROTEIN; KLEBSIELLA-PNEUMONIAE; ADENOSINE 5'-TRIPHOSPHATE; DINITROGENASE REDUCTASE; NITROGENASE CATALYSIS; BIOSYNTHESIS; EPR	The His-tag MoFe protein expressed by the nifH deletion strain Azotobacter vinelandii DJ1165 (DeltanifH MoFe protein) was purified in large quantity. The alpha(2)beta(2) tetrameric (DeltanifH MoFe protein is FeMoco-deficient based on metal analysis and the absence of the S = 3/2 EPR signal, which arises from the FeMo cofactor center in wild-type MoFe protein. The DeltanifH MoFe protein contains 18.6 mol Fe/mol and, upon reduction with dithionite, exhibits an unusually strong S = 1/2 EPR signal in the g approximate to 2 region. The indigo disulfonate-oxidized DeltanifH MoFe protein does not show features of the P2+ state of the P-cluster of the DeltanifH MoFe protein. The oxidized AnitH MoFe protein is able to form a specific complex with the Fe protein containing the [4Fe-4S](1+) cluster and facilitates the hydrolysis of MgATP within this complex. However, it is not able to accept electrons from the [4Fe-4S](1+) cluster of the Fe protein. Furthermore, the dithionite-reduced DeltanifH MoFe can be further reduced by WHU citrate, which is quite unexpected. These unusual catalytic and spectroscopic properties might indicate the presence of a P-cluster precursor or a P-cluster trapped in an unusual conformation or oxidation state.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; California Institute of Technology	Ribbe, MW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	markus@nitrolab.bio.uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; CHEN L, 1994, J BIOL CHEM, V269, P3290; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Erickson JA, 1999, BIOCHEMISTRY-US, V38, P14279, DOI 10.1021/bi991389+; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FISKE CH, 1952, J BIOL CHEM, V66, P325; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V223, P783, DOI 10.1042/bj2230783; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER T R, 1988, Biofactors, V1, P199; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; Musgrave KB, 1998, J BIOL INORG CHEM, V3, P344, DOI 10.1007/s007750050243; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Ribbe MW, 2001, P NATL ACAD SCI USA, V98, P5521, DOI 10.1073/pnas.101119498; Ribbe MW, 2000, J BIOL CHEM, V275, P17631, DOI 10.1074/jbc.275.23.17631; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1997, BIOL NITROGEN FIXATI, P51; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TAL S, 1991, J BIOL CHEM, V266, P10654; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WHITE TC, 1992, J BIOL CHEM, V267, P24007; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x	62	57	58	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23469	23476		10.1074/jbc.M202061200	http://dx.doi.org/10.1074/jbc.M202061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11978793	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000176475700050
J	Amayed, P; Pantaloni, D; Carlier, MF				Amayed, P; Pantaloni, D; Carlier, MF			The effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; DESTABILIZING ACTIVITY; DYNAMIC INSTABILITY; INTACT-CELLS; PROTEIN; ONCOPROTEIN-18; OP18/STATHMIN; MITOSIS; DISSOCIATION; TRANSITION	Stathmin is a phosphorylation-regulated tubulin-binding protein. In vitro and in vivo studies using nonphosphorylatable and pseudophosphorylated mutants of stathmin have questioned the View that stathmin might act only as a tubulin-sequestering factor. Stathmin was proposed to effectively regulate microtubule dynamic instability by increasing the frequency of catastrophe (the transition from steady growth to rapid depolymerization), without interacting with tubulin. We have used a noninvasive method to measure the equilibrium dissociation constants of the T2S complexes of tubulin with stathmin, pseudophosphorylated (4E)-stathmin, and diphosphostathmin. At both pH 6.8 and pH 7.4, the relative sequestering efficiency of the different stathmin variants depends on the concentration of free tubulin, Le. on the dynamic state of microtubules. This control is exerted in a narrow range of tubulin concentration due to the highly cooperative binding of tubulin to stathmin. Changes in pH affect the stability of tubulin-stathmin complexes but do not change stathmin function. The 4E-stathmin mutant mimics inactive phosphorylated stathmin at low tubulin concentration and sequesters tubulin almost as efficiently as stathmin at higher tubulin concentration. We propose that stathmin acts solely by sequestering tubulin, without affecting microtubule dynamics, and that the effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.							Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Diaz JF, 2000, J BIOL CHEM, V275, P26265, DOI 10.1074/jbc.M003120200; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; Gavet O, 1998, J CELL SCI, V111, P3333; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GRADIN HM, 1997, MOL BIOL CELL, V6, P3459; HILL TL, 1987, LINEAR AGGREGATION T, P244; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; MARGOLIS RL, 1978, CELL, V13, P1, DOI 10.1016/0092-8674(78)90132-0; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; McNally FJ, 1998, MOL BIOL CELL, V9, P1847, DOI 10.1091/mbc.9.7.1847; MENDES E, 1995, EUROPHYS LETT, V32, P273, DOI 10.1209/0295-5075/32/3/014; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; Quarmby LM, 1999, CELL MOTIL CYTOSKEL, V43, P1; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; Saoudi Y, 1998, J CELL BIOL, V142, P1519, DOI 10.1083/jcb.142.6.1519; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Vorobjev IA, 1999, J CELL SCI, V112, P2277; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	51	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22718	22724		10.1074/jbc.M111605200	http://dx.doi.org/10.1074/jbc.M111605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956188	hybrid			2022-12-27	WOS:000176313600080
J	Oubrahim, H; Chock, PB; Stadtman, ER				Oubrahim, H; Chock, PB; Stadtman, ER			Manganese(II) induces apoptotic cell death in NIH3T3 cells via a caspase-12-dependent pathway.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; DOUBLE-STRANDED-RNA; HYDROGEN-PEROXIDE; ACTIVATION; PROTEASE; MECHANISM; CASPASES; COMPLEX; ROLES	Under physiological conditions, manganese(II) exhibits catalase-like activity. However, at elevated concentrations, it induces apoptosis via a non-mitochondria-mediated mechanism (Oubrahim, H., Stadtman, E. R., and Chock, P. B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9505-9510). In this study, we show that the Mn(II)-induced apoptosis, as monitored by caspase-3-like activity, in NIH3T3 cells was inhibited by calpain inhibitors I and II or the p38 MAP kinase inhibitor, SB202190. The control experiments showed that each of these inhibitors in the concentration ranges used exerted no effect on activated caspase-3-like activity. Furthermore, caspase-12 was cleaved in Mn(II)-treated cells, suggesting that the Mn(II)-induced apoptosis is mediated by caspase-12. This notion is confirmed by the observations that pretreatment of NIH3T3 cells with either caspase-12 antisense RNA or dsRNA corresponding to the full-length caspase-12 led to a dramatic decrease in caspase-3-like activity induced by Mn(II). The precise mechanism by which Mn(II) induced the apoptosis is not clear. Nevertheless, Mn(II), in part, exerts its effect via its ability to replace Ca(II) in the activation of m-calpain, which in turn activates caspase-12 and degrades Bcl-xL. In addition, the dsRNA, method serves as an effective technique for knocking out caspase-12 in NIH3T3 cells without causing apoptosis.	NHLBI, LB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Stadtman, ER (corresponding author), NHLBI, LB, NIH, Bldg 10,Rm 2140,50 South Dr,MSC-8012, Bethesda, MD 20892 USA.	erstadtman@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000202, Z01HL000211, ZIAHL000202] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERLETT BS, 1990, P NATL ACAD SCI USA, V87, P389, DOI 10.1073/pnas.87.1.389; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kerr J.F.R., 1987, P93; Lander F, 1999, INT ARCH OCC ENV HEA, V72, P546, DOI 10.1007/s004200050414; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Oubrahim H, 2001, P NATL ACAD SCI USA, V98, P9505, DOI 10.1073/pnas.181319898; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; TEKLE E, 1991, P NATL ACAD SCI USA, V88, P4230, DOI 10.1073/pnas.88.10.4230; Troy CM, 1996, J NEUROSCI, V16, P253; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; VARANI J, 1991, INFLAMMATION, V15, P291, DOI 10.1007/BF00917314; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	27	64	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20135	20138		10.1074/jbc.C200226200	http://dx.doi.org/10.1074/jbc.C200226200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11964391	hybrid			2022-12-27	WOS:000176204500007
J	Boskovic, G; Desai, D; Niles, RM				Boskovic, G; Desai, D; Niles, RM			Regulation of retinoic acid receptor alpha by protein kinase C in B16 mouse melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAR-ALPHA; X-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; PHORBOL ESTER; RXR-ALPHA; F9 CELLS; PHOSPHORYLATION; DIFFERENTIATION; PATHWAY; EXPRESSION	We have previously found that retinoic acid stimulates the expression of protein kinase Calpha (PKC) in B16 mouse melanoma cells. Because it has been reported that PKC can phosphorylate retinoic acid receptor (RAR) and alter its function, we determined whether changes in the level and/or activity of PKC could affect the expression or function of the RAR in B16 melanoma. Using in vivo phosphorylation and band shift techniques, we could not demonstrate that altering PKC activity and/or protein level changed the in vivo phosphorylation of RARalpha. However activation of PKC resulted in increased RARalpha protein. Increased receptor protein correlated with a phorbol dibutyrate-stimulated increase in receptor activation function-2 (AF-2)-dependent transcriptional activity. Use of enzyme inhibitors and dominant-negative PKCs indicated that enzyme activity was required for elevation in the RARalpha. The PKC-mediated increase in RARalpha was due to a 2.5-fold increase in the half-life of this protein. In contrast, the down-regulation of PKC diminished RARalpha protein half-life and markedly inhibited AF-2-dependent transcriptional activity. The down-regulation of PKC also inhibited the binding of RAR to a retinoic acid response element and the retinoic acid induction of RARbeta expression. These findings suggest that PKC can influence retinoic acid signaling by altering the stability of RAR protein without directly phosphorylating this receptor.	Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Mol Biol, Huntington, WV 25704 USA; Mayo Clin, Sect Gastroenterol Res, Rochester, MN 55905 USA	Marshall University; Mayo Clinic	Niles, RM (corresponding author), Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Mol Biol, 1542 Spring Valley Dr, Huntington, WV 25704 USA.	niles@marshall.edu			NCI NIH HHS [R01 CA59530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Boudjelal M, 2000, CANCER RES, V60, P2247; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CRETTAZ M, 1990, BIOCHEM J, V272, P91; DE LUCA LM, 1991, FASEB J, V5, P2924; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Desai SH, 2000, BIOCHEM PHARMACOL, V59, P1265, DOI 10.1016/S0006-2952(00)00269-0; DROMS KA, 1991, MOL CARCINOGEN, V4, P1, DOI 10.1002/mc.2940040102; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; HOOPES CW, 1992, GENOMICS, V14, P611, DOI 10.1016/S0888-7543(05)80159-4; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUPULESCU A, 1993, INT J VITAM NUTR RES, V63, P397; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; NILES RM, 1989, CANCER RES, V49, P4483; NILES RM, 1996, J CELL PHYSL, V168, P549; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Xiao YH, 1996, J CELL PHYSIOL, V167, P413, DOI 10.1002/(SICI)1097-4652(199606)167:3<413::AID-JCP5>3.0.CO;2-S; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	47	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26113	26119		10.1074/jbc.M201185200	http://dx.doi.org/10.1074/jbc.M201185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000751	hybrid			2022-12-27	WOS:000176908700038
J	Qi, XM; Pramanik, R; Wang, JT; Schultz, RM; Maitra, RK; Han, JH; DeLuca, HF; Chen, G				Qi, XM; Pramanik, R; Wang, JT; Schultz, RM; Maitra, RK; Han, JH; DeLuca, HF; Chen, G			The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D-3-induced growth inhibition.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTORS; PROTEIN-KINASE; 1,25-DIHYDROXYVITAMIN D-3; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT PHOSPHORYLATION; GENE-EXPRESSION; AP-1 ACTIVITY; MAP KINASES	The signaling connection between mitogen-activated protein kinases(MAPKS) and nuclear steroid receptors is complex and remains mostly unexplored. Here we report that stress-activated protein kinases p38 and JNK trans-activate nuclear steroid vitamin D receptor (VDR) gene and increase vitamin D-3-dependent growth inhibition in human breast cancer cells. Activation of p38 and JNK by an active MAPK kinase 6 stimulates VDR promoter activity independently of the ligand vitamin D-3 and estrogen receptor expression. Moreover, stimulation of the endogenous stress pathways by adenovirus-mediated delivery of recombinant MAPK kinase 6 also activates VDR and sensitizes MCF-7 cells to vitamin D-3-dependent growth inhibition. Both the p38 and JNK MAPK pathways and the downstream transcription factor c-Jun/AP-1 are required for the VDR stimulation, as revealed by application of their dominant negatives, the specific p38 inhibitor SB203580, and site-directed mutagenesis of the AP-1 element in the VDR promoter. The essential role of the p38 and JNK stress pathways in up-regulation of VDR expression is further confirmed by using the chemical stimulator arsenite. These results establish a signaling connection between the stress MAPK pathways and steroid hormone receptor VDR expression and thereby offer new insights into regulation of cell growth by the MAPK pathways through regulation of vitamin D-3/VDR activity.	Loyola Univ, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Dept Cell Biol Neurobiol & Anat, Div Biochem, Maywood, IL 60153 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Cleveland Clin Fdn, Dept Virol, Cleveland, OH 44195 USA	Loyola University Chicago; Loyola University Chicago; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute; Cleveland Clinic Foundation	Chen, G (corresponding author), Loyola Univ, Dept Radiat Oncol, 114B Bldg,1 Hines,2160 S 1st Ave, Maywood, IL 60153 USA.	gchen1@lume.edu	Han, J/G-4671-2010		NCI NIH HHS [CA91576] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Agadir A, 1999, CARCINOGENESIS, V20, P577, DOI 10.1093/carcin/20.4.577; Andrew AS, 2001, AM J PHYSIOL-LUNG C, V281, pL616, DOI 10.1152/ajplung.2001.281.3.L616; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bagowski CP, 2001, J BIOL CHEM, V276, P37708, DOI 10.1074/jbc.M104582200; BERGER U, 1991, CANCER RES, V51, P239; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BURAS RR, 1994, BREAST CANCER RES TR, V31, P191, DOI 10.1007/BF00666153; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; Chen HC, 1999, CURR BIOL, V9, pR478, DOI 10.1016/S0960-9822(99)80300-5; Davoust N, 1998, J NEUROSCI RES, V52, P210, DOI 10.1002/(SICI)1097-4547(19980415)52:2<210::AID-JNR9>3.0.CO;2-D; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Escaleira MTF, 1999, BREAST CANCER RES TR, V54, P123, DOI 10.1023/A:1006198107805; GALANG CK, 1994, ONCOGENE, V9, P2913; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILLIARD GM, 1944, BIOCHEMISTRY-US, V33, P4300; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jehan F, 2000, ARCH BIOCHEM BIOPHYS, V377, P273, DOI 10.1006/abbi.2000.1788; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; KRISHNAN A, 1991, MOL ENDOCRINOL, V86, P2071; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LoveSchimenti CD, 1996, CANCER RES, V56, P2789; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Musiol IM, 1997, ENDOCRINOLOGY, V138, P12, DOI 10.1210/en.138.1.12; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARK K, 1994, CANCER RES, V54, P6087; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROSS TK, 1993, P NATL ACAD SCI USA, V90, P9257, DOI 10.1073/pnas.90.20.9257; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SEBAG M, 1992, J BIOL CHEM, V267, P12162; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Solomon C, 1998, J BIOL CHEM, V273, P17573, DOI 10.1074/jbc.273.28.17573; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Towers TL, 1999, MOL CELL BIOL, V19, P4191; WALTERS MR, 1981, BIOCHEM BIOPH RES CO, V103, P721, DOI 10.1016/0006-291X(81)90509-X; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	75	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25884	25892		10.1074/jbc.M203039200	http://dx.doi.org/10.1074/jbc.M203039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11983707	hybrid			2022-12-27	WOS:000176908700011
J	Bertoni, A; Tadokoro, S; Eto, K; Pampori, N; Parise, LV; White, GC; Shattil, SJ				Bertoni, A; Tadokoro, S; Eto, K; Pampori, N; Parise, LV; White, GC; Shattil, SJ			Relationships between Rap1b, affinity modulation of integrin alpha(IIb)beta(3), and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	43rd Annual Meeting of the American-Society-of-Hematology	DEC 07-11, 2001	ORLANDO, FL	Amer Soc Hematol			PROTEIN-KINASE-C; SMALL GTPASE; PLATELET-AGGREGATION; EXCHANGE FACTOR; CELL-ADHESION; R-RAS; ACTIVATION; ALPHA-IIB-BETA-3; DETERMINANTS; SPECIFICITY	The affinity of integrin alpha(IIb)beta(3) for fibrinogen is controlled by inside-out signals that are triggered by agonists like thrombin. Agonist treatment of platelets also activates Rap1b, a small GTPase known to promote integrin-dependent adhesion of other cells. Therefore, we nvestigated the role of Rap1b in alpha(IIb)beta(3) function by viral transduction of GFP-Rap1 chimeras into murine megakaryocytes, which exhibit inside-out signaling similar to platelets. Expression of constitutively active GFP-Rap1b (V12) had no effect on unstimulated megakaryocytes, but it greatly augmented fibrinogen binding to alpha(IIb)beta(3), induced by a PAR4 thrombin receptor agonist (p < 0.01). The Rap1b effect was cell-autonomous and was prevented by pre-treating cells with cytochalasin D or latrunculin A to inhibit actin polymerization. Rap1b-dependent fibrinogen binding to megakaryocytes was blocked by POW-2, a novel monovalent antibody Fab fragment specific for high affinity murine alpha(IIb)beta(3) In contrast to GFP-Rap1b (V12), expression of GFP-Rap1GAP, which deactivates endogenous Rap1, inhibited agonist-induced fibrinogen binding (p < 0.01), as did dominant-negative GFP-Rap1b (N17) (p < 0.05). None of these treatments affected surface expression of alpha(IIb)beta(3). These studies establish that Rap1b can augment agonist-induced ligand binding to alpha(IIb)beta(3) through effects on integrin affinity, possibly by modulating aHbP3 interactions with the actin cytoskeleton.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Scripps Research Institute; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Shattil, SJ (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.	shattil@scripps.edu						ABRAMS C, 1994, J BIOL CHEM, V269, P18781; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brass L. F, 2000, HEMATOLOGY BASIC PRI, P1753; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Faraday N, 1999, BLOOD, V94, P4084, DOI 10.1182/blood.V94.12.4084.424k28_4084_4092; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kucik DF, 2001, MOL BIOL CELL, V12, P1509, DOI 10.1091/mbc.12.5.1509; Lengweiler S, 1999, BIOCHEM BIOPH RES CO, V262, P167, DOI 10.1006/bbrc.1999.1172; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shibayama H, 1999, BLOOD, V93, P1540, DOI 10.1182/blood.V93.5.1540.405k10_1540_1548; Shiraga M, 1999, J CELL BIOL, V147, P1419, DOI 10.1083/jcb.147.7.1419; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; WALTER U, 1993, ADV EXP MED BIOL, V344, P237; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; White GC, 1998, THROMB HAEMOSTASIS, V79, P832; Wilcox DA, 2000, BLOOD, V95, P3645; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	53	152	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25715	25721		10.1074/jbc.M202791200	http://dx.doi.org/10.1074/jbc.M202791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	571YP	11994301	hybrid			2022-12-27	WOS:000176747000113
J	Dikalov, S; Landmesser, U; Harrison, DG				Dikalov, S; Landmesser, U; Harrison, DG			Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling - Implications for studies of hsp90 and endothelial cell nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN 90; RADICAL GENERATION; ACTIVATION; DISMUTASE; BENZOQUINONE; CONTRIBUTES; INHIBITION; STRESS; ANION; NO	The ansamycin antibiotic geldanamycin has frequently been used as an inhibitor of heat shock protein 90 (Hsp90), and this agent has been widely employed as a probe to examine the interactions of Hsp90 with endothelial nitric-oxide synthase. Geldanamycin contains a quinone group, which may participate in redox cycling. When geldanamycin was exposed to the flavin-containing enzyme cytochrome P-450 reductase, both semiquinone and superoxide (O-2(.-)) radicals were detected using electron spin resonance. The treatment of endothelial cells with geldanamycin resulted in a dramatic increase in 07 generation, which was independent of endothelial nitric oxide synthase, because it was not inhibited by N-nitro-L-arginine methyl ester and also occurred in vascular smooth muscle cells. Diphenylene iodinium inhibited this increase in O-2(.-) by 50%, suggesting that flavin-containing enzymes are involved in geldanamycin-induced O-2(.-) generation. In the absence of cells, geldanamycin directly oxidized ascorbate, consumed oxygen, and produced O-2(.-). Geldanamycin decreased the bioavailable nitric oxide generated by 3,4-dihydrodiazete 1,2-dioxide in smooth muscle cells by 50%, whereas pretreatment with superoxide dismutase inhibited the effect of geldanamycin. These findings demonstrate that geldanamycin generates O-2(.-) which scavenges nitric oxide, leading to loss of its bioavailability. This effect is independent of the inhibition of Hsp90 and indicates that geldanamycin cannot be used as a specific inhibitor of Hsp90. In light of these findings, the studies using geldanamycin as an inhibitor of Hsp90 should be interpreted with caution.	Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA; Atlanta Vet Adm Hosp, Atlanta, GA 30322 USA	Emory University	Dikalov, S (corresponding author), Emory Univ, Sch Med, Div Cardiol, 1639 Pierce Dr,319 WMB, Atlanta, GA 30322 USA.	dikalov@emory.edu		Dikalov, Sergey/0000-0003-2976-6184				ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264; ALEGRIA AE, 1989, BIOCHEMISTRY-US, V28, P8653, DOI 10.1021/bi00447a056; BACHUR NR, 1978, CANCER RES, V38, P1745; BENCHEKROUN MN, 1994, FREE RADICAL BIO MED, V17, P191; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Bucci M, 2000, BRIT J PHARMACOL, V131, P13, DOI 10.1038/sj.bjp.0703549; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; DIKALOV S, 1993, BIOCHEM BIOPH RES CO, V195, P113, DOI 10.1006/bbrc.1993.2017; DIKALOV SI, 1992, BIOCHEMISTRY-US, V31, P8947, DOI 10.1021/bi00152a034; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gusev NB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1112, DOI 10.1023/A:1012480829618; GUTTERIDGE JMC, 1984, BIOCHEM PHARMACOL, V33, P3059, DOI 10.1016/0006-2952(84)90609-9; Harris MB, 2000, GEN PHARMACOL-VASC S, V35, P165, DOI 10.1016/S0306-3623(01)00104-5; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; Khurana VG, 2000, J CEREBR BLOOD F MET, V20, P1563, DOI 10.1097/00004647-200011000-00006; Kleschyov AL, 2000, BIOCHEM BIOPH RES CO, V275, P672, DOI 10.1006/bbrc.2000.3361; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; *NIH, 2001, FEDERAL REGISTER ONL, V66, P35443; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Zwicker K, 1998, ARZNEIMITTEL-FORSCH, V48, P629	31	111	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25480	25485		10.1074/jbc.M203271200	http://dx.doi.org/10.1074/jbc.M203271200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983711	hybrid			2022-12-27	WOS:000176747000083
J	Fryer, LGD; Parbu-Patel, A; Carling, D				Fryer, LGD; Parbu-Patel, A; Carling, D			The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; FATTY-ACID; CELL-LINES; MECHANISM; TROGLITAZONE; STRESS; GAMMA; INHIBITION; DERIVATION; CASCADE	AMP-activated protein kinase (AMPK) is activated within the cell in response to multiple stresses that increase the intracellular AMP:ATP ratio. Here we show that incubation of muscle cells with the thiazolidinedione, rosiglitazone, leads to a dramatic increase in this ratio with the concomitant activation of AMPK. This finding raises the possibility that a number of the beneficial effects of the thiazolidinediones could be mediated via activation of AMPK. Furthermore, we show that in addition to the classical activation pathway, AMPK can also be stimulated without changing the levels of adenine nucleotides. In muscle cells, both hyperosmotic stress and the anti-diabetic agent, metformin, activate AMPK in the absence of any increase in the AMP:ATP ratio. However, although activation is no longer dependent on this ratio, it still involves increased phosphorylation of threonine 172 within the catalytic (a) subunit. AMPK stimulation in response to hyperosmotic stress does not appear to involve phosphatidylinositol 3-phosphate kinase, protein kinase C, mitogen-activated protein (MAP) kinase kinase, or p38 MAP kinase alpha or beta. Our results demonstrate that AMPK can be activated by at least two distinct signaling mechanisms and suggest that it may play a wider role in the cellular stress response than was previously understood.	Hammersmith Hosp, MRC, Ctr Clin Sci, Cellular Stress Grp, London W12 0NN, England	Imperial College London	Carling, D (corresponding author), Hammersmith Hosp, MRC, Ctr Clin Sci, Cellular Stress Grp, DuCane Rd, London W12 0NN, England.	dcarling@csc.mrc.ac.uk	Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830; Parbhu Patel, Asha/0000-0002-7314-4043				Brunmair B, 2001, DIABETES, V50, P2309, DOI 10.2337/diabetes.50.10.2309; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; ELKEBBI IM, 1994, METABOLISM, V43, P953, DOI 10.1016/0026-0495(94)90173-2; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; Hundal RS, 2000, DIABETES, V49, P2063, DOI 10.2337/diabetes.49.12.2063; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kishi K, 2000, BIOCHEM BIOPH RES CO, V276, P16, DOI 10.1006/bbrc.2000.3417; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Mudaliar S, 2001, ANNU REV MED, V52, P239, DOI 10.1146/annurev.med.52.1.239; Schaffler A, 2000, EUR J CLIN INVEST, V30, P586; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	46	870	921	0	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25226	25232		10.1074/jbc.M202489200	http://dx.doi.org/10.1074/jbc.M202489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994296	hybrid			2022-12-27	WOS:000176747000050
J	Pursiheimo, JP; Saari, J; Jalkanen, M; Salmivirta, M				Pursiheimo, JP; Saari, J; Jalkanen, M; Salmivirta, M			Cooperation of protein kinase A and Ras/ERK signaling pathways is required for AP-1-mediated activation of fibroblast growth factor-inducible response element (FiRE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIENTED HETERODIMER BINDING; RAS-DEPENDENT ACTIVATION; MAP KINASE; CYCLIC-AMP; FOS-JUN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; REGULATED KINASE	Recent studies suggest a crucial role for protein kinase A (PKA) in the regulation of growth factor signaling. However, the effect of PKA on the transcription of growth factor-responsive genes has drawn far less attention. Here we have investigated the signaling mechanisms involved in the activation of an activator protein-1 (AP-1)-driven, growth factor-specific enhancer element, fibroblast growth factor-inducible response element (FiRE). The activation was found to be mediated by three phorbol 12-O-tetradecanoate-13-acetate-response element-related DNA elements of FiRE, including motif 4 and two distinct elements of motif 5 (referred to as M5-1 and M5-2). All three elements were required for full FiRE activity. Stimulation of cells with fibroblast growth factor-2 (FGF-2) induced the binding of AP-1 to motif 4 and M5-2, whereas M5-1 did not show detectable binding. The FGF-2-induced FiRE activation appeared to require cooperational function of the Ras/ERK and PKA pathways. Inhibition of either of the pathways abolished the binding of AP-1 complexes to motif 4 and motif 5 and the subsequent FiRE activation. By contrast, costimulation of cells with FGF-2 and the PKA activator 8-bromo-cyclic AMP increased the binding of AP-1 to FiRE and potentiated the level of transcriptional activity. The cooperational function of these two pathways was confirmed by experiments with cell lines stably expressing 4-hydroxytamoxifen-inducible oncogenic Raf-1 (DeltaRaf-1:ER[DD]). Noticeably, the induction systems showed variations with respect to regulation of AP-1-driven activation of FiRE. These differences were likely to originate from the ability of these two systems to induce the differential activation pattern of the Ras/ERK pathway.	Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland; Abo Akad Univ, Turku, Finland; BioTie Therapies Corp, Turku, Finland	University of Turku; Abo Akademi University	Pursiheimo, JP (corresponding author), Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland.	juha-pekka.pursiheimo@juvantia.com						ABATE C, 1991, ONCOGENE, V6, P2179; AUWERX J, 1992, ONCOGENE, V7, P2271; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Baron W, 2000, MOL CELL NEUROSCI, V15, P314, DOI 10.1006/mcne.1999.0827; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; BRUNDER JT, 1992, GENE DEV, V6, P545; Burgun C, 2000, FEBS LETT, V484, P189, DOI 10.1016/S0014-5793(00)02153-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Chytil M, 1998, P NATL ACAD SCI USA, V95, P14076, DOI 10.1073/pnas.95.24.14076; Cook SJ, 1999, MOL CELL BIOL, V19, P330; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Diebold RJ, 1998, P NATL ACAD SCI USA, V95, P7915, DOI 10.1073/pnas.95.14.7915; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GLEGG CH, 1987, J BIOL CHEM, V262, P13111; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRUDA MC, 1994, ONCOGENE, V9, P2537; Guo Z, 1998, J NEUROSCI, V18, P8163; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Jaakkola P, 1998, ONCOGENE, V17, P1279, DOI 10.1038/sj.onc.1202002; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Leonard DA, 1997, P NATL ACAD SCI USA, V94, P4913, DOI 10.1073/pnas.94.10.4913; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XR, 1999, J BIOL CHEM, V274, P35203, DOI 10.1074/jbc.274.49.35203; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mira-Y-Lopez R, 1998, BIOCHEM J, V331, P909, DOI 10.1042/bj3310909; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; PURSIHEIMO JP, 2002, IN PRESS FEBS LETT; Rajaram N, 1997, EMBO J, V16, P2917, DOI 10.1093/emboj/16.10.2917; Ramirez-Carrozzi VR, 2001, J MOL BIOL, V305, P411, DOI 10.1006/jmbi.2000.4286; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; RYSECK RP, 1991, ONCOGENE, V6, P533; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TASKEN K, 1994, ENDOCRINOLOGY, V135, P2109, DOI 10.1210/en.135.5.2109; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YI T, 1994, MOL CELL BIOL, V14, P7546; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	80	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25344	25355		10.1074/jbc.M112381200	http://dx.doi.org/10.1074/jbc.M112381200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12004054	hybrid			2022-12-27	WOS:000176747000066
J	Hlaing, M; Shen, X; Dazin, P; Bernstein, HS				Hlaing, M; Shen, X; Dazin, P; Bernstein, HS			The hypertrophic response in C2C12 myoblasts recruits the G(1) cell cycle machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; DEPENDENT KINASES; ANGIOTENSIN-II; REPRESS TRANSCRIPTION; CARDIAC MYOCYTES; CDK INHIBITORS; MITOTIC ENTRY; PRB; PHOSPHORYLATION	Hypertrophy occurs in postmitotic muscle as an adaptive response to various physiological and pathological stresses. Studies in vascular smooth muscle cells and primary cardiomyocytes suggest that angiotensin II-mediated hypertrophy activates signaling pathways associated with cell proliferation. Regulation of cyclin-dependent kinase (Cdk)-cyclin activities is essential to cell size control in lower eukaryotes, yet their role in the hypertrophic response in muscle is incompletely understood. We describe an in vitro model of hypertrophy in C2C12 skeletal myoblasts and demonstrate that induction of hypertrophy involves transient activation of Cdk4, subsequent phosphorylation of Rb, and release of HDAC I from the Rb inhibitory complex. We also demonstrate that E2F-1 becomes transcriptionally active yet remains associated with Rb. We propose a model whereby partial inactivation of the Rb complex leads to derepression of a subset of E2F-1 targets necessary for cell growth without division during hypertrophy.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bernstein, HS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 505 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07544, HL62174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Douahji M, 1999, KIDNEY INT, V56, P1691, DOI 10.1046/j.1523-1755.1999.00728.x; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Gordon SE, 2001, AM J PHYSIOL-ENDOC M, V280, pE150, DOI 10.1152/ajpendo.2001.280.1.E150; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lei XH, 2000, J CELL SCI, V113, P4523; Lijnen P, 1999, J MOL CELL CARDIOL, V31, P949, DOI 10.1006/jmcc.1999.0934; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf G, 2001, AM J PATHOL, V158, P1091, DOI 10.1016/S0002-9440(10)64056-4; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	33	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23794	23799		10.1074/jbc.M201980200	http://dx.doi.org/10.1074/jbc.M201980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967266	hybrid			2022-12-27	WOS:000176475700091
J	Hammet, A; Pike, BL; Heierhorst, J				Hammet, A; Pike, BL; Heierhorst, J			Posttranscriptional regulation of the RAD5 DNA repair gene by the Dun1 kinase and the Pan2-Pan3 poly(A)-nuclease complex contributes to survival of replication blocks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCIBLE GENE; FHA DOMAIN; SACCHAROMYCES-CEREVISIAE; CHECKPOINT PATHWAYS; PROTEIN; YEAST; ATM; TRANSCRIPTION; TRANSLATION; ENCODES	The yeast Dun1 kinase has complex checkpoint functions including DNA damage-dependent cell cycle arrest in G(2)/M, transcriptional induction of repair genes, and regulation of postreplicative DNA repair pathways. Here we report that the Dun1 forkhead-associated domain interacts with the Pan3 subunit of the poly(A)nuclease complex and that dun1pan2 and dun1pan3 double mutants are dramatically hypersensitive to replicational stress. This phenotype was independent of the function of Dun1 in regulating deoxyribonucleotide levels as it was also observed in strains lacking the ribonucleotide reductase inhibitor Sml1. dun1pan2 mutants initially arrested normally in response to replication blocks but died in the presence of persistent replication blocks with considerably delayed kinetics compared with mutants lacking the Rad53 kinase, indicating that the double mutation does not compromise the intra-S phase checkpoint. Interestingly, the RAD5 gene involved in error-free postreplication repair pathways was specifically up-regulated in dun1pan2 double mutants. Moreover, inducible overexpression of RAD5 mimicked the double mutant phenotype by hypersensitizing dun1 mutants to replication blocks. The data indicate that Dun1 and Pan2-Pan3 cooperate to regulate the stoichiometry and thereby the activity of postreplication repair complexes, suggesting that posttranscriptional mechanisms complement the transcriptional response in the regulation of gene expression by checkpoint signaling pathways in Saccharomyces cerevisiae.	Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Heierhorst, J (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	heier@ariel.its.unimelb.edu.au	Pike, Brietta L./H-5317-2019	Pike, Brietta L./0000-0002-4763-1729				Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; Denis CL, 2001, GENETICS, V158, P627; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fasullo M, 1999, GENETICS, V152, P909; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Hammet A, 2000, FEBS LETT, V471, P141, DOI 10.1016/S0014-5793(00)01392-2; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; James P, 1996, GENETICS, V144, P1425; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Li J, 2000, J CELL SCI, V113, P4143; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xiao W, 2000, GENETICS, V155, P1633; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	42	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22469	22474		10.1074/jbc.M202473200	http://dx.doi.org/10.1074/jbc.M202473200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953437	hybrid			2022-12-27	WOS:000176313600048
J	Konig, S; Burkman, J; Fitzgerald, J; Mitchell, M; Su, L; Stedman, H				Konig, S; Burkman, J; Fitzgerald, J; Mitchell, M; Su, L; Stedman, H			Modular organization of phylogenetically conserved domains controlling developmental regulation of the human skeletal myosin heavy chain gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SEQUENCE ALIGNMENT; EXPRESSION; MUSCLE; TRANSCRIPTION; MEF2; MYOD; DNA; ACTIVATION; PATTERNS	The mammalian skeletal myosin heavy chain locus is composed of a six-membered family of tandemly linked genes whose complex regulation plays a central role in striated muscle development and diversification. We have used publicly available genomic DNA sequences to provide a theoretical foundation for an experimental analysis of transcriptional regulation among the six promoters at this locus. After reconstruction of annotated drafts of the human and murine loci from fragmented DNA sequences, phylogenetic footprint analysis of each of the six promoters using standard and Bayesian alignment algorithms revealed unexpected patterns of DNA sequence conservation among orthologous and paralogous gene pairs. The conserved domains within 2.0 kilobases of each transcriptional start site are rich in putative muscle-specific transcription factor binding sites. Experiments based on plasmid transfection in vitro and electroporation in vivo validated several predictions of the bioinformatic analysis, yielding a picture of synergistic interaction between proximal and distal promoter elements in controlling developmental stage-specific gene activation. Of particular interest for future studies of heterologous gene expression is a 650-base pair construct containing modules from the proximal and distal human embryonic myosin heavy chain promoter that drives extraordinarily powerful transcription during muscle differentiation in vitro.	Univ Penn, Med Syst, Dept Surg, Philadelphia, PA 19104 USA	University of Pennsylvania	Stedman, H (corresponding author), Rm 608,Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	hstedman@mail.med.upenn.edu		Koenig, Stephane/0000-0002-0801-279X; Fitzgerald, Julie/0000-0001-9936-9569				Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andreucci JJ, 2002, J BIOL CHEM, V277, P16426, DOI 10.1074/jbc.M110891200; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Desjardins PR, 2002, MOL BIOL EVOL, V19, P375, DOI 10.1093/oxfordjournals.molbev.a004093; Fickett JW, 1996, MOL CELL BIOL, V16, P437; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; Huey KA, 1998, EUR J BIOCHEM, V256, P45, DOI 10.1046/j.1432-1327.1998.2560045.x; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; Martin KA, 1997, DNA CELL BIOL, V16, P653, DOI 10.1089/dna.1997.16.653; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NAUMANN K, 1994, DIFFERENTIATION, V55, P203, DOI 10.1046/j.1432-0436.1994.5530203.x; Perkins KJ, 2001, NUCLEIC ACIDS RES, V29, P4843, DOI 10.1093/nar/29.23.4843; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Santalucia T, 2001, J MOL BIOL, V314, P195, DOI 10.1006/jmbi.2001.5091; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Shrager JB, 2000, J MUSCLE RES CELL M, V21, P345, DOI 10.1023/A:1005635030494; Sun XY, 2002, AM J PHYSIOL-REG I, V282, pR509, DOI 10.1152/ajpregu.00509.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; YOON SJ, 1992, P NATL ACAD SCI USA, V89, P12078, DOI 10.1073/pnas.89.24.12078; Zhu J, 1998, BIOINFORMATICS, V14, P25, DOI 10.1093/bioinformatics/14.1.25	40	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27593	27605		10.1074/jbc.M203162200	http://dx.doi.org/10.1074/jbc.M203162200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11971910	hybrid			2022-12-27	WOS:000177189800005
J	Iancu, CV; Borza, T; Fromm, HJ; Honzatko, RB				Iancu, CV; Borza, T; Fromm, HJ; Honzatko, RB			IMP, GTP, and 6-Phosphoryl-IMP complexes of recombinant mouse muscle adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; AMMONIA PRODUCTION; CRYSTAL-STRUCTURES; SKELETAL-MUSCLE; HYDANTOCIDIN; BINDING; OVEREXPRESSION; PURIFICATION; HERBICIDE	Prokaryotes have a single form of adenylosuccinate synthetase that controls the committed step of AMP biosynthesis, but vertebrates have two isozymes of the synthetase. The basic isozyme, which predominates in muscle, participates in the purine nucleotide cycle, has an active site conformation different from that of the Escherichia coli enzyme, and exhibits significant differences in ligand recognition. Crystalline complexes presented here of the recombinant basic isozyme from mouse show the following. GTP alone binds to the active site without inducing a conformational change. IMP in combination with an acetate anion induces major conformational changes and organizes the active site for catalysis. IMP, in the absence of GTP, binds to the GTP pocket of the synthetase. The combination of GTP and IMP results in the formation of a stable complex of 6-phosphoryl-IMP and GDP in the presence or absence of hadacidin. The response of the basic isozyme to GTP alone differs from that of synthetases from plants, and yet the conformation of the mouse basic and E. coli synthetases in their complexes with GDP, 6-phosphoryl-IMP, and hadacidin are nearly identical. Hence, reported differences in ligand recognition among synthetases probably arise from conformational variations observed in partially ligated enzymes.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Mol Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu	Borza, Tudor/A-8510-2012; Borza, Tudor/M-4937-2019	Borza, Tudor/0000-0002-2527-6551; Borza, Tudor/0000-0002-2527-6551	NINDS NIH HHS [NS 10548] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASS MB, 1984, J BIOL CHEM, V259, P2330; BAUGHER BW, 1980, BIOCHEM BIOPH RES CO, V94, P123, DOI 10.1016/S0006-291X(80)80196-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; GOODMAN MN, 1977, J BIOL CHEM, V252, P5054; Gorrell A, 2002, J BIOL CHEM, V277, P8817, DOI 10.1074/jbc.M111810200; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Honzatko RB, 1999, ARCH BIOCHEM BIOPHYS, V370, P1, DOI 10.1006/abbi.1999.1383; Hou ZL, 2002, J BIOL CHEM, V277, P5970, DOI 10.1074/jbc.M109561200; Hou ZL, 1999, J BIOL CHEM, V274, P17505, DOI 10.1074/jbc.274.25.17505; Iancu CV, 2001, J BIOL CHEM, V276, P42146, DOI 10.1074/jbc.M106294200; JAYARAM HN, 1979, CANCER TREAT REP, V63, P1095; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lipps G, 1999, BIOCHEM J, V341, P537, DOI 10.1042/0264-6021:3410537; LOWENSTEIN JM, 1972, PHYSIOL REV, V52, P382, DOI 10.1152/physrev.1972.52.2.382; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATSUDA Y, 1977, BIOCHEM BIOPH RES CO, V78, P766, DOI 10.1016/0006-291X(77)90245-5; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUIRHEAD KM, 1974, J BIOL CHEM, V249, P459; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGAWA H, 1976, BIOCHEM BIOPH RES CO, V68, P524, DOI 10.1016/0006-291X(76)91177-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; Prade L, 2000, J MOL BIOL, V296, P569, DOI 10.1006/jmbi.1999.3473; Schmitzer PR, 2000, J NAT PROD, V63, P777, DOI 10.1021/np990590i; Siehl DL, 1996, PLANT PHYSIOL, V110, P753, DOI 10.1104/pp.110.3.753; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; SPECTOR T, 1979, J BIOL CHEM, V254, P8422; SPECTOR T, 1976, BIOCHIM BIOPHYS ACTA, V445, P509, DOI 10.1016/0005-2744(76)90104-2; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TYAGI AK, 1980, CANCER RES, V40, P4390; Wang WY, 1997, J BIOL CHEM, V272, P16911, DOI 10.1074/jbc.272.27.16911; Wang WY, 1998, J BIOL CHEM, V273, P16000, DOI 10.1074/jbc.273.26.16000	43	26	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26779	26787		10.1074/jbc.M203730200	http://dx.doi.org/10.1074/jbc.M203730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12004071	hybrid			2022-12-27	WOS:000177055900011
J	Pusl, T; Wu, JJ; Zimmerman, TL; Zhang, L; Ehrlich, BE; Berchtold, MW; Hoek, JB; Karpen, SJ; Nathanson, MH; Bennett, AM				Pusl, T; Wu, JJ; Zimmerman, TL; Zhang, L; Ehrlich, BE; Berchtold, MW; Hoek, JB; Karpen, SJ; Nathanson, MH; Bennett, AM			Epidermal growth factor-mediated activation of the ETS domain transcription factor Elk-1 requires nuclear calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; GENE-EXPRESSION; PROTEIN-KINASES; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; PARVALBUMIN CDNA; EPITHELIAL-CELLS; BINDING PROTEIN; RAT HEPATOCYTES	Cytosolic and nuclear Ca2+ have been shown to differentially regulate transcription. However, the impact of spatially distinct Ca2+ signals on mitogen-activated protein kinase-mediated gene expression remains unknown. Here we investigated the role of nuclear and cytosolic Ca2+ signals in epidermal growth factor (EGF)-induced transactivation of the ternary complex factor Elk-1 using a GAL4-Elk-1 construct. EGF increased Ca2+ in both the nucleus and cytosol of HepG2 or 293 cells. Pretreatment with the intracellular Ca2+ chelator bis(2-aminophenyl)ethyleneglycol-N,N N',N'-tetraacetic acid significantly reduced EGF-induced transactivation of Elk-1, indicating that EGF-stimulated Elk-1 transcriptional activity is dependent on intracellular Ca2+. To determine the relative contribution of nuclear and cytosolic Ca2+ signals during EGF-mediated Elk-1 transactivation, Ca2+ signals in either compartment were selectively impaired by targeted expression of the Ca2+ binding protein parvalbumin to either the nucleus or cytosol. Suppression of nuclear but not cytosolic Ca2+ signals inhibited EGF-induced transactivation of Elk-1. However, suppression of nuclear Ca2+ signals did not affect the ability of ERK either to become phosphorylated or to undergo translocation to the nucleus in response to EGF. Elk-1 phosphorylation and nuclear localization following EGF stimulation were also unaffected by suppressing nuclear Ca2+ signals. These results suggest that nuclear Ca2+ is required for EGF-mediated transcriptional activation of Elk-1 and that phosphorylation of Elk-1 alone is not sufficient to induce its transcriptional activation in response to EGF. Thus, subcellular targeting of parvalbumin reveals a distinct role for nuclear Ca2+ signals in mitogen-activated protein kinase-mediated gene transcription.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Yale University; Yale University; Baylor College of Medicine; University of Copenhagen; Jefferson University	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B230,333 Cedar St, New Haven, CT 06520 USA.		Berchtold, Martin/L-1695-2014; /AAX-8408-2021	Berchtold, Martin/0000-0001-8995-9047; /0000-0001-9657-9704; Bennett, Anton/0000-0001-5187-7599; Hoek, Jan/0000-0001-7127-4218				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ANDRESSEN C, 1995, EXP CELL RES, V219, P420, DOI 10.1006/excr.1995.1248; BERCHTOLD MW, 1989, BIOCHIM BIOPHYS ACTA, V1009, P201, DOI 10.1016/0167-4781(89)90104-8; Bernal-Mizrachi E, 2001, AM J PHYSIOL-ENDOC M, V281, pE1286, DOI 10.1152/ajpendo.2001.281.6.E1286; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Caillard O, 2000, P NATL ACAD SCI USA, V97, P13372, DOI 10.1073/pnas.230362997; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cruzalegui FH, 2000, CELL MOL LIFE SCI, V57, P402, DOI 10.1007/PL00000702; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ENDO T, 1985, ENDOCRINOLOGY, V117, P527, DOI 10.1210/endo-117-2-527; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HEIZMANN CW, 1984, EXPERIENTIA, V40, P910, DOI 10.1007/BF01946439; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HILL TD, 1988, J CELL BIOCHEM, V38, P137, DOI 10.1002/jcb.240380208; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Ichikawa J, 2001, CELL BIOCHEM FUNCT, V19, P213, DOI 10.1002/cbf.914; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; Johenning FW, 2002, J NEUROSCI, V22, P5344; KAGI U, 1987, J BIOL CHEM, V262, P7314; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LANINI L, 1992, J BIOL CHEM, V267, P11548; Lee MA, 1998, CELL CALCIUM, V23, P91, DOI 10.1016/S0143-4160(98)90107-5; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; LENORMAND P, 1992, MOL CELL BIOL, V12, P2793, DOI 10.1128/MCB.12.6.2793; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LOZA J, 1995, CELL CALCIUM, V17, P301, DOI 10.1016/0143-4160(95)90076-4; MAGNI M, 1991, J BIOL CHEM, V266, P6329; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUNTENER M, 1995, P NATL ACAD SCI USA, V92, P6504, DOI 10.1073/pnas.92.14.6504; NICOTERA P, 1994, MOL CELL BIOCHEM, V135, P89, DOI 10.1007/BF00925964; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; Nojiri S, 2000, HEPATOLOGY, V32, P947, DOI 10.1053/jhep.2000.18662; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; PAULS TL, 1993, J BIOL CHEM, V268, P20897; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; RASMUSSEN CD, 1989, MOL ENDOCRINOL, V3, P588, DOI 10.1210/mend-3-3-588; Santella L, 1997, CELL CALCIUM, V22, P11, DOI 10.1016/S0143-4160(97)90085-3; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHNEEBERGER PR, 1986, FEBS LETT, V201, P51, DOI 10.1016/0014-5793(86)80569-5; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SHEN SS, 1995, CURR TOP DEV BIOL, V30, P63, DOI 10.1016/S0070-2153(08)60564-5; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; TANAKA Y, 1992, HEPATOLOGY, V16, P479, DOI 10.1002/hep.1840160229; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wagstaff SC, 2000, CARCINOGENESIS, V21, P2175, DOI 10.1093/carcin/21.12.2175; Wahr PA, 1999, P NATL ACAD SCI USA, V96, P11982, DOI 10.1073/pnas.96.21.11982; Webb SE, 2000, BIOESSAYS, V22, P113, DOI 10.1002/(SICI)1521-1878(200002)22:2<113::AID-BIES3>3.0.CO;2-L; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; [No title captured]	91	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27517	27527		10.1074/jbc.M203002200	http://dx.doi.org/10.1074/jbc.M203002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11971908	hybrid			2022-12-27	WOS:000177055900102
J	Gaughan, L; Logan, IR; Cook, S; Neal, DE; Robson, CN				Gaughan, L; Logan, IR; Cook, S; Neal, DE; Robson, CN			Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAINS; TRANSCRIPTIONAL REPRESSION; GENE ACTIVATION; PROTEIN; ACETYLTRANSFERASE; COACTIVATOR; COMPLEX; FAMILY; P300; TRANSACTIVATION	The androgen receptor (AR), a member of the nuclear hormone receptor superfamily, is thought to play an important role in the development of prostate cancer. The AR is a hormone-dependent transcription factor that activates expression of numerous androgen-responsive genes. Histone acetyltransferase-containing proteins have been shown to increase activity of several transcription factors, including nuclear hormone receptors, by eliciting histone acetylation, which facilitates promoter access to the transcriptional machinery. Conversely, histone deacetylases (HDACs) have been identified which reduce levels of histone acetylation and are associated with transcriptional repression by various transcription factors. We have previously shown tat Tip60 (Tat-interactive protein, 60 kDa) is a bona fie co-activator protein for the AR. Here we show that Tip60 directly acetylates the AR, which we demonstrate is a requisite for Tip60-mediated transcription. To define a mechanism for repression of AR function, we demonstrate that AR activity is specifically down-regulated by the histone deacetylase activity of HDAC1. Furthermore, using both mammalian two-hybrid and immunoprecipitation experiments, we show that AR and HDAC1 interact, suggestive of a direct role for down-regulation of AR activity by HDAC1. In chromatin immunoprecipitation assays, we provide evidence that AR, Tip60, and HDAC1 form a trimeric complex upon the endogenous AR-responsive PSA promoter, suggesting that acetylation and deacetylation of the AR is an important mechanism for regulating transcriptional activity.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086				Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRINKMANN AO, 1992, J STEROID BIOCHEM, V41, P361, DOI 10.1016/0960-0760(92)90362-M; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	40	238	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25904	25913		10.1074/jbc.M203423200	http://dx.doi.org/10.1074/jbc.M203423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994312	hybrid			2022-12-27	WOS:000176908700013
J	Wallace, LJM; Candlish, D; De Koning, HP				Wallace, LJM; Candlish, D; De Koning, HP			Different substrate recognition motifs of human and trypanosome nucleobase transporters - Selective uptake of purine antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; BRUCEI-BRUCEI; HUMAN-ERYTHROCYTES; ASPERGILLUS-NIDULANS; AFRICAN TRYPANOSOMES; HYPOXANTHINE UPTAKE; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; NUCLEOSIDE; EXPRESSION	The therapeutic index of antimetabolites such as purine analogues is in large part determined by the extent to which it is selectively accumulated by the target cell. In the current study we have compared the transport of purine nucleobase analogues by the H2 transporter of bloodstream form Trypanosoma brucei brucei and the equilibrative nucleobase transporter of human erythrocytes. The H2 transporter forms hydrogen bonds with hypoxanthine at positions N3, N7, N(1)H, and N(9)H of the purine ring, with apparent DeltaG(0) of 7.7-12.6 kJ/mol. The transporter also appears to H-bond with the amine group of adenine. The human transporter forms hydrogen bonds that form to (6)NH2 and N1 of adenine. An H-bond is also formed with N3 and the 6-keto and amine groups of guanine but not with the protonated N1, thus explaining the low affinity for hypoxanthine. N7 and N9 do not directly interact with the human transporter in the form of H-bonds, and it is proposed that pi-pi stacking interactions contribute significantly to permeant binding. The potential for selective uptake of antimetabolites by the parasite transporter was demonstrated.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	De Koning, HP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	H.de-koning@bio.gla.ac.uk		De Koning, Harry/0000-0002-9963-1827				Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; Barrett MP, 1999, LANCET, V353, P1113, DOI 10.1016/S0140-6736(98)00416-4; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; De Koning HP, 1999, MOL PHARMACOL, V56, P1162, DOI 10.1124/mol.56.6.1162; de Koning HP, 1998, BIOCHEM CELL BIOL, V76, P853, DOI 10.1139/bcb-76-5-853; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; de Koning HP, 2001, INT J PARASITOL, V31, P512, DOI 10.1016/S0020-7519(01)00167-9; de Koning HP, 2001, ACTA TROP, V80, P245, DOI 10.1016/S0001-706X(01)00177-2; de Koning HP, 2001, MOL PHARMACOL, V59, P586; DeKoning HP, 1997, EUR J BIOCHEM, V247, P1102, DOI 10.1111/j.1432-1033.1997.01102.x; deKoning HP, 1997, MOL BIOCHEM PARASIT, V89, P245, DOI 10.1016/S0166-6851(97)00129-1; del Santo B, 1998, HEPATOLOGY, V28, P1504, DOI 10.1002/hep.510280609; DIALLINAS G, 1995, J BIOL CHEM, V270, P8610; DIALLINAS G, 1989, GENETICS, V122, P341; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; Dragan Y, 2000, HEPATOLOGY, V32, P239, DOI 10.1053/jhep.2000.9546; FISH WR, 1982, BIOCHIM BIOPHYS ACTA, V719, P223, DOI 10.1016/0304-4165(82)90092-7; GATI WP, 1992, J BIOL CHEM, V267, P22272; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; GRIFFITH DA, 1993, J BIOL CHEM, V268, P20085; HADDOCK PS, 1995, CARDIOVASC RES, V30, P130, DOI 10.1016/0008-6363(96)88605-6; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; KAMEN BA, 1991, SEMIN HEMATOL, V28, P12; Kaminsky R, 2000, CURR OP ANTIINF INV, V2, P76; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Kolb V M, 1997, Prog Drug Res, V48, P195; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; KRAUPP M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P157, DOI 10.1016/0005-2736(91)90158-5; Kyritsis A P, 1993, Oncology (Williston Park), V7, P93; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; Lee Chee-Wee, 1994, In Vivo (Attiki), V8, P795; MAGILL JM, 1974, J BACTERIOL, V119, P202, DOI 10.1128/JB.119.1.202-206.1974; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; MAHONY WB, 1991, BIOCHEM PHARMACOL, V41, P263, DOI 10.1016/0006-2952(91)90485-N; MAHONY WB, 1992, J BIOL CHEM, V267, P19792; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; RAZAVI M, 1993, BIOCHEM PHARMACOL, V45, P893, DOI 10.1016/0006-2952(93)90174-U; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Shayeghi M, 1999, BBA-BIOMEMBRANES, V1416, P109, DOI 10.1016/S0005-2736(98)00213-2; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; ULLMAN B, 1987, MOL CELL BIOL, V7, P97, DOI 10.1128/MCB.7.1.97; Vos S, 1998, J MOL BIOL, V282, P875, DOI 10.1006/jmbi.1998.2051	51	86	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26149	26156		10.1074/jbc.M202835200	http://dx.doi.org/10.1074/jbc.M202835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12004061	hybrid			2022-12-27	WOS:000176908700043
J	Richardson, RT; Starr, R; Angus, LJL; Hilton, DJ				Richardson, RT; Starr, R; Angus, LJL; Hilton, DJ			A somatic cell genetic system for dissecting hemopoietic cytokine signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; KREBS ASCITES-CELLS; DIFFERENTIATION FACTOR; STIMULATING FACTOR; TYROSINE KINASE; C-MYC; RECEPTOR; EXPRESSION; CLONING; BINDING	Somatic cell genetics has proven to be a powerful tool for the dissection of cytokine signal transduction pathways. Here we describe a system in which interleukin-6 (IL-6) signaling may be dissected using myeloid leukemic M1 cells. We utilized two properties of M1 cell differentiation to isolate IL-6-unresponsive mutants. First, M1 differentiation is associated with cessation of cell division. Second, differentiated M1 cells migrate rapidly and form dispersed colonies in agar. Mutant clones that are unresponsive to IL-6 are, therefore, large and compact as compared with clones derived from IL-6-responsive wild type M1 cells. Following spontaneous or chemically induced mutagenesis and selection in a high dose of IL-6, we isolated 27 M1 clones unresponsive to IL-6. Three harbored mutations that acted in a dominant manner, whereas 24 contained recessive mutations. gp130, an IL-6 receptor component, was affected in many mutant clones. We show that these clones display IL-6 and leukemia inhibitory factor receptors with reduced binding affinities and express gp130 at reduced levels. The IL-6-unresponsive phenotype of these mutant clones was fully rescued by the transfection of exogenous gp130 DNA. Therefore, this approach targets components of the IL-6 signaling pathway and may be suitable to study signaling from a variety of cytokines.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Hilton, DJ (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392; Richardson, Rachael/0000-0002-2412-8354	NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; BOYD A, 1982, ANNU REV PHYSIOL, V44, P501, DOI 10.1146/annurev.ph.44.030182.002441; BRASEL K, 1995, LEUKEMIA, V9, P1212; BRUCE AG, 1992, J IMMUNOL, V149, P1271; CHIU CP, 1989, J IMMUNOL, V142, P1909; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FACKLER MJ, 1995, BLOOD, V85, P3040, DOI 10.1182/blood.V85.11.3040.bloodjournal85113040; FELDMAN GM, 1991, BLOOD, V78, P1678; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KRYSTOSEK A, 1976, CELL, V9, P675, DOI 10.1016/0092-8674(76)90131-8; LOTEM J, 1974, P NATL ACAD SCI USA, V71, P3507, DOI 10.1073/pnas.71.9.3507; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; METCALF D, 1989, LEUKEMIA, V3, P349; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NECKERS LM, 1988, J CELL PHYSIOL, V135, P339, DOI 10.1002/jcp.1041350223; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SIMON MA, 1992, COLD SPRING HARB SYM, V57, P375, DOI 10.1101/SQB.1992.057.01.042; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	34	1	1	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25624	25630		10.1074/jbc.M202189200	http://dx.doi.org/10.1074/jbc.M202189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11994291	hybrid			2022-12-27	WOS:000176747000101
J	Kulkarni, S; Goll, DE; Fox, JEB				Kulkarni, S; Goll, DE; Fox, JEB			Calpain cleaves RhoA generating a dominant-negative form that inhibits integrin-induced actin filament assembly and cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; LEUKOCYTE ADHESION; FOCAL COMPLEXES; STRESS FIBERS; RAC; ACTIVATION; GTPASES; CYTOSKELETON; CDC42; FILOPODIA	Integrin-induced cell adhesion results in transmission of signals that induce cytoskeletal reorganizations and resulting changes in cell behavior. The cytoskeletal reorganizations are regulated by transient activation and inactivation of Rho GTPases. Previously, we identified mu-calpain as an enzyme that is activated by signaling across beta(1) and beta(3) integrins. We showed that it mediates cytoskeletal reorganizations in bovine aortic endothelial (BAE) and Chinese hamster ovary (CHO) cells and does so by acting upstream of Rac1 activation. Here we show that mu-calpain is also involved in inactivating RhoA during integrin-induced signaling. Cleavage of RhoA was detectable in BAE cells plated on an integrin substrate; it did not occur in cells plated on poly-(L)-lysine. Cleavage was inhibited by calpain inhibitors. In vitro, mu-calpain cleaved RhoA generating a fragment of the same size as in intact cells. The cleavage site was identified, an HA-tagged construct expressing calpain-cleaved RhoA generated, and the construct expressed in BAE and CHO cells. Calpain-cleaved RhoA inhibited integrin-induced stress fiber assembly and decreased cell spreading. Together, our data show that calpain cleaves RhoA and generates a form that inhibits integrin-induced stress fiber assembly and cell spreading.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University of Arizona; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, 9500 Euclid Ave,NB-50, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030657, R23HL030657, R37HL030657, R01HL056264] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Bialkowska K, 2000, BLOOD, V96, p241A; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EMORI Y, 1986, J BIOL CHEM, V261, P9465; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; GOLL DE, 1983, PROPERTIES REGULATIO, P19; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MURACHI T, 1989, BIOCHEM INT, V18, P263; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Reddy KB, 2001, J BIOL CHEM, V276, P28300, DOI 10.1074/jbc.M102794200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SZPACENKO A, 1981, PROTEINASES THEIR IN, P151; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728	36	84	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24435	24441		10.1074/jbc.M203457200	http://dx.doi.org/10.1074/jbc.M203457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964413	hybrid			2022-12-27	WOS:000176611800062
J	Li, HM; Ryan, TJ; Chave, KJ; Van Roey, P				Li, HM; Ryan, TJ; Chave, KJ; Van Roey, P			Three-dimensional structure of human gamma-glutamyl hydrolase - A class I glutamine amidotransferase adapted for a complex substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ELECTRON-DENSITY MAPS; X-RAY-DIFFRACTION; FOLYLPOLYGLUTAMATE SYNTHETASE; CRYSTAL-STRUCTURE; METHOTREXATE; RESISTANCE; DATABASE; POLYGLUTAMYLATION; CLASSIFICATION	gamma-Glutamyl hydrolase catalyzes the cleavage of the gamma-glutamyl chain of folylpoly-gamma-glutamyl substrates and is a central enzyme in folyl and antifolyl poly-gamma-glutamate metabolism. The crystal structure of human gamma-glutamyl hydrolase, determined at 1.6-Angstrom resolution, reveals that the protein is a homodimer. The overall structure of human gamma-glutamyl hydrolase contains 11 a-helices and 14 beta-strands, with a fold in which a central eight-stranded beta-sheet is sandwiched by three and five a-helices on each side. The topology is very similar to that of the class I glutamine amidotransferase domains, with the only major differences consisting of extensions in four loops and at the C terminus. These insertions are important for defining the substrate binding cleft and/or the dimer interface. Two sequence motifs are found in common between human gamma-glutamyl hydrolase and the class I glutamine amidotransferase family and include the catalytically essential residues, Cys-110 and His-220. These residues are located in the center of a large L-shaped cleft that is closed at one end and open at the other. Several conserved residues, including Glu-114, His-171, Gln-218, and Lys-223, may be important for substrate binding. Modeling of a methotrexate thioester intermediate, based on the corresponding complex of the glutamate thioester intermediate of Escherichia coli carbamoyl-phosphate synthetase, indicates that the substrate binds in an orientation with the pteroyl group toward the open end of the cleft.	Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA	Wadsworth Center	Van Roey, P (corresponding author), Wadsworth Ctr, Div Mol Med, POB 509, Albany, NY 12201 USA.	vanroey@wadsworth.org	Li, Hongmin/ABI-2439-2020	Li, Hongmin/0000-0002-8684-5308	NCI NIH HHS [CA82425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chave KJ, 2000, J BIOL CHEM, V275, P40365, DOI 10.1074/jbc.M007908200; Chave KJ, 1999, BIOCHEM J, V343, P551, DOI 10.1042/0264-6021:3430551; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; GALIVAN J, 1980, MOL PHARMACOL, V17, P105; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Huang XY, 1999, BIOCHEMISTRY-US, V38, P15909, DOI 10.1021/bi991805q; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knochel T, 1999, P NATL ACAD SCI USA, V96, P9479, DOI 10.1073/pnas.96.17.9479; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Longo GSA, 1997, ONCOL RES, V9, P259; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PIZZORNO G, 1995, CANCER RES, V55, P566; RHEE MS, 1993, CANCER RES, V53, P2227; Rhee MS, 1998, MOL PHARMACOL, V53, P1040; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Roussel A, 1991, SILICON GRAPHICS GEO, P81; ROUX B, 1993, BIOCHEMISTRY-US, V32, P3763, DOI 10.1021/bi00065a031; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; Sun XL, 2001, J MOL BIOL, V310, P1067, DOI 10.1006/jmbi.2001.4815; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Waltham MC, 1997, MOL PHARMACOL, V51, P825, DOI 10.1124/mol.51.5.825; YAO R, 1995, MOL PHARMACOL, V48, P505; Yao R, 1996, P NATL ACAD SCI USA, V93, P10134, DOI 10.1073/pnas.93.19.10134; Yao R, 1996, J BIOL CHEM, V271, P8525, DOI 10.1074/jbc.271.15.8525	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24522	24529		10.1074/jbc.M202020200	http://dx.doi.org/10.1074/jbc.M202020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11953431	hybrid			2022-12-27	WOS:000176611800073
J	Startchik, I; Morabito, D; Lang, U; Rossier, MF				Startchik, I; Morabito, D; Lang, U; Rossier, MF			Control of calcium homeostasis by angiotensin II in adrenal glomerulosa cells through activation of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEDIATED ALDOSTERONE SECRETION; BOVINE ADRENOCORTICAL-CELLS; SMOOTH-MUSCLE CELLS; INTRACELLULAR CALCIUM; ARACHIDONIC-ACID; INHIBITION; CAFFEINE; CHANNELS; SIGNAL	Angiotensin II-induced activation of aldosterone secretion in adrenal glomerulosa cells is mediated by an increase of intracellular calcium. We describe here a new Ca2+-regulatory pathway involving the inhibition by angiotensin II of calcium extrusion through the Na+/Ca2+ exchanger. Caffeine reduced both the angiotensin II-induced calcium signal and aldosterone production in bovine glomerulosa cells. These effects were independent of cAMP or calcium release from intracellular stores. The calcium response to angiotensin II was more sensitive to caffeine than the response to potassium, suggesting that the drug interacts with a pathway specifically elicited by the hormone. In calcium-free medium, calcium returned more rapidly to basal levels after angiotensin II stimulation in the presence of caffeine. Thapsigargin had no effect on these kinetics, but diltiazem, which inhibits the Na+/Ca2+ exchanger, markedly reduced the rate of calcium decrease and abolished caffeine action. The involvement of this exchanger was supported by the effect of cell depolarization and of a reduction of extracellular sodium on the rate of calcium extrusion. We also determined the mechanism of angiotensin II action on the exchanger. Phorbol esters reduced the rate of calcium extrusion, which was increased by baicalein, an inhibitor of lipoxygenases, and by SB 203580, an inhibitor of the p38 MAPK. Finally, we showed that angiotensin II acutely activates, in a caffeine-sensitive manner, p38 MAPK in glomerulosa cells. In conclusion, in bovine glomerulosa cells, the Na+/Ca2+ exchanger plays a crucial role in extruding calcium, and, by reducing its activity, angiotensin II influences the amplitude of the calcium signal. The hormone exerts its action on the exchanger through a caffeine-sensitive pathway involving the p38 MAPK and lipoxygenase products.	Univ Hosp, Dept Pathol, Clin Chem Lab, CH-1211 Geneva 14, Switzerland	University of Geneva	Rossier, MF (corresponding author), Univ Hosp, Div Endocrinol & Diabetol, Dept Med, 24 rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.		Rossier, Michel/AAW-2895-2021					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BIANCHI CP, 1961, J GEN PHYSIOL, V44, P845, DOI 10.1085/jgp.44.5.845; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CAPPONI AM, 1994, ENDOCRINE, V2, P579; CHABRE O, 1995, ENDOCRINOLOGY, V136, P956, DOI 10.1210/en.136.3.956; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HUGHES AD, 1990, PFLUG ARCH EUR J PHY, V416, P462, DOI 10.1007/BF00370755; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; KOJIMA I, 1986, BIOCHEM J, V237, P253, DOI 10.1042/bj2370253; KOJIMA I, 1985, ENDOCRINOLOGY, V117, P1057, DOI 10.1210/endo-117-3-1057; KRAMER RH, 1994, PFLUG ARCH EUR J PHY, V426, P12, DOI 10.1007/BF00374665; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; LANG U, 1987, J BIOL CHEM, V262, P8047; Makara JK, 2000, ENDOCRINOLOGY, V141, P1705, DOI 10.1210/en.141.5.1705; McNeill H, 1998, ENDOCR RES, V24, P373, DOI 10.3109/07435809809032617; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; NATARAJAN R, 1988, J CLIN ENDOCR METAB, V67, P584, DOI 10.1210/jcem-67-3-584; NATARAJAN R, 1992, ENDOCRINOLOGY, V131, P1174, DOI 10.1210/en.131.3.1174; NATARAJAN R, 1988, BIOCHEM BIOPH RES CO, V156, P717, DOI 10.1016/S0006-291X(88)80902-1; NATARAJAN R, 1990, MOL CELL ENDOCRINOL, V72, P73, DOI 10.1016/0303-7207(90)90096-Q; NATARAJAN R, 1994, MOL CELL ENDOCRINOL, V101, P59, DOI 10.1016/0303-7207(94)90219-4; Niisato N, 1999, BIOCHEM BIOPH RES CO, V266, P547, DOI 10.1006/bbrc.1999.1843; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PRESTWICH SA, 1995, BRIT J PHARMACOL, V114, P602, DOI 10.1111/j.1476-5381.1995.tb17182.x; Roger F, 1999, J BIOL CHEM, V274, P34103, DOI 10.1074/jbc.274.48.34103; ROSSIER MF, 1987, J BIOL CHEM, V262, P4053; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; ROSSIER MF, 1995, J BIOL CHEM, V270, P15137, DOI 10.1074/jbc.270.25.15137; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; STERN N, 1993, ENDOCRINOLOGY, V133, P843, DOI 10.1210/en.133.2.843; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tian Y, 1998, ENDOCRINOLOGY, V139, P1801, DOI 10.1210/en.139.4.1801; VANDERBENT V, 1993, ENDOCRINOLOGY, V133, P1213, DOI 10.1210/en.133.3.1213; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YANG DC, 1999, 81 ANN M END SOC ABS, P361; Zhang Z, 1996, AM J PHYSIOL-RENAL, V271, pF1234, DOI 10.1152/ajprenal.1996.271.6.F1234	47	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24265	24273		10.1074/jbc.M110947200	http://dx.doi.org/10.1074/jbc.M110947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983686	hybrid			2022-12-27	WOS:000176611800039
J	Tardif, M; Savard, M; Flamand, L; Gosselin, J				Tardif, M; Savard, M; Flamand, L; Gosselin, J			Impaired protein kinase C activation/translocation in Epstein-Barr virus-infected monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZLF-1-ENCODED ZEBRA PROTEIN; NF-KAPPA-B; NONSTRUCTURAL PROTEIN-3; INTRACELLULAR RECEPTOR; MEDIATED PHAGOCYTOSIS; HUMAN NEUTROPHILS; GENE-EXPRESSION; BETA-SUBUNIT; CELLS; RACK1	Infection of human monocytes by Epstein-Barr virus (EBV) has been linked to a decrease in the production of proinflammatory mediators as well as an impairment of phagocytosis. Considering the key role of protein kinases C (PKCs) in many biological functions of monocytes, including phagocytosis, we investigated the effects of EBV on the PKC activity in infected monocytes. Our results indicate that infection of monocytes by EBV impairs both phorbol 12-myristate 13-acetate (PMA)-induced translocation of PKC isozymes alpha and beta from cytosol to membrane as well as the PKC enzymatic activity. Similarly, the subcellular distribution of the receptor for activated C kinase (RACK), an anchoring protein essential to PKC translocation, was also found to be reduced in EBV-infected monocytes. Transfection of 293T cells with an expression vector coding for the immediate-early protein ZEBRA of EBV resulted in impaired PMA-induced translocation and activity of PKC. Using co-immunoprecipitation assays, the ZEBRA protein was found to physically interact with the RACK1 protein. Thus interaction of ZEBRA with RACK likely results in the inhibition of PKC activity, which in turn affects functions of monocytes, such as phagocytosis.	CHU Laval, Lab Viral Immunol, Ctr Rech Rhumatol & Immunol, CHUL Res Ctr CHUQ, St Foy, PQ G1V 4G2, Canada; CHU Laval, Virol Lab, Ctr Rech Rhumatol & Immunol, Res Ctr CHUQ, St Foy, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Gosselin, J (corresponding author), CHU Laval, Lab Viral Immunol, Ctr Rech Rhumatol & Immunol, CHUL Res Ctr CHUQ, 2705 Boul Laurier,Rm T 1-49, St Foy, PQ G1V 4G2, Canada.			Flamand, Louis/0000-0001-5010-4586				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Baumann M, 1998, J VIROL, V72, P8105, DOI 10.1128/JVI.72.10.8105-8114.1998; Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; BEAULIEU AD, 1995, BLOOD, V86, P2789; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Borowski P, 2000, BIOL CHEM, V381, P19, DOI 10.1515/BC.2000.003; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; DELSOL G, 1993, AM J PATHOL, V142, P1729; Dieter P, 2000, CELL SIGNAL, V12, P297, DOI 10.1016/S0898-6568(00)00069-3; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; Dreyfus DH, 1999, J IMMUNOL, V163, P6261; Dreyfus DH, 2000, BLOOD, V96, P625; Gallina A, 2001, VIROLOGY, V283, P7, DOI 10.1006/viro.2001.0855; Giroux M, 2000, J IMMUNOL, V165, P3985, DOI 10.4049/jimmunol.165.7.3985; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; Guan MX, 1998, ANTICANCER RES, V18, P3171; Kanegane H, 1998, LEUKEMIA LYMPHOMA, V29, P491, DOI 10.3109/10428199809050908; KARIMI K, 1995, J IMMUNOL, V155, P5786; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KELLEHER CA, 1995, VIROLOGY, V208, P685, DOI 10.1006/viro.1995.1200; KENT SJ, 1994, CLIN EXP IMMUNOL, V95, P450, DOI 10.1111/j.1365-2249.1994.tb07017.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Korchak HM, 2001, J BIOL CHEM, V276, P8910, DOI 10.1074/jbc.M008326200; Larochelle B, 1998, BLOOD, V92, P291, DOI 10.1182/blood.V92.1.291.413k34_291_299; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PRICE P, 1987, J VIROL, V61, P3602, DOI 10.1128/JVI.61.11.3602-3606.1987; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Savard M, 2000, J VIROL, V74, P2612, DOI 10.1128/JVI.74.6.2612-2619.2000; Savard M, 2000, J IMMUNOL, V164, P6467, DOI 10.4049/jimmunol.164.12.6467; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	42	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24148	24154		10.1074/jbc.M109036200	http://dx.doi.org/10.1074/jbc.M109036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11971896	hybrid			2022-12-27	WOS:000176611800024
J	van den Heuvel, RHH; Ferrari, D; Bossi, RT; Ravasio, S; Curti, B; Vanoni, MA; Florencio, FJ; Mattevi, A				van den Heuvel, RHH; Ferrari, D; Bossi, RT; Ravasio, S; Curti, B; Vanoni, MA; Florencio, FJ; Mattevi, A			Structural studies on the synchronization of catalytic centers in glutamate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; MACROMOLECULAR STRUCTURES; ESCHERICHIA-COLI; PROTEIN MODELS; AMMONIA; REFINEMENT; MOLSCRIPT; SUBSTRATE; PROGRAM; ENZYMES	The complex iron-sulfur flavoprotein glutamate synthase (GltS) plays a prominent role in ammonia assimilation in bacteria, yeasts, and plants. GltS catalyzes the formation of two molecules of (L)-glutamate from 2-oxoglutarate and L- glutamine via intramolecular channeling of ammonia. GltS has the impressive ability of synchronizing its distinct catalytic centers to avoid wasteful consumption of (L)-glutamine. We have determined the crystal structure of the ferredoxin-dependent GUS in several ligation and redox states. The structures reveal the crucial elements in the synchronization between the glutaminase site and the 2-iminoglutarate reduction site. The structural data combined with the catalytic properties of GUS indicate that binding of ferredoxin and 2-oxoglutarate to the FMN-binding domain of GUS induce a conformational change in the loop connecting the two catalytic centers. The rearrangement induces a shift in the catalytic elements of the amidotransferase domain, such that it becomes activated. This machinery, over a distance of more than 30 Angstrom. controls the ability of the enzyme to bind and hydrolyze the ammonia-donating substrate L-glutamine.	Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Milan, Dept Gen Physiol & Biochem, I-20133 Milan, Italy; Univ Insubria, Dept Chem Phys & Math Sci, I-22100 Como, Italy; Univ Sevilla, CSIC, Inst Plant Biochem & Photosynthesis, E-41092 Seville, Spain	University of Pavia; University of Parma; University of Milan; University of Insubria; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Mattevi, A (corresponding author), Univ Pavia, Dept Genet & Microbiol, Via Abbiategrasso 207, I-27100 Pavia, Italy.		Vanoni, Maria/AAP-2089-2021; Florencio, Francisco J/K-7716-2014; mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019	Vanoni, Maria/0000-0001-7213-732X; Florencio, Francisco J/0000-0002-2068-7861; mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; ferrari, davide/0000-0001-7084-6800				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BEALE SI, 1996, ESCHERICHIA COLI SAL, P731; Binda C, 2000, STRUCTURE, V8, P1299, DOI 10.1016/S0969-2126(00)00540-2; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navarro F, 2000, ARCH BIOCHEM BIOPHYS, V379, P267, DOI 10.1006/abbi.2000.1894; OVADI J, 1991, J THEOR BIOL, V152, P135, DOI 10.1016/S0022-5193(05)80528-4; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Ravasio S, 2001, BIOCHEMISTRY-US, V40, P5533, DOI 10.1021/bi0100889; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vanoni MA, 1998, BIOCHEMISTRY-US, V37, P1828, DOI 10.1021/bi972342w; Vanoni MA, 1999, CELL MOL LIFE SCI, V55, P617, DOI 10.1007/s000180050319; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; [No title captured]	31	66	67	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24579	24583		10.1074/jbc.M202541200	http://dx.doi.org/10.1074/jbc.M202541200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11967268	Green Published, hybrid			2022-12-27	WOS:000176611800080
J	Vickrey, JF; Herve, G; Evans, DR				Vickrey, JF; Herve, G; Evans, DR			Pseudomonas aeruginosa aspartate transcarbamoylase - Characterization of its catalytic and regulatory properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC ORGANIZATION; CARBAMOYLPHOSPHATE SYNTHETASE; PYRIMIDINE BIOSYNTHESIS; MULTIFUNCTIONAL PROTEIN; CARBAMOYLTRANSFERASE; PURIFICATION; ARGININE; SUBUNIT; DOMAIN	Aspartate transcarbamoylase from Pseudomonadaceae is a class A enzyme consisting of six copies of a 36-kDa catalytic chain and six copies of a 45-kDa polypeptide of unknown function. The 45-kDa polypeptide is homologous to dihydroorotase but lacks catalytic activity. Pseudomonas aeruginosa aspartate transcarbamoylase was overexpressed in Escherichia coli. The homogeneous His-tagged protein isolated in high yield, 30 mg/liter of culture, by affinity chromatography and crystallized. Attempts to dissociate the catalytic and pseudo-dihydroorotase (pDHO) subunits or to express catalytic subunits only were unsuccessful suggesting that the pDHO subunits are required for the proper folding and assembly of the complex. As reported previously, the enzyme was inhibited by micromolar concentrations of all nucleotide triphosphates. In the absence of effectors, the aspartate saturation curves were hyperbolic but became strongly sigmoidal in the presence of low concentrations of nucleotide triphosphates. The inhibition was unusual in that only free ATP, not MgATP, inhibits the enzyme. Moreover, kinetic and binding studies with a fluorescent ATP analog suggested that ATP induces a conformational change that interferes with the binding of carbamoyl phosphate but has little effect once carbamoyl phosphate is bound. The peculiar allosteric properties suggest that the enzyme may be a potential target for novel chemotherapeutic agents designed to combat Pseudomonas infection.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France	Wayne State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu						ABDELAL AT, 1982, J BACTERIOL, V151, P1411, DOI 10.1128/JB.151.3.1411-1419.1982; ABDELAL AT, 1983, EUR J BIOCHEM, V129, P697; ADAIR LB, 1972, J BIOL CHEM, V247, P2308; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BERGH ST, 1993, P NATL ACAD SCI USA, V90, P9818, DOI 10.1073/pnas.90.21.9818; BRABSON JS, 1975, J BIOL CHEM, V250, P8664; CONDON S, 1976, J GEN MICROBIOL, V92, P375, DOI 10.1099/00221287-92-2-375; DUTTA PK, 1987, J CHROMATOGR, V385, P119, DOI 10.1016/S0021-9673(01)94627-8; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; HAAS D, 1977, MOL GEN GENET, V154, P7, DOI 10.1007/BF00265571; HOBDEN JA, 1993, ANTIMICROB AGENTS CH, V37, P1856, DOI 10.1128/AAC.37.9.1856; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; ISAAC JH, 1968, J BACTERIOL, V96, P1732, DOI 10.1128/JB.96.5.1732-1741.1968; ISSALY I, 1982, BIOCHEMISTRY-US, V21, P1612, DOI 10.1021/bi00536a023; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGER D, 1988, BIOCHEMISTRY-US, V27, P4293, DOI 10.1021/bi00412a015; LERNER CG, 1986, J BIOL CHEM, V261, P1156; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALEY JA, 1988, MOL GEN GENET, V213, P278, DOI 10.1007/BF00339592; Maniatis T., 1982, MOL CLONING; MERCENIER A, 1980, J BACTERIOL, V144, P159, DOI 10.1128/JB.144.1.159-163.1980; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PALMER DA, 1993, APPL ENVIRON MICROB, V59, P1619, DOI 10.1128/AEM.59.5.1619-1626.1993; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; Perrin DD, 1966, BIOCHIM BIOPHYS ACTA, V127, P35, DOI 10.1016/0304-4165(66)90472-7; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; PRESTON MJ, 1993, INFECT IMMUN, V61, P2713, DOI 10.1128/IAI.61.6.2713-2716.1993; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; SCHURR MJ, 1995, J BACTERIOL, V177, P1751, DOI 10.1128/jb.177.7.1751-1759.1995; SHEPHERDSON M, 1993, FEMS MICROBIOL LETT, V114, P201, DOI 10.1111/j.1574-6968.1993.tb06574.x; SHOESMITH JG, 1960, J GEN MICROBIOL, V22, P10, DOI 10.1099/00221287-22-1-10; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; STALON V, 1972, EUR J BIOCHEM, V29, P25, DOI 10.1111/j.1432-1033.1972.tb01953.x; STEVENS RC, 1991, P NATL ACAD SCI USA, V88, P6087, DOI 10.1073/pnas.88.14.6087; TREDGET EE, 1992, CLIN INFECT DIS, V15, P941, DOI 10.1093/clind/15.6.941; VICKREY JF, 1993, THESIS U N TEXAS DEN; Wales ME, 1999, J MOL BIOL, V294, P1387, DOI 10.1006/jmbi.1999.3315; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; WEITZMAN PD, 1966, J BIOL CHEM, V241, P5481; WILD JR, 1990, ANNU REV MICROBIOL, V44, P193; XU GR, 1992, J GEN MICROBIOL, V138, P2459, DOI 10.1099/00221287-138-11-2459; ZHANG YX, 1993, J BACTERIOL, V175, P6451, DOI 10.1128/jb.175.20.6451-6458.1993	50	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24490	24498		10.1074/jbc.M200009200	http://dx.doi.org/10.1074/jbc.M200009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959858	hybrid			2022-12-27	WOS:000176611800069
J	Abe, J; Fukuzawa, T; Hirose, S				Abe, J; Fukuzawa, T; Hirose, S			Cleavage of Ig-Hepta at a "SEA" module and at a conserved G protein-coupled receptor proteolytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; EXTRACELLULAR DOMAIN; SECRETIN FAMILY; CELL-SURFACE; MEMBER; CLONING; 7-TRANSMEMBRANE; GENE; IDENTIFICATION; GLYCOPROTEIN	Ig-Hepta is a member of a new subfamily of the heptahelical receptors and has an unusually long N terminus extending toward the extracellular side of the plasma membrane. Pulse-chase experiments in 293T cells using antisera specifically recognizing its N- and C-terminal regions demonstrated that Ig-Hepta is core-glycosylated cotranslationally and proteolytically processed into a two-chain form in the endoplasmic reticulum, followed by maturation of oligosaccharide chains and dimerization. The cleavage occurs at two highly conserved sites: one in a "SEA" module (a module first identified in sperm protein, enterokinase, and agrin) near the N terminus and the other in the stalk region preceding the first transmembrane span, generating similar to20-, 130-, and 32-kDa fragments. The latter two remain tightly associated non-covalently even after cleavage as revealed by immunoprecipitation of native and myc-tagged Ig-Hepta constructs that were transiently expressed in 293T cells. The dimer consisting of four chains, (130 kDa + 32 kDa)21 is linked by disulfide bonds. A fusion protein of the extracellular domain of Ig-Hepta and the Fe domain of immunoglobulin was found to be a good substrate of the processing enzymes and used for determining the exact cleavage sites in the SEA module and juxtamembrane stalk region.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp						Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Formstone CJ, 2001, MECH DEVELOP, V109, P91, DOI 10.1016/S0925-4773(01)00515-9; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gray JX, 1996, J IMMUNOL, V157, P5438; Hadjantonakis AK, 1997, GENOMICS, V45, P97, DOI 10.1006/geno.1997.4892; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Osterhoff C, 1997, DNA CELL BIOL, V16, P379, DOI 10.1089/dna.1997.16.379; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; WARD CJ, 1994, CELL, V77, P881; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502	36	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23391	23398		10.1074/jbc.M110877200	http://dx.doi.org/10.1074/jbc.M110877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973329	hybrid			2022-12-27	WOS:000176475700039
J	Flinn, EM; Wallberg, AE; Hermann, S; Grant, PA; Workman, JL; Wright, APH				Flinn, EM; Wallberg, AE; Hermann, S; Grant, PA; Workman, JL; Wright, APH			Recruitment of Gen5-containing complexes during c-Myc-dependent gene activation - Structure and function aspects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEXES; BURKITTS-LYMPHOMA CELLS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; IN-VIVO; ESSENTIAL COFACTOR; ACETYLASE COMPLEX	The N-terminal domain of c-Myc plays a key role in cellular transformation and is involved in both activation and repression of target genes as well as in modulated proteolysis of c-Myc via the proteasome. Given this functional complexity, it has been difficult to clarify the structures within the N terminus that contribute to these different processes as well as the mechanisms by which they function. We have used a simplified yeast model system to identify the primary determinants within the N terminus for W chromatin remodeling of a promoter, (ii) gene activation from a chromatin template in vivo, and (iii) interaction with highly purified Gcn5 complexes as well as other chromatin-remodeling complexes in vitro. The results identify two regions that contain autonomous chromatin opening and gene activation activity, but both regions are required for efficient interaction with chromatin-remodeling complexes in vitro. The conserved Myc boxes do not play a direct role in gene activation, and Myc box II is not generally required for in vitro interactions with remodeling complexes. The yeast SAGA complex, which is orthologous to the human GCN5-TRRAP complex that interacts with Myc in human cells, plays a role in Myc-mediated chromatin opening at the promoter but may also be involved in later steps of gene activation.	Sodertorns Hogskola, Sect Nat Sci, S-14104 Huddinge, Sweden; Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Sodertorn University; Karolinska Institutet; University of Virginia; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wright, APH (corresponding author), Sodertorns Hogskola, Sect Nat Sci, Box 4101, S-14104 Huddinge, Sweden.		Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969	NIDDK NIH HHS [DK58646] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058646] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Chen BS, 2001, J BIOL CHEM, V276, P23881, DOI 10.1074/jbc.M102893200; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROUCH DH, 1993, ONCOGENE, V8, P1849; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FISHER F, 1991, ONCOGENE, V6, P1099; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; GREEN JBA, 1988, MOL GEN GENET, V215, P100, DOI 10.1007/BF00331310; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Hermann S, 2001, J BIOL CHEM, V276, P40127, DOI 10.1074/jbc.M103793200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Massari ME, 1996, MOL CELL BIOL, V16, P121; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEYHACK B, 1982, EMBO J, V1, P675, DOI 10.1002/j.1460-2075.1982.tb01229.x; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; Rose MD., 1990, METHODS YEAST GENETI; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHOR J, 1995, ONCOGENE, V10, P1587; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	83	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23399	23406		10.1074/jbc.M201704200	http://dx.doi.org/10.1074/jbc.M201704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11973336	hybrid			2022-12-27	WOS:000176475700040
J	Gaultier, A; Cousin, H; Darribere, T; Alfandari, D				Gaultier, A; Cousin, H; Darribere, T; Alfandari, D			ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC INTERACTION; ADAM-12 MELTRIN-ALPHA; CREST-CELL-MIGRATION; METALLOPROTEASE-DISINTEGRIN; INTEGRIN ALPHA-4-BETA-1; PROTEASE DOMAIN; XENOPUS-LAEVIS; MURINE EGGS; ADHESION; EXPRESSION	ADAM13 is a member of the disintegrin and metalloprotease protein family that is expressed on cranial neural crest cells surface and is essential for their migration. ADAM13 is an active protease that can cleave fibronectin in vitro and remodel a fibronectin substrate in vivo. Using a recombinant secreted protein containing both disintegrin and cysteine-rich domains of ADAM13, we show that this "adhesive" region of the protein binds directly to fibronectin. Fibronectin fusion proteins corresponding to the various functional domains were used to define the second heparin-binding domain as the ADAM13 binding site. Mutation of the syndecan-binding site (PPRR --> PPTM) within this domain abolishes binding of the recombinant disintegrin and cysteine-rich domains of ADAM13. We further show that the adhesive disintegrin and cysteine-rich domain of ADAM13 can promote cell adhesion via P, integrins. This adhesion requires integrin activation and can be prevented by antibodies to the cysteine-rich domain of ADAM13 and P, integrin. Finally, wild type, but not the E/A mutant of ADAM13 metalloprotease domain, can be shed from the cell surface, releasing the metalloprotease domain associated with the disintegrin and cysteine-rich domains. This suggests that ADAM13 shedding may involve its own metalloprotease activity and that the released protease may interact with both integrins and extracellular matrix proteins.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Paris 06, Biol Dev Lab, UMR CNRS 7622, F-75005 Paris, France	University of Virginia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Alfandari, D (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA.	da3s@virginia.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014365] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26402] Funding Source: Medline; NIDCR NIH HHS [DE14365] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alfandari D, 1996, MECH DEVELOP, V56, P83, DOI 10.1016/0925-4773(96)00513-8; Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; Alfandari D, 2001, CURR BIOL, V11, P918, DOI 10.1016/S0960-9822(01)00263-9; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Darribere T, 2000, BIOL CELL, V92, P5, DOI 10.1016/S0248-4900(00)88760-2; DZAMBA BD, 2002, CELL ADHESION FRONTI, P100; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Harlow E., 1988, ANTIBODIES LAB MANUA; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MENDRICK DL, 1995, LAB INVEST, V72, P367; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; Nath D, 2000, J CELL SCI, V113, P2319; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Teel AL, 1996, MECH DEVELOP, V59, P115, DOI 10.1016/0925-4773(96)00584-9; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; WHITE JM, 2001, CELL ADHESION FRONTI, P189; Whittaker CA, 1998, ANN NY ACAD SCI, V857, P56, DOI 10.1111/j.1749-6632.1998.tb10107.x; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	44	58	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23336	23344		10.1074/jbc.M201792200	http://dx.doi.org/10.1074/jbc.M201792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11967265	hybrid			2022-12-27	WOS:000176475700033
J	Gioia, M; Fasciglione, GF; Marini, S; D'Alessio, S; De Sanctis, G; Diekmann, O; Pieper, M; Politi, V; Tschesche, H; Coletta, M				Gioia, M; Fasciglione, GF; Marini, S; D'Alessio, S; De Sanctis, G; Diekmann, O; Pieper, M; Politi, V; Tschesche, H; Coletta, M			Modulation of the catalytic activity of neutrophil collagenase MMP-8 on bovine collagen I - Role of the activation cleavage and of the hemopexin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; MATRIX METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; TRIPLE-HELIX; N-TERMINUS; PROCOLLAGENASE; STROMELYSIN; LEUKOCYTES; GELATINASE; INHIBITOR	The cleavage of bovine collagen I by neutrophil collagenase MMP-8 has been followed at pH 7.4, 37 degreesC. The behavior of the whole enzyme molecule (whMMP-8), displaying both the catalytic domain and the hemopexin-like domain, has been compared under the same experimental conditions with that of the catalytic domain only. The main observation is that whMMP-8 cleaves bovine collagen I only at a single specific site, as already reported by many others (Mallya, S. K., Mookhtiar, K. A., Gao, Y., Brew, K., Dioszegi, M., Birkedal-Hansen, H., and van Wart, H. E. (1990) Biochemistry 29, 10628-10634; Knauper, V., Osthues, A., DeClerk, Y. A., Langley, K. A, Blaser, J., and Tschesche, H. (1993) Biochem. J. 291, 847854; Marini, S., Fasciglione, G. F., De Sanctis, G., D'Alessio, S., Politi, V., and Coletta, M. (2000) J. Biol. Chem. 275, 18657-18663), whereas the catalytic domain lacks this specificity and cleaves the collagen molecule at multiple sites. Furthermore, a meaningful difference is observed for the cleavage features displayed by two forms of the catalytic domain, which differ for the N terminus resulting from the activation process (i.e. the former Met(80)of the proenzyme (MetMMP-8) and the former Phe(79) of the proenzyme (PheMMP-8)). Thus, the PheMMP-8 species is characterized by a much faster k(cat)/K-m, fully attributable to a lower K-m, suggesting that the conformation of the catalytic domain, induced by the insertion of this N-terminal residue in a specific pocket (Reinemer, P., Grams, F., Huber, R., Kleine, T., Schnierer, S., Piper, M., Tschesche, H., and Bode, W. (1994) FEBS Lett. 338, 227-233), brings about a better, although less discriminatory, recognition process of cleavage site(s) on bovine collagen I.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; PoliFarma, I-00155 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, Italy; Univ Bielefeld, Dept Biochem 1, D-33051 Bielefeld, Germany	University of Rome Tor Vergata; University of Camerino; University of Bielefeld	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.		Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022; Gioia, Magda/ABF-8909-2020; Marini, Stefano/B-1161-2012; Fasciglione, Giovanni Francesco/ABF-7738-2020; Danese, Silvio/ABH-9571-2020	Marini, Stefano/0000-0003-1299-6696; Danese, Silvio/0000-0001-7341-1351; COLETTA, Massimiliano/0000-0002-5489-9467; Gioia, Magda/0000-0003-0352-3547				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; BLASER J, 1991, EUR J BIOCHEM, V202, P1223, DOI 10.1111/j.1432-1033.1991.tb16494.x; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; BRADFORD MM, 1975, ANAL BIOCHEM, V72, P241; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; Cole AA, 1995, ACTA ORTHOP SCAND, V66, P98, DOI 10.3109/17453679509157661; Farr M, 1999, BIOCHEMISTRY-US, V38, P7332, DOI 10.1021/bi982618f; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; HASTY KA, 1987, J BIOL CHEM, V262, P10048; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNAUPER V, 1993, BIOCHEM J, V291, P847; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; MAINARDI CL, 1991, AM J MED SCI, V302, P171, DOI 10.1097/00000441-199109000-00010; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; Marini S, 2000, J BIOL CHEM, V275, P18657, DOI 10.1074/jbc.M000283200; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; MOOKHTIAR KA, 1990, BIOCHEMISTRY-US, V29, P10620, DOI 10.1021/bi00499a007; MURPHY G, 1977, BIOCHEM J, V162, P195, DOI 10.1042/bj1620195; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; TSCHESCHE H, 1995, METHOD ENZYMOL, V248, P431; Wess TJ, 1998, J MOL BIOL, V275, P255, DOI 10.1006/jmbi.1997.1449	35	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23123	23130		10.1074/jbc.M110873200	http://dx.doi.org/10.1074/jbc.M110873200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953425	hybrid			2022-12-27	WOS:000176475700005
J	Hiner, ANP; Ruiz, JH; Lopez, JNR; Canovas, FG; Brisset, NC; Smith, AT; Arnao, MB; Acosta, M				Hiner, ANP; Ruiz, JH; Lopez, JNR; Canovas, FG; Brisset, NC; Smith, AT; Arnao, MB; Acosta, M			Reactions of the class II peroxidases, lignin peroxidase and Arthromyces ramosus peroxidase, with hydrogen peroxide - Catalase-like activity, compound III formation, and enzyme inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-CHLOROPEROXYBENZOIC ACID; CYTOCHROME-C PEROXIDASE; HORSERADISH-PEROXIDASE; ASCORBATE PEROXIDASE; ESCHERICHIA-COLI; MECHANISM; OXYGEN; H2O2; IDENTIFICATION; DECOMPOSITION	The reactions of the fungal enzymes Arthromyces ramosus peroxidase (ARP) and Phanerochaete chrysosporium lignin peroxidase (LiP) with hydrogen peroxide (H2O2) have been studied. Both enzymes exhibited catalase activity with hyperbolic H2O2 concentration dependence (K-m approximate to 8-10 mM, k(cat) approximate to 1-3 s(-1)). The catalase and peroxidase activities of LiP were inhibited within 10 min and those of ARP in 1 h. The inactivation constants were calculated using two independent methods; LiP, k(i) approximate to 19 x 10(-3) s(-1); ARP, k(i) approximate to 1.6 x 10(-3) s(-1). Com pound III (oxyperoxidase) was detected as the majority species after the addition of H2O2 to LiP or ARP, and its formation was accompanied by loss of enzyme activity. A reaction scheme is presented which rationalizes the turnover and inactivation of LiP and ARP with H2O2. A similar model is applicable to horseradish peroxidase. The scheme links catalase and compound III forming catalytic pathways and inactivation at the level of the [compound I.H2O2] complex. Inactivation does not occur from compound III. All peroxidases studied to date are sensitive to inactivation by H2O2, and it is suggested that the model will be generally applicable to peroxidases of the plant, fungal, and prokaryotic superfamily.	Univ Murcia, Dept Biol Vegetal Fisiol Vegetal, E-30100 Murcia, Spain; Univ Murcia, Dept Bioquim & Biol Mol A, E-30100 Murcia, Spain; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Murcia; University of Murcia; University of Sussex	Acosta, M (corresponding author), Univ Murcia, Dept Biol Vegetal Fisiol Vegetal, E-30100 Murcia, Spain.	macosta@um.es	Josefa, Hernandez-Ruiz/R-5424-2018; Hu, Ruogu/B-2203-2008; Acosta, Manuel/A-2127-2008; Arnao, Marino B./ABE-9146-2020	Josefa, Hernandez-Ruiz/0000-0002-1847-8809; Acosta, Manuel/0000-0003-0611-6672; Arnao, Marino B./0000-0001-8517-6889; Smith, Andrew/0000-0002-0926-1878				ACOSTA M, 1991, BIOCH MOL PHYSL ASPE, P175; ACOSTA M, 1996, PLANT PEROXIDASES BI, P76; ACOSTA M, 1993, PLANT PEROXIDASES BI, P201; Arnao MB, 1995, J MOL CATAL A-CHEM, V104, P179, DOI 10.1016/1381-1169(95)00114-X; Arnao MB, 1996, BIOCHEM MOL BIOL INT, V39, P97; ARNAO MB, 1990, BIOCHIM BIOPHYS ACTA, V1038, P85, DOI 10.1016/0167-4838(90)90014-7; ARNAO MB, 1990, BIOCHIM BIOPHYS ACTA, V1041, P43, DOI 10.1016/0167-4838(90)90120-5; Baker CJ, 2000, ARCH BIOCHEM BIOPHYS, V382, P232, DOI 10.1006/abbi.2000.2013; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; CAI DY, 1989, BIOCHEM BIOPH RES CO, V162, P464, DOI 10.1016/0006-291X(89)92020-2; CAI DY, 1992, J BIOL CHEM, V267, P11149; CAI DY, 1990, BIOCHEMISTRY-US, V29, P2085, DOI 10.1021/bi00460a018; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; Converso DA, 1998, ARCH BIOCHEM BIOPHYS, V357, P22, DOI 10.1006/abbi.1998.0763; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; Doyle WA, 1996, BIOCHEM J, V315, P15, DOI 10.1042/bj3150015; Dunford H. B., 1999, HEME PEROXIDASES, P281; Dunford H B, 1990, PEROXIDASES CHEM BIO, V2, P1; Garcia-Canovas F, 1989, J Enzyme Inhib, V3, P81, DOI 10.3109/14756368909030367; Hernandez-Ruiz J, 2001, BIOCHEM J, V354, P107, DOI 10.1042/0264-6021:3540107; Hernandez-Ruiz J, 2000, BBA-PROTEIN STRUCT M, V1478, P78, DOI 10.1016/S0167-4838(00)00017-0; Hiner ANP, 1996, BIOTECHNOL BIOENG, V50, P655, DOI 10.1002/(SICI)1097-0290(19960620)50:6<655::AID-BIT6>3.3.CO;2-U; Hiner ANP, 2000, BIOCHEM J, V348, P321, DOI 10.1042/0264-6021:3480321; HINER ANP, 1995, EUR J BIOCHEM, V234, P506, DOI 10.1111/j.1432-1033.1995.506_b.x; Hiner ANP, 2001, ARCH BIOCHEM BIOPHYS, V392, P295, DOI 10.1006/abbi.2001.2460; Hiner ANP, 2001, J BIOL INORG CHEM, V6, P504, DOI 10.1007/s007750100219; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; KJALKE M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P248, DOI 10.1016/0167-4838(92)90244-8; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Obinger C, 1997, BIOCHEM BIOPH RES CO, V235, P545, DOI 10.1006/bbrc.1997.6847; Obinger C, 1999, PHOTOTROPHIC PROKARY, P719; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P13201, DOI 10.1021/bi001150p; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; RODRIGUEZLOPEZ JN, 1992, ANAL BIOCHEM, V202, P356, DOI 10.1016/0003-2697(92)90118-Q; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1990, J BIOL CHEM, V265, P11137; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; YONETANI T, 1966, J BIOL CHEM, V241, P3240	46	47	47	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26879	26885		10.1074/jbc.M200002200	http://dx.doi.org/10.1074/jbc.M200002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11983689	Green Submitted, hybrid			2022-12-27	WOS:000177055900025
J	Grunewald, M; Menaker, D; Kanner, BI				Grunewald, M; Menaker, D; Kanner, BI			Cysteine-scanning mutagenesis reveals a conformationally sensitive reentrant pore-loop in the glutamate transporter GLT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MEMBRANE-VESICLES; ACID TRANSPORTER; CHANNEL; SELECTIVITY; EXPRESSION; SUBSTRATE; TOPOLOGY; RESIDUE; ACCESSIBILITY	Removal of glutamate from the synaptic cleft by (Na+ + K+)-coupled transporters prevents neurotoxicity due to elevated concentrations of the transmitter. These transporters exhibit an unusual topology, including two reentrant loops. Reentrant loop 11 plays a pivotal role in coupling ion and glutamate fluxes. Here we used cysteine-scanning mutagenesis of the GLT-1 transporter to test the idea that this loop undergoes conformational changes following sodium and substrate binding. 15 of 22 consecutive single cysteine mutants in the stretch between Gly-422 and Ser-443 exhibited 30-100% of the transport activity of the cysteine-less transporter when expressed in HeLa cells. The transport activity of 11 of the 15 active mutants including five consecutive residues in the ascending limb was inhibited by small hydrophilic methanethiosulfonate reagents. The sensitivity of seven cysteine mutants, including A438C and S440C, to the reagents was significantly reduced by sodium ions, but the opposite was true for A439C. The non-transportable analogue dihydrokainate protected at almost all positions throughout the loop, and at two of the positions, the analogue protected even in the absence of sodium. Our results indicate that reentrant loop H forms part of an aqueous pore, the access of which is blocked by the glutamate analogue dihydrokainate, and that sodium influences the conformation of this pore-loop.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Diamond JS, 1997, J NEUROSCI, V17, P4672; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; YOUNG VR, 2000, J NUTR, V130, pS829; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26074	26080		10.1074/jbc.M202248200	http://dx.doi.org/10.1074/jbc.M202248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11994293	hybrid			2022-12-27	WOS:000176908700033
J	Muller, S; Hanisch, FG				Muller, S; Hanisch, FG			Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin - High density and prevalent core 2-based glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM REPEAT PEPTIDE; SKIM MILK MUCINS; LINKED POLYLACTOSAMINOGLYCANS; EPITHELIAL MUCIN; T-CELLS; ADENOCARCINOMA; REACTIVITY; ANTIBODIES; PROTEIN; SIALYLTRANSFERASE	Knowledge about the O-linked glycan chains of tumor-associated MUC1 is primarily based on enzymatic and immunochemical evidence. To obtain structural information and to overcome limitations by the scarcity of endogenous mucin, we expressed a recombinant glycosylation probe corresponding to six MUC1 tandem repeats in four breast cancer cell lines. Comparative analyses of the O-glycan profiles were performed after hydrazinolysis and normal phase chromatography of 2-aminobenzamide-labeled glycans. Except for a general reduction in the O-glycan chain lengths and a high density glycosylation, no common structural pattern was revealed. T47D fusion protein exhibits an almost complete shift from core 2 to core 1 expression with a preponderance of sialylated glycans. By contrast, MCF-7, MDA-MB231, and ZR75-1 cells glycosylate the MUC1 repeat peptide preferentially with core 2-based glycans terminating mostly with alpha3-linked sialic acid (MDA-MB231, ZR75-1) or alpha2/3-linked fucose (MCF-7). Endogenous MUC1 from T47D and MCF-7 cell supernatants revealed almost identical O-glycosylation profiles compared with the respective recombinant probes, indicating that the fusion proteins reflected the authentic O-glycan profiles of the cells. The structural patterns in the majority of cells under study are in conflict with biosynthetic models of MUC1 O-glycosylation in breast cancer, which claim that the truncation of normal core 2-based polylactosamine structures to short sialylated core 1-based glycans is due to the reduced activity of core 2-forming beta6-N-acetylglucosaminyltransferases and/or to overexpression of competitive alpha3-sialyltransferase.	Univ Cologne, Ins Biochem 2, Fak Med, D-50931 Cologne, Germany	University of Cologne	Hanisch, FG (corresponding author), Univ Cologne, Ins Biochem 2, Fak Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.				NATIONAL CANCER INSTITUTE [R01CA084106] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA84106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal B, 1998, CANCER RES, V58, P4079; AGRAWAL B, 1995, CANCER RES, V55, P2257; APOSTOLOPOULOS V, 1994, CRIT REV IMMUNOL, V14, P293, DOI 10.1615/CritRevImmunol.v14.i3-4.40; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; Bhavanandan VP, 1998, GLYCOCONJUGATE J, V15, P37, DOI 10.1023/A:1006987315827; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; Dent GA, 1999, AM J CLIN PATHOL, V111, P741; Engelmann K, 2001, J BIOL CHEM, V276, P27764, DOI 10.1074/jbc.M103187200; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GIRLING A, 1989, INT J CANCER, V43, P1972; Goydos JS, 1996, J SURG RES, V63, P298, DOI 10.1006/jsre.1996.0264; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1990, GLYCOCONJUGATE J, V7, P525, DOI 10.1007/BF01189075; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; HANISCH FG, 2000, GLYCOBIOLOGY, V9, P1181; HILKENS J, 1986, CANCER RES, V46, P2582; Hiltbold EM, 1999, CELL IMMUNOL, V194, P143, DOI 10.1006/cimm.1999.1512; Hull S R, 1989, Cancer Commun, V1, P261; Karanikas V, 1997, J CLIN INVEST, V100, P2783, DOI 10.1172/JCI119825; Karsten U, 1998, CANCER RES, V58, P2541; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOTERA Y, 1994, CANCER RES, V54, P2856; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Miles DW, 1999, PHARMACOL THERAPEUT, V82, P97, DOI 10.1016/S0163-7258(99)00003-0; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; von Mensdorff-Pouilly S, 2000, INT J CANCER, V86, P702, DOI 10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	38	122	126	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26103	26112		10.1074/jbc.M202921200	http://dx.doi.org/10.1074/jbc.M202921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12000758	hybrid			2022-12-27	WOS:000176908700037
J	Bishop, AC; Xu, JM; Johnson, RC; Schimmel, P; de Crecy-Lagard, V				Bishop, AC; Xu, JM; Johnson, RC; Schimmel, P; de Crecy-Lagard, V			Identification of the tRNA-dihydrouridine synthase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; POSTTRANSCRIPTIONAL MODIFICATION; BINDING-PROTEIN; DATABASE; LOOP; RECOMBINATION; SEQUENCE; BACTERIA; PATHWAYS	5,6-Dihydrouridine (D) is a modified base found abundantly in the D-loops of tRNA from Archaea, Bacteria, and Eukarya. D is thought to be formed post-transcriptionally by the reduction of uridines in tRNA transcripts. Despite its abundance, no enzymes that catalyze D-formation have been identified. Using comparative genomics and computational methods we have identified members of the cluster of orthologous genes, COG0042, as putative dihydrouridine synthase encoding genes. Escherichia coli contains three COG0042 family members (yjbN, yhdG, and yohI). Strains were created where one, two, or all three of the COG0042 genes were deleted. Purified tRNA samples were investigate from the three single and the three double knockout strains, as well as from the triple deletion strain. The results showed that the COG0042 gene family is responsible for tRNA-dihydrouridine synthase activity in E. coli. They also suggest that the COG0042-encoded family members act site-specifically on the tRNA D-loop and contain non-redundant catalytic functions in vivo.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-379,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Hu, Ruogu/B-2203-2008; de Crecy-Lagard, Valerie/AAN-8995-2020		NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander RW, 1999, BIOCHEMISTRY-US, V38, P16359, DOI 10.1021/bi991948c; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BlondeletRouault MH, 1997, GENE, V190, P315, DOI 10.1016/S0378-1119(97)00014-0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Constantinesco F, 1999, NUCLEIC ACIDS RES, V27, P1308, DOI 10.1093/nar/27.5.1308; Dalluge JJ, 1997, J BACTERIOL, V179, P1918, DOI 10.1128/jb.179.6.1918-1923.1997; Dalluge JJ, 1996, NUCLEIC ACIDS RES, V24, P1073, DOI 10.1093/nar/24.6.1073; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Hendrickson TL, 2001, P NATL ACAD SCI USA, V98, P13473, DOI 10.1073/pnas.251549298; HUNNINGHAKE D, 1966, ANAL BIOCHEM, V16, P200, DOI 10.1016/0003-2697(66)90147-3; JACOBSON M, 1970, ANAL BIOCHEM, V34, P459, DOI 10.1016/0003-2697(70)90130-2; Jensen KF, 1998, PATHS PYRIMIDINES, V6, P20; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOWALAK JA, 1995, J BIOL CHEM, V270, P17758, DOI 10.1074/jbc.270.30.17758; MADISON JT, 1965, BIOCHEM BIOPH RES CO, V18, P153, DOI 10.1016/0006-291X(65)90732-1; Miller J.H., 1972, EXPT MOL GENETICS; MOLINARO M, 1968, J BIOL CHEM, V243, P1277; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Nomanbhoy T, 2001, NAT STRUCT BIOL, V8, P344, DOI 10.1038/86228; Palmeros B, 2000, GENE, V247, P255, DOI 10.1016/S0378-1119(00)00075-5; RICHAUD C, 1993, J BIOL CHEM, V268, P26827; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; Sambrook J., 2002, MOL CLONING LAB MANU; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Swairjo MA, 2000, EMBO J, V19, P6287, DOI 10.1093/emboj/19.23.6287; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; XU JM, 1995, J BACTERIOL, V177, P938, DOI 10.1128/jb.177.4.938-947.1995; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	36	67	73	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25090	25095		10.1074/jbc.M203208200	http://dx.doi.org/10.1074/jbc.M203208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11983710	hybrid			2022-12-27	WOS:000176747000034
J	Phillip, D; Hobe, S; Paulsen, H; Molnar, P; Hashimoto, H; Young, AJ				Phillip, D; Hobe, S; Paulsen, H; Molnar, P; Hashimoto, H; Young, AJ			The binding of xanthophylls to the bulk light-harvesting complex of photosystem II of higher plants - A specific requirement for carotenoids with a 3-hydroxy-beta-end group	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							13-CIS VIOLAXANTHIN; IN-VITRO; RECONSTITUTION; PROTEIN; PIGMENT; NEOXANTHIN; SITES	The pigment composition of the light-harvesting complexes (LHCs) of higher plants is highly conserved. The bulk complex (LHCIIb) binds three xanthophyll molecules in combination with chlorophyll (Chl) a and b. The structural requirements for binding xanthophylls to LHCIIb have been examined using an in vitro reconstitution procedure. Reassembly of the monomeric recombinant LHCIIb was performed using a wide range of native and nonnative xanthophylls, and a specific requirement for the presence of a hydroxy group at C-3 on a single beta-end group was identified. The presence of additional substituents (e.g. at C-4) did not interfere with xanthophyll binding, but they could not, on their own, support reassembly. cis isomers of zeaxanthin, violaxanthin, and lutein were not bound, whereas all-trans-neoxanthin and different chiral forms of lutein and zeaxanthin were incorporated into the complex. The C-3 and C-3' diols lactucaxanthin (a carotenoid native to many plant LHCs) and eschscholtzxanthin (a retro-carotenoid) both behaved very differently from lutein and zeaxanthin in that they would not support complex reassembly when used alone. Lactucaxanthin could, however, be bound when lutein was also present, and it showed a high affinity for xanthophyll binding site N1. In the presence of lutein, lactucaxanthin was readily bound to at least one lutein-binding site, suggesting that the ability to bind to the complex and initiate protein folding may be dependent on different structural features of the carotenoid molecule. The importance of carotenoid end group structure and ring-to-chain conformation around the C-6-C-7 torsion angle of the carotenoid molecule in binding and complex reassembly is discussed.	Liverpool John Moores Univ, Sch Biol & Earth Sci, Liverpool L3 3AF, Merseyside, England; Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Univ Pecs, Sch Med, Dept Med Chem, H-7601 Pecs, Hungary; Osaka City Univ, Dept Phys, Osaka 5600043, Japan	Liverpool John Moores University; Johannes Gutenberg University of Mainz; University of Pecs; Osaka Metropolitan University	Young, AJ (corresponding author), Liverpool John Moores Univ, Sch Biol & Earth Sci, Byrom St, Liverpool L3 3AF, Merseyside, England.	a.j.young@livjm.ac.uk	Paulsen, Harald/D-3742-2011	Young, Andrew/0000-0001-6251-0944				Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bialek-Bylka GE, 1998, PHOTOSYNTH RES, V56, P255, DOI 10.1023/A:1006090210001; Britton G, 1997, PURE APPL CHEM, V69, P2075, DOI 10.1351/pac199769102075; Buchecker R., 1996, SPECTROSCOPY-US, V1B, P63; Bungard RA, 1999, P NATL ACAD SCI USA, V96, P1135, DOI 10.1073/pnas.96.3.1135; CAMMARATA KV, 1992, PHOTOSYNTH RES, V33, P235, DOI 10.1007/BF00030034; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Demmig-Adams B, 1999, ADV PHOTOSYNTH, V8, P245; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Goodwin T.W, 1980, BIOCH CAROTENOIDS, V1; Grudzinski W, 2001, BBA-BIOENERGETICS, V1503, P291, DOI 10.1016/S0005-2728(00)00206-1; Hashimoto H, 2002, J MOL STRUCT, V604, P125, DOI 10.1016/S0022-2860(01)00648-2; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 1999, ADV PHOTOSYNTH, V8, P271; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HUNTER CN, 1994, J BACTERIOL, V176, P3692, DOI 10.1128/JB.176.12.3692-3697.1994; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; Koyama Y, 1999, ADV PHOTOSYNTH, V8, P161; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Kumagai MH, 1998, PLANT J, V14, P305, DOI 10.1046/j.1365-313X.1998.00128.x; Lichtenthaler H.K., 1983, BIOCHEM SOC T, V11, P591, DOI [10.1042/bst0110591, DOI 10.1042/BST0110591]; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; MEYER M, 1993, Z NATURFORSCH C, V48, P461; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PHILLIP D, 1995, PHOTOSYNTH RES, V43, P273, DOI 10.1007/BF00029940; Phillip D, 1999, J PHOTOCH PHOTOBIO B, V49, P89, DOI 10.1016/S1011-1344(99)00019-6; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; RUBAN AV, 1999, J PHOTOCHEM PHOTOBIO, V68, P829; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; Takaichi S, 1998, PLANT CELL PHYSIOL, V39, P968, DOI 10.1093/oxfordjournals.pcp.a029461; Todd JB, 1998, BIOCHEMISTRY-US, V37, P17458, DOI 10.1021/bi981114e; Young A., 1993, CAROTENOIDS PHOTOSYN, P16, DOI DOI 10.1007/978-94-011-2124-8_2	39	46	47	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25160	25169		10.1074/jbc.M202002200	http://dx.doi.org/10.1074/jbc.M202002200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991953	hybrid			2022-12-27	WOS:000176747000042
J	Ariga, A; Namekawa, J; Matsumoto, N; Inoue, J; Umezawa, K				Ariga, A; Namekawa, J; Matsumoto, N; Inoue, J; Umezawa, K			Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; SIGNAL-TRANSDUCTION; TARGET GENES; CANCER CELLS; TNF; TRANSCRIPTION; JNK; EXPRESSION; APOPTOSIS; INDUCTION	We previously designed and synthesized an NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti-inflammatory activity in vivo. In the present study we looked into its mechanism of inhibition. DHMEQ inhibited tumor necrosis factor-alpha (TNF-alpha)-and 12-O-tetradecanoylphorbol-13-acetate-induced transcriptional activity of NF-kappaB in human T cell leukemia Jurkat cells. It also inhibited the TNF-alpha-induced DNA binding of nuclear NF-kappaB but not the phosphorylation and degradation Of IkappaB. Moreover, DHMEQ inhibited the TNF-alpha-induced nuclear accumulation of p65, a component of NF-kappaB. It also inhibited TNF-alpha-induced nuclear transport of green fluorescent protein-tagged p65. On the other hand, DHMEQ did not inhibit the nuclear transport of Smad2 and large T antigen. Also, it did not inhibit TNF-alpha-induced activation of JNK but synergistically induced apoptosis with TNF-alpha in Jurkat cells. Taken together, these data indicate that DHMEQ is a unique inhibitor of NF-kappaB acting at the level of nuclear translocation.	Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2230061, Japan; Inst Microbial Chem, Shinagawa Ku, Tokyo 1410021, Japan	Keio University	Umezawa, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2230061, Japan.							Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2449; ANTWERP DJV, 1996, SCIENCE, V274, P787; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Erkel G, 1996, BIOCHEM BIOPH RES CO, V226, P214, DOI 10.1006/bbrc.1996.1335; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gehrt A, 1998, J ANTIBIOT, V51, P455, DOI 10.7164/antibiotics.51.455; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Matsumoto N, 2000, BIOORG MED CHEM LETT, V10, P865, DOI 10.1016/S0960-894X(00)00114-1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHACOV AN, 1990, J EXP MED, V171, P35; Shoji S, 1998, BIOCHEM BIOPH RES CO, V249, P745, DOI 10.1006/bbrc.1998.9221; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Umezawa K, 2000, ANTI-CANCER DRUG DES, V15, P239; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xia DX, 2000, BIOCHEM PHARMACOL, V60, P717, DOI 10.1016/S0006-2952(00)00367-1; Yang JM, 2001, CANCER RES, V61, P4901; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	46	198	205	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24625	24630		10.1074/jbc.M112063200	http://dx.doi.org/10.1074/jbc.M112063200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11983688	hybrid			2022-12-27	WOS:000176611800086
J	Lu, XQ; Tan, CK; Zhou, JQ; You, M; Carastro, LM; Downey, KM; So, AG				Lu, XQ; Tan, CK; Zhou, JQ; You, M; Carastro, LM; Downey, KM; So, AG			Direct interaction of proliferating cell nuclear antigen with the small subunit of DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; PCNA BINDING; CALF THYMUS; SCHIZOSACCHAROMYCES-POMBE; AUXILIARY PROTEIN; REPLICATION FORK; INHIBITOR; REPAIR; IDENTIFICATION	The interaction between proliferating cell nuclear antigen (PCNA) and DNA polymerase 5 is essential for processive DNA synthesis during DNA replication/repair; however, the identity of the subunit of DNA polymerase 5 that directly interacts with PCNA has not been resolved until now. In the present study we have used reciprocal co-immunoprecipitation experiments to determine which of the two subunits of core DNA polymerase 5, the 125-kDa catalytic subunit or the 50-kDa small subunit, directly interacts with PCNA. We found that PCNA co-immunoprecipitated with human p50, as well as calf thymus DNA polymerase 5 heterodimer, but not with p125 alone, suggesting that PCNA directly interacts with p50 but not with p125. A PCNA-binding motif, similar to the sliding clamp-binding motif of bacteriophage RB69 DNA polymerase, was identified in the N terminus of p50. A 22-amino acid oligopeptide containing this sequence (MRPFL) was shown to bind PCNA by far Western analysis and to compete with p50 for binding to PCNA in co-immunoprecipitation experiments. The binding of p50 to PCNA was inhibited by p21, suggesting that the two proteins compete for the same binding site on PCNA. These results establish that the interaction of PCNA with DNA polymerase 5 is mediated through the small subunit of the enzyme.	Univ Miami, Sch Med, Dept Med R99, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	So, AG (corresponding author), Univ Miami, Sch Med, Dept Med R99, POB 016960, Miami, FL 33101 USA.				NIDDK NIH HHS [DK26206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARROYO MP, 1996, J BIOL CHEM, V271, P1571; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Carastro LM, 2002, NUCLEIC ACIDS RES, V30, P2232, DOI 10.1093/nar/30.10.2232; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Downey KM, 1995, METHOD ENZYMOL, V262, P84; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P6655; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Harlow E, 1999, USING ANTIBODIES LAB, P321; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; He H, 2001, P NATL ACAD SCI USA, V98, P11979, DOI 10.1073/pnas.221452098; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; NG L, 1991, J BIOL CHEM, V266, P11699; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Reynolds N, 1999, GENE, V230, P15, DOI 10.1016/S0378-1119(99)00058-X; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tratner I, 1997, BIOCHEM BIOPH RES CO, V231, P321, DOI 10.1006/bbrc.1997.6082; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG J, 1995, GENOMICS, V29, P179, DOI 10.1006/geno.1995.1229; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; ZHOU JQ, 1997, NUCLEIC ACIDS RES, V25, P1090; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	61	41	48	14	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24340	24345		10.1074/jbc.M200065200	http://dx.doi.org/10.1074/jbc.M200065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11986310	hybrid			2022-12-27	WOS:000176611800049
J	Nakamura, J; Tajima, G; Sato, C; Furukohri, T; Konishi, K				Nakamura, J; Tajima, G; Sato, C; Furukohri, T; Konishi, K			Substrate regulation of calcium binding in Ca2+-ATPase molecules of the sarcoplasmic reticulum - I. Effect of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITE; HIGH-AFFINITY; PUMP PROTEIN; PHOSPHORYLATION; CA-2+-ATPASE; MODULATION; KINETICS; VESICLES; ACID	The effect of ATP on calcium binding of the Ca2+-ATPase of the sarcoplasmic reticulum has not been clarified. By comparing the calcium dependence of the ATPase activity and of phosphorylation of the ATPase molecules with that of calcium binding in the absence of ATP, we show the existence of two types of regulatory site of the enzyme molecules at which ATP binding variously improves the calcium binding performance of the molecules depending on the aggregation state of the molecules and pH; the two regulatory sites bind ATP at submillimolar (0.25 mm) and millimolar (5 mm) ATP, respectively. The results are discussed based on a model of two conformational variants (A and B forms) of the chemically equivalent ATPase molecules (Nakamura, J., and Furukohri, T. (1994) J. Biol. Chem. 269, 30818-30821). For example, in the sarcoplasmic reticulum membrane at pH 7.40, submillimolar ATP converted the calcium binding manner of the A form from noncooperative (Hill number (n(H)) of similar to1) to cooperative (n(H) similar to 2), concurrent with a decrease in the apparent calcium affinity (K-0.5) from 2-6 to 0.1-0.3 muM. The binding of the A form became almost the same as that of the B form (n(H) similar to 2), (K-0.5 similar to 0.2 muM), which was not affected by ATP. Millimolar ATP further decreased the K-0.5 of the cooperative binding of the two forms to similar to0.05 muM. Regulation of the calcium binding performance by ATP is discussed in terms of monomeric and oligomeric pathway models.	Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Tohoku Gakuin Univ, Fac Liberal Arts, Izumi Ku, Sendai, Miyagi 9813193, Japan; Kohchi Univ, Fac Sci, Inst Biol, Akebono, Kohchi 7808520, Japan; Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Tsukuba, Ibaraki 3058568, Japan	Tohoku University; Tohoku Gakuin University; Kochi University; National Institute of Advanced Industrial Science & Technology (AIST)	Nakamura, J (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 9808578, Japan.	jun-n@mail.cc.tohoku.ac.jp	Sato, Chikara/M-7183-2016	Sato, Chikara/0000-0001-5543-4496				BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BONTING SL, 1961, ARCH BIOCHEM BIOPHYS, V95, P416, DOI 10.1016/0003-9861(61)90170-9; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CARVALHOALVES PC, 1985, J BIOL CHEM, V260, P4282; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2307; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HOBBS AS, 1983, J BIOL CHEM, V258, P8163; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1967, J BIOL CHEM, V242, P4637; KHAN MMT, 1966, J AM CHEM SOC, V88, P668; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Mignaco JA, 1996, BIOCHEMISTRY-US, V35, P3886, DOI 10.1021/bi9518353; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; Nakamura J, 1997, J BIOL CHEM, V272, P19290, DOI 10.1074/jbc.272.31.19290; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1319, DOI 10.1093/oxfordjournals.jbchem.a121838; OGAWA Y, 1972, J BIOCHEM-TOKYO, V71, P571; Ogawa Y, 1973, ORG ENERGY TRANSDUCI, P127; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TADA M, 1978, PHYSIOL REV, V58, P1; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792	51	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24180	24190		10.1074/jbc.M111834200	http://dx.doi.org/10.1074/jbc.M111834200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11976321	hybrid			2022-12-27	WOS:000176611800028
J	Rehm, M; Dussmann, H; Janicke, RU; Tavare, JM; Kogel, D; Prehn, JHM				Rehm, M; Dussmann, H; Janicke, RU; Tavare, JM; Kogel, D; Prehn, JHM			Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process - Role of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DEPENDENT PROTEIN-KINASE; DRUG-INDUCED APOPTOSIS; MITOCHONDRIAL DEPOLARIZATION; APAF-1 APOPTOSOME; STRUCTURAL BASIS; ENDONUCLEASE-G; DEATH; CLEAVAGE; PROCASPASE-9	Activation of effector caspases is considered to be the final step in many apoptosis pathways. We transfected HeLa cells with a recombinant caspase substrate composed of cyan and yellow fluorescent protein and a linker peptide containing the caspase cleavage sequence DEVD, and we examined the cleavage kinetics at the single-cell level by fluorescence resonance energy transfer (FRET) analysis. Caspase activation in response to tumor necrosis factor-alpha, staurosporine, or etoposide resulted in cleavage of the linker peptide and subsequent disruption of the FRET signal. The time to caspase activation varied among individual cells, depending on the type of treatment and concentration used. However, once initiated, disruption of the FRET signal was always rapid (less than or equal to15 min) and largely independent of these parameters. In contrast, FRET probe cleavage was significantly slower in the caspase-3-deficient MCF-7 cells, particularly at low concentrations of the pro-apoptotic agents. Under these conditions, MCF-7 cells required up to 90 min for the FRET probe cleavage, whereas MCF-7/Casp-3 cells displayed rapid cleavage kinetics. Interestingly, we could still observe comparable cell death rates in MCF-7 and MCF-7/Casp-3 cells. Our results suggest that caspase activation during apoptosis occurs in an "all or nothing" fashion. Caspase-3 is required for rapid cleavage kinetics when the onset of apoptosis is slow, suggesting the existence of caspase-3-dependent feedback loops.	Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res, D-48149 Munster, Germany; Univ Munster, Dept Expt Dermatol, Div Cell Biol & Immunol, D-48149 Munster, Germany; Univ Munster, Dept Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Munster; University of Munster; University of Munster; University of Bristol	Prehn, JHM (corresponding author), Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res, Rontgenstr 21, D-48149 Munster, Germany.	prehn@uni-muenster.de	Rehm, Markus/C-3398-2012; Prehn, Jochen HM/A-3928-2010	Rehm, Markus/0000-0001-6149-9261; Prehn, Jochen HM/0000-0003-3479-7794; Kogel, Donat/0000-0003-1209-0210; Dussmann, Heiko/0000-0002-3582-8057				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Blanc C, 2000, CANCER RES, V60, P4386; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luetjens CM, 2001, MOL PHARMACOL, V60, P1008, DOI 10.1124/mol.60.5.1008; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P38, DOI 10.1038/sj.cdd.4400800; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tyas L, 2000, EMBO REP, V1, P266, DOI 10.1093/embo-reports/kvd050; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang XD, 2001, CANCER RES, V61, P7339; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	251	258	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24506	24514		10.1074/jbc.M110789200	http://dx.doi.org/10.1074/jbc.M110789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964393	hybrid			2022-12-27	WOS:000176611800071
J	Poock, SR; Leach, ER; Moir, JWB; Cole, JA; Richardson, DJ				Poock, SR; Leach, ER; Moir, JWB; Cole, JA; Richardson, DJ			Respiratory detoxification of nitric oxide by the cytochrome c nitrite reductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES; GENE-EXPRESSION; FLAVOHEMOGLOBIN; NITRATE; BACTERIA; BINDING; IDENTIFICATION; INTERMEDIATE; DIOXYGENASE; CATALYZES	Nitric oxide is a key element in host defense against invasive pathogens. The periplasmic cytochrome c nitrite reductase (NrfA) of Escherichia coli catalyzes the respiratory reduction of nitrite, but in vitro studies have shown that it can also reduce nitric oxide. The physiological significance of the latter reaction in vivo has never been assessed. In this study the reduction of nitric oxide by Escherichia coli was measured in strains active or deficient in periplasmic nitrite reduction. Nrf(+) cells, harvested from cultures grown anaerobically, possessed a nitric-oxide reductase activity with physiological electron donation of 60 nmol min(-1) mg dry wt(-1), and an in vivo turnover number of NrfA of 390 NO. s(-1) was calculated. Nitric-oxide reductase activity could not be detected in Nrf(-) strains. Comparison of the anaerobic growth of Nrf(+) and Nrf(-) strains revealed a higher sensitivity to nitric oxide in the NrfA(-) strains. A higher sensitivity to the nitrosating agent S-nitroso-N-acetyl penicillamine (SNAP) was also observed in agar plate disk-diffusion assays. Oxygen respiration by E. coli was also more sensitive to nitric oxide in the Nrf(-) strains compared with the Nrf(+) parent strain. The results demonstrate that active periplasmic cytochrome c nitrite reductase can confer the capacity for nitric oxide reduction and detoxification on E. coli. Genomic analysis of many pathogenic enteric bacteria reveals the presence of nrf genes. The present study raises the possibility that this reflects an important role for the cytochrome c nitrite reductase in nitric oxide management in oxygen-limited environments.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of East Anglia; University of Birmingham; University of Sheffield	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.		Richardson, David J/E-2275-2011	Moir, James/0000-0003-2972-5235				Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BELL LC, 1992, J GEN MICROBIOL, V138, P437, DOI 10.1099/00221287-138-3-437; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; Contreras I, 1997, MICROBIOL-UK, V143, P2665, DOI 10.1099/00221287-143-8-2665; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DARWIN A, 1993, J GEN MICROBIOL, V139, P1829, DOI 10.1099/00221287-139-8-1829; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; HARBORNE NR, 1992, MOL MICROBIOL, V6, P2805, DOI 10.1111/j.1365-2958.1992.tb01460.x; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POPE NR, 1984, J GEN MICROBIOL, V130, P1279; Potter L, 2001, ADV MICROB PHYSIOL, V45, P51, DOI 10.1016/S0065-2911(01)45002-8; RABIN RS, 1993, J BACTERIOL, V175, P3259, DOI 10.1128/jb.175.11.3259-3268.1993; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Richardson DJ, 1999, CURR OPIN CHEM BIOL, V3, P207, DOI 10.1016/S1367-5931(99)80034-9; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8	32	156	161	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23664	23669		10.1074/jbc.M200731200	http://dx.doi.org/10.1074/jbc.M200731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960983	hybrid			2022-12-27	WOS:000176475700074
